##ANALYSISTYPE=GERMLINE_TRIO
##PIPELINE=megSAP 0.1-819-gb1a13f6
##SAMPLE=<ID=GS140127_01,Gender=male,ExternalSampleName=131787,IsTumor=no,IsFFPE=no,DiseaseGroup=n/a,DiseaseStatus=affected>
##SAMPLE=<ID=GS140550_01,Gender=male,ExternalSampleName=131751,IsTumor=no,IsFFPE=no,DiseaseGroup=n/a,DiseaseStatus=control>
##SAMPLE=<ID=GS140549_01,Gender=female,ExternalSampleName=131752,IsTumor=no,IsFFPE=no,DiseaseGroup=n/a,DiseaseStatus=control>
##DESCRIPTION=GS140127_01=genotype of sample GS140127_01
##DESCRIPTION=GS140550_01=genotype of sample GS140550_01
##DESCRIPTION=GS140549_01=genotype of sample GS140549_01
##DESCRIPTION=filter=Annotations for filtering and ranking variants.
##DESCRIPTION=quality=Quality parameters - SNP quality (QUAL), depth (DP), allele frequency (AF), mean mapping quality of alternate allele (MQM).
##DESCRIPTION=gene=Affected gene list (comma-separated).
##DESCRIPTION=variant_type=Variant type.
##DESCRIPTION=coding_and_splicing=Coding and splicing details (Gene, ENST number, type, impact, exon/intron number, HGVS.c, HGVS.p, Pfam domain).
##DESCRIPTION=OMIM=OMIM database annotation.
##DESCRIPTION=ClinVar=ClinVar database annotation.
##DESCRIPTION=HGMD=HGMD database annotation.
##DESCRIPTION=RepeatMasker=RepeatMasker annotation.
##DESCRIPTION=dbSNP=Identifier in dbSNP database.
##DESCRIPTION=1000g=Allele frequency in 1000 genomes project.
##DESCRIPTION=gnomAD=Allele frequency in gnomAD project.
##DESCRIPTION=gnomAD_hom_hemi=Homoyzgous counts and hemizygous counts of gnomAD project (genome data).
##DESCRIPTION=gnomAD_sub=Sub-population allele frequenciens (AFR,AMR,EAS,NFE,SAS) in gnomAD project.
##DESCRIPTION=ESP_sub=Sub-population allele frequency (EA,AA) in NHLBI Exome Sequencing project.
##DESCRIPTION=phyloP=phyloP (100way vertebrate) annotation. Deleterious threshold > 1.6.
##DESCRIPTION=Sift=Sift effect prediction for each transcript: D=damaging, T=tolerated.
##DESCRIPTION=PolyPhen=PolyPhen (humVar) effect prediction for each transcript: D=probably damaging, P=possibly damaging, B=benign.
##DESCRIPTION=fathmm-MKL=fathmm-MKL score (for coding/non-coding regions). Deleterious threshold > 0.5.
##DESCRIPTION=CADD=CADD pathogenicity prediction scores (scaled phred-like). Deleterious threshold > 15-20.
##DESCRIPTION=REVEL=REVEL pathogenicity prediction score. Deleterious threshold > 0.5.
##DESCRIPTION=MaxEntScan=MaxEntScan splicing prediction (difference in percent/reference bases score/alternate bases score).
##DESCRIPTION=GeneSplicer=GeneSplicer splicing prediction (state/type/coordinates/confidence/score).
##DESCRIPTION=dbscSNV=dbscSNV splicing prediction (ADA/RF score).
##DESCRIPTION=COSMIC=COSMIC somatic variant database anntotation.
##DESCRIPTION=NGSD_hom=Homozygous variant counts in NGSD independent of the processing system.
##DESCRIPTION=NGSD_het=Heterozygous variant counts in NGSD independent of the processing system.
##DESCRIPTION=classification=Classification from the NGSD.
##DESCRIPTION=classification_comment=Classification comment from the NGSD.
##DESCRIPTION=validation=Validation information from the NGSD. Validation results of other samples are listed in brackets!
##DESCRIPTION=comment=Variant comments from the NGSD.
##DESCRIPTION=gene_info=Gene information from NGSD (inheritance mode, ExAC pLI score).
##FILTER=gene_blacklist=The gene(s) are contained on the blacklist of unreliable genes.
##FILTER=off-target=Variant marked as 'off-target'.
#chr	start	end	ref	obs	GS140127_01	GS140550_01	GS140549_01	filter	quality	gene	variant_type	coding_and_splicing	OMIM	ClinVar	HGMD	RepeatMasker	dbSNP	1000g	gnomAD	gnomAD_hom_hemi	gnomAD_sub	ESP_sub	phyloP	Sift	PolyPhen	fathmm-MKL	CADD	REVEL	MaxEntScan	GeneSplicer	dbscSNV	COSMIC	NGSD_hom	NGSD_het	classification	classification_comment	validation	comment	gene_info
chr1	957898	957898	G	T	hom	het	hom	off-target	QUAL=3696;DP=63,55,45;AF=0.98,0.64,1.00;MQM=60	AGRN	intron	AGRN:ENST00000379370:intron_variant:MODIFIER:exon2/35:c.463+56G>T::	103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];				rs2799064	0.3285	0.3620	2049,			-2.0720			0.00,0.12	0.04						n/a (AF>5%)	n/a (AF>5%)					AGRN (inh=AR pLI=0.04)
chr1	977330	977330	T	C	hom	hom	hom		QUAL=1743;DP=13,26,20;AF=1.00,1.00,1.00;MQM=60	AGRN	splice_region&intron	AGRN:ENST00000379370:splice_region_variant&intron_variant:LOW:exon6/35:c.1178-6T>C::	103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];	128292 [benign DISEASE=not specified];			rs2799066	0.8852	0.9235	11978,	0.7093,0.9513,0.9998,0.9177,0.9528	0.9208,0.7194	-0.8450			0.01,0.17	0.11		+2.00% (6.81>6.94)		0.000/0.002		n/a (AF>5%)	n/a (AF>5%)					AGRN (inh=AR pLI=0.04)
chr1	977570	977570	G	A	hom	hom	hom	off-target	QUAL=1516;DP=18,21,15;AF=1.00,1.00,1.00;MQM=59	AGRN	intron	AGRN:ENST00000379370:intron_variant:MODIFIER:exon7/35:c.1384+28G>A::	103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];	263159 [benign DISEASE=not specified];			rs2710876	0.7941	0.8978	10431,	0.4341,0.9314,0.9725,0.9148,0.9448	0.9196,0.4860	-1.5510			0.03,0.18	0.08						n/a (AF>5%)	n/a (AF>5%)					AGRN (inh=AR pLI=0.04)
chr1	978604	978605	CT	-	wt	het	wt	off-target	QUAL=1660;DP=60,194,167;AF=0.00,0.49,0.00;MQM=60	AGRN	intron	AGRN:ENST00000379370:intron_variant:MODIFIER:exon7/35:c.1385-15_1385-14del::	103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];	263160 [benign DISEASE=not specified];			rs35881187	0.4792	0.5516	3546,	0.0925,0.6978,0.7848,0.5381,0.5459	0.5470,0.1127	0.0350				0.14						n/a (AF>5%)	n/a (AF>5%)					AGRN (inh=AR pLI=0.04)
chr1	981087	981087	A	G	hom	hom	hom	off-target	QUAL=5710;DP=67,65,51;AF=1.00,1.00,1.00;MQM=59	AGRN	intron	AGRN:ENST00000379370:intron_variant:MODIFIER:exon14/35:c.2537-26A>G::	103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];	263172 [benign DISEASE=not specified];			rs3128098	0.8694	0.9210	11668,	0.6343,0.9463,0.9998,0.9245,0.9550	0.9270,0.6468	-0.5730			0.04,0.15	-0.11						n/a (AF>5%)	n/a (AF>5%)					AGRN (inh=AR pLI=0.04)
chr1	981931	981931	A	G	hom	hom	hom		QUAL=6215;DP=51,96,70;AF=1.00,1.00,1.00;MQM=59	AGRN	synonymous	AGRN:ENST00000379370:synonymous_variant:LOW:exon18/36:c.3066A>G:p.Ser1022=:	103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];	128297 [benign DISEASE=not specified];			rs2465128	0.7977	0.8872	10542,	0.4965,0.9296,0.9679,0.9055,0.8882	0.9098,0.5268	-1.7540			0.02,0.07	-0.59						n/a (AF>5%)	n/a (AF>5%)					AGRN (inh=AR pLI=0.04)
chr1	982941	982941	T	C	hom	hom	hom	off-target	QUAL=9200;DP=48,149,105;AF=1.00,1.00,1.00;MQM=59	AGRN	intron	AGRN:ENST00000379370:intron_variant:MODIFIER:exon20/35:c.3517-12T>C::	103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];	263181 [benign DISEASE=not specified];			rs3128102		0.8967	10551,	0.4483,0.9319,0.9724,0.9131,0.9441	0.9154,0.4762	0.1090			0.03,0.17	0.01		-8.10% (6.84>6.29)		0.000/0.014		n/a (AF>5%)	n/a (AF>5%)					AGRN (inh=AR pLI=0.04)
chr1	982994	982994	T	C	hom	hom	hom		QUAL=15342;DP=135,208,143;AF=0.99,1.00,1.00;MQM=59	AGRN	synonymous	AGRN:ENST00000379370:synonymous_variant:LOW:exon21/36:c.3558T>C:p.Phe1186=:PF01390	103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];	128302 [benign DISEASE=not specified];			rs10267	0.8359	0.9089	11057,	0.5239,0.9387,0.9994,0.9164,0.9525	0.9187,0.5422	0.5010			0.09,0.93	0.13						n/a (AF>5%)	n/a (AF>5%)					AGRN (inh=AR pLI=0.04)
chr1	984302	984302	T	C	het	hom	wt		QUAL=587;DP=9,19,17;AF=0.67,1.00,0.00;MQM=60	AGRN	synonymous	AGRN:ENST00000379370:synonymous_variant:LOW:exon24/36:c.4161T>C:p.Thr1387=:	103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];	128307 [benign DISEASE=not specified];			rs9442391	0.5457	0.5885	3980,	0.2706,0.7058,0.8200,0.5656,0.5592	0.5494,0.2794	-1.1240			0.01,0.16	-0.55						n/a (AF>5%)	n/a (AF>5%)					AGRN (inh=AR pLI=0.04)
chr1	985266	985266	C	T	het	hom	wt	off-target	QUAL=583;DP=8,20,11;AF=0.50,1.00,0.00;MQM=60	AGRN	intron	AGRN:ENST00000379370:intron_variant:MODIFIER:exon26/35:c.4745-17C>T::	103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];	263188 [benign DISEASE=not specified];			rs2275813	0.4952	0.5574	3503,	0.1472,0.7104,0.8105,0.5355,0.5451	0.5278,0.1584	1.9730			0.19,0.18	-0.15		-1.80% (11.49>11.28)				n/a (AF>5%)	n/a (AF>5%)					AGRN (inh=AR pLI=0.04)
chr1	985444	985444	G	-	hom	wt	hom	off-target	QUAL=329;DP=4,6,10;AF=0.75,1.00,1.00;MQM=60	AGRN	intron	AGRN:ENST00000379370:intron_variant:MODIFIER:exon27/35:c.4879+41del::	103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];				rs774490460		0.5601	3718,	0.7412,0.5298,0.6492,0.4562,0.4874		0.1170				0.19						n/a (AF>5%)	n/a (AF>5%)					AGRN (inh=AR pLI=0.04)
chr1	985446	985446	G	T	wt	het	wt	off-target	QUAL=329;DP=4,6,10;AF=0.75,1.00,1.00;MQM=60	AGRN	intron	AGRN:ENST00000379370:intron_variant:MODIFIER:exon27/35:c.4879+29G>T::	103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];	263191 [benign DISEASE=not specified];			rs2275812	0.3355	0.4163	1513,	0.1009,0.4387,0.1561,0.4608,0.4608		-0.8900			0.08,0.12	-0.14						n/a (AF>5%)	n/a (AF>5%)					AGRN (inh=AR pLI=0.04)
chr1	985449	985449	G	A	wt	hom	wt	off-target	QUAL=329;DP=4,6,10;AF=0.75,1.00,1.00;MQM=60	AGRN	intron	AGRN:ENST00000379370:intron_variant:MODIFIER:exon27/35:c.4879+32G>A::	103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];	263192 [benign DISEASE=not specified];			rs2799067	0.5256	0.5840	2213,	0.2597,0.5478,0.5024,0.6195,0.6166		0.1530			0.03,0.07	-0.49						n/a (AF>5%)	n/a (AF>5%)					AGRN (inh=AR pLI=0.04)
chr1	985450	985450	G	A	hom	wt	hom	off-target	QUAL=329;DP=4,6,10;AF=0.75,1.00,1.00;MQM=60	AGRN	intron	AGRN:ENST00000379370:intron_variant:MODIFIER:exon27/35:c.4879+33G>A::	103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];				rs397834473	0.4465	0.5110	3808,	0.6967,0.4835,0.6049,0.4296,0.4499		-0.4470			0.15,0.26	0.34						n/a (AF>5%)	n/a (AF>5%)					AGRN (inh=AR pLI=0.04)
chr1	987200	987200	C	T	hom	hom	hom		QUAL=10521;DP=63,150,134;AF=0.97,0.99,1.00;MQM=60	AGRN	splice_region&intron	AGRN:ENST00000379370:splice_region_variant&intron_variant:LOW:exon33/35:c.5651+5C>T::	103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];	128317 [benign DISEASE=not specified];			rs9803031	0.7887	0.8880	10551,	0.4376,0.9322,0.9957,0.9078,0.8828	0.9100,0.4580	-0.9360			0.02,0.14	-0.33		-9.47% (9.65>8.73)		0.000/0.016		n/a (AF>5%)	n/a (AF>5%)					AGRN (inh=AR pLI=0.04)
chr1	990280	990280	C	T	wt	het	het		QUAL=4766;DP=101,207,174;AF=0.00,0.59,0.51;MQM=60	AGRN	synonymous	AGRN:ENST00000379370:synonymous_variant:LOW:exon36/36:c.6057C>T:p.Asp2019=:PF00054	103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];	128319 [benign DISEASE=not specified];			rs4275402		0.6766	5679,	0.3087,0.7713,0.8130,0.6980,0.6132	0.7054,0.3322	-0.7110			0.35,0.88	0.85						n/a (AF>5%)	n/a (AF>5%)					AGRN (inh=AR pLI=0.04)
chr1	990380	990380	C	T	hom	het	het		QUAL=12412;DP=162,432,332;AF=0.98,0.49,0.44;MQM=60	AGRN	3'UTR	AGRN:ENST00000379370:3_prime_UTR_variant:MODIFIER:exon36/36:c.*19C>T::	103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];	263157 [benign DISEASE=not specified];			rs3121561	0.3434	0.3626	2172,	0.5220,0.2146,0.1801,0.2917,0.3088	0.2722,0.4760	-0.1240			0.05,0.09	-0.59						n/a (AF>5%)	n/a (AF>5%)					AGRN (inh=AR pLI=0.04)
chr1	990417	990417	T	C	hom	het	het		QUAL=16537;DP=186,502,389;AF=0.99,0.49,0.46;MQM=59	AGRN,RP11-54O7.14	3'UTR,non_coding_transcript_exon	AGRN:ENST00000379370:3_prime_UTR_variant:MODIFIER:exon36/36:c.*56T>C::,RP11-54O7.14:ENST00000418300:non_coding_transcript_exon_variant:MODIFIER:exon1/2:n.5T>C::	103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];				rs2465136	0.3840	0.3948	2673,			0.3020			0.78,0.96	0.91						n/a (AF>5%)	n/a (AF>5%)					AGRN (inh=AR pLI=0.04), RP11-54O7.14 (inh=n/a pLI=n/a)
chr1	990517	990517	C	T	hom	hom	het		QUAL=18363;DP=120,372,285;AF=0.99,1.00,0.48;MQM=60	AGRN,RP11-54O7.14	3'UTR,non_coding_transcript_exon	AGRN:ENST00000379370:3_prime_UTR_variant:MODIFIER:exon36/36:c.*156C>T::,RP11-54O7.14:ENST00000418300:non_coding_transcript_exon_variant:MODIFIER:exon1/2:n.105C>T::	103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];				rs2710872	0.9179	0.8780	11952,			-0.4100			0.04,0.14	0.06						n/a (AF>5%)	n/a (AF>5%)					AGRN (inh=AR pLI=0.04), RP11-54O7.14 (inh=n/a pLI=n/a)
chr1	990773	990773	C	T	hom	hom	het		QUAL=22342;DP=181,404,297;AF=1.00,1.00,0.54;MQM=60	AGRN,RP11-54O7.14	3'UTR,intron&non_coding_transcript	AGRN:ENST00000379370:3_prime_UTR_variant:MODIFIER:exon36/36:c.*412C>T::,RP11-54O7.14:ENST00000418300:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.183+178C>T::	103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];				rs2799072	0.8460	0.8194	10554,			-0.5960			0.05,0.13	-0.05						n/a (AF>5%)	n/a (AF>5%)					AGRN (inh=AR pLI=0.04), RP11-54O7.14 (inh=n/a pLI=n/a)
chr1	990806	990806	G	A	hom	hom	het		QUAL=24555;DP=224,451,312;AF=0.97,1.00,0.54;MQM=60	AGRN,RP11-54O7.14	3'UTR,intron&non_coding_transcript	AGRN:ENST00000379370:3_prime_UTR_variant:MODIFIER:exon36/36:c.*445G>A::,RP11-54O7.14:ENST00000418300:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.183+211G>A::	103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];				rs2799073	0.8462	0.8196	10553,			-0.1840			0.06,0.14	0.21						n/a (AF>5%)	n/a (AF>5%)					AGRN (inh=AR pLI=0.04), RP11-54O7.14 (inh=n/a pLI=n/a)
chr1	990984	990984	G	A	hom	hom	het		QUAL=15892;DP=148,273,190;AF=1.00,1.00,0.59;MQM=59	AGRN,RP11-54O7.14	3'UTR,intron&non_coding_transcript	AGRN:ENST00000379370:3_prime_UTR_variant:MODIFIER:exon36/36:c.*623G>A::,RP11-54O7.14:ENST00000418300:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.184-294G>A::	103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];				rs8014	0.9223	0.8818	12061,			-2.5600			0.00,0.06	-0.19						n/a (AF>5%)	n/a (AF>5%)					AGRN (inh=AR pLI=0.04), RP11-54O7.14 (inh=n/a pLI=n/a)
chr1	1956362	1956362	G	A	hom	het	het	off-target	QUAL=6574;DP=82,170,172;AF=1.00,0.48,0.49;MQM=60	GABRD	intron	GABRD:ENST00000378585:intron_variant:MODIFIER:exon1/8:c.69-19G>A::	137163 [GABRD (confirmed) Epilepsy,generalized,with febrile seizures plus,type 5,susceptibility to,613060/Epilepsy,idiopathic generalized,10,613060/Epilepsy,juvenile myoclonic,susceptibility to,613060];	256824 [benign DISEASE=not specified];			rs2376805	0.7756	0.8126	10214,	0.7943,0.7390,0.7175,0.8311,0.7724	0.8329,0.7939	-0.2280			0.00,0.15	-0.17		-19.11% (7.68>6.22)				n/a (AF>5%)	n/a (AF>5%)					GABRD (inh=AD pLI=0.90)
chr1	1957037	1957037	T	C	het	het	wt		QUAL=6748;DP=160,399,341;AF=0.54,0.49,0.00;MQM=59	GABRD	synonymous	GABRD:ENST00000378585:synonymous_variant:LOW:exon4/9:c.330T>C:p.Gly110=:PF02931	137163 [GABRD (confirmed) Epilepsy,generalized,with febrile seizures plus,type 5,susceptibility to,613060/Epilepsy,idiopathic generalized,10,613060/Epilepsy,juvenile myoclonic,susceptibility to,613060];	256823 [benign DISEASE=not specified];			rs2229110	0.5613	0.6471	6566,	0.7308,0.4730,0.3125,0.6570,0.4739	0.6605,0.7308	-1.3800			0.07,0.88	1.61						n/a (AF>5%)	n/a (AF>5%)					GABRD (inh=AD pLI=0.90)
chr1	1957220	1957220	G	-	het	het	wt	off-target	QUAL=1339;DP=55,76,54;AF=0.49,0.51,0.00;MQM=60	GABRD	intron	GABRD:ENST00000378585:intron_variant:MODIFIER:exon4/8:c.470+45del::	137163 [GABRD (confirmed) Epilepsy,generalized,with febrile seizures plus,type 5,susceptibility to,613060/Epilepsy,idiopathic generalized,10,613060/Epilepsy,juvenile myoclonic,susceptibility to,613060];				rs3831907	0.1080	0.1195	280,	0.2115,0.0547,0.0254,0.1143,0.0775	0.1236,0.2055	-4.7340				-0.40						n/a (AF>5%)	n/a (AF>5%)					GABRD (inh=AD pLI=0.90)
chr1	1960674	1960674	C	T	het	wt	het		QUAL=4929;DP=119,386,267;AF=0.50,0.01,0.56;MQM=59	GABRD	synonymous	GABRD:ENST00000378585:synonymous_variant:LOW:exon7/9:c.816C>T:p.Ser272=:PF02932	137163 [GABRD (confirmed) Epilepsy,generalized,with febrile seizures plus,type 5,susceptibility to,613060/Epilepsy,idiopathic generalized,10,613060/Epilepsy,juvenile myoclonic,susceptibility to,613060];	256825 [benign DISEASE=not specified];			rs28408173	0.1983	0.1923	424,	0.0311,0.2388,0.4728,0.1437,0.2548	0.1313,0.0322	-0.7780			0.10,0.96	0.19						n/a (AF>5%)	n/a (AF>5%)					GABRD (inh=AD pLI=0.90)
chr1	1961408	1961408	C	T	het	wt	het	off-target	QUAL=1609;DP=69,74,64;AF=0.57,0.01,0.50;MQM=59	GABRD	intron	GABRD:ENST00000378585:intron_variant:MODIFIER:exon8/8:c.1060-14C>T::	137163 [GABRD (confirmed) Epilepsy,generalized,with febrile seizures plus,type 5,susceptibility to,613060/Epilepsy,idiopathic generalized,10,613060/Epilepsy,juvenile myoclonic,susceptibility to,613060];	256822 [benign DISEASE=not specified];			rs28431879	0.1999	0.1852	442,	0.0291,0.2374,0.4842,0.1370,0.2434	0.1288,0.0323	-1.4010			0.00,0.11	-0.45		-8.69% (7.60>6.94)				n/a (AF>5%)	n/a (AF>5%)					GABRD (inh=AD pLI=0.90)
chr1	2337277	2337277	C	T	het	wt	wt		QUAL=107;DP=20,1,1;AF=0.40,0.00,0.00;MQM=60	PEX10	splice_region&intron,intron	PEX10:ENST00000288774:splice_region_variant&intron_variant:LOW:exon5/5:c.973-4G>A::,PEX10:ENST00000447513:splice_region_variant&intron_variant:LOW:exon5/5:c.913-4G>A::,PEX10:ENST00000507596:intron_variant:MODIFIER:exon5/5:c.913-10G>A::	602859 [PEX10 (confirmed) Peroxisome biogenesis disorder 6A (Zellweger),614870/Peroxisome biogenesis disorder 6B,614871];	262791 [likely benign DISEASE=Zellweger syndrome,not specified,not provided];			rs11586985	0.0809	0.1049	161,	0.0217,0.0579,0.1205,0.1219,0.1097	0.1113,0.0247	-1.9740			0.08,0.13	-0.22		-1.66% (13.68>13.46),-0.10% (-18.78>-18.77)		0.000/0.002		n/a (AF>5%)	n/a (AF>5%)					PEX10 (inh=AR pLI=0.01)
chr1	2338126	2338126	C	A	wt	het	het	off-target	QUAL=1048;DP=46,55,45;AF=0.00,0.49,0.49;MQM=60	PEX10	intron	PEX10:ENST00000288774:intron_variant:MODIFIER:exon4/5:c.836+33G>T::,PEX10:ENST00000447513:intron_variant:MODIFIER:exon4/5:c.776+33G>T::,PEX10:ENST00000507596:intron_variant:MODIFIER:exon4/5:c.776+33G>T::	602859 [PEX10 (confirmed) Peroxisome biogenesis disorder 6A (Zellweger),614870/Peroxisome biogenesis disorder 6B,614871];				rs3795269	0.3391	0.4032	2537,	0.2885,0.4080,0.2646,0.4332,0.3650	0.4278,0.2942	0.5730			0.20,0.15	0.16						n/a (AF>5%)	n/a (AF>5%)					PEX10 (inh=AR pLI=0.01)
chr1	2340200	2340200	T	C	wt	het	het		QUAL=985;DP=43,48,39;AF=0.02,0.54,0.44;MQM=60	PEX10	synonymous	PEX10:ENST00000288774:synonymous_variant:LOW:exon3/6:c.291A>G:p.Thr97=:PF04757,PEX10:ENST00000447513:synonymous_variant:LOW:exon3/6:c.291A>G:p.Thr97=:PF04757,PEX10:ENST00000507596:synonymous_variant:LOW:exon3/6:c.291A>G:p.Thr97=:PF04757	602859 [PEX10 (confirmed) Peroxisome biogenesis disorder 6A (Zellweger),614870/Peroxisome biogenesis disorder 6B,614871];	129884 [benign DISEASE=Zellweger syndrome,not specified,not provided];			rs2494598		0.7743	8515,	0.5896,0.7707,0.7203,0.8113,0.7253	0.8170,0.6010	-6.5230			0.03,0.05	-0.74						n/a (AF>5%)	n/a (AF>5%)					PEX10 (inh=AR pLI=0.01)
chr1	5922834	5922834	C	A	het	hom	wt	off-target	QUAL=1543;DP=54,42,26;AF=0.37,1.00,0.00;MQM=60	NPHP4,MIR4689	downstream_gene,upstream_gene	NPHP4:ENST00000378156:downstream_gene_variant:MODIFIER::::,MIR4689:ENST00000582517:upstream_gene_variant:MODIFIER::::					rs12133533	0.0966	0.1242	299,	0.0176,0.0839,0.0531,0.1639,0.1088		-0.3700			0.06,0.16	-0.15						n/a (AF>5%)	n/a (AF>5%)					NPHP4 (inh=AR pLI=0.00), MIR4689 (inh=n/a pLI=n/a)
chr1	5926507	5926507	T	C	het	hom	wt		QUAL=8882;DP=277,183,155;AF=0.50,0.99,0.00;MQM=60	NPHP4	synonymous	NPHP4:ENST00000378156:synonymous_variant:LOW:exon26/30:c.3570A>G:p.Glu1190=:	607215 [NPHP4 (provisional) Nephronophthisis 4,606966/Senior-Loken syndrome 4,606996];	95683 [benign DISEASE=Nephronophthisis,Renal dysplasia and retinal aplasia,not specified];			rs555164	0.3197	0.3935	2128,	0.2006,0.3708,0.2574,0.4226,0.4305	0.4197,0.1984	0.2880			0.02,0.92	1.09						n/a (AF>5%)	n/a (AF>5%)					NPHP4 (inh=AR pLI=0.00)
chr1	5927031	5927031	A	G	het	hom	wt	off-target	QUAL=3719;DP=80,96,66;AF=0.48,1.00,0.00;MQM=60	NPHP4	intron	NPHP4:ENST00000378156:intron_variant:MODIFIER:exon25/29:c.3558+59T>C::	607215 [NPHP4 (provisional) Nephronophthisis 4,606966/Senior-Loken syndrome 4,606996];				rs12122135	0.1028	0.1252	294,			-0.2430			0.02,0.10	-0.28						n/a (AF>5%)	n/a (AF>5%)					NPHP4 (inh=AR pLI=0.00)
chr1	5927943	5927943	G	A	wt	het	wt		QUAL=3628;DP=131,360,269;AF=0.00,0.48,0.00;MQM=60	NPHP4	missense	NPHP4:ENST00000378156:missense_variant:MODERATE:exon24/30:c.3329C>T:p.Ala1110Val:	607215 [NPHP4 (provisional) Nephronophthisis 4,606966/Senior-Loken syndrome 4,606996];	95682 [conflicting interpretations of pathogenicity DISEASE=Nephronophthisis,Renal dysplasia and retinal aplasia,not specified];	CM125782 [CLASS=DM MUT=ALT PHEN="Cardiovascular malformations" GENE=NPHP4];		rs139767853	0.0014	0.0037	0,	0.0012,0.0029,0.0000,0.0061,0.0008	0.0067,0.0009	0.0280	T	B	0.08,0.26	0.24	0.32					0	43					NPHP4 (inh=AR pLI=0.00)
chr1	5934490	5934490	A	G	hom	hom	het	off-target	QUAL=5977;DP=75,112,68;AF=0.99,1.00,0.49;MQM=60	NPHP4	intron	NPHP4:ENST00000378156:intron_variant:MODIFIER:exon22/29:c.3231+41T>C::	607215 [NPHP4 (provisional) Nephronophthisis 4,606966/Senior-Loken syndrome 4,606996];	260554 [benign DISEASE=not specified];			rs868163	0.5693	0.6451	6545,	0.7139,0.5001,0.2710,0.6459,0.6154	0.6523,0.7142	-3.6260			0.01,0.09	-0.33						n/a (AF>5%)	n/a (AF>5%)					NPHP4 (inh=AR pLI=0.00)
chr1	5935162	5935162	A	T	het	het	hom		QUAL=4955;DP=87,128,87;AF=0.38,0.52,1.00;MQM=60	NPHP4	splice_acceptor	NPHP4:ENST00000378156:splice_acceptor_variant:HIGH:exon20/29:c.2818-2T>A::	607215 [NPHP4 (provisional) Nephronophthisis 4,606966/Senior-Loken syndrome 4,606996];	167375 [benign DISEASE=not specified];			rs1287637	0.8433	0.8615	11463,	0.8944,0.7946,0.8109,0.8252,0.8290	0.8172,0.8938	0.4530			0.00,0.85	2.49		+927.16% (0.90>9.27)				n/a (AF>5%)	n/a (AF>5%)					NPHP4 (inh=AR pLI=0.00)
chr1	5937391	5937391	C	T	hom	hom	wt	off-target	QUAL=157;DP=1,4,0;AF=1.00,1.00,nan;MQM=60	NPHP4	intron	NPHP4:ENST00000378156:intron_variant:MODIFIER:exon19/29:c.2612-33G>A::	607215 [NPHP4 (provisional) Nephronophthisis 4,606966/Senior-Loken syndrome 4,606996];	260547 [benign DISEASE=not specified];			rs3747989	0.8327	0.8286	10687,	0.9386,0.7300,0.8509,0.8009,0.7366	0.8107,0.9323	-2.2310			0.00,0.05	-0.36						n/a (AF>5%)	n/a (AF>5%)					NPHP4 (inh=AR pLI=0.00)
chr1	5947308	5947308	G	A	wt	het	wt	off-target	QUAL=1780;DP=130,187,146;AF=0.00,0.42,0.01;MQM=60	NPHP4	intron	NPHP4:ENST00000378156:intron_variant:MODIFIER:exon18/29:c.2485+38C>T::	607215 [NPHP4 (provisional) Nephronophthisis 4,606966/Senior-Loken syndrome 4,606996];	260546 [benign DISEASE=not specified];			rs41280814	0.0863	0.1346	252,	0.0277,0.0784,0.0806,0.1719,0.1163	0.1732,0.0294	-1.8090			0.05,0.17	-0.08						n/a (AF>5%)	n/a (AF>5%)					NPHP4 (inh=AR pLI=0.00)
chr1	5965381	5965381	C	T	wt	het	wt		QUAL=2692;DP=208,262,206;AF=0.00,0.43,0.00;MQM=60	NPHP4	synonymous	NPHP4:ENST00000378156:synonymous_variant:LOW:exon15/30:c.1926G>A:p.Glu642=:	607215 [NPHP4 (provisional) Nephronophthisis 4,606966/Senior-Loken syndrome 4,606996];	95673 [benign/likely benign DISEASE=Nephronophthisis,Renal dysplasia and retinal aplasia,not specified];			rs12120967	0.0841	0.1320	251,	0.0274,0.0764,0.0770,0.1673,0.1132	0.1765,0.0297	-0.7650			0.03,0.33	-0.10						n/a (AF>5%)	n/a (AF>5%)					NPHP4 (inh=AR pLI=0.00)
chr1	5987696	5987696	T	C	wt	het	wt	off-target	QUAL=2421;DP=136,184,150;AF=0.00,0.54,0.02;MQM=60	NPHP4	intron	NPHP4:ENST00000378156:intron_variant:MODIFIER:exon11/29:c.1441+13A>G::	607215 [NPHP4 (provisional) Nephronophthisis 4,606966/Senior-Loken syndrome 4,606996];	95671 [benign/likely benign DISEASE=Nephronophthisis,Renal dysplasia and retinal aplasia,not specified];			rs7520105	0.1412	0.1687	420,	0.2101,0.0873,0.0772,0.1683,0.1156	0.1769,0.1985	0.8260			0.31,0.17	0.40						n/a (AF>5%)	n/a (AF>5%)					NPHP4 (inh=AR pLI=0.00)
chr1	6046432	6046432	C	G	wt	het	wt	off-target	QUAL=789;DP=53,52,46;AF=0.00,0.63,0.02;MQM=60	NPHP4	intron	NPHP4:ENST00000378156:intron_variant:MODIFIER:exon1/29:c.-38-45G>C::	607215 [NPHP4 (provisional) Nephronophthisis 4,606966/Senior-Loken syndrome 4,606996];				rs1295111	0.3878	0.4118	2640,			-0.1940			0.09,0.19	-0.05						n/a (AF>5%)	n/a (AF>5%)					NPHP4 (inh=AR pLI=0.00)
chr1	6052571	6052571	G	A	wt	het	wt	off-target	QUAL=398;DP=3,39,29;AF=0.00,0.51,0.00;MQM=60	KCNAB2	5'UTR,intron	KCNAB2:ENST00000378097:5_prime_UTR_variant:MODIFIER:exon1/16:c.-330G>A::,KCNAB2:ENST00000378111:intron_variant:MODIFIER:exon1/7:c.-53+955G>A::					rs61760765	0.0218	0.0350	27,			-0.2790			0.16,0.33	0.61						1	24					KCNAB2 (inh=AD pLI=0.78)
chr1	6052581	6052581	G	A	hom	hom	het	off-target	QUAL=1351;DP=2,34,28;AF=1.00,1.00,0.68;MQM=60	KCNAB2	5'UTR,intron	KCNAB2:ENST00000378097:5_prime_UTR_variant:MODIFIER:exon1/16:c.-320G>A::,KCNAB2:ENST00000378111:intron_variant:MODIFIER:exon1/7:c.-53+965G>A::					rs806109	0.9024	0.8323	10792,			0.0500			0.10,0.21	0.47						n/a (AF>5%)	n/a (AF>5%)					KCNAB2 (inh=AD pLI=0.78)
chr1	6526183	6526183	G	A	het	het	wt		QUAL=375;DP=14,20,5;AF=0.43,0.70,0.00;MQM=59	PLEKHG5,TNFRSF25	3'UTR,5'UTR	PLEKHG5:ENST00000340850:3_prime_UTR_variant:MODIFIER:exon21/21:c.*1440C>T::,TNFRSF25:ENST00000351959:5_prime_UTR_variant:MODIFIER:exon1/9:c.-16C>T::,TNFRSF25:ENST00000356876:5_prime_UTR_variant:MODIFIER:exon1/10:c.-16C>T::,PLEKHG5:ENST00000377748:3_prime_UTR_variant:MODIFIER:exon22/22:c.*1440C>T::,TNFRSF25:ENST00000377782:5_prime_UTR_variant:MODIFIER:exon1/10:c.-16C>T::,PLEKHG5:ENST00000400913:3_prime_UTR_variant:MODIFIER:exon21/21:c.*1440C>T::	611101 [PLEKHG5 (confirmed) Spinal muscular atrophy,distal,autosomal recessive,4,611067/Charcot-Marie-Tooth disease,recessive intermediate C,615376];	297904 [benign DISEASE=Distal spinal muscular atrophy];			rs3007417	0.2023	0.1849	1067,	0.5065,0.0514,0.0000,0.0711,0.0791	0.0577,0.3759	-0.6580			0.06,0.14	0.41						n/a (AF>5%)	n/a (AF>5%)					PLEKHG5 (inh=AR pLI=0.00), TNFRSF25 (inh=n/a pLI=0.36)
chr1	6526203	6526210	CGTGCTCT	-	het	het	wt		QUAL=377;DP=12,21,6;AF=0.58,0.67,0.00;MQM=59	PLEKHG5,TNFRSF25	3'UTR,5'UTR	PLEKHG5:ENST00000340850:3_prime_UTR_variant:MODIFIER:exon21/21:c.*1413_*1420del::,TNFRSF25:ENST00000351959:5_prime_UTR_variant:MODIFIER:exon1/9:c.-43_-36del::,TNFRSF25:ENST00000356876:5_prime_UTR_variant:MODIFIER:exon1/10:c.-43_-36del::,PLEKHG5:ENST00000377748:3_prime_UTR_variant:MODIFIER:exon22/22:c.*1413_*1420del::,TNFRSF25:ENST00000377782:5_prime_UTR_variant:MODIFIER:exon1/10:c.-43_-36del::,PLEKHG5:ENST00000400913:3_prime_UTR_variant:MODIFIER:exon21/21:c.*1413_*1420del::	611101 [PLEKHG5 (confirmed) Spinal muscular atrophy,distal,autosomal recessive,4,611067/Charcot-Marie-Tooth disease,recessive intermediate C,615376];	297905 [benign DISEASE=Distal spinal muscular atrophy];			rs45616733	0.2027	0.1845	1053,	0.4307,0.0470,0.0000,0.0586,0.0691	0.0512,0.3970	0.8620				0.57						n/a (AF>5%)	n/a (AF>5%)					PLEKHG5 (inh=AR pLI=0.00), TNFRSF25 (inh=n/a pLI=0.36)
chr1	6526241	6526244	CGCC	-	hom	het	wt		QUAL=331;DP=5,15,3;AF=1.00,0.73,0.00;MQM=60	PLEKHG5,TNFRSF25	3'UTR,5'UTR	PLEKHG5:ENST00000340850:3_prime_UTR_variant:MODIFIER:exon21/21:c.*1379_*1382del::,TNFRSF25:ENST00000356876:5_prime_UTR_variant:MODIFIER:exon1/10:c.-77_-74del::,PLEKHG5:ENST00000377748:3_prime_UTR_variant:MODIFIER:exon22/22:c.*1379_*1382del::,PLEKHG5:ENST00000400913:3_prime_UTR_variant:MODIFIER:exon21/21:c.*1379_*1382del::	611101 [PLEKHG5 (confirmed) Spinal muscular atrophy,distal,autosomal recessive,4,611067/Charcot-Marie-Tooth disease,recessive intermediate C,615376];	297906 [benign DISEASE=Distal spinal muscular atrophy];			rs45542640	0.2025	0.1844	1072,		0.0517,0.4246	1.0930				0.25						n/a (AF>5%)	n/a (AF>5%)					PLEKHG5 (inh=AR pLI=0.00), TNFRSF25 (inh=n/a pLI=0.36)
chr1	6526319	6526319	C	T	het	het	wt		QUAL=302;DP=31,33,30;AF=0.35,0.39,0.00;MQM=60	PLEKHG5	3'UTR	PLEKHG5:ENST00000340850:3_prime_UTR_variant:MODIFIER:exon21/21:c.*1304G>A::,PLEKHG5:ENST00000377748:3_prime_UTR_variant:MODIFIER:exon22/22:c.*1304G>A::,PLEKHG5:ENST00000400913:3_prime_UTR_variant:MODIFIER:exon21/21:c.*1304G>A::	611101 [PLEKHG5 (confirmed) Spinal muscular atrophy,distal,autosomal recessive,4,611067/Charcot-Marie-Tooth disease,recessive intermediate C,615376];	297910 [likely benign DISEASE=Distal spinal muscular atrophy];			rs45604837	0.0863	0.0837	162,			-0.5600			0.05,0.16	0.14						n/a (AF>5%)	n/a (AF>5%)					PLEKHG5 (inh=AR pLI=0.00)
chr1	6526465	6526465	C	G	het	het	wt		QUAL=3432;DP=81,199,150;AF=0.48,0.54,0.00;MQM=60	PLEKHG5	3'UTR	PLEKHG5:ENST00000340850:3_prime_UTR_variant:MODIFIER:exon21/21:c.*1158G>C::,PLEKHG5:ENST00000377748:3_prime_UTR_variant:MODIFIER:exon22/22:c.*1158G>C::,PLEKHG5:ENST00000400913:3_prime_UTR_variant:MODIFIER:exon21/21:c.*1158G>C::	611101 [PLEKHG5 (confirmed) Spinal muscular atrophy,distal,autosomal recessive,4,611067/Charcot-Marie-Tooth disease,recessive intermediate C,615376];	297912 [benign DISEASE=Distal spinal muscular atrophy];		MIR3	rs2986754	0.2043	0.1820	1156,			-0.5720			0.01,0.10	-0.12						n/a (AF>5%)	n/a (AF>5%)					PLEKHG5 (inh=AR pLI=0.00)
chr1	6526858	6526858	A	-	het	het	het		QUAL=253;DP=45,6,6;AF=0.24,0.17,0.50;MQM=60	PLEKHG5	3'UTR	PLEKHG5:ENST00000340850:3_prime_UTR_variant:MODIFIER:exon21/21:c.*765del::,PLEKHG5:ENST00000377748:3_prime_UTR_variant:MODIFIER:exon22/22:c.*765del::,PLEKHG5:ENST00000400913:3_prime_UTR_variant:MODIFIER:exon21/21:c.*765del::	611101 [PLEKHG5 (confirmed) Spinal muscular atrophy,distal,autosomal recessive,4,611067/Charcot-Marie-Tooth disease,recessive intermediate C,615376];	297922 [uncertain significance DISEASE=Distal spinal muscular atrophy];		AluSz	rs372197062		0.0925	182,			-2.9090				-0.46						n/a (AF>5%)	n/a (AF>5%)					PLEKHG5 (inh=AR pLI=0.00)
chr1	6527333	6527333	A	G	het	het	wt		QUAL=1596;DP=76,59,53;AF=0.51,0.47,0.00;MQM=60	PLEKHG5	3'UTR	PLEKHG5:ENST00000340850:3_prime_UTR_variant:MODIFIER:exon21/21:c.*290T>C::,PLEKHG5:ENST00000377725:3_prime_UTR_variant:MODIFIER:exon22/22:c.*318T>C::,PLEKHG5:ENST00000377728:3_prime_UTR_variant:MODIFIER:exon21/21:c.*290T>C::,PLEKHG5:ENST00000377732:3_prime_UTR_variant:MODIFIER:exon21/21:c.*290T>C::,PLEKHG5:ENST00000377737:3_prime_UTR_variant:MODIFIER:exon22/22:c.*290T>C::,PLEKHG5:ENST00000377740:3_prime_UTR_variant:MODIFIER:exon22/22:c.*290T>C::,PLEKHG5:ENST00000377748:3_prime_UTR_variant:MODIFIER:exon22/22:c.*290T>C::,PLEKHG5:ENST00000400913:3_prime_UTR_variant:MODIFIER:exon21/21:c.*290T>C::,PLEKHG5:ENST00000400915:3_prime_UTR_variant:MODIFIER:exon22/22:c.*290T>C::,PLEKHG5:ENST00000535355:3_prime_UTR_variant:MODIFIER:exon21/21:c.*290T>C::	611101 [PLEKHG5 (confirmed) Spinal muscular atrophy,distal,autosomal recessive,4,611067/Charcot-Marie-Tooth disease,recessive intermediate C,615376];	297928 [benign DISEASE=Distal spinal muscular atrophy];			rs14708	0.2670	0.2637	1687,			2.0370			0.00,0.11	0.75						n/a (AF>5%)	n/a (AF>5%)					PLEKHG5 (inh=AR pLI=0.00)
chr1	6529183	6529185	TCC	-	het	het	wt		QUAL=1167;DP=40,101,58;AF=0.40,0.45,0.05;MQM=60	PLEKHG5	inframe_deletion	PLEKHG5:ENST00000340850:inframe_deletion:MODERATE:exon19/21:c.2166_2168del:p.Glu723del:,PLEKHG5:ENST00000377725:inframe_deletion:MODERATE:exon19/22:c.2166_2168del:p.Glu723del:,PLEKHG5:ENST00000377728:inframe_deletion:MODERATE:exon19/21:c.2166_2168del:p.Glu723del:,PLEKHG5:ENST00000377732:inframe_deletion:MODERATE:exon19/21:c.2277_2279del:p.Glu760del:,PLEKHG5:ENST00000377737:inframe_deletion:MODERATE:exon20/22:c.2166_2168del:p.Glu723del:,PLEKHG5:ENST00000377740:inframe_deletion:MODERATE:exon20/22:c.2397_2399del:p.Glu800del:,PLEKHG5:ENST00000377748:inframe_deletion:MODERATE:exon20/22:c.2397_2399del:p.Glu800del:,PLEKHG5:ENST00000400913:inframe_deletion:MODERATE:exon19/21:c.2166_2168del:p.Glu723del:,PLEKHG5:ENST00000400915:inframe_deletion:MODERATE:exon20/22:c.2334_2336del:p.Glu779del:,PLEKHG5:ENST00000535355:inframe_deletion:MODERATE:exon19/21:c.2373_2375del:p.Glu792del:,PLEKHG5:ENST00000537245:inframe_deletion:MODERATE:exon20/22:c.2403_2405del:p.Glu802del:,PLEKHG5:ENST00000544978:inframe_deletion:MODERATE:exon20/22:c.2166_2168del:p.Glu723del:	611101 [PLEKHG5 (confirmed) Spinal muscular atrophy,distal,autosomal recessive,4,611067/Charcot-Marie-Tooth disease,recessive intermediate C,615376];	194979 [benign/likely benign DISEASE=Distal spinal muscular atrophy,not specified];		(TCC)n	rs113541584	0.0972	0.0841	133,	0.1909,0.0571,0.0088,0.0753,0.0955	0.1205,0.2668	0.1060				0.86					COSM4590012,COSM4590013,COSM911543	n/a (AF>5%)	n/a (AF>5%)					PLEKHG5 (inh=AR pLI=0.00)
chr1	6529443	6529443	A	G	het	het	wt		QUAL=9663;DP=320,488,391;AF=0.48,0.48,0.00;MQM=60	PLEKHG5	synonymous	PLEKHG5:ENST00000340850:synonymous_variant:LOW:exon18/21:c.2001T>C:p.Ser667=:,PLEKHG5:ENST00000377725:synonymous_variant:LOW:exon18/22:c.2001T>C:p.Ser667=:,PLEKHG5:ENST00000377728:synonymous_variant:LOW:exon18/21:c.2001T>C:p.Ser667=:,PLEKHG5:ENST00000377732:synonymous_variant:LOW:exon18/21:c.2112T>C:p.Ser704=:,PLEKHG5:ENST00000377737:synonymous_variant:LOW:exon19/22:c.2001T>C:p.Ser667=:,PLEKHG5:ENST00000377740:synonymous_variant:LOW:exon19/22:c.2232T>C:p.Ser744=:,PLEKHG5:ENST00000377748:synonymous_variant:LOW:exon19/22:c.2232T>C:p.Ser744=:,PLEKHG5:ENST00000400913:synonymous_variant:LOW:exon18/21:c.2001T>C:p.Ser667=:,PLEKHG5:ENST00000400915:synonymous_variant:LOW:exon19/22:c.2169T>C:p.Ser723=:,PLEKHG5:ENST00000535355:synonymous_variant:LOW:exon18/21:c.2208T>C:p.Ser736=:,PLEKHG5:ENST00000537245:synonymous_variant:LOW:exon19/22:c.2238T>C:p.Ser746=:,PLEKHG5:ENST00000544978:synonymous_variant:LOW:exon19/22:c.2001T>C:p.Ser667=:	611101 [PLEKHG5 (confirmed) Spinal muscular atrophy,distal,autosomal recessive,4,611067/Charcot-Marie-Tooth disease,recessive intermediate C,615376];	194881 [benign DISEASE=Distal spinal muscular atrophy,not specified];			rs730600	0.2696	0.2653	1708,	0.5957,0.0929,0.0044,0.1427,0.1768	0.1403,0.5738	-0.2200			0.08,0.79	1.36						n/a (AF>5%)	n/a (AF>5%)					PLEKHG5 (inh=AR pLI=0.00)
chr1	6530435	6530435	A	G	het	het	wt	off-target	QUAL=1088;DP=39,55,49;AF=0.46,0.53,0.00;MQM=60	PLEKHG5	intron	PLEKHG5:ENST00000340850:intron_variant:MODIFIER:exon15/20:c.1681-20T>C::,PLEKHG5:ENST00000377725:intron_variant:MODIFIER:exon15/21:c.1681-20T>C::,PLEKHG5:ENST00000377728:intron_variant:MODIFIER:exon15/20:c.1681-20T>C::,PLEKHG5:ENST00000377732:intron_variant:MODIFIER:exon15/20:c.1792-20T>C::,PLEKHG5:ENST00000377737:intron_variant:MODIFIER:exon16/21:c.1681-20T>C::,PLEKHG5:ENST00000377740:intron_variant:MODIFIER:exon16/21:c.1912-20T>C::,PLEKHG5:ENST00000377748:intron_variant:MODIFIER:exon16/21:c.1912-20T>C::,PLEKHG5:ENST00000400913:intron_variant:MODIFIER:exon15/20:c.1681-20T>C::,PLEKHG5:ENST00000400915:intron_variant:MODIFIER:exon16/21:c.1849-20T>C::,PLEKHG5:ENST00000535355:intron_variant:MODIFIER:exon15/20:c.1888-20T>C::,PLEKHG5:ENST00000537245:intron_variant:MODIFIER:exon16/21:c.1918-20T>C::,PLEKHG5:ENST00000544978:intron_variant:MODIFIER:exon16/21:c.1681-20T>C::	611101 [PLEKHG5 (confirmed) Spinal muscular atrophy,distal,autosomal recessive,4,611067/Charcot-Marie-Tooth disease,recessive intermediate C,615376];				rs2986753	0.1717	0.1807	630,	0.3439,0.0768,0.0042,0.1305,0.1520	0.1273,0.3334	-0.4640			0.01,0.12	0.22		-0.43% (7.80>7.76)				n/a (AF>5%)	n/a (AF>5%)					PLEKHG5 (inh=AR pLI=0.00)
chr1	6530965	6530965	-	G	hom	hom	hom	off-target	QUAL=5974;DP=39,123,91;AF=0.92,0.99,0.97;MQM=60	PLEKHG5	intron	PLEKHG5:ENST00000340850:intron_variant:MODIFIER:exon13/20:c.1393-22dup::,PLEKHG5:ENST00000377725:intron_variant:MODIFIER:exon13/21:c.1393-22dup::,PLEKHG5:ENST00000377728:intron_variant:MODIFIER:exon13/20:c.1393-22dup::,PLEKHG5:ENST00000377732:intron_variant:MODIFIER:exon13/20:c.1504-22dup::,PLEKHG5:ENST00000377737:intron_variant:MODIFIER:exon14/21:c.1393-22dup::,PLEKHG5:ENST00000377740:intron_variant:MODIFIER:exon14/21:c.1624-22dup::,PLEKHG5:ENST00000377748:intron_variant:MODIFIER:exon14/21:c.1624-22dup::,PLEKHG5:ENST00000400913:intron_variant:MODIFIER:exon13/20:c.1393-22dup::,PLEKHG5:ENST00000400915:intron_variant:MODIFIER:exon14/21:c.1561-22dup::,PLEKHG5:ENST00000535355:intron_variant:MODIFIER:exon13/20:c.1600-22dup::,PLEKHG5:ENST00000537245:intron_variant:MODIFIER:exon14/21:c.1630-22dup::,PLEKHG5:ENST00000544978:intron_variant:MODIFIER:exon14/21:c.1393-22dup::	611101 [PLEKHG5 (confirmed) Spinal muscular atrophy,distal,autosomal recessive,4,611067/Charcot-Marie-Tooth disease,recessive intermediate C,615376];				rs111312565	1.0000	1.0000	15287,	1.0000,1.0000,0.9999,1.0000,1.0000	0.9927,0.9948					0.05						n/a (AF>5%)	n/a (AF>5%)					PLEKHG5 (inh=AR pLI=0.00)
chr1	6531589	6531589	C	T	het	het	wt		QUAL=1652;DP=36,114,115;AF=0.67,0.45,0.00;MQM=60	PLEKHG5	missense	PLEKHG5:ENST00000340850:missense_variant:MODERATE:exon12/21:c.1240G>A:p.Ala414Thr:PF00621,PLEKHG5:ENST00000377725:missense_variant:MODERATE:exon12/22:c.1240G>A:p.Ala414Thr:PF00621,PLEKHG5:ENST00000377728:missense_variant:MODERATE:exon12/21:c.1240G>A:p.Ala414Thr:PF00621,PLEKHG5:ENST00000377732:missense_variant:MODERATE:exon12/21:c.1351G>A:p.Ala451Thr:PF00621,PLEKHG5:ENST00000377737:missense_variant:MODERATE:exon13/22:c.1240G>A:p.Ala414Thr:PF00621,PLEKHG5:ENST00000377740:missense_variant:MODERATE:exon13/22:c.1471G>A:p.Ala491Thr:PF00621,PLEKHG5:ENST00000377748:missense_variant:MODERATE:exon13/22:c.1471G>A:p.Ala491Thr:PF00621,PLEKHG5:ENST00000400913:missense_variant:MODERATE:exon12/21:c.1240G>A:p.Ala414Thr:PF00621,PLEKHG5:ENST00000400915:missense_variant:MODERATE:exon13/22:c.1408G>A:p.Ala470Thr:PF00621,PLEKHG5:ENST00000535355:missense_variant:MODERATE:exon12/21:c.1447G>A:p.Ala483Thr:PF00621,PLEKHG5:ENST00000537245:missense_variant:MODERATE:exon13/22:c.1477G>A:p.Ala493Thr:PF00621,PLEKHG5:ENST00000544978:missense_variant:MODERATE:exon13/22:c.1240G>A:p.Ala414Thr:PF00621	611101 [PLEKHG5 (confirmed) Spinal muscular atrophy,distal,autosomal recessive,4,611067/Charcot-Marie-Tooth disease,recessive intermediate C,615376];	297959 [likely benign DISEASE=Distal spinal muscular atrophy];			rs74809741	0.0553	0.0573	68,	0.0876,0.0366,0.0002,0.0594,0.0522	0.0575,0.0878	0.6400	T,T,T,T,T,T,T,T,T,T,T,T	B,B,B,B,B,B,B,B,B,B,B,B	0.73,0.93	1.48	0.04					n/a (AF>5%)	n/a (AF>5%)					PLEKHG5 (inh=AR pLI=0.00)
chr1	6533393	6533393	G	C	het	het	wt		QUAL=479;DP=25,25,19;AF=0.44,0.56,0.00;MQM=60	PLEKHG5	missense	PLEKHG5:ENST00000340850:missense_variant:MODERATE:exon8/21:c.713C>G:p.Thr238Ser:,PLEKHG5:ENST00000377725:missense_variant:MODERATE:exon8/22:c.713C>G:p.Thr238Ser:,PLEKHG5:ENST00000377728:missense_variant:MODERATE:exon8/21:c.713C>G:p.Thr238Ser:,PLEKHG5:ENST00000377732:missense_variant:MODERATE:exon8/21:c.824C>G:p.Thr275Ser:,PLEKHG5:ENST00000377737:missense_variant:MODERATE:exon9/22:c.713C>G:p.Thr238Ser:,PLEKHG5:ENST00000377740:missense_variant:MODERATE:exon9/22:c.944C>G:p.Thr315Ser:,PLEKHG5:ENST00000377748:missense_variant:MODERATE:exon9/22:c.944C>G:p.Thr315Ser:,PLEKHG5:ENST00000400913:missense_variant:MODERATE:exon8/21:c.713C>G:p.Thr238Ser:,PLEKHG5:ENST00000400915:missense_variant:MODERATE:exon9/22:c.881C>G:p.Thr294Ser:,PLEKHG5:ENST00000535355:missense_variant:MODERATE:exon8/21:c.920C>G:p.Thr307Ser:,PLEKHG5:ENST00000537245:missense_variant:MODERATE:exon9/22:c.950C>G:p.Thr317Ser:,PLEKHG5:ENST00000544978:missense_variant:MODERATE:exon9/22:c.713C>G:p.Thr238Ser:	611101 [PLEKHG5 (confirmed) Spinal muscular atrophy,distal,autosomal recessive,4,611067/Charcot-Marie-Tooth disease,recessive intermediate C,615376];	198895 [benign DISEASE=Distal spinal muscular atrophy,not specified];			rs61741379	0.2857	0.2792	1990,	0.6476,0.0988,0.0073,0.1413,0.1629	0.1280,0.5571	0.8480	T,T,T,T,T,T,T,T,T,T,T,T	B,B,B,B,B,B,B,B,B,B,B,B	0.00,0.17	-0.22	0.07					n/a (AF>5%)	n/a (AF>5%)					PLEKHG5 (inh=AR pLI=0.00)
chr1	6579521	6579521	G	C	het	het	het		QUAL=3399;DP=121,91,77;AF=0.53,0.52,0.45;MQM=60	PLEKHG5	5'UTR,missense	PLEKHG5:ENST00000377737:5_prime_UTR_variant:MODIFIER:exon1/22:c.-181C>G::,PLEKHG5:ENST00000377740:missense_variant:MODERATE:exon1/22:c.51C>G:p.Ser17Arg:,PLEKHG5:ENST00000377748:missense_variant:MODERATE:exon1/22:c.51C>G:p.Ser17Arg:	611101 [PLEKHG5 (confirmed) Spinal muscular atrophy,distal,autosomal recessive,4,611067/Charcot-Marie-Tooth disease,recessive intermediate C,615376];				rs17438786	0.0136	0.0245	11,	0.0052,0.0165,0.0000,0.0327,0.0181	0.0301,0.0062	0.0870	 ,T,T	 ,B,B	0.13,0.49	0.54	0.09					2	238					PLEKHG5 (inh=AR pLI=0.00)
chr1	6579607	6579607	C	T	hom	hom	hom		QUAL=20031;DP=180,270,204;AF=1.00,1.00,1.00;MQM=59	PLEKHG5	5'UTR	PLEKHG5:ENST00000377737:5_prime_UTR_variant:MODIFIER:exon1/22:c.-267G>A::,PLEKHG5:ENST00000377740:5_prime_UTR_variant:MODIFIER:exon1/22:c.-36G>A::,PLEKHG5:ENST00000377748:5_prime_UTR_variant:MODIFIER:exon1/22:c.-36G>A::	611101 [PLEKHG5 (confirmed) Spinal muscular atrophy,distal,autosomal recessive,4,611067/Charcot-Marie-Tooth disease,recessive intermediate C,615376];	380860 [benign DISEASE=not specified];			rs1556035	0.7460	0.8596	9844,	0.5162,0.9260,0.7940,0.8821,0.8643	0.8862,0.5486	0.2500			0.07,0.20	0.23						n/a (AF>5%)	n/a (AF>5%)					PLEKHG5 (inh=AR pLI=0.00)
chr1	6579843	6579843	C	T	hom	hom	hom		QUAL=41883;DP=292,586,454;AF=0.99,1.00,1.00;MQM=59	PLEKHG5	5'UTR	PLEKHG5:ENST00000377737:5_prime_UTR_variant:MODIFIER:exon1/22:c.-503G>A::,PLEKHG5:ENST00000377740:5_prime_UTR_variant:MODIFIER:exon1/22:c.-272G>A::,PLEKHG5:ENST00000377748:5_prime_UTR_variant:MODIFIER:exon1/22:c.-272G>A::	611101 [PLEKHG5 (confirmed) Spinal muscular atrophy,distal,autosomal recessive,4,611067/Charcot-Marie-Tooth disease,recessive intermediate C,615376];				rs1010584	0.7354	0.7728	9605,			-0.5650			0.03,0.20	0.18						n/a (AF>5%)	n/a (AF>5%)					PLEKHG5 (inh=AR pLI=0.00)
chr1	10318652	10318652	C	G	wt	wt	het		QUAL=2875;DP=314,250,229;AF=0.00,0.00,0.50;MQM=60	KIF1B	synonymous	KIF1B:ENST00000263934:synonymous_variant:LOW:exon4/47:c.285C>G:p.Ala95=:PF00225,KIF1B:ENST00000377081:synonymous_variant:LOW:exon3/48:c.285C>G:p.Ala95=:PF00225,KIF1B:ENST00000377083:synonymous_variant:LOW:exon4/21:c.285C>G:p.Ala95=:PF00225,KIF1B:ENST00000377086:synonymous_variant:LOW:exon4/49:c.285C>G:p.Ala95=:PF00225,KIF1B:ENST00000377093:synonymous_variant:LOW:exon4/21:c.285C>G:p.Ala95=:PF00225	605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210/Pheochromocytoma,171300/Neuroblastoma,susceptibility to,1,256700];	129399 [benign DISEASE=Pheochromocytoma,Neuroblastoma,Charcot-Marie-Tooth disease, type 2,not specified];			rs12402052	0.2300	0.2765	1019,	0.0847,0.3428,0.2909,0.2913,0.2300	0.2969,0.0915	0.0540			0.81,0.97	0.79						n/a (AF>5%)	n/a (AF>5%)					KIF1B (inh=AD pLI=1.00)
chr1	10322054	10322054	G	A	wt	wt	het	off-target	QUAL=2023;DP=314,272,179;AF=0.00,0.00,0.46;MQM=60	KIF1B	intron	KIF1B:ENST00000263934:intron_variant:MODIFIER:exon5/46:c.429+26G>A::,KIF1B:ENST00000377081:intron_variant:MODIFIER:exon4/47:c.429+26G>A::,KIF1B:ENST00000377083:intron_variant:MODIFIER:exon5/20:c.429+26G>A::,KIF1B:ENST00000377086:intron_variant:MODIFIER:exon5/48:c.429+26G>A::,KIF1B:ENST00000377093:intron_variant:MODIFIER:exon5/20:c.429+26G>A::	605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210/Pheochromocytoma,171300/Neuroblastoma,susceptibility to,1,256700];				rs4846209	0.3399	0.3514	1911,	0.3424,0.3922,0.3668,0.3434,0.2584	0.3488,0.3323	0.0780			0.00,0.08	0.04						n/a (AF>5%)	n/a (AF>5%)					KIF1B (inh=AD pLI=1.00)
chr1	10327407	10327407	A	T	wt	wt	het	off-target	QUAL=1115;DP=257,131,100;AF=0.00,0.00,0.50;MQM=60	KIF1B	intron	KIF1B:ENST00000263934:intron_variant:MODIFIER:exon5/46:c.430-31A>T::,KIF1B:ENST00000377081:intron_variant:MODIFIER:exon4/47:c.430-31A>T::,KIF1B:ENST00000377083:intron_variant:MODIFIER:exon5/20:c.430-31A>T::,KIF1B:ENST00000377086:intron_variant:MODIFIER:exon5/48:c.430-31A>T::,KIF1B:ENST00000377093:intron_variant:MODIFIER:exon5/20:c.430-31A>T::	605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210/Pheochromocytoma,171300/Neuroblastoma,susceptibility to,1,256700];				rs12141246	0.3806	0.3772	2218,	0.4135,0.3959,0.4074,0.3428,0.2583	0.3499,0.4094	-1.8450			0.00,0.07	-0.04						n/a (AF>5%)	n/a (AF>5%)					KIF1B (inh=AD pLI=1.00)
chr1	10328338	10328338	C	T	wt	wt	het	off-target	QUAL=2382;DP=242,187,186;AF=0.00,0.00,0.52;MQM=60	KIF1B	intron	KIF1B:ENST00000263934:intron_variant:MODIFIER:exon7/46:c.720+17C>T::,KIF1B:ENST00000377081:intron_variant:MODIFIER:exon6/47:c.720+17C>T::,KIF1B:ENST00000377083:intron_variant:MODIFIER:exon7/20:c.720+17C>T::,KIF1B:ENST00000377086:intron_variant:MODIFIER:exon7/48:c.720+17C>T::,KIF1B:ENST00000377093:intron_variant:MODIFIER:exon7/20:c.720+17C>T::	605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210/Pheochromocytoma,171300/Neuroblastoma,susceptibility to,1,256700];	260542 [benign DISEASE=not specified];			rs1339458	0.2540	0.2815	1086,	0.1539,0.3470,0.2897,0.2916,0.2306	0.2970,0.1530	-1.1960			0.06,0.15	0.18						n/a (AF>5%)	n/a (AF>5%)					KIF1B (inh=AD pLI=1.00)
chr1	10342629	10342629	G	A	wt	het	het	off-target	QUAL=5605;DP=180,224,219;AF=0.01,0.50,0.49;MQM=60	KIF1B	intron	KIF1B:ENST00000263934:intron_variant:MODIFIER:exon13/46:c.1296+38G>A::,KIF1B:ENST00000377081:intron_variant:MODIFIER:exon14/47:c.1434+38G>A::,KIF1B:ENST00000377083:intron_variant:MODIFIER:exon13/20:c.1296+38G>A::,KIF1B:ENST00000377086:intron_variant:MODIFIER:exon15/48:c.1434+38G>A::,KIF1B:ENST00000377093:intron_variant:MODIFIER:exon13/20:c.1296+38G>A::	605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210/Pheochromocytoma,171300/Neuroblastoma,susceptibility to,1,256700];			L3	rs3748576	0.7127	0.7067	8032,	0.9349,0.7352,0.5300,0.5980,0.6220	0.6030,0.9163	-0.7550			0.01,0.13	0.01						n/a (AF>5%)	n/a (AF>5%)					KIF1B (inh=AD pLI=1.00)
chr1	10355834	10355834	C	T	wt	wt	het		QUAL=1539;DP=134,158,128;AF=0.01,0.00,0.48;MQM=60	KIF1B	intron	KIF1B:ENST00000263934:intron_variant:MODIFIER:exon17/46:c.1639+10C>T::,KIF1B:ENST00000377081:intron_variant:MODIFIER:exon18/47:c.1777+10C>T::,KIF1B:ENST00000377083:intron_variant:MODIFIER:exon17/20:c.1639+10C>T::,KIF1B:ENST00000377086:intron_variant:MODIFIER:exon19/48:c.1777+10C>T::,KIF1B:ENST00000377093:intron_variant:MODIFIER:exon17/20:c.1639+10C>T::	605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210/Pheochromocytoma,171300/Neuroblastoma,susceptibility to,1,256700];	177960 [benign DISEASE=Pheochromocytoma,Neuroblastoma,Charcot-Marie-Tooth disease, type 2,not specified];			rs3753037	0.2640	0.2841	1139,	0.1878,0.3488,0.2905,0.2918,0.2303	0.2970,0.1861	1.0480			0.09,0.20	0.09						n/a (AF>5%)	n/a (AF>5%)					KIF1B (inh=AD pLI=1.00)
chr1	10357207	10357207	T	-	het	het	het	off-target	QUAL=3030;DP=140,220,157;AF=0.34,0.30,0.29;MQM=60	KIF1B	intron	KIF1B:ENST00000263934:intron_variant:MODIFIER:exon19/46:c.1905-9del::,KIF1B:ENST00000377081:intron_variant:MODIFIER:exon20/47:c.2043-9del::,KIF1B:ENST00000377083:intron_variant:MODIFIER:exon19/20:c.1905-9del::,KIF1B:ENST00000377086:intron_variant:MODIFIER:exon21/48:c.2043-9del::,KIF1B:ENST00000377093:intron_variant:MODIFIER:exon19/20:c.1905-9del::	605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210/Pheochromocytoma,171300/Neuroblastoma,susceptibility to,1,256700];			(T)n	rs199617049		0.4227	0,	0.4280,0.4278,0.4248,0.4265,0.4314		-0.0240				-0.64						n/a (AF>5%)	n/a (AF>5%)					KIF1B (inh=AD pLI=1.00)
chr1	10366487	10366487	T	G	wt	wt	het		QUAL=2585;DP=248,227,230;AF=0.00,0.00,0.45;MQM=60	KIF1B	intron,3'UTR	KIF1B:ENST00000263934:intron_variant:MODIFIER:exon20/46:c.1977+9183T>G::,KIF1B:ENST00000377081:intron_variant:MODIFIER:exon21/47:c.2115+9183T>G::,KIF1B:ENST00000377083:3_prime_UTR_variant:MODIFIER:exon21/21:c.*1782T>G::,KIF1B:ENST00000377086:intron_variant:MODIFIER:exon22/48:c.2115+9183T>G::,KIF1B:ENST00000377093:3_prime_UTR_variant:MODIFIER:exon21/21:c.*1782T>G::	605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210/Pheochromocytoma,171300/Neuroblastoma,susceptibility to,1,256700];				rs8019	0.3838	0.3972	2435,			0.6540			0.00,0.09	-0.03						n/a (AF>5%)	n/a (AF>5%)					KIF1B (inh=AD pLI=1.00)
chr1	10366692	10366692	C	G	wt	wt	het		QUAL=2901;DP=288,280,253;AF=0.00,0.00,0.47;MQM=60	KIF1B,RN7SL731P	intron,3'UTR,non_coding_transcript_exon	KIF1B:ENST00000263934:intron_variant:MODIFIER:exon20/46:c.1977+9388C>G::,KIF1B:ENST00000377081:intron_variant:MODIFIER:exon21/47:c.2115+9388C>G::,KIF1B:ENST00000377083:3_prime_UTR_variant:MODIFIER:exon21/21:c.*1987C>G::,KIF1B:ENST00000377086:intron_variant:MODIFIER:exon22/48:c.2115+9388C>G::,KIF1B:ENST00000377093:3_prime_UTR_variant:MODIFIER:exon21/21:c.*1987C>G::,RN7SL731P:ENST00000584329:non_coding_transcript_exon_variant:MODIFIER:exon1/1:n.170C>G::	605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210/Pheochromocytoma,171300/Neuroblastoma,susceptibility to,1,256700];			7SLRNA	rs4623	0.3343	0.3431	1821,			-0.5090			0.00,0.03	0.10						n/a (AF>5%)	n/a (AF>5%)					KIF1B (inh=AD pLI=1.00), RN7SL731P (inh=n/a pLI=n/a)
chr1	10367424	10367424	G	A	wt	wt	het		QUAL=343;DP=114,47,43;AF=0.01,0.00,0.42;MQM=60	KIF1B	intron,3'UTR	KIF1B:ENST00000263934:intron_variant:MODIFIER:exon20/46:c.1977+10120G>A::,KIF1B:ENST00000377081:intron_variant:MODIFIER:exon21/47:c.2115+10120G>A::,KIF1B:ENST00000377086:intron_variant:MODIFIER:exon22/48:c.2115+10120G>A::,KIF1B:ENST00000377093:3_prime_UTR_variant:MODIFIER:exon21/21:c.*2719G>A::	605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210/Pheochromocytoma,171300/Neuroblastoma,susceptibility to,1,256700];			AluSx	rs2004034	0.2316	0.2397	1027,			-0.1060			0.00,0.11	0.06						n/a (AF>5%)	n/a (AF>5%)					KIF1B (inh=AD pLI=1.00)
chr1	10367591	10367591	T	C	wt	wt	het		QUAL=1134;DP=189,99,87;AF=0.00,0.01,0.59;MQM=60	KIF1B	intron,3'UTR	KIF1B:ENST00000263934:intron_variant:MODIFIER:exon20/46:c.1977+10287T>C::,KIF1B:ENST00000377081:intron_variant:MODIFIER:exon21/47:c.2115+10287T>C::,KIF1B:ENST00000377086:intron_variant:MODIFIER:exon22/48:c.2115+10287T>C::,KIF1B:ENST00000377093:3_prime_UTR_variant:MODIFIER:exon21/21:c.*2886T>C::	605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210/Pheochromocytoma,171300/Neuroblastoma,susceptibility to,1,256700];			AluSx	rs1065828	0.3341	0.3431	1836,			-0.8920			0.00,0.03	0.07						n/a (AF>5%)	n/a (AF>5%)					KIF1B (inh=AD pLI=1.00)
chr1	10384176	10384176	-	TTGAAA	het	het	het	off-target	QUAL=5245;DP=226,183,142;AF=0.45,0.43,0.46;MQM=60	KIF1B	intron	KIF1B:ENST00000263934:intron_variant:MODIFIER:exon23/46:c.2399+57_2399+58insTGAAAT::,KIF1B:ENST00000377081:intron_variant:MODIFIER:exon24/47:c.2537+57_2537+58insTGAAAT::,KIF1B:ENST00000377086:intron_variant:MODIFIER:exon25/48:c.2537+57_2537+58insTGAAAT::	605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210/Pheochromocytoma,171300/Neuroblastoma,susceptibility to,1,256700];				rs3831405	0.2326	0.2378	946,							0.21						n/a (AF>5%)	n/a (AF>5%)					KIF1B (inh=AD pLI=1.00)
chr1	10394536	10394536	C	G	het	het	het	off-target	QUAL=8190;DP=248,219,152;AF=0.53,0.53,0.48;MQM=60	KIF1B	intron	KIF1B:ENST00000263934:intron_variant:MODIFIER:exon25/46:c.2787-42C>G::,KIF1B:ENST00000377081:intron_variant:MODIFIER:exon26/47:c.2925-42C>G::,KIF1B:ENST00000377086:intron_variant:MODIFIER:exon27/48:c.2925-42C>G::	605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210/Pheochromocytoma,171300/Neuroblastoma,susceptibility to,1,256700];				rs2276100	0.3339	0.3307	1700,	0.3240,0.3828,0.3666,0.3198,0.2627	0.3271,0.3248	-0.0570			0.09,0.23	0.27						n/a (AF>5%)	n/a (AF>5%)					KIF1B (inh=AD pLI=1.00)
chr1	10397080	10397080	A	G	wt	het	wt	off-target	QUAL=1131;DP=203,101,79;AF=0.00,0.47,0.00;MQM=60	KIF1B	intron	KIF1B:ENST00000263934:intron_variant:MODIFIER:exon27/46:c.2992-52A>G::,KIF1B:ENST00000377081:intron_variant:MODIFIER:exon28/47:c.3130-52A>G::,KIF1B:ENST00000377086:intron_variant:MODIFIER:exon29/48:c.3130-52A>G::	605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210/Pheochromocytoma,171300/Neuroblastoma,susceptibility to,1,256700];				rs71643087	0.0112	0.0277	16,		0.0311,0.0063	0.0100			0.01,0.20	0.08						4	222					KIF1B (inh=AD pLI=1.00)
chr1	10408838	10408838	T	-	het	wt	het	off-target	QUAL=127;DP=132,143,134;AF=0.17,0.10,0.17;MQM=59	KIF1B	intron	KIF1B:ENST00000263934:intron_variant:MODIFIER:exon35/46:c.3811+60del::,KIF1B:ENST00000377081:intron_variant:MODIFIER:exon36/47:c.3949+60del::,KIF1B:ENST00000377086:intron_variant:MODIFIER:exon37/48:c.3949+60del::	605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210/Pheochromocytoma,171300/Neuroblastoma,susceptibility to,1,256700];			FRAM	rs757373471		0.2820	3,	0.2287,0.3615,0.4275,0.2653,0.2578	0.2109,0.1990	1.6680				-0.16						n/a (AF>5%)	n/a (AF>5%)					KIF1B (inh=AD pLI=1.00)
chr1	10420937	10420937	C	T	het	het	het	off-target	QUAL=11890;DP=259,373,298;AF=0.51,0.50,0.51;MQM=59	KIF1B	intron	KIF1B:ENST00000263934:intron_variant:MODIFIER:exon36/46:c.3918-50C>T::,KIF1B:ENST00000377081:intron_variant:MODIFIER:exon37/47:c.4056-50C>T::,KIF1B:ENST00000377086:intron_variant:MODIFIER:exon38/48:c.4056-50C>T::	605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210/Pheochromocytoma,171300/Neuroblastoma,susceptibility to,1,256700];				rs3748579	0.3341	0.3301	1685,	0.3235,0.3825,0.3663,0.3196,0.2632	0.3267,0.3250	-0.4610			0.01,0.18	-0.03						n/a (AF>5%)	n/a (AF>5%)					KIF1B (inh=AD pLI=1.00)
chr1	10425118	10425118	T	-	het	het	het	off-target	QUAL=3241;DP=98,112,90;AF=0.47,0.53,0.46;MQM=60	KIF1B	intron	KIF1B:ENST00000263934:intron_variant:MODIFIER:exon39/46:c.4229-33del::,KIF1B:ENST00000377081:intron_variant:MODIFIER:exon40/47:c.4367-33del::,KIF1B:ENST00000377086:intron_variant:MODIFIER:exon41/48:c.4367-33del::	605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210/Pheochromocytoma,171300/Neuroblastoma,susceptibility to,1,256700];				rs34161257	0.5240	0.5248	4293,	0.6615,0.4685,0.3722,0.4751,0.4645		0.5110				0.10						n/a (AF>5%)	n/a (AF>5%)					KIF1B (inh=AD pLI=1.00)
chr1	10431158	10431158	T	C	het	het	het	off-target	QUAL=7043;DP=219,224,156;AF=0.45,0.53,0.47;MQM=60	KIF1B	intron	KIF1B:ENST00000263934:intron_variant:MODIFIER:exon42/46:c.4687-41T>C::,KIF1B:ENST00000377081:intron_variant:MODIFIER:exon43/47:c.4825-41T>C::,KIF1B:ENST00000377086:intron_variant:MODIFIER:exon44/48:c.4825-41T>C::	605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210/Pheochromocytoma,171300/Neuroblastoma,susceptibility to,1,256700];				rs17411502	0.2490	0.2838	1098,	0.1490,0.3475,0.2832,0.2956,0.2381	0.3003,0.1548	-0.7390			0.03,0.17	0.75						n/a (AF>5%)	n/a (AF>5%)					KIF1B (inh=AD pLI=1.00)
chr1	10435324	10435324	C	A	het	het	het		QUAL=7217;DP=295,148,115;AF=0.45,0.52,0.57;MQM=60	KIF1B	synonymous	KIF1B:ENST00000263934:synonymous_variant:LOW:exon46/47:c.5163C>A:p.Thr1721=:PF00169,KIF1B:ENST00000377081:synonymous_variant:LOW:exon47/48:c.5301C>A:p.Thr1767=:PF00169,KIF1B:ENST00000377086:synonymous_variant:LOW:exon48/49:c.5301C>A:p.Thr1767=:PF00169	605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210/Pheochromocytoma,171300/Neuroblastoma,susceptibility to,1,256700];	129401 [benign DISEASE=Pheochromocytoma,Neuroblastoma,Charcot-Marie-Tooth disease, type 2,not specified];			rs11121552	0.2316	0.2794	1032,	0.0857,0.3447,0.2840,0.2953,0.2380	0.3006,0.0937	-0.4200			0.27,0.97	0.40						n/a (AF>5%)	n/a (AF>5%)					KIF1B (inh=AD pLI=1.00)
chr1	10436892	10436892	-	AC	het	wt	het		QUAL=4095;DP=129,126,109;AF=0.78,0.52,0.32;MQM=59	KIF1B	3'UTR,intron	KIF1B:ENST00000263934:3_prime_UTR_variant:MODIFIER:exon47/47:c.*279_*280dup::,KIF1B:ENST00000377081:intron_variant:MODIFIER:exon47/47:c.5409-1473_5409-1472dup::,KIF1B:ENST00000377086:3_prime_UTR_variant:MODIFIER:exon49/49:c.*279_*280dup::	605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210/Pheochromocytoma,171300/Neuroblastoma,susceptibility to,1,256700];	291586 [uncertain significance DISEASE=Pheochromocytoma,Neuroblastoma,Charcot-Marie-Tooth disease, type 2];		(AC)n			0.0586	36,							-0.01						n/a (AF>5%)	n/a (AF>5%)					KIF1B (inh=AD pLI=1.00)
chr1	10436924	10436924	C	T	het	het	wt		QUAL=4095;DP=129,126,109;AF=0.78,0.52,0.32;MQM=59	KIF1B	3'UTR,intron	KIF1B:ENST00000263934:3_prime_UTR_variant:MODIFIER:exon47/47:c.*279C>T::,KIF1B:ENST00000377081:intron_variant:MODIFIER:exon47/47:c.5409-1473C>T::,KIF1B:ENST00000377086:3_prime_UTR_variant:MODIFIER:exon49/49:c.*279C>T::	605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210/Pheochromocytoma,171300/Neuroblastoma,susceptibility to,1,256700];	291594 [likely benign DISEASE=Pheochromocytoma,Neuroblastoma,Charcot-Marie-Tooth disease, type 2];		(AC)n	rs78490707	0.0403	0.0085	11,			-3.5950			0.04,0.22	-0.05						0	5					KIF1B (inh=AD pLI=1.00)
chr1	10438006	10438006	A	T	het	wt	het		QUAL=1323;DP=82,72,54;AF=0.45,0.00,0.48;MQM=59	KIF1B	intron,3'UTR	KIF1B:ENST00000377081:intron_variant:MODIFIER:exon47/47:c.5409-391A>T::,KIF1B:ENST00000377086:3_prime_UTR_variant:MODIFIER:exon49/49:c.*1361A>T::	605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210/Pheochromocytoma,171300/Neuroblastoma,susceptibility to,1,256700];	291610 [likely benign DISEASE=Pheochromocytoma,Neuroblastoma,Charcot-Marie-Tooth disease, type 2];		AluSg	rs2847347	0.0182	0.0362	21,			0.2110			0.16,0.23	0.01						1	26					KIF1B (inh=AD pLI=1.00)
chr1	10438687	10438687	C	T	het	het	het		QUAL=12143;DP=254,354,281;AF=0.56,0.51,0.51;MQM=60	KIF1B	3'UTR	KIF1B:ENST00000377081:3_prime_UTR_variant:MODIFIER:exon48/48:c.*227C>T::,KIF1B:ENST00000377086:3_prime_UTR_variant:MODIFIER:exon49/49:c.*2042C>T::	605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210/Pheochromocytoma,171300/Neuroblastoma,susceptibility to,1,256700];	291618 [benign DISEASE=Pheochromocytoma,Neuroblastoma,Charcot-Marie-Tooth disease, type 2];			rs1536262	0.5465	0.5499	4872,			-1.2450			0.03,0.16	-0.16						n/a (AF>5%)	n/a (AF>5%)					KIF1B (inh=AD pLI=1.00)
chr1	10438892	10438892	G	A	het	het	het		QUAL=8842;DP=282,193,160;AF=0.54,0.52,0.57;MQM=60	KIF1B	3'UTR	KIF1B:ENST00000377081:3_prime_UTR_variant:MODIFIER:exon48/48:c.*432G>A::,KIF1B:ENST00000377086:3_prime_UTR_variant:MODIFIER:exon49/49:c.*2247G>A::	605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210/Pheochromocytoma,171300/Neuroblastoma,susceptibility to,1,256700];	291619 [benign DISEASE=Pheochromocytoma,Neuroblastoma,Charcot-Marie-Tooth disease, type 2];			rs1002076	0.3337	0.3305	1696,			0.4730			0.09,0.20	-0.09						n/a (AF>5%)	n/a (AF>5%)					KIF1B (inh=AD pLI=1.00)
chr1	10440556	10440556	A	G	het	het	het		QUAL=8902;DP=326,225,182;AF=0.49,0.48,0.49;MQM=51	KIF1B	3'UTR	KIF1B:ENST00000377081:3_prime_UTR_variant:MODIFIER:exon48/48:c.*2096A>G::,KIF1B:ENST00000377086:3_prime_UTR_variant:MODIFIER:exon49/49:c.*3911A>G::	605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210/Pheochromocytoma,171300/Neuroblastoma,susceptibility to,1,256700];	291652 [benign DISEASE=Pheochromocytoma,Neuroblastoma,Charcot-Marie-Tooth disease, type 2];		AluSx	rs1138791	0.3488	0.3604	2003,			-1.5600			0.00,0.08	0.48						n/a (AF>5%)	n/a (AF>5%)					KIF1B (inh=AD pLI=1.00)
chr1	10441664	10441664	T	C	het	het	het		QUAL=13604;DP=456,349,272;AF=0.53,0.50,0.44;MQM=60	KIF1B	downstream_gene	KIF1B:ENST00000263934:downstream_gene_variant:MODIFIER::::,KIF1B:ENST00000377081:downstream_gene_variant:MODIFIER::::,KIF1B:ENST00000377086:downstream_gene_variant:MODIFIER::::	605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210/Pheochromocytoma,171300/Neuroblastoma,susceptibility to,1,256700];	368794 [benign DISEASE=Pheochromocytoma,Neuroblastoma,Charcot-Marie-Tooth disease, type 2];			rs3748581	0.5270	0.5291	4418,			0.2790			0.31,0.74	1.06						n/a (AF>5%)	n/a (AF>5%)					KIF1B (inh=AD pLI=1.00)
chr1	11085004	11085004	-	TGTTT	het	hom	het		QUAL=16566;DP=377,269,257;AF=0.49,1.00,0.51;MQM=60	TARDBP,MASP2,RP4-635E18.8	downstream_gene,upstream_gene	TARDBP:ENST00000240185:downstream_gene_variant:MODIFIER::::,TARDBP:ENST00000315091:downstream_gene_variant:MODIFIER::::,MASP2:ENST00000400897:downstream_gene_variant:MODIFIER::::,TARDBP:ENST00000439080:downstream_gene_variant:MODIFIER::::,RP4-635E18.8:ENST00000607145:upstream_gene_variant:MODIFIER::::		291763 [benign DISEASE=Frontotemporal dementia,MASP2 deficiency,Amyotrophic Lateral Sclerosis, Dominant];			rs5772439	0.9151	0.8780	11922,							0.63						n/a (AF>5%)	n/a (AF>5%)					TARDBP (inh=AD pLI=0.98), MASP2 (inh=AR+AD pLI=0.00), RP4-635E18.8 (inh=n/a pLI=n/a)
chr1	11846092	11846092	-	T	het	hom	hom		QUAL=3891;DP=95,48,36;AF=0.76,0.90,0.89;MQM=59	MTHFR,C1orf167	3'UTR,intron	MTHFR:ENST00000376583:3_prime_UTR_variant:MODIFIER:exon12/12:c.*4644dup::,MTHFR:ENST00000376592:3_prime_UTR_variant:MODIFIER:exon11/11:c.*4644dup::,C1orf167:ENST00000433342:intron_variant:MODIFIER:exon16/20:c.3639+757dup::	607093 [MTHFR (provisional) Homocystinuria due to MTHFR deficiency,236250/Schizophrenia,susceptibility to,181500/Vascular disease,susceptibility to/Neural tube defects,susceptibility to,601634/Thromboembolism,susceptibility to,188050];	292153 [benign DISEASE=Neural tube defects, folate-sensitive];			rs55740775	0.9513	0.9801	13575,							-0.20						n/a (AF>5%)	n/a (AF>5%)					MTHFR (inh=AR pLI=0.00), C1orf167 (inh=n/a pLI=0.15)
chr1	11846252	11846252	G	A	hom	het	het		QUAL=14987;DP=330,181,159;AF=1.00,0.54,0.50;MQM=60	MTHFR,C1orf167	3'UTR,intron	MTHFR:ENST00000376583:3_prime_UTR_variant:MODIFIER:exon12/12:c.*4485C>T::,MTHFR:ENST00000376592:3_prime_UTR_variant:MODIFIER:exon11/11:c.*4485C>T::,C1orf167:ENST00000433342:intron_variant:MODIFIER:exon16/20:c.3639+906G>A::	607093 [MTHFR (provisional) Homocystinuria due to MTHFR deficiency,236250/Schizophrenia,susceptibility to,181500/Vascular disease,susceptibility to/Neural tube defects,susceptibility to,601634/Thromboembolism,susceptibility to,188050];	292158 [likely benign DISEASE=Neural tube defects, folate-sensitive];		Tigger15a	rs4846048	0.7065	0.6860	7437,			0.4870			0.00,0.12	0.20						n/a (AF>5%)	n/a (AF>5%)					MTHFR (inh=AR pLI=0.00), C1orf167 (inh=n/a pLI=0.15)
chr1	11846447	11846447	G	A	hom	hom	hom		QUAL=25252;DP=380,217,181;AF=1.00,1.00,1.00;MQM=60	MTHFR,C1orf167	3'UTR,intron	MTHFR:ENST00000376583:3_prime_UTR_variant:MODIFIER:exon12/12:c.*4290C>T::,MTHFR:ENST00000376592:3_prime_UTR_variant:MODIFIER:exon11/11:c.*4290C>T::,C1orf167:ENST00000433342:intron_variant:MODIFIER:exon16/20:c.3640-998G>A::	607093 [MTHFR (provisional) Homocystinuria due to MTHFR deficiency,236250/Schizophrenia,susceptibility to,181500/Vascular disease,susceptibility to/Neural tube defects,susceptibility to,601634/Thromboembolism,susceptibility to,188050];	292160 [benign DISEASE=Neural tube defects, folate-sensitive];			rs4845884	0.9333	0.9390	13771,			-0.7990			0.00,0.10	0.08						n/a (AF>5%)	n/a (AF>5%)					MTHFR (inh=AR pLI=0.00), C1orf167 (inh=n/a pLI=0.15)
chr1	11846660	11846664	TTTTT	-	het	wt	het		QUAL=1679;DP=67,28,24;AF=0.24,0.11,0.29;MQM=57	MTHFR,C1orf167	3'UTR,intron	MTHFR:ENST00000376583:3_prime_UTR_variant:MODIFIER:exon12/12:c.*4073_*4077del::,MTHFR:ENST00000376590:3_prime_UTR_variant:MODIFIER:exon12/12:::,MTHFR:ENST00000376592:3_prime_UTR_variant:MODIFIER:exon11/11:c.*4073_*4077del::,C1orf167:ENST00000433342:intron_variant:MODIFIER:exon16/20:c.3640-771_3640-767del::	607093 [MTHFR (provisional) Homocystinuria due to MTHFR deficiency,236250/Schizophrenia,susceptibility to,181500/Vascular disease,susceptibility to/Neural tube defects,susceptibility to,601634/Thromboembolism,susceptibility to,188050];			AluJr			0.0068	1,			0.3100				-0.07						0	3					MTHFR (inh=AR pLI=0.00), C1orf167 (inh=n/a pLI=0.15)
chr1	11846660	11846663	TTTT	-	het	hom	het		QUAL=1679;DP=67,28,24;AF=0.63,0.57,0.50;MQM=57	MTHFR,C1orf167	3'UTR,intron	MTHFR:ENST00000376583:3_prime_UTR_variant:MODIFIER:exon12/12:c.*4074_*4077del::,MTHFR:ENST00000376590:3_prime_UTR_variant:MODIFIER:exon12/12:::,MTHFR:ENST00000376592:3_prime_UTR_variant:MODIFIER:exon11/11:c.*4074_*4077del::,C1orf167:ENST00000433342:intron_variant:MODIFIER:exon16/20:c.3640-770_3640-767del::	607093 [MTHFR (provisional) Homocystinuria due to MTHFR deficiency,236250/Schizophrenia,susceptibility to,181500/Vascular disease,susceptibility to/Neural tube defects,susceptibility to,601634/Thromboembolism,susceptibility to,188050];	292164 [likely benign DISEASE=Neural tube defects, folate-sensitive];		AluJr	rs55780505	0.7772	0.5158	3175,			0.3100				-0.07						n/a (AF>5%)	n/a (AF>5%)					MTHFR (inh=AR pLI=0.00), C1orf167 (inh=n/a pLI=0.15)
chr1	11847334	11847334	-	GAA	hom	het	het		QUAL=9593;DP=232,223,133;AF=0.96,0.41,0.58;MQM=59	MTHFR,C1orf167	3'UTR,intron	MTHFR:ENST00000376583:3_prime_UTR_variant:MODIFIER:exon12/12:c.*3400_*3402dup::,MTHFR:ENST00000376590:3_prime_UTR_variant:MODIFIER:exon12/12:c.*3400_*3402dup::,MTHFR:ENST00000376592:3_prime_UTR_variant:MODIFIER:exon11/11:c.*3400_*3402dup::,C1orf167:ENST00000433342:intron_variant:MODIFIER:exon16/20:c.3640-108_3640-106dup::	607093 [MTHFR (provisional) Homocystinuria due to MTHFR deficiency,236250/Schizophrenia,susceptibility to,181500/Vascular disease,susceptibility to/Neural tube defects,susceptibility to,601634/Thromboembolism,susceptibility to,188050];	292171 [likely benign DISEASE=Neural tube defects, folate-sensitive];			rs35134728	0.5701	0.5694	5183,							0.05						n/a (AF>5%)	n/a (AF>5%)					MTHFR (inh=AR pLI=0.00), C1orf167 (inh=n/a pLI=0.15)
chr1	11847759	11847759	C	T	hom	het	het		QUAL=11939;DP=193,292,242;AF=0.98,0.52,0.50;MQM=59	MTHFR,C1orf167	3'UTR,intron	MTHFR:ENST00000376583:3_prime_UTR_variant:MODIFIER:exon12/12:c.*2978G>A::,MTHFR:ENST00000376590:3_prime_UTR_variant:MODIFIER:exon12/12:c.*2978G>A::,MTHFR:ENST00000376592:3_prime_UTR_variant:MODIFIER:exon11/11:c.*2978G>A::,C1orf167:ENST00000433342:intron_variant:MODIFIER:exon17/20:c.3746-171C>T::	607093 [MTHFR (provisional) Homocystinuria due to MTHFR deficiency,236250/Schizophrenia,susceptibility to,181500/Vascular disease,susceptibility to/Neural tube defects,susceptibility to,601634/Thromboembolism,susceptibility to,188050];	292181 [likely benign DISEASE=Neural tube defects, folate-sensitive];			rs3737966	0.5585	0.5599	5073,			0.6900			0.30,0.29	0.32						n/a (AF>5%)	n/a (AF>5%)					MTHFR (inh=AR pLI=0.00), C1orf167 (inh=n/a pLI=0.15)
chr1	11848139	11848139	G	A	wt	het	het		QUAL=2672;DP=121,122,85;AF=0.01,0.48,0.55;MQM=60	MTHFR,C1orf167	3'UTR,intron	MTHFR:ENST00000376583:3_prime_UTR_variant:MODIFIER:exon12/12:c.*2598C>T::,MTHFR:ENST00000376590:3_prime_UTR_variant:MODIFIER:exon12/12:c.*2598C>T::,MTHFR:ENST00000376592:3_prime_UTR_variant:MODIFIER:exon11/11:c.*2598C>T::,C1orf167:ENST00000433342:intron_variant:MODIFIER:exon18/20:c.3920+35G>A::	607093 [MTHFR (provisional) Homocystinuria due to MTHFR deficiency,236250/Schizophrenia,susceptibility to,181500/Vascular disease,susceptibility to/Neural tube defects,susceptibility to,601634/Thromboembolism,susceptibility to,188050];	292191 [likely benign DISEASE=Neural tube defects, folate-sensitive];			rs11559040	0.1268	0.1691	351,	0.0339,0.0848,0.1037,0.1862,0.2666		-0.6770			0.09,0.19	0.14						n/a (AF>5%)	n/a (AF>5%)					MTHFR (inh=AR pLI=0.00), C1orf167 (inh=n/a pLI=0.15)
chr1	11848879	11848879	A	G	hom	hom	hom		QUAL=18995;DP=244,218,151;AF=1.00,1.00,1.00;MQM=60	MTHFR,C1orf167	3'UTR,intron	MTHFR:ENST00000376583:3_prime_UTR_variant:MODIFIER:exon12/12:c.*1858T>C::,MTHFR:ENST00000376585:3_prime_UTR_variant:MODIFIER:exon13/13:c.*1858T>C::,MTHFR:ENST00000376590:3_prime_UTR_variant:MODIFIER:exon12/12:c.*1858T>C::,MTHFR:ENST00000376592:3_prime_UTR_variant:MODIFIER:exon11/11:c.*1858T>C::,C1orf167:ENST00000433342:intron_variant:MODIFIER:exon20/20:c.4245+76A>G::	607093 [MTHFR (provisional) Homocystinuria due to MTHFR deficiency,236250/Schizophrenia,susceptibility to,181500/Vascular disease,susceptibility to/Neural tube defects,susceptibility to,601634/Thromboembolism,susceptibility to,188050];	292203 [benign DISEASE=Neural tube defects, folate-sensitive];			rs2077360	0.9305	0.9363	13702,			-0.5590			0.01,0.11	0.02						n/a (AF>5%)	n/a (AF>5%)					MTHFR (inh=AR pLI=0.00), C1orf167 (inh=n/a pLI=0.15)
chr1	11849447	11849447	A	G	hom	hom	hom		QUAL=17690;DP=148,226,188;AF=1.00,1.00,1.00;MQM=59	MTHFR,C1orf167	3'UTR,missense	MTHFR:ENST00000376583:3_prime_UTR_variant:MODIFIER:exon12/12:c.*1290T>C::,MTHFR:ENST00000376585:3_prime_UTR_variant:MODIFIER:exon13/13:c.*1290T>C::,MTHFR:ENST00000376590:3_prime_UTR_variant:MODIFIER:exon12/12:c.*1290T>C::,MTHFR:ENST00000376592:3_prime_UTR_variant:MODIFIER:exon11/11:c.*1290T>C::,C1orf167:ENST00000433342:missense_variant:MODERATE:exon21/21:c.4366A>G:p.Arg1456Gly:	607093 [MTHFR (provisional) Homocystinuria due to MTHFR deficiency,236250/Schizophrenia,susceptibility to,181500/Vascular disease,susceptibility to/Neural tube defects,susceptibility to,601634/Thromboembolism,susceptibility to,188050];	292209 [benign DISEASE=Neural tube defects, folate-sensitive];			rs868014	0.9329	0.9874	13758,	0.7814,0.9877,1.0000,0.9990,0.9997		-4.9500	 , , , ,T	 , , , ,B	0.02,0.21	0.13	0.03					n/a (AF>5%)	n/a (AF>5%)					MTHFR (inh=AR pLI=0.00), C1orf167 (inh=n/a pLI=0.15)
chr1	11850365	11850365	T	G	hom	het	het		QUAL=18952;DP=313,385,350;AF=1.00,0.49,0.49;MQM=59	MTHFR	3'UTR	MTHFR:ENST00000376583:3_prime_UTR_variant:MODIFIER:exon12/12:c.*372A>C::,MTHFR:ENST00000376585:3_prime_UTR_variant:MODIFIER:exon13/13:c.*372A>C::,MTHFR:ENST00000376590:3_prime_UTR_variant:MODIFIER:exon12/12:c.*372A>C::,MTHFR:ENST00000376592:3_prime_UTR_variant:MODIFIER:exon11/11:c.*372A>C::	607093 [MTHFR (provisional) Homocystinuria due to MTHFR deficiency,236250/Schizophrenia,susceptibility to,181500/Vascular disease,susceptibility to/Neural tube defects,susceptibility to,601634/Thromboembolism,susceptibility to,188050];	292223 [likely benign DISEASE=Neural tube defects, folate-sensitive];			rs4846049	0.6284	0.6376	6407,			-0.6840			0.05,0.19	-0.07						n/a (AF>5%)	n/a (AF>5%)					MTHFR (inh=AR pLI=0.00)
chr1	11851003	11851003	G	C	wt	het	het	off-target	QUAL=3882;DP=207,180,167;AF=0.00,0.43,0.49;MQM=60	MTHFR	intron	MTHFR:ENST00000376583:intron_variant:MODIFIER:exon11/11:c.1876-48C>G::,MTHFR:ENST00000376585:intron_variant:MODIFIER:exon12/12:c.1876-48C>G::,MTHFR:ENST00000376590:intron_variant:MODIFIER:exon11/11:c.1753-48C>G::,MTHFR:ENST00000376592:intron_variant:MODIFIER:exon10/10:c.1753-48C>G::	607093 [MTHFR (provisional) Homocystinuria due to MTHFR deficiency,236250/Schizophrenia,susceptibility to,181500/Vascular disease,susceptibility to/Neural tube defects,susceptibility to,601634/Thromboembolism,susceptibility to,188050];				rs3818762	0.2475	0.2611	873,	0.1337,0.1425,0.2148,0.2753,0.4136	0.2685,0.1543	-1.1340			0.00,0.02	-0.10						n/a (AF>5%)	n/a (AF>5%)					MTHFR (inh=AR pLI=0.00)
chr1	11852300	11852300	C	T	wt	het	het	off-target	QUAL=4643;DP=171,209,198;AF=0.01,0.48,0.47;MQM=60	MTHFR	intron	MTHFR:ENST00000376583:intron_variant:MODIFIER:exon10/11:c.1755+35G>A::,MTHFR:ENST00000376585:intron_variant:MODIFIER:exon11/12:c.1755+35G>A::,MTHFR:ENST00000376590:intron_variant:MODIFIER:exon10/11:c.1632+35G>A::,MTHFR:ENST00000376592:intron_variant:MODIFIER:exon9/10:c.1632+35G>A::	607093 [MTHFR (provisional) Homocystinuria due to MTHFR deficiency,236250/Schizophrenia,susceptibility to,181500/Vascular disease,susceptibility to/Neural tube defects,susceptibility to,601634/Thromboembolism,susceptibility to,188050];				rs1476413	0.2512	0.2628	877,	0.1507,0.1394,0.2262,0.2738,0.4206	0.2607,0.1491	-1.1060			0.07,0.25	0.43						n/a (AF>5%)	n/a (AF>5%)					MTHFR (inh=AR pLI=0.00)
chr1	11854457	11854457	G	A	hom	hom	hom		QUAL=18522;DP=120,265,205;AF=1.00,1.00,1.00;MQM=60	MTHFR	synonymous	MTHFR:ENST00000376583:synonymous_variant:LOW:exon8/12:c.1428C>T:p.Phe476=:,MTHFR:ENST00000376585:synonymous_variant:LOW:exon9/13:c.1428C>T:p.Phe476=:,MTHFR:ENST00000376590:synonymous_variant:LOW:exon8/12:c.1305C>T:p.Phe435=:,MTHFR:ENST00000376592:synonymous_variant:LOW:exon7/11:c.1305C>T:p.Phe435=:	607093 [MTHFR (provisional) Homocystinuria due to MTHFR deficiency,236250/Schizophrenia,susceptibility to,181500/Vascular disease,susceptibility to/Neural tube defects,susceptibility to,601634/Thromboembolism,susceptibility to,188050];	167306 [benign DISEASE=Neural tube defects, folate-sensitive,not specified];			rs4846051	0.9030	0.9755	13050,	0.6770,0.9820,0.9992,0.9984,0.9992	0.9970,0.6827	0.6310			0.47,0.83	0.70						n/a (AF>5%)	n/a (AF>5%)					MTHFR (inh=AR pLI=0.00)
chr1	11854476	11854476	T	G	wt	het	het		QUAL=7158;DP=166,287,228;AF=0.01,0.54,0.54;MQM=60	MTHFR	missense	MTHFR:ENST00000376583:missense_variant:MODERATE:exon8/12:c.1409A>C:p.Glu470Ala:,MTHFR:ENST00000376585:missense_variant:MODERATE:exon9/13:c.1409A>C:p.Glu470Ala:,MTHFR:ENST00000376590:missense_variant:MODERATE:exon8/12:c.1286A>C:p.Glu429Ala:,MTHFR:ENST00000376592:missense_variant:MODERATE:exon7/11:c.1286A>C:p.Glu429Ala:	607093 [MTHFR (provisional) Homocystinuria due to MTHFR deficiency,236250/Schizophrenia,susceptibility to,181500/Vascular disease,susceptibility to/Neural tube defects,susceptibility to,601634/Thromboembolism,susceptibility to,188050];	3521 [conflicting interpretations of pathogenicity, other, risk factor DISEASE=Schizophrenia, susceptibility to,Gastrointestinal stroma tumor,MTHFR deficiency, thermolabile type,Neural tube defects, folate-sensitive,not specified,not provided];	CM981315 [CLASS=DFP MUT=ALT PHEN="Neural tube defect increased risk association with" GENE=MTHFR];		rs1801131	0.2494	0.2902	1085,	0.1579,0.1600,0.2192,0.3189,0.4112	0.3131,0.1550	3.7910	T,T,T,T	B,B,B,B	0.96,0.96	2.33	0.20					n/a (AF>5%)	n/a (AF>5%)					MTHFR (inh=AR pLI=0.00)
chr1	11854755	11854755	G	A	hom	het	het	off-target	QUAL=3026;DP=70,54,57;AF=1.00,0.39,0.46;MQM=59	MTHFR	intron	MTHFR:ENST00000376583:intron_variant:MODIFIER:exon7/11:c.1289+31C>T::,MTHFR:ENST00000376585:intron_variant:MODIFIER:exon8/12:c.1289+31C>T::,MTHFR:ENST00000376590:intron_variant:MODIFIER:exon7/11:c.1166+31C>T::,MTHFR:ENST00000376592:intron_variant:MODIFIER:exon6/10:c.1166+31C>T::	607093 [MTHFR (provisional) Homocystinuria due to MTHFR deficiency,236250/Schizophrenia,susceptibility to,181500/Vascular disease,susceptibility to/Neural tube defects,susceptibility to,601634/Thromboembolism,susceptibility to,188050];				rs1994798	0.5793	0.6070	5178,	0.4319,0.7728,0.7605,0.5879,0.4683	0.5876,0.4346	-3.8760			0.03,0.15	-0.35						n/a (AF>5%)	n/a (AF>5%)					MTHFR (inh=AR pLI=0.00)
chr1	12009955	12009955	C	T	het	het	het		QUAL=6843;DP=122,248,190;AF=0.46,0.49,0.53;MQM=60	PLOD1	synonymous	PLOD1:ENST00000196061:synonymous_variant:LOW:exon3/19:c.294C>T:p.Phe98=:,PLOD1:ENST00000376369:synonymous_variant:LOW:exon4/20:c.435C>T:p.Phe145=:	153454 [PLOD1 (provisional) Ehlers-Danlos syndrome,kyphoscoliotic type,1,225400];	255803 [benign DISEASE=Ehlers-Danlos syndrome, hydroxylysine-deficient,not specified,Cardiovascular phenotype];			rs7529452	0.2678	0.3311	1501,	0.0572,0.3535,0.3727,0.3166,0.4238	0.3119,0.0681	0.9490			0.69,0.83	0.69						n/a (AF>5%)	n/a (AF>5%)					PLOD1 (inh=AR pLI=0.00)
chr1	12009956	12009956	G	A	wt	wt	het		QUAL=2014;DP=146,243,188;AF=0.00,0.00,0.47;MQM=60	PLOD1	missense	PLOD1:ENST00000196061:missense_variant:MODERATE:exon3/19:c.295G>A:p.Ala99Thr:,PLOD1:ENST00000376369:missense_variant:MODERATE:exon4/20:c.436G>A:p.Ala146Thr:	153454 [PLOD1 (provisional) Ehlers-Danlos syndrome,kyphoscoliotic type,1,225400];	196247 [benign DISEASE=Ehlers-Danlos syndrome, hydroxylysine-deficient,not specified,Cardiovascular phenotype];	CM068658 [CLASS=DP MUT=ALT PHEN="Bone mineral density association with" GENE=PLOD1];		rs7551175	0.2995	0.2610	1526,	0.5540,0.0889,0.2520,0.1529,0.2124	0.1503,0.5347	1.4500	T,T	B,B	0.03,0.33	1.22	0.15					n/a (AF>5%)	n/a (AF>5%)					PLOD1 (inh=AR pLI=0.00)
chr1	12016957	12016957	T	G	wt	wt	het	off-target	QUAL=3761;DP=108,392,311;AF=0.00,0.00,0.50;MQM=60	PLOD1	intron	PLOD1:ENST00000196061:intron_variant:MODIFIER:exon6/18:c.644-17T>G::,PLOD1:ENST00000376369:intron_variant:MODIFIER:exon7/19:c.785-17T>G::	153454 [PLOD1 (provisional) Ehlers-Danlos syndrome,kyphoscoliotic type,1,225400];	384719 [benign DISEASE=not specified];			rs41307745	0.0769	0.0681	49,	0.0106,0.0250,0.1424,0.0614,0.1352	0.0541,0.0100	3.2240			0.64,0.22	0.40		-16.22% (10.55>8.84)				n/a (AF>5%)	n/a (AF>5%)					PLOD1 (inh=AR pLI=0.00)
chr1	12024235	12024235	C	T	het	het	het		QUAL=1159;DP=18,53,36;AF=0.56,0.53,0.39;MQM=60	PLOD1	synonymous	PLOD1:ENST00000196061:synonymous_variant:LOW:exon12/19:c.1206C>T:p.Asn402=:,PLOD1:ENST00000376369:synonymous_variant:LOW:exon13/20:c.1347C>T:p.Asn449=:	153454 [PLOD1 (provisional) Ehlers-Danlos syndrome,kyphoscoliotic type,1,225400];	255799 [benign DISEASE=Ehlers-Danlos syndrome, hydroxylysine-deficient,not specified,Cardiovascular phenotype];			rs1130529	0.3484	0.3624	2026,	0.2925,0.3687,0.3874,0.3279,0.4443	0.3210,0.2907	-1.0670			0.12,0.58	0.36						n/a (AF>5%)	n/a (AF>5%)					PLOD1 (inh=AR pLI=0.00)
chr1	12027204	12027204	C	T	het	het	hom	off-target	QUAL=9502;DP=42,211,205;AF=0.45,0.52,1.00;MQM=59	PLOD1	intron	PLOD1:ENST00000196061:intron_variant:MODIFIER:exon16/18:c.1755+56C>T::,PLOD1:ENST00000376369:intron_variant:MODIFIER:exon17/19:c.1896+56C>T::	153454 [PLOD1 (provisional) Ehlers-Danlos syndrome,kyphoscoliotic type,1,225400];				rs2273293	0.5639	0.5225	4288,			-3.7710			0.01,0.05	-0.19						n/a (AF>5%)	n/a (AF>5%)					PLOD1 (inh=AR pLI=0.00)
chr1	12033113	12033113	A	G	het	het	hom	off-target	QUAL=11228;DP=132,264,209;AF=0.51,0.48,1.00;MQM=60	PLOD1	intron	PLOD1:ENST00000196061:intron_variant:MODIFIER:exon18/18:c.2028+59A>G::,PLOD1:ENST00000376369:intron_variant:MODIFIER:exon19/19:c.2169+59A>G::	153454 [PLOD1 (provisional) Ehlers-Danlos syndrome,kyphoscoliotic type,1,225400];				rs3737961	0.6498	0.5837	5474,			-0.4870			0.00,0.07	0.27						n/a (AF>5%)	n/a (AF>5%)					PLOD1 (inh=AR pLI=0.00)
chr1	12040203	12040203	A	G	het	het	hom	off-target	QUAL=901;DP=25,24,20;AF=0.44,0.46,1.00;MQM=60	PLOD1,MFN2	downstream_gene,upstream_gene	PLOD1:ENST00000196061:downstream_gene_variant:MODIFIER::::,MFN2:ENST00000235329:upstream_gene_variant:MODIFIER::::,MFN2:ENST00000444836:upstream_gene_variant:MODIFIER::::					rs2236053		0.5220	4265,			-0.9190			0.00,0.13	0.05						n/a (AF>5%)	n/a (AF>5%)					PLOD1 (inh=AR pLI=0.00), MFN2 (inh=AR+AD pLI=1.00)
chr1	12040324	12040324	A	G	het	het	hom		QUAL=4120;DP=30,123,101;AF=0.47,0.36,1.00;MQM=60	MFN2	5'UTR	MFN2:ENST00000444836:5_prime_UTR_variant:MODIFIER:exon1/18:c.-222A>G::	608507 [MFN2 (confirmed) Charcot-Marie-Tooth disease,axonal,type 2A2A,609260/Hereditary motor and sensory neuropathy VIA,601152/Charcot-Marie-Tooth disease,axonal,type 2A2B,617087];	292362 [benign DISEASE=Hereditary motor and sensory neuropathy,Ehlers-Danlos syndrome, hydroxylysine-deficient,Charcot-Marie-Tooth disease, type 2];			rs2236054		0.5264	4364,			-0.9110			0.00,0.09	0.57						n/a (AF>5%)	n/a (AF>5%)					MFN2 (inh=AR+AD pLI=1.00)
chr1	12040479	12040479	T	C	het	het	hom		QUAL=5102;DP=51,128,113;AF=0.45,0.43,1.00;MQM=60	MFN2	5'UTR	MFN2:ENST00000235329:5_prime_UTR_variant:MODIFIER:exon1/19:c.-212T>C::,MFN2:ENST00000444836:5_prime_UTR_variant:MODIFIER:exon1/18:c.-67T>C::	608507 [MFN2 (confirmed) Charcot-Marie-Tooth disease,axonal,type 2A2A,609260/Hereditary motor and sensory neuropathy VIA,601152/Charcot-Marie-Tooth disease,axonal,type 2A2B,617087];	292368 [benign DISEASE=Hereditary motor and sensory neuropathy,Ehlers-Danlos syndrome, hydroxylysine-deficient,Charcot-Marie-Tooth disease, type 2];			rs2180183	0.6100	0.5525	4890,			-0.2970			0.00,0.05	0.56						n/a (AF>5%)	n/a (AF>5%)					MFN2 (inh=AR+AD pLI=1.00)
chr1	12041977	12041977	-	TTTTTTT	wt	het	het	off-target	QUAL=253;DP=98,135,36;AF=0.08,0.08,0.22;MQM=57	MFN2	intron	MFN2:ENST00000235329:intron_variant:MODIFIER:exon1/18:c.-149-44_-149-38dup::,MFN2:ENST00000444836:intron_variant:MODIFIER:exon1/17:c.-5+1442_-5+1448dup::	608507 [MFN2 (confirmed) Charcot-Marie-Tooth disease,axonal,type 2A2A,609260/Hereditary motor and sensory neuropathy VIA,601152/Charcot-Marie-Tooth disease,axonal,type 2A2B,617087];				rs763918741		0.3097	1473,							0.22						n/a (AF>5%)	n/a (AF>5%)					MFN2 (inh=AR+AD pLI=1.00)
chr1	12041977	12041977	-	TTTTTT	wt	wt	het	off-target	QUAL=253;DP=98,135,36;AF=0.08,0.12,0.28;MQM=59	MFN2	intron	MFN2:ENST00000235329:intron_variant:MODIFIER:exon1/18:c.-149-43_-149-38dup::,MFN2:ENST00000444836:intron_variant:MODIFIER:exon1/17:c.-5+1443_-5+1448dup::	608507 [MFN2 (confirmed) Charcot-Marie-Tooth disease,axonal,type 2A2A,609260/Hereditary motor and sensory neuropathy VIA,601152/Charcot-Marie-Tooth disease,axonal,type 2A2B,617087];				rs763918741		0.0303	51,							0.23						17	0					MFN2 (inh=AR+AD pLI=1.00)
chr1	12062205	12062205	A	G	hom	hom	hom	off-target	QUAL=14565;DP=177,190,139;AF=0.99,0.99,0.99;MQM=59	MFN2	intron	MFN2:ENST00000235329:intron_variant:MODIFIER:exon11/18:c.1160+45A>G::,MFN2:ENST00000444836:intron_variant:MODIFIER:exon10/17:c.1160+45A>G::	608507 [MFN2 (confirmed) Charcot-Marie-Tooth disease,axonal,type 2A2A,609260/Hereditary motor and sensory neuropathy VIA,601152/Charcot-Marie-Tooth disease,axonal,type 2A2B,617087];				rs2236057	0.6579	0.6604	6770,	0.6473,0.5327,0.6752,0.6682,0.7031	0.6514,0.6480	-2.0590			0.01,0.11	0.03						n/a (AF>5%)	n/a (AF>5%)					MFN2 (inh=AR+AD pLI=1.00)
chr1	12071680	12071680	A	G	hom	hom	hom		QUAL=29373;DP=254,425,324;AF=0.99,1.00,0.99;MQM=60	MFN2	3'UTR	MFN2:ENST00000235329:3_prime_UTR_variant:MODIFIER:exon19/19:c.*58A>G::,MFN2:ENST00000444836:3_prime_UTR_variant:MODIFIER:exon18/18:c.*58A>G::	608507 [MFN2 (confirmed) Charcot-Marie-Tooth disease,axonal,type 2A2A,609260/Hereditary motor and sensory neuropathy VIA,601152/Charcot-Marie-Tooth disease,axonal,type 2A2B,617087];	292381 [benign DISEASE=Hereditary motor and sensory neuropathy,Charcot-Marie-Tooth disease, type 2];			rs1042842	0.7324	0.7191	8125,		0.6556,0.8324	-0.8580			0.04,0.13	-0.22						n/a (AF>5%)	n/a (AF>5%)					MFN2 (inh=AR+AD pLI=1.00)
chr1	12072518	12072518	G	C	hom	hom	hom		QUAL=12750;DP=106,172,143;AF=0.99,1.00,1.00;MQM=60	MFN2	3'UTR	MFN2:ENST00000235329:3_prime_UTR_variant:MODIFIER:exon19/19:c.*896G>C::,MFN2:ENST00000444836:3_prime_UTR_variant:MODIFIER:exon18/18:c.*896G>C::	608507 [MFN2 (confirmed) Charcot-Marie-Tooth disease,axonal,type 2A2A,609260/Hereditary motor and sensory neuropathy VIA,601152/Charcot-Marie-Tooth disease,axonal,type 2A2B,617087];	292393 [benign DISEASE=Hereditary motor and sensory neuropathy,Charcot-Marie-Tooth disease, type 2];			rs3088064	0.5441	0.5700	5095,			0.4850			0.22,0.22	0.02						n/a (AF>5%)	n/a (AF>5%)					MFN2 (inh=AR+AD pLI=1.00)
chr1	12072534	12072534	C	T	wt	wt	het		QUAL=1666;DP=102,189,145;AF=0.00,0.00,0.50;MQM=60	MFN2	3'UTR	MFN2:ENST00000235329:3_prime_UTR_variant:MODIFIER:exon19/19:c.*912C>T::,MFN2:ENST00000444836:3_prime_UTR_variant:MODIFIER:exon18/18:c.*912C>T::	608507 [MFN2 (confirmed) Charcot-Marie-Tooth disease,axonal,type 2A2A,609260/Hereditary motor and sensory neuropathy VIA,601152/Charcot-Marie-Tooth disease,axonal,type 2A2B,617087];	292394 [likely benign DISEASE=Hereditary motor and sensory neuropathy,Charcot-Marie-Tooth disease, type 2];			rs14305	0.0843	0.0545	53,			0.1270			0.12,0.31	0.43						n/a (AF>5%)	n/a (AF>5%)					MFN2 (inh=AR+AD pLI=1.00)
chr1	16370428	16370432	GGGGG	-	wt	hom	wt	off-target	QUAL=50;DP=0,3,0;AF=nan,1.00,nan;MQM=60	CLCNKB	intron	CLCNKB:ENST00000375679:intron_variant:MODIFIER:exon1/19:c.-8+61_-8+65del::	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];				rs140434107	0.9447	0.5133	2037,			1.3540				0.09						n/a (AF>5%)	n/a (AF>5%)					CLCNKB (inh=AR pLI=0.00)
chr1	16371067	16371067	G	T	het	hom	hom		QUAL=234;DP=4,5,1;AF=0.75,1.00,1.00;MQM=60	CLCNKB	missense	CLCNKB:ENST00000375679:missense_variant:MODERATE:exon2/20:c.80G>T:p.Arg27Leu:	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];	447107 [benign DISEASE=not specified];			rs2015352		0.6271	4748,	0.2847,0.7316,0.6346,0.6333,0.6876	0.6422,0.3000	-0.4670	D	B	0.14,0.92	2.69	0.30					n/a (AF>5%)	n/a (AF>5%)					CLCNKB (inh=AR pLI=0.00)
chr1	16372003	16372003	G	C	het	hom	het	off-target	QUAL=6446;DP=55,149,129;AF=0.42,1.00,0.48;MQM=60	CLCNKB	intron	CLCNKB:ENST00000375679:intron_variant:MODIFIER:exon2/19:c.101-50G>C::	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];				rs6604910	0.5665	0.6361	4785,	0.2673,0.7372,0.6808,0.6382,0.7116	0.6429,0.2835	0.6820			0.01,0.14	0.16						n/a (AF>5%)	n/a (AF>5%)					CLCNKB (inh=AR pLI=0.00)
chr1	16372971	16372971	G	A	hom	hom	hom	off-target	QUAL=12434;DP=82,182,142;AF=1.00,1.00,1.00;MQM=59	CLCNKB	intron	CLCNKB:ENST00000375679:intron_variant:MODIFIER:exon3/19:c.230-59G>A::	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];				rs2014841	0.7404	0.6927	8052,			-0.2720			0.02,0.13	-0.01						n/a (AF>5%)	n/a (AF>5%)					CLCNKB (inh=AR pLI=0.00)
chr1	16373124	16373124	A	G	hom	hom	hom		QUAL=23098;DP=180,312,248;AF=0.98,1.00,1.00;MQM=59	CLCNKB	synonymous	CLCNKB:ENST00000375679:synonymous_variant:LOW:exon4/20:c.324A>G:p.Ser108=:PF00654	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];	447104 [benign DISEASE=not specified];			rs5257	0.7404	0.8123	8028,	0.3761,0.9003,0.9891,0.8095,0.8739	0.8117,0.3997	-4.7220			0.03,0.24	-0.32						n/a (AF>5%)	n/a (AF>5%)					CLCNKB (inh=AR pLI=0.00)
chr1	16373200	16373202	CTT	-	hom	hom	het	off-target	QUAL=10193;DP=121,227,148;AF=0.99,1.00,0.50;MQM=59	CLCNKB	intron	CLCNKB:ENST00000375679:intron_variant:MODIFIER:exon4/19:c.358+44_358+46del::	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];				rs35820664	0.7234	0.7864	7421,	0.3522,0.8890,0.9890,0.7807,0.8445	0.7798,0.3762	0.5420				0.87						n/a (AF>5%)	n/a (AF>5%)					CLCNKB (inh=AR pLI=0.00)
chr1	16374533	16374533	G	C	hom	hom	hom		QUAL=383;DP=5,3,5;AF=1.00,1.00,1.00;MQM=60	CLCNKB	synonymous	CLCNKB:ENST00000375679:synonymous_variant:LOW:exon5/20:c.492G>C:p.Gly164=:PF00654	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];	447105 [benign DISEASE=not specified];			rs2014562	0.8940	0.9317	12455,	0.7566,0.9581,0.9997,0.9438,0.9276	0.9364,0.7653	-0.3820			0.06,0.95	0.27						n/a (AF>5%)	n/a (AF>5%)					CLCNKB (inh=AR pLI=0.00)
chr1	16374994	16374994	C	T	hom	hom	hom		QUAL=17849;DP=155,245,203;AF=0.99,1.00,1.00;MQM=46	CLCNKB	splice_region&intron	CLCNKB:ENST00000375679:splice_region_variant&intron_variant:LOW:exon6/19:c.577-5C>T::	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];	381050 [benign/likely benign DISEASE=not specified];			rs1889788,rs34666902	0.7386	0.8106	7997,	0.3734,0.8993,0.9890,0.8077,0.8731		-0.3170			0.02,0.22	-0.13		-2.80% (4.28>4.16)		0.000/0.000		n/a (AF>5%)	n/a (AF>5%)					CLCNKB (inh=AR pLI=0.00)
chr1	16375063	16375063	C	G	hom	hom	hom		QUAL=17433;DP=185,217,174;AF=0.99,1.00,1.00;MQM=52	CLCNKB	missense	CLCNKB:ENST00000375679:missense_variant:MODERATE:exon7/20:c.641C>G:p.Ala214Gly:PF00654	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];	504916 [benign DISEASE=not specified];			rs1889789,rs45612832	0.8273	0.9074	10949,	0.5567,0.9396,0.9997,0.9257,0.9253		-0.0390	T	B	0.06,0.42	0.74	0.22					n/a (AF>5%)	n/a (AF>5%)					CLCNKB (inh=AR pLI=0.00)
chr1	16375064	16375064	A	C	hom	hom	hom		QUAL=17433;DP=185,217,174;AF=0.99,1.00,1.00;MQM=52	CLCNKB	synonymous	CLCNKB:ENST00000375679:synonymous_variant:LOW:exon7/20:c.642A>C:p.Ala214=:PF00654	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];	504915 [benign DISEASE=not specified];			rs1889790,rs45575235		0.9074	10949,	0.5567,0.9395,0.9997,0.9256,0.9253		-2.2040			0.07,0.28	0.55						n/a (AF>5%)	n/a (AF>5%)					CLCNKB (inh=AR pLI=0.00)
chr1	16375210	16375210	G	A	het	hom	wt	off-target	QUAL=4190;DP=97,100,103;AF=0.48,0.99,0.00;MQM=60	CLCNKB	intron	CLCNKB:ENST00000375679:intron_variant:MODIFIER:exon7/19:c.655+133G>A::	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];				rs9633514	0.3570	0.2949	1622,			-0.2940			0.09,0.19	0.36						n/a (AF>5%)	n/a (AF>5%)					CLCNKB (inh=AR pLI=0.00)
chr1	16375354	16375354	C	T	hom	hom	hom		QUAL=18622;DP=166,237,202;AF=1.00,1.00,1.00;MQM=59	CLCNKB	5'UTR,intron	CLCNKB:ENST00000375667:5_prime_UTR_variant:MODIFIER:exon1/13:c.-113C>T::,CLCNKB:ENST00000375679:intron_variant:MODIFIER:exon7/19:c.656-261C>T::	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];			MIR	rs9442227	0.7274	0.6829	7837,			-0.1220			0.08,0.21	0.56						n/a (AF>5%)	n/a (AF>5%)					CLCNKB (inh=AR pLI=0.00)
chr1	16376191	16376191	C	T	hom	hom	hom		QUAL=25498;DP=183,405,313;AF=0.99,1.00,1.00;MQM=44	CLCNKB	missense	CLCNKB:ENST00000375667:missense_variant:MODERATE:exon2/13:c.353C>T:p.Ala118Val:PF00654,CLCNKB:ENST00000375679:missense_variant:MODERATE:exon9/20:c.860C>T:p.Ala287Val:PF00654	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];	447108 [benign DISEASE=not specified];			rs7367494,rs34188929	0.8299	0.9247	11085,	0.5579,0.9602,0.9989,0.9475,0.9333		-0.3350	T,T	B,B	0.02,0.12	-0.56	0.22					n/a (AF>5%)	n/a (AF>5%)					CLCNKB (inh=AR pLI=0.00)
chr1	16376230	16376230	-	T	hom	hom	hom	off-target	QUAL=24384;DP=72,440,338;AF=1.00,0.95,0.96;MQM=51	CLCNKB	intron	CLCNKB:ENST00000375667:intron_variant:MODIFIER:exon2/12:c.359+33_359+34insT::,CLCNKB:ENST00000375679:intron_variant:MODIFIER:exon9/19:c.866+33_866+34insT::	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];				rs59006537		0.9268	10546,	0.4387,0.9463,0.9983,0.9566,0.9478	0.9087,0.5279					-0.08						n/a (AF>5%)	n/a (AF>5%)					CLCNKB (inh=AR pLI=0.00)
chr1	16376232	16376232	A	T	hom	hom	hom	off-target	QUAL=24384;DP=72,440,338;AF=1.00,0.95,0.96;MQM=51	CLCNKB	intron	CLCNKB:ENST00000375667:intron_variant:MODIFIER:exon2/12:c.359+35A>T::,CLCNKB:ENST00000375679:intron_variant:MODIFIER:exon9/19:c.866+35A>T::	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];				rs59924562	0.7542	0.9275	10563,	0.4546,0.9471,0.9984,0.9566,0.9471		-2.8490			0.01,0.08	-0.18						n/a (AF>5%)	n/a (AF>5%)					CLCNKB (inh=AR pLI=0.00)
chr1	16376239	16376239	C	-	hom	hom	hom	off-target	QUAL=24233;DP=79,440,336;AF=0.97,0.99,0.99;MQM=52	CLCNKB	intron	CLCNKB:ENST00000375667:intron_variant:MODIFIER:exon2/12:c.359+47del::,CLCNKB:ENST00000375679:intron_variant:MODIFIER:exon9/19:c.866+47del::	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];				rs34589727	0.8301	0.9174	10535,	0.4259,0.9421,0.9987,0.9495,0.9351		-0.1430				-0.08						n/a (AF>5%)	n/a (AF>5%)					CLCNKB (inh=AR pLI=0.00)
chr1	16376278	16376278	G	A	hom	hom	hom	off-target	QUAL=30522;DP=139,503,364;AF=0.99,1.00,1.00;MQM=57	CLCNKB	intron	CLCNKB:ENST00000375667:intron_variant:MODIFIER:exon2/12:c.360-32G>A::,CLCNKB:ENST00000375679:intron_variant:MODIFIER:exon9/19:c.867-32G>A::	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];				rs7365182	0.8279	0.9211	11151,	0.5504,0.9550,0.9999,0.9457,0.9312	0.9355,0.5729	1.2090			0.08,0.18	-0.05						n/a (AF>5%)	n/a (AF>5%)					CLCNKB (inh=AR pLI=0.00)
chr1	16376319	16376319	T	C	hom	hom	hom		QUAL=32789;DP=182,484,361;AF=1.00,1.00,1.00;MQM=59	CLCNKB	synonymous	CLCNKB:ENST00000375667:synonymous_variant:LOW:exon3/13:c.369T>C:p.Cys123=:PF00654,CLCNKB:ENST00000375679:synonymous_variant:LOW:exon10/20:c.876T>C:p.Cys292=:PF00654	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];	377683 [benign DISEASE=not specified];			rs7368151	0.8301	0.9173	11243,	0.5553,0.9490,0.9998,0.9431,0.9268	0.9353,0.5803	-4.5300			0.03,0.87	-0.25						n/a (AF>5%)	n/a (AF>5%)					CLCNKB (inh=AR pLI=0.00)
chr1	16376458	16376458	T	C	hom	hom	hom	off-target	QUAL=16939;DP=125,260,183;AF=0.99,1.00,1.00;MQM=60	CLCNKB	intron	CLCNKB:ENST00000375667:intron_variant:MODIFIER:exon3/12:c.461+47T>C::,CLCNKB:ENST00000375679:intron_variant:MODIFIER:exon10/19:c.968+47T>C::	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];				rs7368166		0.9137	10821,	0.5488,0.9461,0.9985,0.9398,0.9197	0.9303,0.5531	-4.4690			0.00,0.06	0.23						n/a (AF>5%)	n/a (AF>5%)					CLCNKB (inh=AR pLI=0.00)
chr1	16378649	16378649	C	G	het	wt	het	off-target	QUAL=483;DP=19,11,19;AF=0.58,0.00,0.68;MQM=60	CLCNKB	intron	CLCNKB:ENST00000375667:intron_variant:MODIFIER:exon7/12:c.902-44C>G::,CLCNKB:ENST00000375679:intron_variant:MODIFIER:exon14/19:c.1409-44C>G::	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];				rs2297726	0.1625	0.1725	412,	0.0701,0.1583,0.2983,0.1706,0.1630	0.1670,0.0731	0.0970			0.05,0.21	0.33						n/a (AF>5%)	n/a (AF>5%)					CLCNKB (inh=AR pLI=0.00)
chr1	16378739	16378739	G	A	wt	wt	het		QUAL=107;DP=27,16,22;AF=0.00,0.00,0.36;MQM=60	CLCNKB	synonymous	CLCNKB:ENST00000375667:synonymous_variant:LOW:exon8/13:c.948G>A:p.Ala316=:PF00654,CLCNKB:ENST00000375679:synonymous_variant:LOW:exon15/20:c.1455G>A:p.Ala485=:PF00654	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];				rs34652156	0.0302	0.0369	32,	0.0580,0.0120,0.0000,0.0273,0.0295	0.0301,0.0572	-2.6720			0.05,0.21	-0.50						8	246					CLCNKB (inh=AR pLI=0.00)
chr1	16380196	16380196	T	C	hom	hom	hom		QUAL=28255;DP=293,371,251;AF=1.00,1.00,1.00;MQM=51	CLCNKB	missense	CLCNKB:ENST00000375667:missense_variant:MODERATE:exon9/13:c.1178T>C:p.Met393Thr:PF00571,CLCNKB:ENST00000375679:missense_variant:MODERATE:exon16/20:c.1685T>C:p.Met562Thr:PF00571	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];	447094 [benign DISEASE=not specified];			rs5253	0.8383	0.9354	12314,	0.6839,0.9477,0.8066,0.9843,0.9315	0.9844,0.7006	-0.9230	T,T	B,B	0.00,0.10	0.12	0.28					n/a (AF>5%)	n/a (AF>5%)					CLCNKB (inh=AR pLI=0.00)
chr1	16380243	16380243	A	G	hom	hom	het		QUAL=15468;DP=134,313,232;AF=1.00,0.99,0.42;MQM=48	CLCNKB	missense	CLCNKB:ENST00000375667:missense_variant:MODERATE:exon9/13:c.1225A>G:p.Lys409Glu:PF00571,CLCNKB:ENST00000375679:missense_variant:MODERATE:exon16/20:c.1732A>G:p.Lys578Glu:PF00571	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];	447096 [benign DISEASE=not specified];	CM1514575 [CLASS=DM? MUT=ALT PHEN="Migraine without aura" GENE=CLCNKB];		rs2275166	0.7017	0.7160	7998,	0.7984,0.5168,0.7943,0.6598,0.5829	0.6503,0.7994	0.8530	T,T	B,B	0.01,0.19	1.19	0.16					n/a (AF>5%)	n/a (AF>5%)					CLCNKB (inh=AR pLI=0.00)
chr1	16380252	16380252	C	T	hom	hom	het		QUAL=14407;DP=122,302,218;AF=1.00,1.00,0.43;MQM=48	CLCNKB	synonymous	CLCNKB:ENST00000375667:synonymous_variant:LOW:exon9/13:c.1234C>T:p.Leu412=:PF00571,CLCNKB:ENST00000375679:synonymous_variant:LOW:exon16/20:c.1741C>T:p.Leu581=:PF00571	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];	447097 [benign DISEASE=not specified];			rs2275167	0.6136	0.6412	6404,	0.5758,0.4916,0.7888,0.6450,0.5284	0.6278,0.5792	0.5590			0.14,0.85	1.39						n/a (AF>5%)	n/a (AF>5%)					CLCNKB (inh=AR pLI=0.00)
chr1	16382877	16382877	A	G	hom	hom	hom	off-target	QUAL=11602;DP=50,203,147;AF=1.00,1.00,0.99;MQM=59	CLCNKB	intron	CLCNKB:ENST00000375667:intron_variant:MODIFIER:exon11/12:c.1420-40A>G::,CLCNKB:ENST00000375679:intron_variant:MODIFIER:exon18/19:c.1930-40A>G::	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];				rs7517792	0.7841	0.7960	8650,	0.7050,0.8851,0.8072,0.7871,0.8421	0.7907,0.7059	-2.5310			0.01,0.13	0.12						n/a (AF>5%)	n/a (AF>5%)					CLCNKB (inh=AR pLI=0.00)
chr1	16383329	16383329	-	C	hom	hom	het	off-target	QUAL=36;DP=3,6,25;AF=0.00,0.67,0.16;MQM=45	CLCNKB	intron	CLCNKB:ENST00000375667:intron_variant:MODIFIER:exon12/12:c.1507-29dup::,CLCNKB:ENST00000375679:intron_variant:MODIFIER:exon19/19:c.2017-29dup::	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];				rs138507185		0.6237	5165,							0.01						n/a (AF>5%)	n/a (AF>5%)					CLCNKB (inh=AR pLI=0.00)
chr1	16383336	16383336	G	C	hom	hom	het	off-target	QUAL=36;DP=3,6,25;AF=0.00,0.67,0.16;MQM=45	CLCNKB	intron	CLCNKB:ENST00000375667:intron_variant:MODIFIER:exon12/12:c.1507-28G>C::,CLCNKB:ENST00000375679:intron_variant:MODIFIER:exon19/19:c.2017-28G>C::	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];				rs12746138	0.7147	0.7060	5840,	0.4282,0.8359,0.7612,0.6962,0.7947		-1.1840			0.00,0.06	-0.65						n/a (AF>5%)	n/a (AF>5%)					CLCNKB (inh=AR pLI=0.00)
chr1	16383402	16383402	C	T	het	wt	wt		QUAL=701;DP=259,143,140;AF=0.27,0.07,0.00;MQM=34	CLCNKB	synonymous	CLCNKB:ENST00000375667:synonymous_variant:LOW:exon13/13:c.1545C>T:p.Ala515=:,CLCNKB:ENST00000375679:synonymous_variant:LOW:exon20/20:c.2055C>T:p.Ala685=:	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];				rs6698427		0.0849	0,	0.0130,0.0031,0.0135,0.0013,0.0026		0.3830			0.26,0.96	1.07						n/a (AF>5%)	n/a (AF>5%)					CLCNKB (inh=AR pLI=0.00)
chr1	16383448	16383448	A	C	het	hom	hom		QUAL=15901;DP=223,289,241;AF=0.70,0.89,1.00;MQM=40	CLCNKB	3'UTR	CLCNKB:ENST00000375667:3_prime_UTR_variant:MODIFIER:exon13/13:c.*37A>C::,CLCNKB:ENST00000375679:3_prime_UTR_variant:MODIFIER:exon20/20:c.*37A>C::	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];				rs10803415	0.9010	0.9058	5773,	0.8408,0.9244,0.6927,0.9419,0.8839		-1.8510			0.00,0.05	0.29						n/a (AF>5%)	n/a (AF>5%)					CLCNKB (inh=AR pLI=0.00)
chr1	16383547	16383547	T	C	wt	het	wt		QUAL=531;DP=233,597,398;AF=0.05,0.19,0.00;MQM=31	CLCNKB	3'UTR	CLCNKB:ENST00000375667:3_prime_UTR_variant:MODIFIER:exon13/13:c.*136T>C::,CLCNKB:ENST00000375679:3_prime_UTR_variant:MODIFIER:exon20/20:c.*136T>C::	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];				rs1057839		0.2200	4,			0.0660			0.00,0.06	0.30						n/a (AF>5%)	n/a (AF>5%)					CLCNKB (inh=AR pLI=0.00)
chr1	16383574	16383574	A	T	het	het	wt		QUAL=888;DP=245,617,380;AF=0.13,0.20,0.00;MQM=32	CLCNKB	3'UTR	CLCNKB:ENST00000375667:3_prime_UTR_variant:MODIFIER:exon13/13:c.*163A>T::,CLCNKB:ENST00000375679:3_prime_UTR_variant:MODIFIER:exon20/20:c.*163A>T::	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];				rs1057841		0.2504	0,			0.4380			0.07,0.16	0.12						n/a (AF>5%)	n/a (AF>5%)					CLCNKB (inh=AR pLI=0.00)
chr1	16383581	16383581	G	T	het	het	het		QUAL=19872;DP=246,620,383;AF=0.84,0.80,0.52;MQM=37	CLCNKB	3'UTR	CLCNKB:ENST00000375667:3_prime_UTR_variant:MODIFIER:exon13/13:c.*170G>T::,CLCNKB:ENST00000375679:3_prime_UTR_variant:MODIFIER:exon20/20:c.*170G>T::	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];				rs1057844		0.4992	1842,			-1.3730			0.03,0.14	-0.11						n/a (AF>5%)	n/a (AF>5%)					CLCNKB (inh=AR pLI=0.00)
chr1	16383605	16383605	A	G	het	het	het		QUAL=19778;DP=198,648,403;AF=0.74,0.77,0.53;MQM=37	CLCNKB	3'UTR	CLCNKB:ENST00000375667:3_prime_UTR_variant:MODIFIER:exon13/13:c.*194A>G::,CLCNKB:ENST00000375679:3_prime_UTR_variant:MODIFIER:exon20/20:c.*194A>G::	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];				rs1057845		0.4932	1661,			-0.5960			0.01,0.17	0.33						n/a (AF>5%)	n/a (AF>5%)					CLCNKB (inh=AR pLI=0.00)
chr1	16383668	16383668	T	G	hom	hom	hom		QUAL=32791;DP=172,661,360;AF=0.99,1.00,1.00;MQM=41	CLCNKB	3'UTR	CLCNKB:ENST00000375667:3_prime_UTR_variant:MODIFIER:exon13/13:c.*257T>G::,CLCNKB:ENST00000375679:3_prime_UTR_variant:MODIFIER:exon20/20:c.*257T>G::	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];				rs6660218	1.0000	1.0000	15481,	1.0000,1.0000,0.9999,0.9999,1.0000		0.1210			0.00,0.08	0.08						n/a (AF>5%)	n/a (AF>5%)					CLCNKB (inh=AR pLI=0.00)
chr1	16383682	16383682	G	C	het	het	wt		QUAL=4418;DP=219,650,322;AF=0.19,0.36,0.00;MQM=41	CLCNKB	3'UTR	CLCNKB:ENST00000375667:3_prime_UTR_variant:MODIFIER:exon13/13:c.*271G>C::,CLCNKB:ENST00000375679:3_prime_UTR_variant:MODIFIER:exon20/20:c.*271G>C::	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];	402540 [benign DISEASE=not specified];			rs1057854		0.3304	49,	0.4016,0.2172,0.4241,0.3038,0.2889		-3.2740			0.01,0.12	-0.29						n/a (AF>5%)	n/a (AF>5%)					CLCNKB (inh=AR pLI=0.00)
chr1	16383742	16383742	C	G	het	het	hom		QUAL=18360;DP=347,516,224;AF=0.55,0.53,1.00;MQM=57	CLCNKB	3'UTR	CLCNKB:ENST00000375667:3_prime_UTR_variant:MODIFIER:exon13/13:c.*331C>G::,CLCNKB:ENST00000375679:3_prime_UTR_variant:MODIFIER:exon20/20:c.*331C>G::	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];				rs1057857		0.6426	3983,	0.5903,0.6982,0.4933,0.6545,0.6181		-0.3020			0.04,0.20	0.29						n/a (AF>5%)	n/a (AF>5%)					CLCNKB (inh=AR pLI=0.00)
chr1	16383854	16383854	A	G	het	het	wt	off-target	QUAL=616;DP=104,110,56;AF=0.36,0.17,0.00;MQM=38	FAM131C,CLCNKB	downstream_gene	FAM131C:ENST00000375662:downstream_gene_variant:MODIFIER::::,CLCNKB:ENST00000375667:downstream_gene_variant:MODIFIER::::,CLCNKB:ENST00000375679:downstream_gene_variant:MODIFIER::::					rs749928769		0.0227	1,			-0.5780			0.00,0.11	0.02						0	19					FAM131C (inh=n/a pLI=0.24), CLCNKB (inh=AR pLI=0.00)
chr1	17312743	17312743	C	T	het	het	hom		QUAL=709;DP=17,25,19;AF=0.41,0.44,0.95;MQM=60	ATP13A2,RP1-37C10.3	synonymous,missense,intron&non_coding_transcript	ATP13A2:ENST00000326735:synonymous_variant:LOW:exon29/29:c.3516G>A:p.Pro1172=:,ATP13A2:ENST00000341676:missense_variant:MODERATE:exon27/27:c.3214G>A:p.Ala1072Thr:,RP1-37C10.3:ENST00000446261:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.187+7136C>T::,ATP13A2:ENST00000452699:synonymous_variant:LOW:exon29/29:c.3501G>A:p.Pro1167=:	610513 [ATP13A2 (confirmed) Kufor-Rakeb syndrome,606693/Spastic paraplegia 78,autosomal recessive,617225];	128475 [benign DISEASE=Parkinson disease 9,not specified,not provided];			rs3170740	0.3313	0.4714	2943,	0.2016,0.4861,0.2957,0.5289,0.4627	0.5255,0.2168	-2.5490	 ,T, , 	 ,B, , 	0.02,0.13	-0.26	0.24					n/a (AF>5%)	n/a (AF>5%)					ATP13A2 (inh=AR pLI=0.01), RP1-37C10.3 (inh=n/a pLI=n/a)
chr1	17313157	17313157	G	A	het	het	hom	off-target	QUAL=9684;DP=84,299,218;AF=0.38,0.50,1.00;MQM=60	ATP13A2,RP1-37C10.3	intron,intron&non_coding_transcript	ATP13A2:ENST00000326735:intron_variant:MODIFIER:exon27/28:c.3236-30C>T::,ATP13A2:ENST00000341676:intron_variant:MODIFIER:exon26/26:c.3103+143C>T::,RP1-37C10.3:ENST00000446261:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.187+7550G>A::,ATP13A2:ENST00000452699:intron_variant:MODIFIER:exon27/28:c.3221-30C>T::	610513 [ATP13A2 (confirmed) Kufor-Rakeb syndrome,606693/Spastic paraplegia 78,autosomal recessive,617225];	559000 [benign DISEASE=not provided];			rs2076605	0.3468	0.4724	2967,	0.2184,0.4848,0.2981,0.5242,0.4772	0.5195,0.2344	1.8880			0.04,0.13	0.16						n/a (AF>5%)	n/a (AF>5%)					ATP13A2 (inh=AR pLI=0.01), RP1-37C10.3 (inh=n/a pLI=n/a)
chr1	17313245	17313256	CCCAGGGCTCCT	-	het	het	wt	off-target	QUAL=2327;DP=62,210,167;AF=0.42,0.50,0.00;MQM=60	ATP13A2,RP1-37C10.3	intron,intron&non_coding_transcript	ATP13A2:ENST00000326735:intron_variant:MODIFIER:exon27/28:c.3235+44_3235+55del::,ATP13A2:ENST00000341676:intron_variant:MODIFIER:exon26/26:c.3103+44_3103+55del::,RP1-37C10.3:ENST00000446261:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.187+7641_187+7652del::,ATP13A2:ENST00000452699:intron_variant:MODIFIER:exon27/28:c.3220+44_3220+55del::	610513 [ATP13A2 (confirmed) Kufor-Rakeb syndrome,606693/Spastic paraplegia 78,autosomal recessive,617225];				rs143483351	0.3059	0.2361	914,			1.0320				0.36						n/a (AF>5%)	n/a (AF>5%)					ATP13A2 (inh=AR pLI=0.01), RP1-37C10.3 (inh=n/a pLI=n/a)
chr1	17313343	17313343	G	A	het	het	hom		QUAL=10664;DP=92,282,200;AF=0.48,0.49,1.00;MQM=60	ATP13A2,RP1-37C10.3	synonymous,intron&non_coding_transcript	ATP13A2:ENST00000326735:synonymous_variant:LOW:exon27/29:c.3192C>T:p.Ala1064=:,ATP13A2:ENST00000341676:synonymous_variant:LOW:exon26/27:c.3060C>T:p.Ala1020=:,RP1-37C10.3:ENST00000446261:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.187+7736G>A::,ATP13A2:ENST00000452699:synonymous_variant:LOW:exon27/29:c.3177C>T:p.Ala1059=:	610513 [ATP13A2 (confirmed) Kufor-Rakeb syndrome,606693/Spastic paraplegia 78,autosomal recessive,617225];	128473 [benign DISEASE=Parkinson disease 9,not specified,not provided];			rs9435659	0.3385	0.4669	2965,	0.1868,0.4792,0.2913,0.5224,0.4729	0.5234,0.2077	-0.5550			0.07,0.19	-0.07						n/a (AF>5%)	n/a (AF>5%)					ATP13A2 (inh=AR pLI=0.01), RP1-37C10.3 (inh=n/a pLI=n/a)
chr1	17313454	17313454	G	A	het	het	wt		QUAL=2306;DP=59,177,138;AF=0.47,0.44,0.00;MQM=60	ATP13A2,RP1-37C10.3	splice_region&intron,intron&non_coding_transcript	ATP13A2:ENST00000326735:splice_region_variant&intron_variant:LOW:exon26/28:c.3084-3C>T::,ATP13A2:ENST00000341676:splice_region_variant&intron_variant:LOW:exon25/26:c.2952-3C>T::,RP1-37C10.3:ENST00000446261:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.187+7847G>A::,ATP13A2:ENST00000452699:splice_region_variant&intron_variant:LOW:exon26/28:c.3069-3C>T::	610513 [ATP13A2 (confirmed) Kufor-Rakeb syndrome,606693/Spastic paraplegia 78,autosomal recessive,617225];	128471 [benign DISEASE=Parkinson disease 9,not specified,not provided];			rs7531163	0.3065	0.2811	989,	0.1686,0.3598,0.5507,0.2392,0.2313	0.2392,0.1686	0.9070			0.66,0.95	1.03		+6.53% (9.29>9.90)		0.001/0.100		n/a (AF>5%)	n/a (AF>5%)					ATP13A2 (inh=AR pLI=0.01), RP1-37C10.3 (inh=n/a pLI=n/a)
chr1	17313654	17313654	C	T	het	het	hom		QUAL=10654;DP=66,280,246;AF=0.52,0.48,1.00;MQM=60	ATP13A2,RP1-37C10.3	synonymous,intron&non_coding_transcript	ATP13A2:ENST00000326735:synonymous_variant:LOW:exon26/29:c.2970G>A:p.Val990=:,ATP13A2:ENST00000341676:synonymous_variant:LOW:exon25/27:c.2838G>A:p.Val946=:,RP1-37C10.3:ENST00000446261:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.187+8047C>T::,ATP13A2:ENST00000452699:synonymous_variant:LOW:exon26/29:c.2955G>A:p.Val985=:	610513 [ATP13A2 (confirmed) Kufor-Rakeb syndrome,606693/Spastic paraplegia 78,autosomal recessive,617225];	128470 [benign DISEASE=Parkinson disease 9,not specified,not provided];			rs761421	0.3462	0.4670	2984,	0.2153,0.4798,0.2851,0.5201,0.4729	0.5220,0.2374	-0.9690			0.25,0.72	1.03						n/a (AF>5%)	n/a (AF>5%)					ATP13A2 (inh=AR pLI=0.01), RP1-37C10.3 (inh=n/a pLI=n/a)
chr1	17314702	17314702	C	T	het	het	wt		QUAL=11057;DP=281,584,493;AF=0.48,0.51,0.01;MQM=60	ATP13A2,RP1-37C10.3	synonymous,intron&non_coding_transcript	ATP13A2:ENST00000326735:synonymous_variant:LOW:exon25/29:c.2790G>A:p.Ser930=:,ATP13A2:ENST00000341676:synonymous_variant:LOW:exon24/27:c.2658G>A:p.Ser886=:,RP1-37C10.3:ENST00000446261:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.187+9095C>T::,ATP13A2:ENST00000452699:synonymous_variant:LOW:exon25/29:c.2775G>A:p.Ser925=:	610513 [ATP13A2 (confirmed) Kufor-Rakeb syndrome,606693/Spastic paraplegia 78,autosomal recessive,617225];	128468 [benign DISEASE=Parkinson disease 9,not specified,not provided];			rs3738815	0.2909	0.2488	846,	0.1505,0.3344,0.5508,0.1934,0.2224	0.1927,0.1496	-2.3320			0.06,0.15	0.21						n/a (AF>5%)	n/a (AF>5%)					ATP13A2 (inh=AR pLI=0.01), RP1-37C10.3 (inh=n/a pLI=n/a)
chr1	17314942	17314942	G	A	het	het	hom		QUAL=14040;DP=300,321,262;AF=0.50,0.45,0.99;MQM=60	ATP13A2,RP1-37C10.3	synonymous,intron&non_coding_transcript	ATP13A2:ENST00000326735:synonymous_variant:LOW:exon24/29:c.2637C>T:p.Gly879=:PF12710,ATP13A2:ENST00000341676:synonymous_variant:LOW:exon23/27:c.2505C>T:p.Gly835=:PF12710,RP1-37C10.3:ENST00000446261:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.187+9335G>A::,ATP13A2:ENST00000452699:synonymous_variant:LOW:exon24/29:c.2622C>T:p.Gly874=:PF12710	610513 [ATP13A2 (confirmed) Kufor-Rakeb syndrome,606693/Spastic paraplegia 78,autosomal recessive,617225];	128466 [benign DISEASE=Parkinson disease 9,not specified,not provided];			rs9435662	0.3387	0.4650	2930,	0.1860,0.4781,0.2909,0.5192,0.4726	0.5222,0.2070	-4.7600			0.06,0.67	1.18						n/a (AF>5%)	n/a (AF>5%)					ATP13A2 (inh=AR pLI=0.01), RP1-37C10.3 (inh=n/a pLI=n/a)
chr1	17319011	17319011	G	A	het	het	hom		QUAL=6587;DP=81,152,128;AF=0.48,0.48,1.00;MQM=60	ATP13A2,RP1-37C10.3	synonymous,intron&non_coding_transcript	ATP13A2:ENST00000326735:synonymous_variant:LOW:exon17/29:c.1815C>T:p.Pro605=:PF12710,ATP13A2:ENST00000341676:synonymous_variant:LOW:exon17/27:c.1800C>T:p.Pro600=:PF12710,RP1-37C10.3:ENST00000446261:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.188-12127G>A::,ATP13A2:ENST00000452699:synonymous_variant:LOW:exon17/29:c.1800C>T:p.Pro600=:PF12710	610513 [ATP13A2 (confirmed) Kufor-Rakeb syndrome,606693/Spastic paraplegia 78,autosomal recessive,617225];	128465 [benign DISEASE=Parkinson disease 9,not specified,not provided];			rs2076603	0.4485	0.5576	4685,	0.4421,0.5458,0.2882,0.6259,0.5186	0.6323,0.4462	0.1640			0.51,0.95	1.26						n/a (AF>5%)	n/a (AF>5%)					ATP13A2 (inh=AR pLI=0.01), RP1-37C10.3 (inh=n/a pLI=n/a)
chr1	17331268	17331268	C	T	wt	wt	het		QUAL=642;DP=135,121,74;AF=0.00,0.00,0.41;MQM=60	ATP13A2,RP1-37C10.3	synonymous,non_coding_transcript_exon	ATP13A2:ENST00000326735:synonymous_variant:LOW:exon5/29:c.396G>A:p.Ala132=:PF12409,ATP13A2:ENST00000341676:synonymous_variant:LOW:exon5/27:c.396G>A:p.Ala132=:PF12409,RP1-37C10.3:ENST00000446261:non_coding_transcript_exon_variant:MODIFIER:exon2/2:n.318C>T::,ATP13A2:ENST00000452699:synonymous_variant:LOW:exon5/29:c.396G>A:p.Ala132=:PF12409	610513 [ATP13A2 (confirmed) Kufor-Rakeb syndrome,606693/Spastic paraplegia 78,autosomal recessive,617225];	293803 [uncertain significance DISEASE=Parkinson disease 9];			rs140631323		0.0001	0,	0.0000,0.0001,0.0000,0.0001,0.0002	0.0001,0.0000	-4.6690			0.02,0.09	0.10					COSM4946978,COSM80893	0	5					ATP13A2 (inh=AR pLI=0.01), RP1-37C10.3 (inh=n/a pLI=n/a)
chr1	19198064	19198064	T	G	het	het	wt		QUAL=3435;DP=96,185,149;AF=0.52,0.47,0.00;MQM=59	ALDH4A1,RP13-279N23.2	3'UTR,intron&NMD_transcript	ALDH4A1:ENST00000290597:3_prime_UTR_variant:MODIFIER:exon16/16:c.*262A>C::,ALDH4A1:ENST00000375341:3_prime_UTR_variant:MODIFIER:exon15/15:c.*1275A>C::,RP13-279N23.2:ENST00000494072:intron_variant&NMD_transcript_variant:MODIFIER:exon22/26:c.*1742+2893A>C::,ALDH4A1:ENST00000538309:3_prime_UTR_variant:MODIFIER:exon15/15:c.*1275A>C::,ALDH4A1:ENST00000538839:3_prime_UTR_variant:MODIFIER:exon14/14:c.*1275A>C::	606811 [ALDH4A1 (provisional) Hyperprolinemia,type II,239510];	294333 [likely benign DISEASE=Hyperprolinemia];			rs1138333	0.1793	0.2341	879,			1.6090			0.00,0.14	0.39						n/a (AF>5%)	n/a (AF>5%)					ALDH4A1 (inh=AR pLI=0.00), RP13-279N23.2 (inh=n/a pLI=n/a)
chr1	19198100	19198100	C	G	het	het	wt		QUAL=3404;DP=96,166,144;AF=0.55,0.49,0.00;MQM=60	ALDH4A1,RP13-279N23.2	3'UTR,intron&NMD_transcript	ALDH4A1:ENST00000290597:3_prime_UTR_variant:MODIFIER:exon16/16:c.*226G>C::,ALDH4A1:ENST00000375341:3_prime_UTR_variant:MODIFIER:exon15/15:c.*1239G>C::,RP13-279N23.2:ENST00000494072:intron_variant&NMD_transcript_variant:MODIFIER:exon22/26:c.*1742+2857G>C::,ALDH4A1:ENST00000538309:3_prime_UTR_variant:MODIFIER:exon15/15:c.*1239G>C::,ALDH4A1:ENST00000538839:3_prime_UTR_variant:MODIFIER:exon14/14:c.*1239G>C::	606811 [ALDH4A1 (provisional) Hyperprolinemia,type II,239510];	294334 [likely benign DISEASE=Hyperprolinemia];			rs1138328	0.1651	0.2276	849,			0.1130			0.00,0.11	0.10						n/a (AF>5%)	n/a (AF>5%)					ALDH4A1 (inh=AR pLI=0.00), RP13-279N23.2 (inh=n/a pLI=n/a)
chr1	19198141	19198141	T	C	het	het	wt		QUAL=3409;DP=121,146,139;AF=0.53,0.48,0.00;MQM=60	ALDH4A1,RP13-279N23.2	3'UTR,intron&NMD_transcript	ALDH4A1:ENST00000290597:3_prime_UTR_variant:MODIFIER:exon16/16:c.*185A>G::,ALDH4A1:ENST00000375341:3_prime_UTR_variant:MODIFIER:exon15/15:c.*1198A>G::,RP13-279N23.2:ENST00000494072:intron_variant&NMD_transcript_variant:MODIFIER:exon22/26:c.*1742+2816A>G::,ALDH4A1:ENST00000538309:3_prime_UTR_variant:MODIFIER:exon15/15:c.*1198A>G::,ALDH4A1:ENST00000538839:3_prime_UTR_variant:MODIFIER:exon14/14:c.*1198A>G::	606811 [ALDH4A1 (provisional) Hyperprolinemia,type II,239510];	294336 [likely benign DISEASE=Hyperprolinemia];			rs7366541	0.1799	0.2342	887,			-1.2020			0.06,0.15	0.12						n/a (AF>5%)	n/a (AF>5%)					ALDH4A1 (inh=AR pLI=0.00), RP13-279N23.2 (inh=n/a pLI=n/a)
chr1	19198414	19198414	G	A	het	het	wt		QUAL=4782;DP=168,196,168;AF=0.48,0.49,0.00;MQM=60	ALDH4A1,RP13-279N23.2	intron,3'UTR,intron&NMD_transcript	ALDH4A1:ENST00000290597:intron_variant:MODIFIER:exon15/15:c.*42-130C>T::,ALDH4A1:ENST00000375341:3_prime_UTR_variant:MODIFIER:exon15/15:c.*925C>T::,RP13-279N23.2:ENST00000494072:intron_variant&NMD_transcript_variant:MODIFIER:exon22/26:c.*1742+2543C>T::,ALDH4A1:ENST00000538309:3_prime_UTR_variant:MODIFIER:exon15/15:c.*925C>T::,ALDH4A1:ENST00000538839:3_prime_UTR_variant:MODIFIER:exon14/14:c.*925C>T::	606811 [ALDH4A1 (provisional) Hyperprolinemia,type II,239510];	294341 [likely benign DISEASE=Hyperprolinemia];			rs1140477	0.1935	0.2423	899,			0.5800			0.12,0.17	0.09						n/a (AF>5%)	n/a (AF>5%)					ALDH4A1 (inh=AR pLI=0.00), RP13-279N23.2 (inh=n/a pLI=n/a)
chr1	19198418	19198418	C	T	het	het	wt		QUAL=4782;DP=168,196,168;AF=0.48,0.49,0.00;MQM=60	ALDH4A1,RP13-279N23.2	intron,3'UTR,intron&NMD_transcript	ALDH4A1:ENST00000290597:intron_variant:MODIFIER:exon15/15:c.*42-134G>A::,ALDH4A1:ENST00000375341:3_prime_UTR_variant:MODIFIER:exon15/15:c.*921G>A::,RP13-279N23.2:ENST00000494072:intron_variant&NMD_transcript_variant:MODIFIER:exon22/26:c.*1742+2539G>A::,ALDH4A1:ENST00000538309:3_prime_UTR_variant:MODIFIER:exon15/15:c.*921G>A::,ALDH4A1:ENST00000538839:3_prime_UTR_variant:MODIFIER:exon14/14:c.*921G>A::	606811 [ALDH4A1 (provisional) Hyperprolinemia,type II,239510];	294342 [likely benign DISEASE=Hyperprolinemia];			rs1138269	0.1933	0.2424	899,			0.1330			0.06,0.16	0.12						n/a (AF>5%)	n/a (AF>5%)					ALDH4A1 (inh=AR pLI=0.00), RP13-279N23.2 (inh=n/a pLI=n/a)
chr1	19198576	19198576	A	G	hom	hom	hom		QUAL=29697;DP=367,313,238;AF=1.00,0.99,1.00;MQM=59	ALDH4A1,RP13-279N23.2	intron,3'UTR,intron&NMD_transcript	ALDH4A1:ENST00000290597:intron_variant:MODIFIER:exon15/15:c.*42-292T>C::,ALDH4A1:ENST00000375341:3_prime_UTR_variant:MODIFIER:exon15/15:c.*763T>C::,RP13-279N23.2:ENST00000494072:intron_variant&NMD_transcript_variant:MODIFIER:exon22/26:c.*1742+2381T>C::,ALDH4A1:ENST00000538309:3_prime_UTR_variant:MODIFIER:exon15/15:c.*763T>C::,ALDH4A1:ENST00000538839:3_prime_UTR_variant:MODIFIER:exon14/14:c.*763T>C::	606811 [ALDH4A1 (provisional) Hyperprolinemia,type II,239510];	294344 [likely benign DISEASE=Hyperprolinemia];			rs1138267		0.6397	6452,			-5.8090			0.01,0.12	-0.16						n/a (AF>5%)	n/a (AF>5%)					ALDH4A1 (inh=AR pLI=0.00), RP13-279N23.2 (inh=n/a pLI=n/a)
chr1	19198627	19198627	G	A	het	het	wt		QUAL=6384;DP=291,264,205;AF=0.49,0.45,0.01;MQM=60	ALDH4A1,RP13-279N23.2	intron,3'UTR,intron&NMD_transcript	ALDH4A1:ENST00000290597:intron_variant:MODIFIER:exon15/15:c.*42-343C>T::,ALDH4A1:ENST00000375341:3_prime_UTR_variant:MODIFIER:exon15/15:c.*712C>T::,RP13-279N23.2:ENST00000494072:intron_variant&NMD_transcript_variant:MODIFIER:exon22/26:c.*1742+2330C>T::,ALDH4A1:ENST00000538309:3_prime_UTR_variant:MODIFIER:exon15/15:c.*712C>T::,ALDH4A1:ENST00000538839:3_prime_UTR_variant:MODIFIER:exon14/14:c.*712C>T::	606811 [ALDH4A1 (provisional) Hyperprolinemia,type II,239510];	294346 [likely benign DISEASE=Hyperprolinemia];			rs14311	0.1935	0.2425	927,			-0.0360			0.00,0.08	0.09						n/a (AF>5%)	n/a (AF>5%)					ALDH4A1 (inh=AR pLI=0.00), RP13-279N23.2 (inh=n/a pLI=n/a)
chr1	19198637	19198637	G	A	het	het	hom		QUAL=12468;DP=240,259,206;AF=0.48,0.54,1.00;MQM=60	ALDH4A1,RP13-279N23.2	intron,3'UTR,intron&NMD_transcript	ALDH4A1:ENST00000290597:intron_variant:MODIFIER:exon15/15:c.*42-353C>T::,ALDH4A1:ENST00000375341:3_prime_UTR_variant:MODIFIER:exon15/15:c.*702C>T::,RP13-279N23.2:ENST00000494072:intron_variant&NMD_transcript_variant:MODIFIER:exon22/26:c.*1742+2320C>T::,ALDH4A1:ENST00000538309:3_prime_UTR_variant:MODIFIER:exon15/15:c.*702C>T::,ALDH4A1:ENST00000538839:3_prime_UTR_variant:MODIFIER:exon14/14:c.*702C>T::	606811 [ALDH4A1 (provisional) Hyperprolinemia,type II,239510];	294347 [likely benign DISEASE=Hyperprolinemia];			rs3202002	0.4744	0.3870	2498,			-0.3560			0.09,0.20	0.29						n/a (AF>5%)	n/a (AF>5%)					ALDH4A1 (inh=AR pLI=0.00), RP13-279N23.2 (inh=n/a pLI=n/a)
chr1	19198682	19198682	C	-	het	het	hom		QUAL=6609;DP=86,171,152;AF=0.44,0.53,0.97;MQM=60	ALDH4A1,RP13-279N23.2	intron,3'UTR,intron&NMD_transcript	ALDH4A1:ENST00000290597:intron_variant:MODIFIER:exon15/15:c.*42-398del::,ALDH4A1:ENST00000375341:3_prime_UTR_variant:MODIFIER:exon15/15:c.*657del::,RP13-279N23.2:ENST00000494072:intron_variant&NMD_transcript_variant:MODIFIER:exon22/26:c.*1742+2275del::,ALDH4A1:ENST00000538309:3_prime_UTR_variant:MODIFIER:exon15/15:c.*657del::,ALDH4A1:ENST00000538839:3_prime_UTR_variant:MODIFIER:exon14/14:c.*657del::	606811 [ALDH4A1 (provisional) Hyperprolinemia,type II,239510];	294349 [likely benign DISEASE=Hyperprolinemia];			rs11311839	0.4677	0.3943	2602,			-3.2880				-0.24						n/a (AF>5%)	n/a (AF>5%)					ALDH4A1 (inh=AR pLI=0.00), RP13-279N23.2 (inh=n/a pLI=n/a)
chr1	19198895	19198895	A	G	het	het	wt		QUAL=5017;DP=193,248,194;AF=0.48,0.45,0.00;MQM=60	ALDH4A1,RP13-279N23.2	intron,3'UTR,intron&NMD_transcript	ALDH4A1:ENST00000290597:intron_variant:MODIFIER:exon15/15:c.*41+403T>C::,ALDH4A1:ENST00000375341:3_prime_UTR_variant:MODIFIER:exon15/15:c.*444T>C::,RP13-279N23.2:ENST00000494072:intron_variant&NMD_transcript_variant:MODIFIER:exon22/26:c.*1742+2062T>C::,ALDH4A1:ENST00000538309:3_prime_UTR_variant:MODIFIER:exon15/15:c.*444T>C::,ALDH4A1:ENST00000538839:3_prime_UTR_variant:MODIFIER:exon14/14:c.*444T>C::	606811 [ALDH4A1 (provisional) Hyperprolinemia,type II,239510];	294353 [likely benign DISEASE=Hyperprolinemia];			rs9117	0.1102	0.1787	601,			0.2380			0.17,0.18	0.26						n/a (AF>5%)	n/a (AF>5%)					ALDH4A1 (inh=AR pLI=0.00), RP13-279N23.2 (inh=n/a pLI=n/a)
chr1	19199221	19199221	C	T	het	het	hom		QUAL=20910;DP=214,487,404;AF=0.44,0.47,1.00;MQM=60	ALDH4A1,RP13-279N23.2	intron,3'UTR,intron&NMD_transcript	ALDH4A1:ENST00000290597:intron_variant:MODIFIER:exon15/15:c.*41+77G>A::,ALDH4A1:ENST00000375341:3_prime_UTR_variant:MODIFIER:exon15/15:c.*118G>A::,RP13-279N23.2:ENST00000494072:intron_variant&NMD_transcript_variant:MODIFIER:exon22/26:c.*1742+1736G>A::,ALDH4A1:ENST00000538309:3_prime_UTR_variant:MODIFIER:exon15/15:c.*118G>A::,ALDH4A1:ENST00000538839:3_prime_UTR_variant:MODIFIER:exon14/14:c.*118G>A::	606811 [ALDH4A1 (provisional) Hyperprolinemia,type II,239510];	294359 [likely benign DISEASE=Hyperprolinemia];			rs11740	0.4714	0.3870	2493,			-1.0870			0.01,0.12	-0.19						n/a (AF>5%)	n/a (AF>5%)					ALDH4A1 (inh=AR pLI=0.00), RP13-279N23.2 (inh=n/a pLI=n/a)
chr1	19199473	19199473	T	A	het	het	hom	off-target	QUAL=12615;DP=148,285,227;AF=0.47,0.53,0.99;MQM=60	ALDH4A1,RP13-279N23.2	intron,intron&NMD_transcript	ALDH4A1:ENST00000290597:intron_variant:MODIFIER:exon14/15:c.1580-22A>T::,ALDH4A1:ENST00000375341:intron_variant:MODIFIER:exon14/14:c.1580-22A>T::,RP13-279N23.2:ENST00000494072:intron_variant&NMD_transcript_variant:MODIFIER:exon22/26:c.*1742+1484A>T::,ALDH4A1:ENST00000538309:intron_variant:MODIFIER:exon14/14:c.1400-22A>T::,ALDH4A1:ENST00000538839:intron_variant:MODIFIER:exon13/13:c.1427-22A>T::	606811 [ALDH4A1 (provisional) Hyperprolinemia,type II,239510];				rs28700162	0.4714	0.4725	2520,	0.2416,0.5828,0.6746,0.4246,0.5859	0.4273,0.2528	0.1100			0.12,0.19	0.14						n/a (AF>5%)	n/a (AF>5%)					ALDH4A1 (inh=AR pLI=0.00), RP13-279N23.2 (inh=n/a pLI=n/a)
chr1	19199487	19199487	A	G	het	het	wt	off-target	QUAL=4556;DP=103,254,202;AF=0.62,0.47,0.00;MQM=60	ALDH4A1,RP13-279N23.2	intron,intron&NMD_transcript	ALDH4A1:ENST00000290597:intron_variant:MODIFIER:exon14/15:c.1580-36T>C::,ALDH4A1:ENST00000375341:intron_variant:MODIFIER:exon14/14:c.1580-36T>C::,RP13-279N23.2:ENST00000494072:intron_variant&NMD_transcript_variant:MODIFIER:exon22/26:c.*1742+1470T>C::,ALDH4A1:ENST00000538309:intron_variant:MODIFIER:exon14/14:c.1400-36T>C::,ALDH4A1:ENST00000538839:intron_variant:MODIFIER:exon13/13:c.1427-36T>C::	606811 [ALDH4A1 (provisional) Hyperprolinemia,type II,239510];				rs35255325	0.1148	0.1970	608,	0.0969,0.1973,0.0007,0.2520,0.1202	0.2473,0.1030	0.5300			0.05,0.16	0.19						n/a (AF>5%)	n/a (AF>5%)					ALDH4A1 (inh=AR pLI=0.00), RP13-279N23.2 (inh=n/a pLI=n/a)
chr1	19200908	19200908	G	C	het	het	hom	off-target	QUAL=6966;DP=103,166,122;AF=0.55,0.46,1.00;MQM=60	ALDH4A1,RP13-279N23.2	intron,intron&NMD_transcript	ALDH4A1:ENST00000290597:intron_variant:MODIFIER:exon14/15:c.1579+49C>G::,ALDH4A1:ENST00000375341:intron_variant:MODIFIER:exon14/14:c.1579+49C>G::,RP13-279N23.2:ENST00000494072:intron_variant&NMD_transcript_variant:MODIFIER:exon22/26:c.*1742+49C>G::,ALDH4A1:ENST00000538309:intron_variant:MODIFIER:exon14/14:c.1399+49C>G::,ALDH4A1:ENST00000538839:intron_variant:MODIFIER:exon13/13:c.1426+49C>G::	606811 [ALDH4A1 (provisional) Hyperprolinemia,type II,239510];				rs28529092		0.4998	3124,	0.4315,0.5994,0.6758,0.4409,0.6076	0.4428,0.4274	3.0650			0.64,0.60	0.66						n/a (AF>5%)	n/a (AF>5%)					ALDH4A1 (inh=AR pLI=0.00), RP13-279N23.2 (inh=n/a pLI=n/a)
chr1	19201956	19201956	A	G	hom	hom	hom		QUAL=18277;DP=312,138,131;AF=1.00,1.00,1.00;MQM=59	ALDH4A1,RP13-279N23.2	synonymous,3'UTR&NMD_transcript	ALDH4A1:ENST00000290597:synonymous_variant:LOW:exon13/16:c.1380T>C:p.Asp460=:PF00171,ALDH4A1:ENST00000375341:synonymous_variant:LOW:exon13/15:c.1380T>C:p.Asp460=:PF00171,RP13-279N23.2:ENST00000494072:3_prime_UTR_variant&NMD_transcript_variant:MODIFIER:exon21/27:c.*1543T>C::,ALDH4A1:ENST00000538309:synonymous_variant:LOW:exon13/15:c.1200T>C:p.Asp400=:PF00171,ALDH4A1:ENST00000538839:synonymous_variant:LOW:exon12/14:c.1227T>C:p.Asp409=:	606811 [ALDH4A1 (provisional) Hyperprolinemia,type II,239510];	294369 [benign DISEASE=Hyperprolinemia];			rs2230708	0.7372	0.7323	7496,	0.6882,0.8184,0.7132,0.7192,0.7578	0.7140,0.6793	-1.4010			0.01,0.14	-0.05						n/a (AF>5%)	n/a (AF>5%)					ALDH4A1 (inh=AR pLI=0.00), RP13-279N23.2 (inh=n/a pLI=n/a)
chr1	19202770	19202770	T	C	hom	hom	hom	off-target	QUAL=4001;DP=47,54,30;AF=1.00,1.00,1.00;MQM=59	ALDH4A1,RP13-279N23.2	intron,intron&NMD_transcript	ALDH4A1:ENST00000290597:intron_variant:MODIFIER:exon12/15:c.1338+39A>G::,ALDH4A1:ENST00000375341:intron_variant:MODIFIER:exon12/14:c.1338+39A>G::,RP13-279N23.2:ENST00000494072:intron_variant&NMD_transcript_variant:MODIFIER:exon20/26:c.*1501+39A>G::,ALDH4A1:ENST00000538309:intron_variant:MODIFIER:exon12/14:c.1158+39A>G::,ALDH4A1:ENST00000538839:intron_variant:MODIFIER:exon11/13:c.1186-773A>G::	606811 [ALDH4A1 (provisional) Hyperprolinemia,type II,239510];				rs7550822	0.9195	0.9657	13270,	0.7701,0.9759,0.9999,0.9774,0.9834	0.9795,0.7848	-0.2020			0.00,0.06	0.33						n/a (AF>5%)	n/a (AF>5%)					ALDH4A1 (inh=AR pLI=0.00), RP13-279N23.2 (inh=n/a pLI=n/a)
chr1	19202896	19202896	G	A	hom	hom	het		QUAL=7396;DP=135,97,72;AF=0.98,0.99,0.33;MQM=60	ALDH4A1,RP13-279N23.2	synonymous,3'UTR&NMD_transcript,intron	ALDH4A1:ENST00000290597:synonymous_variant:LOW:exon12/16:c.1251C>T:p.Ala417=:PF00171,ALDH4A1:ENST00000375341:synonymous_variant:LOW:exon12/15:c.1251C>T:p.Ala417=:PF00171,RP13-279N23.2:ENST00000494072:3_prime_UTR_variant&NMD_transcript_variant:MODIFIER:exon20/27:c.*1414C>T::,ALDH4A1:ENST00000538309:synonymous_variant:LOW:exon12/15:c.1071C>T:p.Ala357=:PF00171,ALDH4A1:ENST00000538839:intron_variant:MODIFIER:exon11/13:c.1185+806C>T::	606811 [ALDH4A1 (provisional) Hyperprolinemia,type II,239510];	294374 [likely benign DISEASE=Hyperprolinemia];			rs2230707	0.5160	0.5110	3313,	0.4397,0.6940,0.6119,0.4696,0.4988	0.4648,0.4351	-9.2540			0.02,0.29	0.69						n/a (AF>5%)	n/a (AF>5%)					ALDH4A1 (inh=AR pLI=0.00), RP13-279N23.2 (inh=n/a pLI=n/a)
chr1	19202917	19202917	T	C	hom	hom	hom		QUAL=7685;DP=102,88,74;AF=1.00,0.99,0.97;MQM=59	ALDH4A1,RP13-279N23.2	synonymous,3'UTR&NMD_transcript,intron	ALDH4A1:ENST00000290597:synonymous_variant:LOW:exon12/16:c.1230A>G:p.Ser410=:PF00171,ALDH4A1:ENST00000375341:synonymous_variant:LOW:exon12/15:c.1230A>G:p.Ser410=:PF00171,RP13-279N23.2:ENST00000494072:3_prime_UTR_variant&NMD_transcript_variant:MODIFIER:exon20/27:c.*1393A>G::,ALDH4A1:ENST00000538309:synonymous_variant:LOW:exon12/15:c.1050A>G:p.Ser350=:PF00171,ALDH4A1:ENST00000538839:intron_variant:MODIFIER:exon11/13:c.1185+785A>G::	606811 [ALDH4A1 (provisional) Hyperprolinemia,type II,239510];	294375 [benign DISEASE=Hyperprolinemia];			rs7550938	0.6609	0.6990	6112,	0.4836,0.7950,0.7146,0.6943,0.7419	0.6938,0.4848	-5.5180			0.02,0.60	0.98						n/a (AF>5%)	n/a (AF>5%)					ALDH4A1 (inh=AR pLI=0.00), RP13-279N23.2 (inh=n/a pLI=n/a)
chr1	19202926	19202926	T	C	hom	hom	hom		QUAL=6314;DP=65,87,73;AF=1.00,0.99,0.96;MQM=59	ALDH4A1,RP13-279N23.2	synonymous,3'UTR&NMD_transcript,intron	ALDH4A1:ENST00000290597:synonymous_variant:LOW:exon12/16:c.1221A>G:p.Ala407=:PF00171,ALDH4A1:ENST00000375341:synonymous_variant:LOW:exon12/15:c.1221A>G:p.Ala407=:PF00171,RP13-279N23.2:ENST00000494072:3_prime_UTR_variant&NMD_transcript_variant:MODIFIER:exon20/27:c.*1384A>G::,ALDH4A1:ENST00000538309:synonymous_variant:LOW:exon12/15:c.1041A>G:p.Ala347=:PF00171,ALDH4A1:ENST00000538839:intron_variant:MODIFIER:exon11/13:c.1185+776A>G::	606811 [ALDH4A1 (provisional) Hyperprolinemia,type II,239510];	294376 [benign DISEASE=Hyperprolinemia];			rs2230706		0.6985	6098,	0.4825,0.7944,0.7132,0.6930,0.7421	0.6919,0.4837	0.2410			0.67,0.96	0.96						n/a (AF>5%)	n/a (AF>5%)					ALDH4A1 (inh=AR pLI=0.00), RP13-279N23.2 (inh=n/a pLI=n/a)
chr1	19203997	19203997	C	G	hom	hom	hom		QUAL=7520;DP=83,107,56;AF=0.98,1.00,1.00;MQM=59	ALDH4A1,RP13-279N23.2	synonymous,3'UTR&NMD_transcript	ALDH4A1:ENST00000290597:synonymous_variant:LOW:exon10/16:c.1050G>C:p.Ala350=:PF00171,ALDH4A1:ENST00000375341:synonymous_variant:LOW:exon10/15:c.1050G>C:p.Ala350=:PF00171,RP13-279N23.2:ENST00000494072:3_prime_UTR_variant&NMD_transcript_variant:MODIFIER:exon18/27:c.*1213G>C::,ALDH4A1:ENST00000538309:synonymous_variant:LOW:exon10/15:c.870G>C:p.Ala290=:PF00171,ALDH4A1:ENST00000538839:synonymous_variant:LOW:exon10/14:c.1050G>C:p.Ala350=:PF00171	606811 [ALDH4A1 (provisional) Hyperprolinemia,type II,239510];	294382 [benign DISEASE=Hyperprolinemia];			rs2230705	0.6416	0.7198	8042,	0.7223,0.7466,0.4518,0.7184,0.5899	0.7075,0.7193	1.5080			0.18,0.93	0.67						n/a (AF>5%)	n/a (AF>5%)					ALDH4A1 (inh=AR pLI=0.00), RP13-279N23.2 (inh=n/a pLI=n/a)
chr1	19204154	19204154	G	A	het	wt	hom	off-target	QUAL=269;DP=14,20,8;AF=0.43,0.00,1.00;MQM=60	ALDH4A1,RP13-279N23.2	intron,intron&NMD_transcript	ALDH4A1:ENST00000290597:intron_variant:MODIFIER:exon9/15:c.941-48C>T::,ALDH4A1:ENST00000375341:intron_variant:MODIFIER:exon9/14:c.941-48C>T::,RP13-279N23.2:ENST00000494072:intron_variant&NMD_transcript_variant:MODIFIER:exon17/26:c.*1104-48C>T::,ALDH4A1:ENST00000538309:intron_variant:MODIFIER:exon9/14:c.761-48C>T::,ALDH4A1:ENST00000538839:intron_variant:MODIFIER:exon9/13:c.941-48C>T::	606811 [ALDH4A1 (provisional) Hyperprolinemia,type II,239510];				rs6426813	0.8109	0.7696	7845,	0.6959,0.8857,0.9544,0.7074,0.8411	0.7255,0.7279	-0.3830			0.03,0.09	-0.12						n/a (AF>5%)	n/a (AF>5%)					ALDH4A1 (inh=AR pLI=0.00), RP13-279N23.2 (inh=n/a pLI=n/a)
chr1	19208145	19208145	-	GGTTGCCT	het	hom	hom	off-target	QUAL=728;DP=8,16,7;AF=0.88,1.00,1.00;MQM=60	ALDH4A1,RP13-279N23.2	intron,intron&NMD_transcript	ALDH4A1:ENST00000290597:intron_variant:MODIFIER:exon8/15:c.866+48_866+49insAGGCAACC::,ALDH4A1:ENST00000375341:intron_variant:MODIFIER:exon8/14:c.866+48_866+49insAGGCAACC::,RP13-279N23.2:ENST00000494072:intron_variant&NMD_transcript_variant:MODIFIER:exon16/26:c.*1029+48_*1029+49insAGGCAACC::,ALDH4A1:ENST00000538309:intron_variant:MODIFIER:exon8/14:c.686+48_686+49insAGGCAACC::,ALDH4A1:ENST00000538839:intron_variant:MODIFIER:exon8/13:c.866+48_866+49insAGGCAACC::	606811 [ALDH4A1 (provisional) Hyperprolinemia,type II,239510];				rs112548638	0.9830	0.9958	14903,	0.9431,0.9966,0.9999,0.9998,0.9995	0.9888,0.9425					-0.02						n/a (AF>5%)	n/a (AF>5%)					ALDH4A1 (inh=AR pLI=0.00), RP13-279N23.2 (inh=n/a pLI=n/a)
chr1	19211930	19211930	A	C	wt	wt	hom	off-target	QUAL=54;DP=4,5,7;AF=0.00,0.00,0.86;MQM=60	ALDH4A1,RP13-279N23.2	intron,intron&NMD_transcript	ALDH4A1:ENST00000290597:intron_variant:MODIFIER:exon5/15:c.453+37T>G::,ALDH4A1:ENST00000375341:intron_variant:MODIFIER:exon5/14:c.453+37T>G::,RP13-279N23.2:ENST00000494072:intron_variant&NMD_transcript_variant:MODIFIER:exon12/26:c.*501+37T>G::,ALDH4A1:ENST00000538309:intron_variant:MODIFIER:exon5/14:c.273+37T>G::,ALDH4A1:ENST00000538839:intron_variant:MODIFIER:exon5/13:c.453+37T>G::	606811 [ALDH4A1 (provisional) Hyperprolinemia,type II,239510];			(CACCC)n	rs752213358		0.2873	0,	0.3483,0.4498,0.4716,0.2217,0.2209		-3.0270			0.00,0.06	-0.61						n/a (AF>5%)	n/a (AF>5%)					ALDH4A1 (inh=AR pLI=0.00), RP13-279N23.2 (inh=n/a pLI=n/a)
chr1	19211935	19211935	G	C	wt	wt	het	off-target	QUAL=26;DP=2,6,9;AF=0.00,0.00,0.56;MQM=60	ALDH4A1,RP13-279N23.2	intron,intron&NMD_transcript	ALDH4A1:ENST00000290597:intron_variant:MODIFIER:exon5/15:c.453+32C>G::,ALDH4A1:ENST00000375341:intron_variant:MODIFIER:exon5/14:c.453+32C>G::,RP13-279N23.2:ENST00000494072:intron_variant&NMD_transcript_variant:MODIFIER:exon12/26:c.*501+32C>G::,ALDH4A1:ENST00000538309:intron_variant:MODIFIER:exon5/14:c.273+32C>G::,ALDH4A1:ENST00000538839:intron_variant:MODIFIER:exon5/13:c.453+32C>G::	606811 [ALDH4A1 (provisional) Hyperprolinemia,type II,239510];			(CACCC)n	rs188233802		0.3253	0,	0.4042,0.4619,0.4857,0.2667,0.2681		-0.6220			0.06,0.16	0.01						n/a (AF>5%)	n/a (AF>5%)					ALDH4A1 (inh=AR pLI=0.00), RP13-279N23.2 (inh=n/a pLI=n/a)
chr1	19215834	19215834	T	C	hom	hom	hom	off-target	QUAL=11103;DP=122,143,95;AF=1.00,1.00,1.00;MQM=59	ALDH4A1,RP13-279N23.2	intron,intron&NMD_transcript	ALDH4A1:ENST00000290597:intron_variant:MODIFIER:exon3/15:c.249+22A>G::,ALDH4A1:ENST00000375341:intron_variant:MODIFIER:exon3/14:c.249+22A>G::,RP13-279N23.2:ENST00000494072:intron_variant&NMD_transcript_variant:MODIFIER:exon10/26:c.*297+22A>G::,ALDH4A1:ENST00000538309:intron_variant:MODIFIER:exon3/14:c.69+22A>G::,ALDH4A1:ENST00000538839:intron_variant:MODIFIER:exon3/13:c.249+22A>G::	606811 [ALDH4A1 (provisional) Hyperprolinemia,type II,239510];				rs941495	0.9844	0.9674	14478,	0.9924,0.9726,0.9999,0.9567,0.9862	0.9617,0.9931	-0.2240			0.00,0.06	0.13						n/a (AF>5%)	n/a (AF>5%)					ALDH4A1 (inh=AR pLI=0.00), RP13-279N23.2 (inh=n/a pLI=n/a)
chr1	21889635	21889635	T	C	hom	het	hom		QUAL=4782;DP=30,125,90;AF=0.97,0.52,1.00;MQM=60	ALPL	synonymous	ALPL:ENST00000374832:synonymous_variant:LOW:exon5/12:c.330T>C:p.Ser110=:PF00245,ALPL:ENST00000374840:synonymous_variant:LOW:exon5/12:c.330T>C:p.Ser110=:PF00245,ALPL:ENST00000425315:synonymous_variant:LOW:exon4/11:c.330T>C:p.Ser110=:PF00245,ALPL:ENST00000539907:synonymous_variant:LOW:exon3/10:c.99T>C:p.Ser33=:PF00245,ALPL:ENST00000540617:synonymous_variant:LOW:exon4/11:c.165T>C:p.Ser55=:PF00245	171760 [ALPL (confirmed) Hypophosphatasia,infantile,241500/Hypophosphatasia,childhood,241510/Odontohypophosphatasia,146300/Hypophosphatasia,adult,146300];	197678 [benign DISEASE=not specified];			rs1780316	0.9295	0.9473	13286,	0.8639,0.9678,0.9867,0.9436,0.9537	0.9493,0.8679	-0.9200			0.01,0.95	0.29						n/a (AF>5%)	n/a (AF>5%)					ALPL (inh=AR+AD pLI=0.00)
chr1	21896925	21896925	C	T	het	het	wt	off-target	QUAL=6279;DP=188,305,243;AF=0.49,0.55,0.00;MQM=60	ALPL	intron	ALPL:ENST00000374830:intron_variant:MODIFIER:exon1/3:c.-66+58C>T::,ALPL:ENST00000374832:intron_variant:MODIFIER:exon8/11:c.862+58C>T::,ALPL:ENST00000374840:intron_variant:MODIFIER:exon8/11:c.862+58C>T::,ALPL:ENST00000425315:intron_variant:MODIFIER:exon7/10:c.862+58C>T::,ALPL:ENST00000539907:intron_variant:MODIFIER:exon6/9:c.631+58C>T::,ALPL:ENST00000540617:intron_variant:MODIFIER:exon7/10:c.697+58C>T::	171760 [ALPL (confirmed) Hypophosphatasia,infantile,241500/Hypophosphatasia,childhood,241510/Odontohypophosphatasia,146300/Hypophosphatasia,adult,146300];				rs2275375	0.3231	0.2610	1109,		0.2065,0.3114	-1.6000			0.01,0.13	-0.44						n/a (AF>5%)	n/a (AF>5%)					ALPL (inh=AR+AD pLI=0.00)
chr1	21904206	21904206	C	T	wt	wt	het		QUAL=1738;DP=59,235,173;AF=0.00,0.00,0.46;MQM=60	ALPL	3'UTR	ALPL:ENST00000374829:3_prime_UTR_variant:MODIFIER:exon4/4:c.*65C>T::,ALPL:ENST00000374830:3_prime_UTR_variant:MODIFIER:exon4/4:c.*65C>T::,ALPL:ENST00000374832:3_prime_UTR_variant:MODIFIER:exon12/12:c.*65C>T::,ALPL:ENST00000374840:3_prime_UTR_variant:MODIFIER:exon12/12:c.*65C>T::,ALPL:ENST00000425315:3_prime_UTR_variant:MODIFIER:exon11/11:c.*65C>T::,ALPL:ENST00000539907:3_prime_UTR_variant:MODIFIER:exon10/10:c.*65C>T::,ALPL:ENST00000540617:3_prime_UTR_variant:MODIFIER:exon11/11:c.*65C>T::	171760 [ALPL (confirmed) Hypophosphatasia,infantile,241500/Hypophosphatasia,childhood,241510/Odontohypophosphatasia,146300/Hypophosphatasia,adult,146300];	295558 [benign DISEASE=Hypophosphatasia];			rs1697405	0.3367	0.3527	1997,			4.1560			0.71,0.96	0.88						n/a (AF>5%)	n/a (AF>5%)					ALPL (inh=AR+AD pLI=0.00)
chr1	21904263	21904263	C	-	het	wt	het		QUAL=20844;DP=200,281,240;AF=0.98,1.00,0.98;MQM=59	ALPL	3'UTR	ALPL:ENST00000374829:3_prime_UTR_variant:MODIFIER:exon4/4:c.*124del::,ALPL:ENST00000374832:3_prime_UTR_variant:MODIFIER:exon12/12:c.*124del::,ALPL:ENST00000374840:3_prime_UTR_variant:MODIFIER:exon12/12:c.*124del::,ALPL:ENST00000425315:3_prime_UTR_variant:MODIFIER:exon11/11:c.*124del::,ALPL:ENST00000539907:3_prime_UTR_variant:MODIFIER:exon10/10:c.*124del::,ALPL:ENST00000540617:3_prime_UTR_variant:MODIFIER:exon11/11:c.*124del::	171760 [ALPL (confirmed) Hypophosphatasia,infantile,241500/Hypophosphatasia,childhood,241510/Odontohypophosphatasia,146300/Hypophosphatasia,adult,146300];	295560 [likely benign DISEASE=Hypophosphatasia];			rs140511985	0.0228	0.0449	50,			1.4120				1.32						1	30					ALPL (inh=AR+AD pLI=0.00)
chr1	21904267	21904267	A	G	hom	hom	hom		QUAL=20844;DP=200,281,240;AF=0.98,1.00,0.98;MQM=59	ALPL	3'UTR	ALPL:ENST00000374829:3_prime_UTR_variant:MODIFIER:exon4/4:c.*126A>G::,ALPL:ENST00000374832:3_prime_UTR_variant:MODIFIER:exon12/12:c.*126A>G::,ALPL:ENST00000374840:3_prime_UTR_variant:MODIFIER:exon12/12:c.*126A>G::,ALPL:ENST00000425315:3_prime_UTR_variant:MODIFIER:exon11/11:c.*126A>G::,ALPL:ENST00000539907:3_prime_UTR_variant:MODIFIER:exon10/10:c.*126A>G::,ALPL:ENST00000540617:3_prime_UTR_variant:MODIFIER:exon11/11:c.*126A>G::	171760 [ALPL (confirmed) Hypophosphatasia,infantile,241500/Hypophosphatasia,childhood,241510/Odontohypophosphatasia,146300/Hypophosphatasia,adult,146300];	295561 [benign DISEASE=Hypophosphatasia];			rs1697406	0.8682	0.8703	11703,			0.7810			0.00,0.89	1.55						n/a (AF>5%)	n/a (AF>5%)					ALPL (inh=AR+AD pLI=0.00)
chr1	21904374	21904374	A	C	wt	het	wt		QUAL=2236;DP=127,197,191;AF=0.00,0.46,0.00;MQM=60	ALPL	3'UTR	ALPL:ENST00000374829:3_prime_UTR_variant:MODIFIER:exon4/4:c.*233A>C::,ALPL:ENST00000374832:3_prime_UTR_variant:MODIFIER:exon12/12:c.*233A>C::,ALPL:ENST00000374840:3_prime_UTR_variant:MODIFIER:exon12/12:c.*233A>C::,ALPL:ENST00000425315:3_prime_UTR_variant:MODIFIER:exon11/11:c.*233A>C::,ALPL:ENST00000539907:3_prime_UTR_variant:MODIFIER:exon10/10:c.*233A>C::,ALPL:ENST00000540617:3_prime_UTR_variant:MODIFIER:exon11/11:c.*233A>C::	171760 [ALPL (confirmed) Hypophosphatasia,infantile,241500/Hypophosphatasia,childhood,241510/Odontohypophosphatasia,146300/Hypophosphatasia,adult,146300];	295563 [benign DISEASE=Hypophosphatasia];			rs1772719	0.1645	0.1824	526,			0.5040			0.48,0.95	1.25						n/a (AF>5%)	n/a (AF>5%)					ALPL (inh=AR+AD pLI=0.00)
chr1	22149183	22149183	G	C	het	hom	wt		QUAL=1437;DP=26,42,28;AF=0.58,1.00,0.00;MQM=60	LDLRAD2,HSPG2	3'UTR,intron	LDLRAD2:ENST00000344642:3_prime_UTR_variant:MODIFIER:exon5/5:c.*475G>C::,HSPG2:ENST00000374695:3_prime_UTR_variant:MODIFIER:exon97/97:c.*626C>G::,LDLRAD2:ENST00000543870:intron_variant:MODIFIER:exon5/5:c.*218+257G>C::	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];	295685 [benign DISEASE=Schwartz Jampel syndrome type 1,Dyssegmental Dysplasia];			rs1049644	0.3199	0.2999	1504,			2.2390			0.26,0.18	0.26						n/a (AF>5%)	n/a (AF>5%)					LDLRAD2 (inh=n/a pLI=0.00), HSPG2 (inh=AR pLI=0.00)
chr1	22149935	22149935	T	C	hom	hom	hom		QUAL=15110;DP=112,233,143;AF=1.00,1.00,1.00;MQM=60	LDLRAD2,HSPG2	3'UTR,synonymous,intron	LDLRAD2:ENST00000344642:3_prime_UTR_variant:MODIFIER:exon5/5:c.*1227T>C::,HSPG2:ENST00000374695:synonymous_variant:LOW:exon97/97:c.13050A>G:p.Ser4350=:PF00054,LDLRAD2:ENST00000543870:intron_variant:MODIFIER:exon5/5:c.*219-468T>C::	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];	295695 [benign DISEASE=Schwartz Jampel syndrome type 1,Dyssegmental Dysplasia];			rs897467		0.8081	9700,	0.7074,0.7491,0.8181,0.8247,0.8263	0.8281,0.7223	-3.5700			0.04,0.86	1.46						n/a (AF>5%)	n/a (AF>5%)					LDLRAD2 (inh=n/a pLI=0.00), HSPG2 (inh=AR pLI=0.00)
chr1	22150118	22150118	C	T	wt	het	wt		QUAL=3345;DP=144,316,206;AF=0.00,0.44,0.00;MQM=60	LDLRAD2,HSPG2	3'UTR,missense,intron	LDLRAD2:ENST00000344642:3_prime_UTR_variant:MODIFIER:exon5/5:c.*1410C>T::,HSPG2:ENST00000374695:missense_variant:MODERATE:exon96/97:c.12994G>A:p.Val4332Ile:PF00054,LDLRAD2:ENST00000543870:intron_variant:MODIFIER:exon5/5:c.*219-285C>T::	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];	295699 [likely benign DISEASE=Schwartz Jampel syndrome type 1,Dyssegmental Dysplasia];			rs1138469	0.0453	0.0575	42,	0.0281,0.0265,0.0002,0.0620,0.1030	0.0615,0.0379	-1.4120	 ,T, 	 ,B, 	0.03,0.58	0.55	0.21					n/a (AF>5%)	n/a (AF>5%)					LDLRAD2 (inh=n/a pLI=0.00), HSPG2 (inh=AR pLI=0.00)
chr1	22150120	22150120	C	T	het	het	wt		QUAL=5797;DP=150,317,208;AF=0.45,0.55,0.01;MQM=59	LDLRAD2,HSPG2	3'UTR,missense,intron	LDLRAD2:ENST00000344642:3_prime_UTR_variant:MODIFIER:exon5/5:c.*1412C>T::,HSPG2:ENST00000374695:missense_variant:MODERATE:exon96/97:c.12992G>A:p.Ser4331Asn:PF00054,LDLRAD2:ENST00000543870:intron_variant:MODIFIER:exon5/5:c.*219-283C>T::	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];	295700 [benign DISEASE=Schwartz Jampel syndrome type 1,Dyssegmental Dysplasia];			rs3736360	0.1761	0.1826	411,	0.0822,0.1275,0.1609,0.1796,0.2856	0.1762,0.0869	0.0960	 ,T, 	 ,B, 	0.21,0.89	1.87	0.12					n/a (AF>5%)	n/a (AF>5%)					LDLRAD2 (inh=n/a pLI=0.00), HSPG2 (inh=AR pLI=0.00)
chr1	22150160	22150160	G	T	het	het	wt		QUAL=8032;DP=293,325,205;AF=0.49,0.55,0.01;MQM=59	LDLRAD2,HSPG2	3'UTR,synonymous,intron	LDLRAD2:ENST00000344642:3_prime_UTR_variant:MODIFIER:exon5/5:c.*1452G>T::,HSPG2:ENST00000374695:synonymous_variant:LOW:exon96/97:c.12952C>A:p.Arg4318=:PF00054,LDLRAD2:ENST00000543870:intron_variant:MODIFIER:exon5/5:c.*219-243G>T::	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];	295701 [benign DISEASE=Schwartz Jampel syndrome type 1,Dyssegmental Dysplasia];			rs3736358		0.1795	389,	0.0344,0.1264,0.1610,0.1797,0.2857	0.1755,0.0400	3.5060			0.92,0.96	1.92						n/a (AF>5%)	n/a (AF>5%)					LDLRAD2 (inh=n/a pLI=0.00), HSPG2 (inh=AR pLI=0.00)
chr1	22150257	22150257	C	T	het	wt	hom	off-target	QUAL=3618;DP=73,203,108;AF=0.51,0.00,0.99;MQM=60	LDLRAD2,HSPG2	3'UTR,intron	LDLRAD2:ENST00000344642:3_prime_UTR_variant:MODIFIER:exon5/5:c.*1549C>T::,HSPG2:ENST00000374695:intron_variant:MODIFIER:exon95/96:c.12900-45G>A::,LDLRAD2:ENST00000543870:intron_variant:MODIFIER:exon5/5:c.*219-146C>T::	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];				rs3736357	0.3752	0.4678	2836,	0.1374,0.5322,0.6496,0.4900,0.3369	0.4941,0.1410	1.4950			0.09,0.16	0.11						n/a (AF>5%)	n/a (AF>5%)					LDLRAD2 (inh=n/a pLI=0.00), HSPG2 (inh=AR pLI=0.00)
chr1	22154845	22154845	A	G	het	hom	wt		QUAL=1275;DP=42,32,38;AF=0.36,0.97,0.00;MQM=60	HSPG2	synonymous	HSPG2:ENST00000374695:synonymous_variant:LOW:exon89/97:c.12312T>C:p.Asp4104=:	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];	295707 [benign DISEASE=Schwartz Jampel syndrome type 1,Dyssegmental Dysplasia];			rs2228347	0.2572	0.2931	1070,	0.1324,0.1841,0.1598,0.3081,0.4744	0.3063,0.1471	1.3460			0.11,0.83	1.80						n/a (AF>5%)	n/a (AF>5%)					HSPG2 (inh=AR pLI=0.00)
chr1	22155841	22155841	T	C	het	het	wt	off-target	QUAL=1219;DP=39,75,67;AF=0.51,0.52,0.00;MQM=59	HSPG2	intron	HSPG2:ENST00000374695:intron_variant:MODIFIER:exon87/96:c.11992+35A>G::	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];				rs12042189	0.1564	0.1800	392,	0.0342,0.1271,0.1595,0.1793,0.2848	0.1770,0.0402	-1.8010			0.03,0.13	-0.35						n/a (AF>5%)	n/a (AF>5%)					HSPG2 (inh=AR pLI=0.00)
chr1	22155853	22155853	C	T	het	het	wt	off-target	QUAL=1404;DP=59,83,71;AF=0.37,0.54,0.00;MQM=59	HSPG2	intron	HSPG2:ENST00000374695:intron_variant:MODIFIER:exon87/96:c.11992+23G>A::	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];				rs12023794	0.1715	0.1815	423,	0.0840,0.1273,0.1664,0.1788,0.2760	0.1743,0.0887	-0.8760			0.03,0.15	-0.10						n/a (AF>5%)	n/a (AF>5%)					HSPG2 (inh=AR pLI=0.00)
chr1	22157689	22157689	G	A	hom	hom	hom	off-target	QUAL=16289;DP=95,257,206;AF=1.00,1.00,1.00;MQM=60	HSPG2	intron	HSPG2:ENST00000374695:intron_variant:MODIFIER:exon84/96:c.11562+19C>T::	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];				rs3736355	0.7592	0.7916	9214,	0.6953,0.7405,0.8074,0.8011,0.8097	0.8022,0.7068	-2.8310			0.03,0.16	-0.17						n/a (AF>5%)	n/a (AF>5%)					HSPG2 (inh=AR pLI=0.00)
chr1	22158120	22158120	G	T	het	het	wt	off-target	QUAL=2891;DP=81,143,101;AF=0.52,0.55,0.00;MQM=59	HSPG2	intron	HSPG2:ENST00000374695:intron_variant:MODIFIER:exon82/96:c.11352+25C>A::	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];				rs2270701	0.1651	0.1824	392,	0.0588,0.1282,0.1594,0.1799,0.2871	0.1756,0.0640	-2.9900			0.06,0.11	-0.34						n/a (AF>5%)	n/a (AF>5%)					HSPG2 (inh=AR pLI=0.00)
chr1	22159774	22159774	G	A	het	het	wt		QUAL=4199;DP=137,237,207;AF=0.45,0.50,0.00;MQM=60	HSPG2	synonymous	HSPG2:ENST00000374695:synonymous_variant:LOW:exon80/97:c.11082C>T:p.Pro3694=:PF02210	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];	295724 [likely benign DISEASE=Schwartz Jampel syndrome type 1,Dyssegmental Dysplasia];			rs2229486	0.0859	0.0958	184,	0.1717,0.0411,0.0002,0.0795,0.1110	0.0767,0.1729	-3.3550			0.09,0.43	0.41						n/a (AF>5%)	n/a (AF>5%)					HSPG2 (inh=AR pLI=0.00)
chr1	22160043	22160043	C	T	het	het	wt		QUAL=5324;DP=186,284,223;AF=0.44,0.49,0.00;MQM=60	HSPG2	missense	HSPG2:ENST00000374695:missense_variant:MODERATE:exon79/97:c.10895G>A:p.Arg3632Gln:PF07679	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];	295727 [likely benign DISEASE=Schwartz Jampel syndrome type 1,Dyssegmental Dysplasia];			rs2229493	0.0859	0.0960	183,	0.1727,0.0411,0.0001,0.0795,0.1111	0.0769,0.1732	-0.0650	T	B	0.19,0.21	-0.05	0.05					n/a (AF>5%)	n/a (AF>5%)					HSPG2 (inh=AR pLI=0.00)
chr1	22160148	22160148	C	T	het	wt	hom	off-target	QUAL=5257;DP=100,183,131;AF=0.60,0.00,1.00;MQM=60	HSPG2	intron	HSPG2:ENST00000374695:intron_variant:MODIFIER:exon78/96:c.10831-41G>A::	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];				rs7547731	0.3750	0.4640	2850,	0.1376,0.5311,0.6479,0.4864,0.3312	0.4922,0.1437	-2.7290			0.06,0.14	-0.16						n/a (AF>5%)	n/a (AF>5%)					HSPG2 (inh=AR pLI=0.00)
chr1	22163390	22163390	G	A	het	het	wt		QUAL=5507;DP=180,354,226;AF=0.51,0.40,0.00;MQM=60	HSPG2	synonymous	HSPG2:ENST00000374695:synonymous_variant:LOW:exon75/97:c.10260C>T:p.His3420=:PF07679	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];	295741 [likely benign DISEASE=Schwartz Jampel syndrome type 1,Dyssegmental Dysplasia];			rs35444472	0.0861	0.0952	179,	0.1703,0.0429,0.0002,0.0796,0.1121	0.0737,0.1664	2.3820			0.80,0.90	0.50						n/a (AF>5%)	n/a (AF>5%)					HSPG2 (inh=AR pLI=0.00)
chr1	22163402	22163402	G	A	wt	het	wt		QUAL=5289;DP=176,348,223;AF=0.00,0.60,0.00;MQM=60	HSPG2	synonymous	HSPG2:ENST00000374695:synonymous_variant:LOW:exon75/97:c.10248C>T:p.Ser3416=:PF07679	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];	295743 [likely benign DISEASE=Schwartz Jampel syndrome type 1,Dyssegmental Dysplasia];	CS011537 [CLASS=DM? MUT=ALT PHEN="Dyssegmental dysplasia Silverman-Handmaker type" GENE=HSPG2];		rs41310390	0.0437	0.0593	41,	0.0285,0.0280,0.0001,0.0642,0.0970	0.0614,0.0377	-2.4040			0.11,0.76	0.40						n/a (AF>5%)	n/a (AF>5%)					HSPG2 (inh=AR pLI=0.00)
chr1	22165901	22165901	A	G	het	het	wt		QUAL=2726;DP=84,87,39;AF=0.64,0.67,0.00;MQM=59	HSPG2	synonymous	HSPG2:ENST00000374695:synonymous_variant:LOW:exon73/97:c.9852T>C:p.Ala3284=:PF07679	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];	295750 [benign DISEASE=Schwartz Jampel syndrome type 1,Dyssegmental Dysplasia];			rs2291826	0.3460	0.3318	1941,	0.5378,0.1852,0.1611,0.2601,0.3821	0.2571,0.5311	-3.4070			0.02,0.12	-0.35						n/a (AF>5%)	n/a (AF>5%)					HSPG2 (inh=AR pLI=0.00)
chr1	22167605	22167605	C	T	het	het	wt		QUAL=2026;DP=48,182,164;AF=0.46,0.41,0.00;MQM=60	HSPG2	missense	HSPG2:ENST00000374695:missense_variant:MODERATE:exon71/97:c.9502G>A:p.Ala3168Thr:PF07679	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];	295758 [likely benign DISEASE=Schwartz Jampel syndrome type 1,Dyssegmental Dysplasia];			rs2228349	0.0837	0.0929	172,	0.1605,0.0404,0.0001,0.0788,0.1107	0.0755,0.1576	0.9110	T	B	0.31,0.27	0.29	0.12					n/a (AF>5%)	n/a (AF>5%)					HSPG2 (inh=AR pLI=0.00)
chr1	22168216	22168216	C	T	het	wt	hom	off-target	QUAL=6302;DP=76,231,182;AF=0.47,0.00,1.00;MQM=60	HSPG2	intron	HSPG2:ENST00000374695:intron_variant:MODIFIER:exon69/96:c.9194-50G>A::	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];				rs7556412	0.6238	0.6521	6207,	0.5017,0.6170,0.8169,0.6587,0.6022	0.6619,0.5002	-0.8510			0.08,0.23	0.26						n/a (AF>5%)	n/a (AF>5%)					HSPG2 (inh=AR pLI=0.00)
chr1	22168801	22168801	T	C	het	het	wt		QUAL=1433;DP=62,87,76;AF=0.45,0.43,0.00;MQM=59	HSPG2	missense	HSPG2:ENST00000374695:missense_variant:MODERATE:exon68/97:c.8983A>G:p.Ser2995Gly:PF13895	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];	295764 [benign/likely benign DISEASE=Schwartz Jampel syndrome type 1,Dyssegmental Dysplasia,not specified];			rs2229491	0.0887	0.0975	192,	0.1809,0.0412,0.0001,0.0795,0.1105	0.0767,0.1813	-0.0660	T	B	0.01,0.13	-0.03	0.04					n/a (AF>5%)	n/a (AF>5%)					HSPG2 (inh=AR pLI=0.00)
chr1	22168845	22168845	A	T	het	het	wt		QUAL=928;DP=42,57,44;AF=0.52,0.39,0.00;MQM=60	HSPG2	missense	HSPG2:ENST00000374695:missense_variant:MODERATE:exon68/97:c.8939T>A:p.Leu2980His:PF13895	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];	295765 [benign/likely benign DISEASE=Schwartz Jampel syndrome type 1,Dyssegmental Dysplasia,not specified];			rs2229489	0.0343	0.0495	32,	0.0082,0.0239,0.0001,0.0570,0.1052	0.0557,0.0091	1.8860	T	B	0.18,0.31	1.16	0.07					0	0					HSPG2 (inh=AR pLI=0.00)
chr1	22173144	22173144	C	T	het	het	wt	off-target	QUAL=8103;DP=105,508,377;AF=0.54,0.54,0.00;MQM=59	HSPG2	intron	HSPG2:ENST00000374695:intron_variant:MODIFIER:exon62/96:c.8165-52G>A::,HSPG2:ENST00000430507:intron_variant:MODIFIER:exon17/18:c.*1514-52G>A::	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];				rs34792235	0.0347	0.0498	32,	0.0081,0.0239,0.0001,0.0571,0.1064	0.0559,0.0068	-1.2250			0.03,0.15	0.30						0	0					HSPG2 (inh=AR pLI=0.00)
chr1	22173990	22173990	A	G	het	het	wt		QUAL=7178;DP=159,425,326;AF=0.55,0.49,0.00;MQM=59	HSPG2	splice_region&intron	HSPG2:ENST00000374695:splice_region_variant&intron_variant:LOW:exon61/96:c.8026-5T>C::,HSPG2:ENST00000430507:splice_region_variant&intron_variant:LOW:exon16/18:c.*1375-5T>C::	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];	295781 [likely benign DISEASE=Schwartz Jampel syndrome type 1,Dyssegmental Dysplasia];			rs35917892	0.0347	0.0497	32,	0.0082,0.0239,0.0001,0.0571,0.1063	0.0571,0.0093	-1.2120			0.01,0.10	-0.18		-15.35% (4.39>3.72)				0	0					HSPG2 (inh=AR pLI=0.00)
chr1	22174426	22174426	T	G	het	hom	wt	off-target	QUAL=11568;DP=183,324,312;AF=0.45,0.99,0.01;MQM=60	HSPG2	intron	HSPG2:ENST00000374695:intron_variant:MODIFIER:exon60/96:c.7873+25A>C::,HSPG2:ENST00000430507:intron_variant:MODIFIER:exon15/18:c.*1222+25A>C::	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];				rs2290501	0.3748	0.3668	2237,	0.5248,0.2074,0.1707,0.3147,0.4766	0.3108,0.5288	-0.0010			0.01,0.13	0.35						n/a (AF>5%)	n/a (AF>5%)					HSPG2 (inh=AR pLI=0.00)
chr1	22174518	22174518	G	T	het	het	wt		QUAL=7404;DP=270,363,358;AF=0.43,0.51,0.00;MQM=59	HSPG2	synonymous,3'UTR	HSPG2:ENST00000374695:synonymous_variant:LOW:exon60/97:c.7806C>A:p.Val2602=:PF07679,HSPG2:ENST00000430507:3_prime_UTR_variant:MODIFIER:exon15/19:c.*1155C>A::	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];	295785 [likely benign DISEASE=Schwartz Jampel syndrome type 1,Dyssegmental Dysplasia];			rs12737091	0.0347	0.0497	30,	0.0082,0.0239,0.0001,0.0570,0.1063	0.0571,0.0093	1.2660			0.69,0.85	0.35						0	0					HSPG2 (inh=AR pLI=0.00)
chr1	22174600	22174600	A	G	hom	hom	hom	off-target	QUAL=17436;DP=85,247,235;AF=1.00,1.00,1.00;MQM=60	HSPG2	intron	HSPG2:ENST00000374695:intron_variant:MODIFIER:exon59/96:c.7738-14T>C::,HSPG2:ENST00000430507:intron_variant:MODIFIER:exon14/18:c.*1087-14T>C::	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];	295787 [benign DISEASE=Schwartz Jampel syndrome type 1,Dyssegmental Dysplasia];			rs3767138	0.7620	0.7953	9457,	0.7013,0.6932,0.8197,0.8174,0.8138	0.8193,0.7145	0.4330			0.01,0.16	0.69		-1.00% (10.37>10.27)				n/a (AF>5%)	n/a (AF>5%)					HSPG2 (inh=AR pLI=0.00)
chr1	22175096	22175096	T	C	het	het	wt	off-target	QUAL=1838;DP=63,86,56;AF=0.48,0.58,0.00;MQM=60	HSPG2	intron	HSPG2:ENST00000374695:intron_variant:MODIFIER:exon59/96:c.7737+40A>G::,HSPG2:ENST00000430507:intron_variant:MODIFIER:exon14/18:c.*1086+40A>G::	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];				rs34726153	0.0349	0.0500	32,	0.0084,0.0242,0.0001,0.0574,0.1064	0.0574,0.0091	-1.9520			0.04,0.14	-0.06						n/a (AF>5%)	n/a (AF>5%)					HSPG2 (inh=AR pLI=0.00)
chr1	22178469	22178469	A	G	het	het	wt	off-target	QUAL=2490;DP=66,122,84;AF=0.61,0.53,0.02;MQM=60	HSPG2	intron	HSPG2:ENST00000374695:intron_variant:MODIFIER:exon53/96:c.6871-50T>C::,HSPG2:ENST00000430507:intron_variant:MODIFIER:exon8/18:c.*220-50T>C::	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];				rs34346159	0.0347	0.0495	32,	0.0081,0.0239,0.0001,0.0568,0.1063	0.0538,0.0091	-0.3870			0.00,0.08	0.28						0	0					HSPG2 (inh=AR pLI=0.00)
chr1	22179244	22179244	C	T	het	het	wt		QUAL=3493;DP=86,203,152;AF=0.43,0.51,0.00;MQM=60	HSPG2	missense,3'UTR	HSPG2:ENST00000374695:missense_variant:MODERATE:exon52/97:c.6673G>A:p.Gly2225Ser:PF07679,HSPG2:ENST00000430507:3_prime_UTR_variant:MODIFIER:exon7/19:c.*22G>A::	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];	295807 [likely benign DISEASE=Schwartz Jampel syndrome type 1,Dyssegmental Dysplasia];			rs35669711	0.0347	0.0498	31,	0.0083,0.0240,0.0001,0.0571,0.1064	0.0571,0.0095	-0.1820	T, 	B, 	0.13,0.20	0.93	0.23					0	0					HSPG2 (inh=AR pLI=0.00)
chr1	22179451	22179451	C	T	het	het	wt		QUAL=5825;DP=78,434,272;AF=0.49,0.46,0.00;MQM=59	HSPG2	synonymous	HSPG2:ENST00000374695:synonymous_variant:LOW:exon51/97:c.6552G>A:p.Thr2184=:PF07679,HSPG2:ENST00000430507:synonymous_variant:LOW:exon6/19:c.390G>A:p.Thr130=:PF00047	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];	295810 [likely benign DISEASE=Schwartz Jampel syndrome type 1,Dyssegmental Dysplasia];			rs34443576	0.0345	0.0499	32,	0.0084,0.0242,0.0003,0.0570,0.1066	0.0568,0.0095	-10.2480			0.02,0.10	-0.23						0	0					HSPG2 (inh=AR pLI=0.00)
chr1	22180723	22180723	C	T	het	het	wt		QUAL=3033;DP=84,196,143;AF=0.45,0.51,0.00;MQM=60	HSPG2	synonymous,splice_region&intron	HSPG2:ENST00000374695:synonymous_variant:LOW:exon50/97:c.6402G>A:p.Val2134=:PF07679,HSPG2:ENST00000430507:splice_region_variant&intron_variant:LOW:exon4/18:c.249+3G>A::	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];	285614 [benign/likely benign DISEASE=Schwartz Jampel syndrome type 1,Dyssegmental Dysplasia,not specified];			rs12742444	0.0345	0.0477	31,	0.0072,0.0234,0.0001,0.0542,0.1050	0.0547,0.0093	0.5220			0.53,0.86	0.39		-31.48% (-13.40>-9.18)				0	0					HSPG2 (inh=AR pLI=0.00)
chr1	22181322	22181322	A	G	het	het	wt	off-target	QUAL=1239;DP=44,74,63;AF=0.57,0.43,0.00;MQM=60	HSPG2	intron	HSPG2:ENST00000374695:intron_variant:MODIFIER:exon48/96:c.6133+19T>C::,HSPG2:ENST00000430507:intron_variant:MODIFIER:exon2/18:c.-18+19T>C::	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];				rs36080251	0.0345	0.0496	31,	0.0081,0.0241,0.0001,0.0568,0.1065	0.0569,0.0093	-0.7900			0.04,0.15	0.07						0	0					HSPG2 (inh=AR pLI=0.00)
chr1	22181895	22181895	C	T	het	het	wt		QUAL=5746;DP=157,312,258;AF=0.51,0.54,0.00;MQM=59	HSPG2	missense	HSPG2:ENST00000374695:missense_variant:MODERATE:exon47/97:c.5899G>A:p.Val1967Ile:PF07679	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];	295823 [likely benign DISEASE=Schwartz Jampel syndrome type 1,Dyssegmental Dysplasia];			rs2229475	0.0347	0.0492	32,	0.0080,0.0238,0.0001,0.0563,0.1058	0.0565,0.0093	1.8270	T	D	0.81,0.94	2.86	0.24					0	0					HSPG2 (inh=AR pLI=0.00)
chr1	22183471	22183471	A	C	hom	hom	hom	off-target	QUAL=1106;DP=20,13,7;AF=1.00,1.00,1.00;MQM=60	HSPG2	intron	HSPG2:ENST00000374695:intron_variant:MODIFIER:exon44/96:c.5575+37T>G::	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];				rs12024579	0.7490	0.7892	9158,	0.6602,0.7029,0.8161,0.8112,0.7982	0.8131,0.6707	-1.1730			0.01,0.11	0.16						n/a (AF>5%)	n/a (AF>5%)					HSPG2 (inh=AR pLI=0.00)
chr1	22183476	22183476	A	G	het	het	wt	off-target	QUAL=121;DP=20,13,8;AF=0.20,0.54,0.00;MQM=60	HSPG2	intron	HSPG2:ENST00000374695:intron_variant:MODIFIER:exon44/96:c.5575+32T>C::	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];				rs200354565	0.0461	0.0529	33,	0.0407,0.0257,0.0002,0.0586,0.1072		-1.9140			0.01,0.11	0.10						n/a (AF>5%)	n/a (AF>5%)					HSPG2 (inh=AR pLI=0.00)
chr1	22183477	22183477	G	T	het	het	wt	off-target	QUAL=121;DP=20,13,8;AF=0.20,0.54,0.00;MQM=60	HSPG2	intron	HSPG2:ENST00000374695:intron_variant:MODIFIER:exon44/96:c.5575+31C>A::	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];				rs12757277	0.0461	0.0529	33,	0.0407,0.0257,0.0002,0.0586,0.1072		-3.3630			0.04,0.12	-0.40						n/a (AF>5%)	n/a (AF>5%)					HSPG2 (inh=AR pLI=0.00)
chr1	22183739	22183739	A	G	hom	het	hom	off-target	QUAL=7853;DP=98,114,120;AF=1.00,0.48,1.00;MQM=59	HSPG2	intron	HSPG2:ENST00000374695:intron_variant:MODIFIER:exon43/96:c.5394+39T>C::	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];				rs2305562	0.4469	0.5098	3999,	0.4197,0.4833,0.4474,0.5463,0.3858	0.5549,0.4178	1.6230			0.13,0.23	0.55						n/a (AF>5%)	n/a (AF>5%)					HSPG2 (inh=AR pLI=0.00)
chr1	22191454	22191454	G	A	het	wt	hom		QUAL=7124;DP=123,348,210;AF=0.39,0.00,1.00;MQM=59	HSPG2	missense	HSPG2:ENST00000374695:missense_variant:MODERATE:exon36/97:c.4508C>T:p.Ala1503Val:PF00052	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];	291236 [benign DISEASE=Schwartz Jampel syndrome type 1,Dyssegmental Dysplasia,not specified];			rs897471	0.6915	0.7312	7801,	0.6118,0.8066,0.8933,0.7348,0.5761	0.7396,0.6198	2.2610	T	D	0.46,0.70	2.34	0.15					n/a (AF>5%)	n/a (AF>5%)					HSPG2 (inh=AR pLI=0.00)
chr1	22199081	22199081	A	T	hom	hom	hom	off-target	QUAL=5921;DP=54,80,82;AF=0.98,1.00,1.00;MQM=60	HSPG2	intron	HSPG2:ENST00000374695:intron_variant:MODIFIER:exon32/96:c.4029+32T>A::	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];				rs2501266	0.9798	0.9960	14952,	0.9394,0.9970,1.0000,0.9998,0.9999	0.9993,0.9501	-0.4800			0.03,0.08	-0.60						n/a (AF>5%)	n/a (AF>5%)					HSPG2 (inh=AR pLI=0.00)
chr1	22199245	22199245	C	T	het	wt	hom		QUAL=3071;DP=44,76,80;AF=0.64,0.01,1.00;MQM=60	HSPG2	synonymous	HSPG2:ENST00000374695:synonymous_variant:LOW:exon32/97:c.3897G>A:p.Val1299=:PF00053	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];	285755 [benign DISEASE=Schwartz Jampel syndrome type 1,Dyssegmental Dysplasia,not specified];			rs2229482	0.4249	0.5578	4455,	0.2881,0.4023,0.4398,0.6392,0.5035	0.6429,0.2941	0.1280			0.73,0.88	0.54						n/a (AF>5%)	n/a (AF>5%)					HSPG2 (inh=AR pLI=0.00)
chr1	22199821	22199821	G	A	het	wt	hom	off-target	QUAL=1474;DP=44,39,32;AF=0.48,0.00,1.00;MQM=60	HSPG2	intron	HSPG2:ENST00000374695:intron_variant:MODIFIER:exon30/96:c.3793+47C>T::	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];				rs2454290	0.7420	0.8308	9272,	0.4825,0.9133,0.9772,0.8489,0.7338	0.8559,0.4939	0.0910			0.05,0.18	0.13						n/a (AF>5%)	n/a (AF>5%)					HSPG2 (inh=AR pLI=0.00)
chr1	22202109	22202109	C	T	hom	hom	hom	off-target	QUAL=26245;DP=208,401,283;AF=0.98,1.00,1.00;MQM=59	HSPG2	intron	HSPG2:ENST00000374695:intron_variant:MODIFIER:exon25/96:c.3302+13G>A::	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];	295864 [benign DISEASE=Schwartz Jampel syndrome type 1,Dyssegmental Dysplasia];		MIRb	rs2501265	0.9423	0.9863	14081,	0.8161,0.9906,1.0000,0.9993,0.9996	0.9990,0.8275	-6.5090			0.01,0.15	-0.09						n/a (AF>5%)	n/a (AF>5%)					HSPG2 (inh=AR pLI=0.00)
chr1	22205466	22205466	T	-	het	wt	wt	off-target	QUAL=3370;DP=36,35,49;AF=1.00,1.00,1.00;MQM=60	HSPG2	intron	HSPG2:ENST00000374695:intron_variant:MODIFIER:exon18/96:c.2471+21del::	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];				rs749134779		0.0003	0,	0.0004,0.0002,0.0005,0.0003,0.0003	0.9495,0.7992	-0.9090				-0.10						0	77					HSPG2 (inh=AR pLI=0.00)
chr1	22205466	22205466	T	C	het	hom	hom	off-target	QUAL=3370;DP=36,35,49;AF=1.00,1.00,1.00;MQM=60	HSPG2	intron	HSPG2:ENST00000374695:intron_variant:MODIFIER:exon18/96:c.2471+21A>G::	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];				rs2454293		0.9892	14493,	0.8725,0.9920,0.9977,0.9976,0.9977	0.9993,0.8887	-0.9090			0.02,0.13	0.01						n/a (AF>5%)	n/a (AF>5%)					HSPG2 (inh=AR pLI=0.00)
chr1	22206649	22206649	T	C	hom	hom	hom		QUAL=21945;DP=194,255,237;AF=1.00,1.00,1.00;MQM=60	HSPG2	missense	HSPG2:ENST00000374695:missense_variant:MODERATE:exon17/97:c.2294A>G:p.Asn765Ser:PF00053	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];	295881 [benign DISEASE=Schwartz Jampel syndrome type 1,Dyssegmental Dysplasia];			rs989994		0.9849	13844,	0.7857,0.9903,1.0000,0.9996,0.9995	0.9991,0.8105	0.8040	T	B	0.82,0.96	2.41	0.14					n/a (AF>5%)	n/a (AF>5%)					HSPG2 (inh=AR pLI=0.00)
chr1	22206942	22206942	G	A	hom	hom	hom		QUAL=7808;DP=121,73,61;AF=1.00,1.00,1.00;MQM=59	HSPG2	synonymous	HSPG2:ENST00000374695:synonymous_variant:LOW:exon16/97:c.2109C>T:p.Ala703=:PF00052	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];	295882 [benign DISEASE=Schwartz Jampel syndrome type 1,Dyssegmental Dysplasia];			rs1874793		0.9850	13816,	0.7860,0.9903,1.0000,0.9996,0.9996	0.9991,0.8105	1.4460			0.85,0.95	0.93						n/a (AF>5%)	n/a (AF>5%)					HSPG2 (inh=AR pLI=0.00)
chr1	22207065	22207065	G	A	het	het	wt	off-target	QUAL=806;DP=36,52,41;AF=0.33,0.48,0.00;MQM=60	HSPG2	intron	HSPG2:ENST00000374695:intron_variant:MODIFIER:exon15/96:c.1999-13C>T::	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];	295886 [uncertain significance DISEASE=Schwartz Jampel syndrome type 1,Dyssegmental Dysplasia];			rs77828146	0.0082	0.0128	8,	0.0029,0.0052,0.0000,0.0150,0.0199	0.0148,0.0030	-1.5230			0.08,0.19	-0.17		+0.18% (5.42>5.43)				4	130					HSPG2 (inh=AR pLI=0.00)
chr1	22207235	22207235	T	C	hom	hom	hom		QUAL=10998;DP=155,133,75;AF=1.00,1.00,1.00;MQM=60	HSPG2	missense	HSPG2:ENST00000374695:missense_variant:MODERATE:exon15/97:c.1912A>G:p.Met638Val:PF00052	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];	295887 [benign DISEASE=Schwartz Jampel syndrome type 1,Dyssegmental Dysplasia];			rs1874792	0.9736	0.9946	14809,	0.9186,0.9965,1.0000,0.9997,0.9999	0.9994,0.9292	1.5570	T	B	0.17,0.79	0.70	0.07					n/a (AF>5%)	n/a (AF>5%)					HSPG2 (inh=AR pLI=0.00)
chr1	22207805	22207817	CCCAGGGTGGCAG	-	hom	hom	hom	off-target	QUAL=7671;DP=52,144,92;AF=1.00,1.00,1.00;MQM=59	HSPG2	intron	HSPG2:ENST00000374695:intron_variant:MODIFIER:exon14/96:c.1818+15_1818+27del::	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];				rs139046040	0.9597	0.9910	14417,	0.8751,0.9933,0.9998,0.9996,0.9997	0.9980,0.8739	3.6790				0.12						n/a (AF>5%)	n/a (AF>5%)					HSPG2 (inh=AR pLI=0.00)
chr1	22208030	22208030	C	T	het	het	hom	off-target	QUAL=4616;DP=67,124,94;AF=0.46,0.43,1.00;MQM=60	HSPG2	intron	HSPG2:ENST00000374695:intron_variant:MODIFIER:exon13/96:c.1655-35G>A::	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];	439797 [benign DISEASE=not specified];			rs921847	0.9259	0.9726	13537,	0.7929,0.9853,1.0000,0.9844,0.9799	0.9837,0.8159	-0.4860			0.06,0.24	0.33						n/a (AF>5%)	n/a (AF>5%)					HSPG2 (inh=AR pLI=0.00)
chr1	22211222	22211222	T	C	het	het	het	off-target	QUAL=6848;DP=84,302,246;AF=0.52,0.47,0.43;MQM=60	HSPG2	intron	HSPG2:ENST00000374695:intron_variant:MODIFIER:exon12/96:c.1507+38A>G::	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];				rs4654994	0.8964	0.9135	12620,	0.8500,0.8804,0.9665,0.9312,0.8937	0.9348,0.8513	-0.9900			0.01,0.10	-0.07						n/a (AF>5%)	n/a (AF>5%)					HSPG2 (inh=AR pLI=0.00)
chr1	22214127	22214127	A	G	hom	hom	het		QUAL=12612;DP=119,213,181;AF=1.00,1.00,0.50;MQM=60	HSPG2	synonymous	HSPG2:ENST00000374695:synonymous_variant:LOW:exon8/97:c.744T>C:p.Leu248=:	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];	295909 [benign DISEASE=Schwartz Jampel syndrome type 1,Dyssegmental Dysplasia];			rs2229478	0.5363	0.4500	3438,	0.6396,0.5795,0.6254,0.3335,0.4041	0.3237,0.6296	-0.2610			0.06,0.22	-0.09						n/a (AF>5%)	n/a (AF>5%)					HSPG2 (inh=AR pLI=0.00)
chr1	22217108	22217108	G	A	hom	hom	hom		QUAL=25925;DP=226,332,277;AF=1.00,1.00,1.00;MQM=60	HSPG2	synonymous	HSPG2:ENST00000374695:synonymous_variant:LOW:exon4/97:c.324C>T:p.Phe108=:	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800/Dyssegmental dysplasia,Silverman-Handmaker type,224410];	295913 [benign DISEASE=Schwartz Jampel syndrome type 1,Dyssegmental Dysplasia];			rs2501260	0.9481	0.9891	14219,	0.8440,0.9936,1.0000,0.9997,0.9997	0.9991,0.8654	2.4590			0.81,0.94	1.03						n/a (AF>5%)	n/a (AF>5%)					HSPG2 (inh=AR pLI=0.00)
chr1	22779159	22779159	T	C	hom	hom	hom		QUAL=28816;DP=268,396,256;AF=1.00,1.00,1.00;MQM=60	ZBTB40	intron,5'UTR	ZBTB40:ENST00000374651:intron_variant:MODIFIER:exon1/15:c.-70+662T>C::,ZBTB40:ENST00000375647:intron_variant:MODIFIER:exon1/17:c.-70+662T>C::,ZBTB40:ENST00000404138:5_prime_UTR_variant:MODIFIER:exon2/19:c.-350T>C::				MER58B	rs10737466	0.9698	0.9776	14820,			-1.6200			0.00,0.08	0.17						n/a (AF>5%)	n/a (AF>5%)					ZBTB40 (inh=n/a pLI=0.00)
chr1	22832743	22832743	A	T	hom	hom	het		QUAL=15556;DP=213,209,168;AF=1.00,0.99,0.55;MQM=60	ZBTB40	intron	ZBTB40:ENST00000374651:intron_variant:MODIFIER:exon4/15:c.1024+9A>T::,ZBTB40:ENST00000375647:intron_variant:MODIFIER:exon6/17:c.1360+9A>T::,ZBTB40:ENST00000404138:intron_variant:MODIFIER:exon7/18:c.1360+9A>T::					rs209732	0.7991	0.7103	8091,	0.8984,0.8450,0.8962,0.6150,0.7063	0.6164,0.8858	0.8940			0.02,0.92	1.39						n/a (AF>5%)	n/a (AF>5%)					ZBTB40 (inh=n/a pLI=0.00)
chr1	22835677	22835677	A	G	hom	hom	het		QUAL=24845;DP=341,306,273;AF=1.00,1.00,0.53;MQM=60	ZBTB40	missense	ZBTB40:ENST00000374651:missense_variant:MODERATE:exon7/16:c.1448A>G:p.Tyr483Cys:,ZBTB40:ENST00000375647:missense_variant:MODERATE:exon9/18:c.1784A>G:p.Tyr595Cys:,ZBTB40:ENST00000404138:missense_variant:MODERATE:exon10/19:c.1784A>G:p.Tyr595Cys:					rs209729	0.8225	0.7793	9521,	0.9142,0.8848,0.8973,0.7171,0.7166	0.7192,0.9040	0.2230	T,D,D	B,B,B	0.03,0.18	0.92	0.02					n/a (AF>5%)	n/a (AF>5%)					ZBTB40 (inh=n/a pLI=0.00)
chr1	22846709	22846709	G	A	hom	hom	hom		QUAL=12168;DP=169,136,94;AF=1.00,1.00,1.00;MQM=59	ZBTB40	missense	ZBTB40:ENST00000374651:missense_variant:MODERATE:exon12/16:c.2653G>A:p.Val885Met:PF00096,ZBTB40:ENST00000375647:missense_variant:MODERATE:exon14/18:c.2989G>A:p.Val997Met:PF00096,ZBTB40:ENST00000404138:missense_variant:MODERATE:exon15/19:c.2989G>A:p.Val997Met:PF00096					rs209720	0.9984	0.9972	15388,	0.9992,0.9973,1.0000,0.9949,0.9993	0.9947,0.9989	2.3020	T,T,T	B,B,B	0.39,0.96	2.09	0.17					n/a (AF>5%)	n/a (AF>5%)					ZBTB40 (inh=n/a pLI=0.00)
chr1	22849003	22849003	A	C	hom	hom	het	off-target	QUAL=15071;DP=172,256,199;AF=0.99,0.99,0.48;MQM=60	ZBTB40	intron	ZBTB40:ENST00000374651:intron_variant:MODIFIER:exon14/15:c.2962+47A>C::,ZBTB40:ENST00000375647:intron_variant:MODIFIER:exon16/17:c.3298+47A>C::,ZBTB40:ENST00000404138:intron_variant:MODIFIER:exon17/18:c.3298+47A>C::				MIR	rs998978	0.3181	0.3395	1476,	0.1518,0.1770,0.4567,0.3728,0.4211	0.3691,0.1600	-6.2890			0.00,0.08	-0.49						n/a (AF>5%)	n/a (AF>5%)					ZBTB40 (inh=n/a pLI=0.00)
chr1	22852715	22852715	G	C	hom	hom	het		QUAL=10768;DP=167,140,108;AF=0.99,0.99,0.46;MQM=60	ZBTB40	synonymous	ZBTB40:ENST00000374651:synonymous_variant:LOW:exon16/16:c.3210G>C:p.Pro1070=:,ZBTB40:ENST00000375647:synonymous_variant:LOW:exon18/18:c.3546G>C:p.Pro1182=:,ZBTB40:ENST00000404138:synonymous_variant:LOW:exon19/19:c.3546G>C:p.Pro1182=:					rs881646	0.3181	0.3392	1473,	0.1518,0.1762,0.4569,0.3727,0.4210	0.3688,0.1598	-1.1410			0.09,0.18	-0.40						n/a (AF>5%)	n/a (AF>5%)					ZBTB40 (inh=n/a pLI=0.00)
chr1	22853141	22853141	G	A	hom	hom	het		QUAL=17252;DP=141,316,234;AF=1.00,1.00,0.50;MQM=60	ZBTB40	3'UTR	ZBTB40:ENST00000374651:3_prime_UTR_variant:MODIFIER:exon16/16:c.*252G>A::,ZBTB40:ENST00000375647:3_prime_UTR_variant:MODIFIER:exon18/18:c.*252G>A::,ZBTB40:ENST00000404138:3_prime_UTR_variant:MODIFIER:exon19/19:c.*252G>A::					rs2281354	0.2378	0.2480	1154,			0.1290			0.03,0.16	-0.13						n/a (AF>5%)	n/a (AF>5%)					ZBTB40 (inh=n/a pLI=0.00)
chr1	22855194	22855194	-	TT	wt	het	wt		QUAL=793;DP=36,40,33;AF=0.06,0.18,0.00;MQM=58	ZBTB40	3'UTR	ZBTB40:ENST00000375647:3_prime_UTR_variant:MODIFIER:exon18/18:c.*2319_*2320dup::,ZBTB40:ENST00000404138:3_prime_UTR_variant:MODIFIER:exon19/19:c.*2319_*2320dup::				AluJo			0.0024	0,							-0.25						0	0					ZBTB40 (inh=n/a pLI=0.00)
chr1	22855194	22855194	-	T	het	het	het		QUAL=793;DP=36,40,33;AF=0.42,0.55,0.24;MQM=59	ZBTB40	3'UTR	ZBTB40:ENST00000375647:3_prime_UTR_variant:MODIFIER:exon18/18:c.*2320dup::,ZBTB40:ENST00000404138:3_prime_UTR_variant:MODIFIER:exon19/19:c.*2320dup::				AluJo	rs35637563		0.3301	1358,							-0.25						n/a (AF>5%)	n/a (AF>5%)					ZBTB40 (inh=n/a pLI=0.00)
chr1	22856601	22856601	T	C	hom	hom	het		QUAL=18881;DP=224,281,216;AF=0.99,1.00,0.49;MQM=60	ZBTB40	3'UTR	ZBTB40:ENST00000375647:3_prime_UTR_variant:MODIFIER:exon18/18:c.*3712T>C::,ZBTB40:ENST00000404138:3_prime_UTR_variant:MODIFIER:exon19/19:c.*3712T>C::					rs1062663	0.3295	0.3063	1530,			-2.6560			0.01,0.08	-0.47						n/a (AF>5%)	n/a (AF>5%)					ZBTB40 (inh=n/a pLI=0.00)
chr1	22965438	22965438	A	G	het	het	hom		QUAL=330;DP=14,5,2;AF=0.64,0.60,1.00;MQM=60	C1QA	synonymous	C1QA:ENST00000374642:synonymous_variant:LOW:exon3/3:c.276A>G:p.Gly92=:PF01391,C1QA:ENST00000402322:synonymous_variant:LOW:exon2/2:c.276A>G:p.Gly92=:PF01391	120550 [C1QA (confirmed) C1q deficiency,613652];				rs172378	0.6164	0.5073	4323,	0.7395,0.6244,0.5905,0.3868,0.5845	0.3746,0.7100	-0.2950			0.03,0.22	0.07						n/a (AF>5%)	n/a (AF>5%)					C1QA (inh=AR pLI=0.04)
chr1	22966227	22966227	T	G	het	het	het	off-target	QUAL=7784;DP=142,257,222;AF=0.53,0.47,0.54;MQM=59	C1QC,C1QA	upstream_gene,downstream_gene	C1QC:ENST00000374637:upstream_gene_variant:MODIFIER::::,C1QC:ENST00000374639:upstream_gene_variant:MODIFIER::::,C1QC:ENST00000374640:upstream_gene_variant:MODIFIER::::,C1QA:ENST00000374642:downstream_gene_variant:MODIFIER::::,C1QA:ENST00000402322:downstream_gene_variant:MODIFIER::::				AluSq2	rs10917274	0.4309	0.3533	2033,			-2.9170			0.00,0.03	-0.21						n/a (AF>5%)	n/a (AF>5%)					C1QC (inh=AR pLI=0.02), C1QA (inh=AR pLI=0.04)
chr1	22974297	22974297	C	A	wt	wt	het		QUAL=578;DP=123,94,66;AF=0.01,0.00,0.50;MQM=60	C1QC	3'UTR	C1QC:ENST00000374637:3_prime_UTR_variant:MODIFIER:exon3/3:c.*21C>A::,C1QC:ENST00000374639:3_prime_UTR_variant:MODIFIER:exon3/3:c.*21C>A::,C1QC:ENST00000374640:3_prime_UTR_variant:MODIFIER:exon3/3:c.*21C>A::	120575 [C1QC (provisional) C1q deficiency,613652];				rs9434		0.5067	4541,	0.8155,0.5080,0.5847,0.3692,0.4159	0.3673,0.7971	0.4040			0.26,0.93	0.65						n/a (AF>5%)	n/a (AF>5%)					C1QC (inh=AR pLI=0.02)
chr1	22974380	22974396	CCACCAGATGGACTTCT	-	wt	wt	het		QUAL=67;DP=27,16,18;AF=0.00,0.00,0.50;MQM=60	C1QC	3'UTR	C1QC:ENST00000374637:3_prime_UTR_variant:MODIFIER:exon3/3:::,C1QC:ENST00000374639:3_prime_UTR_variant:MODIFIER:exon3/3:c.*106_*122del::,C1QC:ENST00000374640:3_prime_UTR_variant:MODIFIER:exon3/3:c.*106_*122del::	120575 [C1QC (provisional) C1q deficiency,613652];			L2d2	rs142916975	0.3764	0.3413	1776,			1.9050				1.04						n/a (AF>5%)	n/a (AF>5%)					C1QC (inh=AR pLI=0.02)
chr1	22974534	22974535	TT	-	wt	wt	het		QUAL=1442;DP=47,70,40;AF=0.13,0.10,0.25;MQM=60	C1QC	3'UTR	C1QC:ENST00000374639:3_prime_UTR_variant:MODIFIER:exon3/3:c.*272_*273del::,C1QC:ENST00000374640:3_prime_UTR_variant:MODIFIER:exon3/3:c.*272_*273del::	120575 [C1QC (provisional) C1q deficiency,613652];			L2d2	rs10601144	0.6609	0.5156	3539,			0.1990				-0.11						n/a (AF>5%)	n/a (AF>5%)					C1QC (inh=AR pLI=0.02)
chr1	22974534	22974534	T	-	het	het	wt		QUAL=1442;DP=47,70,40;AF=0.43,0.50,0.20;MQM=59	C1QC	3'UTR	C1QC:ENST00000374639:3_prime_UTR_variant:MODIFIER:exon3/3:c.*273del::,C1QC:ENST00000374640:3_prime_UTR_variant:MODIFIER:exon3/3:c.*273del::	120575 [C1QC (provisional) C1q deficiency,613652];			L2d2	rs71020441		0.0880	82,			0.1990				-0.42						n/a (AF>5%)	n/a (AF>5%)					C1QC (inh=AR pLI=0.02)
chr1	22974566	22974566	T	G	het	wt	wt		QUAL=64;DP=53,65,51;AF=0.38,0.12,0.12;MQM=58	C1QC	3'UTR	C1QC:ENST00000374639:3_prime_UTR_variant:MODIFIER:exon3/3:c.*290T>G::,C1QC:ENST00000374640:3_prime_UTR_variant:MODIFIER:exon3/3:c.*290T>G::	120575 [C1QC (provisional) C1q deficiency,613652];				rs1003478565		0.0017	0,			-0.6170			0.02,0.14	0.25						0	18					C1QC (inh=AR pLI=0.02)
chr1	22979655	22979655	T	G	het	het	het	off-target	QUAL=528;DP=26,16,22;AF=0.62,0.31,0.41;MQM=59	C1QB	5'UTR	C1QB:ENST00000509305:5_prime_UTR_variant:MODIFIER:exon1/3:c.-165T>G::	120570 [C1QB (confirmed) C1q deficiency,613652];				rs291990	0.6719	0.5821	5656,			-0.0560			0.01,0.17	0.11						n/a (AF>5%)	n/a (AF>5%)					C1QB (inh=AR pLI=0.08)
chr1	22987958	22987958	A	G	hom	hom	hom		QUAL=37856;DP=406,456,347;AF=1.00,1.00,1.00;MQM=59	C1QB	3'UTR	C1QB:ENST00000314933:3_prime_UTR_variant:MODIFIER:exon3/3:c.*79A>G::,C1QB:ENST00000509305:3_prime_UTR_variant:MODIFIER:exon3/3:c.*79A>G::	120570 [C1QB (confirmed) C1q deficiency,613652];				rs10580		0.9837	14964,			-0.5240			0.00,0.09	0.17						n/a (AF>5%)	n/a (AF>5%)					C1QB (inh=AR pLI=0.08)
chr1	24122986	24122986	C	T	het	wt	het	off-target	QUAL=960;DP=83,54,50;AF=0.57,0.02,0.44;MQM=60	GALE	intron	GALE:ENST00000374497:intron_variant:MODIFIER:exon10/11:c.873+13G>A::	606953 [GALE (confirmed) Galactose epimerase deficiency,230350];	92889 [benign DISEASE=UDPglucose-4-epimerase deficiency,not specified];		G-rich	rs760941		0.6592	3638,	0.5441,0.7031,0.6347,0.6176,0.7370	0.5739,0.4589	-0.8630			0.05,0.15	0.04						n/a (AF>5%)	n/a (AF>5%)					GALE (inh=AR pLI=0.00)
chr1	24128467	24128467	C	T	hom	hom	het		QUAL=30046;DP=373,431,347;AF=0.99,1.00,0.50;MQM=59	HMGCL	3'UTR	HMGCL:ENST00000374483:3_prime_UTR_variant:MODIFIER:exon10/10:c.*486G>A::,HMGCL:ENST00000374490:3_prime_UTR_variant:MODIFIER:exon9/9:c.*486G>A::,HMGCL:ENST00000436439:3_prime_UTR_variant:MODIFIER:exon7/7:c.*486G>A::	613898 [HMGCL (provisional) HMG-CoA lyase deficiency,246450];	296841 [benign DISEASE=Deficiency of hydroxymethylglutaryl-CoA lyase,UDPglucose-4-epimerase deficiency];			rs11714	0.8834	0.9202	13117,			-0.8980			0.00,0.11	0.37						n/a (AF>5%)	n/a (AF>5%)					HMGCL (inh=AR pLI=0.00)
chr1	24134721	24134721	T	C	hom	hom	het		QUAL=21723;DP=290,287,225;AF=1.00,1.00,0.53;MQM=60	HMGCL	synonymous	HMGCL:ENST00000374483:synonymous_variant:LOW:exon8/10:c.579A>G:p.Leu193=:PF00682,HMGCL:ENST00000374490:synonymous_variant:LOW:exon7/9:c.654A>G:p.Leu218=:PF00682,HMGCL:ENST00000436439:synonymous_variant:LOW:exon5/7:c.441A>G:p.Leu147=:PF00682	613898 [HMGCL (provisional) HMG-CoA lyase deficiency,246450];	92602 [benign DISEASE=Deficiency of hydroxymethylglutaryl-CoA lyase,not specified];			rs719400	0.8874	0.9306	13412,	0.9674,0.8938,0.7886,0.9133,0.8744	0.9085,0.9610	0.8740			0.06,0.97	0.85						n/a (AF>5%)	n/a (AF>5%)					HMGCL (inh=AR pLI=0.00)
chr1	24143932	24143932	A	G	hom	hom	het	off-target	QUAL=12971;DP=187,181,117;AF=0.99,1.00,0.50;MQM=60	HMGCL	intron	HMGCL:ENST00000374483:intron_variant:MODIFIER:exon4/9:c.177+34T>C::,HMGCL:ENST00000374490:intron_variant:MODIFIER:exon3/8:c.252+34T>C::,HMGCL:ENST00000436439:intron_variant:MODIFIER:exon3/6:c.252+34T>C::	613898 [HMGCL (provisional) HMG-CoA lyase deficiency,246450];	255488 [benign DISEASE=not specified];			rs2076344	0.8878	0.9305	13438,	0.9674,0.8942,0.7898,0.9140,0.8745	0.9088,0.9610	-1.2250			0.00,0.11	-0.20						n/a (AF>5%)	n/a (AF>5%)					HMGCL (inh=AR pLI=0.00)
chr1	24151996	24151996	C	A	het	hom	het	off-target	QUAL=1458;DP=24,35,34;AF=0.29,1.00,0.47;MQM=60	HMGCL	intron	HMGCL:ENST00000374483:intron_variant:MODIFIER:exon2/9:c.-16+578G>T::	613898 [HMGCL (provisional) HMG-CoA lyase deficiency,246450];				rs6697805	0.3928	0.4035	2449,			-2.8420			0.04,0.16	-0.25						n/a (AF>5%)	n/a (AF>5%)					HMGCL (inh=AR pLI=0.00)
chr1	24171543	24171543	C	G	het	hom	het	off-target	QUAL=2965;DP=103,45,48;AF=0.50,0.98,0.58;MQM=60	FUCA1	downstream_gene	FUCA1:ENST00000374479:downstream_gene_variant:MODIFIER::::					rs4649119	0.3425	0.3692	2219,			-0.2630			0.08,0.16	-0.09						n/a (AF>5%)	n/a (AF>5%)					FUCA1 (inh=AR pLI=0.00)
chr1	24180807	24180807	A	-	het	wt	het	off-target	QUAL=401;DP=68,30,27;AF=0.13,0.10,0.63;MQM=60	FUCA1	intron	FUCA1:ENST00000374479:intron_variant:MODIFIER:exon5/7:c.969+43del::	612280 [FUCA1 (confirmed) Fucosidosis,230000];			(A)n	rs55699941		0.3024	103,	0.2451,0.3205,0.3760,0.2985,0.3159	0.2493,0.2228	2.8690				-0.13						n/a (AF>5%)	n/a (AF>5%)					FUCA1 (inh=AR pLI=0.00)
chr1	24180962	24180962	T	C	het	hom	wt		QUAL=9714;DP=254,202,209;AF=0.50,1.00,0.00;MQM=60	FUCA1	missense	FUCA1:ENST00000374479:missense_variant:MODERATE:exon5/8:c.857A>G:p.Gln286Arg:PF01120	612280 [FUCA1 (confirmed) Fucosidosis,230000];	691 [benign DISEASE=FU1/FU2 POLYMORPHISM,Fucosidosis,not provided];			rs13551	0.2113	0.2798	1361,	0.1409,0.2033,0.2647,0.3357,0.1515	0.3308,0.1459	0.6520	D	B	0.09,0.29	1.45	0.06					n/a (AF>5%)	n/a (AF>5%)					FUCA1 (inh=AR pLI=0.00)
chr1	24194748	24194748	G	C	wt	wt	het		QUAL=1393;DP=155,123,112;AF=0.00,0.01,0.54;MQM=60	FUCA1	missense	FUCA1:ENST00000374479:missense_variant:MODERATE:exon1/8:c.29C>G:p.Pro10Arg:	612280 [FUCA1 (confirmed) Fucosidosis,230000];	193053 [benign DISEASE=Fucosidosis,not specified,not provided];			rs2070956	0.1430	0.1070	183,	0.1115,0.1149,0.1995,0.0894,0.1258		-0.0120	T	B	0.06,0.08	0.52	0.09					n/a (AF>5%)	n/a (AF>5%)					FUCA1 (inh=AR pLI=0.00)
chr1	24194770	24194770	C	G	het	wt	het		QUAL=2488;DP=146,113,107;AF=0.47,0.00,0.45;MQM=59	FUCA1	missense	FUCA1:ENST00000374479:missense_variant:MODERATE:exon1/8:c.7G>C:p.Ala3Pro:	612280 [FUCA1 (confirmed) Fucosidosis,230000];	296895 [benign/likely benign DISEASE=Fucosidosis,not provided];			rs61996282	0.0134	0.0155	3,	0.0026,0.0512,0.0000,0.0078,0.0166	0.0025,0.0012	-2.4990	D	B	0.04,0.08	1.17	0.07					1	71					FUCA1 (inh=AR pLI=0.00)
chr1	24194773	24194773	G	A	wt	wt	het		QUAL=1196;DP=122,113,103;AF=0.00,0.01,0.52;MQM=60	FUCA1	missense	FUCA1:ENST00000374479:missense_variant:MODERATE:exon1/8:c.4C>T:p.Arg2Trp:	612280 [FUCA1 (confirmed) Fucosidosis,230000];	193052 [benign DISEASE=Fucosidosis,not specified,not provided];			rs2070955	0.1430	0.1113	183,	0.1151,0.1169,0.2048,0.0934,0.1263	0.0817,0.0838	-1.0160	D	B	0.02,0.08	1.76	0.08					n/a (AF>5%)	n/a (AF>5%)					FUCA1 (inh=AR pLI=0.00)
chr1	24194788	24194788	A	G	wt	wt	het		QUAL=1136;DP=77,100,96;AF=0.00,0.01,0.52;MQM=60	CNR2,FUCA1	downstream_gene,upstream_gene	CNR2:ENST00000374472:downstream_gene_variant:MODIFIER::::,FUCA1:ENST00000374479:upstream_gene_variant:MODIFIER::::,CNR2:ENST00000536471:downstream_gene_variant:MODIFIER::::	612280 [FUCA1 (confirmed) Fucosidosis,230000];	193051 [benign/likely benign DISEASE=Fucosidosis,not specified,not provided];			rs2070954	0.1428	0.1135	180,	0.1172,0.1172,0.2067,0.0951,0.1268	0.0773,0.0797	0.1910			0.00,0.04	0.74						n/a (AF>5%)	n/a (AF>5%)					CNR2 (inh=n/a pLI=0.00), FUCA1 (inh=AR pLI=0.00)
chr1	24194862	24194862	A	C	wt	wt	het		QUAL=417;DP=27,33,49;AF=0.00,0.03,0.43;MQM=60	CNR2,FUCA1	downstream_gene,upstream_gene	CNR2:ENST00000374472:downstream_gene_variant:MODIFIER::::,FUCA1:ENST00000374479:upstream_gene_variant:MODIFIER::::,CNR2:ENST00000536471:downstream_gene_variant:MODIFIER::::		368872 [likely benign DISEASE=Fucosidosis];			rs2070953	0.1428	0.0996	190,			-0.0750			0.09,0.08	0.70						n/a (AF>5%)	n/a (AF>5%)					CNR2 (inh=n/a pLI=0.00), FUCA1 (inh=AR pLI=0.00)
chr1	24194898	24194898	C	A	wt	wt	het	off-target	QUAL=319;DP=19,20,37;AF=0.00,0.00,0.46;MQM=60	CNR2,FUCA1	downstream_gene,upstream_gene	CNR2:ENST00000374472:downstream_gene_variant:MODIFIER::::,FUCA1:ENST00000374479:upstream_gene_variant:MODIFIER::::,CNR2:ENST00000536471:downstream_gene_variant:MODIFIER::::					rs2070952	0.1428	0.0993	186,			-0.8080			0.04,0.07	0.48						n/a (AF>5%)	n/a (AF>5%)					CNR2 (inh=n/a pLI=0.00), FUCA1 (inh=AR pLI=0.00)
chr1	26131654	26131654	G	A	hom	het	hom		QUAL=15773;DP=159,333,221;AF=0.99,0.52,1.00;MQM=59	SEPN1	missense	SEPN1:ENST00000354177:missense_variant:MODERATE:exon3/13:c.323G>A:p.Cys108Tyr:,SEPN1:ENST00000361547:missense_variant:MODERATE:exon4/13:c.425G>A:p.Cys142Tyr:,SEPN1:ENST00000374315:missense_variant:MODERATE:exon3/12:c.323G>A:p.Cys108Tyr:	606210 [SELENON (confirmed) Muscular dystrophy,rigid spine,1,602771/Myopathy,congenital,with fiber-type disproportion,255310];	95963 [benign DISEASE=Eichsfeld type congenital muscular dystrophy,not specified,SEPN1-Related Disorders];			rs7349185	0.8419	0.8181	9476,	0.7786,0.9056,0.9425,0.7833,0.8774		0.9630	T,T,T	B,B,B	0.01,0.11	0.46	0.04					n/a (AF>5%)	n/a (AF>5%)					SELENON (inh=AR+AD pLI=0.00)
chr1	26138136	26138136	C	A	hom	het	hom	off-target	QUAL=18661;DP=150,381,279;AF=1.00,0.52,1.00;MQM=60	SEPN1	intron	SEPN1:ENST00000354177:intron_variant:MODIFIER:exon7/12:c.991-46C>A::,SEPN1:ENST00000361547:intron_variant:MODIFIER:exon8/12:c.1093-46C>A::,SEPN1:ENST00000374315:intron_variant:MODIFIER:exon7/11:c.991-46C>A::	606210 [SELENON (confirmed) Muscular dystrophy,rigid spine,1,602771/Myopathy,congenital,with fiber-type disproportion,255310];	261271 [benign DISEASE=not specified];			rs760598	0.7470	0.7902	7711,	0.4605,0.8796,0.9652,0.7689,0.8743	0.7721,0.4969	0.9050			0.25,0.26	0.56						n/a (AF>5%)	n/a (AF>5%)					SELENON (inh=AR+AD pLI=0.00)
chr1	26138262	26138262	T	C	hom	het	hom		QUAL=24596;DP=211,489,351;AF=1.00,0.52,1.00;MQM=59	SEPN1	synonymous	SEPN1:ENST00000354177:synonymous_variant:LOW:exon8/13:c.1071T>C:p.Pro357=:,SEPN1:ENST00000361547:synonymous_variant:LOW:exon9/13:c.1173T>C:p.Pro391=:,SEPN1:ENST00000374315:synonymous_variant:LOW:exon8/12:c.1071T>C:p.Pro357=:	606210 [SELENON (confirmed) Muscular dystrophy,rigid spine,1,602771/Myopathy,congenital,with fiber-type disproportion,255310];	95956 [benign DISEASE=Eichsfeld type congenital muscular dystrophy,not specified,SEPN1-Related Disorders];			rs760597		0.8096	8605,	0.6070,0.8895,0.9651,0.7843,0.8773	0.7881,0.6337	0.2830			0.29,0.86	1.96						n/a (AF>5%)	n/a (AF>5%)					SELENON (inh=AR+AD pLI=0.00)
chr1	26139137	26139137	C	T	hom	het	hom	off-target	QUAL=2988;DP=19,70,54;AF=1.00,0.54,1.00;MQM=60	SEPN1	intron	SEPN1:ENST00000354177:intron_variant:MODIFIER:exon8/12:c.1180-41C>T::,SEPN1:ENST00000361547:intron_variant:MODIFIER:exon9/12:c.1282-41C>T::,SEPN1:ENST00000374315:intron_variant:MODIFIER:exon8/11:c.1180-41C>T::	606210 [SELENON (confirmed) Muscular dystrophy,rigid spine,1,602771/Myopathy,congenital,with fiber-type disproportion,255310];	261274 [benign DISEASE=not specified];			rs10902685	0.6977	0.7927	7184,	0.2893,0.8782,0.9663,0.7879,0.8783	0.7872,0.3381	-0.4720			0.02,0.16	0.07						n/a (AF>5%)	n/a (AF>5%)					SELENON (inh=AR+AD pLI=0.00)
chr1	26140573	26140573	C	A	hom	het	hom		QUAL=21877;DP=214,439,326;AF=1.00,0.50,1.00;MQM=60	SEPN1,RP1-317E23.6	missense,missense&NMD_transcript	SEPN1:ENST00000354177:missense_variant:MODERATE:exon12/13:c.1404C>A:p.Asn468Lys:,SEPN1:ENST00000361547:missense_variant:MODERATE:exon12/13:c.1506C>A:p.Asn502Lys:,SEPN1:ENST00000374315:missense_variant:MODERATE:exon11/12:c.1404C>A:p.Asn468Lys:,RP1-317E23.6:ENST00000527604:missense_variant&NMD_transcript_variant:MODERATE:exon2/4:c.27C>A:p.Asn9Lys:	606210 [SELENON (confirmed) Muscular dystrophy,rigid spine,1,602771/Myopathy,congenital,with fiber-type disproportion,255310];	95959 [benign DISEASE=Eichsfeld type congenital muscular dystrophy,not specified,SEPN1-Related Disorders];			rs2294228	0.6975	0.7861	7289,	0.2900,0.8782,0.9655,0.7829,0.8771	0.7872,0.3241	0.1590	T,T,T,T	B,B,B,B	0.37,0.52	1.01	0.09					n/a (AF>5%)	n/a (AF>5%)					SELENON (inh=AR+AD pLI=0.00), RP1-317E23.6 (inh=n/a pLI=n/a)
chr1	26143704	26143704	-	TTTTG	hom	het	hom		QUAL=12949;DP=151,230,188;AF=0.97,0.43,1.00;MQM=58	SEPN1,RP1-317E23.3,RP1-317E23.6	3'UTR,intron&non_coding_transcript,intron&NMD_transcript	SEPN1:ENST00000354177:3_prime_UTR_variant:MODIFIER:exon13/13:c.*1511_*1515dup::,SEPN1:ENST00000361547:3_prime_UTR_variant:MODIFIER:exon13/13:c.*1511_*1515dup::,SEPN1:ENST00000374315:3_prime_UTR_variant:MODIFIER:exon12/12:c.*1511_*1515dup::,RP1-317E23.3:ENST00000442055:intron_variant&non_coding_transcript_variant:MODIFIER:exon3/3:n.304-338_304-334dup::,RP1-317E23.6:ENST00000527604:intron_variant&NMD_transcript_variant:MODIFIER:exon2/3:c.123+3051_123+3055dup::	606210 [SELENON (confirmed) Muscular dystrophy,rigid spine,1,602771/Myopathy,congenital,with fiber-type disproportion,255310];			AluSx	rs3033477	0.7657	0.7101	7931,							0.05						n/a (AF>5%)	n/a (AF>5%)					SELENON (inh=AR+AD pLI=0.00), RP1-317E23.3 (inh=n/a pLI=n/a), RP1-317E23.6 (inh=n/a pLI=n/a)
chr1	26143821	26143821	T	C	hom	het	hom		QUAL=16531;DP=245,268,179;AF=1.00,0.46,0.98;MQM=54	SEPN1,RP1-317E23.3,RP1-317E23.6	3'UTR,intron&non_coding_transcript,intron&NMD_transcript	SEPN1:ENST00000354177:3_prime_UTR_variant:MODIFIER:exon13/13:c.*1612T>C::,SEPN1:ENST00000361547:3_prime_UTR_variant:MODIFIER:exon13/13:c.*1612T>C::,SEPN1:ENST00000374315:3_prime_UTR_variant:MODIFIER:exon12/12:c.*1612T>C::,RP1-317E23.3:ENST00000442055:intron_variant&non_coding_transcript_variant:MODIFIER:exon3/3:n.303+232A>G::,RP1-317E23.6:ENST00000527604:intron_variant&NMD_transcript_variant:MODIFIER:exon2/3:c.123+3152T>C::	606210 [SELENON (confirmed) Muscular dystrophy,rigid spine,1,602771/Myopathy,congenital,with fiber-type disproportion,255310];	297050 [benign DISEASE=SEPN1-Related Disorders];		AluSx	rs3203750	0.7630	0.7113	8103,			-0.0630			0.00,0.13	0.21						n/a (AF>5%)	n/a (AF>5%)					SELENON (inh=AR+AD pLI=0.00), RP1-317E23.3 (inh=n/a pLI=n/a), RP1-317E23.6 (inh=n/a pLI=n/a)
chr1	26143931	26143931	T	C	hom	het	hom		QUAL=22062;DP=336,350,229;AF=1.00,0.45,1.00;MQM=53	SEPN1,RP1-317E23.3,RP1-317E23.6	3'UTR,intron&non_coding_transcript,intron&NMD_transcript	SEPN1:ENST00000354177:3_prime_UTR_variant:MODIFIER:exon13/13:c.*1722T>C::,SEPN1:ENST00000361547:3_prime_UTR_variant:MODIFIER:exon13/13:c.*1722T>C::,SEPN1:ENST00000374315:3_prime_UTR_variant:MODIFIER:exon12/12:c.*1722T>C::,RP1-317E23.3:ENST00000442055:intron_variant&non_coding_transcript_variant:MODIFIER:exon3/3:n.303+122A>G::,RP1-317E23.6:ENST00000527604:intron_variant&NMD_transcript_variant:MODIFIER:exon2/3:c.123+3262T>C::	606210 [SELENON (confirmed) Muscular dystrophy,rigid spine,1,602771/Myopathy,congenital,with fiber-type disproportion,255310];	297053 [benign DISEASE=SEPN1-Related Disorders];		AluSx	rs4659383	0.8622	0.8016	9979,			-1.2050			0.00,0.05	-0.14						n/a (AF>5%)	n/a (AF>5%)					SELENON (inh=AR+AD pLI=0.00), RP1-317E23.3 (inh=n/a pLI=n/a), RP1-317E23.6 (inh=n/a pLI=n/a)
chr1	26144438	26144438	C	-	hom	het	hom		QUAL=4104;DP=69,103,75;AF=0.97,0.62,1.00;MQM=59	SEPN1,RP1-317E23.3,RP1-317E23.6	3'UTR,intron&non_coding_transcript,intron&NMD_transcript	SEPN1:ENST00000354177:3_prime_UTR_variant:MODIFIER:exon13/13:c.*2236del::,SEPN1:ENST00000361547:3_prime_UTR_variant:MODIFIER:exon13/13:c.*2236del::,SEPN1:ENST00000374315:3_prime_UTR_variant:MODIFIER:exon12/12:c.*2236del::,RP1-317E23.3:ENST00000442055:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.152-234del::,RP1-317E23.6:ENST00000527604:intron_variant&NMD_transcript_variant:MODIFIER:exon2/3:c.123+3776del::	606210 [SELENON (confirmed) Muscular dystrophy,rigid spine,1,602771/Myopathy,congenital,with fiber-type disproportion,255310];	297061 [uncertain significance DISEASE=SEPN1-Related Disorders];					0.7146	8143,			-0.8160				-0.09						n/a (AF>5%)	n/a (AF>5%)					SELENON (inh=AR+AD pLI=0.00), RP1-317E23.3 (inh=n/a pLI=n/a), RP1-317E23.6 (inh=n/a pLI=n/a)
chr1	26508293	26508293	G	A	het	wt	het	off-target	QUAL=4935;DP=209,281,206;AF=0.49,0.00,0.51;MQM=60	CNKSR1	intron	CNKSR1:ENST00000361530:intron_variant:MODIFIER:exon3/20:c.393-55G>A::,CNKSR1:ENST00000374253:intron_variant:MODIFIER:exon3/20:c.393-55G>A::,CNKSR1:ENST00000531191:intron_variant:MODIFIER:exon2/19:c.-382-55G>A::				MIRb	rs3819033	0.2859	0.1085	454,		0.0959,0.0340	0.6040			0.15,0.25	0.27						n/a (AF>5%)	n/a (AF>5%)					CNKSR1 (inh=n/a pLI=0.00)
chr1	26508480	26508480	T	C	het	wt	het	off-target	QUAL=5574;DP=212,317,245;AF=0.47,0.00,0.53;MQM=60	CNKSR1	intron	CNKSR1:ENST00000361530:intron_variant:MODIFIER:exon4/20:c.477+48T>C::,CNKSR1:ENST00000374253:intron_variant:MODIFIER:exon4/20:c.477+48T>C::,CNKSR1:ENST00000531191:intron_variant:MODIFIER:exon3/19:c.-298+48T>C::					rs2275945	0.3365	0.2272	617,	0.1594,0.4840,0.6420,0.0980,0.3753	0.0981,0.1641	0.2070			0.01,0.18	0.34						n/a (AF>5%)	n/a (AF>5%)					CNKSR1 (inh=n/a pLI=0.00)
chr1	26511700	26511700	A	G	hom	hom	hom	off-target	QUAL=20225;DP=159,265,212;AF=1.00,1.00,1.00;MQM=60	CNKSR1	intron	CNKSR1:ENST00000361530:intron_variant:MODIFIER:exon14/20:c.1308+23A>G::,CNKSR1:ENST00000374253:intron_variant:MODIFIER:exon14/20:c.1329+23A>G::,CNKSR1:ENST00000531191:intron_variant:MODIFIER:exon13/19:c.534+23A>G::					rs2783680	0.7109	0.6836	5589,	0.4542,0.8005,0.9693,0.5905,0.7831	0.6019,0.5052	-0.9530			0.05,0.15	-0.33						n/a (AF>5%)	n/a (AF>5%)					CNKSR1 (inh=n/a pLI=0.00)
chr1	27106975	27106975	C	T	wt	het	wt		QUAL=3132;DP=157,236,189;AF=0.00,0.52,0.00;MQM=60	ARID1A	synonymous	ARID1A:ENST00000324856:synonymous_variant:LOW:exon20/20:c.6586C>T:p.Leu2196=:PF12031,ARID1A:ENST00000374152:synonymous_variant:LOW:exon19/19:c.5437C>T:p.Leu1813=:PF12031,ARID1A:ENST00000457599:synonymous_variant:LOW:exon20/20:c.5935C>T:p.Leu1979=:PF12031,ARID1A:ENST00000540690:synonymous_variant:LOW:exon6/6:c.1570C>T:p.Leu524=:PF12031	603024 [ARID1A (provisional) Coffin-Siris syndrome 2,614607];	210262 [benign DISEASE=not specified];			rs149633292	0.0016	0.0076	3,	0.0006,0.0007,0.0000,0.0050,0.0006	0.0050,0.0009	0.8780			0.77,0.93	0.64					COSM3724478	0	42	2	Prima Vista kein Anhalt f?r Splice-Defekt; 160727 [2] ahwalds1 28.07.2016			ARID1A (inh=AD pLI=1.00)
chr1	27107651	27107651	A	-	wt	het	het		QUAL=18;DP=52,18,9;AF=0.21,0.28,0.33;MQM=60	ARID1A	3'UTR	ARID1A:ENST00000324856:3_prime_UTR_variant:MODIFIER:exon20/20:c.*421del::	603024 [ARID1A (provisional) Coffin-Siris syndrome 2,614607];			(A)n	rs533673675	0.2159	0.0419	4,			0.0190				-0.25						n/a (AF>5%)	n/a (AF>5%)					ARID1A (inh=AD pLI=1.00)
chr1	27696011	27696011	C	T	hom	hom	hom	off-target	QUAL=25959;DP=311,311,256;AF=1.00,1.00,1.00;MQM=60	FCN3	intron	FCN3:ENST00000270879:intron_variant:MODIFIER:exon7/7:c.659-43G>A::,FCN3:ENST00000354982:intron_variant:MODIFIER:exon6/6:c.626-43G>A::	604973 [FCN3 (provisional) Immunodeficiency due to ficolin 3 deficiency,613860];			MIRb	rs10218730	0.9924	0.9982	15233,	0.9738,0.9990,1.0000,0.9999,0.9999	0.9998,0.9768	-0.2710			0.00,0.13	0.36						n/a (AF>5%)	n/a (AF>5%)					FCN3 (inh=AR pLI=0.01)
chr1	33245802	33245802	C	G	het	het	het		QUAL=9449;DP=260,253,187;AF=0.53,0.46,0.61;MQM=60	YARS	synonymous	YARS:ENST00000373477:synonymous_variant:LOW:exon11/13:c.1218G>C:p.Leu406=:PF01588	603623 [YARS (confirmed) Charcot-Marie-Tooth disease,dominant intermediate C,608323];	297151 [benign DISEASE=Charcot-Marie-Tooth disease, dominant intermediate C,not specified,Charcot-Marie-Tooth, Intermediate];			rs699005	0.0875	0.1073	217,	0.1032,0.2179,0.0003,0.0975,0.0608	0.1005,0.0956	3.1640			0.95,0.94	0.69						n/a (AF>5%)	n/a (AF>5%)					YARS (inh=AD pLI=0.00)
chr1	33252100	33252122	CACATGCATGACTATTCCTAGCC	-	het	wt	het	off-target	QUAL=3575;DP=114,316,227;AF=0.47,0.00,0.50;MQM=60	YARS	intron	YARS:ENST00000373477:intron_variant:MODIFIER:exon7/12:c.821-74_821-52del::	603623 [YARS (confirmed) Charcot-Marie-Tooth disease,dominant intermediate C,608323];				rs149745059	0.1412	0.1466	372,	0.0239,0.0903,0.1855,0.1433,0.2112	0.1369,0.0331	1.7820				0.23						n/a (AF>5%)	n/a (AF>5%)					YARS (inh=AD pLI=0.00)
chr1	33256884	33256884	C	A	hom	het	hom	off-target	QUAL=16321;DP=243,263,165;AF=0.99,0.52,0.99;MQM=60	YARS	intron	YARS:ENST00000373477:intron_variant:MODIFIER:exon5/12:c.592-29G>T::	603623 [YARS (confirmed) Charcot-Marie-Tooth disease,dominant intermediate C,608323];				rs1765223	0.2911	0.3268	1712,	0.3020,0.3495,0.2120,0.3120,0.3039	0.3113,0.3007	1.2300			0.00,0.09	0.09						n/a (AF>5%)	n/a (AF>5%)					YARS (inh=AD pLI=0.00)
chr1	33276424	33276424	G	A	hom	hom	hom	off-target	QUAL=21290;DP=291,212,158;AF=1.00,1.00,1.00;MQM=60	YARS	intron	YARS:ENST00000373477:intron_variant:MODIFIER:exon2/12:c.205-57C>T::	603623 [YARS (confirmed) Charcot-Marie-Tooth disease,dominant intermediate C,608323];				rs4951787	0.9840	0.9866	15067,			-0.3090			0.00,0.11	-0.18						n/a (AF>5%)	n/a (AF>5%)					YARS (inh=AD pLI=0.00)
chr1	33282775	33282775	C	A	het	het	het	off-target	QUAL=3044;DP=122,103,71;AF=0.47,0.44,0.51;MQM=60	YARS	intron	YARS:ENST00000373477:intron_variant:MODIFIER:exon1/12:c.57+14G>T::	603623 [YARS (confirmed) Charcot-Marie-Tooth disease,dominant intermediate C,608323];	297163 [benign DISEASE=not specified,Charcot-Marie-Tooth, Intermediate];			rs72654020	0.0857	0.1055	216,	0.0971,0.2175,0.0003,0.0975,0.0607	0.1002,0.0901	-0.0880			0.03,0.82	0.40						n/a (AF>5%)	n/a (AF>5%)					YARS (inh=AD pLI=0.00)
chr1	33283528	33283528	G	A	het	wt	wt		QUAL=41;DP=7,1,0;AF=0.57,0.00,nan;MQM=60	S100PBP,YARS	intron,5'UTR	S100PBP:ENST00000373475:intron_variant:MODIFIER:exon1/6:c.-120+238G>A::,S100PBP:ENST00000373476:intron_variant:MODIFIER:exon1/6:c.-120+328G>A::,YARS:ENST00000373477:5_prime_UTR_variant:MODIFIER:exon1/13:c.-683C>T::,S100PBP:ENST00000398243:intron_variant:MODIFIER:exon1/6:c.-120+238G>A::	603623 [YARS (confirmed) Charcot-Marie-Tooth disease,dominant intermediate C,608323];	297175 [benign DISEASE=Charcot-Marie-Tooth, Intermediate];			rs72654022	0.0603	0.0834	170,			1.4860			0.02,0.44	0.62						n/a (AF>5%)	n/a (AF>5%)					S100PBP (inh=n/a pLI=0.93), YARS (inh=AD pLI=0.00)
chr1	33475639	33475639	G	A	het	het	het		QUAL=1214;DP=714,540,551;AF=0.14,0.12,0.23;MQM=33	AK2,RP1-117O3.2	3'UTR,intron&non_coding_transcript	AK2:ENST00000373449:3_prime_UTR_variant:MODIFIER:exon7/7:c.*791C>T::,RP1-117O3.2:ENST00000427524:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.246-20997G>A::	103020 [AK2 (confirmed) Reticular dysgenesis,267500];				rs138902451		0.4669	0,	0.0016,0.0281,0.0240,0.0318,0.0104		2.0200			0.61,0.91	2.17						n/a (AF>5%)	n/a (AF>5%)					AK2 (inh=AR pLI=0.00), RP1-117O3.2 (inh=n/a pLI=n/a)
chr1	33475650	33475650	T	C	het	het	het		QUAL=1319;DP=666,556,548;AF=0.13,0.13,0.24;MQM=33	AK2,RP1-117O3.2	3'UTR,intron&non_coding_transcript	AK2:ENST00000373449:3_prime_UTR_variant:MODIFIER:exon7/7:c.*780A>G::,RP1-117O3.2:ENST00000427524:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.246-20986T>C::	103020 [AK2 (confirmed) Reticular dysgenesis,267500];				rs141799861		0.4693	0,	0.0025,0.0175,0.0263,0.0310,0.0074		0.0510			0.20,0.21	0.84						n/a (AF>5%)	n/a (AF>5%)					AK2 (inh=AR pLI=0.00), RP1-117O3.2 (inh=n/a pLI=n/a)
chr1	33475687	33475687	C	G	het	het	het		QUAL=2557;DP=382,580,605;AF=0.11,0.16,0.29;MQM=33	AK2,RP1-117O3.2	3'UTR,intron&non_coding_transcript	AK2:ENST00000373449:3_prime_UTR_variant:MODIFIER:exon7/7:c.*743G>C::,RP1-117O3.2:ENST00000427524:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.246-20949C>G::	103020 [AK2 (confirmed) Reticular dysgenesis,267500];				rs201444233		0.4100	0,	0.0016,0.0329,0.0384,0.0335,0.0104		0.3710			0.61,0.88	1.66						n/a (AF>5%)	n/a (AF>5%)					AK2 (inh=AR pLI=0.00), RP1-117O3.2 (inh=n/a pLI=n/a)
chr1	33475721	33475721	G	C	het	het	het		QUAL=4055;DP=331,551,606;AF=0.11,0.20,0.31;MQM=34	AK2,RP1-117O3.2	3'UTR,intron&non_coding_transcript	AK2:ENST00000373449:3_prime_UTR_variant:MODIFIER:exon7/7:c.*709C>G::,RP1-117O3.2:ENST00000427524:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.246-20915G>C::	103020 [AK2 (confirmed) Reticular dysgenesis,267500];				rs139591926		0.4724	0,	0.0186,0.0552,0.0627,0.0837,0.0123		-0.4810			0.01,0.11	0.14						n/a (AF>5%)	n/a (AF>5%)					AK2 (inh=AR pLI=0.00), RP1-117O3.2 (inh=n/a pLI=n/a)
chr1	33475750	33475750	A	G	het	het	het		QUAL=4691;DP=434,530,576;AF=0.13,0.22,0.32;MQM=39	AK2,RP1-117O3.2	3'UTR,intron&non_coding_transcript	AK2:ENST00000373449:3_prime_UTR_variant:MODIFIER:exon7/7:c.*680T>C::,RP1-117O3.2:ENST00000427524:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.246-20886A>G::	103020 [AK2 (confirmed) Reticular dysgenesis,267500];				rs142975905		0.4963	0,	0.3380,0.4867,0.4963,0.4367,0.4784		1.2420			0.35,0.22	0.42						n/a (AF>5%)	n/a (AF>5%)					AK2 (inh=AR pLI=0.00), RP1-117O3.2 (inh=n/a pLI=n/a)
chr1	33475767	33475767	G	A	het	het	het		QUAL=4573;DP=517,514,547;AF=0.14,0.24,0.33;MQM=40	AK2,RP1-117O3.2	3'UTR,intron&non_coding_transcript	AK2:ENST00000373449:3_prime_UTR_variant:MODIFIER:exon7/7:c.*663C>T::,RP1-117O3.2:ENST00000427524:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.246-20869G>A::	103020 [AK2 (confirmed) Reticular dysgenesis,267500];				rs74066436		0.4981	0,	0.4817,0.4985,0.4998,0.4884,0.4987		0.6460			0.07,0.20	0.22						n/a (AF>5%)	n/a (AF>5%)					AK2 (inh=AR pLI=0.00), RP1-117O3.2 (inh=n/a pLI=n/a)
chr1	33475791	33475791	A	G	het	het	het		QUAL=7348;DP=532,530,614;AF=0.20,0.28,0.37;MQM=42	AK2,RP1-117O3.2	3'UTR,intron&non_coding_transcript	AK2:ENST00000373449:3_prime_UTR_variant:MODIFIER:exon7/7:c.*639T>C::,RP1-117O3.2:ENST00000427524:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.246-20845A>G::	103020 [AK2 (confirmed) Reticular dysgenesis,267500];				rs6884		0.5611	1852,	0.5996,0.6146,0.5705,0.5401,0.5568		0.9860			0.00,0.11	0.30						n/a (AF>5%)	n/a (AF>5%)					AK2 (inh=AR pLI=0.00), RP1-117O3.2 (inh=n/a pLI=n/a)
chr1	33475879	33475879	C	T	het	het	het		QUAL=9227;DP=579,345,397;AF=0.28,0.31,0.41;MQM=54	AK2,RP1-117O3.2	3'UTR,intron&non_coding_transcript	AK2:ENST00000373449:3_prime_UTR_variant:MODIFIER:exon7/7:c.*551G>A::,RP1-117O3.2:ENST00000427524:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.246-20757C>T::	103020 [AK2 (confirmed) Reticular dysgenesis,267500];				rs61800917		0.4999	0,	0.4993,0.5000,0.5000,0.4999,0.5000		0.3020			0.13,0.18	0.21						n/a (AF>5%)	n/a (AF>5%)					AK2 (inh=AR pLI=0.00), RP1-117O3.2 (inh=n/a pLI=n/a)
chr1	33475967	33475967	G	A	het	het	het		QUAL=2753;DP=415,189,173;AF=0.23,0.23,0.29;MQM=48	AK2,RP1-117O3.2	3'UTR,intron&non_coding_transcript	AK2:ENST00000373449:3_prime_UTR_variant:MODIFIER:exon7/7:c.*463C>T::,RP1-117O3.2:ENST00000427524:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.246-20669G>A::	103020 [AK2 (confirmed) Reticular dysgenesis,267500];				rs74066437		0.4963	0,	0.3958,0.4866,0.4877,0.4676,0.4669		-0.5360			0.02,0.16	0.02						n/a (AF>5%)	n/a (AF>5%)					AK2 (inh=AR pLI=0.00), RP1-117O3.2 (inh=n/a pLI=n/a)
chr1	33475977	33475977	G	A	het	het	het		QUAL=1737;DP=341,157,150;AF=0.15,0.17,0.26;MQM=44	AK2,RP1-117O3.2	3'UTR,intron&non_coding_transcript	AK2:ENST00000373449:3_prime_UTR_variant:MODIFIER:exon7/7:c.*453C>T::,RP1-117O3.2:ENST00000427524:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.246-20659G>A::	103020 [AK2 (confirmed) Reticular dysgenesis,267500];				rs115408325		0.4939	0,	0.1274,0.3355,0.3333,0.0994,0.1665		0.9610			0.00,0.06	0.10						n/a (AF>5%)	n/a (AF>5%)					AK2 (inh=AR pLI=0.00), RP1-117O3.2 (inh=n/a pLI=n/a)
chr1	33475979	33475979	A	G	het	het	het		QUAL=1737;DP=341,157,150;AF=0.15,0.17,0.26;MQM=44	AK2,RP1-117O3.2	3'UTR,intron&non_coding_transcript	AK2:ENST00000373449:3_prime_UTR_variant:MODIFIER:exon7/7:c.*451T>C::,RP1-117O3.2:ENST00000427524:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.246-20657A>G::	103020 [AK2 (confirmed) Reticular dysgenesis,267500];				rs4045165		0.4922	0,	0.1017,0.2526,0.2236,0.0496,0.1106		-0.1460			0.00,0.07	0.01						n/a (AF>5%)	n/a (AF>5%)					AK2 (inh=AR pLI=0.00), RP1-117O3.2 (inh=n/a pLI=n/a)
chr1	33475982	33475982	C	A	het	het	het		QUAL=1737;DP=341,157,150;AF=0.15,0.17,0.26;MQM=44	AK2,RP1-117O3.2	3'UTR,intron&non_coding_transcript	AK2:ENST00000373449:3_prime_UTR_variant:MODIFIER:exon7/7:c.*448G>T::,RP1-117O3.2:ENST00000427524:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.246-20654C>A::	103020 [AK2 (confirmed) Reticular dysgenesis,267500];				rs114902220		0.4910	0,	0.0717,0.1788,0.1594,0.0267,0.0681		-0.1050			0.07,0.19	0.14						n/a (AF>5%)	n/a (AF>5%)					AK2 (inh=AR pLI=0.00), RP1-117O3.2 (inh=n/a pLI=n/a)
chr1	33475993	33475993	-	C	wt	het	het		QUAL=375;DP=305,155,150;AF=0.03,0.18,0.24;MQM=39	AK2,RP1-117O3.2	3'UTR,intron&non_coding_transcript	AK2:ENST00000373449:3_prime_UTR_variant:MODIFIER:exon7/7:c.*436dup::,RP1-117O3.2:ENST00000427524:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.246-20642dup::	103020 [AK2 (confirmed) Reticular dysgenesis,267500];				rs753076639		0.4848	0,	0.0126,0.0471,0.0336,0.0021,0.0148						0.48						n/a (AF>5%)	n/a (AF>5%)					AK2 (inh=AR pLI=0.00), RP1-117O3.2 (inh=n/a pLI=n/a)
chr1	33476032	33476032	T	C	het	het	het		QUAL=258;DP=231,153,129;AF=0.11,0.16,0.22;MQM=35	AK2,RP1-117O3.2	3'UTR,intron&non_coding_transcript	AK2:ENST00000373449:3_prime_UTR_variant:MODIFIER:exon7/7:c.*398A>G::,RP1-117O3.2:ENST00000427524:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.246-20604T>C::	103020 [AK2 (confirmed) Reticular dysgenesis,267500];				rs77170021		0.4901	0,	0.0101,0.0993,0.0465,0.0323,0.0300		-0.8450			0.02,0.16	0.72						n/a (AF>5%)	n/a (AF>5%)					AK2 (inh=AR pLI=0.00), RP1-117O3.2 (inh=n/a pLI=n/a)
chr1	33476065	33476065	G	A	het	het	het		QUAL=1058;DP=325,148,114;AF=0.22,0.12,0.20;MQM=34	AK2,RP1-117O3.2	3'UTR,intron&non_coding_transcript	AK2:ENST00000373449:3_prime_UTR_variant:MODIFIER:exon7/7:c.*365C>T::,RP1-117O3.2:ENST00000427524:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.246-20571G>A::	103020 [AK2 (confirmed) Reticular dysgenesis,267500];				rs143947377		0.4972	0,	0.1597,0.4109,0.3231,0.3773,0.3517		1.5880			0.76,0.97	1.57						n/a (AF>5%)	n/a (AF>5%)					AK2 (inh=AR pLI=0.00), RP1-117O3.2 (inh=n/a pLI=n/a)
chr1	33476074	33476074	A	T	het	het	het		QUAL=1124;DP=344,154,119;AF=0.23,0.10,0.18;MQM=34	AK2,RP1-117O3.2	3'UTR,intron&non_coding_transcript	AK2:ENST00000373449:3_prime_UTR_variant:MODIFIER:exon7/7:c.*356T>A::,RP1-117O3.2:ENST00000427524:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.246-20562A>T::	103020 [AK2 (confirmed) Reticular dysgenesis,267500];				rs199780633		0.4969	0,	0.1488,0.4039,0.2983,0.3716,0.3485		1.1940			0.49,0.95	1.29						n/a (AF>5%)	n/a (AF>5%)					AK2 (inh=AR pLI=0.00), RP1-117O3.2 (inh=n/a pLI=n/a)
chr1	33476090	33476090	T	C	het	het	het		QUAL=1436;DP=394,153,119;AF=0.25,0.12,0.16;MQM=34	AK2,RP1-117O3.2	3'UTR,intron&non_coding_transcript	AK2:ENST00000373449:3_prime_UTR_variant:MODIFIER:exon7/7:c.*340A>G::,RP1-117O3.2:ENST00000427524:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.246-20546T>C::,AK2:ENST00000548033:3_prime_UTR_variant:MODIFIER:exon6/6:c.*340A>G::	103020 [AK2 (confirmed) Reticular dysgenesis,267500];				rs140167370		0.4965	0,	0.1073,0.3712,0.2403,0.3337,0.3049		-2.1700			0.01,0.14	0.16						n/a (AF>5%)	n/a (AF>5%)					AK2 (inh=AR pLI=0.00), RP1-117O3.2 (inh=n/a pLI=n/a)
chr1	33476143	33476143	G	A	het	het	het		QUAL=107;DP=256,111,86;AF=0.15,0.14,0.14;MQM=36	AK2,RP1-117O3.2	3'UTR,intron&non_coding_transcript	AK2:ENST00000373449:3_prime_UTR_variant:MODIFIER:exon7/7:c.*287C>T::,RP1-117O3.2:ENST00000427524:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.246-20493G>A::,AK2:ENST00000548033:3_prime_UTR_variant:MODIFIER:exon6/6:c.*287C>T::	103020 [AK2 (confirmed) Reticular dysgenesis,267500];				rs201412582		0.4913	0,	0.0024,0.0258,0.0075,0.0135,0.0111		0.5190			0.04,0.16	0.01						n/a (AF>5%)	n/a (AF>5%)					AK2 (inh=AR pLI=0.00), RP1-117O3.2 (inh=n/a pLI=n/a)
chr1	33476224	33476225	AC	-	het	het	het		QUAL=1691;DP=220,74,72;AF=0.27,0.35,0.28;MQM=46	AK2,RP1-117O3.2	3'UTR,intron&non_coding_transcript	AK2:ENST00000373449:3_prime_UTR_variant:MODIFIER:exon7/7:c.*205_*206del::,RP1-117O3.2:ENST00000427524:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.246-20410_246-20409del::,AK2:ENST00000548033:3_prime_UTR_variant:MODIFIER:exon6/6:c.*205_*206del::	103020 [AK2 (confirmed) Reticular dysgenesis,267500];				rs67829320	0.4665	0.4990	0,	0.2795,0.4496,0.3721,0.4574,0.4691		-0.1330				0.25						n/a (AF>5%)	n/a (AF>5%)					AK2 (inh=AR pLI=0.00), RP1-117O3.2 (inh=n/a pLI=n/a)
chr1	33476239	33476239	T	C	het	het	het		QUAL=2634;DP=270,80,72;AF=0.30,0.38,0.32;MQM=47	AK2,RP1-117O3.2	3'UTR,intron&non_coding_transcript	AK2:ENST00000373449:3_prime_UTR_variant:MODIFIER:exon7/7:c.*191A>G::,RP1-117O3.2:ENST00000427524:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.246-20397T>C::,AK2:ENST00000548033:3_prime_UTR_variant:MODIFIER:exon6/6:c.*191A>G::	103020 [AK2 (confirmed) Reticular dysgenesis,267500];				rs74066438		0.4994	0,	0.3824,0.4822,0.4490,0.4767,0.4877		-0.0310			0.00,0.13	0.13						n/a (AF>5%)	n/a (AF>5%)					AK2 (inh=AR pLI=0.00), RP1-117O3.2 (inh=n/a pLI=n/a)
chr1	33476292	33476292	A	G	het	het	het		QUAL=4646;DP=270,119,136;AF=0.30,0.46,0.49;MQM=49	AK2,RP1-117O3.2	3'UTR,intron&non_coding_transcript	AK2:ENST00000373449:3_prime_UTR_variant:MODIFIER:exon7/7:c.*138T>C::,RP1-117O3.2:ENST00000427524:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.246-20344A>G::,AK2:ENST00000548033:3_prime_UTR_variant:MODIFIER:exon6/6:c.*138T>C::	103020 [AK2 (confirmed) Reticular dysgenesis,267500];				rs74066439		0.4994	0,	0.4683,0.4887,0.4893,0.4821,0.4890		0.1450			0.03,0.16	0.27						n/a (AF>5%)	n/a (AF>5%)					AK2 (inh=AR pLI=0.00), RP1-117O3.2 (inh=n/a pLI=n/a)
chr1	33476353	33476353	C	T	het	het	het		QUAL=2505;DP=233,143,155;AF=0.18,0.33,0.41;MQM=47	AK2,RP1-117O3.2	3'UTR,intron&non_coding_transcript	AK2:ENST00000373449:3_prime_UTR_variant:MODIFIER:exon7/7:c.*77G>A::,RP1-117O3.2:ENST00000427524:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.246-20283C>T::,AK2:ENST00000548033:3_prime_UTR_variant:MODIFIER:exon6/6:c.*77G>A::	103020 [AK2 (confirmed) Reticular dysgenesis,267500];				rs66599471		0.4992	1,	0.2300,0.1406,0.1844,0.2285,0.1575		-0.0210			0.49,0.95	1.35						n/a (AF>5%)	n/a (AF>5%)					AK2 (inh=AR pLI=0.00), RP1-117O3.2 (inh=n/a pLI=n/a)
chr1	33476385	33476385	C	G	het	het	het		QUAL=1845;DP=229,138,141;AF=0.20,0.27,0.37;MQM=48	AK2,RP1-117O3.2	3'UTR,intron&non_coding_transcript	AK2:ENST00000373449:3_prime_UTR_variant:MODIFIER:exon7/7:c.*45G>C::,RP1-117O3.2:ENST00000427524:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.246-20251C>G::,AK2:ENST00000467905:3_prime_UTR_variant:MODIFIER:exon8/8:c.*94G>C::,AK2:ENST00000548033:3_prime_UTR_variant:MODIFIER:exon6/6:c.*45G>C::	103020 [AK2 (confirmed) Reticular dysgenesis,267500];				rs76881767		0.4957	0,	0.0588,0.0098,0.0250,0.0544,0.0142		0.0630			0.25,0.95	1.87						n/a (AF>5%)	n/a (AF>5%)					AK2 (inh=AR pLI=0.00), RP1-117O3.2 (inh=n/a pLI=n/a)
chr1	33476387	33476387	C	T	het	het	het		QUAL=1845;DP=229,138,141;AF=0.20,0.27,0.37;MQM=48	AK2,RP1-117O3.2	3'UTR,intron&non_coding_transcript	AK2:ENST00000373449:3_prime_UTR_variant:MODIFIER:exon7/7:c.*43G>A::,RP1-117O3.2:ENST00000427524:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.246-20249C>T::,AK2:ENST00000467905:3_prime_UTR_variant:MODIFIER:exon8/8:c.*92G>A::,AK2:ENST00000548033:3_prime_UTR_variant:MODIFIER:exon6/6:c.*43G>A::	103020 [AK2 (confirmed) Reticular dysgenesis,267500];				rs201842558		0.4952	0,	0.0493,0.0081,0.0203,0.0459,0.0122		-0.0090			0.07,0.90	1.76						n/a (AF>5%)	n/a (AF>5%)					AK2 (inh=AR pLI=0.00), RP1-117O3.2 (inh=n/a pLI=n/a)
chr1	33476396	33476396	G	A	het	het	het		QUAL=1729;DP=233,137,132;AF=0.20,0.23,0.35;MQM=47	AK2,RP1-117O3.2	3'UTR,intron&non_coding_transcript	AK2:ENST00000373449:3_prime_UTR_variant:MODIFIER:exon7/7:c.*34C>T::,RP1-117O3.2:ENST00000427524:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.246-20240G>A::,AK2:ENST00000467905:3_prime_UTR_variant:MODIFIER:exon8/8:c.*83C>T::,AK2:ENST00000548033:3_prime_UTR_variant:MODIFIER:exon6/6:c.*34C>T::	103020 [AK2 (confirmed) Reticular dysgenesis,267500];				rs79824855		0.4891	0,	0.0222,0.0028,0.0073,0.0208,0.0043		2.0110			0.68,0.97	2.24						n/a (AF>5%)	n/a (AF>5%)					AK2 (inh=AR pLI=0.00), RP1-117O3.2 (inh=n/a pLI=n/a)
chr1	33476404	33476404	T	G	het	het	het		QUAL=1393;DP=220,132,128;AF=0.20,0.23,0.32;MQM=47	AK2,RP1-117O3.2	3'UTR,intron&non_coding_transcript	AK2:ENST00000373449:3_prime_UTR_variant:MODIFIER:exon7/7:c.*26A>C::,RP1-117O3.2:ENST00000427524:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.246-20232T>G::,AK2:ENST00000467905:3_prime_UTR_variant:MODIFIER:exon8/8:c.*75A>C::,AK2:ENST00000548033:3_prime_UTR_variant:MODIFIER:exon6/6:c.*26A>C::	103020 [AK2 (confirmed) Reticular dysgenesis,267500];				rs76230073		0.4786	0,	0.0156,0.0019,0.0036,0.0145,0.0025		1.6190			0.03,0.92	1.89						n/a (AF>5%)	n/a (AF>5%)					AK2 (inh=AR pLI=0.00), RP1-117O3.2 (inh=n/a pLI=n/a)
chr1	33478931	33478931	G	C	het	wt	wt		QUAL=519;DP=659,594,476;AF=0.17,0.02,0.04;MQM=35	AK2,RP1-117O3.2	missense,intron&non_coding_transcript,3'UTR	AK2:ENST00000354858:missense_variant:MODERATE:exon6/6:c.571C>G:p.His191Asp:PF00406,AK2:ENST00000373449:missense_variant:MODERATE:exon6/7:c.571C>G:p.His191Asp:PF00406,RP1-117O3.2:ENST00000427524:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.246-17705G>C::,AK2:ENST00000467905:missense_variant:MODERATE:exon6/8:c.571C>G:p.His191Asp:PF00406,AK2:ENST00000480134:3_prime_UTR_variant:MODIFIER:exon5/5:c.*74C>G::,AK2:ENST00000548033:missense_variant:MODERATE:exon5/6:c.445C>G:p.His149Asp:PF00406	103020 [AK2 (confirmed) Reticular dysgenesis,267500];	529737 [benign DISEASE=Reticular dysgenesis];			rs80324279		0.0366	0,	0.0554,0.0238,0.0279,0.0494,0.0179		9.8310	D,D, ,D, ,D	B,B, ,B, ,P	1.00,1.00	3.05	0.78					0	0					AK2 (inh=AR pLI=0.00), RP1-117O3.2 (inh=n/a pLI=n/a)
chr1	33478959	33478959	C	G	het	wt	wt		QUAL=667;DP=634,555,424;AF=0.17,0.02,0.04;MQM=36	AK2,RP1-117O3.2	missense,intron&non_coding_transcript,3'UTR	AK2:ENST00000354858:missense_variant:MODERATE:exon6/6:c.543G>C:p.Lys181Asn:PF00406,AK2:ENST00000373449:missense_variant:MODERATE:exon6/7:c.543G>C:p.Lys181Asn:PF00406,RP1-117O3.2:ENST00000427524:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.246-17677C>G::,AK2:ENST00000467905:missense_variant:MODERATE:exon6/8:c.543G>C:p.Lys181Asn:PF00406,AK2:ENST00000480134:3_prime_UTR_variant:MODIFIER:exon5/5:c.*46G>C::,AK2:ENST00000548033:missense_variant:MODERATE:exon5/6:c.417G>C:p.Lys139Asn:PF00406	103020 [AK2 (confirmed) Reticular dysgenesis,267500];				rs72884305		0.1174	0,	0.1602,0.0782,0.1040,0.1580,0.0611		-0.4040	D,D, ,D, ,D	B,B, ,B, ,B	0.39,0.96	2.53	0.19					n/a (AF>5%)	n/a (AF>5%)					AK2 (inh=AR pLI=0.00), RP1-117O3.2 (inh=n/a pLI=n/a)
chr1	35246848	35246848	-	C	wt	het	wt		QUAL=150;DP=9,14,10;AF=0.00,0.57,0.00;MQM=60	GJB3,RP1-34M23.5	5'UTR,intron&non_coding_transcript	GJB3:ENST00000373366:5_prime_UTR_variant:MODIFIER:exon1/2:c.-551dup::,RP1-34M23.5:ENST00000542839:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.110+6740dup::	603324 [GJB3 (confirmed) Erythrokeratodermia variabilis et progressiva 1,133200/Deafness,autosomal dominant 2B,612644/Deafness,autosomal recessive/Deafness,autosomal dominant,with peripheral neuropathy/Deafness,digenic,GJB2/GJB3,220290];				rs3831969		0.2674	1241,							0.62						n/a (AF>5%)	n/a (AF>5%)					GJB3 (inh=AR+AD pLI=0.00), RP1-34M23.5 (inh=n/a pLI=n/a)
chr1	35251229	35251229	G	A	wt	het	het		QUAL=9712;DP=258,377,358;AF=0.00,0.50,0.54;MQM=59	GJB3,RP1-34M23.5	3'UTR,intron&non_coding_transcript	GJB3:ENST00000373362:3_prime_UTR_variant:MODIFIER:exon2/2:c.*53G>A::,GJB3:ENST00000373366:3_prime_UTR_variant:MODIFIER:exon2/2:c.*53G>A::,RP1-34M23.5:ENST00000542839:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.110+2360C>T::	603324 [GJB3 (confirmed) Erythrokeratodermia variabilis et progressiva 1,133200/Deafness,autosomal dominant 2B,612644/Deafness,autosomal recessive/Deafness,autosomal dominant,with peripheral neuropathy/Deafness,digenic,GJB2/GJB3,220290];	297196 [benign DISEASE=Erythrokeratodermia variabilis,Nonsyndromic Hearing Loss, Dominant];			rs476220	0.4040	0.4920	3904,			0.0710			0.11,0.23	0.17						n/a (AF>5%)	n/a (AF>5%)					GJB3 (inh=AR+AD pLI=0.00), RP1-34M23.5 (inh=n/a pLI=n/a)
chr1	39491927	39491927	G	C	het	het	hom	off-target	QUAL=4593;DP=72,103,84;AF=0.47,0.50,1.00;MQM=60	NDUFS5	upstream_gene	NDUFS5:ENST00000372967:upstream_gene_variant:MODIFIER::::,NDUFS5:ENST00000372969:upstream_gene_variant:MODIFIER::::					rs1984600	0.5395	0.7144	8314,			-0.2810			0.00,0.64	0.59						n/a (AF>5%)	n/a (AF>5%)					NDUFS5 (inh=n/a pLI=0.09)
chr1	39492080	39492080	G	T	het	het	hom		QUAL=4670;DP=93,115,91;AF=0.52,0.48,1.00;MQM=60	NDUFS5	intron,splice_region&intron	NDUFS5:ENST00000372967:intron_variant:MODIFIER:exon1/2:c.-3+10G>T::,NDUFS5:ENST00000372969:splice_region_variant&intron_variant:LOW:exon1/2:c.-3+6G>T::					rs1122472	0.5377	0.7122	8276,			-1.2950			0.01,0.69	0.42		+21.39% (6.53>7.92)		0.000/0.028		n/a (AF>5%)	n/a (AF>5%)					NDUFS5 (inh=n/a pLI=0.09)
chr1	40539076	40539076	C	T	hom	het	het		QUAL=18425;DP=390,252,208;AF=1.00,0.50,0.39;MQM=60	PPT1	3'UTR	PPT1:ENST00000433473:3_prime_UTR_variant:MODIFIER:exon9/9:c.*657G>A::	600722 [PPT1 (confirmed) Ceroid lipofuscinosis,neuronal,1,256730];	297230 [benign DISEASE=Neuronal Ceroid-Lipofuscinosis, Recessive];			rs1126973	0.6673	0.7068	7758,			0.4520			0.11,0.66	0.63						n/a (AF>5%)	n/a (AF>5%)					PPT1 (inh=AR pLI=0.00)
chr1	40539203	40539203	-	TGAT	hom	het	het		QUAL=20091;DP=350,460,364;AF=0.99,0.47,0.45;MQM=60	PPT1	3'UTR	PPT1:ENST00000433473:3_prime_UTR_variant:MODIFIER:exon9/9:c.*526_*529dup::	600722 [PPT1 (confirmed) Ceroid lipofuscinosis,neuronal,1,256730];	297233 [benign DISEASE=Neuronal Ceroid-Lipofuscinosis, Recessive];					0.6640	6937,							0.06						n/a (AF>5%)	n/a (AF>5%)					PPT1 (inh=AR pLI=0.00)
chr1	40539228	40539228	G	C	hom	het	het		QUAL=29596;DP=533,540,424;AF=1.00,0.48,0.46;MQM=59	PPT1	3'UTR	PPT1:ENST00000433473:3_prime_UTR_variant:MODIFIER:exon9/9:c.*505C>G::	600722 [PPT1 (confirmed) Ceroid lipofuscinosis,neuronal,1,256730];	297234 [benign DISEASE=Neuronal Ceroid-Lipofuscinosis, Recessive];			rs1126972	0.6607	0.7023	7674,			-0.6320			0.02,0.13	-0.30						n/a (AF>5%)	n/a (AF>5%)					PPT1 (inh=AR pLI=0.00)
chr1	40539448	40539448	A	C	hom	het	het		QUAL=39177;DP=861,465,417;AF=1.00,0.45,0.53;MQM=60	PPT1	3'UTR	PPT1:ENST00000433473:3_prime_UTR_variant:MODIFIER:exon9/9:c.*285T>G::	600722 [PPT1 (confirmed) Ceroid lipofuscinosis,neuronal,1,256730];	297240 [benign DISEASE=Neuronal Ceroid-Lipofuscinosis, Recessive];			rs1126970	0.6611	0.7026	7699,			1.4180			0.33,0.40	0.39						n/a (AF>5%)	n/a (AF>5%)					PPT1 (inh=AR pLI=0.00)
chr1	40539572	40539572	A	G	het	het	wt		QUAL=7506;DP=343,267,237;AF=0.46,0.48,0.00;MQM=60	PPT1	3'UTR	PPT1:ENST00000433473:3_prime_UTR_variant:MODIFIER:exon9/9:c.*161T>C::,PPT1:ENST00000449045:3_prime_UTR_variant:MODIFIER:exon6/6:c.*161T>C::	600722 [PPT1 (confirmed) Ceroid lipofuscinosis,neuronal,1,256730];	297242 [likely benign DISEASE=Neuronal Ceroid-Lipofuscinosis, Recessive];			rs11552578	0.1514	0.1191	236,			2.4320			0.75,0.92	1.28						n/a (AF>5%)	n/a (AF>5%)					PPT1 (inh=AR pLI=0.00)
chr1	40546209	40546209	C	T	het	het	wt	off-target	QUAL=6245;DP=234,290,222;AF=0.49,0.49,0.00;MQM=60	PPT1	intron	PPT1:ENST00000433473:intron_variant:MODIFIER:exon5/8:c.537-50G>A::,PPT1:ENST00000449045:intron_variant:MODIFIER:exon2/5:c.228-50G>A::,PPT1:ENST00000530076:intron_variant:MODIFIER:exon1/4:c.-121-50G>A::	600722 [PPT1 (confirmed) Ceroid lipofuscinosis,neuronal,1,256730];				rs77623018	0.0881	0.0869	100,	0.0162,0.1054,0.1410,0.0568,0.1356	0.0558,0.0173	-1.7000			0.02,0.12	-0.32						n/a (AF>5%)	n/a (AF>5%)					PPT1 (inh=AR pLI=0.00)
chr1	40556942	40556942	A	T	wt	wt	het	off-target	QUAL=2666;DP=152,217,207;AF=0.00,0.00,0.51;MQM=60	PPT1	intron	PPT1:ENST00000433473:intron_variant:MODIFIER:exon4/8:c.433+59T>A::,PPT1:ENST00000449045:intron_variant:MODIFIER:exon1/5:c.125-1758T>A::	600722 [PPT1 (confirmed) Ceroid lipofuscinosis,neuronal,1,256730];				rs56654546	0.1154	0.0892	127,		0.0371,0.0304	0.8540			0.00,0.11	0.09						n/a (AF>5%)	n/a (AF>5%)					PPT1 (inh=AR pLI=0.00)
chr1	40557033	40557033	A	G	het	het	wt		QUAL=9340;DP=433,351,344;AF=0.44,0.48,0.00;MQM=59	PPT1	missense,intron	PPT1:ENST00000433473:missense_variant:MODERATE:exon4/9:c.401T>C:p.Ile134Thr:PF02089,PPT1:ENST00000449045:intron_variant:MODIFIER:exon1/5:c.125-1849T>C::	600722 [PPT1 (confirmed) Ceroid lipofuscinosis,neuronal,1,256730];	130022 [benign/likely benign DISEASE=not specified,Neuronal Ceroid-Lipofuscinosis, Recessive,not provided];			rs1800205	0.0739	0.0665	71,	0.0098,0.0359,0.1245,0.0483,0.1206	0.0474,0.0104	0.5750	T, 	B, 	0.86,0.97	1.80	0.20					n/a (AF>5%)	n/a (AF>5%)					PPT1 (inh=AR pLI=0.00)
chr1	40562993	40562993	T	C	hom	hom	hom		QUAL=5692;DP=36,97,56;AF=1.00,1.00,1.00;MQM=60	PPT1	5'UTR	PPT1:ENST00000433473:5_prime_UTR_variant:MODIFIER:exon1/9:c.-83A>G::	600722 [PPT1 (confirmed) Ceroid lipofuscinosis,neuronal,1,256730];	297250 [benign DISEASE=Neuronal Ceroid-Lipofuscinosis, Recessive];			rs6600313	0.8327	0.8462	11138,			-0.7110			0.01,0.11	0.53						n/a (AF>5%)	n/a (AF>5%)					PPT1 (inh=AR pLI=0.00)
chr1	40563019	40563019	G	T	het	het	wt		QUAL=1548;DP=30,83,47;AF=0.60,0.53,0.02;MQM=60	PPT1	5'UTR	PPT1:ENST00000433473:5_prime_UTR_variant:MODIFIER:exon1/9:c.-109C>A::	600722 [PPT1 (confirmed) Ceroid lipofuscinosis,neuronal,1,256730];	297251 [likely benign DISEASE=Neuronal Ceroid-Lipofuscinosis, Recessive];			rs41301070	0.1138	0.0937	181,			-0.6360			0.04,0.12	0.09						n/a (AF>5%)	n/a (AF>5%)					PPT1 (inh=AR pLI=0.00)
chr1	40735817	40735817	T	G	wt	wt	het	off-target	QUAL=327;DP=99,62,43;AF=0.00,0.00,0.40;MQM=60	ZMPSTE24	intron	ZMPSTE24:ENST00000372759:intron_variant:MODIFIER:exon5/9:c.627+18T>G::	606480 [ZMPSTE24 (confirmed) Mandibuloacral dysplasia with type B lipodystrophy,608612/Restrictive dermopathy,lethal,275210];	140531 [benign DISEASE=not specified,not provided];			rs16827109	0.1154	0.1070	112,	0.0635,0.1440,0.1611,0.0898,0.1472	0.0860,0.0654	0.1420			0.25,0.24	0.50						n/a (AF>5%)	n/a (AF>5%)					ZMPSTE24 (inh=AR pLI=0.00)
chr1	40737516	40737516	T	G	hom	hom	hom	off-target	QUAL=11360;DP=124,126,105;AF=1.00,1.00,1.00;MQM=60	ZMPSTE24	intron	ZMPSTE24:ENST00000372759:intron_variant:MODIFIER:exon5/9:c.628-50T>G::	606480 [ZMPSTE24 (confirmed) Mandibuloacral dysplasia with type B lipodystrophy,608612/Restrictive dermopathy,lethal,275210];	140535 [benign DISEASE=not specified,not provided];			rs6677717		0.9850	14977,	0.9984,0.9973,0.9999,0.9870,0.9859	0.9856,0.9982	-0.4140			0.00,0.07	0.07						n/a (AF>5%)	n/a (AF>5%)					ZMPSTE24 (inh=AR pLI=0.00)
chr1	43198722	43198722	C	T	het	hom	wt	off-target	QUAL=167;DP=14,1,0;AF=0.64,1.00,nan;MQM=52	CLDN19	downstream_gene	CLDN19:ENST00000296387:downstream_gene_variant:MODIFIER::::,CLDN19:ENST00000372539:downstream_gene_variant:MODIFIER::::,CLDN19:ENST00000539749:downstream_gene_variant:MODIFIER::::				AluSg	rs11210707	0.6434	0.6367	6079,			-0.2940			0.00,0.09	-0.01						n/a (AF>5%)	n/a (AF>5%)					CLDN19 (inh=AR pLI=0.50)
chr1	43199024	43199024	C	T	het	het	wt		QUAL=6615;DP=213,337,253;AF=0.51,0.51,0.00;MQM=59	CLDN19	3'UTR	CLDN19:ENST00000296387:3_prime_UTR_variant:MODIFIER:exon5/5:c.*1733G>A::,CLDN19:ENST00000539749:3_prime_UTR_variant:MODIFIER:exon3/3:c.*2409G>A::	610036 [CLDN19 (confirmed) Hypomagnesemia 5,renal,with ocular involvement,248190];	297316 [likely benign DISEASE=Renal Hypomagnesemia, Recessive];		AluSx1	rs112310775	0.1254	0.1278	246,			-0.6940			0.00,0.06	-0.21						n/a (AF>5%)	n/a (AF>5%)					CLDN19 (inh=AR pLI=0.50)
chr1	43199115	43199115	A	G	het	het	wt		QUAL=10820;DP=400,441,353;AF=0.49,0.50,0.00;MQM=60	CLDN19	3'UTR	CLDN19:ENST00000296387:3_prime_UTR_variant:MODIFIER:exon5/5:c.*1642T>C::,CLDN19:ENST00000539749:3_prime_UTR_variant:MODIFIER:exon3/3:c.*2318T>C::	610036 [CLDN19 (confirmed) Hypomagnesemia 5,renal,with ocular involvement,248190];	297318 [benign DISEASE=Renal Hypomagnesemia, Recessive];			rs56345167	0.1907	0.1888	604,			0.4220			0.04,0.36	0.19						n/a (AF>5%)	n/a (AF>5%)					CLDN19 (inh=AR pLI=0.50)
chr1	43200526	43200526	T	C	het	het	het		QUAL=4980;DP=134,142,127;AF=0.49,0.51,0.43;MQM=60	CLDN19	3'UTR	CLDN19:ENST00000296387:3_prime_UTR_variant:MODIFIER:exon5/5:c.*231A>G::,CLDN19:ENST00000539749:3_prime_UTR_variant:MODIFIER:exon3/3:c.*907A>G::	610036 [CLDN19 (confirmed) Hypomagnesemia 5,renal,with ocular involvement,248190];	297335 [benign DISEASE=Renal Hypomagnesemia, Recessive];			rs912075	0.6068	0.5875	5389,			-1.2490			0.00,0.06	0.13						n/a (AF>5%)	n/a (AF>5%)					CLDN19 (inh=AR pLI=0.50)
chr1	43200855	43200855	G	A	het	het	het		QUAL=7201;DP=118,254,212;AF=0.53,0.46,0.54;MQM=59	CLDN19	intron,3'UTR	CLDN19:ENST00000296387:intron_variant:MODIFIER:exon4/4:c.627-50C>T::,CLDN19:ENST00000372539:3_prime_UTR_variant:MODIFIER:exon4/4:c.*684C>T::,CLDN19:ENST00000539749:3_prime_UTR_variant:MODIFIER:exon3/3:c.*578C>T::	610036 [CLDN19 (confirmed) Hypomagnesemia 5,renal,with ocular involvement,248190];				rs74885359	0.0387	0.1021	211,	0.0229,0.0526,0.0002,0.1381,0.0403	0.1379,0.0302	-0.7360			0.06,0.18	-0.05						n/a (AF>5%)	n/a (AF>5%)					CLDN19 (inh=AR pLI=0.50)
chr1	43201216	43201216	A	C	het	het	het		QUAL=10366;DP=187,353,285;AF=0.45,0.49,0.49;MQM=60	CLDN19	intron,3'UTR	CLDN19:ENST00000296387:intron_variant:MODIFIER:exon4/4:c.626+333T>G::,CLDN19:ENST00000372539:3_prime_UTR_variant:MODIFIER:exon4/4:c.*323T>G::,CLDN19:ENST00000539749:3_prime_UTR_variant:MODIFIER:exon3/3:c.*217T>G::	610036 [CLDN19 (confirmed) Hypomagnesemia 5,renal,with ocular involvement,248190];			L2b	rs12141833		0.5413	4696,			-0.6380			0.00,0.11	0.01						n/a (AF>5%)	n/a (AF>5%)					CLDN19 (inh=AR pLI=0.50)
chr1	43201534	43201534	G	A	het	het	wt		QUAL=4021;DP=86,243,175;AF=0.44,0.56,0.01;MQM=59	CLDN19	intron,3'UTR,missense	CLDN19:ENST00000296387:intron_variant:MODIFIER:exon4/4:c.626+15C>T::,CLDN19:ENST00000372539:3_prime_UTR_variant:MODIFIER:exon4/4:c.*5C>T::,CLDN19:ENST00000539749:missense_variant:MODERATE:exon3/3:c.556C>T:p.Arg186Cys:	610036 [CLDN19 (confirmed) Hypomagnesemia 5,renal,with ocular involvement,248190];	297339 [benign DISEASE=Renal Hypomagnesemia, Recessive];			rs4660658	0.1905	0.1803	522,	0.2410,0.2470,0.2482,0.1568,0.1289	0.1608,0.2228	-1.1640	 , ,T	 , ,B	0.02,0.20	-0.07	0.12					n/a (AF>5%)	n/a (AF>5%)					CLDN19 (inh=AR pLI=0.50)
chr1	43212111	43212111	C	T	het	het	het		QUAL=9094;DP=297,207,180;AF=0.49,0.48,0.54;MQM=59	LEPRE1	3'UTR	LEPRE1:ENST00000236040:3_prime_UTR_variant:MODIFIER:exon14/14:c.*472G>A::,LEPRE1:ENST00000296388:3_prime_UTR_variant:MODIFIER:exon15/15:c.*257G>A::,LEPRE1:ENST00000397054:3_prime_UTR_variant:MODIFIER:exon15/15:c.*393G>A::	610339 [P3H1 (confirmed) Osteogenesis imperfecta,type VIII,610915];				rs6882	0.6625	0.6421	6417,			0.1860			0.07,0.19	0.39						n/a (AF>5%)	n/a (AF>5%)					P3H1 (inh=AR pLI=0.00)
chr1	43212431	43212431	A	G	hom	hom	hom		QUAL=23209;DP=224,337,213;AF=1.00,1.00,1.00;MQM=59	LEPRE1	3'UTR,synonymous	LEPRE1:ENST00000236040:3_prime_UTR_variant:MODIFIER:exon14/14:c.*152T>C::,LEPRE1:ENST00000296388:synonymous_variant:LOW:exon15/15:c.2148T>C:p.Gly716=:,LEPRE1:ENST00000397054:3_prime_UTR_variant:MODIFIER:exon15/15:c.*73T>C::	610339 [P3H1 (confirmed) Osteogenesis imperfecta,type VIII,610915];	194558 [likely benign DISEASE=not specified];			rs4660662	1.0000	1.0000	15464,	0.9999,1.0000,1.0000,0.9998,1.0000		-0.1550			0.00,0.10	0.24					COSM5745623	n/a (AF>5%)	n/a (AF>5%)					P3H1 (inh=AR pLI=0.00)
chr1	43212869	43212869	A	T	het	het	wt		QUAL=2969;DP=110,126,74;AF=0.48,0.50,0.00;MQM=60	LEPRE1	missense,intron	LEPRE1:ENST00000236040:missense_variant:MODERATE:exon14/14:c.2129T>A:p.Phe710Tyr:,LEPRE1:ENST00000296388:intron_variant:MODIFIER:exon14/14:c.2055+74T>A::,LEPRE1:ENST00000397054:intron_variant:MODIFIER:exon14/14:c.2074+55T>A::	610339 [P3H1 (confirmed) Osteogenesis imperfecta,type VIII,610915];				rs3738496	0.1210	0.1300	208,	0.0726,0.2080,0.2551,0.1134,0.0734	0.1226,0.0715	-0.0100	T, , 	B, , 	0.03,0.15	0.02	0.02					n/a (AF>5%)	n/a (AF>5%)					P3H1 (inh=AR pLI=0.00)
chr1	43213499	43213499	C	T	het	het	het	off-target	QUAL=6006;DP=179,219,136;AF=0.47,0.48,0.49;MQM=60	LEPRE1	intron	LEPRE1:ENST00000236040:intron_variant:MODIFIER:exon12/13:c.1839-30G>A::,LEPRE1:ENST00000296388:intron_variant:MODIFIER:exon12/14:c.1839-30G>A::,LEPRE1:ENST00000397054:intron_variant:MODIFIER:exon12/14:c.1839-30G>A::	610339 [P3H1 (confirmed) Osteogenesis imperfecta,type VIII,610915];				rs3738499	0.5541	0.6026	4631,	0.3564,0.6215,0.6779,0.5940,0.6955	0.5928,0.3702	-0.8330			0.12,0.23	0.13						n/a (AF>5%)	n/a (AF>5%)					P3H1 (inh=AR pLI=0.00)
chr1	43228189	43228189	T	A	hom	hom	hom	off-target	QUAL=19190;DP=190,258,217;AF=0.99,1.00,1.00;MQM=60	LEPRE1	intron	LEPRE1:ENST00000236040:intron_variant:MODIFIER:exon1/13:c.466-43A>T::,LEPRE1:ENST00000296388:intron_variant:MODIFIER:exon1/14:c.466-43A>T::,LEPRE1:ENST00000397054:intron_variant:MODIFIER:exon1/14:c.466-43A>T::	610339 [P3H1 (confirmed) Osteogenesis imperfecta,type VIII,610915];				rs2816593	0.9936	0.9863	15061,	0.9971,0.9972,1.0000,0.9815,0.9927	0.9845,0.9964	-0.1870			0.00,0.08	0.10						n/a (AF>5%)	n/a (AF>5%)					P3H1 (inh=AR pLI=0.00)
chr1	43232798	43232798	G	T	wt	wt	het	off-target	QUAL=349;DP=8,19,27;AF=0.00,0.00,0.67;MQM=60	LEPRE1,C1orf50	upstream_gene	LEPRE1:ENST00000236040:upstream_gene_variant:MODIFIER::::,LEPRE1:ENST00000296388:upstream_gene_variant:MODIFIER::::,C1orf50:ENST00000372525:upstream_gene_variant:MODIFIER::::,LEPRE1:ENST00000397054:upstream_gene_variant:MODIFIER::::,C1orf50:ENST00000536543:upstream_gene_variant:MODIFIER::::					rs11210712	0.1384	0.2129	871,			-0.0780			0.05,0.67	0.08						n/a (AF>5%)	n/a (AF>5%)					P3H1 (inh=AR pLI=0.00), C1orf50 (inh=n/a pLI=0.01)
chr1	43232807	43232807	C	G	het	het	het	off-target	QUAL=605;DP=11,17,22;AF=0.73,0.59,0.64;MQM=60	LEPRE1,C1orf50	upstream_gene	LEPRE1:ENST00000236040:upstream_gene_variant:MODIFIER::::,LEPRE1:ENST00000296388:upstream_gene_variant:MODIFIER::::,C1orf50:ENST00000372525:upstream_gene_variant:MODIFIER::::,LEPRE1:ENST00000397054:upstream_gene_variant:MODIFIER::::,C1orf50:ENST00000536543:upstream_gene_variant:MODIFIER::::					rs3738504	0.6496	0.5957	5504,			0.9360			0.10,0.71	0.36						n/a (AF>5%)	n/a (AF>5%)					P3H1 (inh=AR pLI=0.00), C1orf50 (inh=n/a pLI=0.01)
chr1	43392250	43392250	C	G	wt	wt	het		QUAL=2154;DP=291,266,227;AF=0.00,0.00,0.41;MQM=60	SLC2A1	3'UTR	SLC2A1:ENST00000426263:3_prime_UTR_variant:MODIFIER:exon10/10:c.*462G>C::	138140 [SLC2A1 (confirmed) GLUT1 deficiency syndrome 1,infantile onset,severe,606777/GLUT1 deficiency syndrome 2,childhood onset,612126/Epilepsy,idiopathic generalized,susceptibility to,12,614847/Dystonia 9,601042/Stomatin-deficient cryohydrocytosis with neurologic defects,608885];	297374 [benign DISEASE=Dystonia,Glucose transporter type 1 deficiency syndrome];			rs4658	0.3834	0.3378	2150,			-0.3280			0.01,0.08	-0.27						n/a (AF>5%)	n/a (AF>5%)					SLC2A1 (inh=AR+AD pLI=0.92)
chr1	43393245	43393245	-	GGTGAGAAAT	wt	het	het	off-target	QUAL=925;DP=180,82,99;AF=0.00,0.39,0.36;MQM=60	SLC2A1	intron	SLC2A1:ENST00000426263:intron_variant:MODIFIER:exon9/9:c.1278+30_1278+31insATTTCTCACC::	138140 [SLC2A1 (confirmed) GLUT1 deficiency syndrome 1,infantile onset,severe,606777/GLUT1 deficiency syndrome 2,childhood onset,612126/Epilepsy,idiopathic generalized,susceptibility to,12,614847/Dystonia 9,601042/Stomatin-deficient cryohydrocytosis with neurologic defects,608885];				rs11282849	0.6174	0.5531	4858,		0.4539,0.7516					0.03						n/a (AF>5%)	n/a (AF>5%)					SLC2A1 (inh=AR+AD pLI=0.92)
chr1	43395635	43395635	C	T	wt	wt	het		QUAL=1555;DP=118,235,163;AF=0.00,0.00,0.42;MQM=60	SLC2A1	intron,synonymous	SLC2A1:ENST00000415851:intron_variant:MODIFIER:exon4/4:c.352-441G>A::,SLC2A1:ENST00000426263:synonymous_variant:LOW:exon5/10:c.588G>A:p.Pro196=:PF00083	138140 [SLC2A1 (confirmed) GLUT1 deficiency syndrome 1,infantile onset,severe,606777/GLUT1 deficiency syndrome 2,childhood onset,612126/Epilepsy,idiopathic generalized,susceptibility to,12,614847/Dystonia 9,601042/Stomatin-deficient cryohydrocytosis with neurologic defects,608885];	95414 [benign DISEASE=Dystonia,Glucose transporter type 1 deficiency syndrome,GLUT1 deficiency syndrome 1,not specified];			rs2229682	0.1196	0.1855	459,	0.0411,0.2002,0.0753,0.2086,0.1881	0.2034,0.0493	-4.4130			0.10,0.48	0.75						n/a (AF>5%)	n/a (AF>5%)					SLC2A1 (inh=AR+AD pLI=0.92)
chr1	43396414	43396414	G	A	wt	wt	het		QUAL=2465;DP=253,166,155;AF=0.00,0.01,0.62;MQM=59	SLC2A1	synonymous,intron	SLC2A1:ENST00000372500:synonymous_variant:LOW:exon4/4:c.399C>T:p.Cys133=:PF00083,SLC2A1:ENST00000415851:intron_variant:MODIFIER:exon4/4:c.351+48C>T::,SLC2A1:ENST00000426263:synonymous_variant:LOW:exon4/10:c.399C>T:p.Cys133=:PF00083	138140 [SLC2A1 (confirmed) GLUT1 deficiency syndrome 1,infantile onset,severe,606777/GLUT1 deficiency syndrome 2,childhood onset,612126/Epilepsy,idiopathic generalized,susceptibility to,12,614847/Dystonia 9,601042/Stomatin-deficient cryohydrocytosis with neurologic defects,608885];	95411 [benign DISEASE=Dystonia,Glucose transporter type 1 deficiency syndrome,GLUT1 deficiency syndrome 1,not specified,not provided];			rs11537641	0.1414	0.1906	490,	0.0923,0.2039,0.0994,0.2055,0.1982	0.1987,0.0960	-1.1810			0.20,0.77	0.54						n/a (AF>5%)	n/a (AF>5%)					SLC2A1 (inh=AR+AD pLI=0.92)
chr1	43408966	43408966	G	A	het	wt	het		QUAL=7445;DP=295,489,349;AF=0.45,0.00,0.52;MQM=60	SLC2A1	synonymous	SLC2A1:ENST00000372500:synonymous_variant:LOW:exon2/4:c.45C>T:p.Ala15=:,SLC2A1:ENST00000415851:synonymous_variant:LOW:exon2/5:c.45C>T:p.Ala15=:,SLC2A1:ENST00000426263:synonymous_variant:LOW:exon2/10:c.45C>T:p.Ala15=:	138140 [SLC2A1 (confirmed) GLUT1 deficiency syndrome 1,infantile onset,severe,606777/GLUT1 deficiency syndrome 2,childhood onset,612126/Epilepsy,idiopathic generalized,susceptibility to,12,614847/Dystonia 9,601042/Stomatin-deficient cryohydrocytosis with neurologic defects,608885];	95413 [benign DISEASE=Dystonia,Glucose transporter type 1 deficiency syndrome,GLUT1 deficiency syndrome 1,not specified];			rs1385129	0.2404	0.2416	743,	0.1759,0.3059,0.2861,0.2194,0.2670	0.2155,0.1752	-2.2290			0.12,0.61	1.22						n/a (AF>5%)	n/a (AF>5%)					SLC2A1 (inh=AR+AD pLI=0.92)
chr1	43812075	43812075	G	A	het	het	wt	off-target	QUAL=3886;DP=141,148,112;AF=0.58,0.53,0.01;MQM=60	MPL	intron	MPL:ENST00000372470:intron_variant:MODIFIER:exon6/11:c.981-41G>A::,MPL:ENST00000413998:intron_variant:MODIFIER:exon6/9:c.981-41G>A::	159530 [MPL (confirmed) Thrombocytopenia,congenital amegakaryocytic,604498/Thrombocythemia 2,601977/Myelofibrosis with myeloid metaplasia,somatic,254450];	259760 [benign DISEASE=not specified];			rs1760670	0.2097	0.3034	1517,	0.2185,0.3023,0.0666,0.3790,0.1447	0.3803,0.2290	0.6670			0.02,0.18	0.15						n/a (AF>5%)	n/a (AF>5%)					MPL (inh=AR+AD pLI=0.00)
chr1	43820193	43820193	G	A	wt	wt	het	off-target	QUAL=1537;DP=184,119,123;AF=0.00,0.01,0.51;MQM=60	CDC20,MPL,RP1-92O14.3	upstream_gene,downstream_gene	CDC20:ENST00000310955:upstream_gene_variant:MODIFIER::::,CDC20:ENST00000372462:upstream_gene_variant:MODIFIER::::,MPL:ENST00000372470:downstream_gene_variant:MODIFIER::::,MPL:ENST00000413998:downstream_gene_variant:MODIFIER::::,RP1-92O14.3:ENST00000424948:downstream_gene_variant:MODIFIER::::					rs79064184	0.0296	0.0397	41,			0.0230			0.00,0.07	-0.25						1	20					CDC20 (inh=n/a pLI=0.00), MPL (inh=AR+AD pLI=0.00), RP1-92O14.3 (inh=n/a pLI=n/a)
chr1	44290530	44290530	A	G	het	hom	het		QUAL=7869;DP=266,112,116;AF=0.46,0.98,0.41;MQM=60	ST3GAL3	missense,intron	ST3GAL3:ENST00000262915:missense_variant:MODERATE:exon5/13:c.382A>G:p.Thr128Ala:,ST3GAL3:ENST00000330208:intron_variant:MODIFIER:exon4/6:c.209+9925A>G::,ST3GAL3:ENST00000332628:intron_variant:MODIFIER:exon3/9:c.209+9925A>G::,ST3GAL3:ENST00000335430:intron_variant:MODIFIER:exon3/9:c.161+9925A>G::,ST3GAL3:ENST00000347631:intron_variant:MODIFIER:exon4/11:c.254+9925A>G::,ST3GAL3:ENST00000351035:missense_variant:MODERATE:exon4/12:c.289A>G:p.Thr97Ala:,ST3GAL3:ENST00000353126:intron_variant:MODIFIER:exon4/9:c.209+9925A>G::,ST3GAL3:ENST00000361392:intron_variant:MODIFIER:exon4/11:c.209+9925A>G::,ST3GAL3:ENST00000361400:intron_variant:MODIFIER:exon3/10:c.161+9925A>G::,ST3GAL3:ENST00000361746:missense_variant:MODERATE:exon4/12:c.382A>G:p.Thr128Ala:,ST3GAL3:ENST00000361812:intron_variant:MODIFIER:exon3/5:c.254+9925A>G::,ST3GAL3:ENST00000372362:intron_variant:MODIFIER:exon3/5:c.209+9925A>G::,ST3GAL3:ENST00000372365:intron_variant:MODIFIER:exon3/7:c.209+9925A>G::,ST3GAL3:ENST00000372366:intron_variant:MODIFIER:exon2/6:c.206+9925A>G::,ST3GAL3:ENST00000372367:intron_variant:MODIFIER:exon2/6:c.206+9925A>G::,ST3GAL3:ENST00000372368:missense_variant:MODERATE:exon4/12:c.337A>G:p.Thr113Ala:,ST3GAL3:ENST00000372369:intron_variant:MODIFIER:exon3/10:c.209+9925A>G::,ST3GAL3:ENST00000372372:missense_variant:MODERATE:exon3/11:c.289A>G:p.Thr97Ala:,ST3GAL3:ENST00000372374:intron_variant:MODIFIER:exon4/10:c.209+9925A>G::,ST3GAL3:ENST00000372375:missense_variant:MODERATE:exon5/13:c.337A>G:p.Thr113Ala:,ST3GAL3:ENST00000372377:intron_variant:MODIFIER:exon4/8:c.209+9925A>G::,ST3GAL3:ENST00000528371:intron_variant:MODIFIER:exon2/6:c.161+9925A>G::,ST3GAL3:ENST00000531451:intron_variant:MODIFIER:exon2/4:c.161+9925A>G::,ST3GAL3:ENST00000531816:intron_variant:MODIFIER:exon2/3:c.161+9925A>G::,ST3GAL3:ENST00000531993:intron_variant:MODIFIER:exon2/7:c.161+9925A>G::,ST3GAL3:ENST00000533933:intron_variant:MODIFIER:exon3/8:c.209+9925A>G::,ST3GAL3:ENST00000545417:intron_variant:MODIFIER:exon4/6:c.254+9925A>G::	606494 [ST3GAL3 (provisional) Mental retardation,autosomal recessive 12,611090/Epileptic encephalopathy,early infantile,15,615006];	130378 [benign/likely benign DISEASE=not specified];		MER5B	rs37458	0.2364	0.3187	1620,	0.3229,0.2164,0.1363,0.3570,0.1441	0.3486,0.3093	-0.1510	T, , , , ,T, , , ,T, , , , , ,T, ,T, ,T, , , , , , , 	B, , , , ,B, , , ,B, , , , , ,B, ,B, ,B, , , , , , , 	0.00,0.06	-0.49	0.01					n/a (AF>5%)	n/a (AF>5%)					ST3GAL3 (inh=AR pLI=0.80)
chr1	44365457	44365457	A	G	het	het	wt	off-target	QUAL=3650;DP=140,157,108;AF=0.48,0.56,0.00;MQM=60	ST3GAL3	intron	ST3GAL3:ENST00000262915:intron_variant:MODIFIER:exon10/12:c.951+58A>G::,ST3GAL3:ENST00000330208:intron_variant:MODIFIER:exon6/6:c.397+5308A>G::,ST3GAL3:ENST00000332628:intron_variant:MODIFIER:exon7/9:c.651+58A>G::,ST3GAL3:ENST00000335430:intron_variant:MODIFIER:exon7/9:c.509+522A>G::,ST3GAL3:ENST00000347631:intron_variant:MODIFIER:exon9/11:c.789+58A>G::,ST3GAL3:ENST00000351035:intron_variant:MODIFIER:exon9/11:c.858+58A>G::,ST3GAL3:ENST00000353126:intron_variant:MODIFIER:exon9/9:c.744+58A>G::,ST3GAL3:ENST00000361392:intron_variant:MODIFIER:exon9/11:c.744+58A>G::,ST3GAL3:ENST00000361400:intron_variant:MODIFIER:exon8/10:c.696+58A>G::,ST3GAL3:ENST00000361746:intron_variant:MODIFIER:exon9/11:c.951+58A>G::,ST3GAL3:ENST00000361812:intron_variant:MODIFIER:exon5/5:c.442+5308A>G::,ST3GAL3:ENST00000372362:intron_variant:MODIFIER:exon5/5:c.397+5308A>G::,ST3GAL3:ENST00000372365:intron_variant:MODIFIER:exon7/7:c.*22+496A>G::,ST3GAL3:ENST00000372366:intron_variant:MODIFIER:exon6/6:c.*22+496A>G::,ST3GAL3:ENST00000372367:intron_variant:MODIFIER:exon6/6:c.554+522A>G::,ST3GAL3:ENST00000372368:intron_variant:MODIFIER:exon9/11:c.906+58A>G::,ST3GAL3:ENST00000372369:intron_variant:MODIFIER:exon8/10:c.744+58A>G::,ST3GAL3:ENST00000372372:intron_variant:MODIFIER:exon8/10:c.858+58A>G::,ST3GAL3:ENST00000372374:intron_variant:MODIFIER:exon8/10:c.651+58A>G::,ST3GAL3:ENST00000372375:intron_variant:MODIFIER:exon10/12:c.906+58A>G::,ST3GAL3:ENST00000372377:intron_variant:MODIFIER:exon6/8:c.397+5308A>G::,ST3GAL3:ENST00000528371:intron_variant:MODIFIER:exon6/6:c.509+522A>G::,ST3GAL3:ENST00000531451:intron_variant:MODIFIER:exon4/4:c.349+5308A>G::,ST3GAL3:ENST00000531816:intron_variant:MODIFIER:exon3/3:c.255-30347A>G::,ST3GAL3:ENST00000531993:intron_variant:MODIFIER:exon7/7:c.696+58A>G::,ST3GAL3:ENST00000533933:intron_variant:MODIFIER:exon8/8:c.744+58A>G::,ST3GAL3:ENST00000545417:intron_variant:MODIFIER:exon6/6:c.442+5308A>G::	606494 [ST3GAL3 (provisional) Mental retardation,autosomal recessive 12,611090/Epileptic encephalopathy,early infantile,15,615006];				rs783304	0.2804	0.2247	992,			-0.1060			0.01,0.09	0.16						n/a (AF>5%)	n/a (AF>5%)					ST3GAL3 (inh=AR pLI=0.80)
chr1	44386615	44386615	A	G	hom	hom	hom	off-target	QUAL=11946;DP=76,210,128;AF=0.99,1.00,0.98;MQM=60	ST3GAL3	intron	ST3GAL3:ENST00000262915:intron_variant:MODIFIER:exon12/12:c.1245+15A>G::,ST3GAL3:ENST00000330208:intron_variant:MODIFIER:exon6/6:c.398-9189A>G::,ST3GAL3:ENST00000332628:intron_variant:MODIFIER:exon9/9:c.945+15A>G::,ST3GAL3:ENST00000335430:intron_variant:MODIFIER:exon9/9:c.*116+15A>G::,ST3GAL3:ENST00000347631:intron_variant:MODIFIER:exon11/11:c.1083+15A>G::,ST3GAL3:ENST00000351035:intron_variant:MODIFIER:exon11/11:c.1152+15A>G::,ST3GAL3:ENST00000353126:intron_variant:MODIFIER:exon9/9:c.745-9189A>G::,ST3GAL3:ENST00000361392:intron_variant:MODIFIER:exon11/11:c.1038+15A>G::,ST3GAL3:ENST00000361400:intron_variant:MODIFIER:exon10/10:c.990+15A>G::,ST3GAL3:ENST00000361746:intron_variant:MODIFIER:exon11/11:c.1245+15A>G::,ST3GAL3:ENST00000361812:intron_variant:MODIFIER:exon5/5:c.443-9189A>G::,ST3GAL3:ENST00000372362:intron_variant:MODIFIER:exon5/5:c.398-9189A>G::,ST3GAL3:ENST00000372365:intron_variant:MODIFIER:exon7/7:c.*23-9189A>G::,ST3GAL3:ENST00000372366:intron_variant:MODIFIER:exon6/6:c.*23-9189A>G::,ST3GAL3:ENST00000372367:intron_variant:MODIFIER:exon6/6:c.555-9189A>G::,ST3GAL3:ENST00000372368:intron_variant:MODIFIER:exon11/11:c.1200+15A>G::,ST3GAL3:ENST00000372369:intron_variant:MODIFIER:exon10/10:c.948+15A>G::,ST3GAL3:ENST00000372372:intron_variant:MODIFIER:exon10/10:c.1152+15A>G::,ST3GAL3:ENST00000372374:intron_variant:MODIFIER:exon10/10:c.945+15A>G::,ST3GAL3:ENST00000372375:intron_variant:MODIFIER:exon12/12:c.1200+15A>G::,ST3GAL3:ENST00000372377:intron_variant:MODIFIER:exon8/8:c.*235+15A>G::,ST3GAL3:ENST00000528371:intron_variant:MODIFIER:exon6/6:c.510-9189A>G::,ST3GAL3:ENST00000531451:intron_variant:MODIFIER:exon4/4:c.350-9189A>G::,ST3GAL3:ENST00000531816:intron_variant:MODIFIER:exon3/3:c.255-9189A>G::,ST3GAL3:ENST00000531993:intron_variant:MODIFIER:exon7/7:c.697-9189A>G::,ST3GAL3:ENST00000533933:intron_variant:MODIFIER:exon8/8:c.745-9189A>G::,ST3GAL3:ENST00000545417:intron_variant:MODIFIER:exon6/6:c.443-9189A>G::	606494 [ST3GAL3 (provisional) Mental retardation,autosomal recessive 12,611090/Epileptic encephalopathy,early infantile,15,615006];	262909 [benign DISEASE=not specified];			rs3120803	0.8091	0.8817	11261,	0.6945,0.8482,0.8533,0.9211,0.8666	0.9239,0.7070	-1.1910			0.00,0.06	-0.20						n/a (AF>5%)	n/a (AF>5%)					ST3GAL3 (inh=AR pLI=0.80)
chr1	44386642	44386642	G	C	het	het	wt	off-target	QUAL=3470;DP=85,158,95;AF=0.53,0.64,0.00;MQM=60	ST3GAL3	intron	ST3GAL3:ENST00000262915:intron_variant:MODIFIER:exon12/12:c.1245+42G>C::,ST3GAL3:ENST00000330208:intron_variant:MODIFIER:exon6/6:c.398-9162G>C::,ST3GAL3:ENST00000332628:intron_variant:MODIFIER:exon9/9:c.945+42G>C::,ST3GAL3:ENST00000335430:intron_variant:MODIFIER:exon9/9:c.*116+42G>C::,ST3GAL3:ENST00000347631:intron_variant:MODIFIER:exon11/11:c.1083+42G>C::,ST3GAL3:ENST00000351035:intron_variant:MODIFIER:exon11/11:c.1152+42G>C::,ST3GAL3:ENST00000353126:intron_variant:MODIFIER:exon9/9:c.745-9162G>C::,ST3GAL3:ENST00000361392:intron_variant:MODIFIER:exon11/11:c.1038+42G>C::,ST3GAL3:ENST00000361400:intron_variant:MODIFIER:exon10/10:c.990+42G>C::,ST3GAL3:ENST00000361746:intron_variant:MODIFIER:exon11/11:c.1245+42G>C::,ST3GAL3:ENST00000361812:intron_variant:MODIFIER:exon5/5:c.443-9162G>C::,ST3GAL3:ENST00000372362:intron_variant:MODIFIER:exon5/5:c.398-9162G>C::,ST3GAL3:ENST00000372365:intron_variant:MODIFIER:exon7/7:c.*23-9162G>C::,ST3GAL3:ENST00000372366:intron_variant:MODIFIER:exon6/6:c.*23-9162G>C::,ST3GAL3:ENST00000372367:intron_variant:MODIFIER:exon6/6:c.555-9162G>C::,ST3GAL3:ENST00000372368:intron_variant:MODIFIER:exon11/11:c.1200+42G>C::,ST3GAL3:ENST00000372369:intron_variant:MODIFIER:exon10/10:c.948+42G>C::,ST3GAL3:ENST00000372372:intron_variant:MODIFIER:exon10/10:c.1152+42G>C::,ST3GAL3:ENST00000372374:intron_variant:MODIFIER:exon10/10:c.945+42G>C::,ST3GAL3:ENST00000372375:intron_variant:MODIFIER:exon12/12:c.1200+42G>C::,ST3GAL3:ENST00000372377:intron_variant:MODIFIER:exon8/8:c.*235+42G>C::,ST3GAL3:ENST00000528371:intron_variant:MODIFIER:exon6/6:c.510-9162G>C::,ST3GAL3:ENST00000531451:intron_variant:MODIFIER:exon4/4:c.350-9162G>C::,ST3GAL3:ENST00000531816:intron_variant:MODIFIER:exon3/3:c.255-9162G>C::,ST3GAL3:ENST00000531993:intron_variant:MODIFIER:exon7/7:c.697-9162G>C::,ST3GAL3:ENST00000533933:intron_variant:MODIFIER:exon8/8:c.745-9162G>C::,ST3GAL3:ENST00000545417:intron_variant:MODIFIER:exon6/6:c.443-9162G>C::	606494 [ST3GAL3 (provisional) Mental retardation,autosomal recessive 12,611090/Epileptic encephalopathy,early infantile,15,615006];				rs3764833	0.0687	0.0556	59,	0.0900,0.0489,0.1295,0.0399,0.0434	0.0347,0.0862	0.2340			0.03,0.16	0.36						n/a (AF>5%)	n/a (AF>5%)					ST3GAL3 (inh=AR pLI=0.80)
chr1	44395786	44395786	C	T	het	het	hom	off-target	QUAL=10385;DP=175,258,184;AF=0.45,0.47,1.00;MQM=60	ST3GAL3	intron	ST3GAL3:ENST00000262915:intron_variant:MODIFIER:exon12/12:c.1246-18C>T::,ST3GAL3:ENST00000330208:intron_variant:MODIFIER:exon6/6:c.398-18C>T::,ST3GAL3:ENST00000332628:intron_variant:MODIFIER:exon9/9:c.946-18C>T::,ST3GAL3:ENST00000335430:intron_variant:MODIFIER:exon9/9:c.*117-18C>T::,ST3GAL3:ENST00000347631:intron_variant:MODIFIER:exon11/11:c.1084-18C>T::,ST3GAL3:ENST00000351035:intron_variant:MODIFIER:exon11/11:c.1153-18C>T::,ST3GAL3:ENST00000353126:intron_variant:MODIFIER:exon9/9:c.745-18C>T::,ST3GAL3:ENST00000361392:intron_variant:MODIFIER:exon11/11:c.1039-18C>T::,ST3GAL3:ENST00000361400:intron_variant:MODIFIER:exon10/10:c.991-18C>T::,ST3GAL3:ENST00000361746:intron_variant:MODIFIER:exon11/11:c.1246-18C>T::,ST3GAL3:ENST00000361812:intron_variant:MODIFIER:exon5/5:c.443-18C>T::,ST3GAL3:ENST00000372362:intron_variant:MODIFIER:exon5/5:c.398-18C>T::,ST3GAL3:ENST00000372365:intron_variant:MODIFIER:exon7/7:c.*23-18C>T::,ST3GAL3:ENST00000372366:intron_variant:MODIFIER:exon6/6:c.*23-18C>T::,ST3GAL3:ENST00000372367:intron_variant:MODIFIER:exon6/6:c.555-18C>T::,ST3GAL3:ENST00000372368:intron_variant:MODIFIER:exon11/11:c.1201-18C>T::,ST3GAL3:ENST00000372369:intron_variant:MODIFIER:exon10/10:c.949-18C>T::,ST3GAL3:ENST00000372372:intron_variant:MODIFIER:exon10/10:c.1153-18C>T::,ST3GAL3:ENST00000372374:intron_variant:MODIFIER:exon10/10:c.946-18C>T::,ST3GAL3:ENST00000372375:intron_variant:MODIFIER:exon12/12:c.1201-18C>T::,ST3GAL3:ENST00000372377:intron_variant:MODIFIER:exon8/8:c.*236-18C>T::,ST3GAL3:ENST00000528371:intron_variant:MODIFIER:exon6/6:c.510-18C>T::,ST3GAL3:ENST00000531451:intron_variant:MODIFIER:exon4/4:c.350-18C>T::,ST3GAL3:ENST00000531816:intron_variant:MODIFIER:exon3/3:c.255-18C>T::,ST3GAL3:ENST00000531993:intron_variant:MODIFIER:exon7/7:c.697-18C>T::,ST3GAL3:ENST00000533933:intron_variant:MODIFIER:exon8/8:c.745-18C>T::,ST3GAL3:ENST00000545417:intron_variant:MODIFIER:exon6/6:c.443-18C>T::	606494 [ST3GAL3 (provisional) Mental retardation,autosomal recessive 12,611090/Epileptic encephalopathy,early infantile,15,615006];	262910 [benign DISEASE=not specified];		L3	rs2108202	0.5188	0.6767	6634,	0.2175,0.5741,0.6404,0.7774,0.6133	0.7785,0.2394	1.2100			0.03,0.21	0.82		+5.37% (9.65>10.17)				n/a (AF>5%)	n/a (AF>5%)					ST3GAL3 (inh=AR pLI=0.80)
chr1	44396196	44396196	A	G	het	het	wt		QUAL=3138;DP=152,121,77;AF=0.43,0.50,0.00;MQM=60	ST3GAL3	3'UTR	ST3GAL3:ENST00000262915:3_prime_UTR_variant:MODIFIER:exon13/13:c.*303A>G::,ST3GAL3:ENST00000330208:3_prime_UTR_variant:MODIFIER:exon7/7:c.*322A>G::,ST3GAL3:ENST00000335430:3_prime_UTR_variant:MODIFIER:exon10/10:c.*509A>G::,ST3GAL3:ENST00000351035:3_prime_UTR_variant:MODIFIER:exon12/12:c.*303A>G::,ST3GAL3:ENST00000353126:3_prime_UTR_variant:MODIFIER:exon10/10:c.*303A>G::,ST3GAL3:ENST00000361392:3_prime_UTR_variant:MODIFIER:exon12/12:c.*303A>G::,ST3GAL3:ENST00000361400:3_prime_UTR_variant:MODIFIER:exon11/11:c.*303A>G::,ST3GAL3:ENST00000372374:3_prime_UTR_variant:MODIFIER:exon11/11:c.*303A>G::,ST3GAL3:ENST00000372375:3_prime_UTR_variant:MODIFIER:exon13/13:c.*303A>G::,ST3GAL3:ENST00000372377:3_prime_UTR_variant:MODIFIER:exon9/9:c.*628A>G::,ST3GAL3:ENST00000545417:3_prime_UTR_variant:MODIFIER:exon7/7:c.*322A>G::	606494 [ST3GAL3 (provisional) Mental retardation,autosomal recessive 12,611090/Epileptic encephalopathy,early infantile,15,615006];				rs12561948	0.0507	0.0383	27,			1.5480			0.70,0.94	1.93						n/a (AF>5%)	n/a (AF>5%)					ST3GAL3 (inh=AR pLI=0.80)
chr1	44396646	44396646	C	G	het	het	hom		QUAL=13498;DP=227,263,222;AF=0.49,0.54,1.00;MQM=60	ST3GAL3	3'UTR	ST3GAL3:ENST00000262915:3_prime_UTR_variant:MODIFIER:exon13/13:c.*753C>G::,ST3GAL3:ENST00000330208:3_prime_UTR_variant:MODIFIER:exon7/7:c.*772C>G::,ST3GAL3:ENST00000335430:3_prime_UTR_variant:MODIFIER:exon10/10:c.*959C>G::,ST3GAL3:ENST00000351035:3_prime_UTR_variant:MODIFIER:exon12/12:c.*753C>G::,ST3GAL3:ENST00000353126:3_prime_UTR_variant:MODIFIER:exon10/10:c.*753C>G::,ST3GAL3:ENST00000361392:3_prime_UTR_variant:MODIFIER:exon12/12:c.*753C>G::,ST3GAL3:ENST00000361400:3_prime_UTR_variant:MODIFIER:exon11/11:c.*753C>G::,ST3GAL3:ENST00000372374:3_prime_UTR_variant:MODIFIER:exon11/11:c.*753C>G::,ST3GAL3:ENST00000372375:3_prime_UTR_variant:MODIFIER:exon13/13:c.*753C>G::,ST3GAL3:ENST00000372377:3_prime_UTR_variant:MODIFIER:exon9/9:c.*1078C>G::,ST3GAL3:ENST00000545417:3_prime_UTR_variant:MODIFIER:exon7/7:c.*772C>G::	606494 [ST3GAL3 (provisional) Mental retardation,autosomal recessive 12,611090/Epileptic encephalopathy,early infantile,15,615006];				rs6801	0.5188	0.6083	6635,			0.1600			0.06,0.22	0.31						n/a (AF>5%)	n/a (AF>5%)					ST3GAL3 (inh=AR pLI=0.80)
chr1	45285534	45285534	A	C	wt	wt	het		QUAL=164;DP=127,28,26;AF=0.00,0.00,0.42;MQM=60	PTCH2	3'UTR	PTCH2:ENST00000447098:3_prime_UTR_variant:MODIFIER:exon23/23:c.*827T>G::	603673 [PTCH2 (provisional) Medulloblastoma,somatic,155255/Basal cell carcinoma,somatic,605462/Basal cell nevus syndrome,109400];				rs181782534	0.0104	0.0121	1,			-0.4960			0.00,0.36	-0.14						0	6					PTCH2 (inh=AR+AD pLI=0.00)
chr1	45285648	45285648	C	T	hom	het	het		QUAL=19732;DP=508,176,167;AF=0.99,0.49,0.54;MQM=59	RNU5E-6P,PTCH2	non_coding_transcript_exon,3'UTR	RNU5E-6P:ENST00000365574:non_coding_transcript_exon_variant:MODIFIER:exon1/1:n.22G>A::,PTCH2:ENST00000447098:3_prime_UTR_variant:MODIFIER:exon23/23:c.*713G>A::	603673 [PTCH2 (provisional) Medulloblastoma,somatic,155255/Basal cell carcinoma,somatic,605462/Basal cell nevus syndrome,109400];			U5	rs41269085	0.2290	0.2268	898,			-0.3180			0.00,0.39	-0.07						n/a (AF>5%)	n/a (AF>5%)					RNU5E-6P (inh=n/a pLI=n/a), PTCH2 (inh=AR+AD pLI=0.00)
chr1	45292866	45292866	G	A	hom	het	het		QUAL=9009;DP=165,208,148;AF=0.99,0.50,0.51;MQM=59	PTCH2	synonymous	PTCH2:ENST00000372192:synonymous_variant:LOW:exon16/22:c.2487C>T:p.Asp829=:,PTCH2:ENST00000447098:synonymous_variant:LOW:exon16/23:c.2487C>T:p.Asp829=:	603673 [PTCH2 (provisional) Medulloblastoma,somatic,155255/Basal cell carcinoma,somatic,605462/Basal cell nevus syndrome,109400];				rs2295996	0.1478	0.1622	342,	0.0804,0.1777,0.2119,0.1665,0.1586	0.1670,0.0858	0.7970			0.70,0.93	1.00						n/a (AF>5%)	n/a (AF>5%)					PTCH2 (inh=AR+AD pLI=0.00)
chr1	45293518	45293518	A	G	hom	het	het		QUAL=12995;DP=194,323,269;AF=0.99,0.48,0.48;MQM=60	PTCH2	synonymous	PTCH2:ENST00000372192:synonymous_variant:LOW:exon14/22:c.2055T>C:p.Ala685=:,PTCH2:ENST00000447098:synonymous_variant:LOW:exon14/23:c.2055T>C:p.Ala685=:	603673 [PTCH2 (provisional) Medulloblastoma,somatic,155255/Basal cell carcinoma,somatic,605462/Basal cell nevus syndrome,109400];				rs7525308	0.4455	0.4351	3057,	0.5899,0.4178,0.4807,0.3458,0.3538	0.3423,0.5847	2.0950			0.06,0.81	0.55						n/a (AF>5%)	n/a (AF>5%)					PTCH2 (inh=AR+AD pLI=0.00)
chr1	45294156	45294156	T	C	hom	het	het	off-target	QUAL=21885;DP=235,683,520;AF=1.00,0.48,0.53;MQM=59	PTCH2	intron	PTCH2:ENST00000372192:intron_variant:MODIFIER:exon12/21:c.1590+22A>G::,PTCH2:ENST00000447098:intron_variant:MODIFIER:exon12/22:c.1590+22A>G::	603673 [PTCH2 (provisional) Medulloblastoma,somatic,155255/Basal cell carcinoma,somatic,605462/Basal cell nevus syndrome,109400];				rs2273940	0.4433	0.4335	3015,	0.5800,0.4177,0.4813,0.3454,0.3536	0.3426,0.5756	-1.9150			0.00,0.09	0.11						n/a (AF>5%)	n/a (AF>5%)					PTCH2 (inh=AR+AD pLI=0.00)
chr1	45307506	45307506	G	A	hom	het	het	off-target	QUAL=7538;DP=83,213,183;AF=0.98,0.54,0.51;MQM=60	PTCH2	intron	PTCH2:ENST00000372192:intron_variant:MODIFIER:exon2/21:c.265+13C>T::,PTCH2:ENST00000447098:intron_variant:MODIFIER:exon2/22:c.265+13C>T::	603673 [PTCH2 (provisional) Medulloblastoma,somatic,155255/Basal cell carcinoma,somatic,605462/Basal cell nevus syndrome,109400];				rs3795720	0.3720	0.3741	1934,	0.3293,0.5255,0.4342,0.3461,0.3427	0.3437,0.3300	1.7090			0.03,0.33	0.51						n/a (AF>5%)	n/a (AF>5%)					PTCH2 (inh=AR+AD pLI=0.00)
chr1	45340282	45340282	C	T	hom	het	het		QUAL=20694;DP=403,314,252;AF=1.00,0.48,0.48;MQM=60	EIF2B3	intron,3'UTR	EIF2B3:ENST00000360403:intron_variant:MODIFIER:exon10/11:c.1202+68G>A::,EIF2B3:ENST00000372183:3_prime_UTR_variant:MODIFIER:exon10/10:c.*31G>A::	606273 [EIF2B3 (provisional) Leukoencephalopathy with vanishing white matter,603896];			HAL1	rs9988451	0.4517	0.4364	3035,	0.5910,0.5375,0.4367,0.3534,0.3513	0.3466,0.5882	0.6900			0.00,0.04	0.20						n/a (AF>5%)	n/a (AF>5%)					EIF2B3 (inh=AR pLI=0.67)
chr1	45345446	45345446	T	A	hom	het	het	off-target	QUAL=4385;DP=102,64,44;AF=1.00,0.48,0.57;MQM=60	EIF2B3	intron	EIF2B3:ENST00000360403:intron_variant:MODIFIER:exon8/11:c.975+44A>T::,EIF2B3:ENST00000372183:intron_variant:MODIFIER:exon8/9:c.975+44A>T::	606273 [EIF2B3 (provisional) Leukoencephalopathy with vanishing white matter,603896];	261223 [benign DISEASE=not specified];			rs3738248	0.1448	0.1619	352,	0.1135,0.1555,0.1663,0.1736,0.1602	0.1743,0.1187	0.2890			0.19,0.27	0.43						n/a (AF>5%)	n/a (AF>5%)					EIF2B3 (inh=AR pLI=0.67)
chr1	45362992	45362992	T	C	hom	het	het	off-target	QUAL=6665;DP=142,91,71;AF=1.00,0.57,0.52;MQM=60	EIF2B3	intron	EIF2B3:ENST00000360403:intron_variant:MODIFIER:exon6/11:c.656+35A>G::,EIF2B3:ENST00000372183:intron_variant:MODIFIER:exon6/9:c.656+35A>G::	606273 [EIF2B3 (provisional) Leukoencephalopathy with vanishing white matter,603896];	261222 [benign DISEASE=not specified];			rs263978	0.7911	0.6874	7734,	0.9114,0.7905,0.9740,0.5468,0.6539	0.5436,0.8904	-0.9150			0.00,0.07	-0.05						n/a (AF>5%)	n/a (AF>5%)					EIF2B3 (inh=AR pLI=0.67)
chr1	45452227	45452227	G	C	hom	het	het		QUAL=6875;DP=126,187,109;AF=1.00,0.43,0.43;MQM=60	EIF2B3	5'UTR	EIF2B3:ENST00000360403:5_prime_UTR_variant:MODIFIER:exon1/12:c.-72C>G::,EIF2B3:ENST00000372183:5_prime_UTR_variant:MODIFIER:exon1/10:c.-72C>G::	606273 [EIF2B3 (provisional) Leukoencephalopathy with vanishing white matter,603896];	297453 [benign DISEASE=Leukoencephalopathy with vanishing white matter];			rs489676	0.4806	0.4816	3682,			-3.3680			0.00,0.12	0.05						n/a (AF>5%)	n/a (AF>5%)					EIF2B3 (inh=AR pLI=0.67)
chr1	45975089	45975089	T	-	het	het	het		QUAL=412;DP=66,118,111;AF=0.18,0.10,0.28;MQM=59	MMACHC	3'UTR	MMACHC:ENST00000401061:3_prime_UTR_variant:MODIFIER:exon4/4:c.*217del::	609831 [MMACHC (confirmed) Methylmalonic aciduria and homocystinuria,cblC type,277400];			AluSg7			0.0413	25,			-2.0510				-0.73						2	2					MMACHC (inh=AR pLI=0.00)
chr1	45975166	45975166	A	G	wt	het	wt		QUAL=1058;DP=197,148,130;AF=0.00,0.37,0.00;MQM=59	MMACHC	3'UTR	MMACHC:ENST00000401061:3_prime_UTR_variant:MODIFIER:exon4/4:c.*279A>G::	609831 [MMACHC (confirmed) Methylmalonic aciduria and homocystinuria,cblC type,277400];	297502 [benign DISEASE=Disorders of Intracellular Cobalamin Metabolism];		AluSg7	rs9729395	0.2634	0.2169	721,			0.6090			0.01,0.06	-0.13						n/a (AF>5%)	n/a (AF>5%)					MMACHC (inh=AR pLI=0.00)
chr1	45975300	45975300	G	A	wt	wt	het		QUAL=2026;DP=183,194,136;AF=0.01,0.01,0.59;MQM=59	MMACHC	3'UTR	MMACHC:ENST00000401061:3_prime_UTR_variant:MODIFIER:exon4/4:c.*413G>A::	609831 [MMACHC (confirmed) Methylmalonic aciduria and homocystinuria,cblC type,277400];	297505 [likely benign DISEASE=Disorders of Intracellular Cobalamin Metabolism];		AluSg7	rs12021717	0.1184	0.1897	596,			0.1590			0.02,0.09	0.04						n/a (AF>5%)	n/a (AF>5%)					MMACHC (inh=AR pLI=0.00)
chr1	45975740	45975741	CT	-	wt	het	wt		QUAL=1747;DP=242,190,178;AF=0.00,0.48,0.01;MQM=58	MMACHC	3'UTR	MMACHC:ENST00000401061:3_prime_UTR_variant:MODIFIER:exon4/4:c.*855_*856del::	609831 [MMACHC (confirmed) Methylmalonic aciduria and homocystinuria,cblC type,277400];	297512 [benign DISEASE=Disorders of Intracellular Cobalamin Metabolism];		AluSx4			0.6562	5931,			0.2120				-0.04						n/a (AF>5%)	n/a (AF>5%)					MMACHC (inh=AR pLI=0.00)
chr1	45975749	45975749	A	-	het	het	het		QUAL=281;DP=113,89,89;AF=0.18,0.16,0.28;MQM=59	MMACHC	3'UTR	MMACHC:ENST00000401061:3_prime_UTR_variant:MODIFIER:exon4/4:c.*877del::	609831 [MMACHC (confirmed) Methylmalonic aciduria and homocystinuria,cblC type,277400];			AluSx4			0.1016	107,			0.0860				-0.06						n/a (AF>5%)	n/a (AF>5%)					MMACHC (inh=AR pLI=0.00)
chr1	45976147	45976147	G	A	wt	het	wt		QUAL=4629;DP=343,403,282;AF=0.00,0.49,0.00;MQM=60	MMACHC	3'UTR	MMACHC:ENST00000401061:3_prime_UTR_variant:MODIFIER:exon4/4:c.*1260G>A::	609831 [MMACHC (confirmed) Methylmalonic aciduria and homocystinuria,cblC type,277400];	297522 [benign DISEASE=Disorders of Intracellular Cobalamin Metabolism];		AluJr	rs882803	0.7438	0.6556	6705,			-3.5650			0.00,0.05	-0.08						n/a (AF>5%)	n/a (AF>5%)					MMACHC (inh=AR pLI=0.00)
chr1	45976263	45976263	-	T	wt	het	wt		QUAL=3891;DP=314,316,260;AF=0.01,0.47,0.00;MQM=60	MMACHC	3'UTR	MMACHC:ENST00000401061:3_prime_UTR_variant:MODIFIER:exon4/4:c.*1376_*1377insT::	609831 [MMACHC (confirmed) Methylmalonic aciduria and homocystinuria,cblC type,277400];	297525 [benign DISEASE=Disorders of Intracellular Cobalamin Metabolism];			rs5773883	0.7438	0.6551	6675,							-0.03						n/a (AF>5%)	n/a (AF>5%)					MMACHC (inh=AR pLI=0.00)
chr1	45976587	45976587	A	G	wt	het	wt		QUAL=2459;DP=267,172,153;AF=0.00,0.56,0.00;MQM=60	MMACHC	3'UTR	MMACHC:ENST00000401061:3_prime_UTR_variant:MODIFIER:exon4/4:c.*1700A>G::	609831 [MMACHC (confirmed) Methylmalonic aciduria and homocystinuria,cblC type,277400];	297529 [benign DISEASE=Disorders of Intracellular Cobalamin Metabolism];			rs1044717	0.8255	0.7263	8260,			-0.7830			0.00,0.14	0.08						n/a (AF>5%)	n/a (AF>5%)					MMACHC (inh=AR pLI=0.00)
chr1	46164390	46164399	TTTTTTTTTT	-	hom	hom	hom		QUAL=986;DP=29,5,1;AF=1.00,1.00,1.00;MQM=59	IPP	3'UTR	IPP:ENST00000396478:3_prime_UTR_variant:MODIFIER:exon9/9:c.*1239_*1248del::				AluJb	rs199546340		0.3295	1094,			0.6660				-0.12						n/a (AF>5%)	n/a (AF>5%)					IPP (inh=n/a pLI=0.01)
chr1	46164846	46164846	A	T	hom	hom	het		QUAL=21033;DP=307,300,179;AF=0.99,1.00,0.47;MQM=60	IPP	3'UTR	IPP:ENST00000396478:3_prime_UTR_variant:MODIFIER:exon9/9:c.*792T>A::					rs10749856	0.3249	0.2857	1298,			1.4050			0.25,0.25	0.42						n/a (AF>5%)	n/a (AF>5%)					IPP (inh=n/a pLI=0.01)
chr1	46165875	46165875	-	A	hom	hom	het	off-target	QUAL=9591;DP=141,200,188;AF=0.87,0.89,0.40;MQM=59	IPP	intron	IPP:ENST00000396478:intron_variant:MODIFIER:exon8/8:c.1531-14dup::					rs550999501		0.3251	1149,	0.2482,0.3546,0.3585,0.3149,0.3757	0.2925,0.2506					1.33						n/a (AF>5%)	n/a (AF>5%)					IPP (inh=n/a pLI=0.01)
chr1	46195375	46195375	T	C	hom	hom	het		QUAL=10558;DP=230,65,60;AF=1.00,0.97,0.57;MQM=60	IPP	missense	IPP:ENST00000396478:missense_variant:MODERATE:exon4/9:c.791A>G:p.Lys264Arg:					rs28375469	0.3149	0.3038	1246,	0.2359,0.3237,0.3379,0.2950,0.3617	0.2960,0.2469	7.6250	T	B	0.98,0.99	2.37	0.19					n/a (AF>5%)	n/a (AF>5%)					IPP (inh=n/a pLI=0.01)
chr1	46206540	46206540	A	G	hom	hom	het	off-target	QUAL=9707;DP=269,37,25;AF=1.00,1.00,0.68;MQM=60	IPP	intron	IPP:ENST00000396478:intron_variant:MODIFIER:exon3/8:c.724+33T>C::					rs28507722	0.3149	0.3002	1242,	0.2365,0.3232,0.3336,0.2949,0.3686	0.2958,0.2469	2.9420			0.24,0.19	0.31						n/a (AF>5%)	n/a (AF>5%)					IPP (inh=n/a pLI=0.01)
chr1	46655158	46655158	T	C	hom	hom	hom		QUAL=12747;DP=142,129,141;AF=0.99,1.00,1.00;MQM=60	POMGNT1	missense,missense&splice_region,3'UTR	POMGNT1:ENST00000371984:missense_variant:MODERATE:exon21/22:c.1867A>G:p.Met623Val:,POMGNT1:ENST00000371986:missense_variant&splice_region_variant:MODERATE:exon21/23:c.1867A>G:p.Met623Val:,POMGNT1:ENST00000371992:missense_variant&splice_region_variant:MODERATE:exon21/23:c.1867A>G:p.Met623Val:,POMGNT1:ENST00000396420:3_prime_UTR_variant:MODIFIER:exon18/19:c.*1536A>G::,POMGNT1:ENST00000535522:missense_variant:MODERATE:exon20/22:c.1801A>G:p.Met601Val:	606822 [POMGNT1 (confirmed) Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies),type A,3,253280/Muscular dystrophy-dystroglycanopathy (congenital with mental retardation),type B,3,613151/Muscular dystrophy-dystroglycanopathy (limb-girdle),type C,3,613157/Retinitis pigmentosa 76,617123];	167524 [benign DISEASE=not specified];			rs6659553	0.9425	0.9872	14026,	0.8176,0.9912,1.0000,0.9996,0.9997	0.9994,0.8277	5.7560		B,B,B, ,B	0.18,0.92	2.65	0.33	-83.81% (2.63>0.43)				n/a (AF>5%)	n/a (AF>5%)					POMGNT1 (inh=AR pLI=0.00)
chr1	46659104	46659104	T	C	hom	het	hom	off-target	QUAL=40594;DP=346,796,626;AF=1.00,0.49,1.00;MQM=60	POMGNT1	intron,3'UTR	POMGNT1:ENST00000371984:intron_variant:MODIFIER:exon11/21:c.1027-44A>G::,POMGNT1:ENST00000371986:intron_variant:MODIFIER:exon11/22:c.1027-44A>G::,POMGNT1:ENST00000371992:intron_variant:MODIFIER:exon11/22:c.1027-44A>G::,POMGNT1:ENST00000396420:3_prime_UTR_variant:MODIFIER:exon9/19:c.*652A>G::,POMGNT1:ENST00000535522:intron_variant:MODIFIER:exon10/21:c.961-44A>G::	606822 [POMGNT1 (confirmed) Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies),type A,3,253280/Muscular dystrophy-dystroglycanopathy (congenital with mental retardation),type B,3,613151/Muscular dystrophy-dystroglycanopathy (limb-girdle),type C,3,613157/Retinitis pigmentosa 76,617123];	260869 [benign DISEASE=not specified];			rs7527668	0.3670	0.3894	2456,	0.4486,0.3964,0.1438,0.3563,0.4457	0.3486,0.4428	-1.4020			0.01,0.14	0.27						n/a (AF>5%)	n/a (AF>5%)					POMGNT1 (inh=AR pLI=0.00)
chr1	46659363	46659363	T	C	hom	het	hom	off-target	QUAL=23680;DP=298,334,319;AF=0.99,0.55,1.00;MQM=59	POMGNT1	intron,3'UTR	POMGNT1:ENST00000371984:intron_variant:MODIFIER:exon10/21:c.951-52A>G::,POMGNT1:ENST00000371986:intron_variant:MODIFIER:exon10/22:c.951-52A>G::,POMGNT1:ENST00000371992:intron_variant:MODIFIER:exon10/22:c.951-52A>G::,POMGNT1:ENST00000396420:3_prime_UTR_variant:MODIFIER:exon9/19:c.*393A>G::,POMGNT1:ENST00000535522:intron_variant:MODIFIER:exon9/21:c.885-52A>G::	606822 [POMGNT1 (confirmed) Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies),type A,3,253280/Muscular dystrophy-dystroglycanopathy (congenital with mental retardation),type B,3,613151/Muscular dystrophy-dystroglycanopathy (limb-girdle),type C,3,613157/Retinitis pigmentosa 76,617123];				rs7527935	0.3335	0.3601	2089,	0.3471,0.3894,0.1438,0.3529,0.4453	0.3560,0.3493	-0.0920			0.07,0.18	0.32						n/a (AF>5%)	n/a (AF>5%)					POMGNT1 (inh=AR pLI=0.00)
chr1	46660295	46660295	T	C	hom	het	hom		QUAL=17436;DP=256,303,198;AF=1.00,0.45,0.99;MQM=60	POMGNT1	synonymous,missense	POMGNT1:ENST00000371984:synonymous_variant:LOW:exon8/22:c.681A>G:p.Lys227=:,POMGNT1:ENST00000371986:synonymous_variant:LOW:exon8/23:c.681A>G:p.Lys227=:,POMGNT1:ENST00000371992:synonymous_variant:LOW:exon8/23:c.681A>G:p.Lys227=:,POMGNT1:ENST00000396420:missense_variant:MODERATE:exon7/19:c.563A>G:p.Asn188Ser:,POMGNT1:ENST00000535522:synonymous_variant:LOW:exon7/22:c.615A>G:p.Lys205=:	606822 [POMGNT1 (confirmed) Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies),type A,3,253280/Muscular dystrophy-dystroglycanopathy (congenital with mental retardation),type B,3,613151/Muscular dystrophy-dystroglycanopathy (limb-girdle),type C,3,613157/Retinitis pigmentosa 76,617123];	95761 [benign/likely benign DISEASE=Muscle eye brain disease,Congenital muscular dystrophy-dystroglycanopathy with mental retardation, type B3,Limb-girdle muscular dystrophy-dystroglycanopathy, type C3,not specified,Congenital Muscular Dystrophy, alpha-dystroglycan related,Limb-Girdle Muscular Dystrophy, Recessive];			rs2292487	0.3335	0.3605	2100,	0.3474,0.3895,0.1432,0.3531,0.4458	0.3488,0.3513	0.5750		 , , ,B, 	0.24,0.90	0.94	0.05					n/a (AF>5%)	n/a (AF>5%)					POMGNT1 (inh=AR pLI=0.00)
chr1	47716041	47716042	AA	-	het	wt	het		QUAL=5054;DP=239,164,162;AF=0.52,0.00,0.51;MQM=55	STIL	3'UTR	STIL:ENST00000337817:3_prime_UTR_variant:MODIFIER:exon17/17:c.*766_*767del::,STIL:ENST00000360380:3_prime_UTR_variant:MODIFIER:exon18/18:c.*766_*767del::,STIL:ENST00000371877:3_prime_UTR_variant:MODIFIER:exon17/17:c.*766_*767del::	181590 [STIL (confirmed) Microcephaly 7,primary,autosomal recessive,612703];	297544 [benign DISEASE=Primary Microcephaly, Recessive];			rs75930208	0.3926	0.4363	3413,			1.6250				0.21						n/a (AF>5%)	n/a (AF>5%)					STIL (inh=AR pLI=0.09)
chr1	47717189	47717189	A	G	het	wt	het		QUAL=8426;DP=443,306,231;AF=0.50,0.01,0.40;MQM=60	STIL	synonymous	STIL:ENST00000243182:synonymous_variant:LOW:exon17/17:c.3483T>C:p.Pro1161=:,STIL:ENST00000337817:synonymous_variant:LOW:exon17/17:c.3483T>C:p.Pro1161=:,STIL:ENST00000360380:synonymous_variant:LOW:exon18/18:c.3483T>C:p.Pro1161=:,STIL:ENST00000371877:synonymous_variant:LOW:exon17/17:c.3486T>C:p.Pro1162=:,STIL:ENST00000396221:synonymous_variant:LOW:exon17/17:c.3432T>C:p.Pro1144=:	181590 [STIL (confirmed) Microcephaly 7,primary,autosomal recessive,612703];	94095 [benign DISEASE=Primary autosomal recessive microcephaly 7,not specified,Primary Microcephaly, Recessive];			rs2758735	0.3934	0.5038	3462,	0.1583,0.4400,0.4504,0.5255,0.5373	0.5250,0.1811	0.0230			0.08,0.22	0.01						n/a (AF>5%)	n/a (AF>5%)					STIL (inh=AR pLI=0.09)
chr1	47726087	47726087	T	C	het	het	het		QUAL=6462;DP=211,177,117;AF=0.51,0.47,0.47;MQM=60	STIL	missense	STIL:ENST00000243182:missense_variant:MODERATE:exon16/17:c.2951A>G:p.His984Arg:,STIL:ENST00000337817:missense_variant:MODERATE:exon16/17:c.2951A>G:p.His984Arg:,STIL:ENST00000360380:missense_variant:MODERATE:exon17/18:c.2951A>G:p.His984Arg:,STIL:ENST00000371877:missense_variant:MODERATE:exon16/17:c.2954A>G:p.His985Arg:,STIL:ENST00000396221:missense_variant:MODERATE:exon16/17:c.2900A>G:p.His967Arg:	181590 [STIL (confirmed) Microcephaly 7,primary,autosomal recessive,612703];	94094 [benign/likely benign DISEASE=Primary autosomal recessive microcephaly 7,not specified,Primary Microcephaly, Recessive];			rs13376679	0.1783	0.2479	1050,	0.2048,0.1448,0.0226,0.3083,0.2309	0.3151,0.2192	0.0410	T,T,T,T,T	B,B,B,B,B	0.09,0.25	0.07	0.03					n/a (AF>5%)	n/a (AF>5%)					STIL (inh=AR pLI=0.09)
chr1	47735280	47735280	T	C	het	wt	wt	off-target	QUAL=66;DP=5,0,0;AF=0.60,nan,nan;MQM=60	STIL	intron	STIL:ENST00000243182:intron_variant:MODIFIER:exon14/16:c.2615+27A>G::,STIL:ENST00000337817:intron_variant:MODIFIER:exon14/16:c.2615+27A>G::,STIL:ENST00000360380:intron_variant:MODIFIER:exon15/17:c.2615+27A>G::,STIL:ENST00000371877:intron_variant:MODIFIER:exon14/16:c.2615+27A>G::,STIL:ENST00000396221:intron_variant:MODIFIER:exon14/16:c.2615+27A>G::	181590 [STIL (confirmed) Microcephaly 7,primary,autosomal recessive,612703];	160057 [likely benign DISEASE=not specified];			rs2742104	0.3944	0.5043	3458,	0.1584,0.4406,0.4526,0.5261,0.5374	0.5251,0.1814	-0.1350			0.02,0.11	-0.28						n/a (AF>5%)	n/a (AF>5%)					STIL (inh=AR pLI=0.09)
chr1	47767914	47767914	G	A	het	hom	het		QUAL=13764;DP=245,259,185;AF=0.51,0.99,0.54;MQM=60	STIL	missense	STIL:ENST00000243182:missense_variant:MODERATE:exon4/17:c.257C>T:p.Ala86Val:PF15253,STIL:ENST00000337817:missense_variant:MODERATE:exon4/17:c.257C>T:p.Ala86Val:PF15253,STIL:ENST00000360380:missense_variant:MODERATE:exon5/18:c.257C>T:p.Ala86Val:PF15253,STIL:ENST00000371877:missense_variant:MODERATE:exon4/17:c.257C>T:p.Ala86Val:PF15253,STIL:ENST00000396221:missense_variant:MODERATE:exon4/17:c.257C>T:p.Ala86Val:PF15253	181590 [STIL (confirmed) Microcephaly 7,primary,autosomal recessive,612703];	21354 [benign DISEASE=Primary autosomal recessive microcephaly 7,not specified,Primary Microcephaly, Recessive];			rs3125630	0.6064	0.5630	5386,	0.8441,0.5577,0.5479,0.4757,0.4632	0.4770,0.8198	5.1810	T,T,T,T,T	B,B,B,B,B	0.02,0.93	1.52	0.17					n/a (AF>5%)	n/a (AF>5%)					STIL (inh=AR pLI=0.09)
chr1	51066088	51066088	T	C	het	wt	het		QUAL=3510;DP=166,172,136;AF=0.43,0.00,0.48;MQM=60	FAF1	intron	FAF1:ENST00000371778:intron_variant:MODIFIER:exon9/19:c.745-4200A>G::,FAF1:ENST00000396153:intron_variant:MODIFIER:exon8/18:c.745-4200A>G::,FAF1:ENST00000545823:intron_variant:MODIFIER:exon1/11:c.19-4200A>G::				Charlie1a	rs6679854	0.1695	0.2071	708,			0.3230			0.01,0.11	0.20						n/a (AF>5%)	n/a (AF>5%)					FAF1 (inh=n/a pLI=0.99)
chr1	53662823	53662823	C	A	het	het	wt	off-target	QUAL=1513;DP=12,107,61;AF=0.42,0.60,0.00;MQM=60	CPT2	intron	CPT2:ENST00000371486:intron_variant:MODIFIER:exon1/4:c.152+56C>A::	600650 [CPT2 (confirmed) CPT II deficiency,myopathic,stress-induced,255110/CPT II deficiency,infantile,600649/CPT II deficiency,lethal neonatal,608836/Encephalopathy,acute,infection-induced,4,susceptibility to,614212];				rs72673121	0.0889	0.1361	371,			0.0470			0.06,0.41	0.32						n/a (AF>5%)	n/a (AF>5%)					CPT2 (inh=AR+AD pLI=0.00)
chr1	53676448	53676448	G	A	het	hom	wt		QUAL=11064;DP=287,230,215;AF=0.52,1.00,0.00;MQM=59	CPT2,RP5-1024G6.2	missense,intron&non_coding_transcript	CPT2:ENST00000371486:missense_variant:MODERATE:exon4/5:c.1102G>A:p.Val368Ile:PF00755,RP5-1024G6.2:ENST00000452466:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.436-232C>T::	600650 [CPT2 (confirmed) CPT II deficiency,myopathic,stress-induced,255110/CPT II deficiency,infantile,600649/CPT II deficiency,lethal neonatal,608836/Encephalopathy,acute,infection-induced,4,susceptibility to,614212];	92429 [benign DISEASE=Carnitine palmitoyltransferase II deficiency,not specified]; 30118 [risk factor DISEASE=Encephalopathy, acute, infection-induced, 4, susceptibility to];	CM139511 [CLASS=DP MUT=ALT PHEN="Infuenza infection-associated encephalopathy" GENE=CPT2];		rs1799821	0.4131	0.4869	3699,	0.2788,0.4386,0.7296,0.5443,0.2625	0.5416,0.2901	-0.0530	T, 	B, 	0.11,0.33	0.23	0.23					n/a (AF>5%)	n/a (AF>5%)					CPT2 (inh=AR+AD pLI=0.00), RP5-1024G6.2 (inh=n/a pLI=n/a)
chr1	53679229	53679229	A	G	het	het	wt		QUAL=6121;DP=266,238,177;AF=0.48,0.46,0.00;MQM=60	CPT2,RP5-1024G6.2	missense,non_coding_transcript_exon	CPT2:ENST00000371486:missense_variant:MODERATE:exon5/5:c.1939A>G:p.Met647Val:PF00755,RP5-1024G6.2:ENST00000452466:non_coding_transcript_exon_variant:MODIFIER:exon1/2:n.219T>C::	600650 [CPT2 (confirmed) CPT II deficiency,myopathic,stress-induced,255110/CPT II deficiency,infantile,600649/CPT II deficiency,lethal neonatal,608836/Encephalopathy,acute,infection-induced,4,susceptibility to,614212];	92433 [benign/likely benign DISEASE=Carnitine palmitoyltransferase II deficiency,Carnitine palmitoyltransferase II deficiency, infantile,Carnitine palmitoyltransferase II deficiency, lethal neonatal,not specified];			rs1799822	0.1004	0.1638	397,	0.0434,0.1284,0.0840,0.2184,0.1010	0.2252,0.0545	7.4480	D, 	B, 	0.99,0.99	3.02	0.29					n/a (AF>5%)	n/a (AF>5%)					CPT2 (inh=AR+AD pLI=0.00), RP5-1024G6.2 (inh=n/a pLI=n/a)
chr1	53679878	53679878	T	C	wt	het	wt		QUAL=693;DP=104,47,48;AF=0.00,0.60,0.00;MQM=60	C1orf123	3'UTR	C1orf123:ENST00000294360:3_prime_UTR_variant:MODIFIER:exon8/8:c.*453A>G::	600650 [CPT2 (confirmed) CPT II deficiency,myopathic,stress-induced,255110/CPT II deficiency,infantile,600649/CPT II deficiency,lethal neonatal,608836/Encephalopathy,acute,infection-induced,4,susceptibility to,614212];	368876 [benign DISEASE=Carnitine palmitoyltransferase II deficiency];			rs1056438	0.2282	0.2725	1410,			-0.2740			0.00,0.11	-0.05						n/a (AF>5%)	n/a (AF>5%)					C1orf123 (inh=n/a pLI=0.00)
chr1	55315351	55315351	T	C	hom	hom	hom		QUAL=17101;DP=249,157,129;AF=1.00,1.00,1.00;MQM=59	DHCR24	3'UTR	DHCR24:ENST00000371269:3_prime_UTR_variant:MODIFIER:exon9/9:c.*2555A>G::	606418 [DHCR24 (confirmed) Desmosterolosis,602398];	297612 [benign DISEASE=Desmosterolosis];			rs657688	0.9998	0.9994	15462,			-0.6960			0.01,0.12	0.11						n/a (AF>5%)	n/a (AF>5%)					DHCR24 (inh=AR pLI=0.95)
chr1	55315941	55315941	G	T	het	het	wt		QUAL=10532;DP=447,386,318;AF=0.47,0.50,0.00;MQM=60	DHCR24	3'UTR	DHCR24:ENST00000371269:3_prime_UTR_variant:MODIFIER:exon9/9:c.*1965C>A::	606418 [DHCR24 (confirmed) Desmosterolosis,602398];	297621 [likely benign DISEASE=Desmosterolosis];			rs11555500	0.0102	0.0240	16,			0.8540			0.17,0.20	0.07						0	12					DHCR24 (inh=AR pLI=0.95)
chr1	55316082	55316082	A	C	hom	hom	hom		QUAL=25125;DP=318,258,190;AF=1.00,1.00,1.00;MQM=60	DHCR24	3'UTR	DHCR24:ENST00000371269:3_prime_UTR_variant:MODIFIER:exon9/9:c.*1824T>G::	606418 [DHCR24 (confirmed) Desmosterolosis,602398];	297623 [benign DISEASE=Desmosterolosis];			rs654561	0.9832	0.9905	15199,			-0.2950			0.03,0.14	-0.14						n/a (AF>5%)	n/a (AF>5%)					DHCR24 (inh=AR pLI=0.95)
chr1	55319902	55319902	A	G	hom	hom	hom		QUAL=600;DP=7,9,3;AF=1.00,1.00,1.00;MQM=60	DHCR24	synonymous	DHCR24:ENST00000371269:synonymous_variant:LOW:exon7/9:c.1026T>C:p.Ile342=:,DHCR24:ENST00000535035:synonymous_variant:LOW:exon7/9:c.903T>C:p.Ile301=:,DHCR24:ENST00000537443:synonymous_variant:LOW:exon4/6:c.378T>C:p.Ile126=:	606418 [DHCR24 (confirmed) Desmosterolosis,602398];	297654 [benign DISEASE=Desmosterolosis];			rs718265	0.6276	0.6710	7036,	0.6178,0.5372,0.3979,0.6907,0.8056	0.6933,0.6133	1.6080			0.28,0.87	0.74						n/a (AF>5%)	n/a (AF>5%)					DHCR24 (inh=AR pLI=0.95)
chr1	55464743	55464743	T	C	hom	het	hom		QUAL=35505;DP=340,648,531;AF=0.99,0.49,1.00;MQM=60	BSND	5'UTR	BSND:ENST00000371265:5_prime_UTR_variant:MODIFIER:exon1/4:c.-117T>C::	606412 [BSND (provisional) Bartter syndrome,type 4a,602522/Sensorineural deafness with mild renal dysfunction,602522];	297673 [benign DISEASE=Bartter's syndrome];			rs2500340	0.5941	0.6594	7020,			-0.9270			0.00,0.09	-0.12						n/a (AF>5%)	n/a (AF>5%)					BSND (inh=AR pLI=0.00)
chr1	55464790	55464790	C	G	hom	het	hom		QUAL=37652;DP=336,757,572;AF=0.99,0.48,1.00;MQM=60	BSND	5'UTR	BSND:ENST00000371265:5_prime_UTR_variant:MODIFIER:exon1/4:c.-70C>G::	606412 [BSND (provisional) Bartter syndrome,type 4a,602522/Sensorineural deafness with mild renal dysfunction,602522];	297674 [benign DISEASE=Bartter's syndrome];			rs2500341		0.6602	7024,			-0.5640			0.00,0.09	0.02						n/a (AF>5%)	n/a (AF>5%)					BSND (inh=AR pLI=0.00)
chr1	55474325	55474325	A	C	het	hom	wt		QUAL=18374;DP=295,452,321;AF=0.55,1.00,0.01;MQM=59	BSND	3'UTR	BSND:ENST00000371265:3_prime_UTR_variant:MODIFIER:exon4/4:c.*24A>C::	606412 [BSND (provisional) Bartter syndrome,type 4a,602522/Sensorineural deafness with mild renal dysfunction,602522];	297681 [benign DISEASE=Bartter's syndrome];			rs6682884	0.3624	0.4333	2947,	0.4957,0.1984,0.3007,0.4269,0.2805	0.4220,0.4943	0.5630			0.06,0.17	0.01						n/a (AF>5%)	n/a (AF>5%)					BSND (inh=AR pLI=0.00)
chr1	55474476	55474476	C	G	het	hom	wt	off-target	QUAL=5167;DP=167,124,81;AF=0.43,1.00,0.00;MQM=60	BSND	3'UTR	BSND:ENST00000371265:3_prime_UTR_variant:MODIFIER:exon4/4:c.*175C>G::	606412 [BSND (provisional) Bartter syndrome,type 4a,602522/Sensorineural deafness with mild renal dysfunction,602522];	368877 [benign DISEASE=Bartter's syndrome];			rs4339899	0.4299	0.4672	3484,			-1.0850			0.02,0.09	-0.43						n/a (AF>5%)	n/a (AF>5%)					BSND (inh=AR pLI=0.00)
chr1	57340727	57340727	C	A	het	wt	hom		QUAL=5784;DP=135,210,141;AF=0.44,0.00,0.99;MQM=60	C8A	missense	C8A:ENST00000361249:missense_variant:MODERATE:exon3/11:c.277C>A:p.Gln93Lys:	120950 [C8A (confirmed) C8 deficiency,type I,613790];	17039 [benign DISEASE=COMPLEMENT COMPONENT 8, ALPHA SUBUNIT, A/B POLYMORPHISM,not specified];			rs652785	0.3437	0.3654	1715,	0.2046,0.2100,0.4640,0.3822,0.4983	0.3766,0.2122	0.1090	T	B	0.05,0.25	0.47	0.10					n/a (AF>5%)	n/a (AF>5%)					C8A (inh=AR pLI=0.00)
chr1	57383358	57383358	C	T	wt	het	wt		QUAL=6231;DP=366,467,377;AF=0.00,0.53,0.00;MQM=60	C8A	missense	C8A:ENST00000361249:missense_variant:MODERATE:exon11/11:c.1724C>T:p.Pro575Leu:PF00090	120950 [C8A (confirmed) C8 deficiency,type I,613790];				rs17300936	0.0613	0.0935	135,	0.0298,0.0373,0.0766,0.1261,0.0758	0.1260,0.0343	0.7210	T	B	0.05,0.22	0.52	0.02					n/a (AF>5%)	n/a (AF>5%)					C8A (inh=AR pLI=0.00)
chr1	57395020	57395020	A	G	het	wt	het		QUAL=14099;DP=538,781,529;AF=0.51,0.00,0.49;MQM=60	C8B	3'UTR	C8B:ENST00000371237:3_prime_UTR_variant:MODIFIER:exon12/12:c.*57T>C::,C8B:ENST00000543257:3_prime_UTR_variant:MODIFIER:exon13/13:c.*57T>C::	120960 [C8B (confirmed) C8 deficiency,type II,613789];				rs2795	0.3672	0.3182	1654,			0.0350			0.01,0.16	0.18						n/a (AF>5%)	n/a (AF>5%)					C8B (inh=AR pLI=0.00)
chr1	57395251	57395251	T	C	hom	hom	hom	off-target	QUAL=25373;DP=272,294,249;AF=1.00,1.00,1.00;MQM=60	C8B	intron	C8B:ENST00000371237:intron_variant:MODIFIER:exon11/11:c.1622-20A>G::,C8B:ENST00000535057:intron_variant:MODIFIER:exon12/12:c.1436-20A>G::,C8B:ENST00000543257:intron_variant:MODIFIER:exon12/12:c.1466-20A>G::	120960 [C8B (confirmed) C8 deficiency,type II,613789];				rs605648		0.8868	11228,	0.7905,0.9255,0.9402,0.8567,0.9701	0.8552,0.7798	-1.5990			0.01,0.13	-0.05		-5.49% (8.84>8.35)				n/a (AF>5%)	n/a (AF>5%)					C8B (inh=AR pLI=0.00)
chr1	57409329	57409329	A	G	wt	wt	het	off-target	QUAL=2747;DP=186,229,187;AF=0.00,0.00,0.58;MQM=60	C8B	intron	C8B:ENST00000371237:intron_variant:MODIFIER:exon8/11:c.1234+40T>C::,C8B:ENST00000535057:intron_variant:MODIFIER:exon9/12:c.1048+40T>C::,C8B:ENST00000543257:intron_variant:MODIFIER:exon9/12:c.1078+40T>C::	120960 [C8B (confirmed) C8 deficiency,type II,613789];				rs72670361	0.0168	0.0301	19,	0.0076,0.0200,0.0001,0.0473,0.0066	0.0466,0.0104	0.1490			0.00,0.11	-0.15						12	335					C8B (inh=AR pLI=0.00)
chr1	57422484	57422484	C	T	hom	hom	hom		QUAL=26264;DP=294,267,250;AF=1.00,1.00,1.00;MQM=60	C8B	missense	C8B:ENST00000371237:missense_variant:MODERATE:exon3/12:c.349G>A:p.Gly117Arg:,C8B:ENST00000535057:missense_variant:MODERATE:exon4/13:c.163G>A:p.Gly55Arg:,C8B:ENST00000543257:missense_variant:MODERATE:exon4/13:c.193G>A:p.Gly65Arg:	120960 [C8B (confirmed) C8 deficiency,type II,613789];				rs1013579	0.9864	0.9785	14836,	0.9946,0.9760,0.9999,0.9687,0.9896	0.9672,0.9925	0.5340	T,T,T	B,B,B	0.10,0.93	1.34	0.04					n/a (AF>5%)	n/a (AF>5%)					C8B (inh=AR pLI=0.00)
chr1	63881552	63881552	C	T	het	hom	het		QUAL=7279;DP=245,87,64;AF=0.56,1.00,0.44;MQM=60	ALG6	missense	ALG6:ENST00000263440:missense_variant:MODERATE:exon10/14:c.917C>T:p.Ser306Phe:PF03155,ALG6:ENST00000371108:missense_variant:MODERATE:exon11/15:c.911C>T:p.Ser304Phe:PF03155	604566 [ALG6 (provisional) Congenital disorder of glycosylation,type Ic,603147];	95531 [benign DISEASE=Congenital disorder of glycosylation,not specified];			rs4630153	0.8305	0.7527	8715,	0.8701,0.8238,0.8597,0.6833,0.8566	0.6761,0.8558	0.9670	T,T	B,B	0.01,0.25	1.51	0.19					n/a (AF>5%)	n/a (AF>5%)					ALG6 (inh=AR pLI=0.03)
chr1	63903452	63903452	T	C	het	hom	het		QUAL=2121;DP=96,21,14;AF=0.53,1.00,0.57;MQM=60	ALG6	3'UTR	ALG6:ENST00000371108:3_prime_UTR_variant:MODIFIER:exon15/15:c.*761T>C::	604566 [ALG6 (provisional) Congenital disorder of glycosylation,type Ic,603147];	297858 [benign DISEASE=Congenital disorder of glycosylation];			rs3009572	0.6847	0.5866	5706,			-0.2370			0.02,0.15	0.11						n/a (AF>5%)	n/a (AF>5%)					ALG6 (inh=AR pLI=0.03)
chr1	67465791	67465791	G	A	het	wt	wt		QUAL=75;DP=116,44,25;AF=0.22,0.00,0.04;MQM=58	SLC35D1	3'UTR	SLC35D1:ENST00000235345:3_prime_UTR_variant:MODIFIER:exon12/12:c.*4232C>T::	610804 [SLC35D1 (confirmed) Schneckenbecken dysplasia,269250];			AluJr	rs901342235		0.0036	0,			-0.2840			0.00,0.05	-0.28						4	12					SLC35D1 (inh=AR pLI=0.01)
chr1	67465969	67465969	C	T	hom	wt	hom		QUAL=117;DP=19,4,5;AF=0.32,0.00,0.00;MQM=60	SLC35D1	3'UTR	SLC35D1:ENST00000235345:3_prime_UTR_variant:MODIFIER:exon12/12:c.*4054G>A::	610804 [SLC35D1 (confirmed) Schneckenbecken dysplasia,269250];			AluJr	rs954300836						-3.5290			0.00,0.01	-1.15						0	9					SLC35D1 (inh=AR pLI=0.01)
chr1	67465988	67465988	A	T	hom	wt	hom		QUAL=117;DP=19,4,5;AF=0.32,0.00,0.00;MQM=60	SLC35D1	3'UTR	SLC35D1:ENST00000235345:3_prime_UTR_variant:MODIFIER:exon12/12:c.*4035T>A::	610804 [SLC35D1 (confirmed) Schneckenbecken dysplasia,269250];				rs7540819		0.6303	4356,			-0.6180			0.00,0.09	-0.13						n/a (AF>5%)	n/a (AF>5%)					SLC35D1 (inh=AR pLI=0.01)
chr1	67512903	67512903	G	T	hom	hom	hom	off-target	QUAL=12448;DP=171,112,106;AF=1.00,1.00,1.00;MQM=60	SLC35D1	intron	SLC35D1:ENST00000235345:intron_variant:MODIFIER:exon7/11:c.636+45C>A::,SLC35D1:ENST00000506472:intron_variant:MODIFIER:exon6/10:c.399+45C>A::	610804 [SLC35D1 (confirmed) Schneckenbecken dysplasia,269250];				rs1024229	0.7095	0.6800	7220,	0.7697,0.6616,0.6297,0.6612,0.7500	0.6467,0.7718	-1.0460			0.01,0.12	-0.25						n/a (AF>5%)	n/a (AF>5%)					SLC35D1 (inh=AR pLI=0.01)
chr1	67512920	67512920	A	C	hom	hom	hom	off-target	QUAL=13972;DP=180,140,121;AF=1.00,1.00,1.00;MQM=60	SLC35D1	intron	SLC35D1:ENST00000235345:intron_variant:MODIFIER:exon7/11:c.636+28T>G::,SLC35D1:ENST00000506472:intron_variant:MODIFIER:exon6/10:c.399+28T>G::	610804 [SLC35D1 (confirmed) Schneckenbecken dysplasia,269250];				rs1024230	0.7095	0.6798	7221,	0.7699,0.6622,0.6307,0.6617,0.7504	0.6456,0.7708	-0.3190			0.03,0.20	0.20						n/a (AF>5%)	n/a (AF>5%)					SLC35D1 (inh=AR pLI=0.01)
chr1	67520060	67520061	CA	-	het	hom	het		QUAL=473;DP=22,12,8;AF=0.41,1.00,0.50;MQM=60	SLC35D1	upstream_gene	SLC35D1:ENST00000235345:upstream_gene_variant:MODIFIER::::,SLC35D1:ENST00000506472:upstream_gene_variant:MODIFIER::::					rs3840439	0.6562	0.6041	5670,			0.3240				0.43						n/a (AF>5%)	n/a (AF>5%)					SLC35D1 (inh=AR pLI=0.01)
chr1	67520083	67520083	C	T	het	wt	het		QUAL=193;DP=12,7,6;AF=0.75,0.00,0.50;MQM=60	SLC35D1	upstream_gene	SLC35D1:ENST00000235345:upstream_gene_variant:MODIFIER::::,SLC35D1:ENST00000506472:upstream_gene_variant:MODIFIER::::					rs3806321	0.1567	0.1580	456,			-0.6850			0.03,0.68	0.16						n/a (AF>5%)	n/a (AF>5%)					SLC35D1 (inh=AR pLI=0.01)
chr1	67520140	67520140	T	G	hom	hom	hom	off-target	QUAL=244;DP=4,3,2;AF=1.00,1.00,1.00;MQM=60	SLC35D1	upstream_gene	SLC35D1:ENST00000235345:upstream_gene_variant:MODIFIER::::,SLC35D1:ENST00000506472:upstream_gene_variant:MODIFIER::::					rs2025087	0.8001	0.7546	8818,			-1.1290			0.00,0.60	0.26						n/a (AF>5%)	n/a (AF>5%)					SLC35D1 (inh=AR pLI=0.01)
chr1	76190216	76190216	G	A	hom	het	het		QUAL=2070;DP=15,100,70;AF=0.93,0.43,0.50;MQM=59	ACADM	5'UTR	ACADM:ENST00000370841:5_prime_UTR_variant:MODIFIER:exon1/12:c.-257G>A::	607008 [ACADM (provisional) Acyl-CoA dehydrogenase,medium chain,deficiency of,201450];	298063 [likely benign DISEASE=Medium-chain acyl-coenzyme A dehydrogenase deficiency];			rs17848068	0.2043	0.2659	1145,			-0.4080			0.03,0.12	0.37						n/a (AF>5%)	n/a (AF>5%)					ACADM (inh=AR pLI=0.00)
chr1	76194230	76194230	T	-	hom	hom	hom	off-target	QUAL=16014;DP=169,191,153;AF=1.00,1.00,0.99;MQM=60	ACADM	intron	ACADM:ENST00000370834:intron_variant:MODIFIER:exon2/12:c.118+60del::,ACADM:ENST00000370841:intron_variant:MODIFIER:exon2/11:c.118+60del::,ACADM:ENST00000420607:intron_variant:MODIFIER:exon2/11:c.130+60del::,ACADM:ENST00000541113:intron_variant:MODIFIER:exon1/10:c.10+3731del::,ACADM:ENST00000543667:intron_variant:MODIFIER:exon1/8:c.-268+3731del::	607008 [ACADM (provisional) Acyl-CoA dehydrogenase,medium chain,deficiency of,201450];	226050 [benign DISEASE=Medium-chain acyl-coenzyme A dehydrogenase deficiency];					1.0000	15489,			0.0000				-0.27						n/a (AF>5%)	n/a (AF>5%)					ACADM (inh=AR pLI=0.00)
chr1	76229326	76229326	T	C	wt	het	het		QUAL=125;DP=31,10,6;AF=0.03,0.70,0.17;MQM=60	ACADM	3'UTR	ACADM:ENST00000370841:3_prime_UTR_variant:MODIFIER:exon12/12:c.*878T>C::	607008 [ACADM (provisional) Acyl-CoA dehydrogenase,medium chain,deficiency of,201450];	298081 [benign DISEASE=Medium-chain acyl-coenzyme A dehydrogenase deficiency];			rs1146587	0.6917	0.6522	6596,			-1.2010			0.00,0.09	0.32						n/a (AF>5%)	n/a (AF>5%)					ACADM (inh=AR pLI=0.00)
chr1	92940411	92940411	C	T	het	het	wt		QUAL=6133;DP=278,165,119;AF=0.54,0.49,0.00;MQM=60	GFI1	3'UTR	GFI1:ENST00000294702:3_prime_UTR_variant:MODIFIER:exon7/7:c.*1175G>A::,GFI1:ENST00000370332:3_prime_UTR_variant:MODIFIER:exon7/7:c.*1175G>A::,GFI1:ENST00000427103:3_prime_UTR_variant:MODIFIER:exon7/7:c.*1175G>A::	600871 [GFI1 (confirmed) Neutropenia,severe congenital 2,autosomal dominant,613107/Neutropenia,nonimmune chronic idiopathic,of adults,607847];	298158 [benign DISEASE=Severe congenital neutropenia];			rs41313373	0.0673	0.0925	186,			2.6380			0.62,0.93	1.00						n/a (AF>5%)	n/a (AF>5%)					GFI1 (inh=AD pLI=0.02)
chr1	92941357	92941357	A	G	wt	wt	het		QUAL=3086;DP=448,280,229;AF=0.00,0.00,0.52;MQM=60	GFI1	3'UTR	GFI1:ENST00000294702:3_prime_UTR_variant:MODIFIER:exon7/7:c.*229T>C::,GFI1:ENST00000370332:3_prime_UTR_variant:MODIFIER:exon7/7:c.*229T>C::,GFI1:ENST00000427103:3_prime_UTR_variant:MODIFIER:exon7/7:c.*229T>C::	600871 [GFI1 (confirmed) Neutropenia,severe congenital 2,autosomal dominant,613107/Neutropenia,nonimmune chronic idiopathic,of adults,607847];	298175 [benign DISEASE=Severe congenital neutropenia];			rs4970714	0.8083	0.7134	8000,			-2.7500			0.04,0.14	-0.61						n/a (AF>5%)	n/a (AF>5%)					GFI1 (inh=AD pLI=0.02)
chr1	92944315	92944320	AGAGAG	-	hom	het	het		QUAL=5371;DP=61,154,97;AF=0.00,0.34,0.26;MQM=60	GFI1	splice_region&intron	GFI1:ENST00000294702:splice_region_variant&intron_variant:LOW:exon5/6:c.925-10_925-5del::,GFI1:ENST00000370332:splice_region_variant&intron_variant:LOW:exon5/6:c.925-10_925-5del::,GFI1:ENST00000427103:splice_region_variant&intron_variant:LOW:exon5/6:c.925-10_925-5del::	600871 [GFI1 (confirmed) Neutropenia,severe congenital 2,autosomal dominant,613107/Neutropenia,nonimmune chronic idiopathic,of adults,607847];	298185 [benign DISEASE=Severe congenital neutropenia];		(AG)n	rs200902533		0.1253	243,			3.1710				0.84						n/a (AF>5%)	n/a (AF>5%)					GFI1 (inh=AD pLI=0.02)
chr1	92944314	92944314	-	AGAGAG	wt	wt	het		QUAL=5371;DP=61,154,97;AF=0.70,0.41,0.70;MQM=60	GFI1	splice_region&intron	GFI1:ENST00000294702:splice_region_variant&intron_variant:LOW:exon5/6:c.925-10_925-5dup::,GFI1:ENST00000370332:splice_region_variant&intron_variant:LOW:exon5/6:c.925-10_925-5dup::,GFI1:ENST00000427103:splice_region_variant&intron_variant:LOW:exon5/6:c.925-10_925-5dup::	600871 [GFI1 (confirmed) Neutropenia,severe congenital 2,autosomal dominant,613107/Neutropenia,nonimmune chronic idiopathic,of adults,607847];			(AG)n	rs371078453		0.3601	1664,							0.37						n/a (AF>5%)	n/a (AF>5%)					GFI1 (inh=AD pLI=0.02)
chr1	92944315	92944316	AG	-	wt	het	wt		QUAL=5371;DP=61,154,97;AF=0.70,0.75,0.71;MQM=60	GFI1	splice_region&intron	GFI1:ENST00000294702:splice_region_variant&intron_variant:LOW:exon5/6:c.925-6_925-5del::,GFI1:ENST00000370332:splice_region_variant&intron_variant:LOW:exon5/6:c.925-6_925-5del::,GFI1:ENST00000427103:splice_region_variant&intron_variant:LOW:exon5/6:c.925-6_925-5del::	600871 [GFI1 (confirmed) Neutropenia,severe congenital 2,autosomal dominant,613107/Neutropenia,nonimmune chronic idiopathic,of adults,607847];	298182 [conflicting interpretations of pathogenicity DISEASE=Severe congenital neutropenia];		(AG)n	rs768494519		0.1424	301,			3.1710				0.86						n/a (AF>5%)	n/a (AF>5%)					GFI1 (inh=AD pLI=0.02)
chr1	92948938	92948938	C	T	het	wt	het		QUAL=3337;DP=99,323,266;AF=0.51,0.00,0.46;MQM=59	GFI1	missense	GFI1:ENST00000294702:missense_variant:MODERATE:exon2/7:c.107G>A:p.Ser36Asn:,GFI1:ENST00000370332:missense_variant:MODERATE:exon2/7:c.107G>A:p.Ser36Asn:,GFI1:ENST00000427103:missense_variant:MODERATE:exon2/7:c.107G>A:p.Ser36Asn:	600871 [GFI1 (confirmed) Neutropenia,severe congenital 2,autosomal dominant,613107/Neutropenia,nonimmune chronic idiopathic,of adults,607847];	259699 [benign DISEASE=Severe congenital neutropenia,Severe congenital neutropenia 2, autosomal dominant,not specified];			rs34631763	0.0194	0.0426	46,	0.0092,0.0280,0.0000,0.0564,0.0089	0.0545,0.0134	4.3850	T,T,T	B,B,B	0.90,0.96	2.20	0.06					7	356					GFI1 (inh=AD pLI=0.02)
chr1	92951657	92951657	-	A	het	het	het	off-target	QUAL=2394;DP=80,103,63;AF=0.59,0.35,0.49;MQM=60	GFI1	intron	GFI1:ENST00000294702:intron_variant:MODIFIER:exon1/6:c.-100+625dup::	600871 [GFI1 (confirmed) Neutropenia,severe congenital 2,autosomal dominant,613107/Neutropenia,nonimmune chronic idiopathic,of adults,607847];						0.1246	179,							1.65						n/a (AF>5%)	n/a (AF>5%)					GFI1 (inh=AD pLI=0.02)
chr1	97543752	97543752	G	A	het	het	het		QUAL=15977;DP=471,438,323;AF=0.48,0.48,0.50;MQM=60	DPYD	3'UTR	DPYD:ENST00000370192:3_prime_UTR_variant:MODIFIER:exon23/23:c.*780C>T::	612779 [DPYD (confirmed) Dihydropyrimidine dehydrogenase deficiency,274270/5-fluorouracil toxicity,274270];	100064 [likely benign DISEASE=Dihydropyrimidine dehydrogenase deficiency,not provided];			rs291593	0.3850	0.3020	1581,			-0.6800			0.00,0.09	-0.11						n/a (AF>5%)	n/a (AF>5%)					DPYD (inh=AR pLI=0.00)
chr1	97543764	97543764	C	T	het	het	het		QUAL=15430;DP=403,462,340;AF=0.49,0.47,0.50;MQM=60	DPYD	3'UTR	DPYD:ENST00000370192:3_prime_UTR_variant:MODIFIER:exon23/23:c.*768G>A::	612779 [DPYD (confirmed) Dihydropyrimidine dehydrogenase deficiency,274270/5-fluorouracil toxicity,274270];	100065 [benign DISEASE=Dihydropyrimidine dehydrogenase deficiency,not provided];			rs291592	0.5775	0.4496	3475,			0.1790			0.03,0.16	0.03						n/a (AF>5%)	n/a (AF>5%)					DPYD (inh=AR pLI=0.00)
chr1	97543959	97543959	C	T	het	wt	het		QUAL=7024;DP=325,285,213;AF=0.53,0.00,0.44;MQM=60	DPYD	3'UTR	DPYD:ENST00000370192:3_prime_UTR_variant:MODIFIER:exon23/23:c.*573G>A::	612779 [DPYD (confirmed) Dihydropyrimidine dehydrogenase deficiency,274270/5-fluorouracil toxicity,274270];	100067 [likely benign DISEASE=Dihydropyrimidine dehydrogenase deficiency,not provided];			rs1042482	0.0895	0.0662	70,			0.1710			0.04,0.17	0.09						n/a (AF>5%)	n/a (AF>5%)					DPYD (inh=AR pLI=0.00)
chr1	97547831	97547831	G	A	hom	hom	hom	off-target	QUAL=15063;DP=185,164,126;AF=1.00,1.00,1.00;MQM=60	DPYD	intron	DPYD:ENST00000370192:intron_variant:MODIFIER:exon22/22:c.2907+55C>T::	612779 [DPYD (confirmed) Dihydropyrimidine dehydrogenase deficiency,274270/5-fluorouracil toxicity,274270];				rs290854	1.0000	1.0000	15474,			0.2900			0.02,0.17	0.14						n/a (AF>5%)	n/a (AF>5%)					DPYD (inh=AR pLI=0.00)
chr1	97915624	97915624	A	G	het	het	wt		QUAL=4771;DP=205,187,150;AF=0.44,0.52,0.00;MQM=60	DPYD	synonymous	DPYD:ENST00000370192:synonymous_variant:LOW:exon14/23:c.1896T>C:p.Phe632=:PF01180	612779 [DPYD (confirmed) Dihydropyrimidine dehydrogenase deficiency,274270/5-fluorouracil toxicity,274270];	100088 [likely benign DISEASE=Dihydropyrimidine dehydrogenase deficiency,not specified,not provided];			rs17376848	0.0521	0.0507	49,	0.0223,0.0877,0.1252,0.0410,0.0349	0.0450,0.0207	0.2800			0.52,0.94	0.12						n/a (AF>5%)	n/a (AF>5%)					DPYD (inh=AR pLI=0.00)
chr1	97981242	97981242	T	C	hom	hom	het	off-target	QUAL=8035;DP=188,54,44;AF=1.00,1.00,0.45;MQM=60	DPYD	intron	DPYD:ENST00000370192:intron_variant:MODIFIER:exon13/22:c.1740+40A>G::	612779 [DPYD (confirmed) Dihydropyrimidine dehydrogenase deficiency,274270/5-fluorouracil toxicity,274270];	100090 [not provided DISEASE=not provided];			rs2811178	0.6518	0.6361	5779,	0.6343,0.7030,0.7457,0.5970,0.6268	0.5859,0.6248	-0.0290			0.12,0.17	-0.02						n/a (AF>5%)	n/a (AF>5%)					DPYD (inh=AR pLI=0.00)
chr1	98144726	98144726	T	C	wt	het	wt		QUAL=586;DP=168,55,36;AF=0.01,0.47,0.00;MQM=60	DPYD	missense	DPYD:ENST00000370192:missense_variant:MODERATE:exon8/23:c.775A>G:p.Lys259Glu:	612779 [DPYD (confirmed) Dihydropyrimidine dehydrogenase deficiency,274270/5-fluorouracil toxicity,274270];	235464 [benign/likely benign DISEASE=not specified,not provided];	CM033369 [CLASS=DM MUT=ALT PHEN="Dihydropyrimidine dehydrogenase deficiency" GENE=DPYD];		rs45589337	0.0044	0.0062	4,	0.0014,0.0029,0.0000,0.0081,0.0050	0.0075,0.0011	4.4920	D	B	0.92,0.98	2.80	0.61					0	88	1	[3] Stephan Waldm?ller 18.11.2015 [n/a] comment imported from detected variant: HGMD: DM f?r Dihydropyrimidine dehydrogenase deficiency, Literatur nicht ?berzeugend, VUS3, swal 151118 [1] ahbuchr1 26.09.2016 MAF>1%, homozygote in ExAC			DPYD (inh=AR pLI=0.00)
chr1	98185527	98185527	A	G	hom	hom	hom		QUAL=15788;DP=206,150,123;AF=1.00,1.00,1.00;MQM=60	DPYD	3'UTR,intron	DPYD:ENST00000306031:3_prime_UTR_variant:MODIFIER:exon6/6:c.*917T>C::,DPYD:ENST00000370192:intron_variant:MODIFIER:exon5/22:c.483+1539T>C::,DPYD:ENST00000423006:intron_variant:MODIFIER:exon4/6:c.372+1539T>C::	612779 [DPYD (confirmed) Dihydropyrimidine dehydrogenase deficiency,274270/5-fluorouracil toxicity,274270];				rs2151562	0.9978	0.9951	15293,			0.4030			0.00,0.07	-0.12						n/a (AF>5%)	n/a (AF>5%)					DPYD (inh=AR pLI=0.00)
chr1	98186077	98186077	T	C	hom	hom	hom		QUAL=20030;DP=281,192,136;AF=1.00,1.00,1.00;MQM=60	DPYD	3'UTR,intron	DPYD:ENST00000306031:3_prime_UTR_variant:MODIFIER:exon6/6:c.*367A>G::,DPYD:ENST00000370192:intron_variant:MODIFIER:exon5/22:c.483+989A>G::,DPYD:ENST00000423006:intron_variant:MODIFIER:exon4/6:c.372+989A>G::	612779 [DPYD (confirmed) Dihydropyrimidine dehydrogenase deficiency,274270/5-fluorouracil toxicity,274270];				rs1333718	0.9978	0.9952	15292,			0.7060			0.01,0.92	1.72						n/a (AF>5%)	n/a (AF>5%)					DPYD (inh=AR pLI=0.00)
chr1	98348885	98348885	G	A	hom	het	hom		QUAL=15096;DP=218,217,163;AF=1.00,0.52,1.00;MQM=60	DPYD	missense,intron	DPYD:ENST00000306031:missense_variant:MODERATE:exon2/6:c.85C>T:p.Arg29Cys:,DPYD:ENST00000370192:missense_variant:MODERATE:exon2/23:c.85C>T:p.Arg29Cys:,DPYD:ENST00000423006:intron_variant:MODIFIER:exon1/6:c.39+37555C>T::	612779 [DPYD (confirmed) Dihydropyrimidine dehydrogenase deficiency,274270/5-fluorouracil toxicity,274270];	100123 [not provided DISEASE=not provided];			rs1801265	0.7398	0.7709	8121,	0.5870,0.7883,0.9287,0.7767,0.7451	0.7751,0.6003	2.2360	T,T, 	P,B, 	0.52,0.96	2.81	0.31					n/a (AF>5%)	n/a (AF>5%)					DPYD (inh=AR pLI=0.00)
chr1	98454469	98454469	G	T	wt	het	wt		QUAL=706;DP=246,74,71;AF=0.00,0.42,0.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs41285694	0.0962	0.1254	331,			0.4890			0.03,0.27	0.22						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98455128	98455128	A	-	het	het	het		QUAL=765;DP=80,28,17;AF=0.39,0.21,0.24;MQM=59		intergenic	::intergenic_variant:MODIFIER::::				AluSp	rs543197080	0.1797	0.0464	26,			-0.9110				-0.05						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98455957	98455957	G	A	wt	het	wt		QUAL=1441;DP=173,145,115;AF=0.00,0.42,0.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::				L1PA13	rs61785886	0.0966	0.1255	333,			-1.2470			0.00,0.04	-0.24						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98456643	98456643	G	A	wt	het	wt		QUAL=657;DP=145,77,45;AF=0.00,0.39,0.00;MQM=58		intergenic	::intergenic_variant:MODIFIER::::				AluY	rs61785887	0.0737	0.0916	156,			-0.3260			0.00,0.04	-0.14						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98456731	98456731	C	T	wt	het	wt		QUAL=964;DP=217,114,57;AF=0.00,0.39,0.00;MQM=59		intergenic	::intergenic_variant:MODIFIER::::				AluY	rs61785888	0.0964	0.1261	331,			0.3940			0.00,0.05	0.03						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98456907	98456907	C	A	wt	het	wt		QUAL=1313;DP=193,96,87;AF=0.00,0.53,0.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs4573558	0.1060	0.1348	344,			-1.1730			0.00,0.08	-0.33						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98457303	98457303	C	G	wt	het	wt		QUAL=2096;DP=279,175,106;AF=0.00,0.47,0.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs2893376	0.1492	0.1731	494,			-1.0480			0.00,0.07	-0.10						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98457523	98457523	A	T	wt	het	wt		QUAL=1559;DP=205,126,63;AF=0.00,0.48,0.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs2391873	0.1378	0.1618	424,			-0.1440			0.07,0.95	1.72						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98460060	98460060	A	C	het	het	wt		QUAL=2971;DP=160,88,63;AF=0.48,0.51,0.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::				AluSx							-0.3560			0.01,0.10	0.09						0	2					 (inh=n/a pLI=n/a)
chr1	98460106	98460106	G	A	hom	het	hom		QUAL=9142;DP=169,125,86;AF=1.00,0.53,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::				AluSx	rs9440288	0.8552	0.8330	10750,			-1.3490			0.00,0.05	-0.34						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98461132	98461132	G	C	hom	het	hom		QUAL=22303;DP=266,367,282;AF=1.00,0.47,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::				L2a	rs9324380	0.9267	0.9084	12789,			-4.7750			0.00,0.04	-0.87						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98461257	98461257	-	TTGT	hom	het	hom		QUAL=16419;DP=228,266,208;AF=0.99,0.44,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs10655213	0.8936	0.8638	11548,							-0.12						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98461443	98461443	C	T	het	het	het		QUAL=4940;DP=163,103,96;AF=0.52,0.52,0.47;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs9662365	0.4657	0.4793	3536,			-0.0300			0.29,0.95	1.57						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98461954	98461954	T	C	hom	het	hom		QUAL=5961;DP=151,33,26;AF=0.99,0.58,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs1938570	0.8936	0.8560	11400,			-0.4170			0.01,0.11	-0.14						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98462921	98462921	C	A	het	het	wt		QUAL=5238;DP=253,184,155;AF=0.50,0.48,0.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs146033831	0.0176	0.0066	11,			-0.1570			0.14,0.84	0.60						0	3					 (inh=n/a pLI=n/a)
chr1	98465528	98465528	G	A	hom	het	hom		QUAL=22757;DP=310,336,253;AF=1.00,0.50,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs2154403	0.9034	0.8739	11889,			0.9340			0.00,0.07	0.09						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98465840	98465840	G	A	het	wt	het		QUAL=5690;DP=284,308,226;AF=0.48,0.00,0.42;MQM=60		intergenic	::intergenic_variant:MODIFIER::::				L2a	rs116319667	0.0046	0.0089	3,			-0.3330			0.00,0.06	-0.11						0	7					 (inh=n/a pLI=n/a)
chr1	98466786	98466786	T	C	wt	wt	het		QUAL=1948;DP=338,175,144;AF=0.01,0.00,0.51;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs12138817	0.1697	0.2135	848,			-0.8380			0.01,0.13	0.02						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98468539	98468540	TA	-	hom	het	hom		QUAL=16071;DP=307,197,141;AF=0.99,0.54,1.00;MQM=59		intergenic	::intergenic_variant:MODIFIER::::					rs5776390	0.8920	0.8636	11558,			0.0920				-0.20						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98469687	98469687	A	-	het	het	wt		QUAL=6764;DP=205,309,244;AF=0.50,0.50,0.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs564190891	0.0036	0.0017	3,			1.9190				0.88						0	2					 (inh=n/a pLI=n/a)
chr1	98470051	98470051	-	AT	hom	het	hom		QUAL=23750;DP=515,229,128;AF=1.00,0.48,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs141251091	0.8636	0.8389	10865,							-0.42						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98470605	98470605	A	G	hom	het	hom		QUAL=6792;DP=179,25,20;AF=1.00,0.44,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs10747495	0.9022	0.8737	11888,			0.6230			0.00,0.07	0.22						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98471787	98471787	C	A	wt	wt	het		QUAL=230;DP=278,89,55;AF=0.00,0.00,0.33;MQM=60		intergenic	::intergenic_variant:MODIFIER::::				L1ME4a	rs55635742	0.0106	0.0193	9,			-0.4440			0.03,0.11	-0.29						0	9					 (inh=n/a pLI=n/a)
chr1	98472208	98472208	A	G	het	het	wt		QUAL=2964;DP=167,97,75;AF=0.45,0.41,0.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::				(ATTAC)n	rs78878051	0.0633	0.0176	35,			0.8530			0.04,0.13	-0.03						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98472879	98472879	C	T	hom	het	hom		QUAL=20990;DP=327,254,193;AF=1.00,0.56,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs1938564	0.8137	0.7958	9855,			-0.3770			0.02,0.14	-0.04						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98472958	98472958	T	A	hom	het	hom		QUAL=15857;DP=223,183,171;AF=1.00,0.55,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs1938563	0.9014	0.8727	11826,			0.7930			0.00,0.06	0.32						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98473716	98473716	T	A	hom	het	hom		QUAL=18873;DP=395,129,117;AF=1.00,0.55,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs1938562	0.9014	0.8728	11829,			1.0500			0.00,0.06	0.11						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98474767	98474767	C	T	hom	het	hom		QUAL=15281;DP=289,162,116;AF=1.00,0.49,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs2391902	0.8247	0.8029	10000,			0.3170			0.02,0.91	1.02						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98475522	98475522	T	C	hom	het	hom		QUAL=16419;DP=307,172,118;AF=1.00,0.52,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs2154402	0.9255	0.9082	12769,			0.0780			0.00,0.38	0.42						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98475913	98475913	G	A	hom	het	hom		QUAL=14310;DP=297,126,88;AF=1.00,0.55,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs9324381	0.8606	0.8381	10850,			0.6210			0.27,0.19	0.03						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98476718	98476718	G	A	hom	het	hom		QUAL=26038;DP=420,279,219;AF=1.00,0.59,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs1938561	0.9022	0.8737	11886,			0.2940			0.00,0.10	0.05						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98476950	98476950	T	C	hom	het	hom		QUAL=25147;DP=340,328,267;AF=1.00,0.55,1.00;MQM=59		intergenic	::intergenic_variant:MODIFIER::::				L2c	rs9440293	0.9024	0.8700	11698,			-1.1440			0.00,0.08	-0.00						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98476958	98476958	C	T	hom	het	hom		QUAL=25438;DP=344,337,268;AF=1.00,0.55,1.00;MQM=59		intergenic	::intergenic_variant:MODIFIER::::				L2c	rs9727941	0.8614	0.8352	10718,			-0.2260			0.01,0.12	0.10						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98476966	98476966	G	C	hom	het	hom		QUAL=25212;DP=343,341,265;AF=1.00,0.55,1.00;MQM=59		intergenic	::intergenic_variant:MODIFIER::::				L2c	rs9724773	0.8614	0.8351	10712,			0.3340			0.06,0.15	0.02						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98478159	98478159	-	AC	het	het	hom		QUAL=11091;DP=252,168,116;AF=0.84,0.49,0.92;MQM=59		intergenic	::intergenic_variant:MODIFIER::::				MIRb&(AC)n	rs112555829		0.7620	8425,							-0.05						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98478544	98478544	A	T	hom	het	hom		QUAL=29770;DP=411,453,333;AF=1.00,0.48,1.00;MQM=59		intergenic	::intergenic_variant:MODIFIER::::				L2c	rs1938565	0.9024	0.8737	11894,			0.0650			0.00,0.05	0.36						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98478981	98478981	C	T	hom	het	hom		QUAL=5312;DP=127,28,22;AF=1.00,0.43,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs1938566	0.8247	0.8032	10013,			-1.0060			0.01,0.09	-0.41						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98480128	98480128	T	C	hom	het	hom		QUAL=22035;DP=407,220,194;AF=0.99,0.49,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::				MER102b	rs1938567	0.8772	0.8533	11179,			-0.9290			0.00,0.21	0.45						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98480212	98480212	C	T	het	wt	het		QUAL=7935;DP=430,199,146;AF=0.53,0.01,0.49;MQM=60		intergenic	::intergenic_variant:MODIFIER::::				MER102b	rs11165944	0.3331	0.2968	1518,			-1.1520			0.01,0.14	0.03						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98481750	98481750	C	T	het	wt	het		QUAL=6516;DP=334,299,216;AF=0.45,0.01,0.47;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs6683447	0.3187	0.2736	1385,			-0.8880			0.03,0.13	-0.14						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98482580	98482580	G	A	hom	het	hom		QUAL=14236;DP=268,171,105;AF=1.00,0.50,1.00;MQM=59		intergenic	::intergenic_variant:MODIFIER::::				L1MB1	rs2391903	0.9259	0.9080	12779,			0.1850			0.00,0.05	0.05						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98482693	98482693	A	G	hom	het	hom		QUAL=16870;DP=243,245,159;AF=1.00,0.54,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::				L1MB1	rs1892549	0.8710	0.8477	11141,			-0.1970			0.01,0.10	0.06						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98482828	98482828	A	G	hom	het	hom		QUAL=15806;DP=302,139,122;AF=1.00,0.44,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::				L1MB1	rs1892550	0.8710	0.8479	11151,			-1.2570			0.05,0.13	-0.21						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98482961	98482961	C	T	hom	het	hom		QUAL=14112;DP=279,134,97;AF=1.00,0.45,0.99;MQM=60		intergenic	::intergenic_variant:MODIFIER::::				L1MB1	rs1892551	0.8710	0.8476	11115,			0.8730			0.00,0.11	-0.05						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98483035	98483035	G	A	hom	het	hom		QUAL=9831;DP=215,75,54;AF=1.00,0.48,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs1892552	0.8710	0.8483	11141,			-0.1400			0.00,0.12	0.04						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98483150	98483150	A	G	hom	het	hom		QUAL=6153;DP=147,34,19;AF=1.00,0.62,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs2391904	0.8710	0.8478	11142,			-0.2660			0.00,0.07	0.08						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98483230	98483230	T	A	wt	wt	het		QUAL=148;DP=225,54,29;AF=0.00,0.00,0.41;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs116414424	0.0152	0.0250	14,			-1.0500			0.02,0.16	0.45						1	13					 (inh=n/a pLI=n/a)
chr1	98483322	98483322	T	C	hom	het	hom		QUAL=6597;DP=154,49,33;AF=1.00,0.31,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs9324382	0.8692	0.8468	11110,			0.6070			0.04,0.38	0.68						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98484152	98484152	T	C	hom	het	hom		QUAL=7912;DP=166,91,53;AF=1.00,0.35,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs1938571	0.8157	0.7958	9872,			-0.2760			0.02,0.10	-0.12						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98484291	98484291	G	A	hom	het	hom		QUAL=11146;DP=209,108,97;AF=1.00,0.36,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs4447033		0.8480	11147,			0.0630			0.00,0.05	-0.03						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98484474	98484474	T	C	hom	het	hom		QUAL=3412;DP=60,39,40;AF=1.00,0.36,1.00;MQM=57		intergenic	::intergenic_variant:MODIFIER::::				AluSx1	rs1938572	0.8710	0.8478	11095,			-2.8460			0.00,0.02	-0.32						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98484617	98484617	C	T	hom	het	hom		QUAL=3204;DP=79,27,12;AF=1.00,0.41,1.00;MQM=59		intergenic	::intergenic_variant:MODIFIER::::				AluSx1	rs1938573	0.8706	0.8506	11001,			-0.0880			0.00,0.07	-0.13						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98484954	98484954	G	T	hom	het	hom		QUAL=19097;DP=334,223,157;AF=1.00,0.47,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs1938558	0.8708	0.8476	11149,			1.1760			0.54,0.64	0.52						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98485102	98485102	G	A	hom	het	hom		QUAL=13944;DP=249,154,128;AF=1.00,0.43,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::				MIR	rs1938559	0.8710	0.8477	11147,			0.7790			0.03,0.15	0.07						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98485192	98485192	C	T	hom	het	hom		QUAL=22242;DP=509,138,106;AF=1.00,0.43,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::				MIR	rs1938560	0.8710	0.8479	11151,			0.0080			0.00,0.05	0.08						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98485573	98485573	C	T	hom	het	hom		QUAL=8876;DP=148,74,88;AF=1.00,0.64,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs9324383	0.8710	0.8482	11146,			0.5250			0.00,0.12	0.04						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98485698	98485698	-	TTT	het	wt	hom		QUAL=200;DP=22,2,2;AF=0.23,0.00,0.00;MQM=58		intergenic	::intergenic_variant:MODIFIER::::				AluSx1	rs10637296		0.7896	8158,							-0.15						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98485698	98485698	-	TT	het	wt	wt		QUAL=200;DP=22,2,2;AF=0.41,0.00,1.00;MQM=58		intergenic	::intergenic_variant:MODIFIER::::				AluSx1			0.0484	112,							-0.15						4	0					 (inh=n/a pLI=n/a)
chr1	98485927	98485927	T	C	hom	het	hom		QUAL=7027;DP=106,108,82;AF=1.00,0.44,1.00;MQM=58		intergenic	::intergenic_variant:MODIFIER::::				AluSx1	rs9725319	0.8710	0.8479	11117,			-1.8120			0.00,0.03	0.04						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98485991	98485991	C	T	het	het	wt		QUAL=2533;DP=110,161,136;AF=0.37,0.45,0.00;MQM=59		intergenic	::intergenic_variant:MODIFIER::::				AluSx1	rs74829086	0.0527	0.0141	22,			-1.7340			0.00,0.09	-0.31						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98486162	98486162	T	C	hom	het	hom		QUAL=7539;DP=149,73,66;AF=1.00,0.36,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs4477335		0.8478	11133,			-0.2590			0.00,0.09	0.10						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98486242	98486242	-	A	hom	het	hom		QUAL=3761;DP=105,22,18;AF=0.94,0.41,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs61381274	0.8678	0.8477	11082,							-0.21						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98486370	98486370	G	A	hom	het	hom		QUAL=4962;DP=101,41,32;AF=1.00,0.46,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs4480407	0.8928	0.8650	11612,			0.8280			0.00,0.05	0.04						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98486694	98486694	A	C	wt	wt	het		QUAL=1902;DP=497,184,160;AF=0.00,0.00,0.50;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs79792869	0.0152	0.0250	14,			0.1050			0.05,0.17	0.09						1	13					 (inh=n/a pLI=n/a)
chr1	98487080	98487080	A	G	wt	wt	het		QUAL=3007;DP=493,218,177;AF=0.00,0.00,0.62;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs77482155	0.0222	0.0362	18,			2.9440			0.37,0.59	0.93						1	18					 (inh=n/a pLI=n/a)
chr1	98487333	98487333	A	G	hom	het	hom		QUAL=20767;DP=274,282,220;AF=1.00,0.57,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs9659624		0.8477	11127,			0.7480			0.07,0.32	1.19						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98487510	98487510	C	A	hom	het	hom		QUAL=20815;DP=391,204,162;AF=1.00,0.55,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs5005705	0.8690	0.8466	11087,			-1.3280			0.02,0.16	-0.16						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98487566	98487566	C	T	hom	het	hom		QUAL=13856;DP=235,144,130;AF=1.00,0.53,0.99;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs9324384	0.8710	0.8478	11126,			-0.7030			0.01,0.17	0.07						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98487763	98487763	G	A	hom	het	hom		QUAL=18172;DP=309,182,165;AF=1.00,0.50,0.99;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs4634961	0.8710	0.8480	11131,			-0.3680			0.01,0.15	-0.02						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98487899	98487899	C	A	hom	het	hom		QUAL=19922;DP=274,262,232;AF=1.00,0.52,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs9324385		0.8480	11133,			-0.0390			0.00,0.11	-0.01						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98487959	98487959	G	A	hom	het	hom		QUAL=26112;DP=376,327,265;AF=1.00,0.51,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs9324386	0.8710	0.8481	11133,			-0.0420			0.00,0.08	0.25						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98488030	98488030	G	A	hom	het	hom		QUAL=22575;DP=331,332,214;AF=1.00,0.50,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs9324387	0.8712	0.8476	11128,			-0.1070			0.04,0.18	0.12						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98488155	98488155	G	A	hom	het	hom		QUAL=17805;DP=284,197,169;AF=1.00,0.46,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs9324388	0.8710	0.8479	11134,			0.2610			0.04,0.18	0.01						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98488863	98488863	A	G	hom	het	hom		QUAL=16756;DP=319,131,127;AF=1.00,0.64,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs9659996	0.8710	0.8477	11135,			1.6450			0.13,0.18	0.20						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98488895	98488895	C	T	hom	het	hom		QUAL=10332;DP=169,92,101;AF=1.00,0.58,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs9658841	0.8710	0.8479	11142,			-0.3150			0.01,0.12	-0.22						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98489080	98489080	G	A	hom	het	hom		QUAL=7306;DP=173,38,26;AF=1.00,0.61,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs9661157	0.8710	0.8479	11131,			-0.5770			0.00,0.07	-0.02						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98489277	98489277	-	TACTT	hom	het	hom		QUAL=5940;DP=119,88,54;AF=0.99,0.36,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs142603792	0.8708	0.8462	11003,							0.73						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98489330	98489330	C	T	hom	het	hom		QUAL=9466;DP=220,81,52;AF=1.00,0.31,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs10747496	0.8710	0.8481	11113,			0.3090			0.00,0.07	-0.09						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98489478	98489478	A	G	hom	het	hom		QUAL=19525;DP=401,163,125;AF=1.00,0.42,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs4584446	0.8710	0.8476	11119,			-0.0160			0.01,0.13	0.10						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98489735	98489735	T	C	hom	het	hom		QUAL=14511;DP=325,130,58;AF=1.00,0.51,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs2391905	0.8710	0.8477	11124,			0.2230			0.04,0.13	0.01						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98490012	98490013	TT	-	hom	het	hom		QUAL=10081;DP=278,90,76;AF=0.91,0.57,0.93;MQM=59		intergenic	::intergenic_variant:MODIFIER::::				L2a	rs55633609	0.8706	0.8392	9510,			0.4430				-0.27						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98490165	98490165	C	T	hom	het	hom		QUAL=8594;DP=179,72,46;AF=1.00,0.44,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs4950117	0.8940	0.8657	11613,			0.2440			0.00,0.06	0.11						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98490358	98490358	G	T	hom	het	hom		QUAL=16041;DP=258,169,156;AF=1.00,0.51,0.99;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs4950118	0.8710	0.8473	11103,			0.5330			0.65,0.96	1.67						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98490636	98490636	T	C	hom	het	hom		QUAL=18235;DP=372,172,121;AF=0.99,0.48,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs10783082	0.8710	0.8478	11108,			0.1180			0.02,0.17	1.15						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98490770	98490770	-	TTAAGTAT	hom	het	hom		QUAL=14058;DP=236,151,156;AF=0.95,0.56,0.99;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs5776392	0.8710	0.8429	10858,							-0.06						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98491248	98491248	A	C	hom	het	hom		QUAL=18362;DP=339,192,140;AF=0.99,0.45,1.00;MQM=59		intergenic	::intergenic_variant:MODIFIER::::				MIR3	rs4950119	0.8682	0.8351	10830,			-0.6670			0.00,0.06	-0.02						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98491382	98491382	G	A	hom	het	hom		QUAL=14552;DP=270,175,105;AF=1.00,0.44,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::				MIRb	rs4950120	0.8710	0.8478	11098,			0.1710			0.00,0.04	0.33						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98491473	98491473	A	C	hom	het	hom		QUAL=17765;DP=354,173,116;AF=1.00,0.50,0.99;MQM=60		intergenic	::intergenic_variant:MODIFIER::::				MIRb	rs4245673	0.8710	0.8475	11118,			0.9410			0.09,0.16	0.15						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98491732	98491732	T	C	hom	het	hom		QUAL=18297;DP=252,286,193;AF=1.00,0.49,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs1938568	0.8710	0.8475	11115,			0.6250			0.47,0.94	0.74						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98492462	98492462	C	T	hom	het	hom		QUAL=22566;DP=421,198,185;AF=1.00,0.46,0.99;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs9440393	0.8710	0.8477	11115,			-0.7830			0.00,0.06	-0.38						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98492580	98492580	A	G	het	het	het		QUAL=13337;DP=470,285,262;AF=0.49,0.50,0.48;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs9440302	0.4575	0.4746	3448,			0.5010			0.07,0.20	0.13						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98492854	98492854	T	C	hom	het	hom		QUAL=16872;DP=356,113,95;AF=1.00,0.50,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs9324389	0.8710	0.8479	11110,			-2.2810			0.03,0.17	0.16						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98492901	98492901	G	A	wt	wt	het		QUAL=1386;DP=324,90,92;AF=0.00,0.00,0.59;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs74700717	0.0106	0.0193	9,			-1.3510			0.03,0.19	0.13						0	9					 (inh=n/a pLI=n/a)
chr1	98493263	98493263	A	G	hom	het	hom		QUAL=13393;DP=216,187,124;AF=1.00,0.45,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs1938569	0.8706	0.8476	11103,			0.7980			0.11,0.31	0.23						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98493785	98493785	G	A	hom	het	hom		QUAL=3213;DP=63,14,11;AF=0.98,0.36,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs2022864	0.8712	0.8483	10822,			-0.8400			0.01,0.10	-0.30						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98493789	98493789	A	G	hom	het	hom		QUAL=3213;DP=63,14,11;AF=0.98,0.36,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs2022865	0.8712	0.8478	10828,			0.3550			0.02,0.26	0.22						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98494185	98494185	G	A	hom	het	hom		QUAL=12903;DP=217,153,104;AF=0.99,0.55,0.99;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs10875124	0.8710	0.8472	11031,			0.8860			0.00,0.08	0.18						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98494200	98494200	A	C	hom	het	hom		QUAL=12416;DP=218,141,97;AF=1.00,0.53,0.99;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs10875125	0.8710	0.8470	11030,			0.2010			0.04,0.19	0.14						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98494388	98494388	-	A	hom	het	hom		QUAL=7372;DP=156,79,48;AF=0.99,0.43,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs11404556	0.8700	0.8477	11088,							0.29						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98494606	98494606	A	G	hom	het	hom		QUAL=14526;DP=242,151,132;AF=1.00,0.44,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs1198574	0.8712	0.8475	11090,			0.7390			0.72,0.96	1.81						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98495513	98495513	T	C	hom	het	hom		QUAL=10064;DP=153,129,96;AF=1.00,0.54,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs1198573	0.8708	0.8477	11077,			3.3540			0.32,0.20	0.42						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98496512	98496512	T	-	het	wt	het		QUAL=3249;DP=195,125,93;AF=0.47,0.03,0.59;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs377025796		0.0117	7,			0.8290				-0.32						0	6					 (inh=n/a pLI=n/a)
chr1	98497176	98497176	A	C	hom	het	hom		QUAL=6040;DP=157,15,16;AF=1.00,0.67,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs1198572	0.8441	0.8175	10351,			-0.4370			0.01,0.11	0.57						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98497355	98497355	A	G	het	wt	het		QUAL=773;DP=54,10,14;AF=0.50,0.00,0.57;MQM=58		intergenic	::intergenic_variant:MODIFIER::::					rs188465986	0.0022	0.0075	2,			0.0570			0.04,0.14	0.05						0	5					 (inh=n/a pLI=n/a)
chr1	98497364	98497367	ACAC	-	wt	wt	het		QUAL=41;DP=24,6,9;AF=0.21,0.00,0.44;MQM=60		intergenic	::intergenic_variant:MODIFIER::::				(AC)n			0.0435	25,			0.3450				0.05						7	1					 (inh=n/a pLI=n/a)
chr1	98497363	98497363	T	C	het	wt	wt		QUAL=41;DP=24,6,9;AF=0.21,0.00,0.44;MQM=52		intergenic	::intergenic_variant:MODIFIER::::				(AC)n	rs796242776						-0.6340			0.00,0.09	-0.21						1	3					 (inh=n/a pLI=n/a)
chr1	98497672	98497672	A	G	hom	het	hom		QUAL=4984;DP=120,35,21;AF=1.00,0.37,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs1198571	0.8706	0.8475	11096,			0.1410			0.00,0.07	0.07						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98498339	98498339	C	T	wt	wt	het		QUAL=2122;DP=593,248,197;AF=0.00,0.00,0.47;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs17371457	0.1374	0.1665	549,			-0.6140			0.02,0.18	0.12						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98498898	98498898	C	A	hom	het	hom		QUAL=23957;DP=423,268,190;AF=1.00,0.47,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs1782815	0.8686	0.8468	11097,			0.1660			0.02,0.22	-0.06						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98499590	98499590	A	-	het	het	wt		QUAL=1629;DP=86,36,30;AF=0.58,0.53,0.00;MQM=57		intergenic	::intergenic_variant:MODIFIER::::				(AGAA)n	rs143336786		0.0301	11,			-0.4760				-0.31						0	8					 (inh=n/a pLI=n/a)
chr1	98499651	98499651	G	A	het	het	het		QUAL=1262;DP=67,14,18;AF=0.54,0.36,0.44;MQM=53		intergenic	::intergenic_variant:MODIFIER::::				(AGAA)n	rs1782814		0.2235	457,			0.3370			0.00,0.06	0.04						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98499659	98499659	G	A	wt	het	hom		QUAL=713;DP=17,7,12;AF=0.94,0.29,0.92;MQM=60		intergenic	::intergenic_variant:MODIFIER::::				(AGAA)n	rs58126792		0.1114	76,			-0.5470			0.00,0.10	-0.27						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98499663	98499663	A	G	wt	het	hom		QUAL=713;DP=17,7,12;AF=0.94,0.00,0.08;MQM=60		intergenic	::intergenic_variant:MODIFIER::::				(AGAA)n	rs60475427		0.0839	84,			-0.2610			0.00,0.04	-0.04						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98499663	98499663	-	AAAG	hom	wt	wt		QUAL=713;DP=17,7,12;AF=0.00,0.29,0.83;MQM=60		intergenic	::intergenic_variant:MODIFIER::::				(AGAA)n	rs780129382		0.2598	896,							-0.23						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98499843	98499843	T	C	hom	het	hom		QUAL=10100;DP=169,159,94;AF=0.99,0.47,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs1782813	0.8890	0.8588	11422,			-0.1880			0.01,0.18	0.03						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98500045	98500045	G	C	het	wt	het		QUAL=6850;DP=389,168,133;AF=0.50,0.01,0.44;MQM=60		intergenic	::intergenic_variant:MODIFIER::::				UCON1	rs7554283	0.3195	0.2740	1386,			1.4460			0.81,0.98	1.78						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98501011	98501011	T	C	het	wt	het		QUAL=7061;DP=317,249,202;AF=0.49,0.00,0.53;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs4950101	0.2772	0.2410	1072,			1.6260			0.78,0.97	1.15						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98501984	98501984	T	C	hom	het	hom		QUAL=13803;DP=276,106,85;AF=0.99,0.59,0.99;MQM=60		intergenic	::intergenic_variant:MODIFIER::::					rs1702294	0.8401	0.8111	10219,			-0.3760			0.01,0.10	-0.44						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98502159	98502159	G	C	hom	het	hom		QUAL=29074;DP=323,439,361;AF=1.00,0.51,1.00;MQM=59		intergenic	::intergenic_variant:MODIFIER::::				Tigger3a	rs1702293	0.9257	0.9081	12762,			-2.1860			0.00,0.03	-0.45						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98502340	98502340	G	A	hom	het	hom		QUAL=18805;DP=240,244,231;AF=1.00,0.48,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::				Tigger3a	rs1782810	0.7967	0.7716	9261,			0.6560			0.01,0.06	-0.26						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98502410	98502410	A	C	hom	het	hom		QUAL=21499;DP=276,297,249;AF=1.00,0.51,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::				Tigger3a	rs1782811	0.9026	0.8734	11871,			-2.7760			0.00,0.04	-0.22						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98502594	98502594	A	C	hom	het	hom		QUAL=17997;DP=241,271,208;AF=1.00,0.49,1.00;MQM=59		intergenic	::intergenic_variant:MODIFIER::::					rs1628294	0.9257	0.9081	12765,			-0.4680			0.00,0.10	0.16						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98502934	98502934	G	T	hom	het	hom		QUAL=10741;DP=212,108,74;AF=1.00,0.38,1.00;MQM=60		intergenic	::intergenic_variant:MODIFIER::::			CR159174 [CLASS=DM MUT=ALT PHEN="Schizophrenia increased risk" GENE=MIR137HG];		rs1625579	0.7969	0.7714	9249,			-0.3210			0.00,0.06	-0.42						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr1	98506110	98506110	A	-	het	het	het		QUAL=598;DP=169,133,100;AF=0.20,0.17,0.14;MQM=60	MIR137HG	downstream_gene	MIR137HG:ENST00000580305:downstream_gene_variant:MODIFIER::::					rs879525945		0.0261	0,			-1.7420				-0.51						0	8					MIR137HG (inh=n/a pLI=n/a)
chr1	98506616	98506616	-	TTCATTCATTCATTCA	wt	wt	het		QUAL=2432;DP=83,37,20;AF=0.82,0.51,1.00;MQM=60	MIR137HG	downstream_gene	MIR137HG:ENST00000580305:downstream_gene_variant:MODIFIER::::				(TTCA)n	rs71988022		0.1135	215,							-0.53						n/a (AF>5%)	n/a (AF>5%)					MIR137HG (inh=n/a pLI=n/a)
chr1	98506616	98506616	-	TTCATTCATTCA	het	wt	het		QUAL=2432;DP=83,37,20;AF=0.82,0.51,1.00;MQM=57	MIR137HG	downstream_gene	MIR137HG:ENST00000580305:downstream_gene_variant:MODIFIER::::				(TTCA)n	rs71988022	0.3163	0.5502	4613,							-0.52						n/a (AF>5%)	n/a (AF>5%)					MIR137HG (inh=n/a pLI=n/a)
chr1	98506616	98506616	-	TTCATTCA	het	het	wt		QUAL=2432;DP=83,37,20;AF=0.82,0.51,1.00;MQM=60	MIR137HG	downstream_gene	MIR137HG:ENST00000580305:downstream_gene_variant:MODIFIER::::				(TTCA)n			0.1485	414,							-0.50						n/a (AF>5%)	n/a (AF>5%)					MIR137HG (inh=n/a pLI=n/a)
chr1	98507696	98507696	A	G	hom	het	hom		QUAL=6050;DP=154,35,15;AF=0.99,0.43,1.00;MQM=60	MIR137HG	downstream_gene	MIR137HG:ENST00000385223:downstream_gene_variant:MODIFIER::::,MIR137HG:ENST00000580305:downstream_gene_variant:MODIFIER::::					rs4292998	0.8129	0.7826	9514,			-0.0470			0.06,0.20	0.73						n/a (AF>5%)	n/a (AF>5%)					MIR137HG (inh=n/a pLI=n/a)
chr1	98507718	98507718	C	A	hom	het	hom		QUAL=7209;DP=184,38,18;AF=0.99,0.45,1.00;MQM=60	MIR137HG	downstream_gene	MIR137HG:ENST00000385223:downstream_gene_variant:MODIFIER::::,MIR137HG:ENST00000580305:downstream_gene_variant:MODIFIER::::					rs4411173	0.8896	0.8586	11446,			0.5560			0.00,0.07	0.13						n/a (AF>5%)	n/a (AF>5%)					MIR137HG (inh=n/a pLI=n/a)
chr1	98508258	98508258	C	T	hom	het	hom		QUAL=39523;DP=577,501,412;AF=1.00,0.52,1.00;MQM=60	MIR137HG	downstream_gene	MIR137HG:ENST00000385223:downstream_gene_variant:MODIFIER::::,MIR137HG:ENST00000580305:downstream_gene_variant:MODIFIER::::					rs2802535	0.8097	0.7813	9458,			-0.6370			0.03,0.11	-0.35						n/a (AF>5%)	n/a (AF>5%)					MIR137HG (inh=n/a pLI=n/a)
chr1	98508488	98508488	G	A	het	het	wt		QUAL=8630;DP=418,196,173;AF=0.50,0.56,0.00;MQM=60	MIR137HG	downstream_gene	MIR137HG:ENST00000385223:downstream_gene_variant:MODIFIER::::,MIR137HG:ENST00000580305:downstream_gene_variant:MODIFIER::::					rs78924727	0.0527	0.0140	22,			-0.2230			0.01,0.20	-0.11						n/a (AF>5%)	n/a (AF>5%)					MIR137HG (inh=n/a pLI=n/a)
chr1	98512127	98512127	G	T	hom	het	hom		QUAL=32969;DP=410,498,411;AF=1.00,0.47,1.00;MQM=60	MIR137HG	upstream_gene	MIR137HG:ENST00000385223:upstream_gene_variant:MODIFIER::::,MIR137HG:ENST00000580305:upstream_gene_variant:MODIFIER::::					rs2660304	0.8468	0.8166	10316,			1.2090			0.55,0.64	1.39						n/a (AF>5%)	n/a (AF>5%)					MIR137HG (inh=n/a pLI=n/a)
chr1	98513144	98513144	T	A	hom	het	hom		QUAL=13166;DP=231,132,116;AF=1.00,0.53,1.00;MQM=60	MIR137HG	upstream_gene	MIR137HG:ENST00000385223:upstream_gene_variant:MODIFIER::::,MIR137HG:ENST00000580305:upstream_gene_variant:MODIFIER::::					rs2660303	0.9259	0.9070	12738,			-0.2550			0.02,0.15	-0.23						n/a (AF>5%)	n/a (AF>5%)					MIR137HG (inh=n/a pLI=n/a)
chr1	98513676	98513676	-	CGCACACACA	wt	wt	hom		QUAL=720;DP=11,73,16;AF=0.00,0.00,0.19;MQM=60	MIR137HG	upstream_gene	MIR137HG:ENST00000385223:upstream_gene_variant:MODIFIER::::,MIR137HG:ENST00000580305:upstream_gene_variant:MODIFIER::::				(CA)n											-0.14						0	11					MIR137HG (inh=n/a pLI=n/a)
chr1	98513676	98513676	-	CA	wt	het	wt		QUAL=720;DP=11,73,16;AF=0.00,0.51,0.00;MQM=60	MIR137HG	upstream_gene	MIR137HG:ENST00000385223:upstream_gene_variant:MODIFIER::::,MIR137HG:ENST00000580305:upstream_gene_variant:MODIFIER::::				(CA)n											-0.11						1	0					MIR137HG (inh=n/a pLI=n/a)
chr1	98513712	98513712	-	CACC	wt	wt	hom		QUAL=720;DP=11,73,16;AF=0.00,0.51,0.19;MQM=60	MIR137HG	upstream_gene	MIR137HG:ENST00000385223:upstream_gene_variant:MODIFIER::::,MIR137HG:ENST00000580305:upstream_gene_variant:MODIFIER::::				(CA)n			0.0019	2,							0.16						0	0					MIR137HG (inh=n/a pLI=n/a)
chr1	98513845	98513845	G	A	hom	het	hom		QUAL=13268;DP=149,260,184;AF=1.00,0.47,0.99;MQM=59	MIR137HG	upstream_gene	MIR137HG:ENST00000385223:upstream_gene_variant:MODIFIER::::,MIR137HG:ENST00000580305:upstream_gene_variant:MODIFIER::::					rs61786696	0.9263	0.9081	12794,			0.4930			0.00,0.19	0.31						n/a (AF>5%)	n/a (AF>5%)					MIR137HG (inh=n/a pLI=n/a)
chr1	98513959	98513959	A	G	hom	het	hom		QUAL=18033;DP=247,275,209;AF=1.00,0.49,1.00;MQM=59	MIR137HG	upstream_gene	MIR137HG:ENST00000385223:upstream_gene_variant:MODIFIER::::,MIR137HG:ENST00000580305:upstream_gene_variant:MODIFIER::::					rs61786697	0.9261	0.9080	12782,			2.5710			0.00,0.84	1.25						n/a (AF>5%)	n/a (AF>5%)					MIR137HG (inh=n/a pLI=n/a)
chr1	98514590	98514590	-	CT	wt	het	wt		QUAL=286;DP=88,89,79;AF=0.02,0.36,0.00;MQM=60	MIR137HG	upstream_gene	MIR137HG:ENST00000385223:upstream_gene_variant:MODIFIER::::,MIR137HG:ENST00000580305:upstream_gene_variant:MODIFIER::::				(CT)n			0.0143	4,							0.59						0	6					MIR137HG (inh=n/a pLI=n/a)
chr1	100316589	100316589	A	G	wt	wt	het		QUAL=1880;DP=311,144,107;AF=0.00,0.01,0.66;MQM=60	AGL	5'UTR,splice_acceptor	AGL:ENST00000294724:5_prime_UTR_variant:MODIFIER:exon2/34:c.-10A>G::,AGL:ENST00000361302:5_prime_UTR_variant:MODIFIER:exon1/34:c.-201A>G::,AGL:ENST00000361915:5_prime_UTR_variant:MODIFIER:exon2/34:c.-10A>G::,AGL:ENST00000370163:5_prime_UTR_variant:MODIFIER:exon2/34:c.-10A>G::,AGL:ENST00000370165:splice_acceptor_variant:HIGH:exon1/33:c.-8-2A>G::	610860 [AGL (confirmed) Glycogen storage disease IIIa,232400/Glycogen storage disease IIIb,232400];	195096 [benign DISEASE=Glycogen storage disease type III,not specified,not provided];			rs2307130	0.4271	0.4698	2791,	0.2620,0.4398,0.5355,0.4925,0.5367	0.4866,0.2773	0.3640			0.07,0.39	1.01		-243.22% (3.27>-4.68)		0.000/0.000		n/a (AF>5%)	n/a (AF>5%)					AGL (inh=AR pLI=0.00)
chr1	100318093	100318094	TT	-	het	wt	het	off-target	QUAL=270;DP=15,14,7;AF=0.20,0.14,0.29;MQM=60	AGL	intron	AGL:ENST00000294724:intron_variant:MODIFIER:exon2/33:c.82+1431_82+1432del::,AGL:ENST00000361302:intron_variant:MODIFIER:exon1/33:c.-109-6_-109-5del::,AGL:ENST00000361915:intron_variant:MODIFIER:exon2/33:c.82+1431_82+1432del::,AGL:ENST00000370163:intron_variant:MODIFIER:exon2/33:c.82+1431_82+1432del::,AGL:ENST00000370165:intron_variant:MODIFIER:exon2/33:c.82+1431_82+1432del::	610860 [AGL (confirmed) Glycogen storage disease IIIa,232400/Glycogen storage disease IIIb,232400];			AluJo			0.0003	0,			-0.2470				0.08						0	0					AGL (inh=AR pLI=0.00)
chr1	100318093	100318093	T	-	het	het	wt	off-target	QUAL=270;DP=15,14,7;AF=0.33,0.50,0.14;MQM=58	AGL	intron	AGL:ENST00000294724:intron_variant:MODIFIER:exon2/33:c.82+1432del::,AGL:ENST00000361302:intron_variant:MODIFIER:exon1/33:c.-109-5del::,AGL:ENST00000361915:intron_variant:MODIFIER:exon2/33:c.82+1432del::,AGL:ENST00000370163:intron_variant:MODIFIER:exon2/33:c.82+1432del::,AGL:ENST00000370165:intron_variant:MODIFIER:exon2/33:c.82+1432del::	610860 [AGL (confirmed) Glycogen storage disease IIIa,232400/Glycogen storage disease IIIb,232400];			AluJo			0.0019	0,			-0.2470				0.08						8	3					AGL (inh=AR pLI=0.00)
chr1	100327026	100327026	C	T	het	het	het		QUAL=12697;DP=436,300,201;AF=0.53,0.46,0.48;MQM=60	AGL	intron,5'UTR	AGL:ENST00000294724:intron_variant:MODIFIER:exon2/33:c.83-33C>T::,AGL:ENST00000361302:intron_variant:MODIFIER:exon2/33:c.35-33C>T::,AGL:ENST00000361522:5_prime_UTR_variant:MODIFIER:exon1/32:c.-2C>T::,AGL:ENST00000361915:intron_variant:MODIFIER:exon2/33:c.83-33C>T::,AGL:ENST00000370161:intron_variant:MODIFIER:exon1/32:c.35-33C>T::,AGL:ENST00000370163:intron_variant:MODIFIER:exon2/33:c.83-33C>T::,AGL:ENST00000370165:intron_variant:MODIFIER:exon2/33:c.83-33C>T::	610860 [AGL (confirmed) Glycogen storage disease IIIa,232400/Glycogen storage disease IIIb,232400];	256750 [benign DISEASE=not specified];			rs2307129	0.2272	0.2334	1024,	0.3885,0.1307,0.1208,0.1710,0.1892	0.1707,0.3807	-0.3770			0.05,0.14	-0.01						n/a (AF>5%)	n/a (AF>5%)					AGL (inh=AR pLI=0.00)
chr1	100329889	100329889	G	C	het	het	hom	off-target	QUAL=2603;DP=96,51,33;AF=0.54,0.39,1.00;MQM=60	AGL	intron	AGL:ENST00000294724:intron_variant:MODIFIER:exon4/33:c.461-53G>C::,AGL:ENST00000361302:intron_variant:MODIFIER:exon4/33:c.413-53G>C::,AGL:ENST00000361522:intron_variant:MODIFIER:exon2/31:c.410-53G>C::,AGL:ENST00000361915:intron_variant:MODIFIER:exon4/33:c.461-53G>C::,AGL:ENST00000370161:intron_variant:MODIFIER:exon3/32:c.413-53G>C::,AGL:ENST00000370163:intron_variant:MODIFIER:exon4/33:c.461-53G>C::,AGL:ENST00000370165:intron_variant:MODIFIER:exon4/33:c.461-53G>C::	610860 [AGL (confirmed) Glycogen storage disease IIIa,232400/Glycogen storage disease IIIb,232400];				rs535461	0.7396	0.7220	8146,			-0.0930			0.09,0.16	-0.34						n/a (AF>5%)	n/a (AF>5%)					AGL (inh=AR pLI=0.00)
chr1	100336361	100336361	C	T	het	het	hom		QUAL=8617;DP=341,117,98;AF=0.43,0.51,1.00;MQM=60	AGL	synonymous	AGL:ENST00000294724:synonymous_variant:LOW:exon7/34:c.894C>T:p.Leu298=:PF14701,AGL:ENST00000361302:synonymous_variant:LOW:exon7/34:c.846C>T:p.Leu282=:PF14701,AGL:ENST00000361522:synonymous_variant:LOW:exon5/32:c.843C>T:p.Leu281=:PF14701,AGL:ENST00000361915:synonymous_variant:LOW:exon7/34:c.894C>T:p.Leu298=:PF14701,AGL:ENST00000370161:synonymous_variant:LOW:exon6/33:c.846C>T:p.Leu282=:PF14701,AGL:ENST00000370163:synonymous_variant:LOW:exon7/34:c.894C>T:p.Leu298=:PF14701,AGL:ENST00000370165:synonymous_variant:LOW:exon7/34:c.894C>T:p.Leu298=:PF14701	610860 [AGL (confirmed) Glycogen storage disease IIIa,232400/Glycogen storage disease IIIb,232400];	198432 [benign DISEASE=Glycogen storage disease type III,not specified,not provided];			rs2230306	0.7626	0.7554	8963,	0.9165,0.6916,0.6854,0.7030,0.7511	0.6957,0.9083	1.3620			0.80,0.95	0.76						n/a (AF>5%)	n/a (AF>5%)					AGL (inh=AR pLI=0.00)
chr1	100340225	100340225	G	A	het	het	hom	off-target	QUAL=11583;DP=218,229,169;AF=0.50,0.54,1.00;MQM=60	AGL	intron	AGL:ENST00000294724:intron_variant:MODIFIER:exon7/33:c.959-18G>A::,AGL:ENST00000361302:intron_variant:MODIFIER:exon7/33:c.911-18G>A::,AGL:ENST00000361522:intron_variant:MODIFIER:exon5/31:c.908-18G>A::,AGL:ENST00000361915:intron_variant:MODIFIER:exon7/33:c.959-18G>A::,AGL:ENST00000370161:intron_variant:MODIFIER:exon6/32:c.911-18G>A::,AGL:ENST00000370163:intron_variant:MODIFIER:exon7/33:c.959-18G>A::,AGL:ENST00000370165:intron_variant:MODIFIER:exon7/33:c.959-18G>A::	610860 [AGL (confirmed) Glycogen storage disease IIIa,232400/Glycogen storage disease IIIb,232400];	256751 [benign DISEASE=not specified,not provided];			rs634880	0.7434	0.7321	8345,	0.8458,0.6832,0.7108,0.7102,0.7323	0.7030,0.8368	-1.0390			0.00,0.06	-0.28		+3.64% (10.97>11.37)				n/a (AF>5%)	n/a (AF>5%)					AGL (inh=AR pLI=0.00)
chr1	100343153	100343153	A	G	wt	wt	het	off-target	QUAL=301;DP=176,41,22;AF=0.00,0.00,0.68;MQM=60	AGL	intron	AGL:ENST00000294724:intron_variant:MODIFIER:exon11/33:c.1424-44A>G::,AGL:ENST00000361302:intron_variant:MODIFIER:exon11/33:c.1376-44A>G::,AGL:ENST00000361522:intron_variant:MODIFIER:exon9/31:c.1373-44A>G::,AGL:ENST00000361915:intron_variant:MODIFIER:exon11/33:c.1424-44A>G::,AGL:ENST00000370161:intron_variant:MODIFIER:exon10/32:c.1376-44A>G::,AGL:ENST00000370163:intron_variant:MODIFIER:exon11/33:c.1424-44A>G::,AGL:ENST00000370165:intron_variant:MODIFIER:exon11/33:c.1424-44A>G::	610860 [AGL (confirmed) Glycogen storage disease IIIa,232400/Glycogen storage disease IIIb,232400];	256722 [benign DISEASE=not specified];			rs2291638	0.2843	0.3512	1738,	0.0893,0.3604,0.4467,0.3880,0.3036	0.3751,0.1030	-0.3690			0.13,0.25	0.71						n/a (AF>5%)	n/a (AF>5%)					AGL (inh=AR pLI=0.00)
chr1	100346741	100346741	T	C	wt	wt	het		QUAL=2696;DP=287,284,209;AF=0.00,0.00,0.51;MQM=60	AGL	splice_region&intron	AGL:ENST00000294724:splice_region_variant&intron_variant:LOW:exon15/33:c.2001+8T>C::,AGL:ENST00000361302:splice_region_variant&intron_variant:LOW:exon15/33:c.1953+8T>C::,AGL:ENST00000361522:splice_region_variant&intron_variant:LOW:exon13/31:c.1950+8T>C::,AGL:ENST00000361915:splice_region_variant&intron_variant:LOW:exon15/33:c.2001+8T>C::,AGL:ENST00000370161:splice_region_variant&intron_variant:LOW:exon14/32:c.1953+8T>C::,AGL:ENST00000370163:splice_region_variant&intron_variant:LOW:exon15/33:c.2001+8T>C::,AGL:ENST00000370165:splice_region_variant&intron_variant:LOW:exon15/33:c.2001+8T>C::	610860 [AGL (confirmed) Glycogen storage disease IIIa,232400/Glycogen storage disease IIIb,232400];	256725 [benign DISEASE=Glycogen storage disease type III,not specified,not provided];			rs3736296	0.5585	0.5541	4288,	0.4301,0.6225,0.6602,0.5446,0.5895	0.5383,0.4376	2.1680			0.60,0.41	0.25				0.000/0.002		n/a (AF>5%)	n/a (AF>5%)					AGL (inh=AR pLI=0.00)
chr1	100353675	100353675	G	A	het	het	hom	off-target	QUAL=12232;DP=174,264,206;AF=0.53,0.47,1.00;MQM=60	AGL	intron	AGL:ENST00000294724:intron_variant:MODIFIER:exon21/33:c.2812+11G>A::,AGL:ENST00000361302:intron_variant:MODIFIER:exon21/33:c.2764+11G>A::,AGL:ENST00000361522:intron_variant:MODIFIER:exon19/31:c.2761+11G>A::,AGL:ENST00000361915:intron_variant:MODIFIER:exon21/33:c.2812+11G>A::,AGL:ENST00000370161:intron_variant:MODIFIER:exon20/32:c.2764+11G>A::,AGL:ENST00000370163:intron_variant:MODIFIER:exon21/33:c.2812+11G>A::,AGL:ENST00000370165:intron_variant:MODIFIER:exon21/33:c.2812+11G>A::	610860 [AGL (confirmed) Glycogen storage disease IIIa,232400/Glycogen storage disease IIIb,232400];	256730 [benign DISEASE=Glycogen storage disease type III,not specified,not provided];			rs555929	0.6811	0.6908	6922,	0.5833,0.7234,0.6879,0.6935,0.7301	0.6847,0.5967	-0.7550			0.00,0.17	-0.10						n/a (AF>5%)	n/a (AF>5%)					AGL (inh=AR pLI=0.00)
chr1	100357141	100357141	T	A	wt	wt	het	off-target	QUAL=1409;DP=198,186,121;AF=0.00,0.00,0.47;MQM=60	AGL	intron	AGL:ENST00000294724:intron_variant:MODIFIER:exon22/33:c.2950-21T>A::,AGL:ENST00000361302:intron_variant:MODIFIER:exon22/33:c.2902-21T>A::,AGL:ENST00000361522:intron_variant:MODIFIER:exon20/31:c.2899-21T>A::,AGL:ENST00000361915:intron_variant:MODIFIER:exon22/33:c.2950-21T>A::,AGL:ENST00000370161:intron_variant:MODIFIER:exon21/32:c.2902-21T>A::,AGL:ENST00000370163:intron_variant:MODIFIER:exon22/33:c.2950-21T>A::,AGL:ENST00000370165:intron_variant:MODIFIER:exon22/33:c.2950-21T>A::	610860 [AGL (confirmed) Glycogen storage disease IIIa,232400/Glycogen storage disease IIIb,232400];	256733 [benign DISEASE=not specified];			rs2035961	0.5343	0.5367	3752,	0.3790,0.6131,0.6591,0.5276,0.5856	0.5223,0.3845	0.0470			0.07,0.25	0.23						n/a (AF>5%)	n/a (AF>5%)					AGL (inh=AR pLI=0.00)
chr1	100358103	100358103	C	T	het	het	het		QUAL=8363;DP=251,223,182;AF=0.49,0.51,0.47;MQM=60	AGL	missense	AGL:ENST00000294724:missense_variant:MODERATE:exon24/34:c.3199C>T:p.Pro1067Ser:,AGL:ENST00000361302:missense_variant:MODERATE:exon24/34:c.3151C>T:p.Pro1051Ser:,AGL:ENST00000361522:missense_variant:MODERATE:exon22/32:c.3148C>T:p.Pro1050Ser:,AGL:ENST00000361915:missense_variant:MODERATE:exon24/34:c.3199C>T:p.Pro1067Ser:,AGL:ENST00000370161:missense_variant:MODERATE:exon23/33:c.3151C>T:p.Pro1051Ser:,AGL:ENST00000370163:missense_variant:MODERATE:exon24/34:c.3199C>T:p.Pro1067Ser:,AGL:ENST00000370165:missense_variant:MODERATE:exon24/34:c.3199C>T:p.Pro1067Ser:	610860 [AGL (confirmed) Glycogen storage disease IIIa,232400/Glycogen storage disease IIIb,232400];	256734 [benign/likely benign DISEASE=Glycogen storage disease type III,not specified,not provided];			rs3753494	0.1106	0.1364	341,	0.1168,0.1000,0.0290,0.1493,0.1444	0.1462,0.1264	7.2300	D,D,D,D,D,D,D	B,B,B,B,B,B,B	0.98,0.99	2.33	0.30					n/a (AF>5%)	n/a (AF>5%)					AGL (inh=AR pLI=0.00)
chr1	100358200	100358200	G	A	het	het	hom	off-target	QUAL=5718;DP=136,117,88;AF=0.46,0.49,1.00;MQM=60	AGL	intron	AGL:ENST00000294724:intron_variant:MODIFIER:exon24/33:c.3259+37G>A::,AGL:ENST00000361302:intron_variant:MODIFIER:exon24/33:c.3211+37G>A::,AGL:ENST00000361522:intron_variant:MODIFIER:exon22/31:c.3208+37G>A::,AGL:ENST00000361915:intron_variant:MODIFIER:exon24/33:c.3259+37G>A::,AGL:ENST00000370161:intron_variant:MODIFIER:exon23/32:c.3211+37G>A::,AGL:ENST00000370163:intron_variant:MODIFIER:exon24/33:c.3259+37G>A::,AGL:ENST00000370165:intron_variant:MODIFIER:exon24/33:c.3259+37G>A::	610860 [AGL (confirmed) Glycogen storage disease IIIa,232400/Glycogen storage disease IIIb,232400];	256735 [benign DISEASE=not specified];			rs594249	0.6815	0.6914	6934,	0.5832,0.7237,0.6884,0.6938,0.7341	0.6842,0.5978	-1.3340			0.00,0.05	-0.33						n/a (AF>5%)	n/a (AF>5%)					AGL (inh=AR pLI=0.00)
chr1	100366447	100366448	TT	-	wt	het	hom	off-target	QUAL=1541;DP=79,53,54;AF=0.27,0.04,0.02;MQM=59	AGL	intron	AGL:ENST00000294724:intron_variant:MODIFIER:exon26/33:c.3588+43_3588+44del::,AGL:ENST00000361302:intron_variant:MODIFIER:exon26/33:c.3540+43_3540+44del::,AGL:ENST00000361522:intron_variant:MODIFIER:exon24/31:c.3537+43_3537+44del::,AGL:ENST00000361915:intron_variant:MODIFIER:exon26/33:c.3588+43_3588+44del::,AGL:ENST00000370161:intron_variant:MODIFIER:exon25/32:c.3540+43_3540+44del::,AGL:ENST00000370163:intron_variant:MODIFIER:exon26/33:c.3588+43_3588+44del::,AGL:ENST00000370165:intron_variant:MODIFIER:exon26/33:c.3588+43_3588+44del::	610860 [AGL (confirmed) Glycogen storage disease IIIa,232400/Glycogen storage disease IIIb,232400];			(T)n	rs35956186		0.5184	3132,	0.3365,0.3673,0.3619,0.4270,0.3421		2.7560				-0.16						n/a (AF>5%)	n/a (AF>5%)					AGL (inh=AR pLI=0.00)
chr1	100366446	100366446	G	T	het	wt	wt	off-target	QUAL=1541;DP=79,53,54;AF=0.28,0.45,0.81;MQM=56	AGL	intron	AGL:ENST00000294724:intron_variant:MODIFIER:exon26/33:c.3588+29G>T::,AGL:ENST00000361302:intron_variant:MODIFIER:exon26/33:c.3540+29G>T::,AGL:ENST00000361522:intron_variant:MODIFIER:exon24/31:c.3537+29G>T::,AGL:ENST00000361915:intron_variant:MODIFIER:exon26/33:c.3588+29G>T::,AGL:ENST00000370161:intron_variant:MODIFIER:exon25/32:c.3540+29G>T::,AGL:ENST00000370163:intron_variant:MODIFIER:exon26/33:c.3588+29G>T::,AGL:ENST00000370165:intron_variant:MODIFIER:exon26/33:c.3588+29G>T::	610860 [AGL (confirmed) Glycogen storage disease IIIa,232400/Glycogen storage disease IIIb,232400];			(T)n	rs201885902	0.0083	0.0181	0,	0.0258,0.0189,0.0185,0.0168,0.0188		-0.1580			0.03,0.11	-0.35						109	260	2	[2] auto-classification 22.09.2017  			AGL (inh=AR pLI=0.00)
chr1	100376448	100376448	G	A	wt	wt	het	off-target	QUAL=2102;DP=103,266,176;AF=0.00,0.00,0.49;MQM=60	AGL	intron	AGL:ENST00000294724:intron_variant:MODIFIER:exon28/33:c.3836+45G>A::,AGL:ENST00000361302:intron_variant:MODIFIER:exon28/33:c.3788+45G>A::,AGL:ENST00000361522:intron_variant:MODIFIER:exon26/31:c.3785+45G>A::,AGL:ENST00000361915:intron_variant:MODIFIER:exon28/33:c.3836+45G>A::,AGL:ENST00000370161:intron_variant:MODIFIER:exon27/32:c.3788+45G>A::,AGL:ENST00000370163:intron_variant:MODIFIER:exon28/33:c.3836+45G>A::,AGL:ENST00000370165:intron_variant:MODIFIER:exon28/33:c.3836+45G>A::	610860 [AGL (confirmed) Glycogen storage disease IIIa,232400/Glycogen storage disease IIIb,232400];	256744 [benign DISEASE=not specified];			rs2274570	0.4613	0.4818	3477,	0.3693,0.5719,0.5435,0.5000,0.3649	0.4942,0.3840	-0.8020			0.00,0.07	-0.03						n/a (AF>5%)	n/a (AF>5%)					AGL (inh=AR pLI=0.00)
chr1	100376456	100376456	T	A	wt	wt	het	off-target	QUAL=2113;DP=106,261,173;AF=0.00,0.00,0.50;MQM=60	AGL	intron	AGL:ENST00000294724:intron_variant:MODIFIER:exon28/33:c.3836+53T>A::,AGL:ENST00000361302:intron_variant:MODIFIER:exon28/33:c.3788+53T>A::,AGL:ENST00000361522:intron_variant:MODIFIER:exon26/31:c.3785+53T>A::,AGL:ENST00000361915:intron_variant:MODIFIER:exon28/33:c.3836+53T>A::,AGL:ENST00000370161:intron_variant:MODIFIER:exon27/32:c.3788+53T>A::,AGL:ENST00000370163:intron_variant:MODIFIER:exon28/33:c.3836+53T>A::,AGL:ENST00000370165:intron_variant:MODIFIER:exon28/33:c.3836+53T>A::	610860 [AGL (confirmed) Glycogen storage disease IIIa,232400/Glycogen storage disease IIIb,232400];				rs1541041	0.4599	0.4749	3475,			0.4470			0.00,0.12	0.03						n/a (AF>5%)	n/a (AF>5%)					AGL (inh=AR pLI=0.00)
chr1	100387479	100387479	G	T	wt	wt	het		QUAL=1096;DP=306,96,85;AF=0.00,0.00,0.52;MQM=60	AGL	3'UTR	AGL:ENST00000294724:3_prime_UTR_variant:MODIFIER:exon34/34:c.*272G>T::,AGL:ENST00000361302:3_prime_UTR_variant:MODIFIER:exon34/34:c.*272G>T::,AGL:ENST00000361522:3_prime_UTR_variant:MODIFIER:exon32/32:c.*272G>T::,AGL:ENST00000361915:3_prime_UTR_variant:MODIFIER:exon34/34:c.*272G>T::,AGL:ENST00000370161:3_prime_UTR_variant:MODIFIER:exon33/33:c.*272G>T::,AGL:ENST00000370163:3_prime_UTR_variant:MODIFIER:exon34/34:c.*272G>T::,AGL:ENST00000370165:3_prime_UTR_variant:MODIFIER:exon34/34:c.*272G>T::	610860 [AGL (confirmed) Glycogen storage disease IIIa,232400/Glycogen storage disease IIIb,232400];	291351 [benign DISEASE=Glycogen storage disease type III];			rs1804808	0.3321	0.3325	1974,			0.1010			0.02,0.18	-0.02						n/a (AF>5%)	n/a (AF>5%)					AGL (inh=AR pLI=0.00)
chr1	100387939	100387939	C	T	het	het	hom		QUAL=4301;DP=173,53,41;AF=0.49,0.45,1.00;MQM=59	AGL	3'UTR	AGL:ENST00000294724:3_prime_UTR_variant:MODIFIER:exon34/34:c.*732C>T::,AGL:ENST00000361302:3_prime_UTR_variant:MODIFIER:exon34/34:c.*732C>T::,AGL:ENST00000361522:3_prime_UTR_variant:MODIFIER:exon32/32:c.*732C>T::,AGL:ENST00000361915:3_prime_UTR_variant:MODIFIER:exon34/34:c.*732C>T::,AGL:ENST00000370161:3_prime_UTR_variant:MODIFIER:exon33/33:c.*732C>T::,AGL:ENST00000370163:3_prime_UTR_variant:MODIFIER:exon34/34:c.*732C>T::,AGL:ENST00000370165:3_prime_UTR_variant:MODIFIER:exon34/34:c.*732C>T::	610860 [AGL (confirmed) Glycogen storage disease IIIa,232400/Glycogen storage disease IIIb,232400];	291359 [benign DISEASE=Glycogen storage disease type III];			rs3766600	0.5905	0.6320	6163,			1.0200			0.00,0.11	-0.02						n/a (AF>5%)	n/a (AF>5%)					AGL (inh=AR pLI=0.00)
chr1	100388235	100388235	C	T	wt	wt	het		QUAL=258;DP=191,62,42;AF=0.01,0.00,0.38;MQM=60	AGL	3'UTR	AGL:ENST00000294724:3_prime_UTR_variant:MODIFIER:exon34/34:c.*1028C>T::,AGL:ENST00000361302:3_prime_UTR_variant:MODIFIER:exon34/34:c.*1028C>T::,AGL:ENST00000361522:3_prime_UTR_variant:MODIFIER:exon32/32:c.*1028C>T::,AGL:ENST00000361915:3_prime_UTR_variant:MODIFIER:exon34/34:c.*1028C>T::,AGL:ENST00000370161:3_prime_UTR_variant:MODIFIER:exon33/33:c.*1028C>T::,AGL:ENST00000370163:3_prime_UTR_variant:MODIFIER:exon34/34:c.*1028C>T::,AGL:ENST00000370165:3_prime_UTR_variant:MODIFIER:exon34/34:c.*1028C>T::	610860 [AGL (confirmed) Glycogen storage disease IIIa,232400/Glycogen storage disease IIIb,232400];	291363 [benign DISEASE=Glycogen storage disease type III];			rs3766601	0.4683	0.4865	3672,			1.1110			0.00,0.06	0.03						n/a (AF>5%)	n/a (AF>5%)					AGL (inh=AR pLI=0.00)
chr1	100388503	100388503	A	C	wt	wt	het		QUAL=894;DP=222,69,61;AF=0.00,0.00,0.57;MQM=60	AGL	3'UTR	AGL:ENST00000294724:3_prime_UTR_variant:MODIFIER:exon34/34:c.*1296A>C::,AGL:ENST00000361302:3_prime_UTR_variant:MODIFIER:exon34/34:c.*1296A>C::,AGL:ENST00000361522:3_prime_UTR_variant:MODIFIER:exon32/32:c.*1296A>C::,AGL:ENST00000361915:3_prime_UTR_variant:MODIFIER:exon34/34:c.*1296A>C::,AGL:ENST00000370161:3_prime_UTR_variant:MODIFIER:exon33/33:c.*1296A>C::,AGL:ENST00000370163:3_prime_UTR_variant:MODIFIER:exon34/34:c.*1296A>C::,AGL:ENST00000370165:3_prime_UTR_variant:MODIFIER:exon34/34:c.*1296A>C::	610860 [AGL (confirmed) Glycogen storage disease IIIa,232400/Glycogen storage disease IIIb,232400];	291368 [benign DISEASE=Glycogen storage disease type III];			rs1804809	0.3758	0.3832	2423,			0.3860			0.07,0.13	-0.11						n/a (AF>5%)	n/a (AF>5%)					AGL (inh=AR pLI=0.00)
chr1	100388748	100388748	T	C	wt	wt	het		QUAL=1706;DP=267,168,123;AF=0.00,0.01,0.54;MQM=60	AGL	3'UTR	AGL:ENST00000294724:3_prime_UTR_variant:MODIFIER:exon34/34:c.*1541T>C::,AGL:ENST00000361302:3_prime_UTR_variant:MODIFIER:exon34/34:c.*1541T>C::,AGL:ENST00000361522:3_prime_UTR_variant:MODIFIER:exon32/32:c.*1541T>C::,AGL:ENST00000361915:3_prime_UTR_variant:MODIFIER:exon34/34:c.*1541T>C::,AGL:ENST00000370161:3_prime_UTR_variant:MODIFIER:exon33/33:c.*1541T>C::,AGL:ENST00000370163:3_prime_UTR_variant:MODIFIER:exon34/34:c.*1541T>C::,AGL:ENST00000370165:3_prime_UTR_variant:MODIFIER:exon34/34:c.*1541T>C::	610860 [AGL (confirmed) Glycogen storage disease IIIa,232400/Glycogen storage disease IIIb,232400];	291369 [benign DISEASE=Glycogen storage disease type III];			rs3766603	0.4018	0.4069	2585,			-1.4470			0.00,0.09	-0.02						n/a (AF>5%)	n/a (AF>5%)					AGL (inh=AR pLI=0.00)
chr1	100652729	100652729	G	A	wt	wt	het		QUAL=321;DP=111,41,38;AF=0.00,0.02,0.42;MQM=60	DBT	3'UTR	DBT:ENST00000370132:3_prime_UTR_variant:MODIFIER:exon11/11:c.*9082C>T::	248610 [DBT (confirmed) Maple syrup urine disease,type II,248600];	291375 [likely benign DISEASE=Maple syrup urine disease];			rs72728160	0.0577	0.1177	278,			0.3270			0.15,0.62	0.26						n/a (AF>5%)	n/a (AF>5%)					DBT (inh=AR pLI=0.00)
chr1	100653257	100653257	T	-	het	het	het		QUAL=151;DP=17,10,7;AF=0.35,0.30,0.29;MQM=59	DBT	3'UTR	DBT:ENST00000370132:3_prime_UTR_variant:MODIFIER:exon11/11:c.*8554del::	248610 [DBT (confirmed) Maple syrup urine disease,type II,248600];			AluJb			0.0160	0,			-1.4320				-0.17						4	9					DBT (inh=AR pLI=0.00)
chr1	100654908	100654908	A	-	het	hom	wt		QUAL=985;DP=42,1,8;AF=0.86,1.00,0.38;MQM=56	DBT	3'UTR	DBT:ENST00000370132:3_prime_UTR_variant:MODIFIER:exon11/11:c.*6903del::	248610 [DBT (confirmed) Maple syrup urine disease,type II,248600];	291391 [uncertain significance DISEASE=Maple syrup urine disease];		AluSz	rs886044943		0.7975	8128,			0.0000				-0.24						n/a (AF>5%)	n/a (AF>5%)					DBT (inh=AR pLI=0.00)
chr1	100654908	100654908	A	T	het	wt	hom		QUAL=985;DP=42,1,8;AF=0.86,1.00,0.38;MQM=58	DBT	3'UTR	DBT:ENST00000370132:3_prime_UTR_variant:MODIFIER:exon11/11:c.*6903T>A::	248610 [DBT (confirmed) Maple syrup urine disease,type II,248600];	291392 [benign DISEASE=Maple syrup urine disease];		AluSz	rs10783125	0.9339	0.1288	343,			0.0000			0.01,0.09	-0.06						n/a (AF>5%)	n/a (AF>5%)					DBT (inh=AR pLI=0.00)
chr1	100654909	100654909	A	T	het	hom	wt		QUAL=985;DP=42,1,8;AF=0.86,1.00,0.38;MQM=56	DBT	3'UTR	DBT:ENST00000370132:3_prime_UTR_variant:MODIFIER:exon11/11:c.*6902T>A::	248610 [DBT (confirmed) Maple syrup urine disease,type II,248600];			AluSz	rs200943386		0.7634	7413,			0.0000			0.01,0.09	-0.06						n/a (AF>5%)	n/a (AF>5%)					DBT (inh=AR pLI=0.00)
chr1	100655583	100655583	T	A	hom	hom	hom		QUAL=4321;DP=104,13,15;AF=1.00,1.00,1.00;MQM=59	DBT	3'UTR	DBT:ENST00000370132:3_prime_UTR_variant:MODIFIER:exon11/11:c.*6228A>T::	248610 [DBT (confirmed) Maple syrup urine disease,type II,248600];	291395 [benign DISEASE=Maple syrup urine disease];		MER3	rs4281338	0.7668	0.7571	9365,			-0.7070			0.01,0.07	-0.44						n/a (AF>5%)	n/a (AF>5%)					DBT (inh=AR pLI=0.00)
chr1	100655696	100655697	AA	-	het	het	wt		QUAL=3367;DP=176,89,57;AF=0.48,0.64,0.02;MQM=60	DBT	3'UTR	DBT:ENST00000370132:3_prime_UTR_variant:MODIFIER:exon11/11:c.*6114_*6115del::	248610 [DBT (confirmed) Maple syrup urine disease,type II,248600];	291396 [uncertain significance DISEASE=Maple syrup urine disease];		MLT1J2	rs3081711		0.1787	602,			0.5040				0.01						n/a (AF>5%)	n/a (AF>5%)					DBT (inh=AR pLI=0.00)
chr1	100656265	100656265	C	T	hom	hom	hom		QUAL=13984;DP=174,140,105;AF=0.99,1.00,1.00;MQM=60	DBT	3'UTR	DBT:ENST00000370132:3_prime_UTR_variant:MODIFIER:exon11/11:c.*5546G>A::	248610 [DBT (confirmed) Maple syrup urine disease,type II,248600];	291404 [benign DISEASE=Maple syrup urine disease];			rs11166412	0.8007	0.7965	10120,			-0.8580			0.00,0.07	-0.22						n/a (AF>5%)	n/a (AF>5%)					DBT (inh=AR pLI=0.00)
chr1	100656494	100656494	A	G	wt	wt	het		QUAL=1899;DP=403,261,187;AF=0.00,0.00,0.43;MQM=60	DBT	3'UTR	DBT:ENST00000370132:3_prime_UTR_variant:MODIFIER:exon11/11:c.*5317T>C::	248610 [DBT (confirmed) Maple syrup urine disease,type II,248600];	291406 [benign DISEASE=Maple syrup urine disease];			rs11166413	0.2638	0.3105	1848,			0.7090			0.03,0.11	-0.07						n/a (AF>5%)	n/a (AF>5%)					DBT (inh=AR pLI=0.00)
chr1	100656661	100656661	T	C	hom	hom	hom		QUAL=24029;DP=361,208,156;AF=1.00,1.00,1.00;MQM=60	DBT	3'UTR	DBT:ENST00000370132:3_prime_UTR_variant:MODIFIER:exon11/11:c.*5150A>G::	248610 [DBT (confirmed) Maple syrup urine disease,type II,248600];	291407 [benign DISEASE=Maple syrup urine disease];			rs6701655	0.7696	0.7585	9392,			0.1170			0.01,0.11	0.06						n/a (AF>5%)	n/a (AF>5%)					DBT (inh=AR pLI=0.00)
chr1	100657304	100657331	ATACACACACACACACACACACACACAC	-	het	het	hom		QUAL=1725;DP=28,52,25;AF=0.25,0.54,0.04;MQM=58	DBT	3'UTR	DBT:ENST00000370132:3_prime_UTR_variant:MODIFIER:exon11/11:c.*4480_*4507del::	248610 [DBT (confirmed) Maple syrup urine disease,type II,248600];			(AC)n	rs140341302		0.6569	6192,			0.6450				-0.32						n/a (AF>5%)	n/a (AF>5%)					DBT (inh=AR pLI=0.00)
chr1	100657304	100657329	ATACACACACACACACACACACACAC	-	het	het	wt		QUAL=1725;DP=28,52,25;AF=0.46,0.38,0.80;MQM=57	DBT	3'UTR	DBT:ENST00000370132:3_prime_UTR_variant:MODIFIER:exon11/11:c.*4482_*4507del::	248610 [DBT (confirmed) Maple syrup urine disease,type II,248600];			(AC)n			0.0484	92,			0.6450				-0.31						2	9					DBT (inh=AR pLI=0.00)
chr1	100658578	100658578	G	A	hom	hom	hom		QUAL=34879;DP=344,479,323;AF=0.98,1.00,1.00;MQM=60	DBT	3'UTR	DBT:ENST00000370132:3_prime_UTR_variant:MODIFIER:exon11/11:c.*3233C>T::	248610 [DBT (confirmed) Maple syrup urine disease,type II,248600];	291424 [benign DISEASE=Maple syrup urine disease];			rs2784174	0.7696	0.7586	9390,			0.1820			0.01,0.11	-0.08						n/a (AF>5%)	n/a (AF>5%)					DBT (inh=AR pLI=0.00)
chr1	100671866	100671866	T	A	wt	wt	het		QUAL=781;DP=282,111,76;AF=0.01,0.00,0.49;MQM=60	DBT	intron	DBT:ENST00000370132:intron_variant:MODIFIER:exon9/10:c.1210-9A>T::	248610 [DBT (confirmed) Maple syrup urine disease,type II,248600];	93987 [benign DISEASE=Maple syrup urine disease,not specified];			rs34229137	0.2687	0.4006	1533,	0.1855,0.4511,0.3301,0.4137,0.3894	0.2080,0.0535	0.7540			0.00,0.16	0.05		+22.46% (6.04>7.40)		0.000/0.000		n/a (AF>5%)	n/a (AF>5%)					DBT (inh=AR pLI=0.00)
chr1	100672060	100672060	T	C	hom	hom	hom		QUAL=28889;DP=343,301,245;AF=1.00,1.00,1.00;MQM=60	DBT	missense	DBT:ENST00000370132:missense_variant:MODERATE:exon9/11:c.1150A>G:p.Ser384Gly:PF00198	248610 [DBT (confirmed) Maple syrup urine disease,type II,248600];	128885 [benign DISEASE=not specified];			rs12021720	0.8918	0.9179	12113,	0.7639,0.9548,0.9705,0.9081,0.9522	0.9024,0.7749	1.9050	T	B	0.02,0.23	1.17	0.12					n/a (AF>5%)	n/a (AF>5%)					DBT (inh=AR pLI=0.00)
chr1	100680593	100680593	-	T	het	het	het	off-target	QUAL=1296;DP=89,24,23;AF=0.57,0.63,0.52;MQM=60	DBT	intron	DBT:ENST00000370131:intron_variant:MODIFIER:exon6/7:c.773-55dup::,DBT:ENST00000370132:intron_variant:MODIFIER:exon6/10:c.773-55dup::	248610 [DBT (confirmed) Maple syrup urine disease,type II,248600];				rs11431894	0.5012	0.7462	7035,							-0.13						n/a (AF>5%)	n/a (AF>5%)					DBT (inh=AR pLI=0.00)
chr1	100715454	100715454	G	A	hom	hom	hom	off-target	QUAL=13099;DP=53,283,195;AF=0.98,1.00,0.99;MQM=60	DBT,RP11-305E17.4	upstream_gene,downstream_gene	DBT:ENST00000370131:upstream_gene_variant:MODIFIER::::,DBT:ENST00000370132:upstream_gene_variant:MODIFIER::::,RP11-305E17.4:ENST00000435545:downstream_gene_variant:MODIFIER::::,RP11-305E17.4:ENST00000595511:downstream_gene_variant:MODIFIER::::					rs3806235	0.7250	0.7285	8932,			-1.2120			0.01,0.42	0.08						n/a (AF>5%)	n/a (AF>5%)					DBT (inh=AR pLI=0.00), RP11-305E17.4 (inh=n/a pLI=n/a)
chr1	109771063	109771063	T	C	hom	hom	hom		QUAL=21702;DP=237,230,204;AF=1.00,1.00,1.00;MQM=60	SARS	intron	SARS:ENST00000234677:intron_variant:MODIFIER:exon3/10:c.288+9T>C::,SARS:ENST00000369923:intron_variant:MODIFIER:exon3/11:c.288+9T>C::	607529 [SARS (provisional) Neurodevelopmental disorder with microcephaly,ataxia,and seizures,617709];				rs683182	0.6799	0.7678	8061,	0.4622,0.8115,0.8978,0.7962,0.6577	0.7957,0.4889	-0.8580			0.04,0.16	-0.22						n/a (AF>5%)	n/a (AF>5%)					SARS (inh=n/a pLI=1.00)
chr1	109778577	109778577	T	C	hom	hom	hom	off-target	QUAL=18695;DP=177,263,160;AF=1.00,1.00,1.00;MQM=60	SARS	intron	SARS:ENST00000234677:intron_variant:MODIFIER:exon7/10:c.970-22T>C::,SARS:ENST00000369923:intron_variant:MODIFIER:exon7/11:c.970-22T>C::	607529 [SARS (provisional) Neurodevelopmental disorder with microcephaly,ataxia,and seizures,617709];				rs658092	0.6893	0.7689	8145,	0.4847,0.8138,0.8974,0.7963,0.6583	0.7956,0.5107	0.8080			0.02,0.33	0.64						n/a (AF>5%)	n/a (AF>5%)					SARS (inh=n/a pLI=1.00)
chr1	110709719	110709719	T	C	het	hom	het		QUAL=19091;DP=263,392,332;AF=0.46,1.00,0.54;MQM=60	SLC6A17,RP5-1028L10.1	synonymous,non_coding_transcript_exon	SLC6A17:ENST00000331565:synonymous_variant:LOW:exon2/12:c.168T>C:p.Asp56=:,RP5-1028L10.1:ENST00000418579:non_coding_transcript_exon_variant:MODIFIER:exon2/2:n.168A>G::,RP5-1028L10.1:ENST00000430098:non_coding_transcript_exon_variant:MODIFIER:exon1/2:n.87A>G::,RP5-1028L10.1:ENST00000443008:non_coding_transcript_exon_variant:MODIFIER:exon2/2:n.507A>G::	610299 [SLC6A17 (provisional) Mental retardation,autosomal recessive 48,616269];				rs7527375	0.3930	0.5129	3983,	0.5052,0.2621,0.2118,0.5323,0.3638	0.5255,0.5125	-5.4670			0.02,0.13	0.45						n/a (AF>5%)	n/a (AF>5%)					SLC6A17 (inh=AR pLI=1.00), RP5-1028L10.1 (inh=n/a pLI=n/a)
chr1	110709720	110709720	G	A	het	hom	wt		QUAL=19091;DP=263,392,332;AF=0.46,1.00,0.54;MQM=60	SLC6A17,RP5-1028L10.1	missense,non_coding_transcript_exon	SLC6A17:ENST00000331565:missense_variant:MODERATE:exon2/12:c.169G>A:p.Ala57Thr:,RP5-1028L10.1:ENST00000418579:non_coding_transcript_exon_variant:MODIFIER:exon2/2:n.167C>T::,RP5-1028L10.1:ENST00000430098:non_coding_transcript_exon_variant:MODIFIER:exon1/2:n.86C>T::,RP5-1028L10.1:ENST00000443008:non_coding_transcript_exon_variant:MODIFIER:exon2/2:n.506C>T::	610299 [SLC6A17 (provisional) Mental retardation,autosomal recessive 48,616269];				rs12737742	0.2502	0.3744	2326,	0.0863,0.2107,0.2111,0.4562,0.3461	0.4455,0.1083	0.5370	T, , , 	B, , , 	0.14,0.32	0.98	0.08					n/a (AF>5%)	n/a (AF>5%)					SLC6A17 (inh=AR pLI=1.00), RP5-1028L10.1 (inh=n/a pLI=n/a)
chr1	110709734	110709734	G	A	wt	wt	het		QUAL=4220;DP=250,375,314;AF=0.00,0.00,0.55;MQM=60	SLC6A17,RP5-1028L10.1	synonymous,non_coding_transcript_exon	SLC6A17:ENST00000331565:synonymous_variant:LOW:exon2/12:c.183G>A:p.Pro61=:PF00209,RP5-1028L10.1:ENST00000418579:non_coding_transcript_exon_variant:MODIFIER:exon2/2:n.153C>T::,RP5-1028L10.1:ENST00000430098:non_coding_transcript_exon_variant:MODIFIER:exon1/2:n.72C>T::,RP5-1028L10.1:ENST00000443008:non_coding_transcript_exon_variant:MODIFIER:exon2/2:n.492C>T::	610299 [SLC6A17 (provisional) Mental retardation,autosomal recessive 48,616269];				rs41281364	0.0389	0.0557	58,	0.0527,0.0339,0.0001,0.0742,0.0145	0.0715,0.0497	-3.2570			0.03,0.14	0.55						n/a (AF>5%)	n/a (AF>5%)					SLC6A17 (inh=AR pLI=1.00), RP5-1028L10.1 (inh=n/a pLI=n/a)
chr1	110738296	110738296	G	A	het	het	het		QUAL=16370;DP=298,547,384;AF=0.50,0.53,0.53;MQM=60	SLC6A17	synonymous	SLC6A17:ENST00000331565:synonymous_variant:LOW:exon10/12:c.1581G>A:p.Ser527=:PF00209	610299 [SLC6A17 (provisional) Mental retardation,autosomal recessive 48,616269];				rs2784140	0.2897	0.4178	2723,	0.0952,0.3304,0.2733,0.4963,0.3919	0.4972,0.1146	-1.7640			0.08,0.67	0.51						n/a (AF>5%)	n/a (AF>5%)					SLC6A17 (inh=AR pLI=1.00)
chr1	110740273	110740273	G	T	het	het	het	off-target	QUAL=4588;DP=239,72,57;AF=0.54,0.58,0.40;MQM=60	SLC6A17	intron	SLC6A17:ENST00000331565:intron_variant:MODIFIER:exon11/11:c.1815+52G>T::	610299 [SLC6A17 (provisional) Mental retardation,autosomal recessive 48,616269];				rs2603581	0.3165	0.4161	2822,	0.1789,0.3324,0.2727,0.4941,0.3919	0.4905,0.1858	-0.2040			0.00,0.06	0.11						n/a (AF>5%)	n/a (AF>5%)					SLC6A17 (inh=AR pLI=1.00)
chr1	110740688	110740688	C	T	het	het	het	off-target	QUAL=8841;DP=180,331,258;AF=0.47,0.47,0.50;MQM=60	SLC6A17	intron	SLC6A17:ENST00000331565:intron_variant:MODIFIER:exon11/11:c.1816-10C>T::	610299 [SLC6A17 (provisional) Mental retardation,autosomal recessive 48,616269];				rs2761445	0.3195	0.4276	2898,	0.1809,0.3386,0.2744,0.5056,0.3994	0.5055,0.1888	-0.2780			0.01,0.14	0.11		+9.84% (0.77>0.84)		0.000/		n/a (AF>5%)	n/a (AF>5%)					SLC6A17 (inh=AR pLI=1.00)
chr1	110741081	110741081	C	G	het	wt	het		QUAL=2476;DP=139,160,119;AF=0.50,0.01,0.34;MQM=59	SLC6A17	3'UTR	SLC6A17:ENST00000331565:3_prime_UTR_variant:MODIFIER:exon12/12:c.*15C>G::	610299 [SLC6A17 (provisional) Mental retardation,autosomal recessive 48,616269];				rs2761446	0.0170	0.0367	27,	0.0068,0.0140,0.0000,0.0517,0.0312	0.0486,0.0084	0.1420			0.22,0.37	0.31						21	412					SLC6A17 (inh=AR pLI=1.00)
chr1	110741086	110741086	C	T	wt	wt	het		QUAL=1786;DP=137,207,140;AF=0.00,0.00,0.54;MQM=60	SLC6A17	3'UTR	SLC6A17:ENST00000331565:3_prime_UTR_variant:MODIFIER:exon12/12:c.*20C>T::	610299 [SLC6A17 (provisional) Mental retardation,autosomal recessive 48,616269];				rs41306175	0.0497	0.0809	94,	0.0838,0.0446,0.0044,0.1069,0.0163	0.0977,0.0786	-2.8590			0.03,0.27	0.21						n/a (AF>5%)	n/a (AF>5%)					SLC6A17 (inh=AR pLI=1.00)
chr1	110741349	110741349	G	T	het	het	hom		QUAL=17081;DP=364,332,272;AF=0.46,0.57,1.00;MQM=59	SLC6A17	3'UTR	SLC6A17:ENST00000331565:3_prime_UTR_variant:MODIFIER:exon12/12:c.*283G>T::	610299 [SLC6A17 (provisional) Mental retardation,autosomal recessive 48,616269];				rs2603580	0.5425	0.6453	6612,			-0.1760			0.00,0.05	-0.29						n/a (AF>5%)	n/a (AF>5%)					SLC6A17 (inh=AR pLI=1.00)
chr1	110741583	110741583	C	G	het	het	hom		QUAL=10074;DP=169,215,176;AF=0.39,0.53,1.00;MQM=60	SLC6A17	3'UTR	SLC6A17:ENST00000331565:3_prime_UTR_variant:MODIFIER:exon12/12:c.*517C>G::	610299 [SLC6A17 (provisional) Mental retardation,autosomal recessive 48,616269];				rs2784141	0.5447	0.6452	6608,			-1.4930			0.00,0.06	-0.23						n/a (AF>5%)	n/a (AF>5%)					SLC6A17 (inh=AR pLI=1.00)
chr1	110742085	110742085	T	C	het	het	hom		QUAL=27431;DP=287,681,503;AF=0.44,0.49,1.00;MQM=59	SLC6A17	3'UTR	SLC6A17:ENST00000331565:3_prime_UTR_variant:MODIFIER:exon12/12:c.*1019T>C::	610299 [SLC6A17 (provisional) Mental retardation,autosomal recessive 48,616269];				rs2603579	0.5449	0.6462	6623,			0.6680			0.35,0.79	0.48						n/a (AF>5%)	n/a (AF>5%)					SLC6A17 (inh=AR pLI=1.00)
chr1	110742502	110742502	A	G	het	het	het		QUAL=1526;DP=166,104,83;AF=0.31,0.26,0.25;MQM=58	SLC6A17	3'UTR	SLC6A17:ENST00000331565:3_prime_UTR_variant:MODIFIER:exon12/12:c.*1436A>G::	610299 [SLC6A17 (provisional) Mental retardation,autosomal recessive 48,616269];			(GATG)n	rs2361044	0.2883	0.3756	2053,			-0.8410			0.00,0.06	-0.61						n/a (AF>5%)	n/a (AF>5%)					SLC6A17 (inh=AR pLI=1.00)
chr1	110742615	110742615	A	G	het	het	het		QUAL=2483;DP=124,106,70;AF=0.42,0.43,0.34;MQM=60	SLC6A17	3'UTR	SLC6A17:ENST00000331565:3_prime_UTR_variant:MODIFIER:exon12/12:c.*1549A>G::	610299 [SLC6A17 (provisional) Mental retardation,autosomal recessive 48,616269];			GA-rich	rs12133992	0.2867	0.3672	2497,			0.2940			0.01,0.18	0.04						n/a (AF>5%)	n/a (AF>5%)					SLC6A17 (inh=AR pLI=1.00)
chr1	110742992	110742992	T	G	het	het	het		QUAL=7229;DP=175,269,181;AF=0.51,0.45,0.52;MQM=60	SLC6A17	3'UTR	SLC6A17:ENST00000331565:3_prime_UTR_variant:MODIFIER:exon12/12:c.*1926T>G::	610299 [SLC6A17 (provisional) Mental retardation,autosomal recessive 48,616269];				rs2784142	0.3079	0.3952	2778,			1.1030			0.00,0.08	-0.03						n/a (AF>5%)	n/a (AF>5%)					SLC6A17 (inh=AR pLI=1.00)
chr1	110743588	110743588	G	C	het	het	wt		QUAL=8342;DP=163,474,387;AF=0.53,0.52,0.00;MQM=60	SLC6A17	3'UTR	SLC6A17:ENST00000331565:3_prime_UTR_variant:MODIFIER:exon12/12:c.*2522G>C::	610299 [SLC6A17 (provisional) Mental retardation,autosomal recessive 48,616269];				rs151008748	0.0132	0.0218	14,			-0.6950			0.03,0.15	0.37						1	10					SLC6A17 (inh=AR pLI=1.00)
chr1	110743835	110743835	G	A	wt	wt	het		QUAL=2274;DP=220,184,164;AF=0.00,0.00,0.54;MQM=60	SLC6A17	3'UTR	SLC6A17:ENST00000331565:3_prime_UTR_variant:MODIFIER:exon12/12:c.*2769G>A::	610299 [SLC6A17 (provisional) Mental retardation,autosomal recessive 48,616269];				rs12138403	0.0491	0.0808	98,			0.1620			0.02,0.14	-0.06						n/a (AF>5%)	n/a (AF>5%)					SLC6A17 (inh=AR pLI=1.00)
chr1	110744181	110744181	C	T	wt	wt	het		QUAL=1082;DP=98,124,96;AF=0.01,0.00,0.46;MQM=60	SLC6A17	3'UTR	SLC6A17:ENST00000331565:3_prime_UTR_variant:MODIFIER:exon12/12:c.*3115C>T::	610299 [SLC6A17 (provisional) Mental retardation,autosomal recessive 48,616269];				rs62621393	0.0491	0.0808	98,			-4.4330			0.00,0.10	-0.40						n/a (AF>5%)	n/a (AF>5%)					SLC6A17 (inh=AR pLI=1.00)
chr1	110744874	110744874	G	A	wt	het	wt	off-target	QUAL=1733;DP=61,162,111;AF=0.00,0.46,0.00;MQM=60	SLC6A17	downstream_gene	SLC6A17:ENST00000331565:downstream_gene_variant:MODIFIER::::					rs45445195	0.0138	0.0189	10,			-0.8180			0.00,0.08	-0.24						1	9					SLC6A17 (inh=AR pLI=1.00)
chr1	115247750	115247750	A	-	wt	wt	het		QUAL=984;DP=201,113,75;AF=0.00,0.01,0.59;MQM=60	NRAS	3'UTR	NRAS:ENST00000369535:3_prime_UTR_variant:MODIFIER:exon7/7:c.*2965del::	164790 [NRAS (confirmed) RAS-associated autoimmune lymphoproliferative syndrome type IV,somatic,614470/Noonan syndrome 6,613224/Epidermal nevus,somatic,162900/Thyroid carcinoma,follicular,somatic,188470/Colorectal cancer,somatic,114500/Melanocytic nevus syndrome,congenital,somatic,137550/Neurocutaneous melanosis,somatic,249400/Schimmelpenning-Feuerstein-Mims syndrome,somatic mosaic,163200];	291946 [likely benign DISEASE=Noonan syndrome];			rs61652108	0.1518	0.2080	778,			-0.3110				0.43						n/a (AF>5%)	n/a (AF>5%)					NRAS (inh=AD pLI=0.90)
chr1	115249843	115249843	G	A	wt	wt	het		QUAL=1560;DP=407,196,125;AF=0.00,0.01,0.51;MQM=60	NRAS	3'UTR	NRAS:ENST00000369535:3_prime_UTR_variant:MODIFIER:exon7/7:c.*872C>T::	164790 [NRAS (confirmed) RAS-associated autoimmune lymphoproliferative syndrome type IV,somatic,614470/Noonan syndrome 6,613224/Epidermal nevus,somatic,162900/Thyroid carcinoma,follicular,somatic,188470/Colorectal cancer,somatic,114500/Melanocytic nevus syndrome,congenital,somatic,137550/Neurocutaneous melanosis,somatic,249400/Schimmelpenning-Feuerstein-Mims syndrome,somatic mosaic,163200];	291967 [likely benign DISEASE=Noonan syndrome];			rs14804	0.1510	0.2077	773,			0.3800			0.00,0.06	0.08						n/a (AF>5%)	n/a (AF>5%)					NRAS (inh=AD pLI=0.90)
chr1	115259401	115259401	C	T	het	het	wt		QUAL=3646;DP=183,129,111;AF=0.60,0.38,0.00;MQM=60	NRAS	5'UTR	NRAS:ENST00000369535:5_prime_UTR_variant:MODIFIER:exon1/7:c.-140G>A::	164790 [NRAS (confirmed) RAS-associated autoimmune lymphoproliferative syndrome type IV,somatic,614470/Noonan syndrome 6,613224/Epidermal nevus,somatic,162900/Thyroid carcinoma,follicular,somatic,188470/Colorectal cancer,somatic,114500/Melanocytic nevus syndrome,congenital,somatic,137550/Neurocutaneous melanosis,somatic,249400/Schimmelpenning-Feuerstein-Mims syndrome,somatic mosaic,163200];										3.7740			0.91,0.81	2.63						0	2					NRAS (inh=AD pLI=0.90)
chr1	115572365	115572365	A	G	het	het	hom	off-target	QUAL=8224;DP=163,179,123;AF=0.48,0.48,1.00;MQM=60	TSHB	upstream_gene	TSHB:ENST00000256592:upstream_gene_variant:MODIFIER::::,TSHB:ENST00000369517:upstream_gene_variant:MODIFIER::::					rs1321108	0.3894	0.4257	2953,			1.2590			0.72,0.96	1.58						n/a (AF>5%)	n/a (AF>5%)					TSHB (inh=AR pLI=0.01)
chr1	115576023	115576023	A	G	hom	hom	hom		QUAL=17947;DP=261,149,135;AF=1.00,1.00,1.00;MQM=60	TSHB	missense	TSHB:ENST00000256592:missense_variant:MODERATE:exon2/3:c.40A>G:p.Thr14Ala:,TSHB:ENST00000369517:missense_variant:MODERATE:exon1/2:c.40A>G:p.Thr14Ala:	188540 [TSHB (confirmed) Hypothyroidism,congenital,nongoitrous 4,275100];	256640 [benign DISEASE=Congenital hypothyroidism,Secondary hypothyroidism,not specified];			rs10776792		0.9746	14700,	0.9946,0.9916,0.9999,0.9632,0.9612	0.9655,0.9943	0.2250	T,T	B,B	0.01,0.15	-0.46	0.05					n/a (AF>5%)	n/a (AF>5%)					TSHB (inh=AR pLI=0.01)
chr1	115829313	115829313	G	A	hom	hom	het		QUAL=20292;DP=187,390,277;AF=0.99,0.99,0.51;MQM=60	NGF,RP4-663N10.1	missense,intron&non_coding_transcript	NGF:ENST00000369512:missense_variant:MODERATE:exon3/3:c.104C>T:p.Ala35Val:,RP4-663N10.1:ENST00000425449:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.207+3452G>A::	162030 [NGF (confirmed) Neuropathy,hereditary sensory and autonomic,type V,608654];	291993 [benign DISEASE=Congenital sensory neuropathy with selective loss of small myelinated fibers];			rs6330	0.2474	0.3702	2360,	0.1859,0.3463,0.1628,0.4475,0.2347	0.4523,0.2068	2.2990	D, 	B, 	0.90,0.98	2.65	0.10					n/a (AF>5%)	n/a (AF>5%)					NGF (inh=AR pLI=0.69), RP4-663N10.1 (inh=n/a pLI=n/a)
chr1	119965519	119965519	C	T	het	het	wt		QUAL=10711;DP=464,355,297;AF=0.54,0.41,0.00;MQM=59	HSD3B2	3'UTR	HSD3B2:ENST00000369416:3_prime_UTR_variant:MODIFIER:exon4/4:c.*276C>T::,HSD3B2:ENST00000543831:3_prime_UTR_variant:MODIFIER:exon4/4:c.*276C>T::	613890 [HSD3B2 (confirmed) Adrenal hyperplasia,congenital,due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency,201810];	292274 [benign DISEASE=Congenital adrenal hyperplasia];			rs1819698	0.3101	0.2245	1231,			0.8090			0.00,0.03	0.04						n/a (AF>5%)	n/a (AF>5%)					HSD3B2 (inh=AR pLI=0.00)
chr1	119965564	119965564	C	G	het	het	wt		QUAL=10586;DP=435,356,291;AF=0.54,0.42,0.00;MQM=60	HSD3B2	3'UTR	HSD3B2:ENST00000369416:3_prime_UTR_variant:MODIFIER:exon4/4:c.*321C>G::,HSD3B2:ENST00000543831:3_prime_UTR_variant:MODIFIER:exon4/4:c.*321C>G::	613890 [HSD3B2 (confirmed) Adrenal hyperplasia,congenital,due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency,201810];	292275 [likely benign DISEASE=Congenital adrenal hyperplasia];			rs1361530	0.2560	0.1755	644,			-0.9650			0.01,0.09	0.08						n/a (AF>5%)	n/a (AF>5%)					HSD3B2 (inh=AR pLI=0.00)
chr1	147228529	147228529	G	A	wt	wt	het		QUAL=1650;DP=348,217,145;AF=0.00,0.00,0.46;MQM=60	GJA5	3'UTR	GJA5:ENST00000271348:3_prime_UTR_variant:MODIFIER:exon2/2:c.*1741C>T::	121013 [GJA5 (confirmed) Atrial fibrillation,familial,11,614049/Atrial standstill,digenic (GJA5/SCN5A),108770];						0.0001	0,			0.4560			0.08,0.32	0.35						0	2					GJA5 (inh=AD pLI=0.71)
chr1	147228874	147228874	C	T	het	wt	het		QUAL=6221;DP=267,301,193;AF=0.51,0.00,0.54;MQM=60	GJA5	3'UTR	GJA5:ENST00000271348:3_prime_UTR_variant:MODIFIER:exon2/2:c.*1396G>A::	121013 [GJA5 (confirmed) Atrial fibrillation,familial,11,614049/Atrial standstill,digenic (GJA5/SCN5A),108770];				rs11240121	0.4073	0.3022	1654,			-0.2330			0.00,0.09	0.18						n/a (AF>5%)	n/a (AF>5%)					GJA5 (inh=AD pLI=0.71)
chr1	147229299	147229299	G	A	hom	het	hom		QUAL=12826;DP=218,162,133;AF=1.00,0.50,1.00;MQM=59	GJA5	3'UTR	GJA5:ENST00000271348:3_prime_UTR_variant:MODIFIER:exon2/2:c.*971C>T::	121013 [GJA5 (confirmed) Atrial fibrillation,familial,11,614049/Atrial standstill,digenic (GJA5/SCN5A),108770];				rs1043806	0.8662	0.8007	9923,			0.7320			0.00,0.38	0.64						n/a (AF>5%)	n/a (AF>5%)					GJA5 (inh=AD pLI=0.71)
chr1	147229382	147229382	G	A	hom	hom	hom		QUAL=22625;DP=252,277,196;AF=1.00,1.00,1.00;MQM=60	GJA5	3'UTR	GJA5:ENST00000271348:3_prime_UTR_variant:MODIFIER:exon2/2:c.*888C>T::,GJA5:ENST00000369237:3_prime_UTR_variant:MODIFIER:exon2/2:c.*888C>T::	121013 [GJA5 (confirmed) Atrial fibrillation,familial,11,614049/Atrial standstill,digenic (GJA5/SCN5A),108770];				rs10900395	0.9886	0.9882	15120,			1.1850			0.00,0.11	0.22						n/a (AF>5%)	n/a (AF>5%)					GJA5 (inh=AD pLI=0.71)
chr1	147229563	147229563	G	A	het	wt	het		QUAL=7572;DP=353,383,318;AF=0.43,0.00,0.48;MQM=60	GJA5,RP11-433J22.2	3'UTR,non_coding_transcript_exon	GJA5:ENST00000271348:3_prime_UTR_variant:MODIFIER:exon2/2:c.*707C>T::,GJA5:ENST00000369237:3_prime_UTR_variant:MODIFIER:exon2/2:c.*707C>T::,RP11-433J22.2:ENST00000428911:non_coding_transcript_exon_variant:MODIFIER:exon1/2:n.138G>A::	121013 [GJA5 (confirmed) Atrial fibrillation,familial,11,614049/Atrial standstill,digenic (GJA5/SCN5A),108770];				rs1043802	0.3191	0.2518	1001,			0.3440			0.01,0.20	0.30						n/a (AF>5%)	n/a (AF>5%)					GJA5 (inh=AD pLI=0.71), RP11-433J22.2 (inh=n/a pLI=n/a)
chr1	147229628	147229628	-	GGGCATTTGCCAGAGGTACATACCA	het	het	het		QUAL=8541;DP=220,377,289;AF=0.27,0.46,0.44;MQM=60	GJA5,RP11-433J22.2	3'UTR,non_coding_transcript_exon	GJA5:ENST00000271348:3_prime_UTR_variant:MODIFIER:exon2/2:c.*617_*641dup::,GJA5:ENST00000369237:3_prime_UTR_variant:MODIFIER:exon2/2:c.*617_*641dup::,RP11-433J22.2:ENST00000428911:non_coding_transcript_exon_variant:MODIFIER:exon1/2:n.204_228dup::	121013 [GJA5 (confirmed) Atrial fibrillation,familial,11,614049/Atrial standstill,digenic (GJA5/SCN5A),108770];	292439 [likely benign DISEASE=Familial atrial fibrillation];			rs11267274	0.4667									0.08						n/a (AF>5%)	n/a (AF>5%)					GJA5 (inh=AD pLI=0.71), RP11-433J22.2 (inh=n/a pLI=n/a)
chr1	147229662	147229662	G	A	wt	het	wt		QUAL=5482;DP=438,519,384;AF=0.00,0.42,0.00;MQM=60	GJA5,RP11-433J22.2	3'UTR,non_coding_transcript_exon	GJA5:ENST00000271348:3_prime_UTR_variant:MODIFIER:exon2/2:c.*608C>T::,GJA5:ENST00000369237:3_prime_UTR_variant:MODIFIER:exon2/2:c.*608C>T::,RP11-433J22.2:ENST00000428911:non_coding_transcript_exon_variant:MODIFIER:exon1/2:n.237G>A::	121013 [GJA5 (confirmed) Atrial fibrillation,familial,11,614049/Atrial standstill,digenic (GJA5/SCN5A),108770];	292441 [likely benign DISEASE=Familial atrial fibrillation];			rs36005900	0.0675	0.1507	468,			0.4910			0.15,0.80	1.09						n/a (AF>5%)	n/a (AF>5%)					GJA5 (inh=AD pLI=0.71), RP11-433J22.2 (inh=n/a pLI=n/a)
chr1	147230217	147230217	T	C	hom	het	hom		QUAL=19585;DP=316,233,191;AF=1.00,0.54,0.99;MQM=60	GJA5,RP11-433J22.2	3'UTR,intron&non_coding_transcript	GJA5:ENST00000271348:3_prime_UTR_variant:MODIFIER:exon2/2:c.*53A>G::,GJA5:ENST00000369237:3_prime_UTR_variant:MODIFIER:exon2/2:c.*53A>G::,RP11-433J22.2:ENST00000428911:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.455-245T>C::	121013 [GJA5 (confirmed) Atrial fibrillation,familial,11,614049/Atrial standstill,digenic (GJA5/SCN5A),108770];				rs1692141	0.8804	0.8150	10292,			-0.1160			0.01,0.24	0.17						n/a (AF>5%)	n/a (AF>5%)					GJA5 (inh=AD pLI=0.71), RP11-433J22.2 (inh=n/a pLI=n/a)
chr1	147232555	147232555	T	C	hom	hom	hom	off-target	QUAL=16890;DP=151,240,159;AF=1.00,1.00,1.00;MQM=59	GJA5	intron	GJA5:ENST00000271348:intron_variant:MODIFIER:exon1/1:c.-33-1176A>G::,GJA5:ENST00000369237:intron_variant:MODIFIER:exon1/1:c.-34+52A>G::	121013 [GJA5 (confirmed) Atrial fibrillation,familial,11,614049/Atrial standstill,digenic (GJA5/SCN5A),108770];			L2c	rs791278	0.9852	0.9850	15025,			-1.3250			0.00,0.11	-0.09						n/a (AF>5%)	n/a (AF>5%)					GJA5 (inh=AD pLI=0.71)
chr1	147232646	147232646	G	A	wt	wt	het		QUAL=3094;DP=306,364,251;AF=0.00,0.00,0.52;MQM=60	GJA5	intron,5'UTR	GJA5:ENST00000271348:intron_variant:MODIFIER:exon1/1:c.-33-1267C>T::,GJA5:ENST00000369237:5_prime_UTR_variant:MODIFIER:exon1/2:c.-73C>T::	121013 [GJA5 (confirmed) Atrial fibrillation,familial,11,614049/Atrial standstill,digenic (GJA5/SCN5A),108770];			L2c	rs191717313	0.0004	0.0017	0,			-0.0120			0.03,0.19	0.72						0	5					GJA5 (inh=AD pLI=0.71)
chr1	147232740	147232740	C	T	het	het	het	off-target	QUAL=6564;DP=194,238,169;AF=0.50,0.41,0.44;MQM=60	GJA5	intron	GJA5:ENST00000271348:intron_variant:MODIFIER:exon1/1:c.-33-1361G>A::	121013 [GJA5 (confirmed) Atrial fibrillation,familial,11,614049/Atrial standstill,digenic (GJA5/SCN5A),108770];			L2c	rs10465885	0.5361	0.5477	4652,			-0.1700			0.02,0.18	-0.07						n/a (AF>5%)	n/a (AF>5%)					GJA5 (inh=AD pLI=0.71)
chr1	147245324	147245324	T	C	hom	hom	hom	off-target	QUAL=15883;DP=197,170,140;AF=1.00,1.00,1.00;MQM=60	GJA5	intron	GJA5:ENST00000271348:intron_variant:MODIFIER:exon1/1:c.-34+32A>G::	121013 [GJA5 (confirmed) Atrial fibrillation,familial,11,614049/Atrial standstill,digenic (GJA5/SCN5A),108770];				rs1692137	0.9748	0.9820	14933,			1.3810			0.10,0.15	0.11						n/a (AF>5%)	n/a (AF>5%)					GJA5 (inh=AD pLI=0.71)
chr1	147245474	147245474	G	C	hom	hom	hom		QUAL=20917;DP=216,279,183;AF=1.00,1.00,1.00;MQM=60	GJA5	5'UTR	GJA5:ENST00000271348:5_prime_UTR_variant:MODIFIER:exon1/2:c.-152C>G::	121013 [GJA5 (confirmed) Atrial fibrillation,familial,11,614049/Atrial standstill,digenic (GJA5/SCN5A),108770];	368828 [likely benign DISEASE=Familial atrial fibrillation];			rs791286		0.9821	14927,			0.7030			0.01,0.87	1.96						n/a (AF>5%)	n/a (AF>5%)					GJA5 (inh=AD pLI=0.71)
chr1	150771703	150771703	T	C	hom	hom	hom		QUAL=34879;DP=352,363,341;AF=1.00,1.00,1.00;MQM=60	CTSK	synonymous	CTSK:ENST00000271651:synonymous_variant:LOW:exon7/8:c.831A>G:p.Ala277=:PF00112	601105 [CTSK (provisional) Pycnodysostosis,265800];				rs10788796	0.9633	0.9900	14843,	0.9230,0.9932,0.9935,0.9988,0.9776	0.9986,0.9374	-6.7590			0.02,0.13	0.51						n/a (AF>5%)	n/a (AF>5%)					CTSK (inh=AR pLI=0.00)
chr1	151313774	151313774	A	G	het	wt	hom		QUAL=6567;DP=284,137,90;AF=0.49,0.01,1.00;MQM=60	RFX5,RP11-126K1.8	3'UTR,intron&non_coding_transcript	RFX5:ENST00000290524:3_prime_UTR_variant:MODIFIER:exon11/11:c.*888T>C::,RP11-126K1.8:ENST00000422153:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.255+396A>G::	601863 [RFX5 (confirmed) Bare lymphocyte syndrome,type II,complementation group C,209920/Bare lymphocyte syndrome,type II,complementation group E,209920];	292600 [benign DISEASE=Bare lymphocyte syndrome 2];			rs7552906	0.6280	0.6231	6021,			0.2260			0.07,0.13	0.24						n/a (AF>5%)	n/a (AF>5%)					RFX5 (inh=AR+AD pLI=0.00), RP11-126K1.8 (inh=n/a pLI=n/a)
chr1	151314379	151314379	T	C	het	het	hom		QUAL=8314;DP=199,158,114;AF=0.56,0.47,1.00;MQM=60	RFX5,RP11-126K1.8	3'UTR,non_coding_transcript_exon	RFX5:ENST00000290524:3_prime_UTR_variant:MODIFIER:exon11/11:c.*283A>G::,RFX5:ENST00000368870:3_prime_UTR_variant:MODIFIER:exon11/11:c.*283A>G::,RP11-126K1.8:ENST00000422153:non_coding_transcript_exon_variant:MODIFIER:exon2/2:n.295T>C::	601863 [RFX5 (confirmed) Bare lymphocyte syndrome,type II,complementation group C,209920/Bare lymphocyte syndrome,type II,complementation group E,209920];	292605 [benign DISEASE=Bare lymphocyte syndrome 2];		MLT1K	rs1752387	0.7644	0.7674	9123,			-1.3700			0.00,0.16	0.27						n/a (AF>5%)	n/a (AF>5%)					RFX5 (inh=AR+AD pLI=0.00), RP11-126K1.8 (inh=n/a pLI=n/a)
chr1	151315287	151315287	G	C	het	wt	het		QUAL=3180;DP=118,186,138;AF=0.49,0.00,0.51;MQM=60	RFX5	missense	RFX5:ENST00000290524:missense_variant:MODERATE:exon11/11:c.1226C>G:p.Pro409Arg:PF14621,RFX5:ENST00000368870:missense_variant:MODERATE:exon11/11:c.1226C>G:p.Pro409Arg:PF14621,RFX5:ENST00000452513:missense_variant:MODERATE:exon10/10:c.1106C>G:p.Pro369Arg:PF14621,RFX5:ENST00000452671:missense_variant:MODERATE:exon11/11:c.1226C>G:p.Pro409Arg:PF14621	601863 [RFX5 (confirmed) Bare lymphocyte syndrome,type II,complementation group C,209920/Bare lymphocyte syndrome,type II,complementation group E,209920];	292612 [benign/likely benign DISEASE=Bare lymphocyte syndrome 2,not specified];			rs2233854	0.0635	0.1178	288,	0.0250,0.0717,0.0004,0.1664,0.0992	0.1619,0.0350	1.7470	D,D,D,D	B,B,B,B	0.59,0.64	1.86	0.03					n/a (AF>5%)	n/a (AF>5%)					RFX5 (inh=AR+AD pLI=0.00)
chr1	151316161	151316161	G	A	hom	hom	hom		QUAL=13231;DP=187,132,94;AF=1.00,1.00,1.00;MQM=59	RFX5	synonymous	RFX5:ENST00000290524:synonymous_variant:LOW:exon9/11:c.753C>T:p.Leu251=:,RFX5:ENST00000368870:synonymous_variant:LOW:exon9/11:c.753C>T:p.Leu251=:,RFX5:ENST00000452513:synonymous_variant:LOW:exon8/10:c.633C>T:p.Leu211=:,RFX5:ENST00000452671:synonymous_variant:LOW:exon9/11:c.753C>T:p.Leu251=:	601863 [RFX5 (confirmed) Bare lymphocyte syndrome,type II,complementation group C,209920/Bare lymphocyte syndrome,type II,complementation group E,209920];	403373 [benign DISEASE=not specified];			rs1752386	0.9780	0.9947	14793,	0.9253,0.9963,1.0000,0.9999,0.9998	0.9998,0.9274	0.2350			0.18,0.34	1.02						n/a (AF>5%)	n/a (AF>5%)					RFX5 (inh=AR+AD pLI=0.00)
chr1	152274685	152274685	T	A	hom	hom	hom		QUAL=8564;DP=95,107,63;AF=1.00,1.00,1.00;MQM=60	FLG,FLG-AS1	3'UTR,intron&non_coding_transcript	FLG:ENST00000368799:3_prime_UTR_variant:MODIFIER:exon3/3:c.*491A>T::,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.462+376T>A::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.376+376T>A::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs1933061	0.9994	0.9979	15415,			-2.2810			0.00,0.16	0.02						n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152276149	152276149	C	T	het	het	het		QUAL=43834;DP=482,1876,1287;AF=0.49,0.51,0.50;MQM=59	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.11213G>A:p.Arg3738His:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.462+1840C>T::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.376+1840C>T::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs77422831	0.2869	0.2417	499,	0.0289,0.4289,0.5586,0.1413,0.3680	0.1442,0.0370	-2.2520	T, , 	B, , 	0.01,0.11	0.27	0.02					n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152276377	152276377	C	G	wt	het	het		QUAL=9996;DP=495,2043,1478;AF=0.05,0.31,0.19;MQM=28	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.10985G>C:p.Ser3662Thr:PF03516,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.462+2068C>G::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.376+2068C>G::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs75235053		0.0180	0,	0.0001,0.0299,0.0640,0.0038,0.0201		-0.7420	D, , 	P, , 	0.07,0.17	1.21	0.03					0	841					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152276459	152276459	C	T	wt	het	het		QUAL=17370;DP=413,2203,1555;AF=0.10,0.38,0.22;MQM=30	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.10903G>A:p.Asp3635Asn:PF03516,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.462+2150C>T::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.376+2150C>T::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs75448155		0.0944	0,	0.0096,0.1597,0.2770,0.0601,0.1446	0.1030,0.0268	1.6290	D, , 	D, , 	0.16,0.38	2.72	0.10					n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152276583	152276583	C	G	het	het	het		QUAL=11119;DP=350,632,899;AF=0.15,0.69,0.19;MQM=33	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.10779G>C:p.Glu3593Asp:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.462+2274C>G::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.376+2274C>G::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs12083389	0.3614	0.1565	363,	0.4037,0.1809,0.2768,0.0225,0.1261	0.0319,0.3795	0.3080	T, , 	B, , 	0.00,0.06	0.22	0.04					n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152276598	152276598	G	A	wt	hom	het		QUAL=11642;DP=376,429,810;AF=0.08,0.98,0.21;MQM=31	FLG,FLG-AS1	synonymous,intron&non_coding_transcript	FLG:ENST00000368799:synonymous_variant:LOW:exon3/3:c.10764C>T:p.His3588=:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.462+2289G>A::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.376+2289G>A::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs12742178	0.0887	0.0675	79,	0.0262,0.1394,0.3101,0.0135,0.1043		-2.1460			0.00,0.05	-0.47						n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152276626	152276626	G	C	het	hom	het		QUAL=6400;DP=435,318,759;AF=0.13,0.98,0.16;MQM=33	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.10736C>G:p.Thr3579Arg:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.462+2317G>C::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.376+2317G>C::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs3126075	0.4778	0.1878	918,	0.4809,0.1241,0.3161,0.0114,0.0772	0.0174,0.2548	-5.4480	T, , 	B, , 	0.00,0.05	-0.17	0.01					n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152276671	152276671	C	T	wt	het	het		QUAL=1712;DP=603,494,883;AF=0.10,0.26,0.13;MQM=44	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.10691G>A:p.Arg3564His:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.462+2362C>T::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.376+2362C>T::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs7518080	0.2564	0.0879	0,	0.2144,0.2033,0.3310,0.0229,0.1589		-1.3060	T, , 	B, , 	0.00,0.04	-0.30	0.01					n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152276699	152276699	A	G	het	het	het		QUAL=7952;DP=511,559,900;AF=0.26,0.55,0.14;MQM=35	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.10663T>C:p.Trp3555Arg:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.462+2390A>G::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.376+2390A>G::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs12728605		0.1255	4,	0.2432,0.2052,0.3011,0.0356,0.1825		-1.1810	T, , 	B, , 	0.00,0.03	0.03	0.01					n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152276772	152276772	C	A	het	het	het		QUAL=31917;DP=409,678,1143;AF=0.44,0.86,0.44;MQM=56	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.10590G>T:p.Arg3530Ser:PF03516,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.462+2463C>A::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.376+2463C>A::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs72697000	0.2905	0.2456	334,	0.0287,0.4316,0.5567,0.1438,0.3862	0.1470,0.0365	-5.0060	T, , 	D, , 	0.00,0.09	0.54	0.06					n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152276871	152276871	A	G	het	hom	het		QUAL=38334;DP=530,643,1130;AF=0.41,0.99,0.47;MQM=58	FLG,FLG-AS1	synonymous,intron&non_coding_transcript	FLG:ENST00000368799:synonymous_variant:LOW:exon3/3:c.10491T>C:p.Asp3497=:PF03516,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.462+2562A>G::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.376+2562A>G::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs3126066	0.4471	0.2818	1508,	0.4833,0.4537,0.5931,0.1460,0.3917	0.1485,0.4630	-3.4900			0.00,0.05	-0.16						n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152276889	152276889	A	G	het	hom	het		QUAL=37856;DP=532,634,1142;AF=0.41,0.99,0.46;MQM=58	FLG,FLG-AS1	synonymous,intron&non_coding_transcript	FLG:ENST00000368799:synonymous_variant:LOW:exon3/3:c.10473T>C:p.Asn3491=:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.462+2580A>G::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.376+2580A>G::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs3126067		0.3308	2658,	0.7195,0.4690,0.5952,0.1479,0.3924	0.1510,0.6891	-4.3620			0.00,0.05	0.10						n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152277055	152277055	C	G	het	hom	het		QUAL=26841;DP=476,535,854;AF=0.37,0.91,0.46;MQM=53	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.10307G>C:p.Gly3436Ala:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.462+2746C>G::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.376+2746C>G::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs2065955	0.5142	0.3215	2473,	0.7152,0.4654,0.5878,0.1458,0.3799	0.1505,0.6847	-0.5970	T, , 	P, , 	0.02,0.14	0.59	0.03					n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152277168	152277168	A	G	het	hom	het		QUAL=44831;DP=518,911,1063;AF=0.46,0.99,0.45;MQM=50	FLG,FLG-AS1	synonymous,intron&non_coding_transcript	FLG:ENST00000368799:synonymous_variant:LOW:exon3/3:c.10194T>C:p.Ser3398=:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.462+2859A>G::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.376+2859A>G::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs3091276	0.4736	0.2908	1652,	0.5239,0.4587,0.6013,0.1503,0.4064	0.1474,0.4877	-2.0220			0.00,0.08	-0.17						n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152277309	152277309	G	A	wt	het	wt		QUAL=25915;DP=622,2027,1364;AF=0.00,0.51,0.00;MQM=53	FLG,FLG-AS1	synonymous,intron&non_coding_transcript	FLG:ENST00000368799:synonymous_variant:LOW:exon3/3:c.10053C>T:p.Asp3351=:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.462+3000G>A::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.376+3000G>A::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs34687484	0.0028	0.0039	0,	0.0005,0.0035,0.0001,0.0051,0.0058	0.0050,0.0014	-6.2540			0.00,0.06	-0.53						0	45					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152277345	152277345	C	T	het	het	het		QUAL=47053;DP=555,1990,1338;AF=0.46,0.48,0.48;MQM=58	FLG,FLG-AS1	synonymous,intron&non_coding_transcript	FLG:ENST00000368799:synonymous_variant:LOW:exon3/3:c.10017G>A:p.Gln3339=:PF03516,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.462+3036C>T::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.376+3036C>T::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs2065956	0.2875	0.2422	509,	0.0286,0.4292,0.5591,0.1415,0.3711	0.1447,0.0365	-1.0760			0.01,0.11	0.03						n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152277396	152277396	T	C	het	hom	het		QUAL=80665;DP=512,1870,1284;AF=0.45,0.99,0.49;MQM=58	FLG,FLG-AS1	synonymous,intron&non_coding_transcript	FLG:ENST00000368799:synonymous_variant:LOW:exon3/3:c.9966A>G:p.Gln3322=:PF03516,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.462+3087T>C::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.376+3087T>C::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs6681433	0.3411	0.2721	662,	0.1287,0.4474,0.5786,0.1644,0.4277	0.1683,0.1321	-1.7460			0.01,0.05	-0.45						n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152277554	152277554	G	A	wt	het	wt		QUAL=19243;DP=491,1542,1195;AF=0.00,0.49,0.00;MQM=59	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.9808C>T:p.Arg3270Cys:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.462+3245G>A::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.376+3245G>A::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs35621145	0.0250	0.0228	5,	0.0041,0.0137,0.0195,0.0225,0.0560	0.0234,0.0061	-0.5000	D, , 	P, , 	0.00,0.09	1.45	0.11					3	170					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152277717	152277717	C	A	het	hom	het		QUAL=41687;DP=279,1120,918;AF=0.33,1.00,0.36;MQM=48	FLG,FLG-AS1	synonymous,intron&non_coding_transcript	FLG:ENST00000368799:synonymous_variant:LOW:exon3/3:c.9645G>T:p.Val3215=:PF03516,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.462+3408C>A::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.376+3408C>A::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs9436066	0.4696	0.3027	1530,	0.4851,0.4625,0.6389,0.1660,0.4306	0.1506,0.4489	-6.2400			0.00,0.06	-0.34						n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152277822	152277822	T	C	het	hom	wt		QUAL=12362;DP=345,403,688;AF=0.22,0.98,0.04;MQM=38	FLG,FLG-AS1	synonymous,intron&non_coding_transcript	FLG:ENST00000368799:synonymous_variant:LOW:exon3/3:c.9540A>G:p.Ser3180=:PF03516,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.462+3513T>C::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.376+3513T>C::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs3126069	0.2238	0.1318	357,	0.0343,0.2729,0.4253,0.0407,0.2540		-4.3740			0.00,0.03	-0.84					COSM896103	n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152277826	152277826	A	C	het	hom	wt		QUAL=12362;DP=345,403,688;AF=0.22,0.98,0.04;MQM=38	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.9536T>G:p.Val3179Gly:PF03516,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.462+3517A>C::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.376+3517A>C::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs2065957	0.3936	0.2390	1152,	0.4409,0.3042,0.4609,0.0436,0.2633	0.0240,0.3928	-0.6040	T, , 	B, , 	0.00,0.04	0.12	0.03					n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152278434	152278434	T	G	het	wt	het		QUAL=2696;DP=447,552,490;AF=0.23,0.00,0.24;MQM=39	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.8928A>C:p.Glu2976Asp:PF03516,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.462+4125T>G::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.376+4125T>G::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs61816760	0.2873	0.3862	104,	0.3521,0.3011,0.1153,0.3920,0.3122		-1.3040	T, , 	B, , 	0.03,0.15	0.10	0.02					n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152278484	152278484	C	T	wt	het	wt		QUAL=3334;DP=444,879,705;AF=0.00,0.25,0.00;MQM=39	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.8878G>A:p.Gly2960Ser:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.462+4175C>T::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.376+4175C>T::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs61690342		0.0325	2,	0.0998,0.0149,0.0172,0.0183,0.0457	0.0130,0.0656	-1.1860	T, , 	B, , 	0.01,0.12	-0.34	0.04					1	183					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152278555	152278555	T	C	het	het	het		QUAL=26938;DP=444,1616,1313;AF=0.26,0.50,0.25;MQM=45	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.8807A>G:p.Asp2936Gly:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.462+4246T>C::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.376+4246T>C::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs80221306		0.2065	2,	0.0903,0.3307,0.4025,0.1343,0.3088	0.0964,0.0734	-0.3860	T, , 	B, , 	0.01,0.15	0.60	0.02					n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152278689	152278689	C	A	het	hom	het		QUAL=148765;DP=684,3388,2551;AF=0.56,1.00,0.55;MQM=50	FLG,FLG-AS1	synonymous,intron&non_coding_transcript	FLG:ENST00000368799:synonymous_variant:LOW:exon3/3:c.8673G>T:p.Val2891=:PF03516,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.462+4380C>A::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.376+4380C>A::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs57672167	0.3964	0.2780	1016,	0.2114,0.4535,0.5806,0.1642,0.4238	0.1669,0.2083	-5.7280			0.00,0.03	-0.38						n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152278814	152278814	C	T	wt	het	het		QUAL=19778;DP=1075,4177,2993;AF=0.07,0.24,0.18;MQM=38	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.8548G>A:p.Gly2850Ser:PF03516,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.462+4505C>T::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.376+4505C>T::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs2184952		0.0716	0,	0.0451,0.1831,0.2740,0.0222,0.1600	0.0521,0.0768	-2.5340	T, , 	B, , 	0.00,0.05	-0.17	0.02					n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152278856	152278856	T	G	het	het	het		QUAL=16252;DP=845,3918,2695;AF=0.23,0.18,0.21;MQM=50	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.8506A>C:p.Ser2836Arg:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.462+4547T>G::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.376+4547T>G::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs11582087		0.1775	0,	0.0250,0.3157,0.3948,0.1098,0.2619	0.1107,0.0314	-1.7590	D, , 	B, , 	0.00,0.09	0.92	0.03					n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152279019	152279019	G	A	het	het	het		QUAL=8449;DP=994,4115,2435;AF=0.16,0.17,0.19;MQM=35	FLG,FLG-AS1	synonymous,intron&non_coding_transcript	FLG:ENST00000368799:synonymous_variant:LOW:exon3/3:c.8343C>T:p.Asp2781=:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.462+4710G>A::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.376+4710G>A::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs57670307		0.1231	0,	0.0174,0.2507,0.3696,0.0648,0.1920	0.0767,0.0198	-5.5940			0.00,0.07	-0.37						n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152279729	152279729	C	T	het	hom	het		QUAL=71117;DP=578,1548,1195;AF=0.47,0.99,0.53;MQM=58	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.7633G>A:p.Gly2545Arg:PF03516,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.462+5420C>T::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.376+5420C>T::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs3126072	0.4748	0.3006	1703,	0.5253,0.4632,0.6025,0.1650,0.4257	0.1694,0.4995	-1.5600	T, , 	B, , 	0.00,0.05	0.39	0.02					n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152279841	152279841	G	C	het	hom	het		QUAL=72490;DP=475,1580,1198;AF=0.48,1.00,0.52;MQM=58	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.7521C>G:p.His2507Gln:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.462+5532G>C::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.376+5532G>C::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs3126074	0.4623	0.2981	1552,	0.4845,0.4616,0.6022,0.1649,0.4258	0.1693,0.4660	-7.9550	T, , 	B, , 	0.00,0.04	-0.34	0.02					n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152279920	152279920	A	G	het	hom	het		QUAL=75477;DP=456,1667,1213;AF=0.50,1.00,0.53;MQM=59	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.7442T>C:p.Leu2481Ser:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.462+5611A>G::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.376+5611A>G::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs55650366	0.3425	0.2715	661,	0.1338,0.4470,0.5790,0.1639,0.4236	0.1677,0.1380	-1.3450	T, , 	B, , 	0.00,0.05	-0.30	0.01					n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152279964	152279964	C	T	wt	het	wt		QUAL=22742;DP=619,1675,1225;AF=0.00,0.52,0.00;MQM=59	FLG,FLG-AS1	synonymous,intron&non_coding_transcript	FLG:ENST00000368799:synonymous_variant:LOW:exon3/3:c.7398G>A:p.Pro2466=:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.462+5655C>T::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.376+5655C>T::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs71625199	0.0248	0.0227	5,	0.0033,0.0137,0.0195,0.0224,0.0555	0.0236,0.0059	-8.7560			0.00,0.05	-0.47						2	167					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152280032	152280032	T	C	het	hom	het		QUAL=82558;DP=550,1841,1330;AF=0.48,1.00,0.51;MQM=58	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.7330A>G:p.Lys2444Glu:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.462+5723T>C::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.376+5723T>C::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs71625200	0.3431	0.2715	662,	0.1340,0.4471,0.5789,0.1637,0.4234	0.1636,0.1360	-0.8890	T, , 	B, , 	0.00,0.08	0.32	0.03					n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152280170	152280170	C	G	het	hom	het		QUAL=56448;DP=456,1441,1165;AF=0.44,0.97,0.44;MQM=47	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.7192G>C:p.Glu2398Gln:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.462+5861C>G::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.376+5861C>G::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs71625201	0.3305	0.2578	243,	0.1277,0.4159,0.5204,0.1612,0.4035	0.1657,0.1326	-1.3100	T, , 	B, , 	0.01,0.12	-0.24	0.02					n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152280265	152280265	C	G	het	het	het		QUAL=34927;DP=503,1086,1103;AF=0.38,0.86,0.31;MQM=38	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.7097G>C:p.Ser2366Thr:PF03516,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.462+5956C>G::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.376+5956C>G::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs71625202		0.2129	57,	0.0310,0.3398,0.4092,0.1426,0.3307	0.1329,0.0348	0.0300	D, , 	D, , 	0.07,0.22	1.88	0.09					n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152280347	152280347	C	T	het	het	het		QUAL=29911;DP=475,1019,1153;AF=0.35,0.79,0.29;MQM=37	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.7015G>A:p.Asp2339Asn:PF03516,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.462+6038C>T::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.376+6038C>T::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs139476473		0.1479	221,	0.0223,0.2937,0.3787,0.0702,0.2634	0.0328,0.0185	1.6910	D, , 	D, , 	0.15,0.66	2.63	0.14					n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152280372	152280372	G	A	het	hom	het		QUAL=41058;DP=519,1041,1118;AF=0.49,0.99,0.34;MQM=36	FLG,FLG-AS1	synonymous,intron&non_coding_transcript	FLG:ENST00000368799:synonymous_variant:LOW:exon3/3:c.6990C>T:p.His2330=:PF03516,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.462+6063G>A::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.376+6063G>A::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs6664985	0.4535	0.2751	1506,	0.4574,0.4454,0.6139,0.1017,0.4057		-3.4130			0.01,0.14	-0.23						n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152280471	152280471	C	G	het	het	het		QUAL=9695;DP=660,1876,1351;AF=0.23,0.29,0.14;MQM=36	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.6891G>C:p.Glu2297Asp:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.462+6162C>G::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.376+6162C>G::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs78179835		0.1947	16,	0.0986,0.3206,0.3851,0.1241,0.3039	0.1071,0.0915	-1.8340	T, , 	B, , 	0.00,0.07	-0.42	0.03					n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152280685	152280685	C	A	het	het	wt		QUAL=2926;DP=436,1821,1263;AF=0.11,0.17,0.08;MQM=56	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.6677G>T:p.Gly2226Val:PF03516,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.462+6376C>A::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.376+6376C>A::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs544807449	0.1833	0.0206	0,	0.0568,0.0456,0.1548,0.0029,0.0304		0.1350	T, , 	B, , 	0.03,0.11	0.52	0.17				COSM675348	n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152280687	152280687	C	T	het	het	wt		QUAL=2926;DP=436,1821,1263;AF=0.11,0.17,0.08;MQM=56	FLG,FLG-AS1	synonymous,intron&non_coding_transcript	FLG:ENST00000368799:synonymous_variant:LOW:exon3/3:c.6675G>A:p.Val2225=:PF03516,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.462+6378C>T::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.376+6378C>T::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs564482396	0.1833	0.0227	0,	0.0634,0.0538,0.1719,0.0033,0.0340		-1.6180			0.00,0.05	-0.58					COSM423886	n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152280688	152280688	A	G	het	het	wt		QUAL=2926;DP=436,1821,1263;AF=0.11,0.17,0.08;MQM=56	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.6674T>C:p.Val2225Ala:PF03516,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.462+6379A>G::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.376+6379A>G::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs116918835	0.1833	0.0322	0,	0.0764,0.0915,0.2072,0.0059,0.0495		-0.5260	T, , 	B, , 	0.00,0.08	-0.02	0.04					n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152280691	152280691	A	T	het	het	wt		QUAL=2926;DP=436,1821,1263;AF=0.11,0.17,0.08;MQM=56	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.6671T>A:p.Leu2224Gln:PF03516,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.462+6382A>T::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.376+6382A>T::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs117945779	0.1915	0.0397	0,	0.1152,0.1134,0.2313,0.0075,0.0604		-1.9610	T, , 	B, , 	0.00,0.05	0.06	0.03					n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152280736	152280736	T	C	het	het	het		QUAL=23509;DP=791,2387,1507;AF=0.31,0.33,0.18;MQM=55	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.6626A>G:p.His2209Arg:PF03516,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.462+6427T>C::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.376+6427T>C::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs66977240		0.2184	0,	0.3461,0.3432,0.4136,0.1277,0.3117		-5.2630	T, , 	B, , 	0.00,0.04	-0.00	0.01					n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152280759	152280759	A	G	het	het	het		QUAL=36153;DP=866,2673,1564;AF=0.34,0.40,0.23;MQM=54	FLG,FLG-AS1	synonymous,intron&non_coding_transcript	FLG:ENST00000368799:synonymous_variant:LOW:exon3/3:c.6603T>C:p.Asp2201=:PF03516,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.462+6450A>G::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.376+6450A>G::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs2338554	0.3672	0.2416	513,	0.4279,0.3516,0.4196,0.1470,0.3293	0.1099,0.3872	-2.2170			0.00,0.05	-0.21						n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152280782	152280782	A	G	het	hom	het		QUAL=131403;DP=881,2791,1656;AF=0.65,1.00,0.63;MQM=56	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.6580T>C:p.Tyr2194His:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.462+6473A>G::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.376+6473A>G::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs2184953	0.5397	0.3434	2727,	0.7182,0.4768,0.6038,0.1671,0.4290		-2.7490	T, , 	B, , 	0.00,0.04	-0.37	0.01					n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152280788	152280788	T	G	het	het	het		QUAL=71499;DP=886,2829,1661;AF=0.32,0.73,0.27;MQM=54	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.6574A>C:p.Lys2192Gln:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.462+6479T>G::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.376+6479T>G::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs66954353		0.2399	5,	0.3650,0.3524,0.4193,0.1502,0.3319	0.0952,0.2381	0.4010	T, , 	B, , 	0.00,0.04	0.21	0.02					n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152280864	152280864	A	G	het	hom	het		QUAL=111962;DP=516,2569,1519;AF=0.61,1.00,0.66;MQM=54	FLG,FLG-AS1	synonymous,intron&non_coding_transcript	FLG:ENST00000368799:synonymous_variant:LOW:exon3/3:c.6498T>C:p.Ser2166=:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.463-6518A>G::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.377-6518A>G::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs2184954	0.4637	0.2982	1580,	0.4852,0.4618,0.6024,0.1650,0.4259	0.1690,0.4666	-4.5190			0.00,0.03	-0.34						n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152280900	152280900	T	G	het	het	het		QUAL=31578;DP=697,2365,1472;AF=0.32,0.36,0.31;MQM=51	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.6462A>C:p.Gln2154His:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.463-6482T>G::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.377-6482T>G::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs74129452	0.3438	0.2374	0,	0.3648,0.3513,0.4192,0.1464,0.3278		-3.3330	T, , 	B, , 	0.00,0.02	-0.36	0.11					n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152281007	152281007	A	G	het	het	het		QUAL=30320;DP=831,2310,1587;AF=0.29,0.30,0.30;MQM=59	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.6355T>C:p.Tyr2119His:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.463-6375A>G::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.377-6375A>G::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs7512553	0.3277	0.2243	0,	0.3640,0.3447,0.4126,0.1318,0.2979	0.1266,0.3293	-0.3240	T, , 	B, , 	0.00,0.04	-0.01	0.04					n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152281008	152281008	A	G	het	het	het		QUAL=30320;DP=831,2310,1587;AF=0.29,0.30,0.30;MQM=59	FLG,FLG-AS1	synonymous,intron&non_coding_transcript	FLG:ENST00000368799:synonymous_variant:LOW:exon3/3:c.6354T>C:p.His2118=:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.463-6374A>G::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.377-6374A>G::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs7512554	0.3277	0.2243	0,	0.3640,0.3447,0.4126,0.1318,0.2979	0.1259,0.3282	-1.6980			0.00,0.07	0.08						n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152281039	152281039	G	A	het	het	het		QUAL=33389;DP=941,2399,1652;AF=0.30,0.32,0.33;MQM=59	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.6323C>T:p.Ala2108Val:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.463-6343G>A::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.377-6343G>A::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs7522925		0.2245	0,	0.3652,0.3448,0.4126,0.1319,0.2979	0.1341,0.3568	-3.7960	T, , 	B, , 	0.01,0.09	-0.53	0.07					n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152281228	152281228	C	G	het	het	het		QUAL=37993;DP=733,2613,1966;AF=0.25,0.33,0.35;MQM=53	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.6134G>C:p.Ser2045Thr:PF03516,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.463-6154C>G::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.377-6154C>G::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs7546186		0.2173	0,	0.3456,0.3402,0.4073,0.1235,0.2958	0.1311,0.3280	1.5140	T, , 	P, , 	0.12,0.22	1.10	0.09					n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152281290	152281290	A	G	het	het	het		QUAL=35600;DP=678,2595,1993;AF=0.23,0.33,0.34;MQM=50	FLG,FLG-AS1	synonymous,intron&non_coding_transcript	FLG:ENST00000368799:synonymous_variant:LOW:exon3/3:c.6072T>C:p.His2024=:PF03516,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.463-6092A>G::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.377-6092A>G::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs80353812	0.3281	0.2226	0,	0.3582,0.3440,0.4121,0.1301,0.2979	0.1262,0.2624	-6.8960			0.00,0.08	-0.50						n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152281304	152281304	A	C	het	het	het		QUAL=37072;DP=681,2610,1968;AF=0.27,0.34,0.33;MQM=51	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.6058T>G:p.Ser2020Ala:PF03516,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.463-6078A>C::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.377-6078A>C::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs7512857		0.2224	0,	0.3427,0.3434,0.4124,0.1315,0.2975	0.1329,0.3268	0.3910	T, , 	D, , 	0.01,0.16	1.25	0.03					n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152281317	152281317	G	T	wt	het	wt		QUAL=21139;DP=805,2647,2031;AF=0.00,0.34,0.00;MQM=59	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.6045C>A:p.Asp2015Glu:PF03516,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.463-6065G>T::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.377-6065G>T::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs71626704	0.0248	0.0227	5,	0.0033,0.0137,0.0194,0.0224,0.0555	0.0236,0.0059	0.0400	T, , 	B, , 	0.06,0.49	0.55	0.05					2	168					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152281479	152281479	G	T	het	hom	het		QUAL=105848;DP=884,1998,1623;AF=0.59,1.00,0.68;MQM=56	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.5883C>A:p.His1961Gln:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.463-5903G>T::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.377-5903G>T::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs3126079		0.3429	2726,	0.7179,0.4767,0.6040,0.1670,0.4266	0.1721,0.6882	-4.7170	T, , 	B, , 	0.00,0.04	-0.67	0.02					n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152281523	152281523	A	C	het	het	het		QUAL=20086;DP=827,1838,1558;AF=0.19,0.29,0.30;MQM=48	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.5839T>G:p.Trp1947Gly:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.463-5859A>C::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.377-5859A>C::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs80059102		0.1992	0,	0.3183,0.3211,0.4055,0.1104,0.2686		-0.5520	T, , 	B, , 	0.01,0.14	0.52	0.01					n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152281534	152281534	A	T	het	het	het		QUAL=17135;DP=759,1782,1516;AF=0.18,0.28,0.28;MQM=48	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.5828T>A:p.Leu1943His:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.463-5848A>T::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.377-5848A>T::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs113544881	0.3135	0.1822	0,	0.2380,0.2830,0.3871,0.0727,0.2234		-2.7300	T, , 	B, , 	0.00,0.04	-0.02	0.05					n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152281690	152281690	C	T	het	het	het		QUAL=41141;DP=545,1369,1171;AF=0.48,0.53,0.51;MQM=59	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.5672G>A:p.Arg1891Gln:PF03516,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.463-5692C>T::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.377-5692C>T::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs12407748	0.2875	0.2416	496,	0.0288,0.4288,0.5596,0.1413,0.3675	0.1444,0.0368	-4.3630	T, , 	B, , 	0.00,0.06	-0.46	0.05					n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152281691	152281691	G	A	wt	het	wt		QUAL=16114;DP=555,1373,1173;AF=0.00,0.47,0.00;MQM=59	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.5671C>T:p.Arg1891Trp:PF03516,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.463-5691G>A::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.377-5691G>A::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs36006086	0.0250	0.0228	4,	0.0041,0.0137,0.0194,0.0225,0.0555	0.0236,0.0061	-0.6350	D, , 	D, , 	0.00,0.10	1.88	0.04				COSM4887424	2	169					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152281745	152281745	G	T	wt	het	wt		QUAL=16163;DP=630,1420,1190;AF=0.00,0.45,0.00;MQM=59	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.5617C>A:p.Gln1873Lys:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.463-5637G>T::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.377-5637G>T::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs62623409	0.0250	0.0227	5,	0.0041,0.0136,0.0194,0.0224,0.0553	0.0236,0.0061	-0.9500	T, , 	B, , 	0.01,0.10	0.41	0.04					2	168					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152281907	152281907	A	G	wt	het	wt		QUAL=1160;DP=458,1618,1045;AF=0.00,0.12,0.00;MQM=47	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.5455T>C:p.Ser1819Pro:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.463-5475A>G::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.377-5475A>G::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs754699295		0.0007	0,	0.0000,0.0001,0.0000,0.0001,0.0000		0.7130	T, , 	P, , 	0.02,0.19	1.44	0.02				COSM2185276	0	6					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152281911	152281911	T	C	wt	het	wt		QUAL=1160;DP=458,1618,1045;AF=0.00,0.12,0.00;MQM=47	FLG,FLG-AS1	synonymous,intron&non_coding_transcript	FLG:ENST00000368799:synonymous_variant:LOW:exon3/3:c.5451A>G:p.Pro1817=:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.463-5471T>C::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.377-5471T>C::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs546421577	0.0020	0.0023	0,	0.0029,0.0004,0.0001,0.0002,0.0002		-7.4340			0.00,0.06	-0.63						0	8					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152281948	152281948	G	A	het	het	het		QUAL=37473;DP=464,1972,1120;AF=0.48,0.39,0.51;MQM=58	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.5414C>T:p.Ala1805Val:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.463-5434G>A::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.377-5434G>A::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs12405241	0.2875	0.2416	500,	0.0286,0.4283,0.5597,0.1412,0.3678	0.1443,0.0365	-5.6240	T, , 	D, , 	0.00,0.11	0.29	0.10					n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152282092	152282092	T	C	wt	het	wt		QUAL=2505;DP=539,1987,1249;AF=0.01,0.17,0.00;MQM=52	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.5270A>G:p.Glu1757Gly:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.463-5290T>C::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.377-5290T>C::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs778942937		0.0028	0,	0.0000,0.0000,0.0000,0.0000,0.0001		0.7390	T, , 	B, , 	0.02,0.24	1.19	0.03					0	13					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152282101	152282101	T	C	wt	het	wt		QUAL=209;DP=488,1873,1246;AF=0.00,0.12,0.00;MQM=49	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.5261A>G:p.Gln1754Arg:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.463-5281T>C::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.377-5281T>C::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs761680413		0.0015	0,	0.0000,0.0001,0.0001,0.0001,0.0002		-0.7090	T, , 	B, , 	0.02,0.15	-0.14	0.03					0	2					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152282104	152282104	C	T	wt	het	wt		QUAL=209;DP=488,1873,1246;AF=0.00,0.12,0.00;MQM=49	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.5258G>A:p.Gly1753Asp:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.463-5278C>T::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.377-5278C>T::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs762948644		0.0011	0,	0.0000,0.0000,0.0000,0.0000,0.0000		-0.1810	D, , 	D, , 	0.01,0.12	1.52	0.03					0	2					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152282267	152282267	G	A	het	het	het		QUAL=36166;DP=418,1524,1232;AF=0.46,0.49,0.48;MQM=60	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.5095C>T:p.Arg1699Cys:PF03516,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.463-5115G>A::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.377-5115G>A::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs12405278	0.2877	0.2416	500,	0.0286,0.4285,0.5597,0.1412,0.3678	0.1442,0.0365	0.1370	D, , 	D, , 	0.03,0.15	1.98	0.05					n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152282311	152282311	C	T	het	het	het		QUAL=39254;DP=514,1513,1239;AF=0.46,0.51,0.48;MQM=59	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.5051G>A:p.Arg1684His:PF03516,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.463-5071C>T::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.377-5071C>T::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs12407807	0.2967	0.2440	518,	0.0645,0.4294,0.5597,0.1413,0.3680	0.1443,0.0688	-2.4830	T, , 	D, , 	0.00,0.08	0.75	0.07					n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152282522	152282522	C	T	wt	wt	het		QUAL=11102;DP=553,1246,1018;AF=0.00,0.00,0.48;MQM=60	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.4840G>A:p.Ala1614Thr:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.463-4860C>T::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.377-4860C>T::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];										-1.2150	T, , 	B, , 	0.00,0.08	0.25	0.03				COSM244545	0	1					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152282794	152282794	G	A	wt	het	wt		QUAL=16956;DP=439,1469,1153;AF=0.00,0.48,0.00;MQM=59	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.4568C>T:p.Thr1523Ile:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.463-4588G>A::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.377-4588G>A::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs12750081	0.0250	0.0227	4,	0.0041,0.0136,0.0194,0.0224,0.0555	0.0236,0.0061	-0.3320	D, , 	B, , 	0.01,0.11	0.65	0.01					2	167					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152282910	152282910	G	C	wt	het	wt		QUAL=18572;DP=488,1494,1078;AF=0.00,0.49,0.00;MQM=59	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.4452C>G:p.Asp1484Glu:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.463-4472G>C::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.377-4472G>C::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs71626706	0.0248	0.0227	5,	0.0033,0.0136,0.0194,0.0224,0.0556	0.0236,0.0059	-5.4290	T, , 	B, , 	0.00,0.06	-0.51	0.05					2	169					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152282917	152282917	G	T	het	het	het		QUAL=38020;DP=483,1523,1075;AF=0.49,0.50,0.49;MQM=59	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.4445C>A:p.Ser1482Tyr:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.463-4465G>T::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.377-4465G>T::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs11204978	0.2871	0.2416	501,	0.0286,0.4285,0.5595,0.1412,0.3677	0.1442,0.0365	0.2480	D, , 	B, , 	0.02,0.13	1.02	0.06					n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152282952	152282952	A	G	wt	het	wt		QUAL=19666;DP=545,1570,1142;AF=0.00,0.49,0.00;MQM=59	FLG,FLG-AS1	synonymous,intron&non_coding_transcript	FLG:ENST00000368799:synonymous_variant:LOW:exon3/3:c.4410T>C:p.His1470=:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.463-4430A>G::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.377-4430A>G::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs12732920	0.0250	0.0227	4,	0.0033,0.0136,0.0194,0.0224,0.0558	0.0236,0.0059	-8.9450			0.00,0.05	-0.66						2	170					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152283053	152283053	G	A	wt	het	wt		QUAL=20701;DP=584,1689,1201;AF=0.00,0.49,0.00;MQM=59	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.4309C>T:p.Arg1437Cys:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.463-4329G>A::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.377-4329G>A::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs12750571	0.0048	0.0050	0,	0.0005,0.0049,0.0001,0.0067,0.0067	0.0057,0.0016	-0.2710	D, , 	P, , 	0.01,0.11	1.76	0.04					1	67					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152283236	152283236	T	C	het	hom	het		QUAL=76029;DP=529,1684,1306;AF=0.48,0.99,0.49;MQM=55	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.4126A>G:p.Arg1376Gly:PF03516,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.463-4146T>C::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.377-4146T>C::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs11581433	0.3431	0.2719	668,	0.1336,0.4486,0.5790,0.1641,0.4236	0.1671,0.1378	-2.3740	T, , 	B, , 	0.00,0.09	-0.16	0.01					n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152283283	152283283	C	T	het	het	het		QUAL=40186;DP=524,1663,1248;AF=0.49,0.49,0.50;MQM=53	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.4079G>A:p.Arg1360His:PF03516,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.463-4099C>T::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.377-4099C>T::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs11586631	0.2877	0.2417	501,	0.0291,0.4285,0.5595,0.1412,0.3677	0.1439,0.0370	-6.3060	T, , 	B, , 	0.00,0.10	-0.41	0.02					n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152283862	152283862	G	C	het	hom	het		QUAL=64917;DP=537,1463,1106;AF=0.49,1.00,0.50;MQM=53	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.3500C>G:p.Ala1167Gly:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.463-3520G>C::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.377-3520G>C::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs58001094	0.5341	0.3400	2671,	0.6985,0.4606,0.5984,0.1646,0.4082	0.1619,0.5996	-3.6180	T, , 	B, , 	0.00,0.05	-0.63	0.05					n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152283975	152283975	A	G	het	hom	het		QUAL=75343;DP=585,1701,1211;AF=0.51,1.00,0.50;MQM=51	FLG,FLG-AS1	synonymous,intron&non_coding_transcript	FLG:ENST00000368799:synonymous_variant:LOW:exon3/3:c.3387T>C:p.Ser1129=:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.463-3407A>G::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.377-3407A>G::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs66831674	0.4631	0.2981	1548,	0.4852,0.4615,0.6020,0.1650,0.4256	0.1648,0.4564	-3.4180			0.00,0.05	-0.66						n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152284377	152284377	G	A	het	het	wt		QUAL=30569;DP=583,1614,1318;AF=0.53,0.55,0.02;MQM=55	FLG,FLG-AS1	synonymous,intron&non_coding_transcript	FLG:ENST00000368799:synonymous_variant:LOW:exon3/3:c.2985C>T:p.His995=:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.463-3005G>A::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.377-3005G>A::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs373872833		0.0001	0,	0.0000,0.0004,0.0001,0.0001,0.0001		-0.6480			0.00,0.11	0.01						0	10					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152284424	152284424	G	C	wt	het	wt		QUAL=22832;DP=723,1702,1329;AF=0.02,0.53,0.04;MQM=53	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.2938C>G:p.His980Asp:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.463-2958G>C::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.377-2958G>C::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];	402869 [benign DISEASE=not specified];			rs12756586	0.0339	0.0236	5,	0.0153,0.0140,0.0194,0.0224,0.0561		-1.1170	T, , 	B, , 	0.00,0.06	-0.70	0.02					2	197					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152284478	152284478	A	G	wt	het	wt		QUAL=1698;DP=543,1868,1326;AF=0.02,0.16,0.07;MQM=35	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.2884T>C:p.Trp962Arg:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.463-2904A>G::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.377-2904A>G::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs199888588		0.0268	0,	0.0114,0.0002,0.0002,0.0001,0.0002		-0.8190	T, , 	B, , 	0.00,0.03	-0.48	0.02					0	121					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152284497	152284497	A	G	wt	het	wt		QUAL=3141;DP=513,1998,1350;AF=0.02,0.18,0.07;MQM=35	FLG,FLG-AS1	synonymous,intron&non_coding_transcript	FLG:ENST00000368799:synonymous_variant:LOW:exon3/3:c.2865T>C:p.His955=:PF03516,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.463-2885A>G::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.377-2885A>G::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs144437056	0.0513	0.0381	0,	0.0240,0.0002,0.0003,0.0001,0.0001	0.0000,0.0052	-5.3240			0.00,0.03	-0.74						n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152284505	152284505	C	G	wt	het	wt		QUAL=3481;DP=540,2056,1381;AF=0.02,0.18,0.07;MQM=35	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.2857G>C:p.Glu953Gln:PF03516,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.463-2877C>G::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.377-2877C>G::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs201137357	0.1368	0.0506	10,	0.1367,0.0031,0.0004,0.0005,0.0003	0.0006,0.1003	-0.3120	T, , 	P, , 	0.02,0.14	1.24	0.06					n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152284576	152284576	C	A	wt	het	wt		QUAL=1435;DP=584,2120,1431;AF=0.03,0.15,0.05;MQM=36	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.2786G>T:p.Gly929Val:PF03516,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.463-2806C>A::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.377-2806C>A::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs143382793		0.0190	0,	0.0038,0.0001,0.0001,0.0001,0.0001		-0.1670	D, , 	P, , 	0.01,0.10	1.53	0.03					0	235					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152284854	152284854	A	G	het	hom	het		QUAL=57156;DP=481,1248,878;AF=0.47,0.99,0.51;MQM=58	FLG,FLG-AS1	synonymous,intron&non_coding_transcript	FLG:ENST00000368799:synonymous_variant:LOW:exon3/3:c.2508T>C:p.Asp836=:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.463-2528A>G::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.377-2528A>G::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs3120653	0.4732	0.3011	1600,	0.5242,0.4637,0.6019,0.1654,0.4240	0.1700,0.5011	-0.0990			0.00,0.07	-0.24						n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152285099	152285099	C	T	het	hom	het		QUAL=86315;DP=493,1885,1422;AF=0.52,1.00,0.50;MQM=59	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.2263G>A:p.Glu755Lys:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.463-2283C>T::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.377-2283C>T::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];	377878 [benign DISEASE=not specified];			rs74129461	0.3277	0.2674	603,	0.0751,0.4443,0.5787,0.1639,0.4233	0.1678,0.0835	-0.3090	D, , 	B, , 	0.01,0.14	1.28	0.03					n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152285181	152285181	G	T	wt	het	wt		QUAL=22872;DP=471,1842,1377;AF=0.00,0.48,0.00;MQM=59	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.2181C>A:p.His727Gln:PF03516,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.463-2201G>T::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.377-2201G>T::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs7512779	0.0250	0.0227	6,	0.0041,0.0137,0.0194,0.0224,0.0554	0.0236,0.0061	-2.7370	T, , 	B, , 	0.00,0.09	-0.72	0.01					3	168					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152285930	152285930	G	A	het	hom	het		QUAL=70235;DP=516,1572,1179;AF=0.51,0.99,0.49;MQM=59	FLG,FLG-AS1	missense,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.1432C>T:p.Pro478Ser:,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.463-1452G>A::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.377-1452G>A::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];		CM084968 [CLASS=DP MUT=ALT PHEN="Psoriasis increased risk association with" GENE=FLG];		rs11584340	0.3446	0.2718	670,	0.1367,0.4474,0.5787,0.1639,0.4236	0.1679,0.1396	-1.8930	T, , 	B, , 	0.00,0.05	-0.30	0.04					n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152286002	152286002	T	C	het	hom	het		QUAL=68444;DP=457,1579,1154;AF=0.48,0.99,0.49;MQM=59	FLG,FLG-AS1	missense,non_coding_transcript_exon,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.1360A>G:p.Thr454Ala:,FLG-AS1:ENST00000392688:non_coding_transcript_exon_variant:MODIFIER:exon1/7:n.68T>C::,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.463-1380T>C::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.377-1380T>C::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];		CM1611993 [CLASS=DM? MUT=ALT PHEN="Ichthyosis vulgaris" GENE=FLG];		rs2011331	0.4641	0.2988	1574,	0.4876,0.4630,0.6033,0.1651,0.4257	0.1699,0.4671	-2.8550	T, , , 	B, , , 	0.00,0.05	-0.42	0.08					n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152286032	152286032	C	T	het	het	het		QUAL=40554;DP=564,1564,1213;AF=0.48,0.46,0.50;MQM=59	FLG,FLG-AS1	missense,non_coding_transcript_exon,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.1330G>A:p.Gly444Arg:,FLG-AS1:ENST00000392688:non_coding_transcript_exon_variant:MODIFIER:exon1/7:n.98C>T::,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.463-1350C>T::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.377-1350C>T::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs11588170	0.2871	0.2415	492,	0.0286,0.4287,0.5592,0.1411,0.3676	0.1443,0.0365	-0.6390	T, , , 	P, , , 	0.01,0.11	0.81	0.04					n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152286126	152286126	A	G	het	wt	het		QUAL=20504;DP=467,1522,1204;AF=0.49,0.00,0.50;MQM=60	FLG,FLG-AS1	synonymous,non_coding_transcript_exon,intron&non_coding_transcript	FLG:ENST00000368799:synonymous_variant:LOW:exon3/3:c.1236T>C:p.Arg412=:PF03516,FLG-AS1:ENST00000392688:non_coding_transcript_exon_variant:MODIFIER:exon1/7:n.192A>G::,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.463-1256A>G::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.377-1256A>G::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs11582620	0.0861	0.1164	175,	0.0175,0.0933,0.1031,0.1184,0.2013	0.1166,0.0211	-1.9280			0.00,0.08	-0.49						n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152286367	152286367	C	A	het	hom	het		QUAL=59382;DP=564,1283,912;AF=0.51,1.00,0.50;MQM=59	FLG,FLG-AS1	missense,non_coding_transcript_exon,intron&non_coding_transcript	FLG:ENST00000368799:missense_variant:MODERATE:exon3/3:c.995G>T:p.Gly332Val:,FLG-AS1:ENST00000392688:non_coding_transcript_exon_variant:MODIFIER:exon1/7:n.433C>A::,FLG-AS1:ENST00000420707:intron_variant&non_coding_transcript_variant:MODIFIER:exon4/8:n.463-1015C>A::,FLG-AS1:ENST00000593011:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.377-1015C>A::	135940 [FLG (confirmed) Ichthyosis vulgaris,146700/Dermatitis,atopic,susceptibility to,2,605803];				rs41267154	0.3407	0.2711	654,	0.1286,0.4469,0.5784,0.1639,0.4235	0.1679,0.1321	-1.0190	D, , , 	D, , , 	0.03,0.18	1.65	0.02					n/a (AF>5%)	n/a (AF>5%)					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	154128672	154128672	G	A	wt	wt	het		QUAL=802;DP=183,125,87;AF=0.01,0.00,0.46;MQM=60	TPM3	3'UTR	TPM3:ENST00000368533:3_prime_UTR_variant:MODIFIER:exon8/8:c.*1443C>T::	191030 [TPM3 (confirmed) Nemaline myopathy 1,autosomal dominant or recessive,609284/CAP myopathy 1,609284/Myopathy,congenital,with fiber-type disproportion,255310];			AluSq2	rs4540651	0.7151	0.6048	5897,			-0.8210			0.00,0.04	-0.15						n/a (AF>5%)	n/a (AF>5%)					TPM3 (inh=AR+AD pLI=0.45)
chr1	154129265	154129265	A	G	wt	wt	het		QUAL=131;DP=106,19,11;AF=0.00,0.00,0.73;MQM=59	TPM3	3'UTR	TPM3:ENST00000328159:3_prime_UTR_variant:MODIFIER:exon9/9:c.*929T>C::,TPM3:ENST00000330188:3_prime_UTR_variant:MODIFIER:exon8/8:c.*850T>C::,TPM3:ENST00000341372:3_prime_UTR_variant:MODIFIER:exon8/8:c.*850T>C::,TPM3:ENST00000341485:3_prime_UTR_variant:MODIFIER:exon8/8:c.*850T>C::,TPM3:ENST00000368533:3_prime_UTR_variant:MODIFIER:exon8/8:c.*850T>C::	191030 [TPM3 (confirmed) Nemaline myopathy 1,autosomal dominant or recessive,609284/CAP myopathy 1,609284/Myopathy,congenital,with fiber-type disproportion,255310];				rs1051370	0.3229	0.3015	1532,			-0.4070			0.02,0.38	1.30						n/a (AF>5%)	n/a (AF>5%)					TPM3 (inh=AR+AD pLI=0.45)
chr1	154134557	154134557	A	C	wt	wt	het		QUAL=1947;DP=457,366,218;AF=0.00,0.00,0.44;MQM=60	TPM3	intron	TPM3:ENST00000271850:intron_variant:MODIFIER:exon8/8:c.776-4360T>G::,TPM3:ENST00000302206:intron_variant:MODIFIER:exon7/7:c.395-4360T>G::,TPM3:ENST00000323144:intron_variant:MODIFIER:exon7/7:c.665-3033T>G::,TPM3:ENST00000328159:intron_variant:MODIFIER:exon8/8:c.744-4360T>G::,TPM3:ENST00000330188:intron_variant:MODIFIER:exon7/7:c.665-4360T>G::,TPM3:ENST00000341372:intron_variant:MODIFIER:exon7/7:c.590-4360T>G::,TPM3:ENST00000341485:intron_variant:MODIFIER:exon7/7:c.617-4360T>G::,TPM3:ENST00000368531:intron_variant:MODIFIER:exon7/7:c.665-3033T>G::,TPM3:ENST00000368533:intron_variant:MODIFIER:exon7/7:c.665-4360T>G::	191030 [TPM3 (confirmed) Nemaline myopathy 1,autosomal dominant or recessive,609284/CAP myopathy 1,609284/Myopathy,congenital,with fiber-type disproportion,255310];	292625 [benign DISEASE=Nemaline myopathy,Congenital fiber-type disproportion];			rs3196889	0.3215	0.2963	1458,			0.4210			0.01,0.22	0.33						n/a (AF>5%)	n/a (AF>5%)					TPM3 (inh=AR+AD pLI=0.45)
chr1	154138228	154138228	G	A	wt	wt	het		QUAL=639;DP=198,58,37;AF=0.01,0.00,0.76;MQM=60	TPM3	intron	TPM3:ENST00000271850:intron_variant:MODIFIER:exon8/8:c.775+4648C>T::,TPM3:ENST00000302206:intron_variant:MODIFIER:exon7/7:c.394+4648C>T::,TPM3:ENST00000323144:intron_variant:MODIFIER:exon7/7:c.664+4648C>T::,TPM3:ENST00000328159:intron_variant:MODIFIER:exon8/8:c.743+3553C>T::,TPM3:ENST00000330188:intron_variant:MODIFIER:exon7/7:c.664+4648C>T::,TPM3:ENST00000341372:intron_variant:MODIFIER:exon7/7:c.589+4648C>T::,TPM3:ENST00000341485:intron_variant:MODIFIER:exon7/7:c.616+4648C>T::,TPM3:ENST00000368531:intron_variant:MODIFIER:exon7/7:c.664+4648C>T::,TPM3:ENST00000368533:intron_variant:MODIFIER:exon7/7:c.664+4648C>T::	191030 [TPM3 (confirmed) Nemaline myopathy 1,autosomal dominant or recessive,609284/CAP myopathy 1,609284/Myopathy,congenital,with fiber-type disproportion,255310];	292666 [benign DISEASE=Nemaline myopathy,Congenital fiber-type disproportion];		AluSq2	rs10908723	0.3201	0.2988	1365,			-0.0270			0.01,0.08	-0.01						n/a (AF>5%)	n/a (AF>5%)					TPM3 (inh=AR+AD pLI=0.45)
chr1	154138266	154138266	A	-	het	het	het		QUAL=196;DP=50,25,19;AF=0.30,0.40,0.21;MQM=60	TPM3	intron	TPM3:ENST00000271850:intron_variant:MODIFIER:exon8/8:c.775+4610del::,TPM3:ENST00000302206:intron_variant:MODIFIER:exon7/7:c.394+4610del::,TPM3:ENST00000323144:intron_variant:MODIFIER:exon7/7:c.664+4610del::,TPM3:ENST00000328159:intron_variant:MODIFIER:exon8/8:c.743+3515del::,TPM3:ENST00000330188:intron_variant:MODIFIER:exon7/7:c.664+4610del::,TPM3:ENST00000341372:intron_variant:MODIFIER:exon7/7:c.589+4610del::,TPM3:ENST00000341485:intron_variant:MODIFIER:exon7/7:c.616+4610del::,TPM3:ENST00000368531:intron_variant:MODIFIER:exon7/7:c.664+4610del::,TPM3:ENST00000368533:intron_variant:MODIFIER:exon7/7:c.664+4610del::	191030 [TPM3 (confirmed) Nemaline myopathy 1,autosomal dominant or recessive,609284/CAP myopathy 1,609284/Myopathy,congenital,with fiber-type disproportion,255310];	292667 [likely benign DISEASE=Nemaline myopathy,Congenital fiber-type disproportion];		AluSq2	rs68185418	0.2664	0.2922	240,			-1.6610				-0.85						n/a (AF>5%)	n/a (AF>5%)					TPM3 (inh=AR+AD pLI=0.45)
chr1	154139165	154139165	-	T	wt	wt	het		QUAL=91;DP=160,37,34;AF=0.04,0.00,0.32;MQM=60	TPM3	intron	TPM3:ENST00000271850:intron_variant:MODIFIER:exon8/8:c.775+3710dup::,TPM3:ENST00000302206:intron_variant:MODIFIER:exon7/7:c.394+3710dup::,TPM3:ENST00000323144:intron_variant:MODIFIER:exon7/7:c.664+3710dup::,TPM3:ENST00000328159:intron_variant:MODIFIER:exon8/8:c.743+2615dup::,TPM3:ENST00000330188:intron_variant:MODIFIER:exon7/7:c.664+3710dup::,TPM3:ENST00000341372:intron_variant:MODIFIER:exon7/7:c.589+3710dup::,TPM3:ENST00000341485:intron_variant:MODIFIER:exon7/7:c.616+3710dup::,TPM3:ENST00000368531:intron_variant:MODIFIER:exon7/7:c.664+3710dup::,TPM3:ENST00000368533:intron_variant:MODIFIER:exon7/7:c.664+3710dup::	191030 [TPM3 (confirmed) Nemaline myopathy 1,autosomal dominant or recessive,609284/CAP myopathy 1,609284/Myopathy,congenital,with fiber-type disproportion,255310];	292677 [benign DISEASE=Nemaline myopathy,Congenital fiber-type disproportion];		AluSx1	rs373439338	0.3409	0.4201	2350,							0.03						n/a (AF>5%)	n/a (AF>5%)					TPM3 (inh=AR+AD pLI=0.45)
chr1	154139381	154139381	A	C	wt	wt	het		QUAL=548;DP=148,71,62;AF=0.00,0.01,0.44;MQM=60	TPM3	intron	TPM3:ENST00000271850:intron_variant:MODIFIER:exon8/8:c.775+3495T>G::,TPM3:ENST00000302206:intron_variant:MODIFIER:exon7/7:c.394+3495T>G::,TPM3:ENST00000323144:intron_variant:MODIFIER:exon7/7:c.664+3495T>G::,TPM3:ENST00000328159:intron_variant:MODIFIER:exon8/8:c.743+2400T>G::,TPM3:ENST00000330188:intron_variant:MODIFIER:exon7/7:c.664+3495T>G::,TPM3:ENST00000341372:intron_variant:MODIFIER:exon7/7:c.589+3495T>G::,TPM3:ENST00000341485:intron_variant:MODIFIER:exon7/7:c.616+3495T>G::,TPM3:ENST00000368531:intron_variant:MODIFIER:exon7/7:c.664+3495T>G::,TPM3:ENST00000368533:intron_variant:MODIFIER:exon7/7:c.664+3495T>G::	191030 [TPM3 (confirmed) Nemaline myopathy 1,autosomal dominant or recessive,609284/CAP myopathy 1,609284/Myopathy,congenital,with fiber-type disproportion,255310];	292682 [benign DISEASE=Nemaline myopathy,Congenital fiber-type disproportion];		AluSx1	rs6673171	0.3229	0.2975	1464,			0.7440			0.01,0.09	0.10						n/a (AF>5%)	n/a (AF>5%)					TPM3 (inh=AR+AD pLI=0.45)
chr1	154141908	154141908	A	G	wt	wt	het	off-target	QUAL=3012;DP=183,303,249;AF=0.00,0.00,0.49;MQM=60	TPM3	intron	TPM3:ENST00000271850:intron_variant:MODIFIER:exon8/8:c.775+968T>C::,TPM3:ENST00000302206:intron_variant:MODIFIER:exon7/7:c.394+968T>C::,TPM3:ENST00000323144:intron_variant:MODIFIER:exon7/7:c.664+968T>C::,TPM3:ENST00000328159:intron_variant:MODIFIER:exon7/8:c.665-49T>C::,TPM3:ENST00000330188:intron_variant:MODIFIER:exon7/7:c.664+968T>C::,TPM3:ENST00000341372:intron_variant:MODIFIER:exon7/7:c.589+968T>C::,TPM3:ENST00000341485:intron_variant:MODIFIER:exon7/7:c.616+968T>C::,TPM3:ENST00000368530:intron_variant:MODIFIER:exon8/9:c.776-49T>C::,TPM3:ENST00000368531:intron_variant:MODIFIER:exon7/7:c.664+968T>C::,TPM3:ENST00000368533:intron_variant:MODIFIER:exon7/7:c.664+968T>C::	191030 [TPM3 (confirmed) Nemaline myopathy 1,autosomal dominant or recessive,609284/CAP myopathy 1,609284/Myopathy,congenital,with fiber-type disproportion,255310];	262627 [benign DISEASE=not specified];			rs4845364	0.7322	0.6201	6260,	0.8135,0.7186,0.8689,0.5120,0.6475	0.5028,0.7962	1.4390			0.41,0.82	2.12						n/a (AF>5%)	n/a (AF>5%)					TPM3 (inh=AR+AD pLI=0.45)
chr1	154245142	154245142	T	G	wt	het	wt		QUAL=2985;DP=382,244,167;AF=0.00,0.50,0.02;MQM=60	HAX1	5'UTR	HAX1:ENST00000328703:5_prime_UTR_variant:MODIFIER:exon1/7:c.-58T>G::,HAX1:ENST00000457918:5_prime_UTR_variant:MODIFIER:exon1/7:c.-58T>G::,HAX1:ENST00000483970:5_prime_UTR_variant:MODIFIER:exon1/7:c.-58T>G::	605998 [HAX1 (confirmed) Neutropenia,severe congenital 3,autosomal recessive,610738];	292700 [benign DISEASE=Severe congenital neutropenia];			rs11265425	0.2098	0.2336	1047,		0.2806,0.0564	-2.2010			0.01,0.29	0.22						n/a (AF>5%)	n/a (AF>5%)					HAX1 (inh=AR pLI=0.00)
chr1	154548721	154548721	T	C	hom	het	hom		QUAL=8895;DP=113,109,126;AF=0.98,0.51,1.00;MQM=59	CHRNB2	3'UTR	CHRNB2:ENST00000368476:3_prime_UTR_variant:MODIFIER:exon6/6:c.*313T>C::	118507 [CHRNB2 (confirmed) Epilepsy,nocturnal frontal lobe,3,605375];				rs2072660	0.6927	0.7072	7837,			-1.8830			0.04,0.11	-0.15						n/a (AF>5%)	n/a (AF>5%)					CHRNB2 (inh=AD pLI=0.65)
chr1	154548880	154548880	G	A	wt	het	wt		QUAL=1186;DP=77,106,62;AF=0.01,0.48,0.02;MQM=60	CHRNB2	3'UTR	CHRNB2:ENST00000368476:3_prime_UTR_variant:MODIFIER:exon6/6:c.*472G>A::	118507 [CHRNB2 (confirmed) Epilepsy,nocturnal frontal lobe,3,605375];	375660 [drug response DISEASE=nicotine response - Efficacy, Toxicity/ADR];			rs2072661	0.2646	0.2513	964,			0.6430			0.07,0.13	0.08						n/a (AF>5%)	n/a (AF>5%)					CHRNB2 (inh=AD pLI=0.65)
chr1	154549470	154549470	T	C	wt	het	wt		QUAL=3419;DP=303,299,241;AF=0.00,0.45,0.00;MQM=60	CHRNB2	3'UTR	CHRNB2:ENST00000368476:3_prime_UTR_variant:MODIFIER:exon6/6:c.*1062T>C::	118507 [CHRNB2 (confirmed) Epilepsy,nocturnal frontal lobe,3,605375];				rs12130403	0.2859	0.2949	1347,			-0.0760			0.09,0.11	0.04						n/a (AF>5%)	n/a (AF>5%)					CHRNB2 (inh=AD pLI=0.65)
chr1	154550944	154550945	AG	-	wt	het	wt		QUAL=3302;DP=272,268,213;AF=0.00,0.48,0.00;MQM=60	CHRNB2	3'UTR	CHRNB2:ENST00000368476:3_prime_UTR_variant:MODIFIER:exon6/6:c.*2538_*2539del::	118507 [CHRNB2 (confirmed) Epilepsy,nocturnal frontal lobe,3,605375];				rs3841062	0.2668	0.2719	1141,			0.4860				0.20						n/a (AF>5%)	n/a (AF>5%)					CHRNB2 (inh=AD pLI=0.65)
chr1	154552010	154552010	C	G	het	wt	het		QUAL=8354;DP=295,412,336;AF=0.56,0.00,0.48;MQM=59	CHRNB2,RP11-61L14.6	3'UTR,intron&non_coding_transcript	CHRNB2:ENST00000368476:3_prime_UTR_variant:MODIFIER:exon6/6:c.*3602C>G::,RP11-61L14.6:ENST00000421866:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.47+83G>C::	118507 [CHRNB2 (confirmed) Epilepsy,nocturnal frontal lobe,3,605375];				rs1049998302		0.0001	0,			-0.4130			0.14,0.15	0.05						0	2					CHRNB2 (inh=AD pLI=0.65), RP11-61L14.6 (inh=n/a pLI=n/a)
chr1	155205669	155205669	G	T	hom	hom	hom	off-target	QUAL=19939;DP=96,334,252;AF=1.00,1.00,1.00;MQM=52	GBA	intron	GBA:ENST00000327247:intron_variant:MODIFIER:exon9/11:c.1225-34C>A::,GBA:ENST00000368373:intron_variant:MODIFIER:exon8/10:c.1225-34C>A::,GBA:ENST00000427500:intron_variant:MODIFIER:exon7/9:c.1078-34C>A::,GBA:ENST00000428024:intron_variant:MODIFIER:exon7/9:c.964-34C>A::,GBA:ENST00000536770:intron_variant:MODIFIER:exon6/8:c.886-34C>A::	606463 [GBA (confirmed) Gaucher disease,type I,230800/Gaucher disease,type II,230900/Gaucher disease,type III,231000/Gaucher disease,type IIIC,231005/Gaucher disease,perinatal lethal,608013/Parkinson disease,late-onset,susceptibility to,168600/Lewy body dementia,susceptibility to,127750];	256871 [benign DISEASE=not specified,not provided];			rs3115534	0.9409	0.9868	14070,	0.8389,0.9923,0.9996,0.9975,0.9981		0.6620			0.00,0.04	0.43						n/a (AF>5%)	n/a (AF>5%)					GBA (inh=AR pLI=0.10)
chr1	155207387	155207387	A	T	het	wt	het	off-target	QUAL=3981;DP=191,175,140;AF=0.51,0.00,0.54;MQM=53	GBA	intron	GBA:ENST00000327247:intron_variant:MODIFIER:exon7/11:c.762-18T>A::,GBA:ENST00000368373:intron_variant:MODIFIER:exon6/10:c.762-18T>A::,GBA:ENST00000427500:intron_variant:MODIFIER:exon5/9:c.615-18T>A::,GBA:ENST00000428024:intron_variant:MODIFIER:exon5/9:c.501-18T>A::,GBA:ENST00000536770:intron_variant:MODIFIER:exon4/8:c.423-18T>A::	606463 [GBA (confirmed) Gaucher disease,type I,230800/Gaucher disease,type II,230900/Gaucher disease,type III,231000/Gaucher disease,type IIIC,231005/Gaucher disease,perinatal lethal,608013/Parkinson disease,late-onset,susceptibility to,168600/Lewy body dementia,susceptibility to,127750];	198756 [benign DISEASE=not specified,not provided];			rs140335079	0.0018	0.0090	2,	0.0026,0.0037,0.0001,0.0130,0.0014	0.0127,0.0041	-0.0700			0.03,0.11	-0.07		-26.90% (10.84>7.92)				1	148					GBA (inh=AR pLI=0.10)
chr1	155724315	155724315	G	T	het	wt	het	off-target	QUAL=229;DP=57,86,48;AF=0.42,0.03,0.10;MQM=49	GON4L	intron	GON4L:ENST00000271883:intron_variant:MODIFIER:exon27/31:c.5518-36C>A::,GON4L:ENST00000368331:intron_variant:MODIFIER:exon27/31:c.5518-36C>A::,GON4L:ENST00000437809:intron_variant:MODIFIER:exon27/31:c.5518-36C>A::					rs200722936		0.0630		0.0400,0.0509,0.0480,0.0589,0.1024		0.1270			0.01,0.16	-0.10						n/a (AF>5%)	n/a (AF>5%)					GON4L (inh=n/a pLI=1.00)
chr1	155737385	155737385	C	T	hom	hom	hom	off-target	QUAL=8270;DP=38,156,118;AF=1.00,1.00,1.00;MQM=44	GON4L	intron	GON4L:ENST00000271883:intron_variant:MODIFIER:exon19/31:c.2647-53G>A::,GON4L:ENST00000361040:intron_variant:MODIFIER:exon19/20:c.2647-53G>A::,GON4L:ENST00000368331:intron_variant:MODIFIER:exon19/31:c.2647-53G>A::,GON4L:ENST00000437809:intron_variant:MODIFIER:exon19/31:c.2647-53G>A::					rs849712	0.9279	0.9351	13693,			0.2140			0.00,0.08	-0.10						n/a (AF>5%)	n/a (AF>5%)					GON4L (inh=n/a pLI=1.00)
chr1	155755097	155755097	G	A	hom	hom	hom	off-target	QUAL=25713;DP=235,306,250;AF=1.00,1.00,1.00;MQM=60	GON4L	intron	GON4L:ENST00000271883:intron_variant:MODIFIER:exon13/31:c.1788+28C>T::,GON4L:ENST00000361040:intron_variant:MODIFIER:exon13/20:c.1788+28C>T::,GON4L:ENST00000368331:intron_variant:MODIFIER:exon13/31:c.1788+28C>T::,GON4L:ENST00000437809:intron_variant:MODIFIER:exon13/31:c.1788+28C>T::					rs822021	0.9285	0.9840	13711,	0.7709,0.9902,0.9999,0.9996,0.9995	0.9993,0.7767	-0.2560			0.01,0.12	0.24						n/a (AF>5%)	n/a (AF>5%)					GON4L (inh=n/a pLI=1.00)
chr1	155785579	155785582	AACT	-	hom	hom	hom	off-target	QUAL=23016;DP=246,293,224;AF=1.00,1.00,1.00;MQM=60	GON4L	intron	GON4L:ENST00000271883:intron_variant:MODIFIER:exon8/31:c.1161+14_1161+17del::,GON4L:ENST00000361040:intron_variant:MODIFIER:exon8/20:c.1161+14_1161+17del::,GON4L:ENST00000368331:intron_variant:MODIFIER:exon8/31:c.1161+14_1161+17del::,GON4L:ENST00000437809:intron_variant:MODIFIER:exon8/31:c.1161+14_1161+17del::					rs3028172,rs148569012	0.8626	0.9331	11763,	0.6329,0.9670,0.9991,0.9498,0.9503	0.9481,0.6467	-0.3330				0.78						n/a (AF>5%)	n/a (AF>5%)					GON4L (inh=n/a pLI=1.00)
chr1	156025096	156025096	C	T	wt	wt	het		QUAL=1260;DP=86,167,108;AF=0.00,0.00,0.51;MQM=60	LAMTOR2	synonymous	LAMTOR2:ENST00000368302:synonymous_variant:LOW:exon2/4:c.111C>T:p.Tyr37=:PF03259,LAMTOR2:ENST00000368304:synonymous_variant:LOW:exon2/3:c.111C>T:p.Tyr37=:PF03259,LAMTOR2:ENST00000368305:synonymous_variant:LOW:exon2/4:c.111C>T:p.Tyr37=:PF03259	610389 [LAMTOR2 (provisional) Immunodeficiency due to defect in MAPBP-interacting protein,610798];				rs7541	0.0717	0.1222	222,	0.0511,0.0907,0.0004,0.1614,0.0815	0.1628,0.0572	-0.9570			0.11,0.74	1.90						n/a (AF>5%)	n/a (AF>5%)					LAMTOR2 (inh=AR pLI=0.45)
chr1	156105028	156105028	T	C	wt	wt	het		QUAL=339;DP=94,54,36;AF=0.01,0.00,0.47;MQM=60	LMNA	synonymous	LMNA:ENST00000347559:synonymous_variant:LOW:exon5/11:c.861T>C:p.Ala287=:PF00038,LMNA:ENST00000361308:synonymous_variant:LOW:exon5/10:c.861T>C:p.Ala287=:PF00038,LMNA:ENST00000368297:synonymous_variant:LOW:exon6/11:c.618T>C:p.Ala206=:PF00038,LMNA:ENST00000368299:synonymous_variant:LOW:exon5/12:c.861T>C:p.Ala287=:PF00038,LMNA:ENST00000368300:synonymous_variant:LOW:exon5/12:c.861T>C:p.Ala287=:PF00038,LMNA:ENST00000368301:synonymous_variant:LOW:exon8/13:c.861T>C:p.Ala287=:PF00038,LMNA:ENST00000392353:synonymous_variant:LOW:exon5/10:c.618T>C:p.Ala206=:PF00038,LMNA:ENST00000448611:synonymous_variant:LOW:exon5/13:c.525T>C:p.Ala175=:PF00038,LMNA:ENST00000473598:synonymous_variant:LOW:exon6/13:c.564T>C:p.Ala188=:PF00038	150330 [LMNA (confirmed) Emery-Dreifuss muscular dystrophy 2,AD,181350/Cardiomyopathy,dilated,1A,115200/Lipodystrophy,familial partial,type 2,151660/Emery-Dreifuss muscular dystrophy 3,AR,616516/Charcot-Marie-Tooth disease,type 2B1,605588/Muscular dystrophy,congenital,613205/Muscular dystrophy,limb-girdle,type 1B,159001/Mandibuloacral dysplasia,248370/Hutchinson-Gilford progeria,176670/Restrictive dermopathy,lethal,275210/Heart-hand syndrome,Slovenian type,610140/Malouf syndrome,212112];	48088 [benign DISEASE=Hutchinson-Gilford syndrome,Charcot-Marie-Tooth disease, type 2,Familial partial lipodystrophy,Lethal tight skin contracture syndrome,Emery-Dreifuss muscular dystrophy,Congenital muscular dystrophy, LMNA-related,Mandibuloacral dysplasia,not specified,Cardiovascular phenotype,Lipoatrophy with Diabetes, Hepatic Steatosis, Hypertrophic Cardiomyopathy, and Leukomelanodermic Papules,Dilated Cardiomyopathy, Dominant,Limb-Girdle Muscular Dystrophy, Recessive,not provided];			rs538089	0.1931	0.1739	927,	0.4589,0.0647,0.0192,0.0722,0.1378	0.0751,0.4374	-7.5170			0.04,0.13	0.50						n/a (AF>5%)	n/a (AF>5%)					LMNA (inh=AR+AD pLI=0.99)
chr1	156105928	156105928	G	A	wt	wt	het	off-target	QUAL=3072;DP=91,311,261;AF=0.01,0.00,0.49;MQM=60	LMNA	intron	LMNA:ENST00000347559:intron_variant:MODIFIER:exon6/10:c.1157+16G>A::,LMNA:ENST00000361308:intron_variant:MODIFIER:exon6/9:c.1157+16G>A::,LMNA:ENST00000368297:intron_variant:MODIFIER:exon7/10:c.914+16G>A::,LMNA:ENST00000368299:intron_variant:MODIFIER:exon6/11:c.1157+16G>A::,LMNA:ENST00000368300:intron_variant:MODIFIER:exon6/11:c.1157+16G>A::,LMNA:ENST00000368301:intron_variant:MODIFIER:exon9/12:c.1157+16G>A::,LMNA:ENST00000392353:intron_variant:MODIFIER:exon6/9:c.914+16G>A::,LMNA:ENST00000448611:intron_variant:MODIFIER:exon6/12:c.821+16G>A::,LMNA:ENST00000473598:intron_variant:MODIFIER:exon7/12:c.860+16G>A::	150330 [LMNA (confirmed) Emery-Dreifuss muscular dystrophy 2,AD,181350/Cardiomyopathy,dilated,1A,115200/Lipodystrophy,familial partial,type 2,151660/Emery-Dreifuss muscular dystrophy 3,AR,616516/Charcot-Marie-Tooth disease,type 2B1,605588/Muscular dystrophy,congenital,613205/Muscular dystrophy,limb-girdle,type 1B,159001/Mandibuloacral dysplasia,248370/Hutchinson-Gilford progeria,176670/Restrictive dermopathy,lethal,275210/Heart-hand syndrome,Slovenian type,610140/Malouf syndrome,212112];	36474 [benign/likely benign DISEASE=Primary dilated cardiomyopathy,not specified,not provided];			rs534807	0.1923	0.1732	924,	0.4598,0.0644,0.0192,0.0713,0.1317	0.0748,0.4371	-0.1280			0.23,0.23	-0.08						n/a (AF>5%)	n/a (AF>5%)					LMNA (inh=AR+AD pLI=0.99)
chr1	156106185	156106185	T	C	wt	wt	het		QUAL=1107;DP=45,140,108;AF=0.00,0.00,0.46;MQM=60	LMNA	synonymous	LMNA:ENST00000347559:synonymous_variant:LOW:exon7/11:c.1338T>C:p.Asp446=:PF00932,LMNA:ENST00000361308:synonymous_variant:LOW:exon7/10:c.1338T>C:p.Asp446=:PF00932,LMNA:ENST00000368297:synonymous_variant:LOW:exon8/11:c.1095T>C:p.Asp365=:PF00932,LMNA:ENST00000368299:synonymous_variant:LOW:exon7/12:c.1338T>C:p.Asp446=:PF00932,LMNA:ENST00000368300:synonymous_variant:LOW:exon7/12:c.1338T>C:p.Asp446=:PF00932,LMNA:ENST00000368301:synonymous_variant:LOW:exon10/13:c.1338T>C:p.Asp446=:PF00932,LMNA:ENST00000392353:synonymous_variant:LOW:exon7/10:c.1095T>C:p.Asp365=:PF00932,LMNA:ENST00000448611:synonymous_variant:LOW:exon7/13:c.1002T>C:p.Asp334=:PF00932,LMNA:ENST00000473598:synonymous_variant:LOW:exon8/13:c.1041T>C:p.Asp347=:PF00932	150330 [LMNA (confirmed) Emery-Dreifuss muscular dystrophy 2,AD,181350/Cardiomyopathy,dilated,1A,115200/Lipodystrophy,familial partial,type 2,151660/Emery-Dreifuss muscular dystrophy 3,AR,616516/Charcot-Marie-Tooth disease,type 2B1,605588/Muscular dystrophy,congenital,613205/Muscular dystrophy,limb-girdle,type 1B,159001/Mandibuloacral dysplasia,248370/Hutchinson-Gilford progeria,176670/Restrictive dermopathy,lethal,275210/Heart-hand syndrome,Slovenian type,610140/Malouf syndrome,212112];	48037 [benign DISEASE=Hutchinson-Gilford syndrome,Charcot-Marie-Tooth disease, type 2,Familial partial lipodystrophy,Lethal tight skin contracture syndrome,Emery-Dreifuss muscular dystrophy,Limb-girdle muscular dystrophy, type 1B,Charcot-Marie-Tooth disease type 2B1,Emery-Dreifuss muscular dystrophy 3, autosomal recessive,Congenital muscular dystrophy, LMNA-related,Mandibuloacral dysplasia,not specified,Cardiovascular phenotype,Lipoatrophy with Diabetes, Hepatic Steatosis, Hypertrophic Cardiomyopathy, and Leukomelanodermic Papules,Dilated Cardiomyopathy, Dominant,Limb-Girdle Muscular Dystrophy, Recessive,not provided];			rs505058	0.2492	0.2262	1798,	0.6407,0.0743,0.0198,0.0734,0.1430	0.0760,0.6015	-0.3620			0.17,0.86	0.65						n/a (AF>5%)	n/a (AF>5%)					LMNA (inh=AR+AD pLI=0.99)
chr1	156106863	156106863	C	T	wt	wt	het	off-target	QUAL=2844;DP=182,371,241;AF=0.00,0.00,0.54;MQM=60	LMNA	intron	LMNA:ENST00000347559:intron_variant:MODIFIER:exon8/10:c.1489-41C>T::,LMNA:ENST00000361308:intron_variant:MODIFIER:exon8/9:c.1489-41C>T::,LMNA:ENST00000368297:intron_variant:MODIFIER:exon9/10:c.1246-41C>T::,LMNA:ENST00000368299:intron_variant:MODIFIER:exon8/11:c.1489-41C>T::,LMNA:ENST00000368300:intron_variant:MODIFIER:exon8/11:c.1489-41C>T::,LMNA:ENST00000368301:intron_variant:MODIFIER:exon11/12:c.1489-41C>T::,LMNA:ENST00000392353:intron_variant:MODIFIER:exon8/9:c.1246-41C>T::,LMNA:ENST00000448611:intron_variant:MODIFIER:exon8/12:c.1153-41C>T::,LMNA:ENST00000473598:intron_variant:MODIFIER:exon9/12:c.1192-41C>T::	150330 [LMNA (confirmed) Emery-Dreifuss muscular dystrophy 2,AD,181350/Cardiomyopathy,dilated,1A,115200/Lipodystrophy,familial partial,type 2,151660/Emery-Dreifuss muscular dystrophy 3,AR,616516/Charcot-Marie-Tooth disease,type 2B1,605588/Muscular dystrophy,congenital,613205/Muscular dystrophy,limb-girdle,type 1B,159001/Mandibuloacral dysplasia,248370/Hutchinson-Gilford progeria,176670/Restrictive dermopathy,lethal,275210/Heart-hand syndrome,Slovenian type,610140/Malouf syndrome,212112];	66834 [benign DISEASE=not specified,not provided];			rs553016	0.1823	0.1657	815,	0.4288,0.0628,0.0193,0.0715,0.1371	0.0751,0.4063	0.3060			0.22,0.27	0.02						n/a (AF>5%)	n/a (AF>5%)					LMNA (inh=AR+AD pLI=0.99)
chr1	156107534	156107534	C	T	het	het	wt		QUAL=6879;DP=149,354,263;AF=0.61,0.55,0.00;MQM=60	LMNA	intron,synonymous,splice_region&synonymous	LMNA:ENST00000347559:intron_variant:MODIFIER:exon9/10:c.1608+511C>T::,LMNA:ENST00000361308:synonymous_variant:LOW:exon10/10:c.1698C>T:p.His566=:,LMNA:ENST00000368297:synonymous_variant:LOW:exon11/11:c.1455C>T:p.His485=:,LMNA:ENST00000368299:splice_region_variant&synonymous_variant:LOW:exon10/12:c.1698C>T:p.His566=:,LMNA:ENST00000368300:splice_region_variant&synonymous_variant:LOW:exon10/12:c.1698C>T:p.His566=:,LMNA:ENST00000368301:synonymous_variant:LOW:exon13/13:c.1698C>T:p.His566=:,LMNA:ENST00000392353:synonymous_variant:LOW:exon10/10:c.1455C>T:p.His485=:,LMNA:ENST00000448611:splice_region_variant&synonymous_variant:LOW:exon10/13:c.1362C>T:p.His454=:,LMNA:ENST00000473598:splice_region_variant&synonymous_variant:LOW:exon11/13:c.1401C>T:p.His467=:	150330 [LMNA (confirmed) Emery-Dreifuss muscular dystrophy 2,AD,181350/Cardiomyopathy,dilated,1A,115200/Lipodystrophy,familial partial,type 2,151660/Emery-Dreifuss muscular dystrophy 3,AR,616516/Charcot-Marie-Tooth disease,type 2B1,605588/Muscular dystrophy,congenital,613205/Muscular dystrophy,limb-girdle,type 1B,159001/Mandibuloacral dysplasia,248370/Hutchinson-Gilford progeria,176670/Restrictive dermopathy,lethal,275210/Heart-hand syndrome,Slovenian type,610140/Malouf syndrome,212112];	48048 [benign DISEASE=Hutchinson-Gilford syndrome,Charcot-Marie-Tooth disease, type 2,Familial partial lipodystrophy,Lethal tight skin contracture syndrome,Emery-Dreifuss muscular dystrophy,Limb-girdle muscular dystrophy, type 1B,Charcot-Marie-Tooth disease type 2B1,Emery-Dreifuss muscular dystrophy 3, autosomal recessive,Congenital muscular dystrophy, LMNA-related,Mandibuloacral dysplasia,not specified,Cardiovascular phenotype,Mandibuloacral dysplasia with type A lipodystrophy,Lipoatrophy with Diabetes, Hepatic Steatosis, Hypertrophic Cardiomyopathy, and Leukomelanodermic Papules,Dilated Cardiomyopathy, Dominant,Limb-Girdle Muscular Dystrophy, Recessive,not provided];	CM003892 [CLASS=DP MUT=ALT PHEN="Metabolic syndrome association with" GENE=LMNA];		rs4641	0.2202	0.2634	702,	0.0905,0.3240,0.2656,0.2649,0.2926	0.2531,0.0881	-1.2430			0.31,0.89	0.68		-15.83% (9.30>7.83)				n/a (AF>5%)	n/a (AF>5%)					LMNA (inh=AR+AD pLI=0.99)
chr1	156108976	156108976	G	C	wt	wt	het		QUAL=36;DP=68,15,7;AF=0.00,0.00,0.57;MQM=60	LMNA	3'UTR,intron	LMNA:ENST00000347559:3_prime_UTR_variant:MODIFIER:exon11/11:c.*79G>C::,LMNA:ENST00000368299:3_prime_UTR_variant:MODIFIER:exon12/12:c.*79G>C::,LMNA:ENST00000368300:3_prime_UTR_variant:MODIFIER:exon12/12:c.*79G>C::,LMNA:ENST00000448611:intron_variant:MODIFIER:exon12/12:c.1655+83G>C::,LMNA:ENST00000473598:3_prime_UTR_variant:MODIFIER:exon13/13:c.*79G>C::	150330 [LMNA (confirmed) Emery-Dreifuss muscular dystrophy 2,AD,181350/Cardiomyopathy,dilated,1A,115200/Lipodystrophy,familial partial,type 2,151660/Emery-Dreifuss muscular dystrophy 3,AR,616516/Charcot-Marie-Tooth disease,type 2B1,605588/Muscular dystrophy,congenital,613205/Muscular dystrophy,limb-girdle,type 1B,159001/Mandibuloacral dysplasia,248370/Hutchinson-Gilford progeria,176670/Restrictive dermopathy,lethal,275210/Heart-hand syndrome,Slovenian type,610140/Malouf syndrome,212112];	66756 [not provided DISEASE=not provided];			rs7339	0.1853	0.1680	834,		0.0773,0.4053	-0.0730			0.01,0.12	0.35						n/a (AF>5%)	n/a (AF>5%)					LMNA (inh=AR+AD pLI=0.99)
chr1	156109094	156109094	-	A	wt	wt	het		QUAL=50;DP=57,52,33;AF=0.00,0.06,0.24;MQM=60	LMNA	3'UTR,intron	LMNA:ENST00000347559:3_prime_UTR_variant:MODIFIER:exon11/11:c.*211dup::,LMNA:ENST00000368299:3_prime_UTR_variant:MODIFIER:exon12/12:::,LMNA:ENST00000368300:3_prime_UTR_variant:MODIFIER:exon12/12:c.*211dup::,LMNA:ENST00000448611:intron_variant:MODIFIER:exon12/12:c.1655+215dup::	150330 [LMNA (confirmed) Emery-Dreifuss muscular dystrophy 2,AD,181350/Cardiomyopathy,dilated,1A,115200/Lipodystrophy,familial partial,type 2,151660/Emery-Dreifuss muscular dystrophy 3,AR,616516/Charcot-Marie-Tooth disease,type 2B1,605588/Muscular dystrophy,congenital,613205/Muscular dystrophy,limb-girdle,type 1B,159001/Mandibuloacral dysplasia,248370/Hutchinson-Gilford progeria,176670/Restrictive dermopathy,lethal,275210/Heart-hand syndrome,Slovenian type,610140/Malouf syndrome,212112];				rs535843454	0.0990	0.1380	284,							1.23						n/a (AF>5%)	n/a (AF>5%)					LMNA (inh=AR+AD pLI=0.99)
chr1	156785617	156785617	G	A	hom	hom	hom		QUAL=22370;DP=197,299,210;AF=1.00,1.00,1.00;MQM=59	SH2D2A,NTRK1	intron,5'UTR	SH2D2A:ENST00000368198:intron_variant:MODIFIER:exon2/8:c.69+181C>T::,SH2D2A:ENST00000368199:intron_variant:MODIFIER:exon2/8:c.123+181C>T::,NTRK1:ENST00000392302:5_prime_UTR_variant:MODIFIER:exon1/17:c.-5G>A::,SH2D2A:ENST00000392306:intron_variant:MODIFIER:exon2/8:c.123+181C>T::	191315 [NTRK1 (confirmed) Insensitivity to pain,congenital,with anhidrosis,256800/Medullary thyroid carcinoma,familial,155240];	380853 [benign DISEASE=not specified];			rs1800601	0.6370	0.6737	6122,	0.4980,0.6963,0.8180,0.6776,0.6547	0.6759,0.5041	-1.8140			0.00,0.07	-0.07						n/a (AF>5%)	n/a (AF>5%)					SH2D2A (inh=n/a pLI=0.00), NTRK1 (inh=AR+AD pLI=0.00)
chr1	156845492	156845492	-	GTGT	het	het	wt	off-target	QUAL=1036;DP=20,48,43;AF=0.25,0.83,0.60;MQM=60	NTRK1	intron	NTRK1:ENST00000358660:intron_variant:MODIFIER:exon11/15:c.1483+67_1483+70dup::,NTRK1:ENST00000368196:intron_variant:MODIFIER:exon11/15:c.1483+67_1483+70dup::,NTRK1:ENST00000392302:intron_variant:MODIFIER:exon12/16:c.1393+67_1393+70dup::,NTRK1:ENST00000524377:intron_variant:MODIFIER:exon12/16:c.1501+67_1501+70dup::	191315 [NTRK1 (confirmed) Insensitivity to pain,congenital,with anhidrosis,256800/Medullary thyroid carcinoma,familial,155240];			(GT)n			0.4944	3551,							0.11						n/a (AF>5%)	n/a (AF>5%)					NTRK1 (inh=AR+AD pLI=0.00)
chr1	156845493	156845494	GT	-	wt	wt	het	off-target	QUAL=1036;DP=20,48,43;AF=0.15,0.29,0.60;MQM=60	NTRK1	intron	NTRK1:ENST00000358660:intron_variant:MODIFIER:exon11/15:c.1483+69_1483+70del::,NTRK1:ENST00000368196:intron_variant:MODIFIER:exon11/15:c.1483+69_1483+70del::,NTRK1:ENST00000392302:intron_variant:MODIFIER:exon12/16:c.1393+69_1393+70del::,NTRK1:ENST00000524377:intron_variant:MODIFIER:exon12/16:c.1501+69_1501+70del::	191315 [NTRK1 (confirmed) Insensitivity to pain,congenital,with anhidrosis,256800/Medullary thyroid carcinoma,familial,155240];			(GT)n	rs766543019		0.1494	321,			1.6560				0.12						n/a (AF>5%)	n/a (AF>5%)					NTRK1 (inh=AR+AD pLI=0.00)
chr1	156845492	156845492	-	GT	wt	het	wt	off-target	QUAL=1036;DP=20,48,43;AF=0.15,0.83,0.02;MQM=59	NTRK1	intron	NTRK1:ENST00000358660:intron_variant:MODIFIER:exon11/15:c.1483+69_1483+70dup::,NTRK1:ENST00000368196:intron_variant:MODIFIER:exon11/15:c.1483+69_1483+70dup::,NTRK1:ENST00000392302:intron_variant:MODIFIER:exon12/16:c.1393+69_1393+70dup::,NTRK1:ENST00000524377:intron_variant:MODIFIER:exon12/16:c.1501+69_1501+70dup::	191315 [NTRK1 (confirmed) Insensitivity to pain,congenital,with anhidrosis,256800/Medullary thyroid carcinoma,familial,155240];			(GT)n			0.1035	302,							0.12						n/a (AF>5%)	n/a (AF>5%)					NTRK1 (inh=AR+AD pLI=0.00)
chr1	156846233	156846233	G	A	het	wt	hom		QUAL=6474;DP=149,146,149;AF=0.51,0.00,1.00;MQM=60	NTRK1	synonymous	NTRK1:ENST00000358660:synonymous_variant:LOW:exon13/16:c.1665G>A:p.Gln555=:PF07714,NTRK1:ENST00000368196:synonymous_variant:LOW:exon13/16:c.1656G>A:p.Gln552=:PF07714,NTRK1:ENST00000392302:synonymous_variant:LOW:exon14/17:c.1566G>A:p.Gln522=:PF07714,NTRK1:ENST00000524377:synonymous_variant:LOW:exon14/17:c.1674G>A:p.Gln558=:PF07714	191315 [NTRK1 (confirmed) Insensitivity to pain,congenital,with anhidrosis,256800/Medullary thyroid carcinoma,familial,155240];	292889 [benign DISEASE=Hereditary insensitivity to pain with anhidrosis,not specified];			rs6334	0.2129	0.2202	620,	0.1332,0.2154,0.3505,0.2147,0.2353	0.2194,0.1432	0.2840			0.84,0.91	1.59						n/a (AF>5%)	n/a (AF>5%)					NTRK1 (inh=AR+AD pLI=0.00)
chr1	156848995	156848995	C	T	het	hom	wt		QUAL=3876;DP=49,128,104;AF=0.33,0.97,0.01;MQM=59	NTRK1	synonymous	NTRK1:ENST00000358660:synonymous_variant:LOW:exon14/16:c.1878C>T:p.Ala626=:PF07714,NTRK1:ENST00000368196:synonymous_variant:LOW:exon14/16:c.1869C>T:p.Ala623=:PF07714,NTRK1:ENST00000392302:synonymous_variant:LOW:exon15/17:c.1779C>T:p.Ala593=:PF07714,NTRK1:ENST00000524377:synonymous_variant:LOW:exon15/17:c.1887C>T:p.Ala629=:PF07714	191315 [NTRK1 (confirmed) Insensitivity to pain,congenital,with anhidrosis,256800/Medullary thyroid carcinoma,familial,155240];	138564 [benign DISEASE=Hereditary insensitivity to pain with anhidrosis,not specified];			rs6337	0.3341	0.5806	5495,	0.1951,0.5753,0.0396,0.7246,0.3930	0.7262,0.2262	-4.5650			0.07,0.92	0.30						n/a (AF>5%)	n/a (AF>5%)					NTRK1 (inh=AR+AD pLI=0.00)
chr1	160009121	160009121	A	C	het	wt	het		QUAL=3017;DP=172,80,68;AF=0.50,0.00,0.46;MQM=59	KCNJ10	3'UTR	KCNJ10:ENST00000368089:3_prime_UTR_variant:MODIFIER:exon2/2:c.*2062T>G::	602208 [KCNJ10 (confirmed) SESAME syndrome,612780/Enlarged vestibular aqueduct,digenic,600791];	293090 [likely benign DISEASE=Pendred's syndrome,Seizures, Sensorineural Deafness, Ataxia, Intellectual Disability, and Electrolyte Imbalance Syndrome,Nonsyndromic Hearing Loss, Mixed];			rs1053074	0.4810	0.4439	3248,			1.4870			0.77,0.94	0.39						n/a (AF>5%)	n/a (AF>5%)					KCNJ10 (inh=AR pLI=0.87)
chr1	160009143	160009143	G	C	hom	hom	hom		QUAL=8494;DP=143,69,59;AF=1.00,1.00,0.97;MQM=59	KCNJ10	3'UTR	KCNJ10:ENST00000368089:3_prime_UTR_variant:MODIFIER:exon2/2:c.*2040C>G::	602208 [KCNJ10 (confirmed) SESAME syndrome,612780/Enlarged vestibular aqueduct,digenic,600791];	293091 [benign DISEASE=Pendred's syndrome,Seizures, Sensorineural Deafness, Ataxia, Intellectual Disability, and Electrolyte Imbalance Syndrome,Nonsyndromic Hearing Loss, Mixed];			rs2486254	0.9982	0.9972	15233,			0.2730			0.00,0.12	0.01						n/a (AF>5%)	n/a (AF>5%)					KCNJ10 (inh=AR pLI=0.87)
chr1	160009164	160009169	ACACAC	-	hom	wt	het		QUAL=885;DP=15,41,37;AF=0.40,0.66,0.84;MQM=60	KCNJ10	3'UTR	KCNJ10:ENST00000368089:3_prime_UTR_variant:MODIFIER:exon2/2:c.*2014_*2019del::	602208 [KCNJ10 (confirmed) SESAME syndrome,612780/Enlarged vestibular aqueduct,digenic,600791];	293097 [uncertain significance DISEASE=Pendred's syndrome,Seizures, Sensorineural Deafness, Ataxia, Intellectual Disability, and Electrolyte Imbalance Syndrome,Nonsyndromic Hearing Loss, Mixed];		(AC)n	rs886045404		0.0973	163,			-0.0330				-0.14						n/a (AF>5%)	n/a (AF>5%)					KCNJ10 (inh=AR pLI=0.87)
chr1	160009164	160009167	ACAC	-	wt	wt	het		QUAL=885;DP=15,41,37;AF=0.40,0.66,0.84;MQM=59	KCNJ10	3'UTR	KCNJ10:ENST00000368089:3_prime_UTR_variant:MODIFIER:exon2/2:c.*2016_*2019del::	602208 [KCNJ10 (confirmed) SESAME syndrome,612780/Enlarged vestibular aqueduct,digenic,600791];	293095 [likely benign DISEASE=Pendred's syndrome,Seizures, Sensorineural Deafness, Ataxia, Intellectual Disability, and Electrolyte Imbalance Syndrome,Nonsyndromic Hearing Loss, Mixed];		(AC)n	rs374594439	0.2965	0.1645	380,			-0.0330				-0.14						n/a (AF>5%)	n/a (AF>5%)					KCNJ10 (inh=AR pLI=0.87)
chr1	160009164	160009165	AC	-	wt	het	wt		QUAL=885;DP=15,41,37;AF=0.40,0.66,0.84;MQM=60	KCNJ10	3'UTR	KCNJ10:ENST00000368089:3_prime_UTR_variant:MODIFIER:exon2/2:c.*2018_*2019del::	602208 [KCNJ10 (confirmed) SESAME syndrome,612780/Enlarged vestibular aqueduct,digenic,600791];	293094 [uncertain significance DISEASE=Pendred's syndrome,Seizures, Sensorineural Deafness, Ataxia, Intellectual Disability, and Electrolyte Imbalance Syndrome,Nonsyndromic Hearing Loss, Mixed];		(AC)n	rs72013077		0.1178	193,			-0.0330				-0.14						n/a (AF>5%)	n/a (AF>5%)					KCNJ10 (inh=AR pLI=0.87)
chr1	160009419	160009419	A	C	hom	hom	hom		QUAL=31885;DP=367,345,263;AF=0.99,1.00,1.00;MQM=60	KCNJ10	3'UTR	KCNJ10:ENST00000368089:3_prime_UTR_variant:MODIFIER:exon2/2:c.*1764T>G::	602208 [KCNJ10 (confirmed) SESAME syndrome,612780/Enlarged vestibular aqueduct,digenic,600791];	293102 [benign DISEASE=Pendred's syndrome,Seizures, Sensorineural Deafness, Ataxia, Intellectual Disability, and Electrolyte Imbalance Syndrome,Nonsyndromic Hearing Loss, Mixed];			rs2486253	0.8628	0.8136	10257,			0.4040			0.12,0.26	0.67						n/a (AF>5%)	n/a (AF>5%)					KCNJ10 (inh=AR pLI=0.87)
chr1	160010151	160010151	C	T	wt	wt	het		QUAL=2286;DP=335,282,197;AF=0.00,0.00,0.50;MQM=60	KCNJ10	3'UTR	KCNJ10:ENST00000368089:3_prime_UTR_variant:MODIFIER:exon2/2:c.*1032G>A::	602208 [KCNJ10 (confirmed) SESAME syndrome,612780/Enlarged vestibular aqueduct,digenic,600791];				rs17375748	0.0244	0.0428	31,			0.1640			0.05,0.19	0.07						1	29					KCNJ10 (inh=AR pLI=0.87)
chr1	160246990	160246990	T	-	het	het	het		QUAL=1014;DP=258,184,134;AF=0.17,0.15,0.22;MQM=59	PEX19,DCAF8	3'UTR,intron	PEX19:ENST00000368072:3_prime_UTR_variant:MODIFIER:exon8/8:c.*2351del::,DCAF8:ENST00000556710:intron_variant:MODIFIER:exon6/17:c.436+931del::,DCAF8:ENST00000608310:intron_variant:MODIFIER:exon6/17:c.436+931del::	615820 [DCAF8 (provisional) Giant axonal neuropathy 2,autosomal dominant,610100],600279 [PEX19 (confirmed) Peroxisome biogenesis disorder 12A (Zellweger),614886];			Charlie10	rs751979135		0.2458	0,	0.2090,0.2262,0.2281,0.2549,0.2481		-0.2200				-0.13						n/a (AF>5%)	n/a (AF>5%)					PEX19 (inh=AR pLI=0.03), DCAF8 (inh=AD pLI=1.00)
chr1	160247185	160247185	G	C	het	hom	wt		QUAL=10242;DP=282,218,165;AF=0.44,1.00,0.01;MQM=60	PEX19,DCAF8	3'UTR,intron	PEX19:ENST00000368072:3_prime_UTR_variant:MODIFIER:exon8/8:c.*2156C>G::,DCAF8:ENST00000556710:intron_variant:MODIFIER:exon6/17:c.436+736C>G::,DCAF8:ENST00000608310:intron_variant:MODIFIER:exon6/17:c.436+736C>G::	615820 [DCAF8 (provisional) Giant axonal neuropathy 2,autosomal dominant,610100],600279 [PEX19 (confirmed) Peroxisome biogenesis disorder 12A (Zellweger),614886];	293196 [benign DISEASE=Zellweger syndrome];		Charlie10	rs10594	0.4523	0.4953	3060,	0.3385,0.4810,0.3477,0.5058,0.6153		0.4560			0.17,0.16	-0.20						n/a (AF>5%)	n/a (AF>5%)					PEX19 (inh=AR pLI=0.03), DCAF8 (inh=AD pLI=1.00)
chr1	160251792	160251792	A	G	het	hom	wt	off-target	QUAL=6834;DP=210,149,91;AF=0.44,1.00,0.00;MQM=60	PEX19,DCAF8	intron	PEX19:ENST00000368072:intron_variant:MODIFIER:exon5/7:c.594+37T>C::,PEX19:ENST00000440949:intron_variant:MODIFIER:exon5/7:c.324+37T>C::,DCAF8:ENST00000556710:intron_variant:MODIFIER:exon3/17:c.153+37T>C::,DCAF8:ENST00000608310:intron_variant:MODIFIER:exon3/17:c.153+37T>C::	615820 [DCAF8 (provisional) Giant axonal neuropathy 2,autosomal dominant,610100],600279 [PEX19 (confirmed) Peroxisome biogenesis disorder 12A (Zellweger),614886];				rs2795067	0.6703	0.6300	6479,	0.8699,0.5592,0.4651,0.5547,0.7051	0.5528,0.8559	-1.5860			0.01,0.10	-0.02						n/a (AF>5%)	n/a (AF>5%)					PEX19 (inh=AR pLI=0.03), DCAF8 (inh=AD pLI=1.00)
chr1	161140278	161140278	A	-	het	het	wt		QUAL=6425;DP=228,379,326;AF=0.46,0.46,0.00;MQM=59	PPOX	frameshift,intron	PPOX:ENST00000352210:frameshift_variant:HIGH:exon10/13:c.1067del:p.Gln356ArgfsTer10:PF01593,PPOX:ENST00000367999:frameshift_variant:HIGH:exon10/13:c.1067del:p.Gln356ArgfsTer10:PF01593,PPOX:ENST00000432542:frameshift_variant:HIGH:exon4/6:c.302del:p.Gln101ArgfsTer10:PF01593,PPOX:ENST00000535223:intron_variant:MODIFIER:exon2/3:c.88-132del::,PPOX:ENST00000544598:intron_variant:MODIFIER:exon3/5:c.223-132del::	600923 [PPOX (provisional) Porphyria variegata,176200];										7.3390										0	2					PPOX (inh=AD pLI=0.89)
chr1	161184059	161184059	-	TGTG	wt	wt	het		QUAL=1565;DP=210,211,161;AF=0.02,0.30,0.35;MQM=60	NDUFS2	3'UTR	NDUFS2:ENST00000367993:3_prime_UTR_variant:MODIFIER:exon15/15:c.*104_*107dup::,NDUFS2:ENST00000392179:3_prime_UTR_variant:MODIFIER:exon13/13:c.*356_*359dup::	602985 [NDUFS2 (provisional) Mitochondrial complex I deficiency,252010];			(TG)n	rs10629771		0.1278	226,							1.26						n/a (AF>5%)	n/a (AF>5%)					NDUFS2 (inh=AR pLI=1.00)
chr1	161184059	161184059	-	TG	wt	het	wt		QUAL=1565;DP=210,211,161;AF=0.02,0.30,0.35;MQM=59	NDUFS2	3'UTR	NDUFS2:ENST00000367993:3_prime_UTR_variant:MODIFIER:exon15/15:c.*106_*107dup::,NDUFS2:ENST00000392179:3_prime_UTR_variant:MODIFIER:exon13/13:c.*358_*359dup::	602985 [NDUFS2 (provisional) Mitochondrial complex I deficiency,252010];	293284 [uncertain significance DISEASE=Mitochondrial complex I deficiency];		(TG)n	rs10629771		0.2837	1188,							1.27						n/a (AF>5%)	n/a (AF>5%)					NDUFS2 (inh=AR pLI=1.00)
chr1	161184097	161184097	A	G	wt	het	wt		QUAL=2159;DP=362,252,186;AF=0.00,0.39,0.00;MQM=59	NDUFS2	3'UTR	NDUFS2:ENST00000367993:3_prime_UTR_variant:MODIFIER:exon15/15:c.*114A>G::,NDUFS2:ENST00000392179:3_prime_UTR_variant:MODIFIER:exon13/13:c.*366A>G::	602985 [NDUFS2 (provisional) Mitochondrial complex I deficiency,252010];	293289 [likely benign DISEASE=Mitochondrial complex I deficiency];			rs1136224	0.1821	0.1396	353,			-0.2700			0.00,0.12	0.01						n/a (AF>5%)	n/a (AF>5%)					NDUFS2 (inh=AR pLI=1.00)
chr1	161274648	161274648	G	C	wt	het	het		QUAL=67;DP=35,34,28;AF=0.00,0.29,0.29;MQM=60	MPZ	3'UTR	MPZ:ENST00000360451:3_prime_UTR_variant:MODIFIER:exon6/6:c.*1018C>G::,MPZ:ENST00000491222:3_prime_UTR_variant:MODIFIER:exon5/5:c.*1018C>G::,MPZ:ENST00000533357:3_prime_UTR_variant:MODIFIER:exon6/6:c.*1018C>G::	159440 [MPZ (confirmed) Charcot-Marie-Tooth disease,type 1B,118200/Dejerine-Sottas disease,145900/Neuropathy,congenital hypomyelinating,605253/Charcot-Marie-Tooth disease,type 2J,607736/Roussy-Levy syndrome,180800/Charcot-Marie-Tooth disease,type 2I,607677/Charcot-Marie-Tooth disease,dominant intermediate D,607791];				rs185093979		0.2973	0,			-0.6030			0.01,0.16	-0.27						n/a (AF>5%)	n/a (AF>5%)					MPZ (inh=AR+AD pLI=0.91)
chr1	161274905	161274905	T	C	wt	wt	het		QUAL=172;DP=68,18,29;AF=0.00,0.00,0.38;MQM=60	MPZ	3'UTR	MPZ:ENST00000360451:3_prime_UTR_variant:MODIFIER:exon6/6:c.*761A>G::,MPZ:ENST00000491222:3_prime_UTR_variant:MODIFIER:exon5/5:c.*761A>G::,MPZ:ENST00000533357:3_prime_UTR_variant:MODIFIER:exon6/6:c.*761A>G::	159440 [MPZ (confirmed) Charcot-Marie-Tooth disease,type 1B,118200/Dejerine-Sottas disease,145900/Neuropathy,congenital hypomyelinating,605253/Charcot-Marie-Tooth disease,type 2J,607736/Roussy-Levy syndrome,180800/Charcot-Marie-Tooth disease,type 2I,607677/Charcot-Marie-Tooth disease,dominant intermediate D,607791];	293304 [benign DISEASE=Roussy-Levy syndrome,Congenital hypomyelinating neuropathy,Charcot-Marie-Tooth disease, type I,Charcot-Marie-Tooth, Intermediate];			rs16832786	0.1364	0.1281	313,			-1.1460			0.02,0.13	-0.06						n/a (AF>5%)	n/a (AF>5%)					MPZ (inh=AR+AD pLI=0.91)
chr1	167399868	167399868	-	AG	hom	hom	hom		QUAL=15343;DP=189,177,147;AF=0.99,0.99,0.99;MQM=60	CD247,POU2F1	downstream_gene	CD247:ENST00000362089:downstream_gene_variant:MODIFIER::::,POU2F1:ENST00000367862:downstream_gene_variant:MODIFIER::::,POU2F1:ENST00000367866:downstream_gene_variant:MODIFIER::::,CD247:ENST00000392122:downstream_gene_variant:MODIFIER::::	186780 [CD247 (confirmed) Immunodeficiency 25,610163];				rs5778549	0.9870	0.9884	15134,							-0.10						n/a (AF>5%)	n/a (AF>5%)					CD247 (inh=AR pLI=0.59), POU2F1 (inh=n/a pLI=0.99)
chr1	167399962	167399962	T	C	hom	hom	hom		QUAL=39500;DP=382,465,381;AF=1.00,1.00,1.00;MQM=60	CD247	3'UTR	CD247:ENST00000362089:3_prime_UTR_variant:MODIFIER:exon8/8:c.*956A>G::,CD247:ENST00000392122:3_prime_UTR_variant:MODIFIER:exon8/8:c.*956A>G::	186780 [CD247 (confirmed) Immunodeficiency 25,610163];				rs947480		0.9884	15138,			-1.3530			0.00,0.12	0.32						n/a (AF>5%)	n/a (AF>5%)					CD247 (inh=AR pLI=0.59)
chr1	167400074	167400074	T	A	hom	hom	hom		QUAL=45561;DP=403,593,434;AF=1.00,1.00,1.00;MQM=60	CD247	3'UTR	CD247:ENST00000362089:3_prime_UTR_variant:MODIFIER:exon8/8:c.*844A>T::,CD247:ENST00000392122:3_prime_UTR_variant:MODIFIER:exon8/8:c.*844A>T::	186780 [CD247 (confirmed) Immunodeficiency 25,610163];				rs1052231	0.8111	0.8148	10319,			-0.1760			0.02,0.15	-0.17						n/a (AF>5%)	n/a (AF>5%)					CD247 (inh=AR pLI=0.59)
chr1	167408670	167408670	C	T	het	hom	het	off-target	QUAL=11542;DP=76,288,224;AF=0.51,0.99,0.50;MQM=60	CD247	intron	CD247:ENST00000362089:intron_variant:MODIFIER:exon2/7:c.163-33G>A::,CD247:ENST00000392122:intron_variant:MODIFIER:exon2/7:c.163-33G>A::	186780 [CD247 (confirmed) Immunodeficiency 25,610163];				rs840016	0.1907	0.3113	1376,	0.0783,0.2344,0.1047,0.3992,0.2975	0.4031,0.0987	0.5230			0.06,0.20	0.58						n/a (AF>5%)	n/a (AF>5%)					CD247 (inh=AR pLI=0.59)
chr1	167487586	167487586	C	G	het	wt	het	off-target	QUAL=1434;DP=49,87,67;AF=0.53,0.00,0.55;MQM=60	CD247	intron	CD247:ENST00000362089:intron_variant:MODIFIER:exon1/7:c.58+59G>C::,CD247:ENST00000392122:intron_variant:MODIFIER:exon1/7:c.58+59G>C::	186780 [CD247 (confirmed) Immunodeficiency 25,610163];			(CCACTC)n	rs35864197	0.1108	0.1396	347,		0.1892,0.0802	0.7990			0.15,0.20	0.05						n/a (AF>5%)	n/a (AF>5%)					CD247 (inh=AR pLI=0.59)
chr1	173795804	173795804	T	-	het	het	het	off-target	QUAL=427;DP=73,44,18;AF=0.23,0.20,0.28;MQM=60	DARS2	intron	DARS2:ENST00000239457:intron_variant:MODIFIER:exon1/15:c.-1127-5del::,DARS2:ENST00000361951:intron_variant:MODIFIER:exon1/16:c.128-5del::	610956 [DARS2 (provisional) Leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation,611105];	559192 [benign DISEASE=not provided];		(T)n	rs772280960		0.4266	1,	0.3573,0.4100,0.4069,0.4367,0.4471		0.8260				-0.08						n/a (AF>5%)	n/a (AF>5%)					DARS2 (inh=AR pLI=0.00)
chr1	173819422	173819422	A	-	het	het	het	off-target	QUAL=401;DP=82,30,20;AF=0.20,0.23,0.25;MQM=60	DARS2	intron	DARS2:ENST00000239457:intron_variant:MODIFIER:exon12/15:c.-63-29del::,DARS2:ENST00000361951:intron_variant:MODIFIER:exon12/16:c.1192-29del::	610956 [DARS2 (provisional) Leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation,611105];				rs199872112		0.1362	0,	0.1021,0.1324,0.1022,0.1603,0.1246		-2.2520				-0.26						n/a (AF>5%)	n/a (AF>5%)					DARS2 (inh=AR pLI=0.00)
chr1	179519638	179519641	TTTC	-	wt	het	wt	off-target	QUAL=707;DP=124,61,52;AF=0.00,0.52,0.00;MQM=60	AXDND1	intron	AXDND1:ENST00000367618:intron_variant:MODIFIER:exon25/25:c.3032-4006_3032-4003del::					rs147171656	0.1324	0.2077	837,			0.8270				0.55						n/a (AF>5%)	n/a (AF>5%)					AXDND1 (inh=n/a pLI=0.00)
chr1	179519880	179519880	T	C	hom	hom	hom		QUAL=27909;DP=268,330,273;AF=1.00,1.00,1.00;MQM=60	NPHS2,AXDND1	3'UTR,intron	NPHS2:ENST00000367615:3_prime_UTR_variant:MODIFIER:exon8/8:c.*428A>G::,NPHS2:ENST00000367616:3_prime_UTR_variant:MODIFIER:exon7/7:c.*428A>G::,AXDND1:ENST00000367618:intron_variant:MODIFIER:exon25/25:c.3032-3767T>C::	604766 [NPHS2 (confirmed) Nephrotic syndrome,type 2,600995];	224486 [benign DISEASE=Steroid-resistant nephrotic syndrome,Nephrotic syndrome, idiopathic, steroid-resistant];			rs1060775	0.9018	0.9089	12826,			0.2720			0.03,0.16	-0.38						n/a (AF>5%)	n/a (AF>5%)					NPHS2 (inh=AR pLI=0.01), AXDND1 (inh=n/a pLI=0.00)
chr1	179520050	179520050	T	C	het	wt	hom		QUAL=8002;DP=330,177,121;AF=0.46,0.00,1.00;MQM=60	NPHS2,AXDND1	3'UTR,intron	NPHS2:ENST00000367615:3_prime_UTR_variant:MODIFIER:exon8/8:c.*258A>G::,NPHS2:ENST00000367616:3_prime_UTR_variant:MODIFIER:exon7/7:c.*258A>G::,AXDND1:ENST00000367618:intron_variant:MODIFIER:exon25/25:c.3032-3597T>C::	604766 [NPHS2 (confirmed) Nephrotic syndrome,type 2,600995];	224485 [likely benign DISEASE=Steroid-resistant nephrotic syndrome,Nephrotic syndrome, idiopathic, steroid-resistant];			rs2274622	0.2831	0.2323	902,			0.2690			0.13,0.36	0.40						n/a (AF>5%)	n/a (AF>5%)					NPHS2 (inh=AR pLI=0.01), AXDND1 (inh=n/a pLI=0.00)
chr1	179520151	179520151	C	T	hom	hom	hom		QUAL=24160;DP=286,263,194;AF=1.00,0.99,1.00;MQM=60	NPHS2,AXDND1	3'UTR,intron	NPHS2:ENST00000367615:3_prime_UTR_variant:MODIFIER:exon8/8:c.*157G>A::,NPHS2:ENST00000367616:3_prime_UTR_variant:MODIFIER:exon7/7:c.*157G>A::,AXDND1:ENST00000367618:intron_variant:MODIFIER:exon25/25:c.3032-3496C>T::	604766 [NPHS2 (confirmed) Nephrotic syndrome,type 2,600995];	224483 [benign DISEASE=Steroid-resistant nephrotic syndrome,Nephrotic syndrome, idiopathic, steroid-resistant];			rs1410590	0.9052	0.9118	12911,			-1.2820			0.00,0.14	-0.22						n/a (AF>5%)	n/a (AF>5%)					NPHS2 (inh=AR pLI=0.01), AXDND1 (inh=n/a pLI=0.00)
chr1	179520254	179520254	C	G	hom	hom	hom		QUAL=22139;DP=391,175,131;AF=0.99,0.99,0.99;MQM=60	NPHS2,AXDND1	3'UTR,intron	NPHS2:ENST00000367615:3_prime_UTR_variant:MODIFIER:exon8/8:c.*54G>C::,NPHS2:ENST00000367616:3_prime_UTR_variant:MODIFIER:exon7/7:c.*54G>C::,AXDND1:ENST00000367618:intron_variant:MODIFIER:exon25/25:c.3032-3393C>G::	604766 [NPHS2 (confirmed) Nephrotic syndrome,type 2,600995];	293845 [likely benign DISEASE=Steroid-resistant nephrotic syndrome];			rs1410591	0.5879	0.6116	5813,			0.9020			0.00,0.13	0.07						n/a (AF>5%)	n/a (AF>5%)					NPHS2 (inh=AR pLI=0.01), AXDND1 (inh=n/a pLI=0.00)
chr1	179520506	179520506	G	A	hom	hom	hom		QUAL=20723;DP=345,184,128;AF=0.99,1.00,0.99;MQM=60	NPHS2,AXDND1	synonymous,intron	NPHS2:ENST00000367615:synonymous_variant:LOW:exon8/8:c.954C>T:p.Ala318=:,NPHS2:ENST00000367616:synonymous_variant:LOW:exon7/7:c.750C>T:p.Ala250=:,AXDND1:ENST00000367618:intron_variant:MODIFIER:exon25/25:c.3032-3141G>A::	604766 [NPHS2 (confirmed) Nephrotic syndrome,type 2,600995];	260432 [benign/likely benign DISEASE=Steroid-resistant nephrotic syndrome,Nephrotic syndrome, idiopathic, steroid-resistant,not specified,not provided];			rs1410592		0.6197	5784,	0.6013,0.6667,0.4724,0.6310,0.6031	0.6262,0.5996	-0.5630			0.03,0.33	0.22						n/a (AF>5%)	n/a (AF>5%)					NPHS2 (inh=AR pLI=0.01), AXDND1 (inh=n/a pLI=0.00)
chr1	179521684	179521684	T	C	het	het	wt	off-target	QUAL=3081;DP=148,125,83;AF=0.46,0.47,0.00;MQM=60	NPHS2,AXDND1	intron	NPHS2:ENST00000367615:intron_variant:MODIFIER:exon7/7:c.873+54A>G::,NPHS2:ENST00000367616:intron_variant:MODIFIER:exon6/6:c.669+54A>G::,AXDND1:ENST00000367618:intron_variant:MODIFIER:exon25/25:c.3032-1963T>C::	604766 [NPHS2 (confirmed) Nephrotic syndrome,type 2,600995];				rs11808359	0.0214	0.0510	46,		0.0616,0.0116	0.1240			0.01,0.16	0.39						n/a (AF>5%)	n/a (AF>5%)					NPHS2 (inh=AR pLI=0.01), AXDND1 (inh=n/a pLI=0.00)
chr1	179521731	179521731	T	C	wt	wt	het		QUAL=1107;DP=138,198,114;AF=0.01,0.00,0.45;MQM=60	NPHS2,AXDND1	splice_region&intron,intron	NPHS2:ENST00000367615:splice_region_variant&intron_variant:LOW:exon7/7:c.873+7A>G::,NPHS2:ENST00000367616:splice_region_variant&intron_variant:LOW:exon6/6:c.669+7A>G::,AXDND1:ENST00000367618:intron_variant:MODIFIER:exon25/25:c.3032-1916T>C::	604766 [NPHS2 (confirmed) Nephrotic syndrome,type 2,600995];	260430 [benign DISEASE=not specified];			rs115778946	0.0160	0.0306	18,	0.0081,0.0232,0.0000,0.0491,0.0104	0.0472,0.0109	-1.5420			0.07,0.27	0.97				0.000/0.064		17	434					NPHS2 (inh=AR pLI=0.01), AXDND1 (inh=n/a pLI=0.00)
chr1	179528917	179528917	G	A	wt	het	wt	off-target	QUAL=2053;DP=167,157,135;AF=0.00,0.53,0.00;MQM=60	NPHS2	intron	NPHS2:ENST00000367615:intron_variant:MODIFIER:exon3/7:c.452-21C>T::,NPHS2:ENST00000367616:intron_variant:MODIFIER:exon3/6:c.452-21C>T::	604766 [NPHS2 (confirmed) Nephrotic syndrome,type 2,600995];				rs12401708	0.1334	0.2389	870,	0.0628,0.2420,0.0435,0.2750,0.2015	0.2691,0.0699	0.0010			0.04,0.14	-0.20						n/a (AF>5%)	n/a (AF>5%)					NPHS2 (inh=AR pLI=0.01)
chr1	179528942	179528942	G	A	wt	het	wt	off-target	QUAL=1842;DP=145,139,116;AF=0.00,0.55,0.00;MQM=60	NPHS2	intron	NPHS2:ENST00000367615:intron_variant:MODIFIER:exon3/7:c.452-46C>T::,NPHS2:ENST00000367616:intron_variant:MODIFIER:exon3/6:c.452-46C>T::	604766 [NPHS2 (confirmed) Nephrotic syndrome,type 2,600995];				rs12401711	0.1334	0.2381	872,	0.0624,0.2403,0.0434,0.2737,0.2003	0.2586,0.0673	-0.2810			0.03,0.18	0.25						n/a (AF>5%)	n/a (AF>5%)					NPHS2 (inh=AR pLI=0.01)
chr1	179544898	179544898	T	C	hom	hom	hom		QUAL=441;DP=1,13,3;AF=1.00,1.00,1.00;MQM=60	NPHS2	synonymous	NPHS2:ENST00000367615:synonymous_variant:LOW:exon1/8:c.102A>G:p.Gly34=:,NPHS2:ENST00000367616:synonymous_variant:LOW:exon1/7:c.102A>G:p.Gly34=:	604766 [NPHS2 (confirmed) Nephrotic syndrome,type 2,600995];	260424 [benign DISEASE=Steroid-resistant nephrotic syndrome,Nephrotic syndrome, idiopathic, steroid-resistant,not specified];			rs1079292	0.9309	0.9774	13954,	0.8064,0.9856,0.9753,0.9931,0.9452	0.9933,0.9031	-0.4500			0.01,0.06	-0.23						n/a (AF>5%)	n/a (AF>5%)					NPHS2 (inh=AR pLI=0.01)
chr1	179545050	179545050	C	A	wt	het	wt		QUAL=195;DP=1,18,9;AF=0.00,0.61,0.00;MQM=60	NPHS2	5'UTR	NPHS2:ENST00000367615:5_prime_UTR_variant:MODIFIER:exon1/8:c.-51G>T::,NPHS2:ENST00000367616:5_prime_UTR_variant:MODIFIER:exon1/7:c.-51G>T::	604766 [NPHS2 (confirmed) Nephrotic syndrome,type 2,600995];	225144 [likely benign DISEASE=Steroid-resistant nephrotic syndrome,Nephrotic syndrome, idiopathic, steroid-resistant]; 225143 [pathogenic DISEASE=Nephrotic syndrome, idiopathic, steroid-resistant];	CR068160 [CLASS=FP MUT=ALT PHEN="Reduced expression" GENE=NPHS2];		rs12406197	0.1833	0.2548	963,	0.1418,0.3443,0.0993,0.2757,0.2015	0.2212,0.1310	-1.1450			0.01,0.20	0.55						n/a (AF>5%)	n/a (AF>5%)					NPHS2 (inh=AR pLI=0.01)
chr1	179545115	179545115	G	A	hom	wt	hom	off-target	QUAL=61;DP=1,7,4;AF=1.00,0.00,1.00;MQM=60	NPHS2,RNU5F-2P	upstream_gene	NPHS2:ENST00000367615:upstream_gene_variant:MODIFIER::::,NPHS2:ENST00000367616:upstream_gene_variant:MODIFIER::::,RNU5F-2P:ENST00000516066:upstream_gene_variant:MODIFIER::::			CR068161 [CLASS=FP MUT=ALT PHEN="Reduced expression" GENE=NPHS2];		rs1079291	0.2746	0.2223	858,			-3.7360			0.01,0.14	0.39						n/a (AF>5%)	n/a (AF>5%)					NPHS2 (inh=AR pLI=0.01), RNU5F-2P (inh=n/a pLI=n/a)
chr1	180199384	180199384	-	AG	het	wt	hom	off-target	QUAL=242;DP=33,9,10;AF=0.39,0.00,1.00;MQM=60	LHX4	upstream_gene	LHX4:ENST00000263726:upstream_gene_variant:MODIFIER::::				G-rich	rs138033992	0.3672	0.4080	2592,							2.08						n/a (AF>5%)	n/a (AF>5%)					LHX4 (inh=AD pLI=0.32)
chr1	180235728	180235728	C	T	het	het	wt		QUAL=1869;DP=75,107,91;AF=0.52,0.42,0.00;MQM=60	LHX4	splice_region&synonymous	LHX4:ENST00000263726:splice_region_variant&synonymous_variant:LOW:exon3/6:c.450C>T:p.Asn150=:	602146 [LHX4 (confirmed) Pituitary hormone deficiency,combined,4,262700];	262223 [benign/likely benign DISEASE=not specified,Combined Pituitary Hormone Deficiency, Dominant];			rs16855642	0.0427	0.0370	46,	0.1053,0.0093,0.0109,0.0104,0.0176	0.0134,0.0978	-0.7970			0.16,0.87	1.44		-6.36% (9.89>9.26)		0.000/0.054		2	151					LHX4 (inh=AD pLI=0.32)
chr1	180240510	180240510	T	C	het	wt	het		QUAL=1636;DP=67,115,77;AF=0.52,0.00,0.47;MQM=60	LHX4,RP5-1180C10.2	splice_region&intron,non_coding_transcript_exon	LHX4:ENST00000263726:splice_region_variant&intron_variant:LOW:exon3/5:c.452-5T>C::,RP5-1180C10.2:ENST00000415414:non_coding_transcript_exon_variant:MODIFIER:exon5/5:n.945A>G::	602146 [LHX4 (confirmed) Pituitary hormone deficiency,combined,4,262700];	293866 [likely benign DISEASE=Combined Pituitary Hormone Deficiency, Dominant];			rs2764449	0.0413	0.0664	89,	0.0132,0.0291,0.0113,0.0784,0.0797	0.0804,0.0175	1.9980			0.33,0.91	1.48		-8.25% (10.03>9.20)				n/a (AF>5%)	n/a (AF>5%)					LHX4 (inh=AD pLI=0.32), RP5-1180C10.2 (inh=n/a pLI=n/a)
chr1	180243524	180243524	A	G	het	het	het		QUAL=7713;DP=211,204,155;AF=0.48,0.57,0.48;MQM=60	LHX4,RP5-1180C10.2	missense,intron&non_coding_transcript	LHX4:ENST00000263726:missense_variant:MODERATE:exon6/6:c.983A>G:p.Asn328Ser:,RP5-1180C10.2:ENST00000415414:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/4:n.31+262T>C::,RP5-1180C10.2:ENST00000440959:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/2:n.1574+262T>C::	602146 [LHX4 (confirmed) Pituitary hormone deficiency,combined,4,262700];	262225 [benign DISEASE=Pituitary hormone deficiency, combined 4,not specified,Combined Pituitary Hormone Deficiency, Dominant];			rs7536561	0.4263	0.4835	3210,	0.1809,0.2550,0.5897,0.5227,0.6011	0.5160,0.2049	2.5300	T, , 	B, , 	0.92,0.98	1.99	0.26					n/a (AF>5%)	n/a (AF>5%)					LHX4 (inh=AD pLI=0.32), RP5-1180C10.2 (inh=n/a pLI=n/a)
chr1	180257692	180257692	A	C	hom	hom	hom	off-target	QUAL=19116;DP=251,203,156;AF=1.00,1.00,1.00;MQM=60	ACBD6	intron	ACBD6:ENST00000367595:intron_variant:MODIFIER:exon7/7:c.695-40T>G::					rs2254465		0.9567	14178,	0.9628,0.9680,0.9870,0.9419,0.9132	0.9388,0.9650	-3.3430			0.01,0.15	-0.32						n/a (AF>5%)	n/a (AF>5%)					ACBD6 (inh=n/a pLI=0.05)
chr1	183155228	183155228	C	A	wt	wt	het		QUAL=2646;DP=172,307,250;AF=0.00,0.01,0.49;MQM=60	LAMC2	upstream_gene	LAMC2:ENST00000264144:upstream_gene_variant:MODIFIER::::,LAMC2:ENST00000493293:upstream_gene_variant:MODIFIER::::		293975 [benign DISEASE=Epidermolysis bullosa, junctional];			rs2276544	0.1603	0.1407	383,			0.2470			0.35,0.21	0.31						n/a (AF>5%)	n/a (AF>5%)					LAMC2 (inh=AR pLI=0.00)
chr1	183155305	183155305	G	A	het	hom	wt		QUAL=19369;DP=268,500,354;AF=0.54,1.00,0.00;MQM=60	LAMC2	upstream_gene	LAMC2:ENST00000264144:upstream_gene_variant:MODIFIER::::,LAMC2:ENST00000493293:upstream_gene_variant:MODIFIER::::		293977 [benign DISEASE=Epidermolysis bullosa, junctional];			rs2276543	0.2989	0.2733	1230,			2.8840			0.70,0.90	2.40						n/a (AF>5%)	n/a (AF>5%)					LAMC2 (inh=AR pLI=0.00)
chr1	183155399	183155399	A	G	wt	wt	het		QUAL=3316;DP=367,400,283;AF=0.01,0.00,0.48;MQM=60	LAMC2	5'UTR	LAMC2:ENST00000493293:5_prime_UTR_variant:MODIFIER:exon1/22:c.-89A>G::	150292 [LAMC2 (confirmed) Epidermolysis bullosa,junctional,Herlitz type,226700/Epidermolysis bullosa,junctional,non-Herlitz type,226650];	293979 [benign DISEASE=Epidermolysis bullosa, junctional];			rs2276542	0.2091	0.1820	560,			2.8120			0.62,0.75	1.29						n/a (AF>5%)	n/a (AF>5%)					LAMC2 (inh=AR pLI=0.00)
chr1	183155482	183155482	C	A	wt	het	wt		QUAL=798;DP=25,91,68;AF=0.00,0.47,0.00;MQM=60	LAMC2	5'UTR	LAMC2:ENST00000264144:5_prime_UTR_variant:MODIFIER:exon1/23:c.-6C>A::,LAMC2:ENST00000493293:5_prime_UTR_variant:MODIFIER:exon1/22:c.-6C>A::	150292 [LAMC2 (confirmed) Epidermolysis bullosa,junctional,Herlitz type,226700/Epidermolysis bullosa,junctional,non-Herlitz type,226650];	293983 [benign DISEASE=Epidermolysis bullosa, junctional];			rs684527	0.2748	0.3126	1261,	0.0992,0.3332,0.4173,0.2977,0.3598	0.2808,0.1053	1.3870			0.39,0.33	1.55						n/a (AF>5%)	n/a (AF>5%)					LAMC2 (inh=AR pLI=0.00)
chr1	183176970	183176970	-	TT	wt	het	wt	off-target	QUAL=1134;DP=79,46,53;AF=0.09,0.39,0.06;MQM=59	LAMC2	intron	LAMC2:ENST00000264144:intron_variant:MODIFIER:exon1/22:c.80-32_80-31dup::,LAMC2:ENST00000493293:intron_variant:MODIFIER:exon1/21:c.80-32_80-31dup::	150292 [LAMC2 (confirmed) Epidermolysis bullosa,junctional,Herlitz type,226700/Epidermolysis bullosa,junctional,non-Herlitz type,226650];				rs11480551		0.3212	1283,	0.2022,0.2509,0.2386,0.1934,0.1493						0.10						n/a (AF>5%)	n/a (AF>5%)					LAMC2 (inh=AR pLI=0.00)
chr1	183176970	183176970	-	T	het	het	het	off-target	QUAL=1134;DP=79,46,53;AF=0.19,0.28,0.40;MQM=60	LAMC2	intron	LAMC2:ENST00000264144:intron_variant:MODIFIER:exon1/22:c.80-31dup::,LAMC2:ENST00000493293:intron_variant:MODIFIER:exon1/21:c.80-31dup::	150292 [LAMC2 (confirmed) Epidermolysis bullosa,junctional,Herlitz type,226700/Epidermolysis bullosa,junctional,non-Herlitz type,226650];				rs11480551		0.2721	448,	0.2767,0.2614,0.3211,0.2664,0.2770						0.10						n/a (AF>5%)	n/a (AF>5%)					LAMC2 (inh=AR pLI=0.00)
chr1	183177218	183177218	A	G	het	hom	wt	off-target	QUAL=9009;DP=134,242,214;AF=0.48,1.00,0.00;MQM=60	LAMC2	intron	LAMC2:ENST00000264144:intron_variant:MODIFIER:exon2/22:c.268+14A>G::,LAMC2:ENST00000493293:intron_variant:MODIFIER:exon2/21:c.268+14A>G::	150292 [LAMC2 (confirmed) Epidermolysis bullosa,junctional,Herlitz type,226700/Epidermolysis bullosa,junctional,non-Herlitz type,226650];	259785 [benign DISEASE=Epidermolysis bullosa, junctional,not specified];		GA-rich	rs647347	0.4962	0.4735	3177,	0.4671,0.5095,0.5620,0.4382,0.5151	0.4320,0.4778	-1.4960			0.00,0.05	-0.18						n/a (AF>5%)	n/a (AF>5%)					LAMC2 (inh=AR pLI=0.00)
chr1	183184616	183184616	C	T	wt	wt	het		QUAL=2920;DP=271,345,244;AF=0.00,0.01,0.48;MQM=60	LAMC2	synonymous	LAMC2:ENST00000264144:synonymous_variant:LOW:exon3/23:c.297C>T:p.Ser99=:PF00053,LAMC2:ENST00000493293:synonymous_variant:LOW:exon3/22:c.297C>T:p.Ser99=:PF00053	150292 [LAMC2 (confirmed) Epidermolysis bullosa,junctional,Herlitz type,226700/Epidermolysis bullosa,junctional,non-Herlitz type,226650];	259787 [benign DISEASE=Epidermolysis bullosa, junctional,not specified];			rs2274980	0.3137	0.2528	1153,	0.3884,0.3797,0.3464,0.1766,0.3162	0.1766,0.3818	0.0150			0.02,0.16	0.37						n/a (AF>5%)	n/a (AF>5%)					LAMC2 (inh=AR pLI=0.00)
chr1	183187494	183187494	T	C	wt	wt	het	off-target	QUAL=3525;DP=342,465,295;AF=0.00,0.00,0.48;MQM=60	LAMC2	intron	LAMC2:ENST00000264144:intron_variant:MODIFIER:exon3/22:c.405-31T>C::,LAMC2:ENST00000493293:intron_variant:MODIFIER:exon3/21:c.405-31T>C::	150292 [LAMC2 (confirmed) Epidermolysis bullosa,junctional,Herlitz type,226700/Epidermolysis bullosa,junctional,non-Herlitz type,226650];				rs10911285	0.3139	0.2529	1155,	0.3884,0.3803,0.3465,0.1765,0.3160	0.1767,0.3790	-0.8980			0.00,0.09	-0.30						n/a (AF>5%)	n/a (AF>5%)					LAMC2 (inh=AR pLI=0.00)
chr1	183187603	183187603	C	T	wt	wt	het		QUAL=3065;DP=195,324,250;AF=0.00,0.00,0.50;MQM=60	LAMC2	synonymous	LAMC2:ENST00000264144:synonymous_variant:LOW:exon4/23:c.483C>T:p.Val161=:PF00053,LAMC2:ENST00000493293:synonymous_variant:LOW:exon4/22:c.483C>T:p.Val161=:PF00053	150292 [LAMC2 (confirmed) Epidermolysis bullosa,junctional,Herlitz type,226700/Epidermolysis bullosa,junctional,non-Herlitz type,226650];	259789 [benign DISEASE=Epidermolysis bullosa, junctional,not specified];			rs1129723	0.3139	0.2528	1157,	0.3874,0.3798,0.3455,0.1761,0.3161	0.1765,0.3820	0.7130			0.54,0.97	0.87						n/a (AF>5%)	n/a (AF>5%)					LAMC2 (inh=AR pLI=0.00)
chr1	183192304	183192304	T	G	wt	wt	het		QUAL=2774;DP=230,281,208;AF=0.00,0.00,0.53;MQM=60	LAMC2	synonymous	LAMC2:ENST00000264144:synonymous_variant:LOW:exon7/23:c.798T>G:p.Gly266=:PF00052,LAMC2:ENST00000493293:synonymous_variant:LOW:exon7/22:c.798T>G:p.Gly266=:PF00052	150292 [LAMC2 (confirmed) Epidermolysis bullosa,junctional,Herlitz type,226700/Epidermolysis bullosa,junctional,non-Herlitz type,226650];	259790 [benign DISEASE=Epidermolysis bullosa, junctional,not specified];			rs1047980	0.3550	0.2881	1642,	0.5155,0.3885,0.3474,0.1779,0.3172	0.1774,0.5011	-0.4130			0.12,0.91	0.92						n/a (AF>5%)	n/a (AF>5%)					LAMC2 (inh=AR pLI=0.00)
chr1	183192496	183192496	A	G	wt	wt	het	off-target	QUAL=2028;DP=214,172,137;AF=0.00,0.00,0.59;MQM=60	LAMC2	intron	LAMC2:ENST00000264144:intron_variant:MODIFIER:exon7/22:c.953+37A>G::,LAMC2:ENST00000493293:intron_variant:MODIFIER:exon7/21:c.953+37A>G::	150292 [LAMC2 (confirmed) Epidermolysis bullosa,junctional,Herlitz type,226700/Epidermolysis bullosa,junctional,non-Herlitz type,226650];				rs3738824	0.1132	0.1347	289,	0.1111,0.1653,0.1808,0.1266,0.0913	0.1279,0.1117	0.7180			0.18,0.19	0.12						n/a (AF>5%)	n/a (AF>5%)					LAMC2 (inh=AR pLI=0.00)
chr1	183201970	183201970	G	C	wt	wt	het		QUAL=907;DP=128,163,109;AF=0.00,0.00,0.39;MQM=60	LAMC2	missense	LAMC2:ENST00000264144:missense_variant:MODERATE:exon14/23:c.2198G>C:p.Ser733Thr:,LAMC2:ENST00000493293:missense_variant:MODERATE:exon14/22:c.2198G>C:p.Ser733Thr:	150292 [LAMC2 (confirmed) Epidermolysis bullosa,junctional,Herlitz type,226700/Epidermolysis bullosa,junctional,non-Herlitz type,226650];	259784 [likely benign DISEASE=Epidermolysis bullosa, junctional,not specified];			rs2296303	0.1450	0.1691	494,	0.2282,0.1705,0.1822,0.1272,0.0921	0.1287,0.2263	1.2080	D,D	B,B	0.35,0.50	0.81	0.07					n/a (AF>5%)	n/a (AF>5%)					LAMC2 (inh=AR pLI=0.00)
chr1	183206573	183206573	G	A	wt	wt	het		QUAL=3682;DP=362,405,276;AF=0.00,0.00,0.51;MQM=60	LAMC2	synonymous	LAMC2:ENST00000264144:synonymous_variant:LOW:exon18/23:c.2688G>A:p.Gln896=:,LAMC2:ENST00000493293:synonymous_variant:LOW:exon18/22:c.2688G>A:p.Gln896=:	150292 [LAMC2 (confirmed) Epidermolysis bullosa,junctional,Herlitz type,226700/Epidermolysis bullosa,junctional,non-Herlitz type,226650];	259786 [benign DISEASE=Epidermolysis bullosa, junctional,not specified];			rs1047981	0.3524	0.2871	1626,	0.5117,0.3867,0.3463,0.1779,0.3168	0.1776,0.4989	-0.3580			0.01,0.10	-0.47						n/a (AF>5%)	n/a (AF>5%)					LAMC2 (inh=AR pLI=0.00)
chr1	183207603	183207603	T	C	wt	wt	het	off-target	QUAL=1090;DP=197,112,82;AF=0.00,0.00,0.56;MQM=60	LAMC2	intron	LAMC2:ENST00000264144:intron_variant:MODIFIER:exon19/22:c.2869+47T>C::,LAMC2:ENST00000493293:intron_variant:MODIFIER:exon19/21:c.2869+47T>C::	150292 [LAMC2 (confirmed) Epidermolysis bullosa,junctional,Herlitz type,226700/Epidermolysis bullosa,junctional,non-Herlitz type,226650];				rs1925043	0.3588	0.2930	1723,	0.5346,0.3891,0.3475,0.1783,0.3171	0.1777,0.5204	-1.2960			0.00,0.09	0.24						n/a (AF>5%)	n/a (AF>5%)					LAMC2 (inh=AR pLI=0.00)
chr1	183212548	183212548	T	G	wt	wt	het		QUAL=2492;DP=213,247,175;AF=0.00,0.00,0.56;MQM=60	LAMC2	3'UTR	LAMC2:ENST00000264144:3_prime_UTR_variant:MODIFIER:exon23/23:c.*13T>G::	150292 [LAMC2 (confirmed) Epidermolysis bullosa,junctional,Herlitz type,226700/Epidermolysis bullosa,junctional,non-Herlitz type,226650];	294025 [benign DISEASE=Epidermolysis bullosa, junctional];			rs3768593	0.3109	0.2393	973,	0.3646,0.3793,0.3704,0.1653,0.3134	0.1679,0.3501	0.2330			0.00,0.15	0.63						n/a (AF>5%)	n/a (AF>5%)					LAMC2 (inh=AR pLI=0.00)
chr1	183213410	183213410	G	T	wt	wt	het		QUAL=2295;DP=275,200,178;AF=0.00,0.01,0.49;MQM=60	LAMC2	3'UTR	LAMC2:ENST00000264144:3_prime_UTR_variant:MODIFIER:exon23/23:c.*875G>T::	150292 [LAMC2 (confirmed) Epidermolysis bullosa,junctional,Herlitz type,226700/Epidermolysis bullosa,junctional,non-Herlitz type,226650];	294036 [likely benign DISEASE=Epidermolysis bullosa, junctional];			rs10797863	0.0913	0.1034	210,			-0.1180			0.09,0.17	-0.22						n/a (AF>5%)	n/a (AF>5%)					LAMC2 (inh=AR pLI=0.00)
chr1	183213933	183213933	C	T	wt	het	wt		QUAL=4918;DP=469,395,284;AF=0.00,0.47,0.00;MQM=60	LAMC2	3'UTR	LAMC2:ENST00000264144:3_prime_UTR_variant:MODIFIER:exon23/23:c.*1398C>T::	150292 [LAMC2 (confirmed) Epidermolysis bullosa,junctional,Herlitz type,226700/Epidermolysis bullosa,junctional,non-Herlitz type,226650];	294053 [uncertain significance DISEASE=Epidermolysis bullosa, junctional];			rs564740740	0.0012	0.0031	0,			0.4840			0.08,0.80	1.53						0	3					LAMC2 (inh=AR pLI=0.00)
chr1	183524855	183524855	C	A	hom	hom	hom		QUAL=44495;DP=475,548,388;AF=1.00,0.99,0.99;MQM=59	NCF2	3'UTR	NCF2:ENST00000367536:3_prime_UTR_variant:MODIFIER:exon16/16:c.*398G>T::,NCF2:ENST00000413720:3_prime_UTR_variant:MODIFIER:exon14/14:c.*398G>T::,NCF2:ENST00000418089:3_prime_UTR_variant:MODIFIER:exon13/13:c.*398G>T::	608515 [NCF2 (confirmed) Chronic granulomatous disease due to deficiency of NCF-2,233710];	294066 [benign DISEASE=Chronic granulomatous disease];			rs796860	0.9393	0.9058	12688,			-2.0230			0.00,0.08	-0.21						n/a (AF>5%)	n/a (AF>5%)					NCF2 (inh=AR pLI=0.00)
chr1	183534935	183534935	C	T	hom	het	hom	off-target	QUAL=13726;DP=148,253,193;AF=1.00,0.51,1.00;MQM=60	NCF2	intron	NCF2:ENST00000367535:intron_variant:MODIFIER:exon9/14:c.925-21G>A::,NCF2:ENST00000367536:intron_variant:MODIFIER:exon10/15:c.925-21G>A::,NCF2:ENST00000413720:intron_variant:MODIFIER:exon8/13:c.790-21G>A::,NCF2:ENST00000418089:intron_variant:MODIFIER:exon7/12:c.682-21G>A::	608515 [NCF2 (confirmed) Chronic granulomatous disease due to deficiency of NCF-2,233710];				rs2296164	0.4776	0.4929	3262,	0.3545,0.6471,0.6093,0.4667,0.4650	0.4676,0.3541	-3.2360			0.01,0.09	-0.92						n/a (AF>5%)	n/a (AF>5%)					NCF2 (inh=AR pLI=0.00)
chr1	183542387	183542387	T	C	hom	het	hom		QUAL=18371;DP=257,266,192;AF=0.99,0.55,1.00;MQM=59	NCF2	missense,intron	NCF2:ENST00000367535:missense_variant:MODERATE:exon5/15:c.542A>G:p.Lys181Arg:,NCF2:ENST00000367536:missense_variant:MODERATE:exon6/16:c.542A>G:p.Lys181Arg:,NCF2:ENST00000413720:missense_variant:MODERATE:exon4/14:c.407A>G:p.Lys136Arg:,NCF2:ENST00000418089:intron_variant:MODIFIER:exon3/12:c.367-2413A>G::	608515 [NCF2 (confirmed) Chronic granulomatous disease due to deficiency of NCF-2,233710];	256116 [benign DISEASE=Chronic granulomatous disease,not specified];			rs2274064	0.4916	0.4988	3259,	0.3594,0.6463,0.6233,0.4657,0.5068	0.4665,0.3588	0.5830	T,T,T, 	B,B,B, 	0.46,0.95	1.73	0.08					n/a (AF>5%)	n/a (AF>5%)					NCF2 (inh=AR pLI=0.00)
chr1	196642072	196642072	C	T	wt	wt	het	off-target	QUAL=323;DP=121,75,48;AF=0.00,0.00,0.38;MQM=60	CFH	intron	CFH:ENST00000359637:intron_variant:MODIFIER:exon1/8:c.59-36C>T::,CFH:ENST00000367429:intron_variant:MODIFIER:exon1/21:c.59-36C>T::,CFH:ENST00000439155:intron_variant:MODIFIER:exon1/9:c.59-36C>T::	134370 [CFH (confirmed) Hemolytic uremic syndrome,atypical,susceptibility to,1,235400/Complement factor H deficiency,609814/Macular degeneration,age-related,4,610698/Basal laminar drusen,126700];				rs551397	0.4681	0.3942	3037,	0.7252,0.3735,0.4160,0.2316,0.3110	0.2187,0.6910	-0.1960			0.00,0.05	-0.05						n/a (AF>5%)	n/a (AF>5%)					CFH (inh=AR+AD pLI=1.00)
chr1	196642233	196642233	G	A	wt	wt	het		QUAL=923;DP=232,138,83;AF=0.00,0.00,0.48;MQM=60	CFH	missense	CFH:ENST00000359637:missense_variant:MODERATE:exon2/9:c.184G>A:p.Val62Ile:PF00084,CFH:ENST00000367429:missense_variant:MODERATE:exon2/22:c.184G>A:p.Val62Ile:PF00084,CFH:ENST00000439155:missense_variant:MODERATE:exon2/10:c.184G>A:p.Val62Ile:PF00084	134370 [CFH (confirmed) Hemolytic uremic syndrome,atypical,susceptibility to,1,235400/Complement factor H deficiency,609814/Macular degeneration,age-related,4,610698/Basal laminar drusen,126700];	16550 [benign DISEASE=Macular degeneration,Mesangiocapillary glomerulonephritis, type II,Basal laminar drusen,Age-related macular degeneration 4,Atypical hemolytic uremic syndrome,not provided];			rs800292	0.4681	0.3935	3024,	0.7265,0.3761,0.4197,0.2353,0.3139	0.2220,0.7079	1.7350	T,T,T	B,B,B	0.00,0.09	0.30	0.14					n/a (AF>5%)	n/a (AF>5%)					CFH (inh=AR+AD pLI=1.00)
chr1	196642969	196642969	-	TT	wt	wt	het	off-target	QUAL=993;DP=98,131,112;AF=0.00,0.00,0.40;MQM=60	CFH	intron	CFH:ENST00000359637:intron_variant:MODIFIER:exon2/8:c.245-10_245-9dup::,CFH:ENST00000367429:intron_variant:MODIFIER:exon2/21:c.245-10_245-9dup::,CFH:ENST00000439155:intron_variant:MODIFIER:exon2/9:c.245-10_245-9dup::	134370 [CFH (confirmed) Hemolytic uremic syndrome,atypical,susceptibility to,1,235400/Complement factor H deficiency,609814/Macular degeneration,age-related,4,610698/Basal laminar drusen,126700];				rs552281857		0.2361	810,							-0.22						n/a (AF>5%)	n/a (AF>5%)					CFH (inh=AR+AD pLI=1.00)
chr1	196654324	196654324	A	C	het	het	het		QUAL=9406;DP=284,267,209;AF=0.49,0.48,0.48;MQM=60	CFH	synonymous	CFH:ENST00000359637:synonymous_variant:LOW:exon6/9:c.729A>C:p.Ala243=:PF00084,CFH:ENST00000367429:synonymous_variant:LOW:exon7/22:c.921A>C:p.Ala307=:PF00084,CFH:ENST00000439155:synonymous_variant:LOW:exon7/10:c.921A>C:p.Ala307=:PF00084	134370 [CFH (confirmed) Hemolytic uremic syndrome,atypical,susceptibility to,1,235400/Complement factor H deficiency,609814/Macular degeneration,age-related,4,610698/Basal laminar drusen,126700];	294488 [benign DISEASE=Macular degeneration,Mesangiocapillary glomerulonephritis, type II,Basal laminar drusen,Atypical hemolytic uremic syndrome];			rs1061147	0.7131	0.6753	6040,	0.5721,0.8324,0.9535,0.6171,0.6983	0.6172,0.5903	-0.0870			0.02,0.15	0.06						n/a (AF>5%)	n/a (AF>5%)					CFH (inh=AR+AD pLI=1.00)
chr1	196658497	196658497	G	T	het	het	het	off-target	QUAL=1472;DP=93,17,15;AF=0.54,0.18,0.53;MQM=60	CFH	intron	CFH:ENST00000359637:intron_variant:MODIFIER:exon6/8:c.773-53G>T::,CFH:ENST00000367429:intron_variant:MODIFIER:exon7/21:c.965-53G>T::,CFH:ENST00000439155:intron_variant:MODIFIER:exon7/9:c.965-53G>T::	134370 [CFH (confirmed) Hemolytic uremic syndrome,atypical,susceptibility to,1,235400/Complement factor H deficiency,609814/Macular degeneration,age-related,4,610698/Basal laminar drusen,126700];				rs482934	0.7816	0.6785	7272,			-0.0470			0.00,0.13	-0.11						n/a (AF>5%)	n/a (AF>5%)					CFH (inh=AR+AD pLI=1.00)
chr1	196659237	196659237	C	T	het	het	het		QUAL=5479;DP=191,108,104;AF=0.57,0.49,0.41;MQM=56	CFH	missense	CFH:ENST00000359637:missense_variant:MODERATE:exon8/9:c.1012C>T:p.His338Tyr:PF00084,CFH:ENST00000367429:missense_variant:MODERATE:exon9/22:c.1204C>T:p.His402Tyr:PF00084,CFH:ENST00000439155:missense_variant:MODERATE:exon9/10:c.1204C>T:p.His402Tyr:PF00084	134370 [CFH (confirmed) Hemolytic uremic syndrome,atypical,susceptibility to,1,235400/Complement factor H deficiency,609814/Macular degeneration,age-related,4,610698/Basal laminar drusen,126700];	294490 [benign DISEASE=Macular degeneration,Mesangiocapillary glomerulonephritis, type II,Basal laminar drusen,Atypical hemolytic uremic syndrome];			rs1061170	0.7334	0.6787	6303,	0.6262,0.8348,0.9535,0.6163,0.6983	0.6177,0.6373	-6.7160	T,T,T	B,B,B	0.00,0.04	-2.11	0.09					n/a (AF>5%)	n/a (AF>5%)					CFH (inh=AR+AD pLI=1.00)
chr1	196682947	196682947	G	A	het	het	het		QUAL=8619;DP=262,257,192;AF=0.42,0.48,0.49;MQM=60	CFH	synonymous	CFH:ENST00000367429:synonymous_variant:LOW:exon10/22:c.1419G>A:p.Ala473=:PF00084	134370 [CFH (confirmed) Hemolytic uremic syndrome,atypical,susceptibility to,1,235400/Complement factor H deficiency,609814/Macular degeneration,age-related,4,610698/Basal laminar drusen,126700];	294491 [benign DISEASE=Macular degeneration,Mesangiocapillary glomerulonephritis, type II,Basal laminar drusen,Atypical hemolytic uremic syndrome];	CM062504 [CLASS=DP MUT=ALT PHEN="Membranoproliferative glomerulonephritis association" GENE=CFH];		rs2274700	0.4790	0.4439	2786,	0.4606,0.4600,0.4310,0.4126,0.5462	0.4043,0.4689	0.4760			0.00,0.09	-0.44						n/a (AF>5%)	n/a (AF>5%)					CFH (inh=AR+AD pLI=1.00)
chr1	196705926	196705926	C	A	het	het	het	off-target	QUAL=138;DP=16,13,4;AF=0.25,0.38,0.50;MQM=60	CFH	intron	CFH:ENST00000367429:intron_variant:MODIFIER:exon15/21:c.2414-28C>A::	134370 [CFH (confirmed) Hemolytic uremic syndrome,atypical,susceptibility to,1,235400/Complement factor H deficiency,609814/Macular degeneration,age-related,4,610698/Basal laminar drusen,126700];			(TTAATT)n	rs375046	0.7748	0.6625	6681,	0.7379,0.7128,0.9056,0.5542,0.6861		-0.3700			0.00,0.11	-0.65						n/a (AF>5%)	n/a (AF>5%)					CFH (inh=AR+AD pLI=1.00)
chr1	196709816	196709816	G	T	het	het	wt		QUAL=6959;DP=283,217,187;AF=0.53,0.52,0.00;MQM=60	CFH	missense	CFH:ENST00000367429:missense_variant:MODERATE:exon18/22:c.2850G>T:p.Gln950His:PF00084	134370 [CFH (confirmed) Hemolytic uremic syndrome,atypical,susceptibility to,1,235400/Complement factor H deficiency,609814/Macular degeneration,age-related,4,610698/Basal laminar drusen,126700];	294510 [likely benign DISEASE=Macular degeneration,Mesangiocapillary glomerulonephritis, type II,Basal laminar drusen,Atypical hemolytic uremic syndrome];	CM034428 [CLASS=DM MUT=ALT PHEN="Haemolytic uraemic syndrome" GENE=CFH];		rs149474608	0.0016	0.0039	0,	0.0007,0.0018,0.0000,0.0059,0.0001	0.0062,0.0009	-0.2730	D	D	0.02,0.17	1.20	0.32					0	54	2	[2] Ute Grasshoff 30.01.2015 [n/a] comment imported from detected variant: conflicting evidence			CFH (inh=AR+AD pLI=1.00)
chr1	196712577	196712577	T	C	wt	wt	het		QUAL=305;DP=179,120,132;AF=0.00,0.00,0.23;MQM=45	CFH	splice_region&intron	CFH:ENST00000367429:splice_region_variant&intron_variant:LOW:exon19/21:c.3134-5T>C::	134370 [CFH (confirmed) Hemolytic uremic syndrome,atypical,susceptibility to,1,235400/Complement factor H deficiency,609814/Macular degeneration,age-related,4,610698/Basal laminar drusen,126700];				rs513699		0.0450	0,	0.0308,0.0674,0.1127,0.0389,0.0175		2.9620			0.62,0.39	0.36		-7.60% (9.26>8.55)		0.000/0.028		0	0					CFH (inh=AR+AD pLI=1.00)
chr1	196712586	196712586	C	T	wt	wt	het		QUAL=512;DP=191,135,149;AF=0.00,0.00,0.26;MQM=46	CFH	synonymous	CFH:ENST00000367429:synonymous_variant:LOW:exon20/22:c.3138C>T:p.Thr1046=:	134370 [CFH (confirmed) Hemolytic uremic syndrome,atypical,susceptibility to,1,235400/Complement factor H deficiency,609814/Macular degeneration,age-related,4,610698/Basal laminar drusen,126700];	294519 [benign DISEASE=Macular degeneration,Mesangiocapillary glomerulonephritis, type II,Basal laminar drusen,Atypical hemolytic uremic syndrome];			rs61822181		0.1262	0,	0.0968,0.1898,0.2402,0.1123,0.0744		-0.0290			0.00,0.17	0.33						n/a (AF>5%)	n/a (AF>5%)					CFH (inh=AR+AD pLI=1.00)
chr1	197053373	197053373	G	A	hom	hom	hom		QUAL=19011;DP=240,198,138;AF=1.00,1.00,1.00;MQM=60	ASPM	3'UTR	ASPM:ENST00000294732:3_prime_UTR_variant:MODIFIER:exon27/27:c.*81C>T::,ASPM:ENST00000367408:3_prime_UTR_variant:MODIFIER:exon23/23:c.*81C>T::,ASPM:ENST00000367409:3_prime_UTR_variant:MODIFIER:exon28/28:c.*81C>T::	605481 [ASPM (confirmed) Microcephaly 5,primary,autosomal recessive,608716];	294591 [benign DISEASE=Primary Microcephaly, Recessive];			rs12677	0.7823	0.7916	10373,			1.4990			0.00,0.17	0.01						n/a (AF>5%)	n/a (AF>5%)					ASPM (inh=AR pLI=0.00)
chr1	197053562	197053562	A	-	het	het	het		QUAL=326;DP=97,42,26;AF=0.18,0.29,0.12;MQM=59	ASPM	splice_region&intron	ASPM:ENST00000294732:splice_region_variant&intron_variant:LOW:exon26/26:c.5577-6del::,ASPM:ENST00000367408:splice_region_variant&intron_variant:LOW:exon22/22:c.3327-6del::,ASPM:ENST00000367409:splice_region_variant&intron_variant:LOW:exon27/27:c.10332-6del::	605481 [ASPM (confirmed) Microcephaly 5,primary,autosomal recessive,608716];				rs369160994		0.2062	0,	0.2987,0.2917,0.2926,0.1557,0.2343		-1.2230				-0.57					COSM5445356	n/a (AF>5%)	n/a (AF>5%)					ASPM (inh=AR pLI=0.00)
chr1	197055925	197055925	T	C	hom	hom	hom		QUAL=13638;DP=169,137,108;AF=1.00,1.00,1.00;MQM=60	ASPM	splice_region&intron	ASPM:ENST00000294732:splice_region_variant&intron_variant:LOW:exon26/26:c.5576+8A>G::,ASPM:ENST00000367408:splice_region_variant&intron_variant:LOW:exon22/22:c.3326+8A>G::,ASPM:ENST00000367409:splice_region_variant&intron_variant:LOW:exon27/27:c.10331+8A>G::	605481 [ASPM (confirmed) Microcephaly 5,primary,autosomal recessive,608716];	157775 [benign DISEASE=Primary autosomal recessive microcephaly 5,not specified,Primary Microcephaly, Recessive];			rs10754213	0.7827	0.8882	10382,	0.4415,0.9349,0.9998,0.9064,0.8986	0.9076,0.4575	-0.2090			0.00,0.34	0.37				0.000/0.000		n/a (AF>5%)	n/a (AF>5%)					ASPM (inh=AR pLI=0.00)
chr1	197059928	197059928	A	G	hom	hom	hom	off-target	QUAL=8867;DP=104,101,80;AF=1.00,1.00,1.00;MQM=60	ASPM	intron	ASPM:ENST00000294732:intron_variant:MODIFIER:exon22/26:c.4881+52T>C::,ASPM:ENST00000367408:intron_variant:MODIFIER:exon18/22:c.2631+52T>C::,ASPM:ENST00000367409:intron_variant:MODIFIER:exon23/27:c.9636+52T>C::	605481 [ASPM (confirmed) Microcephaly 5,primary,autosomal recessive,608716];				rs4915316	0.7564	0.7688	10056,		0.9066,0.3783	0.0220			0.03,0.22	0.25						n/a (AF>5%)	n/a (AF>5%)					ASPM (inh=AR pLI=0.00)
chr1	197070521	197070521	C	G	wt	wt	het		QUAL=1188;DP=301,129,97;AF=0.00,0.00,0.49;MQM=60	ASPM	intron,missense	ASPM:ENST00000294732:intron_variant:MODIFIER:exon17/26:c.4066-5227G>C::,ASPM:ENST00000367408:intron_variant:MODIFIER:exon13/22:c.1816-5227G>C::,ASPM:ENST00000367409:missense_variant:MODERATE:exon18/28:c.7860G>C:p.Gln2620His:	605481 [ASPM (confirmed) Microcephaly 5,primary,autosomal recessive,608716];	21609 [benign/likely benign DISEASE=Primary autosomal recessive microcephaly 5,not specified,Primary Microcephaly, Recessive];			rs12138336	0.0288	0.0508	34,	0.0125,0.0322,0.0001,0.0715,0.0305	0.0697,0.0132	-1.0950	 , ,T	 , ,B	0.08,0.16	-0.51	0.08					n/a (AF>5%)	n/a (AF>5%)					ASPM (inh=AR pLI=0.00)
chr1	197070776	197070776	C	T	het	het	het		QUAL=8717;DP=227,246,190;AF=0.55,0.49,0.46;MQM=60	ASPM	intron,synonymous	ASPM:ENST00000294732:intron_variant:MODIFIER:exon17/26:c.4066-5482G>A::,ASPM:ENST00000367408:intron_variant:MODIFIER:exon13/22:c.1816-5482G>A::,ASPM:ENST00000367409:synonymous_variant:LOW:exon18/28:c.7605G>A:p.Val2535=:PF00612	605481 [ASPM (confirmed) Microcephaly 5,primary,autosomal recessive,608716];	21603 [benign DISEASE=Primary autosomal recessive microcephaly 5,not specified,Primary Microcephaly, Recessive];			rs10922162	0.2949	0.2562	785,	0.0390,0.4675,0.7065,0.1566,0.2771	0.1510,0.0443	0.1820			0.14,0.43	0.08						n/a (AF>5%)	n/a (AF>5%)					ASPM (inh=AR pLI=0.00)
chr1	197070815	197070815	T	C	hom	hom	hom		QUAL=19696;DP=238,197,155;AF=1.00,1.00,1.00;MQM=60	ASPM	intron,synonymous	ASPM:ENST00000294732:intron_variant:MODIFIER:exon17/26:c.4066-5521A>G::,ASPM:ENST00000367408:intron_variant:MODIFIER:exon13/22:c.1816-5521A>G::,ASPM:ENST00000367409:synonymous_variant:LOW:exon18/28:c.7566A>G:p.Leu2522=:	605481 [ASPM (confirmed) Microcephaly 5,primary,autosomal recessive,608716];	21602 [benign DISEASE=Primary autosomal recessive microcephaly 5,not specified,Primary Microcephaly, Recessive];			rs1412640		0.8957	10766,	0.5411,0.9398,0.9997,0.9066,0.8990	0.9077,0.5513	-0.1270			0.06,0.15	0.02						n/a (AF>5%)	n/a (AF>5%)					ASPM (inh=AR pLI=0.00)
chr1	197070901	197070901	A	G	hom	hom	hom		QUAL=23190;DP=319,205,168;AF=1.00,1.00,1.00;MQM=60	ASPM	intron,missense	ASPM:ENST00000294732:intron_variant:MODIFIER:exon17/26:c.4066-5607T>C::,ASPM:ENST00000367408:intron_variant:MODIFIER:exon13/22:c.1816-5607T>C::,ASPM:ENST00000367409:missense_variant:MODERATE:exon18/28:c.7480T>C:p.Tyr2494His:	605481 [ASPM (confirmed) Microcephaly 5,primary,autosomal recessive,608716];	21599 [benign DISEASE=Primary autosomal recessive microcephaly 5,not specified,Primary Microcephaly, Recessive];			rs964201	0.9974	0.9963	15322,	0.9989,0.9990,1.0000,0.9935,0.9974	0.9941,0.9989	3.0000	 , ,T	 , ,B	0.09,0.87	1.77	0.19					n/a (AF>5%)	n/a (AF>5%)					ASPM (inh=AR pLI=0.00)
chr1	197091537	197091537	A	T	hom	hom	hom		QUAL=24420;DP=311,251,203;AF=1.00,1.00,1.00;MQM=59	ASPM	synonymous	ASPM:ENST00000294732:synonymous_variant:LOW:exon14/27:c.3579T>A:p.Ser1193=:,ASPM:ENST00000367408:synonymous_variant:LOW:exon10/23:c.1329T>A:p.Ser443=:,ASPM:ENST00000367409:synonymous_variant:LOW:exon14/28:c.3579T>A:p.Ser1193=:	605481 [ASPM (confirmed) Microcephaly 5,primary,autosomal recessive,608716];	21578 [benign DISEASE=Primary autosomal recessive microcephaly 5,not specified,Primary Microcephaly, Recessive];			rs4915337	0.7825	0.8880	10368,	0.4414,0.9348,0.9998,0.9062,0.8987	0.9074,0.4567	-0.3320			0.05,0.27	0.27						n/a (AF>5%)	n/a (AF>5%)					ASPM (inh=AR pLI=0.00)
chr1	197094030	197094030	C	T	het	het	het		QUAL=9368;DP=392,184,152;AF=0.49,0.48,0.48;MQM=60	ASPM	synonymous	ASPM:ENST00000294732:synonymous_variant:LOW:exon12/27:c.3138G>A:p.Arg1046=:,ASPM:ENST00000367408:synonymous_variant:LOW:exon8/23:c.888G>A:p.Arg296=:,ASPM:ENST00000367409:synonymous_variant:LOW:exon12/28:c.3138G>A:p.Arg1046=:	605481 [ASPM (confirmed) Microcephaly 5,primary,autosomal recessive,608716];	21573 [benign/likely benign DISEASE=Primary autosomal recessive microcephaly 5,not specified,Primary Microcephaly, Recessive];			rs6676084	0.2167	0.2802	1036,	0.1555,0.2502,0.1103,0.3144,0.3086	0.3181,0.1571	-1.1000			0.03,0.20	0.31					COSM3677510	n/a (AF>5%)	n/a (AF>5%)					ASPM (inh=AR pLI=0.00)
chr1	197102745	197102745	A	G	het	het	het	off-target	QUAL=3189;DP=141,73,70;AF=0.48,0.45,0.40;MQM=60	ASPM	intron	ASPM:ENST00000294732:intron_variant:MODIFIER:exon5/26:c.2174-20T>C::,ASPM:ENST00000367408:intron_variant:MODIFIER:exon1/22:c.-77-20T>C::,ASPM:ENST00000367409:intron_variant:MODIFIER:exon5/27:c.2174-20T>C::	605481 [ASPM (confirmed) Microcephaly 5,primary,autosomal recessive,608716];	95887 [benign DISEASE=Primary autosomal recessive microcephaly 5,not specified];			rs4915344	0.2997	0.2566	800,	0.0418,0.4669,0.7063,0.1564,0.2819	0.1500,0.0438	1.0580			0.04,0.21	0.61		-5.93% (6.90>6.50)				n/a (AF>5%)	n/a (AF>5%)					ASPM (inh=AR pLI=0.00)
chr1	197108946	197108946	A	G	het	wt	het		QUAL=4087;DP=256,143,109;AF=0.41,0.00,0.44;MQM=60	ASPM	synonymous	ASPM:ENST00000294732:synonymous_variant:LOW:exon4/27:c.1977T>C:p.Ile659=:,ASPM:ENST00000367409:synonymous_variant:LOW:exon4/28:c.1977T>C:p.Ile659=:	605481 [ASPM (confirmed) Microcephaly 5,primary,autosomal recessive,608716];	21561 [benign/likely benign DISEASE=Primary autosomal recessive microcephaly 5,not specified,Primary Microcephaly, Recessive];			rs17550662	0.0192	0.0449	36,	0.0082,0.0216,0.0001,0.0653,0.0105	0.0623,0.0114	1.6300			0.85,0.95	1.11						13	469					ASPM (inh=AR pLI=0.00)
chr1	197109042	197109042	C	T	hom	hom	hom	off-target	QUAL=12541;DP=234,88,65;AF=1.00,1.00,1.00;MQM=60	ASPM	intron	ASPM:ENST00000294732:intron_variant:MODIFIER:exon3/26:c.1922-41G>A::,ASPM:ENST00000367409:intron_variant:MODIFIER:exon3/27:c.1922-41G>A::	605481 [ASPM (confirmed) Microcephaly 5,primary,autosomal recessive,608716];	157788 [likely benign DISEASE=not specified];			rs1332663	0.7825	0.8878	10392,	0.4399,0.9347,0.9998,0.9054,0.8984	0.9079,0.4582	-0.7260			0.00,0.06	0.09						n/a (AF>5%)	n/a (AF>5%)					ASPM (inh=AR pLI=0.00)
chr1	197112533	197112533	G	A	hom	hom	hom		QUAL=7457;DP=113,52,61;AF=1.00,1.00,0.98;MQM=60	ASPM	synonymous	ASPM:ENST00000294732:synonymous_variant:LOW:exon3/27:c.849C>T:p.Ser283=:,ASPM:ENST00000367409:synonymous_variant:LOW:exon3/28:c.849C>T:p.Ser283=:	605481 [ASPM (confirmed) Microcephaly 5,primary,autosomal recessive,608716];	95890 [benign DISEASE=Primary autosomal recessive microcephaly 5,not specified,Primary Microcephaly, Recessive];			rs6677082	0.7556	0.8810	10072,	0.3628,0.9307,0.9815,0.9058,0.8984	0.9068,0.3872	-0.0770			0.01,0.14	-0.06						n/a (AF>5%)	n/a (AF>5%)					ASPM (inh=AR pLI=0.00)
chr1	197113073	197113073	G	A	hom	hom	hom	off-target	QUAL=4415;DP=107,21,14;AF=1.00,1.00,1.00;MQM=60	ASPM	intron	ASPM:ENST00000294732:intron_variant:MODIFIER:exon2/26:c.441+14C>T::,ASPM:ENST00000367409:intron_variant:MODIFIER:exon2/27:c.441+14C>T::	605481 [ASPM (confirmed) Microcephaly 5,primary,autosomal recessive,608716];	95888 [benign/likely benign DISEASE=Primary autosomal recessive microcephaly 5,not specified,Primary Microcephaly, Recessive];			rs1571964	0.7556	0.8807	10057,	0.3609,0.9309,0.9816,0.9052,0.8983	0.9065,0.3871	-0.6110			0.05,0.43	0.50						n/a (AF>5%)	n/a (AF>5%)					ASPM (inh=AR pLI=0.00)
chr1	198661668	198661668	G	A	het	wt	het		QUAL=807;DP=56,5,7;AF=0.46,0.00,0.86;MQM=60	PTPRC	intron,3'UTR	PTPRC:ENST00000348564:intron_variant:MODIFIER:exon3/29:c.100+166G>A::,PTPRC:ENST00000352140:intron_variant:MODIFIER:exon3/31:c.94+166G>A::,PTPRC:ENST00000367364:3_prime_UTR_variant:MODIFIER:exon3/3:c.*155G>A::,PTPRC:ENST00000367376:intron_variant:MODIFIER:exon3/32:c.94+166G>A::,PTPRC:ENST00000413409:intron_variant:MODIFIER:exon3/3:c.100+166G>A::,PTPRC:ENST00000442510:intron_variant:MODIFIER:exon3/32:c.100+166G>A::,PTPRC:ENST00000594404:intron_variant:MODIFIER:exon3/29:c.94+166G>A::,PTPRC:ENST00000598951:3_prime_UTR_variant:MODIFIER:exon3/3:c.*155G>A::	151460 [PTPRC (confirmed) Hepatitis C virus,susceptibility to,609532/Severe combined immunodeficiency,T cell-negative,B-cell/natural killer-cell positive,608971];				rs115067628	0.0040	0.0117	2,			-0.7770			0.01,0.10	-0.33						0	8					PTPRC (inh=AR pLI=1.00)
chr1	198665917	198665917	C	G	wt	wt	het		QUAL=3199;DP=450,293,206;AF=0.00,0.00,0.58;MQM=60	PTPRC	intron,synonymous	PTPRC:ENST00000348564:intron_variant:MODIFIER:exon3/29:c.100+4415C>G::,PTPRC:ENST00000352140:synonymous_variant:LOW:exon4/32:c.171C>G:p.Pro57=:PF12453,PTPRC:ENST00000367376:synonymous_variant:LOW:exon4/33:c.171C>G:p.Pro57=:PF12453,PTPRC:ENST00000442510:synonymous_variant:LOW:exon4/33:c.177C>G:p.Pro59=:PF12453,PTPRC:ENST00000594404:intron_variant:MODIFIER:exon3/29:c.94+4415C>G::	151460 [PTPRC (confirmed) Hepatitis C virus,susceptibility to,609532/Severe combined immunodeficiency,T cell-negative,B-cell/natural killer-cell positive,608971];	378444 [benign/likely benign DISEASE=Severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-positive, NK cell-positive,not specified];	CS952043 [CLASS=DFP MUT=ALT PHEN="Defective splicing" GENE=PTPRC];		rs17612648	0.0044	0.0088	2,	0.0020,0.0037,0.0001,0.0134,0.0117	0.0136,0.0043	0.5020			0.10,0.31	0.24						1	100					PTPRC (inh=AR pLI=1.00)
chr1	198677420	198677420	T	A	wt	het	wt	off-target	QUAL=520;DP=105,45,37;AF=0.00,0.51,0.00;MQM=60	PTPRC	intron	PTPRC:ENST00000348564:intron_variant:MODIFIER:exon7/29:c.550+30T>A::,PTPRC:ENST00000352140:intron_variant:MODIFIER:exon9/31:c.883+30T>A::,PTPRC:ENST00000367376:intron_variant:MODIFIER:exon10/32:c.1027+30T>A::,PTPRC:ENST00000442510:intron_variant:MODIFIER:exon10/32:c.1033+30T>A::,PTPRC:ENST00000594404:intron_variant:MODIFIER:exon7/29:c.544+30T>A::	151460 [PTPRC (confirmed) Hepatitis C virus,susceptibility to,609532/Severe combined immunodeficiency,T cell-negative,B-cell/natural killer-cell positive,608971];				rs2274368	0.0845	0.0592	51,	0.0742,0.1209,0.1404,0.0309,0.0775	0.0314,0.0682	-0.3210			0.03,0.14	-0.27						n/a (AF>5%)	n/a (AF>5%)					PTPRC (inh=AR pLI=1.00)
chr1	198717218	198717218	-	T	wt	het	hom	off-target	QUAL=244;DP=57,38,19;AF=0.28,0.24,0.47;MQM=59	PTPRC	intron	PTPRC:ENST00000348564:intron_variant:MODIFIER:exon23/29:c.2365-4dup::,PTPRC:ENST00000352140:intron_variant:MODIFIER:exon25/31:c.2698-4dup::,PTPRC:ENST00000367376:intron_variant:MODIFIER:exon26/32:c.2842-4dup::,PTPRC:ENST00000442510:intron_variant:MODIFIER:exon26/32:c.2848-4dup::,PTPRC:ENST00000594404:intron_variant:MODIFIER:exon23/29:c.2359-4dup::	151460 [PTPRC (confirmed) Hepatitis C virus,susceptibility to,609532/Severe combined immunodeficiency,T cell-negative,B-cell/natural killer-cell positive,608971];			(T)n	rs371692042		0.2606	809,	0.1441,0.2086,0.2029,0.2850,0.2503						-0.18						n/a (AF>5%)	n/a (AF>5%)					PTPRC (inh=AR pLI=1.00)
chr1	198718732	198718732	A	G	het	het	wt	off-target	QUAL=3757;DP=213,108,81;AF=0.46,0.50,0.00;MQM=60	PTPRC	intron	PTPRC:ENST00000348564:intron_variant:MODIFIER:exon25/29:c.2589+54A>G::,PTPRC:ENST00000352140:intron_variant:MODIFIER:exon27/31:c.2922+54A>G::,PTPRC:ENST00000367376:intron_variant:MODIFIER:exon28/32:c.3066+54A>G::,PTPRC:ENST00000442510:intron_variant:MODIFIER:exon28/32:c.3072+54A>G::,PTPRC:ENST00000594404:intron_variant:MODIFIER:exon25/29:c.2583+54A>G::	151460 [PTPRC (confirmed) Hepatitis C virus,susceptibility to,609532/Severe combined immunodeficiency,T cell-negative,B-cell/natural killer-cell positive,608971];				rs549239314	0.0004	0.0009	0,			-0.9030			0.02,0.23	0.82						0	10					PTPRC (inh=AR pLI=1.00)
chr1	201008582	201008582	-	G	hom	het	het	off-target	QUAL=1982;DP=42,55,30;AF=0.95,0.53,0.53;MQM=60	RP11-168O16.2	intron&non_coding_transcript	RP11-168O16.2:ENST00000415359:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.211-2397dup::					rs35360610	0.5064	0.5491	5005,							-0.25						n/a (AF>5%)	n/a (AF>5%)					RP11-168O16.2 (inh=n/a pLI=n/a)
chr1	201009556	201009556	A	G	hom	het	het	off-target	QUAL=5828;DP=128,83,63;AF=0.99,0.48,0.52;MQM=60	CACNA1S,RP11-168O16.2	intron,intron&non_coding_transcript	CACNA1S:ENST00000362061:intron_variant:MODIFIER:exon42/43:c.5227-54T>C::,CACNA1S:ENST00000367338:intron_variant:MODIFIER:exon41/42:c.5170-54T>C::,RP11-168O16.2:ENST00000415359:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.211-1427A>G::	114208 [CACNA1S (confirmed) Hypokalemic periodic paralysis,type 1,170400/Malignant hyperthermia susceptibility 5,601887/Thyrotoxic periodic paralysis,susceptibility to,1,188580];				rs1546416	0.3325	0.3572	2023,			-0.3490			0.03,0.12	0.03						n/a (AF>5%)	n/a (AF>5%)					CACNA1S (inh=AR+AD pLI=0.00), RP11-168O16.2 (inh=n/a pLI=n/a)
chr1	201009897	201009897	T	C	hom	hom	hom	off-target	QUAL=3769;DP=52,46,30;AF=1.00,1.00,1.00;MQM=60	CACNA1S,RP11-168O16.2	intron,intron&non_coding_transcript	CACNA1S:ENST00000362061:intron_variant:MODIFIER:exon41/43:c.5135-56A>G::,CACNA1S:ENST00000367338:intron_variant:MODIFIER:exon40/42:c.5078-56A>G::,RP11-168O16.2:ENST00000415359:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.211-1086T>C::	114208 [CACNA1S (confirmed) Hypokalemic periodic paralysis,type 1,170400/Malignant hyperthermia susceptibility 5,601887/Thyrotoxic periodic paralysis,susceptibility to,1,188580];				rs6427875	0.9970	0.9949	15312,		0.9877,0.9957	-5.3380			0.00,0.06	-0.32						n/a (AF>5%)	n/a (AF>5%)					CACNA1S (inh=AR+AD pLI=0.00), RP11-168O16.2 (inh=n/a pLI=n/a)
chr1	201012597	201012597	G	A	hom	hom	wt		QUAL=366;DP=10,4,3;AF=1.00,1.00,0.00;MQM=60	CACNA1S	synonymous	CACNA1S:ENST00000362061:synonymous_variant:LOW:exon40/44:c.4860C>T:p.Pro1620=:,CACNA1S:ENST00000367338:synonymous_variant:LOW:exon39/43:c.4803C>T:p.Pro1601=:	114208 [CACNA1S (confirmed) Hypokalemic periodic paralysis,type 1,170400/Malignant hyperthermia susceptibility 5,601887/Thyrotoxic periodic paralysis,susceptibility to,1,188580];	254841 [benign DISEASE=Malignant hyperthermia susceptibility,Hypokalemic periodic paralysis,not specified];			rs41267497	0.0461	0.1056	181,	0.0257,0.0676,0.0004,0.1616,0.0264	0.1621,0.0336	-1.1950			0.08,0.13	-0.45						n/a (AF>5%)	n/a (AF>5%)					CACNA1S (inh=AR+AD pLI=0.00)
chr1	201016296	201016296	G	A	wt	het	wt		QUAL=3274;DP=346,245,183;AF=0.00,0.52,0.00;MQM=60	CACNA1S	missense	CACNA1S:ENST00000362061:missense_variant:MODERATE:exon38/44:c.4615C>T:p.Arg1539Cys:PF08763,CACNA1S:ENST00000367338:missense_variant:MODERATE:exon37/43:c.4558C>T:p.Arg1520Cys:PF08763	114208 [CACNA1S (confirmed) Hypokalemic periodic paralysis,type 1,170400/Malignant hyperthermia susceptibility 5,601887/Thyrotoxic periodic paralysis,susceptibility to,1,188580];	197021 [benign DISEASE=Malignant hyperthermia susceptibility,Hypokalemic periodic paralysis,not specified];			rs3850625	0.0841	0.1166	179,	0.0201,0.0953,0.0328,0.1184,0.2104	0.1238,0.0218	6.1960	D,D	B,B	0.96,0.98	3.67	0.28					n/a (AF>5%)	n/a (AF>5%)					CACNA1S (inh=AR+AD pLI=0.00)
chr1	201020105	201020105	A	G	wt	het	het		QUAL=6115;DP=134,276,211;AF=0.01,0.49,0.53;MQM=60	CACNA1S	splice_region&intron	CACNA1S:ENST00000362061:splice_region_variant&intron_variant:LOW:exon33/43:c.4113+7T>C::,CACNA1S:ENST00000367338:splice_region_variant&intron_variant:LOW:exon32/42:c.4056+7T>C::	114208 [CACNA1S (confirmed) Hypokalemic periodic paralysis,type 1,170400/Malignant hyperthermia susceptibility 5,601887/Thyrotoxic periodic paralysis,susceptibility to,1,188580];	199680 [benign DISEASE=Malignant hyperthermia susceptibility,Hypokalemic periodic paralysis,not specified,not provided];			rs6702590	0.8804	0.7864	9746,	0.9379,0.8672,0.9961,0.6689,0.8667	0.6685,0.9233	-0.1250			0.01,0.16	-0.26				0.000/0.000		n/a (AF>5%)	n/a (AF>5%)					CACNA1S (inh=AR+AD pLI=0.00)
chr1	201038687	201038687	A	G	het	het	wt		QUAL=8123;DP=219,428,343;AF=0.47,0.51,0.00;MQM=60	CACNA1S	synonymous	CACNA1S:ENST00000362061:synonymous_variant:LOW:exon18/44:c.2403T>C:p.Phe801=:,CACNA1S:ENST00000367338:synonymous_variant:LOW:exon18/43:c.2403T>C:p.Phe801=:	114208 [CACNA1S (confirmed) Hypokalemic periodic paralysis,type 1,170400/Malignant hyperthermia susceptibility 5,601887/Thyrotoxic periodic paralysis,susceptibility to,1,188580];	254814 [benign DISEASE=Malignant hyperthermia susceptibility,Hypokalemic periodic paralysis,not specified,not provided];			rs7415038	0.2941	0.4083	2825,	0.5296,0.2184,0.0031,0.4498,0.1849	0.4502,0.5139	5.5810			0.07,0.95	0.91						n/a (AF>5%)	n/a (AF>5%)					CACNA1S (inh=AR+AD pLI=0.00)
chr1	201042618	201042618	G	A	het	hom	wt	off-target	QUAL=4974;DP=81,140,101;AF=0.49,1.00,0.00;MQM=60	CACNA1S	intron	CACNA1S:ENST00000362061:intron_variant:MODIFIER:exon15/43:c.2157+59C>T::,CACNA1S:ENST00000367338:intron_variant:MODIFIER:exon15/42:c.2157+59C>T::	114208 [CACNA1S (confirmed) Hypokalemic periodic paralysis,type 1,170400/Malignant hyperthermia susceptibility 5,601887/Thyrotoxic periodic paralysis,susceptibility to,1,188580];				rs9333652	0.5913	0.4516	3435,			0.2760			0.04,0.17	0.06						n/a (AF>5%)	n/a (AF>5%)					CACNA1S (inh=AR+AD pLI=0.00)
chr1	201044748	201044748	A	G	het	hom	wt		QUAL=10492;DP=152,278,259;AF=0.51,1.00,0.00;MQM=59	CACNA1S	splice_region&intron	CACNA1S:ENST00000362061:splice_region_variant&intron_variant:LOW:exon12/43:c.1828-5T>C::,CACNA1S:ENST00000367338:splice_region_variant&intron_variant:LOW:exon12/42:c.1828-5T>C::	114208 [CACNA1S (confirmed) Hypokalemic periodic paralysis,type 1,170400/Malignant hyperthermia susceptibility 5,601887/Thyrotoxic periodic paralysis,susceptibility to,1,188580];	254804 [benign DISEASE=Malignant hyperthermia susceptibility,Hypokalemic periodic paralysis,not specified,not provided];			rs1998721	0.7596	0.7820	8247,	0.5425,0.7205,0.9591,0.7764,0.8904	0.7770,0.5595	-1.1900			0.00,0.12	-0.28		-5.15% (11.26>10.68)		0.000/0.002		n/a (AF>5%)	n/a (AF>5%)					CACNA1S (inh=AR+AD pLI=0.00)
chr1	201046025	201046025	G	T	het	het	wt	off-target	QUAL=4291;DP=82,337,275;AF=0.48,0.53,0.01;MQM=60	CACNA1S	intron	CACNA1S:ENST00000362061:intron_variant:MODIFIER:exon12/43:c.1827+23C>A::,CACNA1S:ENST00000367338:intron_variant:MODIFIER:exon12/42:c.1827+23C>A::	114208 [CACNA1S (confirmed) Hypokalemic periodic paralysis,type 1,170400/Malignant hyperthermia susceptibility 5,601887/Thyrotoxic periodic paralysis,susceptibility to,1,188580];			L2c	rs7549030	0.0457	0.0686	75,	0.0778,0.0387,0.0001,0.0741,0.0251	0.0713,0.0772	0.0950			0.07,0.22	0.02						n/a (AF>5%)	n/a (AF>5%)					CACNA1S (inh=AR+AD pLI=0.00)
chr1	201047062	201047062	G	A	hom	het	hom		QUAL=15050;DP=143,267,260;AF=0.99,0.48,1.00;MQM=60	CACNA1S	synonymous	CACNA1S:ENST00000362061:synonymous_variant:LOW:exon11/44:c.1564C>T:p.Leu522=:PF00520,CACNA1S:ENST00000367338:synonymous_variant:LOW:exon11/43:c.1564C>T:p.Leu522=:PF00520	114208 [CACNA1S (confirmed) Hypokalemic periodic paralysis,type 1,170400/Malignant hyperthermia susceptibility 5,601887/Thyrotoxic periodic paralysis,susceptibility to,1,188580];	254801 [benign DISEASE=Malignant hyperthermia susceptibility,Hypokalemic periodic paralysis,not specified];	CM023570 [CLASS=DP MUT=ALT PHEN="Hypokalaemic periodic paralysis association with" GENE=CACNA1S];		rs4915476	0.1909	0.2205	789,	0.2618,0.2748,0.0415,0.2293,0.1122	0.2227,0.2660	3.9470			0.93,0.98	0.52						n/a (AF>5%)	n/a (AF>5%)					CACNA1S (inh=AR+AD pLI=0.00)
chr1	201047075	201047075	A	G	hom	het	hom		QUAL=17407;DP=186,286,267;AF=0.99,0.50,1.00;MQM=60	CACNA1S	synonymous	CACNA1S:ENST00000362061:synonymous_variant:LOW:exon11/44:c.1551T>C:p.Gly517=:PF00520,CACNA1S:ENST00000367338:synonymous_variant:LOW:exon11/43:c.1551T>C:p.Gly517=:PF00520	114208 [CACNA1S (confirmed) Hypokalemic periodic paralysis,type 1,170400/Malignant hyperthermia susceptibility 5,601887/Thyrotoxic periodic paralysis,susceptibility to,1,188580];	254800 [benign DISEASE=Malignant hyperthermia susceptibility,Hypokalemic periodic paralysis,Malignant hyperthermia susceptibility type 5,Hypokalemic periodic paralysis 1,not specified,not provided];			rs4915477	0.5711	0.6651	7289,	0.8985,0.5872,0.2243,0.6546,0.3211	0.6605,0.8836	-1.5080			0.02,0.47	0.47						n/a (AF>5%)	n/a (AF>5%)					CACNA1S (inh=AR+AD pLI=0.00)
chr1	201054197	201054197	G	T	wt	wt	het	off-target	QUAL=922;DP=82,114,88;AF=0.00,0.00,0.50;MQM=60	CACNA1S	intron	CACNA1S:ENST00000362061:intron_variant:MODIFIER:exon8/43:c.1151-38C>A::,CACNA1S:ENST00000367338:intron_variant:MODIFIER:exon8/42:c.1151-38C>A::	114208 [CACNA1S (confirmed) Hypokalemic periodic paralysis,type 1,170400/Malignant hyperthermia susceptibility 5,601887/Thyrotoxic periodic paralysis,susceptibility to,1,188580];				rs41267505	0.1286	0.1583	355,	0.1410,0.2467,0.0371,0.1663,0.0880	0.1635,0.1450	-0.2930			0.07,0.23	0.15						n/a (AF>5%)	n/a (AF>5%)					CACNA1S (inh=AR+AD pLI=0.00)
chr1	201060865	201060865	G	A	wt	het	wt		QUAL=2467;DP=166,185,158;AF=0.01,0.54,0.00;MQM=60	CACNA1S	synonymous	CACNA1S:ENST00000362061:synonymous_variant:LOW:exon5/44:c.597C>T:p.Ile199=:PF00520,CACNA1S:ENST00000367338:synonymous_variant:LOW:exon5/43:c.597C>T:p.Ile199=:PF00520	114208 [CACNA1S (confirmed) Hypokalemic periodic paralysis,type 1,170400/Malignant hyperthermia susceptibility 5,601887/Thyrotoxic periodic paralysis,susceptibility to,1,188580];	254852 [benign DISEASE=Malignant hyperthermia susceptibility,Hypokalemic periodic paralysis,not specified,not provided];			rs2296383	0.3051	0.3900	1955,	0.0999,0.3508,0.3573,0.4290,0.4491	0.4417,0.1112	-0.7520			0.15,0.96	0.60						n/a (AF>5%)	n/a (AF>5%)					CACNA1S (inh=AR+AD pLI=0.00)
chr1	209788213	209788213	T	C	hom	het	het		QUAL=5650;DP=152,72,41;AF=0.99,0.46,0.59;MQM=60	CAMK1G,LAMB3	downstream_gene	CAMK1G:ENST00000009105:downstream_gene_variant:MODIFIER::::,LAMB3:ENST00000356082:downstream_gene_variant:MODIFIER::::,CAMK1G:ENST00000361322:downstream_gene_variant:MODIFIER::::,LAMB3:ENST00000367030:downstream_gene_variant:MODIFIER::::,LAMB3:ENST00000391911:downstream_gene_variant:MODIFIER::::	150310 [LAMB3 (provisional) Epidermolysis bullosa,junctional,Herlitz type,226700/Epidermolysis bullosa,junctional,non-Herlitz type,226650/Amelogenesis imperfecta,type IA,104530];	368859 [benign DISEASE=Epidermolysis bullosa, junctional];			rs926387	0.7748	0.7552	9017,			-1.1700			0.00,0.11	-0.20						n/a (AF>5%)	n/a (AF>5%)					CAMK1G (inh=n/a pLI=0.06), LAMB3 (inh=AR+AD pLI=0.00)
chr1	209788514	209788514	G	A	het	het	wt		QUAL=5430;DP=185,262,240;AF=0.52,0.46,0.00;MQM=60	LAMB3	3'UTR	LAMB3:ENST00000356082:3_prime_UTR_variant:MODIFIER:exon23/23:c.*102C>T::,LAMB3:ENST00000367030:3_prime_UTR_variant:MODIFIER:exon23/23:c.*102C>T::,LAMB3:ENST00000391911:3_prime_UTR_variant:MODIFIER:exon22/22:c.*102C>T::	150310 [LAMB3 (provisional) Epidermolysis bullosa,junctional,Herlitz type,226700/Epidermolysis bullosa,junctional,non-Herlitz type,226650/Amelogenesis imperfecta,type IA,104530];	295059 [benign DISEASE=Epidermolysis bullosa, junctional];	CR1010233 [CLASS=DP MUT=ALT PHEN="Cervical cancer increased risk association with" GENE=LAMB3];		rs2566	0.2951	0.2760	1181,			1.1010			0.10,0.19	0.19						n/a (AF>5%)	n/a (AF>5%)					LAMB3 (inh=AR+AD pLI=0.00)
chr1	209792015	209792015	-	C	hom	hom	hom	off-target	QUAL=13149;DP=160,187,129;AF=0.98,0.99,0.98;MQM=60	LAMB3	intron	LAMB3:ENST00000356082:intron_variant:MODIFIER:exon18/22:c.2702-12dup::,LAMB3:ENST00000367030:intron_variant:MODIFIER:exon18/22:c.2702-12dup::,LAMB3:ENST00000391911:intron_variant:MODIFIER:exon17/21:c.2702-12dup::	150310 [LAMB3 (provisional) Epidermolysis bullosa,junctional,Herlitz type,226700/Epidermolysis bullosa,junctional,non-Herlitz type,226650/Amelogenesis imperfecta,type IA,104530];	255590 [benign DISEASE=Epidermolysis bullosa, junctional,not specified,not provided];			rs5780528		0.9573	14135,	0.9898,0.9831,0.9998,0.9316,0.9886	0.9352,0.9841					0.61						n/a (AF>5%)	n/a (AF>5%)					LAMB3 (inh=AR+AD pLI=0.00)
chr1	209799253	209799253	A	G	het	het	hom		QUAL=21364;DP=301,547,382;AF=0.40,0.50,1.00;MQM=59	LAMB3	synonymous	LAMB3:ENST00000356082:synonymous_variant:LOW:exon14/23:c.1716T>C:p.Cys572=:PF00053,LAMB3:ENST00000367030:synonymous_variant:LOW:exon14/23:c.1716T>C:p.Cys572=:PF00053,LAMB3:ENST00000391911:synonymous_variant:LOW:exon13/22:c.1716T>C:p.Cys572=:PF00053	150310 [LAMB3 (provisional) Epidermolysis bullosa,junctional,Herlitz type,226700/Epidermolysis bullosa,junctional,non-Herlitz type,226650/Amelogenesis imperfecta,type IA,104530];	255587 [benign DISEASE=Epidermolysis bullosa, junctional,not specified];			rs2179402	0.7650	0.7538	8529,	0.7677,0.7736,0.8226,0.7370,0.7434	0.7350,0.7675	-0.8090			0.06,0.75	0.91						n/a (AF>5%)	n/a (AF>5%)					LAMB3 (inh=AR+AD pLI=0.00)
chr1	209804095	209804095	G	A	hom	hom	hom	off-target	QUAL=12075;DP=113,158,124;AF=1.00,1.00,1.00;MQM=60	LAMB3	intron	LAMB3:ENST00000356082:intron_variant:MODIFIER:exon8/22:c.823-15C>T::,LAMB3:ENST00000367030:intron_variant:MODIFIER:exon8/22:c.823-15C>T::,LAMB3:ENST00000391911:intron_variant:MODIFIER:exon7/21:c.823-15C>T::	150310 [LAMB3 (provisional) Epidermolysis bullosa,junctional,Herlitz type,226700/Epidermolysis bullosa,junctional,non-Herlitz type,226650/Amelogenesis imperfecta,type IA,104530];	255598 [benign DISEASE=Epidermolysis bullosa, junctional,not specified];			rs4844863	0.8233	0.8457	10994,	0.8285,0.8284,0.8239,0.8548,0.8125	0.8485,0.8252	-2.2320			0.01,0.10	-0.49		-8.46% (8.36>7.66)				n/a (AF>5%)	n/a (AF>5%)					LAMB3 (inh=AR+AD pLI=0.00)
chr1	209807972	209807972	G	A	hom	hom	hom		QUAL=5425;DP=37,91,58;AF=1.00,1.00,1.00;MQM=60	LAMB3	synonymous	LAMB3:ENST00000356082:synonymous_variant:LOW:exon6/23:c.384C>T:p.Pro128=:PF00055,LAMB3:ENST00000367030:synonymous_variant:LOW:exon6/23:c.384C>T:p.Pro128=:PF00055,LAMB3:ENST00000391911:synonymous_variant:LOW:exon5/22:c.384C>T:p.Pro128=:PF00055	150310 [LAMB3 (provisional) Epidermolysis bullosa,junctional,Herlitz type,226700/Epidermolysis bullosa,junctional,non-Herlitz type,226650/Amelogenesis imperfecta,type IA,104530];	255596 [benign DISEASE=Epidermolysis bullosa, junctional,not specified];			rs1130667	0.2454	0.3438	1684,	0.1299,0.2134,0.2275,0.4050,0.3402	0.3956,0.1539	-4.0330			0.08,0.78	0.08						n/a (AF>5%)	n/a (AF>5%)					LAMB3 (inh=AR+AD pLI=0.00)
chr1	209811886	209811886	T	G	hom	hom	hom		QUAL=18952;DP=255,210,137;AF=1.00,1.00,1.00;MQM=59	LAMB3	synonymous	LAMB3:ENST00000356082:synonymous_variant:LOW:exon4/23:c.291A>C:p.Ser97=:PF00055,LAMB3:ENST00000367030:synonymous_variant:LOW:exon4/23:c.291A>C:p.Ser97=:PF00055,LAMB3:ENST00000391911:synonymous_variant:LOW:exon3/22:c.291A>C:p.Ser97=:PF00055	150310 [LAMB3 (provisional) Epidermolysis bullosa,junctional,Herlitz type,226700/Epidermolysis bullosa,junctional,non-Herlitz type,226650/Amelogenesis imperfecta,type IA,104530];	255592 [benign DISEASE=Epidermolysis bullosa, junctional,not specified];			rs2076356	0.4325	0.5704	5351,	0.4096,0.4434,0.2863,0.6549,0.4963	0.6460,0.4351	-0.9220			0.06,0.45	0.18						n/a (AF>5%)	n/a (AF>5%)					LAMB3 (inh=AR+AD pLI=0.00)
chr1	209824707	209824707	A	T	hom	hom	hom	off-target	QUAL=9214;DP=168,84,81;AF=0.99,1.00,1.00;MQM=59	LAMB3	intron	LAMB3:ENST00000356082:intron_variant:MODIFIER:exon1/22:c.-37-381T>A::,LAMB3:ENST00000367030:intron_variant:MODIFIER:exon1/22:c.-37-381T>A::	150310 [LAMB3 (provisional) Epidermolysis bullosa,junctional,Herlitz type,226700/Epidermolysis bullosa,junctional,non-Herlitz type,226650/Amelogenesis imperfecta,type IA,104530];				rs10779510	0.8966	0.8769	11966,			-0.2920			0.00,0.06	0.44						n/a (AF>5%)	n/a (AF>5%)					LAMB3 (inh=AR+AD pLI=0.00)
chr1	209959614	209959614	G	T	het	het	wt		QUAL=6915;DP=339,185,126;AF=0.54,0.50,0.00;MQM=57	IRF6	3'UTR	IRF6:ENST00000367021:3_prime_UTR_variant:MODIFIER:exon9/9:c.*2151C>A::	607199 [IRF6 (confirmed) van der Woude syndrome,119300/Popliteal pterygium syndrome 1,119500/Orofacial cleft 6,608864];	295175 [benign DISEASE=Van der Woude syndrome,Popliteal pterygium syndrome,Cleft Lip +/- Cleft Palate, Autosomal Dominant];			rs1044516	0.3099	0.2170	874,			-0.3100			0.02,0.11	-0.20						n/a (AF>5%)	n/a (AF>5%)					IRF6 (inh=AD pLI=0.96)
chr1	209959872	209959872	G	A	hom	hom	hom		QUAL=19022;DP=311,150,125;AF=1.00,0.99,0.99;MQM=56	IRF6	3'UTR	IRF6:ENST00000367021:3_prime_UTR_variant:MODIFIER:exon9/9:c.*1893C>T::	607199 [IRF6 (confirmed) van der Woude syndrome,119300/Popliteal pterygium syndrome 1,119500/Orofacial cleft 6,608864];	295178 [benign DISEASE=Van der Woude syndrome,Popliteal pterygium syndrome,Cleft Lip +/- Cleft Palate, Autosomal Dominant];			rs680331	0.8081	0.8034	9959,			-0.0130			0.00,0.06	0.17						n/a (AF>5%)	n/a (AF>5%)					IRF6 (inh=AD pLI=0.96)
chr1	209960087	209960087	A	-	wt	het	wt		QUAL=1538;DP=244,113,128;AF=0.00,0.53,0.00;MQM=59	IRF6	3'UTR	IRF6:ENST00000367021:3_prime_UTR_variant:MODIFIER:exon9/9:c.*1678del::	607199 [IRF6 (confirmed) van der Woude syndrome,119300/Popliteal pterygium syndrome 1,119500/Orofacial cleft 6,608864];	295181 [benign DISEASE=Van der Woude syndrome,Popliteal pterygium syndrome,Cleft Lip +/- Cleft Palate, Autosomal Dominant];			rs141112353	0.1673	0.2003	580,			0.4150				-0.02						n/a (AF>5%)	n/a (AF>5%)					IRF6 (inh=AD pLI=0.96)
chr1	209960152	209960152	T	A	wt	het	wt		QUAL=1228;DP=264,105,102;AF=0.00,0.49,0.00;MQM=59	IRF6	3'UTR	IRF6:ENST00000367021:3_prime_UTR_variant:MODIFIER:exon9/9:c.*1613A>T::	607199 [IRF6 (confirmed) van der Woude syndrome,119300/Popliteal pterygium syndrome 1,119500/Orofacial cleft 6,608864];										-0.6290			0.05,0.13	-0.02						0	1					IRF6 (inh=AD pLI=0.96)
chr1	209960436	209960436	G	A	het	het	wt		QUAL=6339;DP=255,249,202;AF=0.46,0.51,0.00;MQM=59	IRF6,RP3-434O14.8	3'UTR,non_coding_transcript_exon	IRF6:ENST00000367021:3_prime_UTR_variant:MODIFIER:exon9/9:c.*1329C>T::,RP3-434O14.8:ENST00000430751:non_coding_transcript_exon_variant:MODIFIER:exon2/2:n.479C>T::	607199 [IRF6 (confirmed) van der Woude syndrome,119300/Popliteal pterygium syndrome 1,119500/Orofacial cleft 6,608864];	295184 [benign DISEASE=Van der Woude syndrome,Popliteal pterygium syndrome,Cleft Lip +/- Cleft Palate, Autosomal Dominant];		AluJo	rs2235372	0.2991	0.2102	788,			-1.0970			0.00,0.09	0.02						n/a (AF>5%)	n/a (AF>5%)					IRF6 (inh=AD pLI=0.96), RP3-434O14.8 (inh=n/a pLI=n/a)
chr1	209960922	209960922	A	C	het	wt	hom		QUAL=2847;DP=126,125,45;AF=0.47,0.00,1.00;MQM=60	IRF6,RP3-434O14.8	3'UTR,splice_donor&non_coding_transcript	IRF6:ENST00000367021:3_prime_UTR_variant:MODIFIER:exon9/9:c.*843T>G::,RP3-434O14.8:ENST00000430751:splice_donor_variant&non_coding_transcript_variant:HIGH:exon1/1:n.115+2T>G::	607199 [IRF6 (confirmed) van der Woude syndrome,119300/Popliteal pterygium syndrome 1,119500/Orofacial cleft 6,608864];	295189 [benign DISEASE=Van der Woude syndrome,Popliteal pterygium syndrome,Cleft Lip +/- Cleft Palate, Autosomal Dominant];			rs599021	0.3043	0.3670	2177,			0.2650			0.09,0.22	1.42		-1,145.29% (0.67>-6.98)				n/a (AF>5%)	n/a (AF>5%)					IRF6 (inh=AD pLI=0.96), RP3-434O14.8 (inh=n/a pLI=n/a)
chr1	209960925	209960925	T	C	het	het	wt		QUAL=3117;DP=129,123,43;AF=0.54,0.45,0.00;MQM=60	IRF6,RP3-434O14.8	3'UTR,splice_region&non_coding_transcript_exon	IRF6:ENST00000367021:3_prime_UTR_variant:MODIFIER:exon9/9:c.*840A>G::,RP3-434O14.8:ENST00000430751:splice_region_variant&non_coding_transcript_exon_variant:LOW:exon1/2:n.114A>G::	607199 [IRF6 (confirmed) van der Woude syndrome,119300/Popliteal pterygium syndrome 1,119500/Orofacial cleft 6,608864];	295190 [benign DISEASE=Van der Woude syndrome,Popliteal pterygium syndrome,Cleft Lip +/- Cleft Palate, Autosomal Dominant];			rs742214	0.2971	0.2095	787,			-1.1730			0.04,0.15	-0.01		-622.44% (0.67>-3.49)				n/a (AF>5%)	n/a (AF>5%)					IRF6 (inh=AD pLI=0.96), RP3-434O14.8 (inh=n/a pLI=n/a)
chr1	209961023	209961023	T	A	het	het	wt		QUAL=2211;DP=98,81,51;AF=0.50,0.49,0.02;MQM=60	IRF6,RP3-434O14.8	3'UTR,non_coding_transcript_exon	IRF6:ENST00000367021:3_prime_UTR_variant:MODIFIER:exon9/9:c.*742A>T::,RP3-434O14.8:ENST00000430751:non_coding_transcript_exon_variant:MODIFIER:exon1/2:n.16A>T::	607199 [IRF6 (confirmed) van der Woude syndrome,119300/Popliteal pterygium syndrome 1,119500/Orofacial cleft 6,608864];	295193 [benign DISEASE=Van der Woude syndrome,Popliteal pterygium syndrome,Cleft Lip +/- Cleft Palate, Autosomal Dominant];			rs742215	0.3037	0.2156	835,			0.9660			0.09,0.28	0.61						n/a (AF>5%)	n/a (AF>5%)					IRF6 (inh=AD pLI=0.96), RP3-434O14.8 (inh=n/a pLI=n/a)
chr1	209961314	209961314	T	C	het	het	wt		QUAL=6570;DP=269,239,188;AF=0.51,0.47,0.01;MQM=60	IRF6	3'UTR	IRF6:ENST00000367021:3_prime_UTR_variant:MODIFIER:exon9/9:c.*451A>G::	607199 [IRF6 (confirmed) van der Woude syndrome,119300/Popliteal pterygium syndrome 1,119500/Orofacial cleft 6,608864];	295199 [benign DISEASE=Van der Woude syndrome,Popliteal pterygium syndrome,Cleft Lip +/- Cleft Palate, Autosomal Dominant];			rs17317411	0.0875	0.0997	210,			0.3060			0.26,0.20	1.14						n/a (AF>5%)	n/a (AF>5%)					IRF6 (inh=AD pLI=0.96)
chr1	209961354	209961354	G	A	wt	het	wt		QUAL=2558;DP=332,208,163;AF=0.00,0.47,0.00;MQM=60	IRF6	3'UTR	IRF6:ENST00000367021:3_prime_UTR_variant:MODIFIER:exon9/9:c.*411C>T::	607199 [IRF6 (confirmed) van der Woude syndrome,119300/Popliteal pterygium syndrome 1,119500/Orofacial cleft 6,608864];	295200 [likely benign DISEASE=Van der Woude syndrome,Popliteal pterygium syndrome,Cleft Lip +/- Cleft Palate, Autosomal Dominant];		MIR3	rs187379424	0.0008	0.0067	2,			1.8560			0.20,0.22	0.32						0	1					IRF6 (inh=AD pLI=0.96)
chr1	209963803	209963803	G	A	het	het	wt	off-target	QUAL=3807;DP=194,127,88;AF=0.51,0.52,0.00;MQM=60	IRF6	intron	IRF6:ENST00000367021:intron_variant:MODIFIER:exon7/8:c.1060+37C>T::,IRF6:ENST00000542854:intron_variant:MODIFIER:exon5/6:c.775+37C>T::	607199 [IRF6 (confirmed) van der Woude syndrome,119300/Popliteal pterygium syndrome 1,119500/Orofacial cleft 6,608864];				rs2235373	0.2883	0.2345	710,	0.2307,0.3492,0.4833,0.1755,0.2970	0.1740,0.2425	-0.5940			0.04,0.14	-0.07						n/a (AF>5%)	n/a (AF>5%)					IRF6 (inh=AD pLI=0.96)
chr1	209965587	209965587	G	C	het	hom	wt	off-target	QUAL=10460;DP=196,261,215;AF=0.46,1.00,0.00;MQM=60	IRF6	intron	IRF6:ENST00000367021:intron_variant:MODIFIER:exon6/8:c.667+27C>G::,IRF6:ENST00000542854:intron_variant:MODIFIER:exon4/6:c.382+27C>G::	607199 [IRF6 (confirmed) van der Woude syndrome,119300/Popliteal pterygium syndrome 1,119500/Orofacial cleft 6,608864];	259926 [benign DISEASE=not specified];			rs2235375	0.4052	0.4097	2080,	0.2800,0.5587,0.5736,0.3727,0.4174	0.3684,0.2980	0.0930			0.00,0.11	0.01						n/a (AF>5%)	n/a (AF>5%)					IRF6 (inh=AD pLI=0.96)
chr1	209968684	209968684	C	A	het	hom	wt		QUAL=18499;DP=340,459,326;AF=0.45,1.00,0.00;MQM=60	IRF6	synonymous	IRF6:ENST00000367021:synonymous_variant:LOW:exon5/9:c.459G>T:p.Ser153=:,IRF6:ENST00000542854:synonymous_variant:LOW:exon3/7:c.174G>T:p.Ser58=:	607199 [IRF6 (confirmed) van der Woude syndrome,119300/Popliteal pterygium syndrome 1,119500/Orofacial cleft 6,608864];	259925 [benign DISEASE=Van der Woude syndrome,Popliteal pterygium syndrome,not specified,Cleft Lip +/- Cleft Palate, Autosomal Dominant];			rs2013162	0.4038	0.4095	2051,	0.2727,0.5617,0.5742,0.3727,0.4159	0.3685,0.2914	-1.6140			0.07,0.83	1.23						n/a (AF>5%)	n/a (AF>5%)					IRF6 (inh=AD pLI=0.96)
chr1	209969902	209969902	G	C	het	hom	wt		QUAL=4762;DP=210,86,51;AF=0.47,0.99,0.02;MQM=60	IRF6	splice_region&intron	IRF6:ENST00000367021:splice_region_variant&intron_variant:LOW:exon3/8:c.175-5C>G::,IRF6:ENST00000542854:splice_region_variant&intron_variant:LOW:exon1/6:c.-111-5C>G::	607199 [IRF6 (confirmed) van der Woude syndrome,119300/Popliteal pterygium syndrome 1,119500/Orofacial cleft 6,608864];	259923 [benign DISEASE=Van der Woude syndrome,not specified];			rs7552506	0.2710	0.3229	1618,	0.2649,0.2974,0.1543,0.3576,0.3317	0.3551,0.2826	1.2850			0.47,0.29	0.51		-28.92% (9.65>6.86)		0.002/0.074		n/a (AF>5%)	n/a (AF>5%)					IRF6 (inh=AD pLI=0.96)
chr1	209975386	209975386	A	G	het	wt	hom		QUAL=11954;DP=285,351,263;AF=0.49,0.00,1.00;MQM=60	IRF6	splice_region&5'UTR,intron	IRF6:ENST00000367021:splice_region_variant&5_prime_UTR_variant:LOW:exon2/9:c.-73T>C::,IRF6:ENST00000542854:intron_variant:MODIFIER:exon1/6:c.-112+3906T>C::	607199 [IRF6 (confirmed) van der Woude syndrome,119300/Popliteal pterygium syndrome 1,119500/Orofacial cleft 6,608864];	295214 [benign DISEASE=Van der Woude syndrome,Popliteal pterygium syndrome,Cleft Lip +/- Cleft Palate, Autosomal Dominant];			rs861019	0.3864	0.4353	2992,			-0.2130			0.04,0.15	-0.00		+2.37% (10.77>11.03)				n/a (AF>5%)	n/a (AF>5%)					IRF6 (inh=AD pLI=0.96)
chr1	209979518	209979518	T	A	wt	het	wt		QUAL=1271;DP=34,127,94;AF=0.00,0.54,0.00;MQM=60	IRF6	upstream_gene	IRF6:ENST00000367021:upstream_gene_variant:MODIFIER::::,IRF6:ENST00000542854:upstream_gene_variant:MODIFIER::::		295219 [benign DISEASE=Van der Woude syndrome,Popliteal pterygium syndrome,Cleft Lip +/- Cleft Palate, Autosomal Dominant];			rs12403006	0.1180	0.1679	522,			-0.0120			0.01,0.19	0.49						n/a (AF>5%)	n/a (AF>5%)					IRF6 (inh=AD pLI=0.96)
chr1	209979529	209979529	A	T	wt	het	wt		QUAL=1221;DP=27,120,82;AF=0.00,0.54,0.00;MQM=60	IRF6	upstream_gene	IRF6:ENST00000367021:upstream_gene_variant:MODIFIER::::,IRF6:ENST00000542854:upstream_gene_variant:MODIFIER::::		368864 [benign DISEASE=Van der Woude syndrome,Popliteal pterygium syndrome,Cleft Lip +/- Cleft Palate, Autosomal Dominant];	CR173661 [CLASS=DM? MUT=ALT PHEN="Orofacial clefting" GENE=IRF6];		rs34743335	0.1182	0.1681	523,			0.0230			0.39,0.86	1.79						n/a (AF>5%)	n/a (AF>5%)					IRF6 (inh=AD pLI=0.96)
chr1	215796196	215796196	-	TTATT	het	wt	het	off-target	QUAL=541;DP=83,34,19;AF=0.34,0.00,0.26;MQM=60	KCTD3,USH2A	downstream_gene	KCTD3:ENST00000259154:downstream_gene_variant:MODIFIER::::,USH2A:ENST00000307340:downstream_gene_variant:MODIFIER::::,USH2A:ENST00000366943:downstream_gene_variant:MODIFIER::::							0.2228	837,							-0.17						n/a (AF>5%)	n/a (AF>5%)					KCTD3 (inh=n/a pLI=0.96), USH2A (inh=AR pLI=0.00)
chr1	215796350	215796350	T	G	het	hom	wt	gene_blacklist	QUAL=13523;DP=354,266,178;AF=0.52,1.00,0.00;MQM=60	USH2A	3'UTR	USH2A:ENST00000307340:3_prime_UTR_variant:MODIFIER:exon72/72:c.*2773A>C::,USH2A:ENST00000366943:3_prime_UTR_variant:MODIFIER:exon73/73:c.*2773A>C::	608400 [USH2A (confirmed) Usher syndrome,type 2A,276901/Retinitis pigmentosa 39,613809];				rs6667509	0.1030	0.0987	163,			2.2250			0.13,0.19	0.27						n/a (AF>5%)	n/a (AF>5%)					USH2A (inh=AR pLI=0.00)
chr1	215798014	215798014	G	A	hom	hom	hom	gene_blacklist	QUAL=33442;DP=445,327,226;AF=1.00,1.00,1.00;MQM=60	USH2A	3'UTR	USH2A:ENST00000307340:3_prime_UTR_variant:MODIFIER:exon72/72:c.*1109C>T::,USH2A:ENST00000366943:3_prime_UTR_variant:MODIFIER:exon73/73:c.*1109C>T::	608400 [USH2A (confirmed) Usher syndrome,type 2A,276901/Retinitis pigmentosa 39,613809];				rs2797255	0.9912	0.9896	15166,			-0.3140			0.02,0.10	-0.32						n/a (AF>5%)	n/a (AF>5%)					USH2A (inh=AR pLI=0.00)
chr1	215808007	215808007	G	A	het	wt	het	gene_blacklist	QUAL=3670;DP=175,196,136;AF=0.48,0.00,0.50;MQM=60	USH2A	missense	USH2A:ENST00000307340:missense_variant:MODERATE:exon70/72:c.15091C>T:p.Arg5031Trp:,USH2A:ENST00000366943:missense_variant:MODERATE:exon70/73:c.15091C>T:p.Arg5031Trp:	608400 [USH2A (confirmed) Usher syndrome,type 2A,276901/Retinitis pigmentosa 39,613809];	48455 [benign/likely benign DISEASE=Usher syndrome, type 2A,Retinitis pigmentosa 39,not specified,not provided];	CM165975 [CLASS=DM? MUT=ALT PHEN="Retinitis pigmentosa" GENE=USH2A];		rs56038610	0.0060	0.0161	5,	0.0030,0.0030,0.0000,0.0189,0.0101	0.0174,0.0039	3.0680	D, 	B,B	0.24,0.45	1.76	0.09					0	141	1	[3] auto-classification 14.09.2017 [1] harmuth 08.05.2018			USH2A (inh=AR pLI=0.00)
chr1	215848062	215848062	C	T	het	wt	het	gene_blacklist	QUAL=8128;DP=377,314,246;AF=0.51,0.01,0.50;MQM=60	USH2A	synonymous	USH2A:ENST00000307340:synonymous_variant:LOW:exon63/72:c.13191G>A:p.Glu4397=:PF00041,USH2A:ENST00000366943:synonymous_variant:LOW:exon63/73:c.13191G>A:p.Glu4397=:PF00041	608400 [USH2A (confirmed) Usher syndrome,type 2A,276901/Retinitis pigmentosa 39,613809];	48413 [benign DISEASE=not specified];			rs2009923	0.2035	0.2029	452,	0.0535,0.1758,0.3515,0.1837,0.2860	0.1866,0.0622	0.2840			0.16,0.61	-0.29						n/a (AF>5%)	n/a (AF>5%)					USH2A (inh=AR pLI=0.00)
chr1	215848587	215848587	T	C	wt	wt	het	gene_blacklist	QUAL=3267;DP=276,319,245;AF=0.00,0.00,0.51;MQM=60	USH2A	synonymous	USH2A:ENST00000307340:synonymous_variant:LOW:exon63/72:c.12666A>G:p.Thr4222=:PF00041,USH2A:ENST00000366943:synonymous_variant:LOW:exon63/73:c.12666A>G:p.Thr4222=:PF00041	608400 [USH2A (confirmed) Usher syndrome,type 2A,276901/Retinitis pigmentosa 39,613809];	48403 [benign DISEASE=not specified];			rs2797234	0.3031	0.3704	2004,	0.2137,0.4701,0.3267,0.3857,0.3016	0.3903,0.2231	-0.3630			0.13,0.41	-0.18						n/a (AF>5%)	n/a (AF>5%)					USH2A (inh=AR pLI=0.00)
chr1	215848641	215848641	T	C	het	hom	het	gene_blacklist	QUAL=20784;DP=387,377,280;AF=0.48,0.99,0.50;MQM=60	USH2A	synonymous	USH2A:ENST00000307340:synonymous_variant:LOW:exon63/72:c.12612A>G:p.Thr4204=:PF00041,USH2A:ENST00000366943:synonymous_variant:LOW:exon63/73:c.12612A>G:p.Thr4204=:PF00041	608400 [USH2A (confirmed) Usher syndrome,type 2A,276901/Retinitis pigmentosa 39,613809];	177993 [benign DISEASE=not specified];			rs2797235	0.6897	0.7673	8653,	0.6274,0.8081,0.6486,0.8129,0.6955	0.8140,0.6382	0.0940			0.10,0.32	-0.23						n/a (AF>5%)	n/a (AF>5%)					USH2A (inh=AR pLI=0.00)
chr1	215853749	215853749	T	-	het	hom	het	off-target;gene_blacklist	QUAL=3445;DP=149,68,53;AF=0.50,0.87,0.64;MQM=60	USH2A	intron	USH2A:ENST00000307340:intron_variant:MODIFIER:exon61/71:c.12067-31del::,USH2A:ENST00000366943:intron_variant:MODIFIER:exon61/72:c.12067-31del::	608400 [USH2A (confirmed) Usher syndrome,type 2A,276901/Retinitis pigmentosa 39,613809];				rs5780842		0.8802	10374,	0.6296,0.6577,0.7381,0.7271,0.6140		0.0640				-0.25						n/a (AF>5%)	n/a (AF>5%)					USH2A (inh=AR pLI=0.00)
chr1	215901492	215901492	C	T	hom	hom	het	gene_blacklist	QUAL=39516;DP=411,642,543;AF=0.99,0.99,0.42;MQM=60	USH2A	synonymous	USH2A:ENST00000307340:synonymous_variant:LOW:exon61/72:c.11946G>A:p.Leu3982=:PF00041,USH2A:ENST00000366943:synonymous_variant:LOW:exon61/73:c.11946G>A:p.Leu3982=:PF00041	608400 [USH2A (confirmed) Usher syndrome,type 2A,276901/Retinitis pigmentosa 39,613809];	48387 [benign DISEASE=not specified];			rs2820718	0.1188	0.1772	503,	0.1687,0.0787,0.0012,0.1846,0.1449	0.1845,0.1714	1.0060			0.87,0.94	0.27						n/a (AF>5%)	n/a (AF>5%)					USH2A (inh=AR pLI=0.00)
chr1	215914751	215914751	G	T	het	wt	het	gene_blacklist	QUAL=5386;DP=208,253,192;AF=0.53,0.00,0.52;MQM=60	USH2A	missense	USH2A:ENST00000307340:missense_variant:MODERATE:exon60/72:c.11677C>A:p.Pro3893Thr:,USH2A:ENST00000366943:missense_variant:MODERATE:exon60/73:c.11677C>A:p.Pro3893Thr:	608400 [USH2A (confirmed) Usher syndrome,type 2A,276901/Retinitis pigmentosa 39,613809];	48380 [benign DISEASE=not specified];	CM165987 [CLASS=DM? MUT=ALT PHEN="Usher syndrome 2" GENE=USH2A];		rs41303285	0.0062	0.0159	5,	0.0031,0.0036,0.0000,0.0224,0.0137	0.0224,0.0050	5.6550	D, 	D,D	0.96,0.99	3.46	0.34					2	153	3	[3] auto-classification 14.09.2017  			USH2A (inh=AR pLI=0.00)
chr1	215931928	215931928	T	A	wt	het	wt	gene_blacklist	QUAL=2192;DP=223,196,176;AF=0.00,0.46,0.00;MQM=60	USH2A	intron	USH2A:ENST00000307340:intron_variant:MODIFIER:exon58/71:c.11389+9A>T::,USH2A:ENST00000366943:intron_variant:MODIFIER:exon58/72:c.11389+9A>T::	608400 [USH2A (confirmed) Usher syndrome,type 2A,276901/Retinitis pigmentosa 39,613809];	48372 [benign DISEASE=not specified];			rs12095085	0.0749	0.1256	269,	0.1329,0.0675,0.0003,0.1295,0.0527	0.1248,0.1314	-0.0740			0.04,0.21	-0.07						n/a (AF>5%)	n/a (AF>5%)					USH2A (inh=AR pLI=0.00)
chr1	215932957	215932957	G	A	wt	wt	het	off-target;gene_blacklist	QUAL=1056;DP=203,122,82;AF=0.00,0.00,0.55;MQM=60	USH2A	intron	USH2A:ENST00000307340:intron_variant:MODIFIER:exon57/71:c.11231+45C>T::,USH2A:ENST00000366943:intron_variant:MODIFIER:exon57/72:c.11231+45C>T::	608400 [USH2A (confirmed) Usher syndrome,type 2A,276901/Retinitis pigmentosa 39,613809];				rs17025373	0.1322	0.1062	170,	0.0126,0.2058,0.3712,0.0656,0.0851	0.0630,0.0123	-1.3270			0.05,0.17	-0.27						n/a (AF>5%)	n/a (AF>5%)					USH2A (inh=AR pLI=0.00)
chr1	215956304	215956304	A	G	hom	hom	hom	off-target;gene_blacklist	QUAL=3937;DP=81,27,22;AF=0.99,1.00,1.00;MQM=60	USH2A	intron	USH2A:ENST00000307340:intron_variant:MODIFIER:exon52/71:c.10388-27T>C::,USH2A:ENST00000366943:intron_variant:MODIFIER:exon52/72:c.10388-27T>C::	608400 [USH2A (confirmed) Usher syndrome,type 2A,276901/Retinitis pigmentosa 39,613809];				rs7518466	0.6016	0.5902	5490,	0.7297,0.5770,0.6320,0.5277,0.4956	0.5183,0.7124	-1.5270			0.01,0.13	-0.28						n/a (AF>5%)	n/a (AF>5%)					USH2A (inh=AR pLI=0.00)
chr1	215960153	215960153	A	C	het	wt	wt	gene_blacklist	QUAL=64;DP=230,279,233;AF=0.35,0.02,0.01;MQM=59	USH2A	missense	USH2A:ENST00000307340:missense_variant:MODERATE:exon52/72:c.10246T>G:p.Cys3416Gly:,USH2A:ENST00000366943:missense_variant:MODERATE:exon52/73:c.10246T>G:p.Cys3416Gly:	608400 [USH2A (confirmed) Usher syndrome,type 2A,276901/Retinitis pigmentosa 39,613809];	143168 [likely benign DISEASE=not provided];	CM135012 [CLASS=DM MUT=ALT PHEN="Usher syndrome" GENE=USH2A];		rs527236140		0.2227	0,	0.2583,0.1405,0.1918,0.2617,0.1646		5.2290	D, 	D,D	0.98,0.99	3.66	0.28					n/a (AF>5%)	n/a (AF>5%)					USH2A (inh=AR pLI=0.00)
chr1	215960167	215960167	T	G	hom	hom	hom	gene_blacklist	QUAL=26866;DP=220,368,287;AF=1.00,1.00,1.00;MQM=60	USH2A	missense	USH2A:ENST00000307340:missense_variant:MODERATE:exon52/72:c.10232A>C:p.Glu3411Ala:,USH2A:ENST00000366943:missense_variant:MODERATE:exon52/73:c.10232A>C:p.Glu3411Ala:	608400 [USH2A (confirmed) Usher syndrome,type 2A,276901/Retinitis pigmentosa 39,613809];	48344 [benign DISEASE=not specified];			rs10864198	0.5887	0.5802	5270,	0.6846,0.5756,0.6340,0.5222,0.4938	0.5188,0.6716	2.5990	T, 	B,B	0.02,0.80	1.19	0.09					n/a (AF>5%)	n/a (AF>5%)					USH2A (inh=AR pLI=0.00)
chr1	215963374	215963374	G	A	wt	het	wt	off-target;gene_blacklist	QUAL=1532;DP=130,128,110;AF=0.00,0.50,0.00;MQM=60	USH2A	intron	USH2A:ENST00000307340:intron_variant:MODIFIER:exon51/71:c.10182+27C>T::,USH2A:ENST00000366943:intron_variant:MODIFIER:exon51/72:c.10182+27C>T::	608400 [USH2A (confirmed) Usher syndrome,type 2A,276901/Retinitis pigmentosa 39,613809];				rs11120629	0.0805	0.1297	286,	0.1485,0.0682,0.0004,0.1296,0.0530	0.1278,0.1396	-0.0130			0.10,0.24	0.62						n/a (AF>5%)	n/a (AF>5%)					USH2A (inh=AR pLI=0.00)
chr1	215987222	215987222	T	C	wt	het	wt	gene_blacklist	QUAL=3233;DP=271,280,169;AF=0.00,0.46,0.00;MQM=60	USH2A	missense	USH2A:ENST00000307340:missense_variant:MODERATE:exon49/72:c.9595A>G:p.Asn3199Asp:,USH2A:ENST00000366943:missense_variant:MODERATE:exon49/73:c.9595A>G:p.Asn3199Asp:	608400 [USH2A (confirmed) Usher syndrome,type 2A,276901/Retinitis pigmentosa 39,613809];	48631 [benign DISEASE=not specified];			rs4129843	0.0871	0.0546	67,	0.0820,0.0619,0.1685,0.0375,0.0820	0.0398,0.0781	0.1850	T, 	B,B	0.01,0.19	-0.20	0.04					n/a (AF>5%)	n/a (AF>5%)					USH2A (inh=AR pLI=0.00)
chr1	216011361	216011361	T	C	wt	het	wt	gene_blacklist	QUAL=3249;DP=341,263,238;AF=0.00,0.49,0.00;MQM=60	USH2A	missense	USH2A:ENST00000307340:missense_variant:MODERATE:exon47/72:c.9343A>G:p.Thr3115Ala:,USH2A:ENST00000366943:missense_variant:MODERATE:exon47/73:c.9343A>G:p.Thr3115Ala:	608400 [USH2A (confirmed) Usher syndrome,type 2A,276901/Retinitis pigmentosa 39,613809];	48623 [benign DISEASE=not specified,not provided];			rs56032526	0.0647	0.0495	37,	0.0086,0.0587,0.1682,0.0375,0.0822	0.0398,0.0123	0.1260	T, 	B,B	0.08,0.28	-0.64	0.14					n/a (AF>5%)	n/a (AF>5%)					USH2A (inh=AR pLI=0.00)
chr1	216019427	216019427	A	-	wt	het	wt	off-target;gene_blacklist	QUAL=372;DP=123,44,42;AF=0.02,0.48,0.00;MQM=60	USH2A	intron	USH2A:ENST00000307340:intron_variant:MODIFIER:exon44/71:c.8846-52del::,USH2A:ENST00000366943:intron_variant:MODIFIER:exon44/72:c.8846-52del::	608400 [USH2A (confirmed) Usher syndrome,type 2A,276901/Retinitis pigmentosa 39,613809];				rs146638027		0.0646	40,	0.0130,0.0790,0.2084,0.0490,0.1041	0.0618,0.0352	0.0630				-0.77						n/a (AF>5%)	n/a (AF>5%)					USH2A (inh=AR pLI=0.00)
chr1	216051125	216051125	G	A	wt	het	wt	gene_blacklist	QUAL=2911;DP=195,216,198;AF=0.00,0.52,0.00;MQM=60	USH2A	missense	USH2A:ENST00000307340:missense_variant:MODERATE:exon43/72:c.8656C>T:p.Leu2886Phe:PF00041,USH2A:ENST00000366943:missense_variant:MODERATE:exon43/73:c.8656C>T:p.Leu2886Phe:PF00041	608400 [USH2A (confirmed) Usher syndrome,type 2A,276901/Retinitis pigmentosa 39,613809];	48607 [benign DISEASE=not specified,not provided];	CM1413302 [CLASS=R MUT=ALT PHEN="Hearing loss" GENE=USH2A];		rs41277200	0.0777	0.0519	42,	0.0608,0.0630,0.1553,0.0366,0.0806	0.0381,0.0624	6.9270	T, 	B,B	0.20,0.97	2.13	0.14					n/a (AF>5%)	n/a (AF>5%)					USH2A (inh=AR pLI=0.00)
chr1	216166454	216166454	T	G	het	wt	het	gene_blacklist	QUAL=2801;DP=128,98,94;AF=0.48,0.00,0.57;MQM=60	USH2A	missense	USH2A:ENST00000307340:missense_variant:MODERATE:exon35/72:c.6713A>C:p.Glu2238Ala:,USH2A:ENST00000366943:missense_variant:MODERATE:exon35/73:c.6713A>C:p.Glu2238Ala:	608400 [USH2A (confirmed) Usher syndrome,type 2A,276901/Retinitis pigmentosa 39,613809];	48568 [benign DISEASE=not specified,not provided];	CM140482 [CLASS=DM? MUT=ALT PHEN="Retinitis pigmentosa autosomal recessive" GENE=USH2A];		rs41277212	0.0076	0.0225	7,	0.0052,0.0174,0.0001,0.0285,0.0149	0.0295,0.0059	4.8830	D, 	P,D	0.92,0.95	3.37	0.27					5	207	3	[3] auto-classification 14.09.2017  			USH2A (inh=AR pLI=0.00)
chr1	216172380	216172380	A	G	hom	hom	hom	gene_blacklist	QUAL=19008;DP=180,229,188;AF=0.99,1.00,1.00;MQM=60	USH2A	missense	USH2A:ENST00000307340:missense_variant:MODERATE:exon34/72:c.6506T>C:p.Ile2169Thr:,USH2A:ENST00000366943:missense_variant:MODERATE:exon34/73:c.6506T>C:p.Ile2169Thr:	608400 [USH2A (confirmed) Usher syndrome,type 2A,276901/Retinitis pigmentosa 39,613809];	48562 [benign DISEASE=not specified];			rs10864219	0.5934	0.5625	4165,	0.4323,0.6702,0.8396,0.4995,0.5976	0.5027,0.4385	2.3960	T, 	B,B	0.92,0.96	2.02	0.11					n/a (AF>5%)	n/a (AF>5%)					USH2A (inh=AR pLI=0.00)
chr1	216219781	216219781	A	G	het	hom	het	gene_blacklist	QUAL=8814;DP=201,147,125;AF=0.49,1.00,0.50;MQM=60	USH2A	missense	USH2A:ENST00000307340:missense_variant:MODERATE:exon32/72:c.6317T>C:p.Ile2106Thr:,USH2A:ENST00000366943:missense_variant:MODERATE:exon32/73:c.6317T>C:p.Ile2106Thr:	608400 [USH2A (confirmed) Usher syndrome,type 2A,276901/Retinitis pigmentosa 39,613809];	167815 [benign DISEASE=not specified];			rs6657250	0.5956	0.6759	7147,	0.7711,0.3509,0.4395,0.6711,0.5076	0.6695,0.7608	0.9870	T, 	B,B	0.04,0.66	1.35	0.13					n/a (AF>5%)	n/a (AF>5%)					USH2A (inh=AR pLI=0.00)
chr1	216246676	216246676	G	-	het	het	het	off-target	QUAL=5152;DP=176,132,100;AF=0.52,0.55,0.53;MQM=60	USH2A,RP11-22M7.2	intron,intron&non_coding_transcript	USH2A:ENST00000307340:intron_variant:MODIFIER:exon27/71:c.5573-34del::,USH2A:ENST00000366943:intron_variant:MODIFIER:exon27/72:c.5573-34del::,RP11-22M7.2:ENST00000430890:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/2:n.78+530del::,RP11-22M7.2:ENST00000445619:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.159+372del::,RP11-22M7.2:ENST00000446411:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/2:n.136+736del::	608400 [USH2A (confirmed) Usher syndrome,type 2A,276901/Retinitis pigmentosa 39,613809];				rs35944387	0.7873	0.7324	7864,	0.7455,0.7842,0.9536,0.6880,0.7707	0.6919,0.7407	0.7670				1.16						n/a (AF>5%)	n/a (AF>5%)					USH2A (inh=AR pLI=0.00), RP11-22M7.2 (inh=n/a pLI=n/a)
chr1	216258194	216258194	G	T	het	het	het		QUAL=5971;DP=156,177,133;AF=0.49,0.51,0.51;MQM=60	USH2A,RP11-22M7.2	synonymous,intron&non_coding_transcript	USH2A:ENST00000307340:synonymous_variant:LOW:exon25/72:c.5013C>A:p.Gly1671=:PF02210,USH2A:ENST00000366943:synonymous_variant:LOW:exon25/73:c.5013C>A:p.Gly1671=:PF02210,RP11-22M7.2:ENST00000430890:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/2:n.208-1870G>T::,RP11-22M7.2:ENST00000442606:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/2:n.207-1870G>T::,RP11-22M7.2:ENST00000445619:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.160-1870G>T::,RP11-22M7.2:ENST00000446411:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/2:n.266-1870G>T::	608400 [USH2A (confirmed) Usher syndrome,type 2A,276901/Retinitis pigmentosa 39,613809];	48527 [benign DISEASE=not specified];			rs56110889	0.1058	0.1597	434,	0.1969,0.0939,0.0001,0.1746,0.0771	0.1722,0.1916	0.1420			0.68,0.96	1.72						n/a (AF>5%)	n/a (AF>5%)					USH2A (inh=AR pLI=0.00), RP11-22M7.2 (inh=n/a pLI=n/a)
chr1	216347452	216347452	C	A	het	wt	het	gene_blacklist	QUAL=3568;DP=219,121,108;AF=0.42,0.00,0.45;MQM=60	USH2A	intron,3'UTR	USH2A:ENST00000307340:intron_variant:MODIFIER:exon21/71:c.4627+1142G>T::,USH2A:ENST00000366942:3_prime_UTR_variant:MODIFIER:exon21/21:c.*1128G>T::,USH2A:ENST00000366943:intron_variant:MODIFIER:exon21/72:c.4627+1142G>T::	608400 [USH2A (confirmed) Usher syndrome,type 2A,276901/Retinitis pigmentosa 39,613809];	295405 [likely benign DISEASE=Retinitis pigmentosa-deafness syndrome,Retinitis Pigmentosa, Recessive];			rs401269	0.1945	0.1987	657,			-0.1910			0.04,0.19	-0.06						n/a (AF>5%)	n/a (AF>5%)					USH2A (inh=AR pLI=0.00)
chr1	216347556	216347556	A	G	het	wt	het	gene_blacklist	QUAL=3709;DP=224,55,56;AF=0.48,0.00,0.54;MQM=60	USH2A	intron,3'UTR	USH2A:ENST00000307340:intron_variant:MODIFIER:exon21/71:c.4627+1038T>C::,USH2A:ENST00000366942:3_prime_UTR_variant:MODIFIER:exon21/21:c.*1024T>C::,USH2A:ENST00000366943:intron_variant:MODIFIER:exon21/72:c.4627+1038T>C::	608400 [USH2A (confirmed) Usher syndrome,type 2A,276901/Retinitis pigmentosa 39,613809];	295407 [likely benign DISEASE=Retinitis pigmentosa-deafness syndrome,Retinitis Pigmentosa, Recessive];			rs439940	0.1953	0.1998	666,			0.7440			0.08,0.22	0.23						n/a (AF>5%)	n/a (AF>5%)					USH2A (inh=AR pLI=0.00)
chr1	216348764	216348764	C	T	het	hom	het	gene_blacklist	QUAL=29575;DP=480,509,457;AF=0.53,1.00,0.49;MQM=60	USH2A	missense	USH2A:ENST00000307340:missense_variant:MODERATE:exon21/72:c.4457G>A:p.Arg1486Lys:,USH2A:ENST00000366942:missense_variant:MODERATE:exon21/21:c.4457G>A:p.Arg1486Lys:,USH2A:ENST00000366943:missense_variant:MODERATE:exon21/73:c.4457G>A:p.Arg1486Lys:	608400 [USH2A (confirmed) Usher syndrome,type 2A,276901/Retinitis pigmentosa 39,613809];	177992 [benign DISEASE=not specified];			rs1805049	0.6623	0.6608	6373,	0.5800,0.7184,0.7802,0.6226,0.6987	0.6117,0.5960	-1.6250	T,T, 	B,B,B	0.03,0.16	0.55	0.02					n/a (AF>5%)	n/a (AF>5%)					USH2A (inh=AR pLI=0.00)
chr1	216370108	216370108	C	T	het	wt	het	off-target	QUAL=3474;DP=188,127,93;AF=0.51,0.00,0.51;MQM=60	USH2A,RP5-1099E6.3	intron,intron&non_coding_transcript	USH2A:ENST00000307340:intron_variant:MODIFIER:exon18/71:c.4082-44G>A::,USH2A:ENST00000366942:intron_variant:MODIFIER:exon18/20:c.4082-44G>A::,USH2A:ENST00000366943:intron_variant:MODIFIER:exon18/72:c.4082-44G>A::,RP5-1099E6.3:ENST00000420867:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/2:n.362+841C>T::	608400 [USH2A (confirmed) Usher syndrome,type 2A,276901/Retinitis pigmentosa 39,613809];				rs447102	0.1645	0.2091	561,	0.0695,0.1883,0.2111,0.2382,0.2315	0.2293,0.0752	-0.7920			0.00,0.10	-0.31						n/a (AF>5%)	n/a (AF>5%)					USH2A (inh=AR pLI=0.00), RP5-1099E6.3 (inh=n/a pLI=n/a)
chr1	216371934	216371934	A	C	het	wt	het		QUAL=4091;DP=223,90,82;AF=0.54,0.00,0.55;MQM=59	USH2A,RP5-1099E6.3	splice_region&intron,intron&non_coding_transcript	USH2A:ENST00000307340:splice_region_variant&intron_variant:LOW:exon17/71:c.3812-8T>G::,USH2A:ENST00000366942:splice_region_variant&intron_variant:LOW:exon17/20:c.3812-8T>G::,USH2A:ENST00000366943:splice_region_variant&intron_variant:LOW:exon17/72:c.3812-8T>G::,RP5-1099E6.3:ENST00000420867:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/2:n.362+2667A>C::	608400 [USH2A (confirmed) Usher syndrome,type 2A,276901/Retinitis pigmentosa 39,613809];	48508 [benign/likely benign DISEASE=Retinitis pigmentosa-deafness syndrome,not specified,Retinitis Pigmentosa, Recessive];			rs646094	0.1977	0.2128	663,	0.1638,0.1884,0.2071,0.2334,0.2293	0.2306,0.1673	1.0410			0.41,0.79	1.06		-8.16% (9.73>8.94)		0.003/0.164		n/a (AF>5%)	n/a (AF>5%)					USH2A (inh=AR pLI=0.00), RP5-1099E6.3 (inh=n/a pLI=n/a)
chr1	216390694	216390694	C	T	het	hom	het	off-target;gene_blacklist	QUAL=7346;DP=178,125,110;AF=0.48,1.00,0.52;MQM=60	USH2A	intron	USH2A:ENST00000307340:intron_variant:MODIFIER:exon15/71:c.3157+35G>A::,USH2A:ENST00000366942:intron_variant:MODIFIER:exon15/20:c.3157+35G>A::,USH2A:ENST00000366943:intron_variant:MODIFIER:exon15/72:c.3157+35G>A::	608400 [USH2A (confirmed) Usher syndrome,type 2A,276901/Retinitis pigmentosa 39,613809];			L3b	rs1324330	0.5875	0.6384	5357,	0.3326,0.7050,0.7778,0.6182,0.6833	0.6072,0.3584	0.0420			0.01,0.15	0.04						n/a (AF>5%)	n/a (AF>5%)					USH2A (inh=AR pLI=0.00)
chr1	216592003	216592003	T	C	hom	hom	hom	gene_blacklist	QUAL=18965;DP=160,255,190;AF=1.00,1.00,0.99;MQM=60	USH2A	synonymous	USH2A:ENST00000307340:synonymous_variant:LOW:exon3/72:c.504A>G:p.Thr168=:PF13385,USH2A:ENST00000366942:synonymous_variant:LOW:exon3/21:c.504A>G:p.Thr168=:PF13385,USH2A:ENST00000366943:synonymous_variant:LOW:exon3/73:c.504A>G:p.Thr168=:PF13385	608400 [USH2A (confirmed) Usher syndrome,type 2A,276901/Retinitis pigmentosa 39,613809];	48528 [benign DISEASE=Retinitis pigmentosa-deafness syndrome,not specified,Retinitis Pigmentosa, Recessive];			rs4253963	0.6328	0.6525	6153,	0.4917,0.6959,0.8402,0.6474,0.6004	0.6431,0.5050	-0.6980			0.02,0.14	-0.23						n/a (AF>5%)	n/a (AF>5%)					USH2A (inh=AR pLI=0.00)
chr1	216595306	216595306	C	T	hom	hom	hom	gene_blacklist	QUAL=33005;DP=294,445,279;AF=0.99,1.00,1.00;MQM=60	USH2A	missense	USH2A:ENST00000307340:missense_variant:MODERATE:exon2/72:c.373G>A:p.Ala125Thr:,USH2A:ENST00000366942:missense_variant:MODERATE:exon2/21:c.373G>A:p.Ala125Thr:,USH2A:ENST00000366943:missense_variant:MODERATE:exon2/73:c.373G>A:p.Ala125Thr:	608400 [USH2A (confirmed) Usher syndrome,type 2A,276901/Retinitis pigmentosa 39,613809];	48507 [benign DISEASE=Retinitis pigmentosa-deafness syndrome,not specified,Retinitis Pigmentosa, Recessive];			rs10779261	0.7612	0.7398	8458,	0.7556,0.7318,0.8374,0.7052,0.7319	0.6991,0.7578	0.3550	T,T, 	B,B,B	0.01,0.12	0.18	0.08					n/a (AF>5%)	n/a (AF>5%)					USH2A (inh=AR pLI=0.00)
chr1	220323449	220323449	T	-	het	het	het		QUAL=1283;DP=141,50,39;AF=0.28,0.26,0.36;MQM=59	RAB3GAP2	3'UTR	RAB3GAP2:ENST00000358951:3_prime_UTR_variant:MODIFIER:exon35/35:c.*1144del::	609275 [RAB3GAP2 (provisional) Martsolf syndrome,212720/Warburg micro syndrome 2,614225];	295627 [uncertain significance DISEASE=Martsolf syndrome,Warburg micro syndrome];		FLAM_C	rs11316594		0.4718	2462,			-2.8180				-0.11						n/a (AF>5%)	n/a (AF>5%)					RAB3GAP2 (inh=AR pLI=0.99)
chr1	220323794	220323794	T	-	het	het	het		QUAL=526;DP=57,21,14;AF=0.25,0.29,0.43;MQM=60	RAB3GAP2	3'UTR	RAB3GAP2:ENST00000358951:3_prime_UTR_variant:MODIFIER:exon35/35:c.*799del::	609275 [RAB3GAP2 (provisional) Martsolf syndrome,212720/Warburg micro syndrome 2,614225];			(T)n	rs577626438	0.3638	0.1804	404,			0.1390				0.41						n/a (AF>5%)	n/a (AF>5%)					RAB3GAP2 (inh=AR pLI=0.99)
chr1	220324189	220324189	A	G	het	het	wt		QUAL=9731;DP=414,267,218;AF=0.54,0.53,0.00;MQM=60	RAB3GAP2	3'UTR	RAB3GAP2:ENST00000358951:3_prime_UTR_variant:MODIFIER:exon35/35:c.*404T>C::	609275 [RAB3GAP2 (provisional) Martsolf syndrome,212720/Warburg micro syndrome 2,614225];	295635 [likely benign DISEASE=Martsolf syndrome,Warburg micro syndrome];			rs1059140	0.0627	0.0695	100,			0.4840			0.01,0.20	0.69						n/a (AF>5%)	n/a (AF>5%)					RAB3GAP2 (inh=AR pLI=0.99)
chr1	220330672	220330672	C	T	het	het	wt		QUAL=9364;DP=417,288,211;AF=0.54,0.48,0.00;MQM=60	RAB3GAP2	synonymous	RAB3GAP2:ENST00000358951:synonymous_variant:LOW:exon31/35:c.3495G>A:p.Leu1165=:PF14656	609275 [RAB3GAP2 (provisional) Martsolf syndrome,212720/Warburg micro syndrome 2,614225];	130080 [benign/likely benign DISEASE=Martsolf syndrome,Warburg micro syndrome,not specified];			rs11547779	0.0605	0.0867	102,	0.0150,0.0476,0.0573,0.0970,0.1336	0.0936,0.0216	-0.6200			0.14,0.31	0.25						n/a (AF>5%)	n/a (AF>5%)					RAB3GAP2 (inh=AR pLI=0.99)
chr1	220331205	220331205	C	G	het	het	wt		QUAL=6506;DP=291,248,182;AF=0.45,0.46,0.00;MQM=60	RAB3GAP2	missense	RAB3GAP2:ENST00000358951:missense_variant:MODERATE:exon30/35:c.3275G>C:p.Ser1092Thr:PF14656	609275 [RAB3GAP2 (provisional) Martsolf syndrome,212720/Warburg micro syndrome 2,614225];	130079 [benign/likely benign DISEASE=Martsolf syndrome,Warburg micro syndrome,not specified];			rs2289189	0.0603	0.0860	101,	0.0150,0.0453,0.0573,0.0963,0.1334	0.0936,0.0216	7.4320	D	P	0.99,0.99	4.01	0.18					n/a (AF>5%)	n/a (AF>5%)					RAB3GAP2 (inh=AR pLI=0.99)
chr1	220369746	220369746	A	-	wt	wt	het		QUAL=827;DP=101,94,89;AF=0.06,0.01,0.49;MQM=60	RAB3GAP2	splice_region&intron	RAB3GAP2:ENST00000358951:splice_region_variant&intron_variant:LOW:exon9/34:c.812-6del::	609275 [RAB3GAP2 (provisional) Martsolf syndrome,212720/Warburg micro syndrome 2,614225];	295665 [benign DISEASE=Martsolf syndrome,Warburg micro syndrome];			rs35396665	0.3041	0.3766	1005,	0.3393,0.4775,0.4504,0.3379,0.3871	0.2472,0.2667	0.3690				-0.15						n/a (AF>5%)	n/a (AF>5%)					RAB3GAP2 (inh=AR pLI=0.99)
chr1	223101939	223101939	A	C	het	het	het	off-target	QUAL=5386;DP=179,156,136;AF=0.42,0.50,0.47;MQM=60	DISP1	intron	DISP1:ENST00000284476:intron_variant:MODIFIER:exon1/7:c.-18+27A>C::,DISP1:ENST00000360254:intron_variant:MODIFIER:exon2/3:c.-18+27A>C::					rs35491159	0.2486	0.3305	1776,			-0.1080			0.03,0.23	0.19						n/a (AF>5%)	n/a (AF>5%)					DISP1 (inh=AD pLI=0.00)
chr1	223116109	223116109	C	T	het	het	het	off-target	QUAL=3244;DP=102,104,91;AF=0.48,0.48,0.51;MQM=60	DISP1	intron	DISP1:ENST00000284476:intron_variant:MODIFIER:exon1/7:c.-17-40C>T::,DISP1:ENST00000360254:intron_variant:MODIFIER:exon2/3:c.-17-40C>T::					rs75109669	0.1220	0.1791	552,			-0.3380			0.02,0.26	0.22						n/a (AF>5%)	n/a (AF>5%)					DISP1 (inh=AD pLI=0.00)
chr1	223156382	223156382	C	T	hom	hom	hom	off-target	QUAL=17367;DP=271,157,113;AF=1.00,1.00,1.00;MQM=60	DISP1	intron	DISP1:ENST00000284476:intron_variant:MODIFIER:exon2/7:c.510-40C>T::					rs2926159	0.9998	0.9999	15047,	0.9991,1.0000,1.0000,1.0000,1.0000	1.0000,0.9995	0.6990			0.00,0.11	0.29						n/a (AF>5%)	n/a (AF>5%)					DISP1 (inh=AD pLI=0.00)
chr1	223168213	223168213	T	C	wt	het	wt	off-target	QUAL=1099;DP=182,93,56;AF=0.00,0.48,0.00;MQM=60	DISP1	intron	DISP1:ENST00000284476:intron_variant:MODIFIER:exon6/7:c.890-14T>C::		262132 [benign DISEASE=not specified];			rs2609359	0.3796	0.3446	1913,	0.4332,0.3775,0.2992,0.3011,0.4583	0.2848,0.4210	1.5460			0.18,0.46	0.83		-9.87% (10.87>9.80)				n/a (AF>5%)	n/a (AF>5%)					DISP1 (inh=AD pLI=0.00)
chr1	223177574	223177574	A	G	wt	het	wt		QUAL=5300;DP=505,407,263;AF=0.00,0.50,0.00;MQM=60	DISP1	synonymous	DISP1:ENST00000284476:synonymous_variant:LOW:exon8/8:c.2835A>G:p.Lys945=:		262128 [benign DISEASE=not specified];			rs2609355	0.2414	0.2900	1126,	0.1790,0.2988,0.2127,0.3014,0.3116	0.3002,0.1868	-0.6020			0.04,0.19	0.17						n/a (AF>5%)	n/a (AF>5%)					DISP1 (inh=AD pLI=0.00)
chr1	223178561	223178561	A	C	hom	het	hom		QUAL=20441;DP=190,372,288;AF=1.00,0.53,1.00;MQM=60	DISP1	synonymous	DISP1:ENST00000284476:synonymous_variant:LOW:exon8/8:c.3822A>C:p.Pro1274=:		262131 [benign DISEASE=not specified];			rs9441941	0.4980	0.5468	4643,	0.4484,0.5371,0.5141,0.5765,0.4764	0.5767,0.4532	-1.2410			0.04,0.15	-0.18						n/a (AF>5%)	n/a (AF>5%)					DISP1 (inh=AD pLI=0.00)
chr1	225589473	225589473	C	T	het	het	wt		QUAL=8367;DP=322,352,266;AF=0.50,0.44,0.00;MQM=60	LBR	3'UTR	LBR:ENST00000272163:3_prime_UTR_variant:MODIFIER:exon14/14:c.*1532G>A::,LBR:ENST00000338179:3_prime_UTR_variant:MODIFIER:exon14/14:c.*1532G>A::	600024 [LBR (confirmed) Pelger-Huet anomaly,169400/Greenberg skeletal dysplasia,215140/Reynolds syndrome,613471/Pelger-Huet anomaly with mild skeletal anomalies,618019];	295917 [benign DISEASE=Greenberg dysplasia];			rs7406	0.2726	0.2483	1388,			0.7820			0.16,0.37	1.14						n/a (AF>5%)	n/a (AF>5%)					LBR (inh=AR+AD pLI=0.99)
chr1	225590750	225590750	G	C	het	het	wt		QUAL=4476;DP=310,56,46;AF=0.47,0.50,0.00;MQM=60	LBR	3'UTR	LBR:ENST00000272163:3_prime_UTR_variant:MODIFIER:exon14/14:c.*255C>G::,LBR:ENST00000338179:3_prime_UTR_variant:MODIFIER:exon14/14:c.*255C>G::	600024 [LBR (confirmed) Pelger-Huet anomaly,169400/Greenberg skeletal dysplasia,215140/Reynolds syndrome,613471/Pelger-Huet anomaly with mild skeletal anomalies,618019];	295928 [benign DISEASE=Greenberg dysplasia];			rs11551874	0.1020	0.0907	125,			0.4490			0.18,0.22	0.21						n/a (AF>5%)	n/a (AF>5%)					LBR (inh=AR+AD pLI=0.99)
chr1	225607144	225607144	C	T	het	het	hom		QUAL=1838;DP=75,47,20;AF=0.40,0.45,1.00;MQM=60	LBR	missense	LBR:ENST00000272163:missense_variant:MODERATE:exon5/14:c.461G>A:p.Ser154Asn:,LBR:ENST00000338179:missense_variant:MODERATE:exon5/14:c.461G>A:p.Ser154Asn:	600024 [LBR (confirmed) Pelger-Huet anomaly,169400/Greenberg skeletal dysplasia,215140/Reynolds syndrome,613471/Pelger-Huet anomaly with mild skeletal anomalies,618019];	258619 [benign DISEASE=Greenberg dysplasia,not specified];			rs2230419	0.7123	0.8117	8921,	0.4159,0.8734,0.9582,0.8383,0.6985	0.8397,0.4371	-0.1880	T,T	B,B	0.01,0.10	-1.02	0.17					n/a (AF>5%)	n/a (AF>5%)					LBR (inh=AR+AD pLI=0.99)
chr1	225609884	225609884	A	G	het	het	hom		QUAL=2373;DP=126,18,16;AF=0.57,0.61,1.00;MQM=60	LBR	synonymous	LBR:ENST00000272163:synonymous_variant:LOW:exon3/14:c.261T>C:p.Pro87=:,LBR:ENST00000338179:synonymous_variant:LOW:exon3/14:c.261T>C:p.Pro87=:	600024 [LBR (confirmed) Pelger-Huet anomaly,169400/Greenberg skeletal dysplasia,215140/Reynolds syndrome,613471/Pelger-Huet anomaly with mild skeletal anomalies,618019];	258617 [benign DISEASE=Greenberg dysplasia,not specified];			rs1056608		0.7632	7741,	0.3824,0.8492,0.8981,0.7867,0.6554	0.7909,0.4020	-0.4330			0.28,0.95	1.24						n/a (AF>5%)	n/a (AF>5%)					LBR (inh=AR+AD pLI=0.99)
chr1	225611661	225611661	C	T	het	hom	het		QUAL=17147;DP=366,283,211;AF=0.53,1.00,0.49;MQM=60	LBR	synonymous	LBR:ENST00000272163:synonymous_variant:LOW:exon2/14:c.117G>A:p.Val39=:PF09465,LBR:ENST00000338179:synonymous_variant:LOW:exon2/14:c.117G>A:p.Val39=:PF09465	600024 [LBR (confirmed) Pelger-Huet anomaly,169400/Greenberg skeletal dysplasia,215140/Reynolds syndrome,613471/Pelger-Huet anomaly with mild skeletal anomalies,618019];	258616 [benign DISEASE=Greenberg dysplasia,not specified];			rs1056607	0.6571	0.7261	8216,	0.6381,0.7878,0.7708,0.7352,0.5217	0.7313,0.6360	-2.9810			0.04,0.70	0.36						n/a (AF>5%)	n/a (AF>5%)					LBR (inh=AR+AD pLI=0.99)
chr1	225611845	225611845	C	T	wt	het	het	off-target	QUAL=2279;DP=183,111,83;AF=0.00,0.52,0.43;MQM=60	LBR	intron	LBR:ENST00000272163:intron_variant:MODIFIER:exon1/13:c.-14-54G>A::,LBR:ENST00000338179:intron_variant:MODIFIER:exon1/13:c.-14-54G>A::	600024 [LBR (confirmed) Pelger-Huet anomaly,169400/Greenberg skeletal dysplasia,215140/Reynolds syndrome,613471/Pelger-Huet anomaly with mild skeletal anomalies,618019];				rs1340867	0.6018	0.6256	6110,			-0.4700			0.01,0.08	-0.01						n/a (AF>5%)	n/a (AF>5%)					LBR (inh=AR+AD pLI=0.99)
chr1	225616378	225616378	G	C	het	wt	het	off-target	QUAL=4072;DP=192,251,179;AF=0.55,0.00,0.50;MQM=60	LBR	intron	LBR:ENST00000338179:intron_variant:MODIFIER:exon1/13:c.-15+30C>G::	600024 [LBR (confirmed) Pelger-Huet anomaly,169400/Greenberg skeletal dysplasia,215140/Reynolds syndrome,613471/Pelger-Huet anomaly with mild skeletal anomalies,618019];				rs75691342	0.0996	0.0725	86,			-0.4440			0.05,0.33	0.24						n/a (AF>5%)	n/a (AF>5%)					LBR (inh=AR+AD pLI=0.99)
chr1	226548554	226548554	A	G	wt	wt	het		QUAL=859;DP=168,97,77;AF=0.01,0.00,0.49;MQM=60	PARP1	3'UTR	PARP1:ENST00000366794:3_prime_UTR_variant:MODIFIER:exon23/23:c.*607T>C::			CR122378 [CLASS=DP MUT=ALT PHEN="Bladder cancer increased risk association with" GENE=PARP1];		rs8679	0.1428	0.1517	447,			-0.4050			0.01,0.20	0.08						n/a (AF>5%)	n/a (AF>5%)					PARP1 (inh=n/a pLI=0.06)
chr1	226555302	226555302	A	G	het	het	wt		QUAL=5798;DP=196,302,220;AF=0.47,0.47,0.00;MQM=60	PARP1	missense	PARP1:ENST00000366794:missense_variant:MODERATE:exon17/23:c.2285T>C:p.Val762Ala:PF02877			CM042761 [CLASS=DFP MUT=ALT PHEN="Prostate cancer susceptibility association with" GENE=PARP1];		rs1136410	0.1969	0.2127	553,	0.0477,0.4248,0.4464,0.1668,0.1028	0.1594,0.0529	8.9590	D	P	0.98,0.98	4.01	0.18					n/a (AF>5%)	n/a (AF>5%)					PARP1 (inh=n/a pLI=0.06)
chr1	226555348	226555348	G	A	wt	wt	het	off-target	QUAL=2128;DP=205,243,175;AF=0.00,0.00,0.49;MQM=60	PARP1	intron	PARP1:ENST00000366794:intron_variant:MODIFIER:exon16/22:c.2278-39C>T::					rs3219123	0.0266	0.0445	29,	0.0085,0.0238,0.0004,0.0597,0.0451	0.0605,0.0123	0.9070			0.07,0.19	-0.15						22	555					PARP1 (inh=n/a pLI=0.06)
chr1	226570840	226570840	T	C	het	het	hom		QUAL=4870;DP=93,92,72;AF=0.57,0.51,1.00;MQM=59	PARP1	synonymous	PARP1:ENST00000366794:synonymous_variant:LOW:exon8/23:c.1056A>G:p.Lys352=:					rs1805415		0.8228	10581,	0.9007,0.5734,0.5545,0.8333,0.8972	0.8408,0.8976	-0.1150			0.12,0.95	0.60						n/a (AF>5%)	n/a (AF>5%)					PARP1 (inh=n/a pLI=0.06)
chr1	226573364	226573364	A	G	het	het	wt		QUAL=4695;DP=153,248,208;AF=0.54,0.45,0.00;MQM=60	PARP1	synonymous	PARP1:ENST00000366794:synonymous_variant:LOW:exon7/23:c.852T>C:p.Ala284=:PF08063			CM071915 [CLASS=DP MUT=ALT PHEN="Colorectal adenoma association with" GENE=PARP1];		rs1805414	0.5166	0.4306	3105,	0.5531,0.5542,0.8121,0.3384,0.3646	0.3415,0.5370	-2.5850			0.12,0.46	0.20						n/a (AF>5%)	n/a (AF>5%)					PARP1 (inh=n/a pLI=0.06)
chr1	226578099	226578099	T	C	hom	hom	het	off-target	QUAL=9069;DP=93,162,122;AF=1.00,0.99,0.54;MQM=60	PARP1	intron	PARP1:ENST00000366794:intron_variant:MODIFIER:exon4/22:c.617+12A>G::					rs1805403	0.8576	0.8477	11186,	0.9422,0.8707,0.9383,0.7689,0.7391	0.7669,0.9335	-5.6250			0.01,0.16	-0.27						n/a (AF>5%)	n/a (AF>5%)					PARP1 (inh=n/a pLI=0.06)
chr1	226589958	226589958	G	A	het	het	wt		QUAL=9316;DP=299,470,299;AF=0.47,0.49,0.00;MQM=59	PARP1	synonymous	PARP1:ENST00000366790:synonymous_variant:LOW:exon2/2:c.243C>T:p.Asp81=:PF00645,PARP1:ENST00000366791:synonymous_variant:LOW:exon2/3:c.243C>T:p.Asp81=:PF00645,PARP1:ENST00000366792:synonymous_variant:LOW:exon2/4:c.243C>T:p.Asp81=:PF00645,PARP1:ENST00000366794:synonymous_variant:LOW:exon2/23:c.243C>T:p.Asp81=:PF00645					rs1805404	0.2183	0.2178	629,	0.1231,0.4276,0.4465,0.1668,0.1032	0.1591,0.1255	3.3120			0.86,0.92	0.77						n/a (AF>5%)	n/a (AF>5%)					PARP1 (inh=n/a pLI=0.06)
chr1	226595647	226595647	C	G	het	het	wt		QUAL=2217;DP=40,146,139;AF=0.55,0.50,0.00;MQM=59	PARP1	5'UTR	PARP1:ENST00000366790:5_prime_UTR_variant:MODIFIER:exon1/2:c.-17G>C::,PARP1:ENST00000366791:5_prime_UTR_variant:MODIFIER:exon1/3:c.-17G>C::,PARP1:ENST00000366792:5_prime_UTR_variant:MODIFIER:exon1/4:c.-17G>C::,PARP1:ENST00000366794:5_prime_UTR_variant:MODIFIER:exon1/23:c.-17G>C::					rs907187	0.1991	0.2127	582,	0.0450,0.4193,0.4419,0.1651,0.1022	0.1548,0.0495	1.1800			0.12,0.67	0.95						n/a (AF>5%)	n/a (AF>5%)					PARP1 (inh=n/a pLI=0.06)
chr1	227149203	227149203	G	A	wt	wt	het		QUAL=307;DP=72,36,32;AF=0.00,0.00,0.50;MQM=60	ADCK3	synonymous,splice_region&intron,intron	ADCK3:ENST00000366777:synonymous_variant:LOW:exon2/15:c.117G>A:p.Ala39=:,ADCK3:ENST00000366778:splice_region_variant&intron_variant:LOW:exon1/14:c.-34-6G>A::,ADCK3:ENST00000366779:synonymous_variant:LOW:exon7/20:c.117G>A:p.Ala39=:,ADCK3:ENST00000458507:intron_variant:MODIFIER:exon1/11:c.-182-15947G>A::	606980 [COQ8A (confirmed) Coenzyme Q10 deficiency,primary,4,612016];	128273 [benign DISEASE=Coenzyme Q10 deficiency, primary, 4,not specified,Autosomal recessive cerebellar ataxia,Coenzyme Q10 deficiency, Spinocerebellar Ataxia Type,not provided];			rs11549708	0.0807	0.1651	505,	0.0451,0.0973,0.0005,0.2375,0.0771	0.2390,0.0556	-3.4260			0.01,0.13	-0.36		+933.86% (-0.47>-4.84)				n/a (AF>5%)	n/a (AF>5%)					COQ8A (inh=AR pLI=0.00)
chr1	227152662	227152662	C	T	wt	wt	het	off-target	QUAL=930;DP=83,86,67;AF=0.01,0.00,0.63;MQM=60	ADCK3	intron	ADCK3:ENST00000366777:intron_variant:MODIFIER:exon2/14:c.178-39C>T::,ADCK3:ENST00000366778:intron_variant:MODIFIER:exon2/14:c.22-39C>T::,ADCK3:ENST00000366779:intron_variant:MODIFIER:exon7/19:c.178-39C>T::,ADCK3:ENST00000458507:intron_variant:MODIFIER:exon1/11:c.-182-12488C>T::	606980 [COQ8A (confirmed) Coenzyme Q10 deficiency,primary,4,612016];				rs759581953		0.0001		0.0000,0.0000,0.0001,0.0001,0.0001		-1.6860			0.01,0.11	-0.43						0	2					COQ8A (inh=AR pLI=0.00)
chr1	227165235	227165235	C	T	het	het	wt	off-target	QUAL=438;DP=18,25,31;AF=0.50,0.52,0.00;MQM=60	ADCK3	intron	ADCK3:ENST00000366777:intron_variant:MODIFIER:exon5/14:c.730+11C>T::,ADCK3:ENST00000366778:intron_variant:MODIFIER:exon5/14:c.574+11C>T::,ADCK3:ENST00000366779:intron_variant:MODIFIER:exon10/19:c.730+11C>T::,ADCK3:ENST00000433743:intron_variant:MODIFIER:exon2/10:c.-108+11C>T::,ADCK3:ENST00000458507:intron_variant:MODIFIER:exon2/11:c.-108+11C>T::	606980 [COQ8A (confirmed) Coenzyme Q10 deficiency,primary,4,612016];				rs759489004		0.0001	0,	0.0000,0.0000,0.0000,0.0001,0.0000		1.0160			0.08,0.16	0.13						0	3					COQ8A (inh=AR pLI=0.00)
chr1	227170543	227170543	C	G	het	wt	het	off-target	QUAL=3771;DP=114,294,177;AF=0.61,0.01,0.47;MQM=60	ADCK3	intron	ADCK3:ENST00000366777:intron_variant:MODIFIER:exon7/14:c.940-52C>G::,ADCK3:ENST00000366778:intron_variant:MODIFIER:exon7/14:c.784-52C>G::,ADCK3:ENST00000366779:intron_variant:MODIFIER:exon12/19:c.940-52C>G::,ADCK3:ENST00000433743:intron_variant:MODIFIER:exon4/10:c.102+79C>G::,ADCK3:ENST00000458507:intron_variant:MODIFIER:exon4/11:c.103-52C>G::	606980 [COQ8A (confirmed) Coenzyme Q10 deficiency,primary,4,612016];				rs2297413	0.1983	0.1996	672,		0.2336,0.1343	0.6440			0.00,0.09	-0.10						n/a (AF>5%)	n/a (AF>5%)					COQ8A (inh=AR pLI=0.00)
chr1	227171210	227171210	G	A	het	hom	wt	off-target	QUAL=5904;DP=83,175,144;AF=0.51,0.99,0.00;MQM=59	ADCK3	intron	ADCK3:ENST00000366777:intron_variant:MODIFIER:exon8/14:c.1081-43G>A::,ADCK3:ENST00000366778:intron_variant:MODIFIER:exon8/14:c.925-43G>A::,ADCK3:ENST00000366779:intron_variant:MODIFIER:exon13/19:c.1081-43G>A::,ADCK3:ENST00000433743:intron_variant:MODIFIER:exon4/10:c.103-43G>A::,ADCK3:ENST00000458507:intron_variant:MODIFIER:exon5/11:c.244-43G>A::	606980 [COQ8A (confirmed) Coenzyme Q10 deficiency,primary,4,612016];				rs12739480	0.0871	0.1259	273,	0.0325,0.0453,0.0449,0.1410,0.2080	0.1392,0.0409	-0.2170			0.10,0.16	-0.23						n/a (AF>5%)	n/a (AF>5%)					COQ8A (inh=AR pLI=0.00)
chr1	227171585	227171585	T	-	het	wt	hom	off-target	QUAL=2003;DP=107,77,43;AF=0.44,0.00,1.00;MQM=60	ADCK3	intron	ADCK3:ENST00000366777:intron_variant:MODIFIER:exon10/14:c.1256+32del::,ADCK3:ENST00000366778:intron_variant:MODIFIER:exon10/14:c.1100+32del::,ADCK3:ENST00000366779:intron_variant:MODIFIER:exon15/19:c.1256+32del::,ADCK3:ENST00000433743:intron_variant:MODIFIER:exon6/10:c.278+32del::,ADCK3:ENST00000458507:intron_variant:MODIFIER:exon7/11:c.419+32del::	606980 [COQ8A (confirmed) Coenzyme Q10 deficiency,primary,4,612016];				rs3215919	0.2622	0.3623	2124,	0.2909,0.2770,0.1388,0.4443,0.2055	0.4421,0.2960	-0.6290				-0.29						n/a (AF>5%)	n/a (AF>5%)					COQ8A (inh=AR pLI=0.00)
chr1	227171737	227171737	G	T	het	wt	hom	off-target	QUAL=1870;DP=54,39,55;AF=0.72,0.00,0.96;MQM=60	ADCK3	intron	ADCK3:ENST00000366777:intron_variant:MODIFIER:exon10/14:c.1257-58G>T::,ADCK3:ENST00000366778:intron_variant:MODIFIER:exon10/14:c.1101-58G>T::,ADCK3:ENST00000366779:intron_variant:MODIFIER:exon15/19:c.1257-58G>T::,ADCK3:ENST00000433743:intron_variant:MODIFIER:exon6/10:c.279-58G>T::,ADCK3:ENST00000458507:intron_variant:MODIFIER:exon7/11:c.420-58G>T::	606980 [COQ8A (confirmed) Coenzyme Q10 deficiency,primary,4,612016];				rs1574184	0.2812	0.2895	756,			2.3640			0.53,0.16	-0.08						n/a (AF>5%)	n/a (AF>5%)					COQ8A (inh=AR pLI=0.00)
chr1	227171738	227171738	-	T	wt	wt	het	off-target	QUAL=1870;DP=54,39,55;AF=0.72,0.00,0.96;MQM=60	ADCK3	intron	ADCK3:ENST00000366777:intron_variant:MODIFIER:exon10/14:c.1257-57_1257-56insT::,ADCK3:ENST00000366778:intron_variant:MODIFIER:exon10/14:c.1101-57_1101-56insT::,ADCK3:ENST00000366779:intron_variant:MODIFIER:exon15/19:c.1257-57_1257-56insT::,ADCK3:ENST00000433743:intron_variant:MODIFIER:exon6/10:c.279-57_279-56insT::,ADCK3:ENST00000458507:intron_variant:MODIFIER:exon7/11:c.420-57_420-56insT::	606980 [COQ8A (confirmed) Coenzyme Q10 deficiency,primary,4,612016];				rs201300405										-0.07						12	84	2	[2] auto-classification 20.10.2017  			COQ8A (inh=AR pLI=0.00)
chr1	227171739	227171739	G	T	het	wt	het	off-target	QUAL=1870;DP=54,39,55;AF=0.72,0.00,0.96;MQM=59	ADCK3	intron	ADCK3:ENST00000366777:intron_variant:MODIFIER:exon10/14:c.1257-56G>T::,ADCK3:ENST00000366778:intron_variant:MODIFIER:exon10/14:c.1101-56G>T::,ADCK3:ENST00000366779:intron_variant:MODIFIER:exon15/19:c.1257-56G>T::,ADCK3:ENST00000433743:intron_variant:MODIFIER:exon6/10:c.279-56G>T::,ADCK3:ENST00000458507:intron_variant:MODIFIER:exon7/11:c.420-56G>T::	606980 [COQ8A (confirmed) Coenzyme Q10 deficiency,primary,4,612016];				rs1574185	0.2802	0.2302	695,			-0.0790			0.17,0.13	-0.35						n/a (AF>5%)	n/a (AF>5%)					COQ8A (inh=AR pLI=0.00)
chr1	227171958	227171958	G	C	wt	wt	het	off-target	QUAL=1013;DP=114,107,75;AF=0.00,0.00,0.53;MQM=60	ADCK3	intron	ADCK3:ENST00000366777:intron_variant:MODIFIER:exon11/14:c.1398+22G>C::,ADCK3:ENST00000366778:intron_variant:MODIFIER:exon11/14:c.1242+22G>C::,ADCK3:ENST00000366779:intron_variant:MODIFIER:exon16/19:c.1398+22G>C::,ADCK3:ENST00000433743:intron_variant:MODIFIER:exon7/10:c.420+22G>C::,ADCK3:ENST00000458507:intron_variant:MODIFIER:exon8/11:c.561+22G>C::	606980 [COQ8A (confirmed) Coenzyme Q10 deficiency,primary,4,612016];				rs7530213	0.1683	0.2489	1038,	0.1523,0.2019,0.0928,0.3131,0.1316	0.3127,0.1714	0.8940			0.11,0.31	0.27						n/a (AF>5%)	n/a (AF>5%)					COQ8A (inh=AR pLI=0.00)
chr1	227172290	227172290	C	T	het	wt	hom		QUAL=15708;DP=331,506,380;AF=0.47,0.00,0.98;MQM=60	ADCK3	synonymous	ADCK3:ENST00000366777:synonymous_variant:LOW:exon12/15:c.1440C>T:p.Phe480=:,ADCK3:ENST00000366778:synonymous_variant:LOW:exon12/15:c.1284C>T:p.Phe428=:,ADCK3:ENST00000366779:synonymous_variant:LOW:exon17/20:c.1440C>T:p.Phe480=:,ADCK3:ENST00000433743:synonymous_variant:LOW:exon8/11:c.462C>T:p.Phe154=:,ADCK3:ENST00000458507:synonymous_variant:LOW:exon9/12:c.603C>T:p.Phe201=:	606980 [COQ8A (confirmed) Coenzyme Q10 deficiency,primary,4,612016];	128274 [benign DISEASE=Coenzyme Q10 deficiency, primary, 4,not specified,Autosomal recessive cerebellar ataxia,Coenzyme Q10 deficiency, Spinocerebellar Ataxia Type,not provided];			rs12593	0.2386	0.3536	2031,	0.1958,0.2675,0.1752,0.4531,0.2032	0.4580,0.2090	-0.0650			0.20,0.87	0.59						n/a (AF>5%)	n/a (AF>5%)					COQ8A (inh=AR pLI=0.00)
chr1	227172903	227172903	G	A	het	wt	hom	off-target	QUAL=8116;DP=103,303,230;AF=0.59,0.00,0.98;MQM=60	ADCK3	intron	ADCK3:ENST00000366777:intron_variant:MODIFIER:exon13/14:c.1573-52G>A::,ADCK3:ENST00000366778:intron_variant:MODIFIER:exon13/14:c.1417-52G>A::,ADCK3:ENST00000366779:intron_variant:MODIFIER:exon18/19:c.1573-52G>A::,ADCK3:ENST00000433743:intron_variant:MODIFIER:exon9/10:c.595-52G>A::,ADCK3:ENST00000458507:intron_variant:MODIFIER:exon10/11:c.736-52G>A::	606980 [COQ8A (confirmed) Coenzyme Q10 deficiency,primary,4,612016];				rs2297415	0.2696	0.3720	2249,		0.4655,0.2959	-0.7670			0.01,0.14	0.01						n/a (AF>5%)	n/a (AF>5%)					COQ8A (inh=AR pLI=0.00)
chr1	227172935	227172935	C	G	het	wt	hom	off-target	QUAL=9661;DP=113,343,267;AF=0.62,0.00,1.00;MQM=60	ADCK3	intron	ADCK3:ENST00000366777:intron_variant:MODIFIER:exon13/14:c.1573-20C>G::,ADCK3:ENST00000366778:intron_variant:MODIFIER:exon13/14:c.1417-20C>G::,ADCK3:ENST00000366779:intron_variant:MODIFIER:exon18/19:c.1573-20C>G::,ADCK3:ENST00000433743:intron_variant:MODIFIER:exon9/10:c.595-20C>G::,ADCK3:ENST00000458507:intron_variant:MODIFIER:exon10/11:c.736-20C>G::	606980 [COQ8A (confirmed) Coenzyme Q10 deficiency,primary,4,612016];	518313 [likely benign DISEASE=Coenzyme Q10 deficiency, primary, 4];			rs2297416	0.2652	0.3672	2210,	0.2670,0.2794,0.1671,0.4594,0.2071	0.4626,0.2737	-1.1720			0.10,0.22	0.02		-11.00% (12.28>10.93)				n/a (AF>5%)	n/a (AF>5%)					COQ8A (inh=AR pLI=0.00)
chr1	227174122	227174122	C	G	wt	wt	het	off-target	QUAL=939;DP=88,139,73;AF=0.00,0.00,0.56;MQM=60	ADCK3	intron	ADCK3:ENST00000366777:intron_variant:MODIFIER:exon14/14:c.1660-32C>G::,ADCK3:ENST00000366778:intron_variant:MODIFIER:exon14/14:c.1504-32C>G::,ADCK3:ENST00000366779:intron_variant:MODIFIER:exon19/19:c.1660-32C>G::,ADCK3:ENST00000433743:intron_variant:MODIFIER:exon10/10:c.682-32C>G::,ADCK3:ENST00000458507:intron_variant:MODIFIER:exon11/11:c.823-32C>G::	606980 [COQ8A (confirmed) Coenzyme Q10 deficiency,primary,4,612016];				rs41303131	0.1136	0.1984	698,	0.0869,0.1151,0.0030,0.2798,0.1231	0.2813,0.0967	-0.8240			0.03,0.13	-0.34						n/a (AF>5%)	n/a (AF>5%)					COQ8A (inh=AR pLI=0.00)
chr1	227174145	227174145	T	C	het	wt	hom		QUAL=4105;DP=105,169,90;AF=0.53,0.00,1.00;MQM=60	ADCK3	intron	ADCK3:ENST00000366777:intron_variant:MODIFIER:exon14/14:c.1660-9T>C::,ADCK3:ENST00000366778:intron_variant:MODIFIER:exon14/14:c.1504-9T>C::,ADCK3:ENST00000366779:intron_variant:MODIFIER:exon19/19:c.1660-9T>C::,ADCK3:ENST00000433743:intron_variant:MODIFIER:exon10/10:c.682-9T>C::,ADCK3:ENST00000458507:intron_variant:MODIFIER:exon11/11:c.823-9T>C::	606980 [COQ8A (confirmed) Coenzyme Q10 deficiency,primary,4,612016];	296024 [benign DISEASE=Coenzyme Q10 deficiency, primary, 4,Autosomal recessive cerebellar ataxia,Coenzyme Q10 deficiency, Spinocerebellar Ataxia Type,not provided];			rs7552783	0.3516	0.4382	2984,	0.4150,0.3025,0.2193,0.5013,0.2753	0.5050,0.4185	-0.4800			0.04,0.18	0.55		-6.99% (11.51>10.71)		0.001/0.006	COSM3997298,COSM3997299	n/a (AF>5%)	n/a (AF>5%)					COQ8A (inh=AR pLI=0.00)
chr1	227174210	227174210	T	C	het	wt	hom		QUAL=5290;DP=159,185,119;AF=0.45,0.00,1.00;MQM=60	ADCK3	synonymous	ADCK3:ENST00000366777:synonymous_variant:LOW:exon15/15:c.1716T>C:p.Ser572=:,ADCK3:ENST00000366778:synonymous_variant:LOW:exon15/15:c.1560T>C:p.Ser520=:,ADCK3:ENST00000366779:synonymous_variant:LOW:exon20/20:c.1716T>C:p.Ser572=:,ADCK3:ENST00000433743:synonymous_variant:LOW:exon11/11:c.738T>C:p.Ser246=:,ADCK3:ENST00000458507:synonymous_variant:LOW:exon12/12:c.879T>C:p.Ser293=:	606980 [COQ8A (confirmed) Coenzyme Q10 deficiency,primary,4,612016];	128275 [benign DISEASE=Coenzyme Q10 deficiency, primary, 4,not specified,Autosomal recessive cerebellar ataxia,Coenzyme Q10 deficiency, Spinocerebellar Ataxia Type,not provided];			rs3738725	0.3139	0.4085	2654,	0.3095,0.2960,0.2225,0.5018,0.2751	0.5053,0.3189	-5.9700			0.07,0.08	-0.72						n/a (AF>5%)	n/a (AF>5%)					COQ8A (inh=AR pLI=0.00)
chr1	227174823	227174823	-	T	het	wt	hom		QUAL=13714;DP=244,472,371;AF=0.48,0.00,1.00;MQM=60	ADCK3	3'UTR	ADCK3:ENST00000366777:3_prime_UTR_variant:MODIFIER:exon15/15:c.*389dup::,ADCK3:ENST00000366778:3_prime_UTR_variant:MODIFIER:exon15/15:c.*389dup::,ADCK3:ENST00000366779:3_prime_UTR_variant:MODIFIER:exon20/20:c.*389dup::,ADCK3:ENST00000458507:3_prime_UTR_variant:MODIFIER:exon12/12:c.*389dup::	606980 [COQ8A (confirmed) Coenzyme Q10 deficiency,primary,4,612016];	296038 [benign DISEASE=Autosomal recessive cerebellar ataxia,Coenzyme Q10 deficiency, Spinocerebellar Ataxia Type];			rs11420839	0.2927	0.3979	2582,							0.35						n/a (AF>5%)	n/a (AF>5%)					COQ8A (inh=AR pLI=0.00)
chr1	227175245	227175245	-	T	het	wt	hom		QUAL=8083;DP=156,319,215;AF=0.45,0.00,0.99;MQM=60	ADCK3	3'UTR	ADCK3:ENST00000366779:3_prime_UTR_variant:MODIFIER:exon20/20:c.*807_*808insT::	606980 [COQ8A (confirmed) Coenzyme Q10 deficiency,primary,4,612016];	296050 [benign DISEASE=Autosomal recessive cerebellar ataxia,Coenzyme Q10 deficiency, Spinocerebellar Ataxia Type];			rs3215920	0.2548	0.3663	2308,							-0.23						n/a (AF>5%)	n/a (AF>5%)					COQ8A (inh=AR pLI=0.00)
chr1	227175253	227175253	C	T	het	wt	hom		QUAL=8793;DP=165,325,218;AF=0.48,0.00,1.00;MQM=60	CDC42BPA,ADCK3,RP5-1087E8.3	downstream_gene,upstream_gene	CDC42BPA:ENST00000334218:downstream_gene_variant:MODIFIER::::,CDC42BPA:ENST00000366764:downstream_gene_variant:MODIFIER::::,CDC42BPA:ENST00000366766:downstream_gene_variant:MODIFIER::::,CDC42BPA:ENST00000366767:downstream_gene_variant:MODIFIER::::,CDC42BPA:ENST00000366769:downstream_gene_variant:MODIFIER::::,ADCK3:ENST00000366777:downstream_gene_variant:MODIFIER::::,ADCK3:ENST00000366778:downstream_gene_variant:MODIFIER::::,ADCK3:ENST00000366779:downstream_gene_variant:MODIFIER::::,ADCK3:ENST00000433743:downstream_gene_variant:MODIFIER::::,RP5-1087E8.3:ENST00000433837:upstream_gene_variant:MODIFIER::::,ADCK3:ENST00000458507:downstream_gene_variant:MODIFIER::::	606980 [COQ8A (confirmed) Coenzyme Q10 deficiency,primary,4,612016];	368867 [benign DISEASE=Autosomal recessive cerebellar ataxia,Coenzyme Q10 deficiency, Spinocerebellar Ataxia Type];			rs10495274	0.4191	0.5212	4391,			-0.6030			0.03,0.10	-0.42						n/a (AF>5%)	n/a (AF>5%)					CDC42BPA (inh=n/a pLI=1.00), COQ8A (inh=AR pLI=0.00), RP5-1087E8.3 (inh=n/a pLI=n/a)
chr1	228346936	228346936	G	A	het	het	wt		QUAL=2230;DP=41,130,92;AF=0.59,0.54,0.00;MQM=59	GJC2	3'UTR	GJC2:ENST00000366714:3_prime_UTR_variant:MODIFIER:exon2/2:c.*157G>A::	608803 [GJC2 (confirmed) Leukodystrophy,hypomyelinating,2,608804/Spastic paraplegia 44,autosomal recessive,613206/Lymphedema,hereditary,IC,613480];				rs45491398	0.0234	0.0596	71,			-1.0290			0.01,0.14	-0.05						n/a (AF>5%)	n/a (AF>5%)					GJC2 (inh=AR+AD pLI=0.45)
chr1	228347352	228347352	A	G	hom	hom	hom		QUAL=1505;DP=31,13,8;AF=1.00,1.00,1.00;MQM=60	GJC2	3'UTR	GJC2:ENST00000366714:3_prime_UTR_variant:MODIFIER:exon2/2:c.*573A>G::	608803 [GJC2 (confirmed) Leukodystrophy,hypomyelinating,2,608804/Spastic paraplegia 44,autosomal recessive,613206/Lymphedema,hereditary,IC,613480];				rs6668719	0.8043	0.8406	11160,			-0.0280			0.01,0.11	-0.04						n/a (AF>5%)	n/a (AF>5%)					GJC2 (inh=AR+AD pLI=0.45)
chr1	228612838	228612838	G	T	het	hom	het		QUAL=18494;DP=283,384,284;AF=0.52,1.00,0.46;MQM=60	HIST3H3	synonymous	HIST3H3:ENST00000366696:synonymous_variant:LOW:exon1/1:c.189C>A:p.Ile63=:PF00125					rs2230656	0.6903	0.8331	8810,	0.3958,0.9266,0.6591,0.8862,0.8561	0.8852,0.4172	2.3090			0.89,0.92	0.10						n/a (AF>5%)	n/a (AF>5%)					HIST3H3 (inh=n/a pLI=0.00)
chr1	228612892	228612892	G	A	wt	het	wt		QUAL=2233;DP=173,260,211;AF=0.00,0.47,0.00;MQM=60	HIST3H3	synonymous	HIST3H3:ENST00000366696:synonymous_variant:LOW:exon1/1:c.135C>T:p.Gly45=:					rs56336130	0.0433	0.0710	75,	0.0123,0.0360,0.0194,0.0923,0.0906	0.0867,0.0173	-0.0050			0.72,0.96	-0.09						n/a (AF>5%)	n/a (AF>5%)					HIST3H3 (inh=n/a pLI=0.00)
chr1	228613052	228613052	T	C	het	hom	het	off-target	QUAL=1574;DP=56,31,34;AF=0.38,1.00,0.41;MQM=60	HIST3H3	upstream_gene	HIST3H3:ENST00000366696:upstream_gene_variant:MODIFIER::::					rs1188474	0.8662	0.8785	11974,	0.9295,0.9612,0.6686,0.8914,0.8650	0.8949,0.9246	-2.7120			0.01,0.16	-0.37						n/a (AF>5%)	n/a (AF>5%)					HIST3H3 (inh=n/a pLI=0.00)
chr1	229568231	229568231	T	G	hom	hom	hom	off-target	QUAL=2167;DP=8,46,34;AF=1.00,1.00,1.00;MQM=60	ACTA1	intron	ACTA1:ENST00000366683:intron_variant:MODIFIER:exon3/5:c.352+174A>C::,ACTA1:ENST00000366684:intron_variant:MODIFIER:exon3/6:c.455-53A>C::	102610 [ACTA1 (confirmed) Nemaline myopathy 3,autosomal dominant or recessive,161800/Myopathy,actin,congenital,with excess of thin myofilaments,161800/Myopathy,actin,congenital,with cores,161800/Myopathy,congenital,with fiber-type disproportion 1,255310/Myopathy,scapulohumeroperoneal,616852];				rs527621	0.9990	0.9992	14292,			-1.1130			0.02,0.12	0.26						n/a (AF>5%)	n/a (AF>5%)					ACTA1 (inh=AR+AD pLI=0.01)
chr1	229569803	229569803	A	G	het	het	het		QUAL=3198;DP=64,110,74;AF=0.58,0.55,0.49;MQM=60	ACTA1	5'UTR	ACTA1:ENST00000366683:5_prime_UTR_variant:MODIFIER:exon1/6:c.-65T>C::,ACTA1:ENST00000366684:5_prime_UTR_variant:MODIFIER:exon1/7:c.-65T>C::	102610 [ACTA1 (confirmed) Nemaline myopathy 3,autosomal dominant or recessive,161800/Myopathy,actin,congenital,with excess of thin myofilaments,161800/Myopathy,actin,congenital,with cores,161800/Myopathy,congenital,with fiber-type disproportion 1,255310/Myopathy,scapulohumeroperoneal,616852];	296060 [likely benign DISEASE=Nemaline myopathy,Familial restrictive cardiomyopathy,Congenital fiber-type disproportion];			rs605430,rs879788591	0.6302	0.6055	5763,			0.4410			0.01,0.32	1.49						n/a (AF>5%)	n/a (AF>5%)					ACTA1 (inh=AR+AD pLI=0.01)
chr1	229569804	229569804	G	A	het	het	het		QUAL=3198;DP=64,110,74;AF=0.58,0.55,0.49;MQM=60	ACTA1	5'UTR	ACTA1:ENST00000366683:5_prime_UTR_variant:MODIFIER:exon1/6:c.-66C>T::,ACTA1:ENST00000366684:5_prime_UTR_variant:MODIFIER:exon1/7:c.-66C>T::	102610 [ACTA1 (confirmed) Nemaline myopathy 3,autosomal dominant or recessive,161800/Myopathy,actin,congenital,with excess of thin myofilaments,161800/Myopathy,actin,congenital,with cores,161800/Myopathy,congenital,with fiber-type disproportion 1,255310/Myopathy,scapulohumeroperoneal,616852];	296062 [likely benign DISEASE=Nemaline myopathy,Familial restrictive cardiomyopathy,Congenital fiber-type disproportion];			rs605428	0.6436	0.6052	5763,			-0.0810			0.02,0.41	1.34						n/a (AF>5%)	n/a (AF>5%)					ACTA1 (inh=AR+AD pLI=0.01)
chr1	231377081	231377081	C	T	hom	het	hom		QUAL=19028;DP=311,317,251;AF=0.96,0.55,0.99;MQM=60	GNPAT	5'UTR	GNPAT:ENST00000366646:5_prime_UTR_variant:MODIFIER:exon1/15:c.-44C>T::,GNPAT:ENST00000366647:5_prime_UTR_variant:MODIFIER:exon1/16:c.-44C>T::	602744 [GNPAT (provisional) Rhizomelic chondrodysplasia punctata,type 2,222765];	296108 [benign DISEASE=Rhizomelic chondrodysplasia punctata,not specified];			rs518686	0.5819	0.5532	4325,	0.5716,0.6056,0.5913,0.5284,0.6247	0.5383,0.5756	0.1150			0.03,0.50	0.80						n/a (AF>5%)	n/a (AF>5%)					GNPAT (inh=AR pLI=0.51)
chr1	231401204	231401204	T	C	hom	het	het	off-target	QUAL=12314;DP=212,233,178;AF=1.00,0.52,0.48;MQM=60	GNPAT	intron	GNPAT:ENST00000366646:intron_variant:MODIFIER:exon4/14:c.513+38T>C::,GNPAT:ENST00000366647:intron_variant:MODIFIER:exon5/15:c.696+38T>C::	602744 [GNPAT (provisional) Rhizomelic chondrodysplasia punctata,type 2,222765];				rs6702011	0.2678	0.2746	1035,	0.2833,0.3889,0.2115,0.2547,0.2726	0.2578,0.2944	-0.6740			0.09,0.20	0.48						n/a (AF>5%)	n/a (AF>5%)					GNPAT (inh=AR pLI=0.51)
chr1	231401902	231401902	G	A	hom	het	het		QUAL=17590;DP=348,258,202;AF=1.00,0.50,0.49;MQM=60	GNPAT	synonymous	GNPAT:ENST00000366646:synonymous_variant:LOW:exon6/15:c.732G>A:p.Glu244=:,GNPAT:ENST00000366647:synonymous_variant:LOW:exon7/16:c.915G>A:p.Glu305=:	602744 [GNPAT (provisional) Rhizomelic chondrodysplasia punctata,type 2,222765];	260363 [benign DISEASE=Rhizomelic chondrodysplasia punctata,not specified,not provided];			rs574553	0.6286	0.5688	5141,	0.6955,0.6135,0.5950,0.5394,0.6252	0.5484,0.6854	1.6170			0.61,0.96	0.43						n/a (AF>5%)	n/a (AF>5%)					GNPAT (inh=AR pLI=0.51)
chr1	231500353	231500353	-	T	hom	hom	het		QUAL=17444;DP=341,184,162;AF=0.97,0.97,0.44;MQM=60	EGLN1	3'UTR	EGLN1:ENST00000366641:3_prime_UTR_variant:MODIFIER:exon5/5:c.*1803dup::	606425 [EGLN1 (confirmed) Erythrocytosis,familial,3,609820/Hemoglobin,high altitude adaptation,609070];				rs541569859		0.5882	5576,							0.18						n/a (AF>5%)	n/a (AF>5%)					EGLN1 (inh=AD pLI=0.90)
chr1	231502245	231502245	T	-	het	het	wt	off-target	QUAL=11739;DP=212,213,175;AF=0.89,0.91,0.38;MQM=59	EGLN1	intron	EGLN1:ENST00000366641:intron_variant:MODIFIER:exon4/4:c.1217-24del::	606425 [EGLN1 (confirmed) Erythrocytosis,familial,3,609820/Hemoglobin,high altitude adaptation,609070];				rs371204614	0.1103	0.1485	0,	0.0685,0.1075,0.1671,0.1727,0.1283		-0.0460				-0.94						n/a (AF>5%)	n/a (AF>5%)					EGLN1 (inh=AD pLI=0.90)
chr1	231502245	231502245	T	A	het	het	het	off-target	QUAL=11739;DP=212,213,175;AF=0.89,0.91,0.38;MQM=59	EGLN1	intron	EGLN1:ENST00000366641:intron_variant:MODIFIER:exon4/4:c.1217-24A>T::	606425 [EGLN1 (confirmed) Erythrocytosis,familial,3,609820/Hemoglobin,high altitude adaptation,609070];				rs1435167	0.4297	0.5720	4960,	0.3314,0.3783,0.4146,0.4511,0.4126	0.4963,0.3116	-0.0460			0.00,0.08	-0.78						n/a (AF>5%)	n/a (AF>5%)					EGLN1 (inh=AD pLI=0.90)
chr1	231557255	231557255	C	G	het	wt	hom		QUAL=206;DP=3,3,9;AF=0.67,0.00,1.00;MQM=60	EGLN1	missense	EGLN1:ENST00000366641:missense_variant:MODERATE:exon1/5:c.380G>C:p.Cys127Ser:	606425 [EGLN1 (confirmed) Erythrocytosis,familial,3,609820/Hemoglobin,high altitude adaptation,609070];	242640 [benign DISEASE=Familial erythrocytosis]; 156155 [affects DISEASE=Hemoglobin, high altitude adaptation];	CM140742 [CLASS=DFP MUT=ALT PHEN="Reduced haemoglobin levels" GENE=EGLN1];	(GCC)n	rs12097901	0.2604	0.1584	629,	0.5000,0.2169,0.5082,0.0929,0.3281		-0.0300	T	B	0.00,0.09	0.66	0.21					n/a (AF>5%)	n/a (AF>5%)					EGLN1 (inh=AD pLI=0.90)
chr1	231559226	231559226	A	G	het	wt	hom		QUAL=5108;DP=197,82,71;AF=0.51,0.02,1.00;MQM=60	EGLN1	5'UTR	EGLN1:ENST00000366641:5_prime_UTR_variant:MODIFIER:exon1/5:c.-1592T>C::	606425 [EGLN1 (confirmed) Erythrocytosis,familial,3,609820/Hemoglobin,high altitude adaptation,609070];	296223 [benign DISEASE=Familial erythrocytosis];			rs12406290	0.2915	0.1910	663,			3.1480			0.17,0.40	0.54						n/a (AF>5%)	n/a (AF>5%)					EGLN1 (inh=AD pLI=0.90)
chr1	231560220	231560220	A	G	het	wt	hom		QUAL=15505;DP=597,205,209;AF=0.54,0.00,1.00;MQM=60	EGLN1	5'UTR	EGLN1:ENST00000366641:5_prime_UTR_variant:MODIFIER:exon1/5:c.-2586T>C::	606425 [EGLN1 (confirmed) Erythrocytosis,familial,3,609820/Hemoglobin,high altitude adaptation,609070];	296240 [benign DISEASE=Familial erythrocytosis];			rs2153364	0.2939	0.1914	668,			0.2300			0.03,0.19	0.05						n/a (AF>5%)	n/a (AF>5%)					EGLN1 (inh=AD pLI=0.90)
chr1	235543477	235543494	TGTGTGTGTGTGTGTGTG	-	wt	wt	het	off-target	QUAL=2025;DP=54,30,94;AF=0.63,0.33,0.80;MQM=60	TBCE	intron	TBCE:ENST00000366601:intron_variant:MODIFIER:exon2/16:c.100+48_100+65del::,TBCE:ENST00000406207:intron_variant:MODIFIER:exon2/16:c.100+48_100+65del::,TBCE:ENST00000543662:intron_variant:MODIFIER:exon2/17:c.100+48_100+65del::	604934 [TBCE (confirmed) Kenny-Caffey syndrome,type 1,244460/Hypoparathyroidism-retardation-dysmorphism syndrome,241410/Encephalopathy,progressive,with amyotrophy and optic atrophy,617207];			(TG)n	rs200922223		0.1719	597,	0.1334,0.2158,0.3168,0.0675,0.1600		0.8290				0.21						n/a (AF>5%)	n/a (AF>5%)					TBCE (inh=AR pLI=0.00)
chr1	235543477	235543490	TGTGTGTGTGTGTG	-	hom	wt	het	off-target	QUAL=2025;DP=54,30,94;AF=0.63,0.33,0.80;MQM=60	TBCE	intron	TBCE:ENST00000366601:intron_variant:MODIFIER:exon2/16:c.100+52_100+65del::,TBCE:ENST00000406207:intron_variant:MODIFIER:exon2/16:c.100+52_100+65del::,TBCE:ENST00000543662:intron_variant:MODIFIER:exon2/17:c.100+52_100+65del::	604934 [TBCE (confirmed) Kenny-Caffey syndrome,type 1,244460/Hypoparathyroidism-retardation-dysmorphism syndrome,241410/Encephalopathy,progressive,with amyotrophy and optic atrophy,617207];			(TG)n	rs750237565		0.3320	1471,	0.1004,0.1021,0.0730,0.2055,0.0686		0.8290				0.23						n/a (AF>5%)	n/a (AF>5%)					TBCE (inh=AR pLI=0.00)
chr1	235543477	235543480	TGTG	-	wt	het	wt	off-target	QUAL=2025;DP=54,30,94;AF=0.63,0.33,0.80;MQM=60	TBCE	intron	TBCE:ENST00000366601:intron_variant:MODIFIER:exon2/16:c.100+62_100+65del::,TBCE:ENST00000406207:intron_variant:MODIFIER:exon2/16:c.100+62_100+65del::,TBCE:ENST00000543662:intron_variant:MODIFIER:exon2/17:c.100+62_100+65del::	604934 [TBCE (confirmed) Kenny-Caffey syndrome,type 1,244460/Hypoparathyroidism-retardation-dysmorphism syndrome,241410/Encephalopathy,progressive,with amyotrophy and optic atrophy,617207];			(TG)n			0.0678	138,			0.5310				0.26						n/a (AF>5%)	n/a (AF>5%)					TBCE (inh=AR pLI=0.00)
chr1	235612320	235612320	C	T	het	wt	hom	off-target	QUAL=4420;DP=135,91,84;AF=0.55,0.00,0.99;MQM=60	B3GALNT2,TBCE	downstream_gene	B3GALNT2:ENST00000366600:downstream_gene_variant:MODIFIER::::,TBCE:ENST00000366601:downstream_gene_variant:MODIFIER::::,TBCE:ENST00000406207:downstream_gene_variant:MODIFIER::::,TBCE:ENST00000543662:downstream_gene_variant:MODIFIER::::					rs704705	0.7446	0.7420	8720,			0.7840			0.00,0.12	0.50						n/a (AF>5%)	n/a (AF>5%)					B3GALNT2 (inh=AR pLI=0.00), TBCE (inh=AR pLI=0.00)
chr1	235825643	235825643	G	A	het	wt	het		QUAL=2730;DP=207,66,30;AF=0.46,0.00,0.33;MQM=60	LYST	3'UTR	LYST:ENST00000389793:3_prime_UTR_variant:MODIFIER:exon53/53:c.*597C>T::,LYST:ENST00000389794:3_prime_UTR_variant:MODIFIER:exon53/53:c.*597C>T::	606897 [LYST (confirmed) Chediak-Higashi syndrome,214500];						0.0001	0,			1.0370			0.03,0.22	0.01						0	2					LYST (inh=AR pLI=1.00)
chr1	235826383	235826383	A	-	hom	hom	het		QUAL=14513;DP=224,270,186;AF=0.90,0.89,0.51;MQM=59	LYST	splice_region&intron	LYST:ENST00000389793:splice_region_variant&intron_variant:LOW:exon52/52:c.11268-5del::,LYST:ENST00000389794:splice_region_variant&intron_variant:LOW:exon52/52:c.11268-5del::	606897 [LYST (confirmed) Chediak-Higashi syndrome,214500];	403065 [benign/likely benign DISEASE=Chediak-Higashi syndrome,not specified];	CD181021 [CLASS=DM? MUT=ALT PHEN="Haemophagocytic lymphohistiocytosis" GENE=LYST];		rs36014994		0.5810	5014,	0.6841,0.4473,0.2342,0.5345,0.4135		0.0090				0.25					COSM5491310	n/a (AF>5%)	n/a (AF>5%)					LYST (inh=AR pLI=1.00)
chr1	235860340	235860340	C	T	hom	hom	het	off-target	QUAL=3178;DP=67,23,29;AF=1.00,1.00,0.59;MQM=60	LYST	intron	LYST:ENST00000389793:intron_variant:MODIFIER:exon46/52:c.10564+43G>A::,LYST:ENST00000389794:intron_variant:MODIFIER:exon46/52:c.10564+43G>A::	606897 [LYST (confirmed) Chediak-Higashi syndrome,214500];	254908 [benign DISEASE=not specified];			rs7541057	0.4000	0.5458	4976,	0.7315,0.2721,0.0501,0.5149,0.1858	0.5093,0.7247	-1.5040			0.00,0.07	-0.14						n/a (AF>5%)	n/a (AF>5%)					LYST (inh=AR pLI=1.00)
chr1	235872665	235872665	T	C	hom	hom	het	off-target	QUAL=7712;DP=179,56,47;AF=0.99,1.00,0.51;MQM=60	LYST	intron	LYST:ENST00000389793:intron_variant:MODIFIER:exon43/52:c.9926-57A>G::,LYST:ENST00000389794:intron_variant:MODIFIER:exon43/52:c.9926-57A>G::	606897 [LYST (confirmed) Chediak-Higashi syndrome,214500];				rs2275856	0.4137	0.5122	4763,			-0.8160			0.00,0.08	-0.06						n/a (AF>5%)	n/a (AF>5%)					LYST (inh=AR pLI=1.00)
chr1	235887276	235887276	G	T	hom	hom	het	off-target	QUAL=9189;DP=133,116,99;AF=0.99,1.00,0.52;MQM=60	LYST	intron	LYST:ENST00000389793:intron_variant:MODIFIER:exon39/52:c.9315+52C>A::,LYST:ENST00000389794:intron_variant:MODIFIER:exon39/52:c.9315+52C>A::	606897 [LYST (confirmed) Chediak-Higashi syndrome,214500];				rs6667717	0.4117	0.5103	4750,		0.3990,0.8219	-2.8510			0.00,0.07	-0.42						n/a (AF>5%)	n/a (AF>5%)					LYST (inh=AR pLI=1.00)
chr1	235922228	235922228	T	C	het	het	wt	off-target	QUAL=2277;DP=142,43,28;AF=0.56,0.44,0.04;MQM=60	LYST	intron	LYST:ENST00000389793:intron_variant:MODIFIER:exon23/52:c.6881+44A>G::,LYST:ENST00000389794:intron_variant:MODIFIER:exon23/52:c.6881+44A>G::	606897 [LYST (confirmed) Chediak-Higashi syndrome,214500];	254935 [benign DISEASE=not specified];			rs3738519	0.2300	0.3157	1680,	0.4267,0.1909,0.0092,0.2694,0.1679	0.2644,0.4253	-4.9410			0.02,0.16	-0.22						n/a (AF>5%)	n/a (AF>5%)					LYST (inh=AR pLI=1.00)
chr1	235940450	235940450	C	T	hom	hom	het		QUAL=17715;DP=241,237,203;AF=1.00,1.00,0.43;MQM=60	LYST	synonymous,3'UTR	LYST:ENST00000389793:synonymous_variant:LOW:exon17/53:c.5373G>A:p.Lys1791=:,LYST:ENST00000389794:synonymous_variant:LOW:exon17/53:c.5373G>A:p.Lys1791=:,LYST:ENST00000536965:3_prime_UTR_variant:MODIFIER:exon16/22:c.*797G>A::	606897 [LYST (confirmed) Chediak-Higashi syndrome,214500];	254927 [benign DISEASE=Chediak-Higashi syndrome,not specified];			rs2273584	0.3009	0.4193	2879,	0.5016,0.2772,0.0588,0.4053,0.2020	0.3993,0.5059	0.6140			0.09,0.31	0.17						n/a (AF>5%)	n/a (AF>5%)					LYST (inh=AR pLI=1.00)
chr1	235945186	235945186	G	A	het	het	het	off-target	QUAL=4511;DP=135,152,93;AF=0.44,0.51,0.54;MQM=59	LYST	intron	LYST:ENST00000389793:intron_variant:MODIFIER:exon15/52:c.5023+41C>T::,LYST:ENST00000389794:intron_variant:MODIFIER:exon15/52:c.5023+41C>T::,LYST:ENST00000536965:intron_variant:MODIFIER:exon14/21:c.*447+41C>T::	606897 [LYST (confirmed) Chediak-Higashi syndrome,214500];	254924 [benign DISEASE=not specified];		AluJo	rs72763416	0.0707	0.1043	186,	0.0697,0.0880,0.0493,0.1375,0.0407	0.1366,0.0767	-1.1670			0.00,0.14	-0.30						n/a (AF>5%)	n/a (AF>5%)					LYST (inh=AR pLI=1.00)
chr1	235945294	235945294	T	C	hom	hom	het		QUAL=15470;DP=184,232,150;AF=0.99,1.00,0.51;MQM=60	LYST	synonymous,3'UTR	LYST:ENST00000389793:synonymous_variant:LOW:exon15/53:c.4956A>G:p.Leu1652=:,LYST:ENST00000389794:synonymous_variant:LOW:exon15/53:c.4956A>G:p.Leu1652=:,LYST:ENST00000536965:3_prime_UTR_variant:MODIFIER:exon14/22:c.*380A>G::	606897 [LYST (confirmed) Chediak-Higashi syndrome,214500];	254923 [benign DISEASE=Chediak-Higashi syndrome,not specified];			rs6696123	0.3035	0.4200	2893,	0.5024,0.2775,0.0588,0.4056,0.2078	0.3994,0.5077	-0.4200			0.05,0.21	0.19						n/a (AF>5%)	n/a (AF>5%)					LYST (inh=AR pLI=1.00)
chr1	235955150	235955150	G	A	wt	het	wt		QUAL=6495;DP=583,522,414;AF=0.00,0.48,0.00;MQM=60	LYST	synonymous,intron	LYST:ENST00000389793:synonymous_variant:LOW:exon12/53:c.4392C>T:p.Asn1464=:,LYST:ENST00000389794:synonymous_variant:LOW:exon12/53:c.4392C>T:p.Asn1464=:,LYST:ENST00000536965:intron_variant:MODIFIER:exon11/21:c.4116+1653C>T::	606897 [LYST (confirmed) Chediak-Higashi syndrome,214500];	254921 [likely benign DISEASE=Chediak-Higashi syndrome,not specified];			rs11583387	0.0643	0.0881	144,	0.0648,0.0780,0.0492,0.1125,0.0380	0.1117,0.0704	3.0230			0.93,0.98	0.56						n/a (AF>5%)	n/a (AF>5%)					LYST (inh=AR pLI=1.00)
chr1	235971763	235971763	A	G	het	het	het		QUAL=8481;DP=203,270,197;AF=0.53,0.51,0.51;MQM=60	LYST	synonymous	LYST:ENST00000389793:synonymous_variant:LOW:exon5/53:c.2355T>C:p.Leu785=:,LYST:ENST00000389794:synonymous_variant:LOW:exon5/53:c.2355T>C:p.Leu785=:,LYST:ENST00000536965:synonymous_variant:LOW:exon5/22:c.2355T>C:p.Leu785=:	606897 [LYST (confirmed) Chediak-Higashi syndrome,214500];	254915 [likely benign DISEASE=Chediak-Higashi syndrome,not specified];			rs3768066	0.0707	0.1047	187,	0.0704,0.0884,0.0496,0.1375,0.0412	0.1366,0.0772	-0.0400			0.44,0.49	0.55						n/a (AF>5%)	n/a (AF>5%)					LYST (inh=AR pLI=1.00)
chr1	235972435	235972435	T	C	hom	hom	het		QUAL=27862;DP=483,287,198;AF=0.99,1.00,0.52;MQM=60	LYST	synonymous	LYST:ENST00000389793:synonymous_variant:LOW:exon5/53:c.1683A>G:p.Leu561=:,LYST:ENST00000389794:synonymous_variant:LOW:exon5/53:c.1683A>G:p.Leu561=:,LYST:ENST00000536965:synonymous_variant:LOW:exon5/22:c.1683A>G:p.Leu561=:	606897 [LYST (confirmed) Chediak-Higashi syndrome,214500];	254912 [benign DISEASE=Chediak-Higashi syndrome,not specified];			rs3820553	0.3027	0.4199	2898,	0.5028,0.2781,0.0588,0.4060,0.2076	0.3997,0.5089	-0.4530			0.04,0.73	0.13						n/a (AF>5%)	n/a (AF>5%)					LYST (inh=AR pLI=1.00)
chr1	235972867	235972867	T	C	hom	hom	het		QUAL=27833;DP=454,307,190;AF=1.00,0.99,0.56;MQM=60	LYST	synonymous	LYST:ENST00000389793:synonymous_variant:LOW:exon5/53:c.1251A>G:p.Gln417=:,LYST:ENST00000389794:synonymous_variant:LOW:exon5/53:c.1251A>G:p.Gln417=:,LYST:ENST00000536965:synonymous_variant:LOW:exon5/22:c.1251A>G:p.Gln417=:	606897 [LYST (confirmed) Chediak-Higashi syndrome,214500];	254910 [benign DISEASE=Chediak-Higashi syndrome,not specified];			rs1063128	0.3033	0.4197	2888,	0.5033,0.2780,0.0587,0.4061,0.2076	0.3994,0.5089	-0.0600			0.52,0.97	0.42						n/a (AF>5%)	n/a (AF>5%)					LYST (inh=AR pLI=1.00)
chr1	236030277	236030277	C	G	wt	het	wt	off-target	QUAL=25;DP=0,6,1;AF=nan,0.50,0.00;MQM=60	LYST	intron	LYST:ENST00000536965:intron_variant:MODIFIER:exon1/21:c.-98+16210G>C::	606897 [LYST (confirmed) Chediak-Higashi syndrome,214500];				rs3820556	0.0561	0.0835	148,			0.8250			0.34,0.83	2.19						n/a (AF>5%)	n/a (AF>5%)					LYST (inh=AR pLI=1.00)
chr1	236557771	236557771	G	A	hom	hom	hom		QUAL=24507;DP=251,289,225;AF=1.00,1.00,1.00;MQM=60	EDARADD	missense	EDARADD:ENST00000334232:missense_variant:MODERATE:exon1/6:c.27G>A:p.Met9Ile:	606603 [EDARADD (confirmed) Ectodermal dysplasia 11B,hypohidrotic/hair/tooth type,autosomal recessive,614941/Ectodermal dysplasia 11A,hypohidrotic/hair/tooth type,autosomal dominant,614940];	262600 [benign DISEASE=not specified,Hypohidrotic Ectodermal Dysplasia, Recessive];			rs966365		0.8412	9056,	0.5350,0.9075,0.9192,0.8363,0.9122	0.8398,0.5404	-0.0830	T	B	0.04,0.21	0.21	0.13					n/a (AF>5%)	n/a (AF>5%)					EDARADD (inh=AR+AD pLI=0.72)
chr1	236572475	236572475	A	G	het	het	hom	off-target	QUAL=10241;DP=180,161,172;AF=0.49,0.55,1.00;MQM=60	EDARADD	intron	EDARADD:ENST00000334232:intron_variant:MODIFIER:exon1/5:c.62-41A>G::,EDARADD:ENST00000359362:intron_variant:MODIFIER:exon1/5:c.32-41A>G::	606603 [EDARADD (confirmed) Ectodermal dysplasia 11B,hypohidrotic/hair/tooth type,autosomal recessive,614941/Ectodermal dysplasia 11A,hypohidrotic/hair/tooth type,autosomal dominant,614940];				rs669710	0.4619	0.5419	4676,	0.4762,0.4356,0.2605,0.5947,0.4910	0.5809,0.4741	0.2900			0.09,0.17	0.08						n/a (AF>5%)	n/a (AF>5%)					EDARADD (inh=AR+AD pLI=0.72)
chr1	236590659	236590659	G	C	het	het	hom	off-target	QUAL=6447;DP=151,154,90;AF=0.50,0.51,0.99;MQM=60	EDARADD	intron	EDARADD:ENST00000334232:intron_variant:MODIFIER:exon3/5:c.161-33G>C::,EDARADD:ENST00000359362:intron_variant:MODIFIER:exon3/5:c.131-33G>C::	606603 [EDARADD (confirmed) Ectodermal dysplasia 11B,hypohidrotic/hair/tooth type,autosomal recessive,614941/Ectodermal dysplasia 11A,hypohidrotic/hair/tooth type,autosomal dominant,614940];			(T)n	rs636048	0.3582	0.4950	3653,	0.1850,0.4182,0.2271,0.5871,0.4567	0.5797,0.2030	0.8840			0.04,0.14	-0.07						n/a (AF>5%)	n/a (AF>5%)					EDARADD (inh=AR+AD pLI=0.72)
chr1	236645670	236645670	C	T	wt	het	wt		QUAL=5229;DP=209,480,357;AF=0.00,0.44,0.01;MQM=60	EDARADD	synonymous	EDARADD:ENST00000334232:synonymous_variant:LOW:exon6/6:c.369C>T:p.Asp123=:,EDARADD:ENST00000359362:synonymous_variant:LOW:exon6/6:c.339C>T:p.Asp113=:	606603 [EDARADD (confirmed) Ectodermal dysplasia 11B,hypohidrotic/hair/tooth type,autosomal recessive,614941/Ectodermal dysplasia 11A,hypohidrotic/hair/tooth type,autosomal dominant,614940];	262602 [benign/likely benign DISEASE=not specified,Hypohidrotic Ectodermal Dysplasia, Recessive];			rs604070	0.1332	0.2005	668,	0.0704,0.1091,0.0901,0.2557,0.1494	0.2457,0.0803	0.1880			0.19,0.44	0.69						n/a (AF>5%)	n/a (AF>5%)					EDARADD (inh=AR+AD pLI=0.72)
chr1	236647511	236647511	T	C	het	hom	het		QUAL=12976;DP=273,225,142;AF=0.53,1.00,0.49;MQM=60	EDARADD,ENO1P1	3'UTR,non_coding_transcript_exon	EDARADD:ENST00000359362:3_prime_UTR_variant:MODIFIER:exon6/6:c.*1562T>C::,ENO1P1:ENST00000366587:non_coding_transcript_exon_variant:MODIFIER:exon1/1:n.1047T>C::	606603 [EDARADD (confirmed) Ectodermal dysplasia 11B,hypohidrotic/hair/tooth type,autosomal recessive,614941/Ectodermal dysplasia 11A,hypohidrotic/hair/tooth type,autosomal dominant,614940];	296476 [likely benign DISEASE=Hypohidrotic Ectodermal Dysplasia, Recessive];			rs7513402	0.2540	0.3102	1615,			-2.0580			0.01,0.58	0.23						n/a (AF>5%)	n/a (AF>5%)					EDARADD (inh=AR+AD pLI=0.72), ENO1P1 (inh=n/a pLI=n/a)
chr1	236647550	236647550	C	G	het	hom	het		QUAL=13835;DP=328,225,127;AF=0.54,1.00,0.53;MQM=60	EDARADD,ENO1P1	3'UTR,non_coding_transcript_exon	EDARADD:ENST00000359362:3_prime_UTR_variant:MODIFIER:exon6/6:c.*1601C>G::,ENO1P1:ENST00000366587:non_coding_transcript_exon_variant:MODIFIER:exon1/1:n.1086C>G::	606603 [EDARADD (confirmed) Ectodermal dysplasia 11B,hypohidrotic/hair/tooth type,autosomal recessive,614941/Ectodermal dysplasia 11A,hypohidrotic/hair/tooth type,autosomal dominant,614940];	296479 [likely benign DISEASE=Hypohidrotic Ectodermal Dysplasia, Recessive];			rs3916983	0.2033	0.2232	847,			-0.0890			0.15,0.87	0.28						n/a (AF>5%)	n/a (AF>5%)					EDARADD (inh=AR+AD pLI=0.72), ENO1P1 (inh=n/a pLI=n/a)
chr1	236647736	236647736	C	T	het	hom	het		QUAL=7165;DP=155,129,73;AF=0.54,0.99,0.53;MQM=59	EDARADD,ENO1P1	3'UTR,non_coding_transcript_exon	EDARADD:ENST00000359362:3_prime_UTR_variant:MODIFIER:exon6/6:c.*1787C>T::,ENO1P1:ENST00000366587:non_coding_transcript_exon_variant:MODIFIER:exon1/1:n.1272C>T::	606603 [EDARADD (confirmed) Ectodermal dysplasia 11B,hypohidrotic/hair/tooth type,autosomal recessive,614941/Ectodermal dysplasia 11A,hypohidrotic/hair/tooth type,autosomal dominant,614940];	296481 [likely benign DISEASE=Hypohidrotic Ectodermal Dysplasia, Recessive];			rs6428955	0.1378	0.1736	581,			0.1490			0.03,0.80	0.34						n/a (AF>5%)	n/a (AF>5%)					EDARADD (inh=AR+AD pLI=0.72), ENO1P1 (inh=n/a pLI=n/a)
chr1	236648008	236648008	G	-	hom	wt	het		QUAL=106;DP=10,19,13;AF=0.30,0.42,0.62;MQM=58	EDARADD	3'UTR	EDARADD:ENST00000359362:3_prime_UTR_variant:MODIFIER:exon6/6:c.*2059del::	606603 [EDARADD (confirmed) Ectodermal dysplasia 11B,hypohidrotic/hair/tooth type,autosomal recessive,614941/Ectodermal dysplasia 11A,hypohidrotic/hair/tooth type,autosomal dominant,614940];	296489 [uncertain significance DISEASE=Hypohidrotic Ectodermal Dysplasia, Recessive];		AluSc	rs886046200		0.0002	0,			-4.5420				-0.62						0	0					EDARADD (inh=AR+AD pLI=0.72)
chr1	236648009	236648010	AA	-	wt	het	wt		QUAL=106;DP=10,19,13;AF=0.30,0.42,0.62;MQM=60	EDARADD	3'UTR	EDARADD:ENST00000359362:3_prime_UTR_variant:MODIFIER:exon6/6:c.*2077_*2078del::	606603 [EDARADD (confirmed) Ectodermal dysplasia 11B,hypohidrotic/hair/tooth type,autosomal recessive,614941/Ectodermal dysplasia 11A,hypohidrotic/hair/tooth type,autosomal dominant,614940];			AluSc	rs768439661		0.0022	0,			-2.3350				-0.63						9	5					EDARADD (inh=AR+AD pLI=0.72)
chr1	236958532	236958532	G	T	het	hom	het	off-target	QUAL=1125;DP=15,29,23;AF=0.47,1.00,0.48;MQM=60	MTR	upstream_gene	MTR:ENST00000366577:upstream_gene_variant:MODIFIER::::,MTR:ENST00000418145:upstream_gene_variant:MODIFIER::::,MTR:ENST00000535889:upstream_gene_variant:MODIFIER::::					rs28372871	0.4673	0.4687	3420,			-0.7480			0.01,0.21	0.23						n/a (AF>5%)	n/a (AF>5%)					MTR (inh=AR pLI=0.00)
chr1	236978992	236978992	-	TCTG	het	hom	het	off-target	QUAL=8864;DP=161,176,112;AF=0.55,0.98,0.55;MQM=60	MTR	intron	MTR:ENST00000366577:intron_variant:MODIFIER:exon7/32:c.669+32_669+33insGTCT::,MTR:ENST00000418145:intron_variant:MODIFIER:exon7/7:c.*204+32_*204+33insGTCT::,MTR:ENST00000535889:intron_variant:MODIFIER:exon7/31:c.669+32_669+33insGTCT::	156570 [MTR (confirmed) Homocystinuria-megaloblastic anemia,cblG complementation type,250940/Neural tube defects,folate-sensitive,susceptibility to,601634];				rs5781924	0.7696	0.7277	8403,	0.9269,0.6886,0.8119,0.6225,0.7317	0.6357,0.9140					-0.02						n/a (AF>5%)	n/a (AF>5%)					MTR (inh=AR pLI=0.00)
chr1	236988593	236988593	-	T	het	hom	het	off-target	QUAL=4032;DP=138,50,38;AF=0.57,1.00,0.68;MQM=60	MTR	intron	MTR:ENST00000366577:intron_variant:MODIFIER:exon9/32:c.866-40dup::,MTR:ENST00000535889:intron_variant:MODIFIER:exon9/31:c.866-40dup::	156570 [MTR (confirmed) Homocystinuria-megaloblastic anemia,cblG complementation type,250940/Neural tube defects,folate-sensitive,susceptibility to,601634];				rs5781926	0.3155	0.3840	2022,	0.2055,0.4487,0.4062,0.4064,0.3106	0.4110,0.2145					0.03						n/a (AF>5%)	n/a (AF>5%)					MTR (inh=AR pLI=0.00)
chr1	236990141	236990141	G	A	wt	wt	het		QUAL=1793;DP=295,221,153;AF=0.00,0.00,0.47;MQM=60	MTR	missense	MTR:ENST00000366577:missense_variant:MODERATE:exon11/33:c.940G>A:p.Asp314Asn:PF02574,MTR:ENST00000535889:missense_variant:MODERATE:exon11/32:c.940G>A:p.Asp314Asn:PF02574	156570 [MTR (confirmed) Homocystinuria-megaloblastic anemia,cblG complementation type,250940/Neural tube defects,folate-sensitive,susceptibility to,601634];	296556 [benign/likely benign DISEASE=Disorders of Intracellular Cobalamin Metabolism,not specified];			rs2229274	0.0084	0.0187	3,	0.0078,0.0151,0.0000,0.0256,0.0049	0.0262,0.0082	4.0180	T,T	B,B	0.97,0.98	2.37	0.12					4	216					MTR (inh=AR pLI=0.00)
chr1	237001926	237001926	A	G	het	hom	het	off-target	QUAL=12905;DP=177,256,180;AF=0.51,1.00,0.51;MQM=60	MTR	intron	MTR:ENST00000366577:intron_variant:MODIFIER:exon15/32:c.1515+27A>G::,MTR:ENST00000535889:intron_variant:MODIFIER:exon15/31:c.1515+27A>G::	156570 [MTR (confirmed) Homocystinuria-megaloblastic anemia,cblG complementation type,250940/Neural tube defects,folate-sensitive,susceptibility to,601634];				rs3820568	0.3277	0.3937	2218,	0.2093,0.4541,0.4356,0.4124,0.3143	0.4195,0.2177	-1.0070			0.03,0.18	-0.27						n/a (AF>5%)	n/a (AF>5%)					MTR (inh=AR pLI=0.00)
chr1	237024414	237024414	G	T	het	wt	wt	off-target	QUAL=27;DP=46,28,20;AF=0.39,0.18,0.15;MQM=48	MTR	intron	MTR:ENST00000366577:intron_variant:MODIFIER:exon19/32:c.2044-11G>T::,MTR:ENST00000535889:intron_variant:MODIFIER:exon19/31:c.2044-1122G>T::	156570 [MTR (confirmed) Homocystinuria-megaloblastic anemia,cblG complementation type,250940/Neural tube defects,folate-sensitive,susceptibility to,601634];	516909 [benign DISEASE=not specified];		(T)n	rs570088952	0.3079	0.4583	0,	0.4101,0.4863,0.4262,0.4516,0.4910		0.8970			0.01,0.13	-0.24		-1.85% (14.66>14.39)		0.000/0.000		n/a (AF>5%)	n/a (AF>5%)					MTR (inh=AR pLI=0.00)
chr1	237024416	237024416	C	T	het	wt	wt		QUAL=27;DP=46,28,20;AF=0.39,0.18,0.15;MQM=48	MTR	intron	MTR:ENST00000366577:intron_variant:MODIFIER:exon19/32:c.2044-9C>T::,MTR:ENST00000535889:intron_variant:MODIFIER:exon19/31:c.2044-1120C>T::	156570 [MTR (confirmed) Homocystinuria-megaloblastic anemia,cblG complementation type,250940/Neural tube defects,folate-sensitive,susceptibility to,601634];	506702 [benign DISEASE=not specified];		(T)n	rs531027742	0.3099	0.4364	0,	0.3903,0.4831,0.4082,0.4189,0.4853		0.1440			0.00,0.12	-0.07		-9.11% (14.66>13.33)		0.000/0.000		n/a (AF>5%)	n/a (AF>5%)					MTR (inh=AR pLI=0.00)
chr1	237037999	237037999	T	-	het	hom	het	off-target	QUAL=1973;DP=102,61,35;AF=0.20,0.74,0.54;MQM=59	MTR	intron	MTR:ENST00000366577:intron_variant:MODIFIER:exon23/32:c.2474-18del::,MTR:ENST00000535889:intron_variant:MODIFIER:exon22/31:c.2321-18del::	156570 [MTR (confirmed) Homocystinuria-megaloblastic anemia,cblG complementation type,250940/Neural tube defects,folate-sensitive,susceptibility to,601634];				rs150727404		0.6400	5400,	0.5597,0.4888,0.5407,0.4522,0.4888		0.1560				-0.02						n/a (AF>5%)	n/a (AF>5%)					MTR (inh=AR pLI=0.00)
chr1	237038008	237038008	T	A	het	hom	het	off-target	QUAL=1973;DP=102,61,35;AF=0.20,0.74,0.54;MQM=59	MTR	intron	MTR:ENST00000366577:intron_variant:MODIFIER:exon23/32:c.2474-18T>A::,MTR:ENST00000535889:intron_variant:MODIFIER:exon22/31:c.2321-18T>A::	156570 [MTR (confirmed) Homocystinuria-megaloblastic anemia,cblG complementation type,250940/Neural tube defects,folate-sensitive,susceptibility to,601634];	378884 [benign DISEASE=not specified];			rs10925256	0.3832	0.4335	2320,	0.4760,0.4588,0.4481,0.4168,0.3783	0.0000,0.0021	-0.2600			0.08,0.37	0.02		+11.77% (-1.58>-1.77)				n/a (AF>5%)	n/a (AF>5%)					MTR (inh=AR pLI=0.00)
chr1	237038161	237038161	T	C	het	wt	het	off-target	QUAL=2563;DP=81,168,127;AF=0.47,0.00,0.51;MQM=60	MTR	intron	MTR:ENST00000366577:intron_variant:MODIFIER:exon24/32:c.2594+15T>C::,MTR:ENST00000535889:intron_variant:MODIFIER:exon23/31:c.2441+15T>C::	156570 [MTR (confirmed) Homocystinuria-megaloblastic anemia,cblG complementation type,250940/Neural tube defects,folate-sensitive,susceptibility to,601634];	138288 [benign DISEASE=Disorders of Intracellular Cobalamin Metabolism,not specified];			rs1770449	0.2322	0.3225	1372,	0.0692,0.3114,0.1908,0.3746,0.2790	0.3608,0.0828	-0.0530			0.05,0.22	-0.01						n/a (AF>5%)	n/a (AF>5%)					MTR (inh=AR pLI=0.00)
chr1	237048562	237048562	G	A	het	hom	het	off-target	QUAL=11041;DP=332,149,114;AF=0.55,1.00,0.49;MQM=60	MTR	intron	MTR:ENST00000366577:intron_variant:MODIFIER:exon26/32:c.2775+43G>A::,MTR:ENST00000535889:intron_variant:MODIFIER:exon25/31:c.2622+43G>A::	156570 [MTR (confirmed) Homocystinuria-megaloblastic anemia,cblG complementation type,250940/Neural tube defects,folate-sensitive,susceptibility to,601634];				rs2275566	0.7618	0.7243	8332,	0.9057,0.6847,0.8097,0.6232,0.7189	0.6368,0.8894	-0.8130			0.03,0.11	-0.27						n/a (AF>5%)	n/a (AF>5%)					MTR (inh=AR pLI=0.00)
chr1	237054569	237054569	A	G	het	hom	het		QUAL=7209;DP=100,145,101;AF=0.54,1.00,0.50;MQM=60	MTR	synonymous	MTR:ENST00000366577:synonymous_variant:LOW:exon29/33:c.3144A>G:p.Ala1048=:PF02965,MTR:ENST00000535889:synonymous_variant:LOW:exon28/32:c.2991A>G:p.Ala997=:PF02965	156570 [MTR (confirmed) Homocystinuria-megaloblastic anemia,cblG complementation type,250940/Neural tube defects,folate-sensitive,susceptibility to,601634];	138290 [benign DISEASE=Disorders of Intracellular Cobalamin Metabolism,not specified];			rs2229276	0.3233	0.3905	2157,	0.1941,0.4493,0.4456,0.4053,0.3214	0.4134,0.1984	-1.1260			0.10,0.16	-0.37						n/a (AF>5%)	n/a (AF>5%)					MTR (inh=AR pLI=0.00)
chr1	237057608	237057608	G	A	het	hom	het	off-target	QUAL=8013;DP=98,175,140;AF=0.50,1.00,0.50;MQM=60	MTR	intron	MTR:ENST00000366577:intron_variant:MODIFIER:exon29/32:c.3205-49G>A::,MTR:ENST00000535889:intron_variant:MODIFIER:exon28/31:c.3052-49G>A::	156570 [MTR (confirmed) Homocystinuria-megaloblastic anemia,cblG complementation type,250940/Neural tube defects,folate-sensitive,susceptibility to,601634];				rs2297965	0.5375	0.5916	5105,	0.4576,0.6340,0.5430,0.5953,0.6249	0.6100,0.4641	-0.5190			0.03,0.14	0.02						n/a (AF>5%)	n/a (AF>5%)					MTR (inh=AR pLI=0.00)
chr1	237058744	237058744	C	A	het	hom	het		QUAL=14704;DP=213,310,223;AF=0.53,1.00,0.46;MQM=60	MTR	synonymous	MTR:ENST00000366577:synonymous_variant:LOW:exon31/33:c.3492C>A:p.Arg1164=:PF02965,MTR:ENST00000535889:synonymous_variant:LOW:exon30/32:c.3339C>A:p.Arg1113=:PF02965	156570 [MTR (confirmed) Homocystinuria-megaloblastic anemia,cblG complementation type,250940/Neural tube defects,folate-sensitive,susceptibility to,601634];	138283 [benign DISEASE=Disorders of Intracellular Cobalamin Metabolism,not specified];			rs12070777	0.3215	0.3875	2146,	0.1978,0.4472,0.4345,0.4016,0.3127	0.4106,0.2072	0.0720			0.58,0.23	0.18						n/a (AF>5%)	n/a (AF>5%)					MTR (inh=AR pLI=0.00)
chr1	237058828	237058828	C	T	wt	het	het		QUAL=4192;DP=135,182,168;AF=0.00,0.53,0.43;MQM=60	MTR	synonymous	MTR:ENST00000366577:synonymous_variant:LOW:exon31/33:c.3576C>T:p.Leu1192=:PF02965,MTR:ENST00000535889:synonymous_variant:LOW:exon30/32:c.3423C>T:p.Leu1141=:PF02965	156570 [MTR (confirmed) Homocystinuria-megaloblastic anemia,cblG complementation type,250940/Neural tube defects,folate-sensitive,susceptibility to,601634];	138284 [benign DISEASE=Disorders of Intracellular Cobalamin Metabolism,not specified];			rs1131449		0.5775	4895,	0.4605,0.6163,0.5460,0.5725,0.6201	0.5870,0.4661	-3.4610			0.02,0.09	-0.48						n/a (AF>5%)	n/a (AF>5%)					MTR (inh=AR pLI=0.00)
chr1	237060433	237060433	G	T	het	hom	het	off-target	QUAL=12410;DP=205,245,200;AF=0.41,0.99,0.50;MQM=60	MTR	intron	MTR:ENST00000366577:intron_variant:MODIFIER:exon32/32:c.3711+15G>T::,MTR:ENST00000535889:intron_variant:MODIFIER:exon31/31:c.3558+15G>T::	156570 [MTR (confirmed) Homocystinuria-megaloblastic anemia,cblG complementation type,250940/Neural tube defects,folate-sensitive,susceptibility to,601634];	138285 [benign DISEASE=Disorders of Intracellular Cobalamin Metabolism,not specified];			rs3820571	0.7524	0.7178	8166,	0.8871,0.6826,0.8095,0.6184,0.7189	0.6317,0.8727	-0.2760			0.00,0.13	-0.03						n/a (AF>5%)	n/a (AF>5%)					MTR (inh=AR pLI=0.00)
chr1	237061056	237061056	A	C	het	hom	het		QUAL=10744;DP=309,154,80;AF=0.54,1.00,0.53;MQM=60	MTR	3'UTR	MTR:ENST00000366577:3_prime_UTR_variant:MODIFIER:exon33/33:c.*112A>C::,MTR:ENST00000535889:3_prime_UTR_variant:MODIFIER:exon32/32:c.*112A>C::	156570 [MTR (confirmed) Homocystinuria-megaloblastic anemia,cblG complementation type,250940/Neural tube defects,folate-sensitive,susceptibility to,601634];	296587 [benign DISEASE=Disorders of Intracellular Cobalamin Metabolism];			rs2853522	0.5401	0.5720	5136,			-1.1210			0.00,0.05	0.16						n/a (AF>5%)	n/a (AF>5%)					MTR (inh=AR pLI=0.00)
chr1	237061705	237061705	T	-	het	hom	het		QUAL=2044;DP=99,38,29;AF=0.49,0.82,0.59;MQM=58	MTR	3'UTR	MTR:ENST00000366577:3_prime_UTR_variant:MODIFIER:exon33/33:c.*773del::	156570 [MTR (confirmed) Homocystinuria-megaloblastic anemia,cblG complementation type,250940/Neural tube defects,folate-sensitive,susceptibility to,601634];	296595 [benign DISEASE=Disorders of Intracellular Cobalamin Metabolism];		AluY			0.6828	5642,			0.1060				0.27						n/a (AF>5%)	n/a (AF>5%)					MTR (inh=AR pLI=0.00)
chr1	237061849	237061849	G	A	het	wt	het		QUAL=1254;DP=82,66,34;AF=0.44,0.00,0.59;MQM=51	MTR	3'UTR	MTR:ENST00000366577:3_prime_UTR_variant:MODIFIER:exon33/33:c.*905G>A::	156570 [MTR (confirmed) Homocystinuria-megaloblastic anemia,cblG complementation type,250940/Neural tube defects,folate-sensitive,susceptibility to,601634];	296598 [benign DISEASE=Disorders of Intracellular Cobalamin Metabolism];		AluY	rs1131450	0.2460	0.2744	1312,			0.1700			0.00,0.07	-0.04						n/a (AF>5%)	n/a (AF>5%)					MTR (inh=AR pLI=0.00)
chr1	237062198	237062198	A	C	het	hom	het		QUAL=16918;DP=266,297,243;AF=0.55,1.00,0.47;MQM=60	MTR	3'UTR	MTR:ENST00000366577:3_prime_UTR_variant:MODIFIER:exon33/33:c.*1254A>C::	156570 [MTR (confirmed) Homocystinuria-megaloblastic anemia,cblG complementation type,250940/Neural tube defects,folate-sensitive,susceptibility to,601634];	296610 [benign DISEASE=Disorders of Intracellular Cobalamin Metabolism];			rs2853523	0.7646	0.7284	8461,			-0.2270			0.00,0.06	0.33						n/a (AF>5%)	n/a (AF>5%)					MTR (inh=AR pLI=0.00)
chr1	237062305	237062305	A	G	het	hom	het		QUAL=21939;DP=413,370,295;AF=0.52,0.99,0.52;MQM=60	MTR	3'UTR	MTR:ENST00000366577:3_prime_UTR_variant:MODIFIER:exon33/33:c.*1361A>G::	156570 [MTR (confirmed) Homocystinuria-megaloblastic anemia,cblG complementation type,250940/Neural tube defects,folate-sensitive,susceptibility to,601634];	296611 [benign DISEASE=Disorders of Intracellular Cobalamin Metabolism];			rs1050993	0.7644	0.7284	8460,			-0.4580			0.00,0.06	0.03						n/a (AF>5%)	n/a (AF>5%)					MTR (inh=AR pLI=0.00)
chr1	237063335	237063335	G	C	het	hom	het		QUAL=12869;DP=227,221,207;AF=0.49,1.00,0.53;MQM=60	MTR	3'UTR	MTR:ENST00000366577:3_prime_UTR_variant:MODIFIER:exon33/33:c.*2391G>C::	156570 [MTR (confirmed) Homocystinuria-megaloblastic anemia,cblG complementation type,250940/Neural tube defects,folate-sensitive,susceptibility to,601634];	296631 [benign DISEASE=Disorders of Intracellular Cobalamin Metabolism];		L1ME3F	rs1050996	0.7328	0.6990	7676,			-0.1640			0.00,0.07	0.06						n/a (AF>5%)	n/a (AF>5%)					MTR (inh=AR pLI=0.00)
chr1	237063504	237063504	A	G	het	hom	het		QUAL=11943;DP=379,147,108;AF=0.50,1.00,0.55;MQM=60	MTR	3'UTR	MTR:ENST00000366577:3_prime_UTR_variant:MODIFIER:exon33/33:c.*2560A>G::	156570 [MTR (confirmed) Homocystinuria-megaloblastic anemia,cblG complementation type,250940/Neural tube defects,folate-sensitive,susceptibility to,601634];	296633 [benign DISEASE=Disorders of Intracellular Cobalamin Metabolism];		L1ME3F	rs9779	0.3219	0.3701	2095,	0.1892,0.4347,0.4319,0.3915,0.2994		-1.1440			0.01,0.12	0.06						n/a (AF>5%)	n/a (AF>5%)					MTR (inh=AR pLI=0.00)
chr1	237063709	237063709	-	A	het	hom	het		QUAL=12656;DP=172,173,132;AF=0.91,0.94,0.94;MQM=59	MTR	3'UTR	MTR:ENST00000366577:3_prime_UTR_variant:MODIFIER:exon33/33:c.*2774dup::	156570 [MTR (confirmed) Homocystinuria-megaloblastic anemia,cblG complementation type,250940/Neural tube defects,folate-sensitive,susceptibility to,601634];	296635 [benign DISEASE=Disorders of Intracellular Cobalamin Metabolism];		L1ME3F			0.7257	6577,							0.08						n/a (AF>5%)	n/a (AF>5%)					MTR (inh=AR pLI=0.00)
chr1	237063718	237063719	AG	-	het	wt	het		QUAL=12656;DP=172,173,132;AF=0.91,0.94,0.94;MQM=60	MTR	3'UTR	MTR:ENST00000366577:3_prime_UTR_variant:MODIFIER:exon33/33:c.*2775_*2776del::	156570 [MTR (confirmed) Homocystinuria-megaloblastic anemia,cblG complementation type,250940/Neural tube defects,folate-sensitive,susceptibility to,601634];	296637 [benign DISEASE=Disorders of Intracellular Cobalamin Metabolism];		L1ME3F	rs34686098	0.2332	0.2684	1350,			0.5860				0.04						n/a (AF>5%)	n/a (AF>5%)					MTR (inh=AR pLI=0.00)
chr1	237064626	237064626	T	G	het	hom	het		QUAL=33703;DP=419,671,513;AF=0.49,0.99,0.48;MQM=60	MTR	3'UTR	MTR:ENST00000366577:3_prime_UTR_variant:MODIFIER:exon33/33:c.*3682T>G::	156570 [MTR (confirmed) Homocystinuria-megaloblastic anemia,cblG complementation type,250940/Neural tube defects,folate-sensitive,susceptibility to,601634];	296655 [benign DISEASE=Disorders of Intracellular Cobalamin Metabolism];			rs6676866	0.5397	0.5727	5144,			1.5630			0.10,0.14	-0.03						n/a (AF>5%)	n/a (AF>5%)					MTR (inh=AR pLI=0.00)
chr1	237065326	237065326	C	T	het	hom	het		QUAL=8119;DP=170,158,113;AF=0.55,1.00,0.47;MQM=60	MTR	3'UTR	MTR:ENST00000366577:3_prime_UTR_variant:MODIFIER:exon33/33:c.*4382C>T::	156570 [MTR (confirmed) Homocystinuria-megaloblastic anemia,cblG complementation type,250940/Neural tube defects,folate-sensitive,susceptibility to,601634];	296668 [benign DISEASE=Disorders of Intracellular Cobalamin Metabolism];			rs4659746	0.5447	0.5783	5255,			-0.6210			0.00,0.10	-0.14						n/a (AF>5%)	n/a (AF>5%)					MTR (inh=AR pLI=0.00)
chr1	237065583	237065583	G	T	het	hom	het		QUAL=13270;DP=220,256,175;AF=0.52,1.00,0.57;MQM=60	MTR	3'UTR	MTR:ENST00000366577:3_prime_UTR_variant:MODIFIER:exon33/33:c.*4639G>T::	156570 [MTR (confirmed) Homocystinuria-megaloblastic anemia,cblG complementation type,250940/Neural tube defects,folate-sensitive,susceptibility to,601634];	296673 [benign DISEASE=Disorders of Intracellular Cobalamin Metabolism];			rs10925264	0.7646	0.7282	8429,			-0.3240			0.00,0.07	-0.17						n/a (AF>5%)	n/a (AF>5%)					MTR (inh=AR pLI=0.00)
chr1	237065810	237065810	T	G	het	het	wt		QUAL=4850;DP=179,171,179;AF=0.53,0.55,0.00;MQM=60	MTR	3'UTR	MTR:ENST00000366577:3_prime_UTR_variant:MODIFIER:exon33/33:c.*4866T>G::	156570 [MTR (confirmed) Homocystinuria-megaloblastic anemia,cblG complementation type,250940/Neural tube defects,folate-sensitive,susceptibility to,601634];	296677 [uncertain significance DISEASE=Disorders of Intracellular Cobalamin Metabolism];		L2c	rs45563435	0.0076	0.0132	2,			-0.3090			0.02,0.12	-0.12						0	19					MTR (inh=AR pLI=0.00)
chr1	237066114	237066114	A	G	het	wt	het		QUAL=3125;DP=156,113,85;AF=0.49,0.00,0.59;MQM=60	MTR	3'UTR	MTR:ENST00000366577:3_prime_UTR_variant:MODIFIER:exon33/33:c.*5170A>G::	156570 [MTR (confirmed) Homocystinuria-megaloblastic anemia,cblG complementation type,250940/Neural tube defects,folate-sensitive,susceptibility to,601634];	296679 [likely benign DISEASE=Disorders of Intracellular Cobalamin Metabolism];			rs6680753	0.0104	0.0203	7,			0.5380			0.05,0.20	0.28						0	11					MTR (inh=AR pLI=0.00)
chr1	240939104	240939104	G	A	het	wt	hom		QUAL=9092;DP=345,165,146;AF=0.48,0.00,0.99;MQM=60	RGS7	intron,3'UTR	RGS7:ENST00000331110:intron_variant:MODIFIER:exon17/17:c.*7-7526C>T::,RGS7:ENST00000348120:3_prime_UTR_variant:MODIFIER:exon15/15:c.*416C>T::,RGS7:ENST00000366563:3_prime_UTR_variant:MODIFIER:exon18/18:c.*416C>T::,RGS7:ENST00000366564:3_prime_UTR_variant:MODIFIER:exon17/17:c.*359C>T::,RGS7:ENST00000366565:3_prime_UTR_variant:MODIFIER:exon18/18:c.*359C>T::,RGS7:ENST00000446183:3_prime_UTR_variant:MODIFIER:exon18/18:c.*416C>T::					rs35557904	0.1727	0.1728	597,			0.5550			0.22,0.93	1.12						n/a (AF>5%)	n/a (AF>5%)					RGS7 (inh=n/a pLI=1.00)
chr1	240939152	240939152	A	G	het	wt	hom		QUAL=9448;DP=319,209,181;AF=0.44,0.00,0.99;MQM=60	RGS7	intron,3'UTR	RGS7:ENST00000331110:intron_variant:MODIFIER:exon17/17:c.*7-7574T>C::,RGS7:ENST00000348120:3_prime_UTR_variant:MODIFIER:exon15/15:c.*368T>C::,RGS7:ENST00000366563:3_prime_UTR_variant:MODIFIER:exon18/18:c.*368T>C::,RGS7:ENST00000366564:3_prime_UTR_variant:MODIFIER:exon17/17:c.*311T>C::,RGS7:ENST00000366565:3_prime_UTR_variant:MODIFIER:exon18/18:c.*311T>C::,RGS7:ENST00000446183:3_prime_UTR_variant:MODIFIER:exon18/18:c.*368T>C::					rs16840577	0.1727	0.1720	597,			2.3800			0.05,0.93	1.49						n/a (AF>5%)	n/a (AF>5%)					RGS7 (inh=n/a pLI=1.00)
chr1	240939391	240939391	C	T	het	wt	het		QUAL=12760;DP=503,687,550;AF=0.46,0.00,0.47;MQM=60	RGS7	intron,3'UTR	RGS7:ENST00000331110:intron_variant:MODIFIER:exon17/17:c.*7-7813G>A::,RGS7:ENST00000348120:3_prime_UTR_variant:MODIFIER:exon15/15:c.*129G>A::,RGS7:ENST00000366563:3_prime_UTR_variant:MODIFIER:exon18/18:c.*129G>A::,RGS7:ENST00000366564:3_prime_UTR_variant:MODIFIER:exon17/17:c.*72G>A::,RGS7:ENST00000366565:3_prime_UTR_variant:MODIFIER:exon18/18:c.*72G>A::,RGS7:ENST00000446183:3_prime_UTR_variant:MODIFIER:exon18/18:c.*129G>A::					rs12757054	0.0497	0.0595	68,		0.0918,0.0369	1.8120			0.71,0.97	1.50						n/a (AF>5%)	n/a (AF>5%)					RGS7 (inh=n/a pLI=1.00)
chr1	240975213	240975213	T	C	het	hom	wt		QUAL=11078;DP=255,237,201;AF=0.55,1.00,0.00;MQM=60	RGS7	splice_region&intron	RGS7:ENST00000331110:splice_region_variant&intron_variant:LOW:exon14/17:c.1004+5A>G::,RGS7:ENST00000348120:splice_region_variant&intron_variant:LOW:exon11/14:c.923+5A>G::,RGS7:ENST00000366562:splice_region_variant&intron_variant:LOW:exon13/15:c.1082+5A>G::,RGS7:ENST00000366563:splice_region_variant&intron_variant:LOW:exon14/17:c.1082+5A>G::,RGS7:ENST00000366564:splice_region_variant&intron_variant:LOW:exon14/16:c.1082+5A>G::,RGS7:ENST00000366565:splice_region_variant&intron_variant:LOW:exon14/17:c.1082+5A>G::,RGS7:ENST00000401882:splice_region_variant&intron_variant:LOW:exon11/13:c.923+5A>G::,RGS7:ENST00000407727:splice_region_variant&intron_variant:LOW:exon13/16:c.1082+5A>G::,RGS7:ENST00000446183:splice_region_variant&intron_variant:LOW:exon14/17:c.830+5A>G::					rs2275742	0.4046	0.5082	4165,	0.2539,0.4101,0.4601,0.5761,0.4329	0.5766,0.2724	0.4500			0.04,0.89	1.00		+26.16% (8.38>10.57)		0.000/0.002		n/a (AF>5%)	n/a (AF>5%)					RGS7 (inh=n/a pLI=1.00)
chr1	240977964	240977964	G	T	hom	hom	het	off-target	QUAL=9590;DP=169,108,64;AF=0.99,1.00,0.44;MQM=60	RGS7	intron	RGS7:ENST00000331110:intron_variant:MODIFIER:exon12/17:c.767+52C>A::,RGS7:ENST00000348120:intron_variant:MODIFIER:exon9/14:c.686+52C>A::,RGS7:ENST00000366562:intron_variant:MODIFIER:exon11/15:c.845+52C>A::,RGS7:ENST00000366563:intron_variant:MODIFIER:exon12/17:c.845+52C>A::,RGS7:ENST00000366564:intron_variant:MODIFIER:exon12/16:c.845+52C>A::,RGS7:ENST00000366565:intron_variant:MODIFIER:exon12/17:c.845+52C>A::,RGS7:ENST00000401882:intron_variant:MODIFIER:exon9/13:c.686+52C>A::,RGS7:ENST00000407727:intron_variant:MODIFIER:exon11/16:c.845+52C>A::,RGS7:ENST00000446183:intron_variant:MODIFIER:exon12/17:c.593+52C>A::					rs12744536	0.5292	0.6287	6465,		0.7275,0.4113	-1.2830			0.00,0.08	0.10						n/a (AF>5%)	n/a (AF>5%)					RGS7 (inh=n/a pLI=1.00)
chr1	241146322	241146322	A	G	het	het	wt	off-target	QUAL=4121;DP=215,82,57;AF=0.53,0.54,0.00;MQM=60	RGS7	intron	RGS7:ENST00000331110:intron_variant:MODIFIER:exon4/17:c.148+57T>C::,RGS7:ENST00000348120:intron_variant:MODIFIER:exon3/14:c.226+57T>C::,RGS7:ENST00000366562:intron_variant:MODIFIER:exon3/15:c.226+57T>C::,RGS7:ENST00000366563:intron_variant:MODIFIER:exon4/17:c.226+57T>C::,RGS7:ENST00000366564:intron_variant:MODIFIER:exon4/16:c.226+57T>C::,RGS7:ENST00000366565:intron_variant:MODIFIER:exon4/17:c.226+57T>C::,RGS7:ENST00000401882:intron_variant:MODIFIER:exon3/13:c.226+57T>C::,RGS7:ENST00000407727:intron_variant:MODIFIER:exon3/16:c.226+57T>C::,RGS7:ENST00000446183:intron_variant:MODIFIER:exon4/17:c.-27+57T>C::					rs7520707	0.3560	0.3618	2089,		0.4038,0.3251	0.6750			0.03,0.13	-0.02						n/a (AF>5%)	n/a (AF>5%)					RGS7 (inh=n/a pLI=1.00)
chr1	241519098	241519098	T	A	hom	hom	hom		QUAL=35195;DP=434,422,287;AF=1.00,1.00,1.00;MQM=60	RGS7	5'UTR	RGS7:ENST00000366563:5_prime_UTR_variant:MODIFIER:exon2/18:c.-22A>T::,RGS7:ENST00000366564:5_prime_UTR_variant:MODIFIER:exon2/17:c.-22A>T::,RGS7:ENST00000366565:5_prime_UTR_variant:MODIFIER:exon2/18:c.-22A>T::					rs4659599	0.9483	0.9797	14179,	0.8680,0.9880,0.9974,0.9877,0.9871	0.9864,0.8822	1.2450			0.34,0.42	0.65						n/a (AF>5%)	n/a (AF>5%)					RGS7 (inh=n/a pLI=1.00)
chr1	241520188	241520188	T	C	wt	hom	hom	off-target	QUAL=979;DP=0,16,17;AF=nan,1.00,1.00;MQM=60	RGS7	intron	RGS7:ENST00000366563:intron_variant:MODIFIER:exon1/17:c.-51+11A>G::,RGS7:ENST00000366564:intron_variant:MODIFIER:exon1/16:c.-51+11A>G::,RGS7:ENST00000366565:intron_variant:MODIFIER:exon1/17:c.-51+11A>G::					rs1891130	0.9485	0.9559	13806,			0.5930			0.00,0.25	1.40						n/a (AF>5%)	n/a (AF>5%)					RGS7 (inh=n/a pLI=1.00)
chr1	241663902	241663902	-	GAGAGAGAGA	wt	het	wt	off-target	QUAL=1278;DP=9,119,77;AF=0.00,0.58,0.42;MQM=59	FH	intron	FH:ENST00000366560:intron_variant:MODIFIER:exon8/9:c.1237-22_1237-13dup::	136850 [FH (confirmed) Fumarase deficiency,606812/Leiomyomatosis and renal cell cancer,150800];	296869 [uncertain significance DISEASE=Multiple cutaneous leiomyomas,Fumarase deficiency,Multiple Cutaneous and Uterine Leiomyomas];		(GA)n	rs144131869		0.0424	53,							-0.08						19	1					FH (inh=AR+AD pLI=0.76)
chr1	241663902	241663902	-	GAGAGA	wt	wt	het	off-target	QUAL=1278;DP=9,119,77;AF=0.00,0.58,0.42;MQM=60	FH	intron	FH:ENST00000366560:intron_variant:MODIFIER:exon8/9:c.1237-18_1237-13dup::	136850 [FH (confirmed) Fumarase deficiency,606812/Leiomyomatosis and renal cell cancer,150800];	296867 [uncertain significance DISEASE=Multiple cutaneous leiomyomas,Fumarase deficiency,Multiple Cutaneous and Uterine Leiomyomas];		(GA)n	rs144131869		0.2092	584,							-0.06						n/a (AF>5%)	n/a (AF>5%)					FH (inh=AR+AD pLI=0.76)
chr1	241663902	241663902	-	GAGA	wt	het	het	off-target	QUAL=1278;DP=9,119,77;AF=0.00,0.58,0.42;MQM=60	FH	intron	FH:ENST00000366560:intron_variant:MODIFIER:exon8/9:c.1237-16_1237-13dup::	136850 [FH (confirmed) Fumarase deficiency,606812/Leiomyomatosis and renal cell cancer,150800];	296866 [uncertain significance DISEASE=Multiple cutaneous leiomyomas,Fumarase deficiency,not specified,Multiple Cutaneous and Uterine Leiomyomas];		(GA)n	rs144131869		0.2505	814,							-0.05						n/a (AF>5%)	n/a (AF>5%)					FH (inh=AR+AD pLI=0.76)
chr1	247581560	247581560	A	T	het	het	wt		QUAL=12538;DP=501,469,357;AF=0.50,0.52,0.00;MQM=60	NLRP3	5'UTR	NLRP3:ENST00000336119:5_prime_UTR_variant:MODIFIER:exon1/9:c.-537A>T::,NLRP3:ENST00000348069:5_prime_UTR_variant:MODIFIER:exon1/7:c.-537A>T::,NLRP3:ENST00000366496:5_prime_UTR_variant:MODIFIER:exon1/8:c.-537A>T::,NLRP3:ENST00000366497:5_prime_UTR_variant:MODIFIER:exon2/9:c.-537A>T::,NLRP3:ENST00000391828:5_prime_UTR_variant:MODIFIER:exon2/11:c.-71A>T::	606416 [NLRP3 (confirmed) Familial cold inflammatory syndrome 1,120100/Muckle-Wells syndrome,191900/CINCA syndrome,607115/Deafness,autosomal dominant 34,with or without inflammation,617772/Keratoendothelitis fugax hereditaria,148200];	296927 [likely benign DISEASE=Familial amyloid nephropathy with urticaria AND deafness,Chronic infantile neurological, cutaneous and articular syndrome,Familial cold autoinflammatory syndrome];			rs116502550	0.0030	0.0111	6,			0.2450			0.03,0.10	-0.15						0	13					NLRP3 (inh=AD pLI=0.66)
chr1	247581692	247581692	T	C	hom	hom	hom		QUAL=17680;DP=264,169,161;AF=1.00,1.00,1.00;MQM=58	NLRP3	5'UTR,intron	NLRP3:ENST00000336119:5_prime_UTR_variant:MODIFIER:exon1/9:c.-405T>C::,NLRP3:ENST00000348069:5_prime_UTR_variant:MODIFIER:exon1/7:c.-405T>C::,NLRP3:ENST00000366496:5_prime_UTR_variant:MODIFIER:exon1/8:c.-405T>C::,NLRP3:ENST00000366497:5_prime_UTR_variant:MODIFIER:exon2/9:c.-405T>C::,NLRP3:ENST00000391828:intron_variant:MODIFIER:exon2/10:c.-39+100T>C::	606416 [NLRP3 (confirmed) Familial cold inflammatory syndrome 1,120100/Muckle-Wells syndrome,191900/CINCA syndrome,607115/Deafness,autosomal dominant 34,with or without inflammation,617772/Keratoendothelitis fugax hereditaria,148200];	296931 [benign DISEASE=Familial amyloid nephropathy with urticaria AND deafness,Chronic infantile neurological, cutaneous and articular syndrome,Familial cold autoinflammatory syndrome];		AluSx1	rs7523422	0.9978	0.9975	15356,			-2.9100			0.00,0.02	-0.29						n/a (AF>5%)	n/a (AF>5%)					NLRP3 (inh=AD pLI=0.66)
chr1	247581872	247581872	G	A	het	het	het		QUAL=5055;DP=217,85,68;AF=0.54,0.44,0.56;MQM=58	NLRP3	5'UTR,intron	NLRP3:ENST00000336119:5_prime_UTR_variant:MODIFIER:exon1/9:c.-225G>A::,NLRP3:ENST00000348069:5_prime_UTR_variant:MODIFIER:exon1/7:c.-225G>A::,NLRP3:ENST00000366496:5_prime_UTR_variant:MODIFIER:exon1/8:c.-225G>A::,NLRP3:ENST00000366497:5_prime_UTR_variant:MODIFIER:exon2/9:c.-225G>A::,NLRP3:ENST00000391828:intron_variant:MODIFIER:exon2/10:c.-38-187G>A::	606416 [NLRP3 (confirmed) Familial cold inflammatory syndrome 1,120100/Muckle-Wells syndrome,191900/CINCA syndrome,607115/Deafness,autosomal dominant 34,with or without inflammation,617772/Keratoendothelitis fugax hereditaria,148200];	296932 [likely benign DISEASE=Familial amyloid nephropathy with urticaria AND deafness,Chronic infantile neurological, cutaneous and articular syndrome,Familial cold autoinflammatory syndrome];		AluSx1	rs138900557	0.0158	0.0455	52,			0.3960			0.00,0.07	-0.06						1	28					NLRP3 (inh=AD pLI=0.66)
chr1	247582063	247582063	G	T	het	het	het		QUAL=9883;DP=331,287,231;AF=0.48,0.50,0.41;MQM=60	NLRP3	5'UTR	NLRP3:ENST00000336119:5_prime_UTR_variant:MODIFIER:exon1/9:c.-34G>T::,NLRP3:ENST00000348069:5_prime_UTR_variant:MODIFIER:exon1/7:c.-34G>T::,NLRP3:ENST00000366496:5_prime_UTR_variant:MODIFIER:exon1/8:c.-34G>T::,NLRP3:ENST00000366497:5_prime_UTR_variant:MODIFIER:exon2/9:c.-34G>T::,NLRP3:ENST00000391828:5_prime_UTR_variant:MODIFIER:exon3/11:c.-34G>T::	606416 [NLRP3 (confirmed) Familial cold inflammatory syndrome 1,120100/Muckle-Wells syndrome,191900/CINCA syndrome,607115/Deafness,autosomal dominant 34,with or without inflammation,617772/Keratoendothelitis fugax hereditaria,148200];	296937 [benign DISEASE=Familial amyloid nephropathy with urticaria AND deafness,Chronic infantile neurological, cutaneous and articular syndrome,Familial cold autoinflammatory syndrome];			rs73136263	0.0270	0.0553	60,	0.0361,0.0127,0.0009,0.0473,0.0218	0.0469,0.0320	0.0630			0.07,0.17	-0.05						n/a (AF>5%)	n/a (AF>5%)					NLRP3 (inh=AD pLI=0.66)
chr1	247587477	247587477	G	A	het	het	het		QUAL=6223;DP=162,191,152;AF=0.48,0.58,0.41;MQM=60	NLRP3	synonymous	NLRP3:ENST00000336119:synonymous_variant:LOW:exon3/9:c.732G>A:p.Ala244=:PF05729,NLRP3:ENST00000348069:synonymous_variant:LOW:exon3/7:c.732G>A:p.Ala244=:PF05729,NLRP3:ENST00000366496:synonymous_variant:LOW:exon3/8:c.732G>A:p.Ala244=:PF05729,NLRP3:ENST00000366497:synonymous_variant:LOW:exon4/9:c.732G>A:p.Ala244=:PF05729,NLRP3:ENST00000391827:synonymous_variant:LOW:exon3/8:c.732G>A:p.Ala244=:PF05729,NLRP3:ENST00000391828:synonymous_variant:LOW:exon5/11:c.732G>A:p.Ala244=:PF05729	606416 [NLRP3 (confirmed) Familial cold inflammatory syndrome 1,120100/Muckle-Wells syndrome,191900/CINCA syndrome,607115/Deafness,autosomal dominant 34,with or without inflammation,617772/Keratoendothelitis fugax hereditaria,148200];	138528 [benign DISEASE=Familial amyloid nephropathy with urticaria AND deafness,Chronic infantile neurological, cutaneous and articular syndrome,not specified,Familial cold autoinflammatory syndrome];			rs3806268	0.3874	0.5034	3521,	0.1002,0.4070,0.5336,0.5575,0.5454	0.5526,0.1198	-2.1770			0.01,0.10	-0.36						n/a (AF>5%)	n/a (AF>5%)					NLRP3 (inh=AD pLI=0.66)
chr1	247587531	247587531	A	G	hom	hom	hom		QUAL=14051;DP=154,163,118;AF=1.00,1.00,1.00;MQM=60	NLRP3	synonymous	NLRP3:ENST00000336119:synonymous_variant:LOW:exon3/9:c.786A>G:p.Arg262=:PF05729,NLRP3:ENST00000348069:synonymous_variant:LOW:exon3/7:c.786A>G:p.Arg262=:PF05729,NLRP3:ENST00000366496:synonymous_variant:LOW:exon3/8:c.786A>G:p.Arg262=:PF05729,NLRP3:ENST00000366497:synonymous_variant:LOW:exon4/9:c.786A>G:p.Arg262=:PF05729,NLRP3:ENST00000391827:synonymous_variant:LOW:exon3/8:c.786A>G:p.Arg262=:PF05729,NLRP3:ENST00000391828:synonymous_variant:LOW:exon5/11:c.786A>G:p.Arg262=:PF05729	606416 [NLRP3 (confirmed) Familial cold inflammatory syndrome 1,120100/Muckle-Wells syndrome,191900/CINCA syndrome,607115/Deafness,autosomal dominant 34,with or without inflammation,617772/Keratoendothelitis fugax hereditaria,148200];	403243 [benign DISEASE=not specified];			rs4925543		0.9462	13504,	0.8472,0.9714,0.9988,0.9579,0.8834	0.9536,0.8509	-0.1580			0.30,0.95	0.26						n/a (AF>5%)	n/a (AF>5%)					NLRP3 (inh=AD pLI=0.66)
chr1	247597349	247597349	G	A	het	het	het	off-target	QUAL=2340;DP=148,31,16;AF=0.63,0.19,0.19;MQM=57	NLRP3	intron	NLRP3:ENST00000336119:intron_variant:MODIFIER:exon4/8:c.2328-56G>A::,NLRP3:ENST00000348069:intron_variant:MODIFIER:exon3/6:c.2157-56G>A::,NLRP3:ENST00000366496:intron_variant:MODIFIER:exon4/7:c.2328-56G>A::,NLRP3:ENST00000366497:intron_variant:MODIFIER:exon5/8:c.2328-56G>A::,NLRP3:ENST00000391827:intron_variant:MODIFIER:exon3/7:c.2157-56G>A::,NLRP3:ENST00000391828:intron_variant:MODIFIER:exon6/10:c.2328-56G>A::	606416 [NLRP3 (confirmed) Familial cold inflammatory syndrome 1,120100/Muckle-Wells syndrome,191900/CINCA syndrome,607115/Deafness,autosomal dominant 34,with or without inflammation,617772/Keratoendothelitis fugax hereditaria,148200];				rs75241539		0.0112	3,			-0.1560			0.00,0.09	-0.46						57	105	2	[2] auto-classification 20.10.2017  			NLRP3 (inh=AD pLI=0.66)
chr1	247597365	247597365	G	ATGTGTTCTGAGGCCTTCTCTATTCCAGAGCTCTCTGGTCAGA	wt	het	het	off-target	QUAL=4549;DP=106,40,32;AF=0.00,0.40,0.25;MQM=59	NLRP3	intron	NLRP3:ENST00000336119:intron_variant:MODIFIER:exon4/8:c.2328-40delinsATGTGTTCTGAGGCCTTCTCTATTCCAGAGCTCTCTGGTCAGA::,NLRP3:ENST00000348069:intron_variant:MODIFIER:exon3/6:c.2157-40delinsATGTGTTCTGAGGCCTTCTCTATTCCAGAGCTCTCTGGTCAGA::,NLRP3:ENST00000366496:intron_variant:MODIFIER:exon4/7:c.2328-40delinsATGTGTTCTGAGGCCTTCTCTATTCCAGAGCTCTCTGGTCAGA::,NLRP3:ENST00000366497:intron_variant:MODIFIER:exon5/8:c.2328-40delinsATGTGTTCTGAGGCCTTCTCTATTCCAGAGCTCTCTGGTCAGA::,NLRP3:ENST00000391827:intron_variant:MODIFIER:exon3/7:c.2157-40delinsATGTGTTCTGAGGCCTTCTCTATTCCAGAGCTCTCTGGTCAGA::,NLRP3:ENST00000391828:intron_variant:MODIFIER:exon6/10:c.2328-40delinsATGTGTTCTGAGGCCTTCTCTATTCCAGAGCTCTCTGGTCAGA::	606416 [NLRP3 (confirmed) Familial cold inflammatory syndrome 1,120100/Muckle-Wells syndrome,191900/CINCA syndrome,607115/Deafness,autosomal dominant 34,with or without inflammation,617772/Keratoendothelitis fugax hereditaria,148200];										-2.1850										0	0					NLRP3 (inh=AD pLI=0.66)
chr1	247597365	247597365	G	A	hom	het	het	off-target	QUAL=4549;DP=106,40,32;AF=0.97,0.58,0.75;MQM=56	NLRP3	intron	NLRP3:ENST00000336119:intron_variant:MODIFIER:exon4/8:c.2328-40G>A::,NLRP3:ENST00000348069:intron_variant:MODIFIER:exon3/6:c.2157-40G>A::,NLRP3:ENST00000366496:intron_variant:MODIFIER:exon4/7:c.2328-40G>A::,NLRP3:ENST00000366497:intron_variant:MODIFIER:exon5/8:c.2328-40G>A::,NLRP3:ENST00000391827:intron_variant:MODIFIER:exon3/7:c.2157-40G>A::,NLRP3:ENST00000391828:intron_variant:MODIFIER:exon6/10:c.2328-40G>A::	606416 [NLRP3 (confirmed) Familial cold inflammatory syndrome 1,120100/Muckle-Wells syndrome,191900/CINCA syndrome,607115/Deafness,autosomal dominant 34,with or without inflammation,617772/Keratoendothelitis fugax hereditaria,148200];				rs10925022	0.8902	0.3134	2190,		0.9493,0.8257	-2.1850			0.00,0.06	-0.38						n/a (AF>5%)	n/a (AF>5%)					NLRP3 (inh=AD pLI=0.66)
chr1	247599232	247599232	G	A	het	het	het	off-target	QUAL=1387;DP=47,64,39;AF=0.49,0.52,0.41;MQM=60	NLRP3	intron	NLRP3:ENST00000336119:intron_variant:MODIFIER:exon5/8:c.2499-40G>A::,NLRP3:ENST00000348069:intron_variant:MODIFIER:exon4/6:c.2327+1657G>A::,NLRP3:ENST00000366496:intron_variant:MODIFIER:exon5/7:c.2498+1657G>A::,NLRP3:ENST00000366497:intron_variant:MODIFIER:exon6/8:c.2498+1657G>A::,NLRP3:ENST00000391827:intron_variant:MODIFIER:exon4/7:c.2328-40G>A::,NLRP3:ENST00000391828:intron_variant:MODIFIER:exon7/10:c.2499-40G>A::	606416 [NLRP3 (confirmed) Familial cold inflammatory syndrome 1,120100/Muckle-Wells syndrome,191900/CINCA syndrome,607115/Deafness,autosomal dominant 34,with or without inflammation,617772/Keratoendothelitis fugax hereditaria,148200];				rs10754557	0.4840	0.5922	4810,	0.2379,0.4929,0.6712,0.6209,0.6050	0.6253,0.2460	-0.8120			0.04,0.17	-0.01						n/a (AF>5%)	n/a (AF>5%)					NLRP3 (inh=AD pLI=0.66)
chr1	247611660	247611661	AG	-	het	wt	het	off-target	QUAL=2199;DP=186,77,39;AF=0.46,0.00,0.54;MQM=60	NLRP3	intron	NLRP3:ENST00000336119:intron_variant:MODIFIER:exon8/8:c.3012-45_3012-44del::,NLRP3:ENST00000348069:intron_variant:MODIFIER:exon6/6:c.2670-45_2670-44del::,NLRP3:ENST00000366496:intron_variant:MODIFIER:exon7/7:c.2841-45_2841-44del::,NLRP3:ENST00000366497:intron_variant:MODIFIER:exon8/8:c.2841-45_2841-44del::,NLRP3:ENST00000391827:intron_variant:MODIFIER:exon7/7:c.2841-45_2841-44del::,NLRP3:ENST00000391828:intron_variant:MODIFIER:exon10/10:c.3012-45_3012-44del::	606416 [NLRP3 (confirmed) Familial cold inflammatory syndrome 1,120100/Muckle-Wells syndrome,191900/CINCA syndrome,607115/Deafness,autosomal dominant 34,with or without inflammation,617772/Keratoendothelitis fugax hereditaria,148200];				rs201053423	0.0485	0.0496	31,	0.0095,0.0262,0.0350,0.0562,0.0965	0.0553,0.0124	-0.3230				0.01						0	0					NLRP3 (inh=AD pLI=0.66)
chr1	247612036	247612036	G	C	hom	hom	hom		QUAL=49973;DP=693,504,384;AF=1.00,1.00,1.00;MQM=60	NLRP3	3'UTR	NLRP3:ENST00000336119:3_prime_UTR_variant:MODIFIER:exon9/9:c.*230G>C::,NLRP3:ENST00000348069:3_prime_UTR_variant:MODIFIER:exon7/7:c.*230G>C::,NLRP3:ENST00000366496:3_prime_UTR_variant:MODIFIER:exon8/8:c.*230G>C::,NLRP3:ENST00000366497:3_prime_UTR_variant:MODIFIER:exon9/9:c.*230G>C::,NLRP3:ENST00000391828:3_prime_UTR_variant:MODIFIER:exon11/11:c.*230G>C::	606416 [NLRP3 (confirmed) Familial cold inflammatory syndrome 1,120100/Muckle-Wells syndrome,191900/CINCA syndrome,607115/Deafness,autosomal dominant 34,with or without inflammation,617772/Keratoendothelitis fugax hereditaria,148200];	296956 [benign DISEASE=Familial amyloid nephropathy with urticaria AND deafness,Chronic infantile neurological, cutaneous and articular syndrome,Familial cold autoinflammatory syndrome];			rs10754558		0.6328	6295,			0.1530			0.00,0.09	0.17						n/a (AF>5%)	n/a (AF>5%)					NLRP3 (inh=AD pLI=0.66)
chr1	247612435	247612435	A	T	hom	hom	hom	off-target	QUAL=1322;DP=38,1,3;AF=1.00,1.00,1.00;MQM=60	OR2B11,NLRP3	downstream_gene	OR2B11:ENST00000318749:downstream_gene_variant:MODIFIER::::,NLRP3:ENST00000336119:downstream_gene_variant:MODIFIER::::,NLRP3:ENST00000348069:downstream_gene_variant:MODIFIER::::,NLRP3:ENST00000366496:downstream_gene_variant:MODIFIER::::,NLRP3:ENST00000366497:downstream_gene_variant:MODIFIER::::,NLRP3:ENST00000391827:downstream_gene_variant:MODIFIER::::,NLRP3:ENST00000391828:downstream_gene_variant:MODIFIER::::					rs4925547	0.4157	0.3575	2083,			2.0950			0.82,0.94	0.98						n/a (AF>5%)	n/a (AF>5%)					OR2B11 (inh=n/a pLI=0.02), NLRP3 (inh=AD pLI=0.66)
chrMT	72	72	T	C	hom	wt	hom		QUAL=256031;DP=4368,4589,4383;AF=0.99,0.00,0.99;MQM=54	MT-ND1,MT-ND2,MT-TL1,MT-TF,MT-TV,MT-RNR2,MT-TI,MT-TQ,MT-TM,MT-RNR1	upstream_gene,downstream_gene	MT-ND1:ENST00000361390:upstream_gene_variant:MODIFIER::::,MT-ND2:ENST00000361453:upstream_gene_variant:MODIFIER::::,MT-TL1:ENST00000386347:upstream_gene_variant:MODIFIER::::,MT-TF:ENST00000387314:upstream_gene_variant:MODIFIER::::,MT-TV:ENST00000387342:upstream_gene_variant:MODIFIER::::,MT-RNR2:ENST00000387347:upstream_gene_variant:MODIFIER::::,MT-TI:ENST00000387365:upstream_gene_variant:MODIFIER::::,MT-TQ:ENST00000387372:downstream_gene_variant:MODIFIER::::,MT-TM:ENST00000387377:upstream_gene_variant:MODIFIER::::,MT-RNR1:ENST00000389680:upstream_gene_variant:MODIFIER::::					rs879158303																112	9					MT-ND1 (inh=MT pLI=n/a), MT-ND2 (inh=MT pLI=n/a), MT-TL1 (inh=MT pLI=n/a), MT-TF (inh=MT pLI=n/a), MT-TV (inh=MT pLI=n/a), MT-RNR2 (inh=MT pLI=n/a), MT-TI (inh=MT pLI=n/a), MT-TQ (inh=MT pLI=n/a), MT-TM (inh=MT pLI=n/a), MT-RNR1 (inh=MT pLI=n/a)
chrMT	73	73	A	G	wt	hom	wt		QUAL=123645;DP=4330,4680,4424;AF=0.01,1.00,0.00;MQM=50	MT-ND1,MT-ND2,MT-TL1,MT-TF,MT-TV,MT-RNR2,MT-TI,MT-TQ,MT-TM,MT-RNR1	upstream_gene,downstream_gene	MT-ND1:ENST00000361390:upstream_gene_variant:MODIFIER::::,MT-ND2:ENST00000361453:upstream_gene_variant:MODIFIER::::,MT-TL1:ENST00000386347:upstream_gene_variant:MODIFIER::::,MT-TF:ENST00000387314:upstream_gene_variant:MODIFIER::::,MT-TV:ENST00000387342:upstream_gene_variant:MODIFIER::::,MT-RNR2:ENST00000387347:upstream_gene_variant:MODIFIER::::,MT-TI:ENST00000387365:upstream_gene_variant:MODIFIER::::,MT-TQ:ENST00000387372:downstream_gene_variant:MODIFIER::::,MT-TM:ENST00000387377:upstream_gene_variant:MODIFIER::::,MT-RNR1:ENST00000389680:upstream_gene_variant:MODIFIER::::					rs869183622																2232	66					MT-ND1 (inh=MT pLI=n/a), MT-ND2 (inh=MT pLI=n/a), MT-TL1 (inh=MT pLI=n/a), MT-TF (inh=MT pLI=n/a), MT-TV (inh=MT pLI=n/a), MT-RNR2 (inh=MT pLI=n/a), MT-TI (inh=MT pLI=n/a), MT-TQ (inh=MT pLI=n/a), MT-TM (inh=MT pLI=n/a), MT-RNR1 (inh=MT pLI=n/a)
chrMT	150	150	C	T	wt	hom	wt		QUAL=131582;DP=4152,4001,3296;AF=0.00,0.99,0.00;MQM=59	MT-ND1,MT-ND2,MT-TL1,MT-TF,MT-TV,MT-RNR2,MT-TI,MT-TQ,MT-TM,MT-RNR1	upstream_gene,downstream_gene	MT-ND1:ENST00000361390:upstream_gene_variant:MODIFIER::::,MT-ND2:ENST00000361453:upstream_gene_variant:MODIFIER::::,MT-TL1:ENST00000386347:upstream_gene_variant:MODIFIER::::,MT-TF:ENST00000387314:upstream_gene_variant:MODIFIER::::,MT-TV:ENST00000387342:upstream_gene_variant:MODIFIER::::,MT-RNR2:ENST00000387347:upstream_gene_variant:MODIFIER::::,MT-TI:ENST00000387365:upstream_gene_variant:MODIFIER::::,MT-TQ:ENST00000387372:downstream_gene_variant:MODIFIER::::,MT-TM:ENST00000387377:upstream_gene_variant:MODIFIER::::,MT-RNR1:ENST00000389680:upstream_gene_variant:MODIFIER::::					rs62581312																370	28					MT-ND1 (inh=MT pLI=n/a), MT-ND2 (inh=MT pLI=n/a), MT-TL1 (inh=MT pLI=n/a), MT-TF (inh=MT pLI=n/a), MT-TV (inh=MT pLI=n/a), MT-RNR2 (inh=MT pLI=n/a), MT-TI (inh=MT pLI=n/a), MT-TQ (inh=MT pLI=n/a), MT-TM (inh=MT pLI=n/a), MT-RNR1 (inh=MT pLI=n/a)
chrMT	152	152	T	C	wt	hom	wt		QUAL=131582;DP=4152,4001,3296;AF=0.00,0.99,0.00;MQM=59	MT-ND1,MT-ND2,MT-TL1,MT-TF,MT-TV,MT-RNR2,MT-TI,MT-TQ,MT-TM,MT-RNR1	upstream_gene,downstream_gene	MT-ND1:ENST00000361390:upstream_gene_variant:MODIFIER::::,MT-ND2:ENST00000361453:upstream_gene_variant:MODIFIER::::,MT-TL1:ENST00000386347:upstream_gene_variant:MODIFIER::::,MT-TF:ENST00000387314:upstream_gene_variant:MODIFIER::::,MT-TV:ENST00000387342:upstream_gene_variant:MODIFIER::::,MT-RNR2:ENST00000387347:upstream_gene_variant:MODIFIER::::,MT-TI:ENST00000387365:upstream_gene_variant:MODIFIER::::,MT-TQ:ENST00000387372:downstream_gene_variant:MODIFIER::::,MT-TM:ENST00000387377:upstream_gene_variant:MODIFIER::::,MT-RNR1:ENST00000389680:upstream_gene_variant:MODIFIER::::					rs117135796																831	64					MT-ND1 (inh=MT pLI=n/a), MT-ND2 (inh=MT pLI=n/a), MT-TL1 (inh=MT pLI=n/a), MT-TF (inh=MT pLI=n/a), MT-TV (inh=MT pLI=n/a), MT-RNR2 (inh=MT pLI=n/a), MT-TI (inh=MT pLI=n/a), MT-TQ (inh=MT pLI=n/a), MT-TM (inh=MT pLI=n/a), MT-RNR1 (inh=MT pLI=n/a)
chrMT	195	195	T	C	wt	hom	wt		QUAL=107961;DP=3721,3383,2441;AF=0.00,1.00,0.00;MQM=59	MT-ND1,MT-ND2,MT-TL1,MT-TF,MT-TV,MT-RNR2,MT-TI,MT-TQ,MT-TM,MT-RNR1	upstream_gene,downstream_gene	MT-ND1:ENST00000361390:upstream_gene_variant:MODIFIER::::,MT-ND2:ENST00000361453:upstream_gene_variant:MODIFIER::::,MT-TL1:ENST00000386347:upstream_gene_variant:MODIFIER::::,MT-TF:ENST00000387314:upstream_gene_variant:MODIFIER::::,MT-TV:ENST00000387342:upstream_gene_variant:MODIFIER::::,MT-RNR2:ENST00000387347:upstream_gene_variant:MODIFIER::::,MT-TI:ENST00000387365:upstream_gene_variant:MODIFIER::::,MT-TQ:ENST00000387372:downstream_gene_variant:MODIFIER::::,MT-TM:ENST00000387377:upstream_gene_variant:MODIFIER::::,MT-RNR1:ENST00000389680:upstream_gene_variant:MODIFIER::::					rs2857291																742	57					MT-ND1 (inh=MT pLI=n/a), MT-ND2 (inh=MT pLI=n/a), MT-TL1 (inh=MT pLI=n/a), MT-TF (inh=MT pLI=n/a), MT-TV (inh=MT pLI=n/a), MT-RNR2 (inh=MT pLI=n/a), MT-TI (inh=MT pLI=n/a), MT-TQ (inh=MT pLI=n/a), MT-TM (inh=MT pLI=n/a), MT-RNR1 (inh=MT pLI=n/a)
chrMT	215	215	A	G	wt	hom	wt		QUAL=100135;DP=3350,3150,2044;AF=0.00,0.99,0.00;MQM=59	MT-ND1,MT-ND2,MT-TL1,MT-TF,MT-TV,MT-RNR2,MT-TI,MT-TQ,MT-TM,MT-RNR1	upstream_gene,downstream_gene	MT-ND1:ENST00000361390:upstream_gene_variant:MODIFIER::::,MT-ND2:ENST00000361453:upstream_gene_variant:MODIFIER::::,MT-TL1:ENST00000386347:upstream_gene_variant:MODIFIER::::,MT-TF:ENST00000387314:upstream_gene_variant:MODIFIER::::,MT-TV:ENST00000387342:upstream_gene_variant:MODIFIER::::,MT-RNR2:ENST00000387347:upstream_gene_variant:MODIFIER::::,MT-TI:ENST00000387365:upstream_gene_variant:MODIFIER::::,MT-TQ:ENST00000387372:downstream_gene_variant:MODIFIER::::,MT-TM:ENST00000387377:upstream_gene_variant:MODIFIER::::,MT-RNR1:ENST00000389680:upstream_gene_variant:MODIFIER::::					rs879219259																51	7					MT-ND1 (inh=MT pLI=n/a), MT-ND2 (inh=MT pLI=n/a), MT-TL1 (inh=MT pLI=n/a), MT-TF (inh=MT pLI=n/a), MT-TV (inh=MT pLI=n/a), MT-RNR2 (inh=MT pLI=n/a), MT-TI (inh=MT pLI=n/a), MT-TQ (inh=MT pLI=n/a), MT-TM (inh=MT pLI=n/a), MT-RNR1 (inh=MT pLI=n/a)
chrMT	263	263	A	G	hom	hom	hom		QUAL=194828;DP=2678,2353,1163;AF=1.00,1.00,1.00;MQM=59	MT-ND1,MT-ND2,MT-TL1,MT-TF,MT-TV,MT-RNR2,MT-TI,MT-TQ,MT-TM,MT-RNR1	upstream_gene,downstream_gene	MT-ND1:ENST00000361390:upstream_gene_variant:MODIFIER::::,MT-ND2:ENST00000361453:upstream_gene_variant:MODIFIER::::,MT-TL1:ENST00000386347:upstream_gene_variant:MODIFIER::::,MT-TF:ENST00000387314:upstream_gene_variant:MODIFIER::::,MT-TV:ENST00000387342:upstream_gene_variant:MODIFIER::::,MT-RNR2:ENST00000387347:upstream_gene_variant:MODIFIER::::,MT-TI:ENST00000387365:upstream_gene_variant:MODIFIER::::,MT-TQ:ENST00000387372:downstream_gene_variant:MODIFIER::::,MT-TM:ENST00000387377:upstream_gene_variant:MODIFIER::::,MT-RNR1:ENST00000389680:upstream_gene_variant:MODIFIER::::		441147 [not provided DISEASE=not provided];			rs2853515																3849	4					MT-ND1 (inh=MT pLI=n/a), MT-ND2 (inh=MT pLI=n/a), MT-TL1 (inh=MT pLI=n/a), MT-TF (inh=MT pLI=n/a), MT-TV (inh=MT pLI=n/a), MT-RNR2 (inh=MT pLI=n/a), MT-TI (inh=MT pLI=n/a), MT-TQ (inh=MT pLI=n/a), MT-TM (inh=MT pLI=n/a), MT-RNR1 (inh=MT pLI=n/a)
chrMT	295	295	C	T	wt	hom	wt		QUAL=56639;DP=2169,1909,784;AF=0.00,0.99,0.00;MQM=59	MT-ND1,MT-ND2,MT-TL1,MT-TF,MT-TV,MT-RNR2,MT-TI,MT-TQ,MT-TM,MT-RNR1	upstream_gene,downstream_gene	MT-ND1:ENST00000361390:upstream_gene_variant:MODIFIER::::,MT-ND2:ENST00000361453:upstream_gene_variant:MODIFIER::::,MT-TL1:ENST00000386347:upstream_gene_variant:MODIFIER::::,MT-TF:ENST00000387314:upstream_gene_variant:MODIFIER::::,MT-TV:ENST00000387342:upstream_gene_variant:MODIFIER::::,MT-RNR2:ENST00000387347:upstream_gene_variant:MODIFIER::::,MT-TI:ENST00000387365:upstream_gene_variant:MODIFIER::::,MT-TQ:ENST00000387372:downstream_gene_variant:MODIFIER::::,MT-TM:ENST00000387377:upstream_gene_variant:MODIFIER::::,MT-RNR1:ENST00000389680:upstream_gene_variant:MODIFIER::::					rs41528348																327	14					MT-ND1 (inh=MT pLI=n/a), MT-ND2 (inh=MT pLI=n/a), MT-TL1 (inh=MT pLI=n/a), MT-TF (inh=MT pLI=n/a), MT-TV (inh=MT pLI=n/a), MT-RNR2 (inh=MT pLI=n/a), MT-TI (inh=MT pLI=n/a), MT-TQ (inh=MT pLI=n/a), MT-TM (inh=MT pLI=n/a), MT-RNR1 (inh=MT pLI=n/a)
chrMT	302	302	A	CCC	wt	wt	wt		QUAL=44546;DP=745,1305,308;AF=0.06,0.97,0.15;MQM=58	MT-ND1,MT-ND2,MT-TL1,MT-TF,MT-TV,MT-RNR2,MT-TI,MT-TQ,MT-TM,MT-RNR1	upstream_gene,downstream_gene	MT-ND1:ENST00000361390:upstream_gene_variant:MODIFIER::::,MT-ND2:ENST00000361453:upstream_gene_variant:MODIFIER::::,MT-TL1:ENST00000386347:upstream_gene_variant:MODIFIER::::,MT-TF:ENST00000387314:upstream_gene_variant:MODIFIER::::,MT-TV:ENST00000387342:upstream_gene_variant:MODIFIER::::,MT-RNR2:ENST00000387347:upstream_gene_variant:MODIFIER::::,MT-TI:ENST00000387365:upstream_gene_variant:MODIFIER::::,MT-TQ:ENST00000387372:downstream_gene_variant:MODIFIER::::,MT-TM:ENST00000387377:upstream_gene_variant:MODIFIER::::,MT-RNR1:ENST00000389680:upstream_gene_variant:MODIFIER::::																					1	0					MT-ND1 (inh=MT pLI=n/a), MT-ND2 (inh=MT pLI=n/a), MT-TL1 (inh=MT pLI=n/a), MT-TF (inh=MT pLI=n/a), MT-TV (inh=MT pLI=n/a), MT-RNR2 (inh=MT pLI=n/a), MT-TI (inh=MT pLI=n/a), MT-TQ (inh=MT pLI=n/a), MT-TM (inh=MT pLI=n/a), MT-RNR1 (inh=MT pLI=n/a)
chrMT	302	302	A	C	wt	wt	wt		QUAL=44546;DP=745,1305,308;AF=0.78,0.96,0.90;MQM=49	MT-ND1,MT-ND2,MT-TL1,MT-TF,MT-TV,MT-RNR2,MT-TI,MT-TQ,MT-TM,MT-RNR1	upstream_gene,downstream_gene	MT-ND1:ENST00000361390:upstream_gene_variant:MODIFIER::::,MT-ND2:ENST00000361453:upstream_gene_variant:MODIFIER::::,MT-TL1:ENST00000386347:upstream_gene_variant:MODIFIER::::,MT-TF:ENST00000387314:upstream_gene_variant:MODIFIER::::,MT-TV:ENST00000387342:upstream_gene_variant:MODIFIER::::,MT-RNR2:ENST00000387347:upstream_gene_variant:MODIFIER::::,MT-TI:ENST00000387365:upstream_gene_variant:MODIFIER::::,MT-TQ:ENST00000387372:downstream_gene_variant:MODIFIER::::,MT-TM:ENST00000387377:upstream_gene_variant:MODIFIER::::,MT-RNR1:ENST00000389680:upstream_gene_variant:MODIFIER::::					rs879048927																0	2					MT-ND1 (inh=MT pLI=n/a), MT-ND2 (inh=MT pLI=n/a), MT-TL1 (inh=MT pLI=n/a), MT-TF (inh=MT pLI=n/a), MT-TV (inh=MT pLI=n/a), MT-RNR2 (inh=MT pLI=n/a), MT-TI (inh=MT pLI=n/a), MT-TQ (inh=MT pLI=n/a), MT-TM (inh=MT pLI=n/a), MT-RNR1 (inh=MT pLI=n/a)
chrMT	302	302	-	CCCC	wt	wt	wt		QUAL=44546;DP=745,1305,308;AF=0.11,0.96,0.21;MQM=56	MT-ND1,MT-ND2,MT-TL1,MT-TF,MT-TV,MT-RNR2,MT-TI,MT-TQ,MT-TM,MT-RNR1	upstream_gene,downstream_gene	MT-ND1:ENST00000361390:upstream_gene_variant:MODIFIER::::,MT-ND2:ENST00000361453:upstream_gene_variant:MODIFIER::::,MT-TL1:ENST00000386347:upstream_gene_variant:MODIFIER::::,MT-TF:ENST00000387314:upstream_gene_variant:MODIFIER::::,MT-TV:ENST00000387342:upstream_gene_variant:MODIFIER::::,MT-RNR2:ENST00000387347:upstream_gene_variant:MODIFIER::::,MT-TI:ENST00000387365:upstream_gene_variant:MODIFIER::::,MT-TQ:ENST00000387372:downstream_gene_variant:MODIFIER::::,MT-TM:ENST00000387377:upstream_gene_variant:MODIFIER::::,MT-RNR1:ENST00000389680:upstream_gene_variant:MODIFIER::::																					0	1					MT-ND1 (inh=MT pLI=n/a), MT-ND2 (inh=MT pLI=n/a), MT-TL1 (inh=MT pLI=n/a), MT-TF (inh=MT pLI=n/a), MT-TV (inh=MT pLI=n/a), MT-RNR2 (inh=MT pLI=n/a), MT-TI (inh=MT pLI=n/a), MT-TQ (inh=MT pLI=n/a), MT-TM (inh=MT pLI=n/a), MT-RNR1 (inh=MT pLI=n/a)
chrMT	302	302	-	CCC	wt	wt	wt		QUAL=44546;DP=745,1305,308;AF=0.12,0.96,0.17;MQM=58	MT-ND1,MT-ND2,MT-TL1,MT-TF,MT-TV,MT-RNR2,MT-TI,MT-TQ,MT-TM,MT-RNR1	upstream_gene,downstream_gene	MT-ND1:ENST00000361390:upstream_gene_variant:MODIFIER::::,MT-ND2:ENST00000361453:upstream_gene_variant:MODIFIER::::,MT-TL1:ENST00000386347:upstream_gene_variant:MODIFIER::::,MT-TF:ENST00000387314:upstream_gene_variant:MODIFIER::::,MT-TV:ENST00000387342:upstream_gene_variant:MODIFIER::::,MT-RNR2:ENST00000387347:upstream_gene_variant:MODIFIER::::,MT-TI:ENST00000387365:upstream_gene_variant:MODIFIER::::,MT-TQ:ENST00000387372:downstream_gene_variant:MODIFIER::::,MT-TM:ENST00000387377:upstream_gene_variant:MODIFIER::::,MT-RNR1:ENST00000389680:upstream_gene_variant:MODIFIER::::																					6	41					MT-ND1 (inh=MT pLI=n/a), MT-ND2 (inh=MT pLI=n/a), MT-TL1 (inh=MT pLI=n/a), MT-TF (inh=MT pLI=n/a), MT-TV (inh=MT pLI=n/a), MT-RNR2 (inh=MT pLI=n/a), MT-TI (inh=MT pLI=n/a), MT-TQ (inh=MT pLI=n/a), MT-TM (inh=MT pLI=n/a), MT-RNR1 (inh=MT pLI=n/a)
chrMT	302	302	-	CC	hom	wt	hom		QUAL=44546;DP=745,1305,308;AF=0.07,0.96,0.15;MQM=59	MT-ND1,MT-ND2,MT-TL1,MT-TF,MT-TV,MT-RNR2,MT-TI,MT-TQ,MT-TM,MT-RNR1	upstream_gene,downstream_gene	MT-ND1:ENST00000361390:upstream_gene_variant:MODIFIER::::,MT-ND2:ENST00000361453:upstream_gene_variant:MODIFIER::::,MT-TL1:ENST00000386347:upstream_gene_variant:MODIFIER::::,MT-TF:ENST00000387314:upstream_gene_variant:MODIFIER::::,MT-TV:ENST00000387342:upstream_gene_variant:MODIFIER::::,MT-RNR2:ENST00000387347:upstream_gene_variant:MODIFIER::::,MT-TI:ENST00000387365:upstream_gene_variant:MODIFIER::::,MT-TQ:ENST00000387372:downstream_gene_variant:MODIFIER::::,MT-TM:ENST00000387377:upstream_gene_variant:MODIFIER::::,MT-RNR1:ENST00000389680:upstream_gene_variant:MODIFIER::::																					137	310					MT-ND1 (inh=MT pLI=n/a), MT-ND2 (inh=MT pLI=n/a), MT-TL1 (inh=MT pLI=n/a), MT-TF (inh=MT pLI=n/a), MT-TV (inh=MT pLI=n/a), MT-RNR2 (inh=MT pLI=n/a), MT-TI (inh=MT pLI=n/a), MT-TQ (inh=MT pLI=n/a), MT-TM (inh=MT pLI=n/a), MT-RNR1 (inh=MT pLI=n/a)
chrMT	302	302	-	C	wt	wt	wt		QUAL=44546;DP=745,1305,308;AF=0.07,0.96,0.16;MQM=59	MT-ND1,MT-ND2,MT-TL1,MT-TF,MT-TV,MT-RNR2,MT-TI,MT-TQ,MT-TM,MT-RNR1	upstream_gene,downstream_gene	MT-ND1:ENST00000361390:upstream_gene_variant:MODIFIER::::,MT-ND2:ENST00000361453:upstream_gene_variant:MODIFIER::::,MT-TL1:ENST00000386347:upstream_gene_variant:MODIFIER::::,MT-TF:ENST00000387314:upstream_gene_variant:MODIFIER::::,MT-TV:ENST00000387342:upstream_gene_variant:MODIFIER::::,MT-RNR2:ENST00000387347:upstream_gene_variant:MODIFIER::::,MT-TI:ENST00000387365:upstream_gene_variant:MODIFIER::::,MT-TQ:ENST00000387372:downstream_gene_variant:MODIFIER::::,MT-TM:ENST00000387377:upstream_gene_variant:MODIFIER::::,MT-RNR1:ENST00000389680:upstream_gene_variant:MODIFIER::::					rs878871521																527	785					MT-ND1 (inh=MT pLI=n/a), MT-ND2 (inh=MT pLI=n/a), MT-TL1 (inh=MT pLI=n/a), MT-TF (inh=MT pLI=n/a), MT-TV (inh=MT pLI=n/a), MT-RNR2 (inh=MT pLI=n/a), MT-TI (inh=MT pLI=n/a), MT-TQ (inh=MT pLI=n/a), MT-TM (inh=MT pLI=n/a), MT-RNR1 (inh=MT pLI=n/a)
chrMT	309	309	-	CT	wt	wt	wt		QUAL=44546;DP=745,1305,308;AF=0.91,0.97,0.98;MQM=60	MT-ND1,MT-ND2,MT-TL1,MT-TF,MT-TV,MT-RNR2,MT-TI,MT-TQ,MT-TM,MT-RNR1	upstream_gene,downstream_gene	MT-ND1:ENST00000361390:upstream_gene_variant:MODIFIER::::,MT-ND2:ENST00000361453:upstream_gene_variant:MODIFIER::::,MT-TL1:ENST00000386347:upstream_gene_variant:MODIFIER::::,MT-TF:ENST00000387314:upstream_gene_variant:MODIFIER::::,MT-TV:ENST00000387342:upstream_gene_variant:MODIFIER::::,MT-RNR2:ENST00000387347:upstream_gene_variant:MODIFIER::::,MT-TI:ENST00000387365:upstream_gene_variant:MODIFIER::::,MT-TQ:ENST00000387372:downstream_gene_variant:MODIFIER::::,MT-TM:ENST00000387377:upstream_gene_variant:MODIFIER::::,MT-RNR1:ENST00000389680:upstream_gene_variant:MODIFIER::::																					1	1					MT-ND1 (inh=MT pLI=n/a), MT-ND2 (inh=MT pLI=n/a), MT-TL1 (inh=MT pLI=n/a), MT-TF (inh=MT pLI=n/a), MT-TV (inh=MT pLI=n/a), MT-RNR2 (inh=MT pLI=n/a), MT-TI (inh=MT pLI=n/a), MT-TQ (inh=MT pLI=n/a), MT-TM (inh=MT pLI=n/a), MT-RNR1 (inh=MT pLI=n/a)
chrMT	310	310	-	TC	wt	hom	wt		QUAL=44546;DP=745,1305,308;AF=0.89,0.97,0.97;MQM=59	MT-ND1,MT-ND2,MT-TL1,MT-TF,MT-TV,MT-RNR2,MT-TI,MT-TQ,MT-TM,MT-RNR1	upstream_gene,downstream_gene	MT-ND1:ENST00000361390:upstream_gene_variant:MODIFIER::::,MT-ND2:ENST00000361453:upstream_gene_variant:MODIFIER::::,MT-TL1:ENST00000386347:upstream_gene_variant:MODIFIER::::,MT-TF:ENST00000387314:upstream_gene_variant:MODIFIER::::,MT-TV:ENST00000387342:upstream_gene_variant:MODIFIER::::,MT-RNR2:ENST00000387347:upstream_gene_variant:MODIFIER::::,MT-TI:ENST00000387365:upstream_gene_variant:MODIFIER::::,MT-TQ:ENST00000387372:downstream_gene_variant:MODIFIER::::,MT-TM:ENST00000387377:upstream_gene_variant:MODIFIER::::,MT-RNR1:ENST00000389680:upstream_gene_variant:MODIFIER::::																					30	6					MT-ND1 (inh=MT pLI=n/a), MT-ND2 (inh=MT pLI=n/a), MT-TL1 (inh=MT pLI=n/a), MT-TF (inh=MT pLI=n/a), MT-TV (inh=MT pLI=n/a), MT-RNR2 (inh=MT pLI=n/a), MT-TI (inh=MT pLI=n/a), MT-TQ (inh=MT pLI=n/a), MT-TM (inh=MT pLI=n/a), MT-RNR1 (inh=MT pLI=n/a)
chrMT	310	310	-	C	hom	wt	hom		QUAL=44546;DP=745,1305,308;AF=0.84,0.97,0.95;MQM=59	MT-ND1,MT-ND2,MT-TL1,MT-TF,MT-TV,MT-RNR2,MT-TI,MT-TQ,MT-TM,MT-RNR1	upstream_gene,downstream_gene	MT-ND1:ENST00000361390:upstream_gene_variant:MODIFIER::::,MT-ND2:ENST00000361453:upstream_gene_variant:MODIFIER::::,MT-TL1:ENST00000386347:upstream_gene_variant:MODIFIER::::,MT-TF:ENST00000387314:upstream_gene_variant:MODIFIER::::,MT-TV:ENST00000387342:upstream_gene_variant:MODIFIER::::,MT-RNR2:ENST00000387347:upstream_gene_variant:MODIFIER::::,MT-TI:ENST00000387365:upstream_gene_variant:MODIFIER::::,MT-TQ:ENST00000387372:downstream_gene_variant:MODIFIER::::,MT-TM:ENST00000387377:upstream_gene_variant:MODIFIER::::,MT-RNR1:ENST00000389680:upstream_gene_variant:MODIFIER::::					rs369786048																1587	1753					MT-ND1 (inh=MT pLI=n/a), MT-ND2 (inh=MT pLI=n/a), MT-TL1 (inh=MT pLI=n/a), MT-TF (inh=MT pLI=n/a), MT-TV (inh=MT pLI=n/a), MT-RNR2 (inh=MT pLI=n/a), MT-TI (inh=MT pLI=n/a), MT-TQ (inh=MT pLI=n/a), MT-TM (inh=MT pLI=n/a), MT-RNR1 (inh=MT pLI=n/a)
chrMT	310	310	T	C	wt	wt	wt		QUAL=44546;DP=745,1305,308;AF=0.84,0.97,0.96;MQM=49	MT-ND1,MT-ND2,MT-TL1,MT-TF,MT-TV,MT-RNR2,MT-TI,MT-TQ,MT-TM,MT-RNR1	upstream_gene,downstream_gene	MT-ND1:ENST00000361390:upstream_gene_variant:MODIFIER::::,MT-ND2:ENST00000361453:upstream_gene_variant:MODIFIER::::,MT-TL1:ENST00000386347:upstream_gene_variant:MODIFIER::::,MT-TF:ENST00000387314:upstream_gene_variant:MODIFIER::::,MT-TV:ENST00000387342:upstream_gene_variant:MODIFIER::::,MT-RNR2:ENST00000387347:upstream_gene_variant:MODIFIER::::,MT-TI:ENST00000387365:upstream_gene_variant:MODIFIER::::,MT-TQ:ENST00000387372:downstream_gene_variant:MODIFIER::::,MT-TM:ENST00000387377:upstream_gene_variant:MODIFIER::::,MT-RNR1:ENST00000389680:upstream_gene_variant:MODIFIER::::																					240	1307					MT-ND1 (inh=MT pLI=n/a), MT-ND2 (inh=MT pLI=n/a), MT-TL1 (inh=MT pLI=n/a), MT-TF (inh=MT pLI=n/a), MT-TV (inh=MT pLI=n/a), MT-RNR2 (inh=MT pLI=n/a), MT-TI (inh=MT pLI=n/a), MT-TQ (inh=MT pLI=n/a), MT-TM (inh=MT pLI=n/a), MT-RNR1 (inh=MT pLI=n/a)
chrMT	319	319	T	C	wt	hom	wt		QUAL=44546;DP=745,1305,308;AF=0.91,0.97,0.98;MQM=59	MT-ND1,MT-ND2,MT-TL1,MT-TF,MT-TV,MT-RNR2,MT-TI,MT-TQ,MT-TM,MT-RNR1	upstream_gene,downstream_gene	MT-ND1:ENST00000361390:upstream_gene_variant:MODIFIER::::,MT-ND2:ENST00000361453:upstream_gene_variant:MODIFIER::::,MT-TL1:ENST00000386347:upstream_gene_variant:MODIFIER::::,MT-TF:ENST00000387314:upstream_gene_variant:MODIFIER::::,MT-TV:ENST00000387342:upstream_gene_variant:MODIFIER::::,MT-RNR2:ENST00000387347:upstream_gene_variant:MODIFIER::::,MT-TI:ENST00000387365:upstream_gene_variant:MODIFIER::::,MT-TQ:ENST00000387372:downstream_gene_variant:MODIFIER::::,MT-TM:ENST00000387377:upstream_gene_variant:MODIFIER::::,MT-RNR1:ENST00000389680:upstream_gene_variant:MODIFIER::::					rs879055956																45	3					MT-ND1 (inh=MT pLI=n/a), MT-ND2 (inh=MT pLI=n/a), MT-TL1 (inh=MT pLI=n/a), MT-TF (inh=MT pLI=n/a), MT-TV (inh=MT pLI=n/a), MT-RNR2 (inh=MT pLI=n/a), MT-TI (inh=MT pLI=n/a), MT-TQ (inh=MT pLI=n/a), MT-TM (inh=MT pLI=n/a), MT-RNR1 (inh=MT pLI=n/a)
chrMT	430	430	T	C	wt	hom	wt		QUAL=54790;DP=2920,1860,1269;AF=0.00,0.99,0.00;MQM=59	MT-ND1,MT-ND2,MT-TL1,MT-TF,MT-TV,MT-RNR2,MT-TI,MT-TQ,MT-TM,MT-RNR1	upstream_gene,downstream_gene	MT-ND1:ENST00000361390:upstream_gene_variant:MODIFIER::::,MT-ND2:ENST00000361453:upstream_gene_variant:MODIFIER::::,MT-TL1:ENST00000386347:upstream_gene_variant:MODIFIER::::,MT-TF:ENST00000387314:upstream_gene_variant:MODIFIER::::,MT-TV:ENST00000387342:upstream_gene_variant:MODIFIER::::,MT-RNR2:ENST00000387347:upstream_gene_variant:MODIFIER::::,MT-TI:ENST00000387365:upstream_gene_variant:MODIFIER::::,MT-TQ:ENST00000387372:downstream_gene_variant:MODIFIER::::,MT-TM:ENST00000387377:upstream_gene_variant:MODIFIER::::,MT-RNR1:ENST00000389680:upstream_gene_variant:MODIFIER::::																					0	1					MT-ND1 (inh=MT pLI=n/a), MT-ND2 (inh=MT pLI=n/a), MT-TL1 (inh=MT pLI=n/a), MT-TF (inh=MT pLI=n/a), MT-TV (inh=MT pLI=n/a), MT-RNR2 (inh=MT pLI=n/a), MT-TI (inh=MT pLI=n/a), MT-TQ (inh=MT pLI=n/a), MT-TM (inh=MT pLI=n/a), MT-RNR1 (inh=MT pLI=n/a)
chrMT	489	489	T	C	wt	hom	wt		QUAL=66226;DP=3067,2276,1856;AF=0.00,0.99,0.00;MQM=60	MT-ND1,MT-ND2,MT-TL1,MT-TF,MT-TV,MT-RNR2,MT-TI,MT-TQ,MT-TM,MT-RNR1	upstream_gene,downstream_gene	MT-ND1:ENST00000361390:upstream_gene_variant:MODIFIER::::,MT-ND2:ENST00000361453:upstream_gene_variant:MODIFIER::::,MT-TL1:ENST00000386347:upstream_gene_variant:MODIFIER::::,MT-TF:ENST00000387314:upstream_gene_variant:MODIFIER::::,MT-TV:ENST00000387342:upstream_gene_variant:MODIFIER::::,MT-RNR2:ENST00000387347:upstream_gene_variant:MODIFIER::::,MT-TI:ENST00000387365:upstream_gene_variant:MODIFIER::::,MT-TQ:ENST00000387372:downstream_gene_variant:MODIFIER::::,MT-TM:ENST00000387377:upstream_gene_variant:MODIFIER::::,MT-RNR1:ENST00000389680:upstream_gene_variant:MODIFIER::::					rs28625645																480	33					MT-ND1 (inh=MT pLI=n/a), MT-ND2 (inh=MT pLI=n/a), MT-TL1 (inh=MT pLI=n/a), MT-TF (inh=MT pLI=n/a), MT-TV (inh=MT pLI=n/a), MT-RNR2 (inh=MT pLI=n/a), MT-TI (inh=MT pLI=n/a), MT-TQ (inh=MT pLI=n/a), MT-TM (inh=MT pLI=n/a), MT-RNR1 (inh=MT pLI=n/a)
chrMT	513	513	G	A	wt	hom	wt		QUAL=66453;DP=3199,2301,1870;AF=0.00,0.99,0.00;MQM=59	MT-ND1,MT-ND2,MT-TL1,MT-TF,MT-TV,MT-RNR2,MT-TI,MT-TQ,MT-TM,MT-TW,MT-RNR1	upstream_gene,downstream_gene	MT-ND1:ENST00000361390:upstream_gene_variant:MODIFIER::::,MT-ND2:ENST00000361453:upstream_gene_variant:MODIFIER::::,MT-TL1:ENST00000386347:upstream_gene_variant:MODIFIER::::,MT-TF:ENST00000387314:upstream_gene_variant:MODIFIER::::,MT-TV:ENST00000387342:upstream_gene_variant:MODIFIER::::,MT-RNR2:ENST00000387347:upstream_gene_variant:MODIFIER::::,MT-TI:ENST00000387365:upstream_gene_variant:MODIFIER::::,MT-TQ:ENST00000387372:downstream_gene_variant:MODIFIER::::,MT-TM:ENST00000387377:upstream_gene_variant:MODIFIER::::,MT-TW:ENST00000387382:upstream_gene_variant:MODIFIER::::,MT-RNR1:ENST00000389680:upstream_gene_variant:MODIFIER::::					rs879162984																63	5					MT-ND1 (inh=MT pLI=n/a), MT-ND2 (inh=MT pLI=n/a), MT-TL1 (inh=MT pLI=n/a), MT-TF (inh=MT pLI=n/a), MT-TV (inh=MT pLI=n/a), MT-RNR2 (inh=MT pLI=n/a), MT-TI (inh=MT pLI=n/a), MT-TQ (inh=MT pLI=n/a), MT-TM (inh=MT pLI=n/a), MT-TW (inh=MT pLI=n/a), MT-RNR1 (inh=MT pLI=n/a)
chrMT	750	750	A	G	hom	hom	hom		QUAL=291558;DP=3367,3131,2670;AF=1.00,1.00,1.00;MQM=59	MT-RNR1	non_coding_transcript_exon	MT-RNR1:ENST00000389680:non_coding_transcript_exon_variant:MODIFIER:exon1/1:n.103A>G::		441148 [not provided DISEASE=not provided];			rs2853518																3860	5					MT-RNR1 (inh=MT pLI=n/a)
chrMT	1438	1438	A	G	hom	hom	hom		QUAL=708752;DP=8514,7288,6313;AF=1.00,1.00,1.00;MQM=55	MT-RNR1	non_coding_transcript_exon	MT-RNR1:ENST00000389680:non_coding_transcript_exon_variant:MODIFIER:exon1/1:n.791A>G::		42220 [benign DISEASE=not specified,not provided];			rs2001030																3757	4					MT-RNR1 (inh=MT pLI=n/a)
chrMT	1850	1850	T	C	wt	hom	wt		QUAL=121445;DP=5795,3826,3337;AF=0.00,0.99,0.00;MQM=59	MT-RNR2	non_coding_transcript_exon	MT-RNR2:ENST00000387347:non_coding_transcript_exon_variant:MODIFIER:exon1/1:n.180T>C::					rs878878913																33	7					MT-RNR2 (inh=MT pLI=n/a)
chrMT	2706	2706	A	G	hom	hom	hom		QUAL=181685;DP=3111,1475,1282;AF=1.00,1.00,1.00;MQM=59	MT-RNR2	non_coding_transcript_exon	MT-RNR2:ENST00000387347:non_coding_transcript_exon_variant:MODIFIER:exon1/1:n.1036A>G::					rs2854128																2302	114					MT-RNR2 (inh=MT pLI=n/a)
chrMT	3107	3107	N	T	het	het	het		QUAL=11714;DP=152,41,44;AF=0.58,0.59,0.41;MQM=60	MT-RNR2	non_coding_transcript_exon	MT-RNR2:ENST00000387347:non_coding_transcript_exon_variant:MODIFIER:exon1/1:n.1437N>T::																					0	1					MT-RNR2 (inh=MT pLI=n/a)
chrMT	3107	3107	N	C	het	het	het		QUAL=11714;DP=152,41,44;AF=0.41,0.41,0.57;MQM=60	MT-RNR2	non_coding_transcript_exon	MT-RNR2:ENST00000387347:non_coding_transcript_exon_variant:MODIFIER:exon1/1:n.1437N>C::																					0	0					MT-RNR2 (inh=MT pLI=n/a)
chrMT	3109	3109	T	C	het	het	het		QUAL=11714;DP=152,41,44;AF=0.99,1.00,0.98;MQM=60	MT-RNR2	non_coding_transcript_exon	MT-RNR2:ENST00000387347:non_coding_transcript_exon_variant:MODIFIER:exon1/1:n.1439T>C::																					0	0					MT-RNR2 (inh=MT pLI=n/a)
chrMT	4216	4216	T	C	wt	hom	wt		QUAL=105368;DP=3798,3519,3107;AF=0.00,0.99,0.00;MQM=44	MT-ND1	missense	MT-ND1:ENST00000361390:missense_variant:MODERATE:exon1/1:c.910T>C:p.Tyr304His:PF00146		9724 [conflicting interpretations of pathogenicity DISEASE=Leber's optic atrophy];			rs1599988							T	B							COSM1138370,COSM1138371	616	36					MT-ND1 (inh=MT pLI=n/a)
chrMT	4580	4580	G	A	hom	wt	hom		QUAL=102747;DP=2465,1946,1686;AF=0.99,0.00,0.99;MQM=31	MT-ND2	synonymous	MT-ND2:ENST00000361453:synonymous_variant:LOW:exon1/1:c.111G>A:p.Met37=:PF00361					rs28357975																76	5					MT-ND2 (inh=MT pLI=n/a)
chrMT	4769	4769	A	G	hom	hom	hom		QUAL=170539;DP=2353,2318,2040;AF=1.00,1.00,1.00;MQM=32	MT-ND2	synonymous	MT-ND2:ENST00000361453:synonymous_variant:LOW:exon1/1:c.300A>G:p.Met100=:PF00361		441150 [not provided DISEASE=not provided];			rs3021086																3235	10					MT-ND2 (inh=MT pLI=n/a)
chrMT	7028	7028	C	T	hom	hom	hom		QUAL=309208;DP=3131,4004,3484;AF=0.99,1.00,1.00;MQM=42	MT-CO1	synonymous	MT-CO1:ENST00000361624:synonymous_variant:LOW:exon1/1:c.1125C>T:p.Ala375=:PF00115					rs2015062																2256	70					MT-CO1 (inh=MT pLI=n/a)
chrMT	7476	7476	C	T	wt	hom	wt		QUAL=45076;DP=4073,1612,1393;AF=0.00,0.99,0.00;MQM=42	MT-TS1	non_coding_transcript_exon	MT-TS1:ENST00000387416:non_coding_transcript_exon_variant:MODIFIER:exon1/1:n.39G>A::		42228 [likely benign DISEASE=not specified];			rs201950015																63	6					MT-TS1 (inh=MT pLI=n/a)
chrMT	7789	7789	G	A	wt	hom	wt		QUAL=144624;DP=7846,5174,5681;AF=0.00,0.98,0.00;MQM=57	MT-CO2	synonymous	MT-CO2:ENST00000361739:synonymous_variant:LOW:exon1/1:c.204G>A:p.Leu68=:PF02790		376897 [benign DISEASE=not provided];			rs386829014																59	8					MT-CO2 (inh=MT pLI=n/a)
chrMT	8860	8860	A	G	hom	hom	hom		QUAL=172606;DP=1904,2332,2145;AF=0.99,1.00,1.00;MQM=33	MT-ATP6	missense	MT-ATP6:ENST00000361899:missense_variant:MODERATE:exon1/1:c.334A>G:p.Thr112Ala:PF00119					rs2001031							T	B								3237	13					MT-ATP6 (inh=MT pLI=n/a)
chrMT	10398	10398	A	G	wt	hom	wt		QUAL=119873;DP=4715,3738,3114;AF=0.00,0.99,0.00;MQM=59	MT-ND3	missense	MT-ND3:ENST00000361227:missense_variant:MODERATE:exon1/1:c.340A>G:p.Thr114Ala:		9713 [protective DISEASE=Parkinson disease, resistance to];			rs2853826							T	B								765	53					MT-ND3 (inh=MT pLI=n/a)
chrMT	10499	10499	A	G	wt	hom	wt		QUAL=122682;DP=4633,3757,3083;AF=0.00,0.99,0.00;MQM=59	MT-ND4L	synonymous	MT-ND4L:ENST00000361335:synonymous_variant:LOW:exon1/1:c.30A>G:p.Leu10=:PF00420		376866 [benign DISEASE=not provided];			rs1057520074																47	4					MT-ND4L (inh=MT pLI=n/a)
chrMT	11251	11251	A	G	wt	hom	wt		QUAL=178294;DP=6514,5633,4785;AF=0.00,0.99,0.00;MQM=59	MT-ND4	synonymous	MT-ND4:ENST00000361381:synonymous_variant:LOW:exon1/1:c.492A>G:p.Leu164=:PF00361					rs869096886															COSM1138232	693	43					MT-ND4 (inh=MT pLI=n/a)
chrMT	11377	11377	G	A	wt	hom	wt		QUAL=145272;DP=6172,4567,4078;AF=0.00,0.99,0.00;MQM=59	MT-ND4	synonymous	MT-ND4:ENST00000361381:synonymous_variant:LOW:exon1/1:c.618G>A:p.Lys206=:PF00361					rs193302938																72	10					MT-ND4 (inh=MT pLI=n/a)
chrMT	11719	11719	G	A	wt	hom	wt		QUAL=166047;DP=6970,5348,4198;AF=0.00,1.00,0.01;MQM=57	MT-ND4	synonymous	MT-ND4:ENST00000361381:synonymous_variant:LOW:exon1/1:c.960G>A:p.Gly320=:PF00361					rs2853495																2111	71					MT-ND4 (inh=MT pLI=n/a)
chrMT	12612	12612	A	G	wt	hom	wt		QUAL=164420;DP=7659,5150,4372;AF=0.00,0.99,0.00;MQM=59	MT-ND5	synonymous	MT-ND5:ENST00000361567:synonymous_variant:LOW:exon1/1:c.276A>G:p.Val92=:PF00662					rs28359172																305	43					MT-ND5 (inh=MT pLI=n/a)
chrMT	13708	13708	G	A	wt	hom	wt		QUAL=51224;DP=4591,1718,1557;AF=0.00,0.99,0.00;MQM=59	MT-ND5	missense	MT-ND5:ENST00000361567:missense_variant:MODERATE:exon1/1:c.1372G>A:p.Ala458Thr:PF06455		9696 [conflicting interpretations of pathogenicity DISEASE=Leber's optic atrophy];			rs28359178							T	B								390	22					MT-ND5 (inh=MT pLI=n/a)
chrMT	13722	13722	A	G	wt	hom	wt		QUAL=53886;DP=4687,1811,1674;AF=0.00,0.99,0.00;MQM=60	MT-ND5	synonymous	MT-ND5:ENST00000361567:synonymous_variant:LOW:exon1/1:c.1386A>G:p.Leu462=:PF06455		377244 [benign DISEASE=not provided];			rs386829190																52	3					MT-ND5 (inh=MT pLI=n/a)
chrMT	14133	14133	A	G	wt	hom	wt		QUAL=97084;DP=3929,3084,2797;AF=0.00,1.00,0.00;MQM=59	MT-ND5	synonymous	MT-ND5:ENST00000361567:synonymous_variant:LOW:exon1/1:c.1797A>G:p.Leu599=:PF06455		377029 [benign DISEASE=not provided];			rs879100848																50	5					MT-ND5 (inh=MT pLI=n/a)
chrMT	14370	14370	A	G	hom	wt	hom		QUAL=191704;DP=3964,2358,2182;AF=0.99,0.00,0.99;MQM=59	MT-ND6	synonymous	MT-ND6:ENST00000361681:synonymous_variant:LOW:exon1/1:c.304T>C:p.Leu102=:PF00499																					2	0					MT-ND6 (inh=MT pLI=n/a)
chrMT	14766	14766	C	T	wt	hom	wt		QUAL=71324;DP=3293,2293,2105;AF=0.00,1.00,0.01;MQM=59	MT-CYB	missense	MT-CYB:ENST00000361789:missense_variant:MODERATE:exon1/1:c.20C>T:p.Thr7Ile:		140587 [likely pathogenic DISEASE=Familial cancer of breast];			rs193302980,rs527236041							D	B								2108	91					MT-CYB (inh=MT pLI=n/a)
chrMT	15257	15257	G	A	wt	hom	wt		QUAL=122492;DP=4501,3833,3617;AF=0.00,0.99,0.00;MQM=60	MT-CYB	missense	MT-CYB:ENST00000361789:missense_variant:MODERATE:exon1/1:c.511G>A:p.Asp171Asn:PF13631		9674 [conflicting interpretations of pathogenicity DISEASE=Leber's optic atrophy];			rs41518645							D	B							COSM1138306,COSM1138307	69	11					MT-CYB (inh=MT pLI=n/a)
chrMT	15326	15326	A	G	hom	hom	hom		QUAL=369671;DP=4453,3655,3489;AF=1.00,1.00,1.00;MQM=59	MT-CYB	missense	MT-CYB:ENST00000361789:missense_variant:MODERATE:exon1/1:c.580A>G:p.Thr194Ala:PF13631		140592 [likely pathogenic DISEASE=Familial cancer of breast];			rs2853508							T	B								3861	3	1	[1] harmuth 09.04.2018		most likely WT variant; in 98,6% of all full length sequences (MitoMap); FH 09.04.2018	MT-CYB (inh=MT pLI=n/a)
chrMT	15452	15452	C	A	wt	hom	wt		QUAL=107159;DP=6656,3397,3240;AF=0.00,0.99,0.00;MQM=59	MT-CYB	missense	MT-CYB:ENST00000361789:missense_variant:MODERATE:exon1/1:c.706C>A:p.Leu236Ile:PF13631		143925 [likely pathogenic DISEASE=Neoplasm of ovary];			rs193302994,rs527236209							T	B								676	61					MT-CYB (inh=MT pLI=n/a)
chrMT	15904	15904	C	T	hom	wt	hom		QUAL=301290;DP=5998,3779,3326;AF=0.99,0.00,0.99;MQM=59	MT-TT	non_coding_transcript_exon	MT-TT:ENST00000387460:non_coding_transcript_exon_variant:MODIFIER:exon1/1:n.17C>T::					rs35788393																77	10					MT-TT (inh=MT pLI=n/a)
chrMT	16069	16069	C	T	wt	hom	wt		QUAL=119067;DP=5777,3746,3613;AF=0.00,0.99,0.00;MQM=60	MT-ND4,MT-ND5,MT-ND6,MT-CYB,MT-TH,MT-TS2,MT-TL2,MT-TE,MT-TT,MT-TP	downstream_gene,upstream_gene	MT-ND4:ENST00000361381:downstream_gene_variant:MODIFIER::::,MT-ND5:ENST00000361567:downstream_gene_variant:MODIFIER::::,MT-ND6:ENST00000361681:upstream_gene_variant:MODIFIER::::,MT-CYB:ENST00000361789:downstream_gene_variant:MODIFIER::::,MT-TH:ENST00000387441:downstream_gene_variant:MODIFIER::::,MT-TS2:ENST00000387449:downstream_gene_variant:MODIFIER::::,MT-TL2:ENST00000387456:downstream_gene_variant:MODIFIER::::,MT-TE:ENST00000387459:upstream_gene_variant:MODIFIER::::,MT-TT:ENST00000387460:downstream_gene_variant:MODIFIER::::,MT-TP:ENST00000387461:upstream_gene_variant:MODIFIER::::					rs147903261																301	25					MT-ND4 (inh=MT pLI=n/a), MT-ND5 (inh=MT pLI=n/a), MT-ND6 (inh=MT pLI=n/a), MT-CYB (inh=MT pLI=n/a), MT-TH (inh=MT pLI=n/a), MT-TS2 (inh=MT pLI=n/a), MT-TL2 (inh=MT pLI=n/a), MT-TE (inh=MT pLI=n/a), MT-TT (inh=MT pLI=n/a), MT-TP (inh=MT pLI=n/a)
chrMT	16126	16126	T	C	wt	hom	wt		QUAL=123580;DP=5729,3911,4034;AF=0.00,0.99,0.00;MQM=60	MT-ND4,MT-ND5,MT-ND6,MT-CYB,MT-TH,MT-TS2,MT-TL2,MT-TE,MT-TT,MT-TP	downstream_gene,upstream_gene	MT-ND4:ENST00000361381:downstream_gene_variant:MODIFIER::::,MT-ND5:ENST00000361567:downstream_gene_variant:MODIFIER::::,MT-ND6:ENST00000361681:upstream_gene_variant:MODIFIER::::,MT-CYB:ENST00000361789:downstream_gene_variant:MODIFIER::::,MT-TH:ENST00000387441:downstream_gene_variant:MODIFIER::::,MT-TS2:ENST00000387449:downstream_gene_variant:MODIFIER::::,MT-TL2:ENST00000387456:downstream_gene_variant:MODIFIER::::,MT-TE:ENST00000387459:upstream_gene_variant:MODIFIER::::,MT-TT:ENST00000387460:downstream_gene_variant:MODIFIER::::,MT-TP:ENST00000387461:upstream_gene_variant:MODIFIER::::					rs147029798																670	132					MT-ND4 (inh=MT pLI=n/a), MT-ND5 (inh=MT pLI=n/a), MT-ND6 (inh=MT pLI=n/a), MT-CYB (inh=MT pLI=n/a), MT-TH (inh=MT pLI=n/a), MT-TS2 (inh=MT pLI=n/a), MT-TL2 (inh=MT pLI=n/a), MT-TE (inh=MT pLI=n/a), MT-TT (inh=MT pLI=n/a), MT-TP (inh=MT pLI=n/a)
chrMT	16145	16145	G	A	wt	hom	wt		QUAL=123979;DP=5680,3936,4059;AF=0.00,0.99,0.00;MQM=60	MT-ND4,MT-ND5,MT-ND6,MT-CYB,MT-TH,MT-TS2,MT-TL2,MT-TE,MT-TT,MT-TP	downstream_gene,upstream_gene	MT-ND4:ENST00000361381:downstream_gene_variant:MODIFIER::::,MT-ND5:ENST00000361567:downstream_gene_variant:MODIFIER::::,MT-ND6:ENST00000361681:upstream_gene_variant:MODIFIER::::,MT-CYB:ENST00000361789:downstream_gene_variant:MODIFIER::::,MT-TH:ENST00000387441:downstream_gene_variant:MODIFIER::::,MT-TS2:ENST00000387449:downstream_gene_variant:MODIFIER::::,MT-TL2:ENST00000387456:downstream_gene_variant:MODIFIER::::,MT-TE:ENST00000387459:upstream_gene_variant:MODIFIER::::,MT-TT:ENST00000387460:downstream_gene_variant:MODIFIER::::,MT-TP:ENST00000387461:upstream_gene_variant:MODIFIER::::					rs41419246																106	40					MT-ND4 (inh=MT pLI=n/a), MT-ND5 (inh=MT pLI=n/a), MT-ND6 (inh=MT pLI=n/a), MT-CYB (inh=MT pLI=n/a), MT-TH (inh=MT pLI=n/a), MT-TS2 (inh=MT pLI=n/a), MT-TL2 (inh=MT pLI=n/a), MT-TE (inh=MT pLI=n/a), MT-TT (inh=MT pLI=n/a), MT-TP (inh=MT pLI=n/a)
chrMT	16231	16231	T	C	wt	hom	wt		QUAL=148552;DP=6691,4768,4468;AF=0.00,0.99,0.00;MQM=59	MT-ND4,MT-ND5,MT-ND6,MT-CYB,MT-TH,MT-TS2,MT-TL2,MT-TE,MT-TT,MT-TP	downstream_gene,upstream_gene	MT-ND4:ENST00000361381:downstream_gene_variant:MODIFIER::::,MT-ND5:ENST00000361567:downstream_gene_variant:MODIFIER::::,MT-ND6:ENST00000361681:upstream_gene_variant:MODIFIER::::,MT-CYB:ENST00000361789:downstream_gene_variant:MODIFIER::::,MT-TH:ENST00000387441:downstream_gene_variant:MODIFIER::::,MT-TS2:ENST00000387449:downstream_gene_variant:MODIFIER::::,MT-TL2:ENST00000387456:downstream_gene_variant:MODIFIER::::,MT-TE:ENST00000387459:upstream_gene_variant:MODIFIER::::,MT-TT:ENST00000387460:downstream_gene_variant:MODIFIER::::,MT-TP:ENST00000387461:upstream_gene_variant:MODIFIER::::					rs386829286																43	13					MT-ND4 (inh=MT pLI=n/a), MT-ND5 (inh=MT pLI=n/a), MT-ND6 (inh=MT pLI=n/a), MT-CYB (inh=MT pLI=n/a), MT-TH (inh=MT pLI=n/a), MT-TS2 (inh=MT pLI=n/a), MT-TL2 (inh=MT pLI=n/a), MT-TE (inh=MT pLI=n/a), MT-TT (inh=MT pLI=n/a), MT-TP (inh=MT pLI=n/a)
chrMT	16261	16261	C	T	wt	hom	wt		QUAL=148448;DP=7129,4752,4289;AF=0.00,0.99,0.00;MQM=60	MT-ND4,MT-ND5,MT-ND6,MT-CYB,MT-TH,MT-TS2,MT-TL2,MT-TE,MT-TT,MT-TP	downstream_gene,upstream_gene	MT-ND4:ENST00000361381:downstream_gene_variant:MODIFIER::::,MT-ND5:ENST00000361567:downstream_gene_variant:MODIFIER::::,MT-ND6:ENST00000361681:upstream_gene_variant:MODIFIER::::,MT-CYB:ENST00000361789:downstream_gene_variant:MODIFIER::::,MT-TH:ENST00000387441:downstream_gene_variant:MODIFIER::::,MT-TS2:ENST00000387449:downstream_gene_variant:MODIFIER::::,MT-TL2:ENST00000387456:downstream_gene_variant:MODIFIER::::,MT-TE:ENST00000387459:upstream_gene_variant:MODIFIER::::,MT-TT:ENST00000387460:downstream_gene_variant:MODIFIER::::,MT-TP:ENST00000387461:upstream_gene_variant:MODIFIER::::					rs138126107																138	37					MT-ND4 (inh=MT pLI=n/a), MT-ND5 (inh=MT pLI=n/a), MT-ND6 (inh=MT pLI=n/a), MT-CYB (inh=MT pLI=n/a), MT-TH (inh=MT pLI=n/a), MT-TS2 (inh=MT pLI=n/a), MT-TL2 (inh=MT pLI=n/a), MT-TE (inh=MT pLI=n/a), MT-TT (inh=MT pLI=n/a), MT-TP (inh=MT pLI=n/a)
chrMT	16298	16298	T	C	hom	wt	hom		QUAL=332101;DP=6117,4794,4220;AF=0.99,0.00,0.99;MQM=59	MT-ND4,MT-ND5,MT-ND6,MT-CYB,MT-TH,MT-TS2,MT-TL2,MT-TE,MT-TT,MT-TP	downstream_gene,upstream_gene	MT-ND4:ENST00000361381:downstream_gene_variant:MODIFIER::::,MT-ND5:ENST00000361567:downstream_gene_variant:MODIFIER::::,MT-ND6:ENST00000361681:upstream_gene_variant:MODIFIER::::,MT-CYB:ENST00000361789:downstream_gene_variant:MODIFIER::::,MT-TH:ENST00000387441:downstream_gene_variant:MODIFIER::::,MT-TS2:ENST00000387449:downstream_gene_variant:MODIFIER::::,MT-TL2:ENST00000387456:downstream_gene_variant:MODIFIER::::,MT-TE:ENST00000387459:upstream_gene_variant:MODIFIER::::,MT-TT:ENST00000387460:downstream_gene_variant:MODIFIER::::,MT-TP:ENST00000387461:upstream_gene_variant:MODIFIER::::					rs148377232																149	43					MT-ND4 (inh=MT pLI=n/a), MT-ND5 (inh=MT pLI=n/a), MT-ND6 (inh=MT pLI=n/a), MT-CYB (inh=MT pLI=n/a), MT-TH (inh=MT pLI=n/a), MT-TS2 (inh=MT pLI=n/a), MT-TL2 (inh=MT pLI=n/a), MT-TE (inh=MT pLI=n/a), MT-TT (inh=MT pLI=n/a), MT-TP (inh=MT pLI=n/a)
chrMT	16519	16519	T	C	hom	wt	hom		QUAL=371683;DP=7015,4954,4522;AF=1.00,0.01,1.00;MQM=58	MT-ND4,MT-ND5,MT-ND6,MT-CYB,MT-TH,MT-TS2,MT-TL2,MT-TE,MT-TT,MT-TP	downstream_gene,upstream_gene	MT-ND4:ENST00000361381:downstream_gene_variant:MODIFIER::::,MT-ND5:ENST00000361567:downstream_gene_variant:MODIFIER::::,MT-ND6:ENST00000361681:upstream_gene_variant:MODIFIER::::,MT-CYB:ENST00000361789:downstream_gene_variant:MODIFIER::::,MT-TH:ENST00000387441:downstream_gene_variant:MODIFIER::::,MT-TS2:ENST00000387449:downstream_gene_variant:MODIFIER::::,MT-TL2:ENST00000387456:downstream_gene_variant:MODIFIER::::,MT-TE:ENST00000387459:upstream_gene_variant:MODIFIER::::,MT-TT:ENST00000387460:downstream_gene_variant:MODIFIER::::,MT-TP:ENST00000387461:upstream_gene_variant:MODIFIER::::					rs3937033																2449	86					MT-ND4 (inh=MT pLI=n/a), MT-ND5 (inh=MT pLI=n/a), MT-ND6 (inh=MT pLI=n/a), MT-CYB (inh=MT pLI=n/a), MT-TH (inh=MT pLI=n/a), MT-TS2 (inh=MT pLI=n/a), MT-TL2 (inh=MT pLI=n/a), MT-TE (inh=MT pLI=n/a), MT-TT (inh=MT pLI=n/a), MT-TP (inh=MT pLI=n/a)
